var images_info;if (!images_info) images_info =[]; images_info["76"]={"76000":{"type":"graphic_diagnosticimage","displayName":"Paravertebral mass MRI II","title":"Invasive neuroblastoma on MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Invasive neuroblastoma on MRI</div><div class=\"cntnt\"><img style=\"width:236px; height:272px;\" src=\"images/PULM/76000_Paravertebral_mass_MRI_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal T1-weighted section through the mass shows both chest wall invasion (arrow) and extension into the spinal canal (arrowhead).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 76000 Version 3.0</div></div></div>"},"76001":{"type":"graphic_picture","displayName":"Path of papillary fibroelastoma","title":"Papillary fibroelastoma of mitral valve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Papillary fibroelastoma of mitral valve</div><div class=\"cntnt\"><img style=\"width:335px; height:215px;\" src=\"images/CARD/76001_Path_of_papillary_fibroelas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross and microscopic pathology of a papillary fibroelastoma of the mitral valve. The gross specimen (left) reveals multiple frond-like structures when photographed underwater. Low (right, top) and high power (right, bottom) microscopic features include dense elastin (black) at the core of each frond coated with collagen (red pink) and lined by flat endocardial cells.</div><div class=\"graphic_reference\">Reprinted from Journal of the American College of Cardiology, volume 30, Klarich, KW, Enriquez-Sarano, M, Gura, GM, et al. Papillary fibroelastoma: Echocardiographic characteristics for diagnosis and pathogenesis correlation, p.784, Copyright 1997, with permission from the American College of Cardiology.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 76001 Version 2.0</div></div></div>"},"76002":{"type":"graphic_diagnosticimage","displayName":"Measuring scapholunate angle","title":"Scapholunate angle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scapholunate angle</div><div class=\"cntnt\"><img style=\"width:346px; height:504px;\" src=\"images/EM/76002_Measuring_scapholunate_angl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The scapholunate angle, formed by bisecting the scaphoid and the lunate, can be measured in the lateral radiograph of the wrist. A normal scapholunate angle (40 to 60&#186;) is present in this example.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 76002 Version 2.0</div></div></div>"},"76003":{"type":"graphic_figure","displayName":"Intestines bulging through hernia PI","title":"Intestines bulging through hernia","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Intestines bulging through hernia</div><div class=\"cntnt\"><img style=\"width:491px; height:618px;\" src=\"images/PI/76003_Intestines-bulging-through-hernia-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In some cases, a loop of intestine can poke through a hernia. Often surgeons can push the loop of intestine back in. But if the loop gets trapped or does not get enough blood, surgeons sometimes have to remove it and reconnect the 2 ends of intestine that are left.</div><div id=\"graphicVersion\">Graphic 76003 Version 2.0</div></div></div>"},"76004":{"type":"graphic_picture","displayName":"Hailey-Hailey 3","title":"Hailey-Hailey disease","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hailey-Hailey disease</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/76004_Hailey_Hailey_3_new.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red, macerated, and cracked axillary plaque in a woman with Hailey-Hailey disease.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76004 Version 5.0</div></div></div>"},"76005":{"type":"graphic_diagnosticimage","displayName":"Hallux abductus angle","title":"Hallux abductus angle","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hallux abductus angle</div><div class=\"cntnt\"><img style=\"width:504px; height:419px;\" src=\"images/SM/76005_Hallux_abductus_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This angle is created by the bisection of the longitudinal axes of the first metatarsal and the proximal phalanx of the great toe. An angle greater than 20 degrees is considered abnormal; the angle here is approximately 25 degrees.</div><div class=\"graphic_reference\">Courtesy of Jill Ferrari, PhD, BSc.</div><div id=\"graphicVersion\">Graphic 76005 Version 4.0</div></div></div>"},"76006":{"type":"graphic_figure","displayName":"Theca cell androgen production","title":"Ovarian androgen and estrogen production","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Ovarian androgen and estrogen production</div><div class=\"cntnt\"><img style=\"width:486px; height:339px;\" src=\"images/ENDO/76006_Theca_cell_androgen_product.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ovarian androgens, mostly androstenedione and some testosterone, are produced in the theca cells, which respond to LH. The androgens diffuse across the basement membrane to the granulosa cells. The granulosa cells, in response to stimulation by FSH, produce aromatase, which converts the androgen precursors to estrone and estradiol.</div><div class=\"graphic_footnotes\">FSH: follicle-stimulating hormone; LH: luteinizing hormone.</div><div class=\"graphic_reference\">Adapted from: Erickson GF, Magoffin DA, Dyer CA, Hofeditz C. The ovarian androgen producing cells: a review of structure/function relationships. Endocr Rev 1985; 6:371.</div><div id=\"graphicVersion\">Graphic 76006 Version 3.0</div></div></div>"},"76007":{"type":"graphic_figure","displayName":"Precut fistulotomy 1","title":"Precut fistulotomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Precut fistulotomy</div><div class=\"cntnt\"><img style=\"width:423px; height:505px;\" src=\"images/GAST/76007_Precut_fistulotomy_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Martin L Freeman, MD.</div><div id=\"graphicVersion\">Graphic 76007 Version 1.0</div></div></div>"},"76009":{"type":"graphic_table","displayName":"Military triage radiation","title":"Triage considerations: nuclear detonation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Triage considerations: nuclear detonation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Conventional triage for injuries with no radiation exposure*</td> <td class=\"subtitle1\" colspan=\"3\">Triage Categories for those with injuries (eg, burns, trauma) in addition to radiation exposure</td> </tr> <tr> <td class=\"subtitle2\">&#60;1.5 Gy</td> <td class=\"subtitle2\">1.5-4.5 Gy</td> <td class=\"subtitle2\">4.5-10 Gy</td> </tr> <tr> <td>Delayed</td> <td>Delayed</td> <td>Variable</td> <td>Expectant</td> </tr> <tr> <td>Immediate</td> <td>Immediate</td> <td>Immediate</td> <td>Expectant</td> </tr> <tr> <td>Minimal</td> <td>Minimal</td> <td>Minimal</td> <td>Minimal</td> </tr> <tr> <td>Expectant</td> <td>Expectant</td> <td>Expectant</td> <td>Expectant</td> </tr> <tr> <td>Absent</td> <td>Ambulatory<sup>&#182;</sup></td> <td>As needed<sup>&#182;</sup></td> <td>As needed<sup>​&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* This column contains the conventional military triage treatment system for subjects with significant mechanical trauma or burns. The categories are defined as follows: Delayed treatment: Medically stable with significant injury, but may survive until definitive treatment is available; Immediate treatment: Subjects with high survivability and significant injury, provided that immediate therapy is available; Minimal therapy: Medically stable subjects with minor injury; Expectant therapy: Subjects who are seriously injured in whom survivability is poor.<br />¶ Subjects with radiation injury alone and an exposure of &lt;1.5 Gy should be monitored in an ambulatory setting. Those with exposures &gt;1.5 Gy should be given routine care (eg, cytokines, antimicrobial agents, transfusions, laboratory monitoring) and hospitalization, if required, as indicated in the text.</div><div class=\"graphic_reference\">Modified with permission from: Waselenko JK, MacVittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: Recommendations of the strategic national stockpile radiation working group. Ann Intern Med 2004; 140:1037. Copyright &copy; 2004 American College of Physicians.</div><div id=\"graphicVersion\">Graphic 76009 Version 16.0</div></div></div>"},"76010":{"type":"graphic_table","displayName":"New daily persistent headache criteria","title":"New daily persistent headache diagnostic criteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">New daily persistent headache diagnostic criteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Description:</td> </tr> <tr> <td class=\"indent1\">Persistent headache, daily from its onset, which is clearly remembered. The pain lacks characteristic features, and may be migraine-like or tension-type-like, or have elements of both.</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic criteria:</td> </tr> <tr> <td class=\"indent1\">A. Persistent headache fulfilling criteria B and C</td> </tr> <tr> <td class=\"indent1\">B. Distinct and clearly remembered onset, with pain becoming continuous and unremitting within 24 hours</td> </tr> <tr> <td class=\"indent1\">C. Present for more than three months</td> </tr> <tr> <td class=\"indent1\">D. Not better accounted for by another ICHD-3 diagnosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICHD-3: International Classification of Headache Disorders, 3rd edition.</div><div class=\"graphic_reference\">Data from: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33:629.</div><div id=\"graphicVersion\">Graphic 76010 Version 4.0</div></div></div>"},"76012":{"type":"graphic_picture","displayName":"LGPUC","title":"Non-invasive low-grade papillary urothelial carcinoma (LGPUC)","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Non-invasive low-grade papillary urothelial carcinoma (LGPUC)</div><div class=\"cntnt\"><img style=\"width:601px; height:161px;\" src=\"images/ONC/76012_LGPUC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At low power (A, 20x) LGPUC papillary fronds show frequent branching and minimal fusion. At higher power (B-C, 40x) the urothelial cells maintain an overall orderly appearance with easily recognizable variations in cytologic features. The nuclei are enlarged; mild differences in shape, contour, and chromatin distribution are noted.</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 76012 Version 1.0</div></div></div>"},"76013":{"type":"graphic_table","displayName":"Paclitaxel-carboplatin-bevacizumab chemotherapy for NSCLC","title":"Paclitaxel, carboplatin, and bevacizumab chemotherapy for advanced non-small cell lung cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Paclitaxel, carboplatin, and bevacizumab chemotherapy for advanced non-small cell lung cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> Every 21 days for a maximum of six cycles, followed by maintenance therapy with bevacizumab every three weeks. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Paclitaxel</td> <td>200 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline (NS, final concentration of 0.3 to 1.2 mg/mL) and administer over three hours.*</td> <td>Day 1</td> </tr> <tr> <td>Carboplatin</td> <td>AUC<sup>&#182;</sup> = 6 mg/mL per min IV</td> <td>Dilute in 250 mL NS and administer over 30 minutes<sup>&#916;</sup> (administer 60 minutes after the completion of the paclitaxel infusion).</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Bevacizumab</td> <td>15 mg/kg IV</td> <td>Dilute into a total volume of 100 mL of NS.<sup>&#916;</sup> The first dose should be administered over 90 minutes one hour after carboplatin. If well tolerated, the second infusion may be administered over 60 minutes. If well tolerated, all subsequent infusions may be administered over 10 to 30 minutes.<sup>[2]</sup></td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE (MINIMAL when bevacizumab is given as maintenance). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedicate with dexamethasone plus both an H1 and an H2 receptor antagonist prior to paclitaxel administration. There is no standard premedication regimen for bevacizumab. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Paclitaxel can cause significant tissue damage and carboplatin is an irritant; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with hematopoietic growth factors is not recommended (risk of febrile neutropenia is approximately 5%<sup>[1]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Each carboplatin dose should be calculated based upon renal function by use of the Calvert formula.<sup>&#182;</sup></li> <li>A lower starting dose of paclitaxel may be needed in patients with liver impairment. Bevacizumab does not require dosage adjustments for liver or renal dysfunction.<sup>[2]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Dosing of anticancer agents in adults\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Serum electrolytes and liver and renal function tests prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function, blood pressure, urine protein concentration, and risk for bleeding prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Treatment with paclitaxel and carboplatin should be delayed until the absolute neutrophil count is &#62;2000/microL and platelet count is &#62;100,000/microL.<sup>[3,4]</sup> If a patient develops severe neutropenia (&#60;500/microL) for a week or longer, or febrile neutropenia during the prior course, then the paclitaxel and carboplatin doses should be reduced by 20 to 25% for subsequent courses.<sup>[5]</sup> An alternative to dose reduction is the institution of hematopoietic growth factor support. Both the carboplatin and paclitaxel doses should be decreased by 25% in patients whose platelet count nadir is &#60;50,000/microL for longer than five days.<sup>[4]</sup></li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Renal/hepatic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Alterations in renal function during therapy may require a recalculation of the carboplatin dose. Paclitaxel dose may need to be adjusted for hepatic impairment on day 1 of each cycle.</li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Dosing of anticancer agents in adults\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>For patients who develop severe peripheral neuropathy (grade 3 or 4) for a week or longer, the dose of paclitaxel should be reduced by 20% for subsequent courses.<sup>[4]</sup></li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Assess changes in blood pressure, urine protein concentration, and risk for bleeding prior to each treatment. Discontinue bevacizumab for hypertensive crisis or hypertensive encephalopathy, serious hemorrhage, arterial thromboembolism, nephrotic syndrome, gastrointestinal perforation, fistula formation, or reversible posterior leukoencephalopathy syndrome (RPLS).<sup>[2]</sup> Do not administer within 28 days of surgery.</li> </ul> </td> </tr> <tr class=\"divider_top divider_bottom\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Dose reductions may also be indicated if there are other grade 2 or higher nonhematologic toxicities. The dose reduction is at the discretion of the clinician, as formal guidelines are not available.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count; GFR: glomerular filtration rate.<br />* Paclitaxel can be administered in NS, D5W, or NS/D5W at varying concentrations between 0.3 to 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-lined administration sets with a microporous membrane 0.22 microns or less.<br />¶ AUC (area under the concentration × time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) × (GFR + 25). If using measured serum creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topic on \"Dosing of anticancer agents in adults\".<br />Δ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Sandler A, et al. N Engl J Med 2006; 355:2542.</LI>&#xD;&#xA;<LI>Bevacizumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).</LI>&#xD;&#xA;<LI>Carboplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).</LI>&#xD;&#xA;<LI>Paclitaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).</LI>&#xD;&#xA;<LI>Langer CT, et al. J Clin Oncol 1995; 13:1860.</LI></OL></div><div id=\"graphicVersion\">Graphic 76013 Version 30.0</div></div></div>"},"76015":{"type":"graphic_figure","displayName":"Outcome surgery vs surveillance","title":"Patients undergoing elective repair of an abdominal aortic aneurysm do better at eight years","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patients undergoing elective repair of an abdominal aortic aneurysm do better at eight years</div><div class=\"cntnt\"><img style=\"width:429px; height:281px;\" src=\"images/CARD/76015_Outcome_surg_vs_surv_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the UK Small Aneurysm trial of 1090 patients with a medium-sized abdominal aortic aneurysm, there is no difference in survival with early elective surgery compared with initial surveillance. However, by eight years patients undergoing early surgery have a significantly better outcome than those in the surveillance group (P=0.05 ). I bars represent the 95 percent confidence intervals for the point estimates.</div><div class=\"graphic_reference\">Data from: The United Kingdom Small Aneurysm Trial Participants. N Engl J Med 2002; 346:1445.</div><div id=\"graphicVersion\">Graphic 76015 Version 4.0</div></div></div>"},"76016":{"type":"graphic_picture","displayName":"Multiple bruises","title":"Multiple bruises","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple bruises</div><div class=\"cntnt\"><img style=\"width:360px; height:503px;\" src=\"images/EM/76016_Multiple_bruises.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Stephen Ludwig, MD.</div><div id=\"graphicVersion\">Graphic 76016 Version 1.0</div></div></div>"},"76017":{"type":"graphic_diagnosticimage","displayName":"Salter III radius fracture","title":"Anteroposterior radiograph showing a Salter-Harris type III fracture of the distal radius","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anteroposterior radiograph showing a Salter-Harris type III fracture of the distal radius</div><div class=\"cntnt\"><img style=\"width:293px; height:396px;\" src=\"images/EM/76017_SalterIIIradiusfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This Salter-Harris III fracture is evident as a vertical line that passes from the physis (growth plate, seen as a lucency between the distal radial metaphysis and epiphysis), through the epiphysis, and into the articulation between the radial epiphysis and the metacarpal bones.</div><div class=\"graphic_reference\">Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 76017 Version 16.0</div></div></div>"},"76019":{"type":"graphic_diagnosticimage","displayName":"Cystgastrostomy for treatment of a pancreatic pseudocyst","title":"Creation of a cystgastrostomy for treatment of a pancreatic pseudocyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Creation of a cystgastrostomy for treatment of a pancreatic pseudocyst</div><div class=\"cntnt\"><img style=\"width:396px; height:303px;\" src=\"images/GAST/76019_Fluoroscopyballoondilat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluoroscopy view of guidewire exiting the curvilinear array echoendoscope and curling within the pseudocyst. The cystgastrostomy tract is being dilated with a balloon.</div><div class=\"graphic_reference\">Courtesy of Dr. Raj J Shah, MD.</div><div id=\"graphicVersion\">Graphic 76019 Version 6.0</div></div></div>"},"76021":{"type":"graphic_table","displayName":"Vulvar cancer survival","title":"Survival by FIGO stage for patients with vulvar cancer 1999 to 2001 FIGO statistics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Survival by FIGO stage for patients with vulvar cancer 1999 to 2001 FIGO statistics</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">FIGO stage</td> <td class=\"subtitle1\" rowspan=\"2\">Number of patients</td> <td class=\"subtitle1\" colspan=\"3\">Overall survival (percent)</td> </tr> <tr> <td class=\"subtitle2\">One year</td> <td class=\"subtitle2\">Two years</td> <td class=\"subtitle2\">Five years</td> </tr> <tr> <td class=\"centered\">I</td> <td class=\"centered\">286</td> <td class=\"centered\">96.4</td> <td class=\"centered\">90.4</td> <td class=\"centered\">78.5</td> </tr> <tr> <td class=\"centered\">II</td> <td class=\"centered\">266</td> <td class=\"centered\">87.6</td> <td class=\"centered\">73.2</td> <td class=\"centered\">58.8</td> </tr> <tr> <td class=\"centered\">III</td> <td class=\"centered\">216</td> <td class=\"centered\">74.7</td> <td class=\"centered\">53.8</td> <td class=\"centered\">43.2</td> </tr> <tr> <td class=\"centered\">IV</td> <td class=\"centered\">71</td> <td class=\"centered\">35.3</td> <td class=\"centered\">16.9</td> <td class=\"centered\">13.0</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FIGO: International Federation of Gynecology and Obstetrics.</div><div class=\"graphic_reference\">Original table modified for this publication. From: Beller U, Quinn MA, Benedet JL, et al. Carcinoma of the vulva. Int J Gynaecol Obstet 2006; 95:S7. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 76021 Version 12.0</div></div></div>"},"76022":{"type":"graphic_figure","displayName":"T piece adapter","title":"T-piece adapter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">T-piece adapter</div><div class=\"cntnt\"><img style=\"width:389px; height:258px;\" src=\"images/PULM/76022_T_piece_adapter.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 76022 Version 1.0</div></div></div>"},"76023":{"type":"graphic_table","displayName":"Conditions incorrectly diagnosed as syncope","title":"Conditions incorrectly diagnosed as syncope","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions incorrectly diagnosed as syncope</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Disorders with partial or complete LOC but without global cerebral hypoperfusion</td> </tr> <tr> <td>Epilepsy</td> </tr> <tr> <td>Metabolic disorders including hypoglycaemia, hypoxia, hyperventilation with hypocapnia</td> </tr> <tr> <td>Intoxication</td> </tr> <tr> <td>Vertebrobasilar TIA</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders without impairment of consciousness</td> </tr> <tr> <td>Cataplexy</td> </tr> <tr> <td>Drop attacks</td> </tr> <tr> <td>Falls</td> </tr> <tr> <td>Functional (psychogenic pseudosyncope)</td> </tr> <tr> <td>TIA or carotid origin</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LOC: loss of consciousness; TIA: transient ischaemic attack.</div><div class=\"graphic_reference\">Reproduced with permission from: European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009; 30:2631. Copyright © 2009 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 76023 Version 6.0</div></div></div>"},"76025":{"type":"graphic_picture","displayName":"Bowenoid papulosis","title":"Bowenoid papulosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bowenoid papulosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ONC/76025_Bowenoid_papulosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple reddish, small papules on the penis of this patient with Bowenoid papulosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76025 Version 5.0</div></div></div>"},"76026":{"type":"graphic_table","displayName":"Childhood features of SFTPC and ABCA3","title":"Clinical features of children with SFTPC and ABCA3 mutations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of children with SFTPC and ABCA3 mutations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">SFTPC<sup>[1,2,3,4]</sup></td> <td class=\"subtitle1\">ABCA3<sup>[5,6]</sup></td> </tr> <tr> <td>Tachypnea</td> <td class=\"centered\">+++</td> <td class=\"centered\">+++</td> </tr> <tr> <td>Cough</td> <td class=\"centered\">+++</td> <td class=\"centered\">+++</td> </tr> <tr> <td>Hypoxemia</td> <td class=\"centered\">+++</td> <td class=\"centered\">+++</td> </tr> <tr> <td>Failure to thrive</td> <td class=\"centered\">+++</td> <td class=\"centered\">++</td> </tr> <tr> <td>Crackles</td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> </tr> <tr> <td>Clubbing</td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> </tr> <tr> <td>Pectus excavatum</td> <td class=\"centered\">NS</td> <td class=\"centered\">++</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Clinical features observed in children with SFTPC and ABCA3 related lung disease who presented after the neonatal period. (+ indicates that up to 1/3 of patients exhibited the finding, ++ indicates that up to 2/3 exhibited the finding, +++ indicates that more than 2/3 exhibited the finding.)</div><div class=\"graphic_footnotes\">SFTPC: surfactant protein C; ABCA3: member A3 of the ATP Binding Cassette family of proteins; NS: not specified.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Abou Taam R, Jaubert F, Emond S, et al. Familial interstitial disease with I73T mutation: A mid- and long-term study. Pediatr Pulmonol 2009; 44:167. </LI>&#xD;&#xA;<LI>Thouvenin G, Abou Taam R, Flamein F, et al. Characteristics of disorders associated with genetic mutations of surfactant protein C. Arch Dis Child 2010; 95:449. </LI>&#xD;&#xA;<LI>Kröner C, Reu S, Teusch V, et al. Genotype alone does not predict the clinical course of SFTPC deficiency in paediatric patients. Eur Respir J 2015; 46:197.</LI>&#xD;&#xA;<LI>Litao MK, Hayes D Jr, Chiwane S, et al. A novel surfactant protein C gene mutation associated with progressive respiratory failure in infancy. Pediatr Pulmonol 2017; 52:57.</LI>&#xD;&#xA;<LI>Doan ML, Guillerman RP, Dishop MK, et al. Clinical, radiological and pathological features of ABCA3 mutations in children. Thorax 2008; 63:366. </LI>&#xD;&#xA;<LI>Kröner C, Wittmann T, Reu S, et al. Lung disease caused by ABCA3 mutations. Thorax 2017; 72:213.</LI></OL></div><div id=\"graphicVersion\">Graphic 76026 Version 4.0</div></div></div>"},"76027":{"type":"graphic_picture","displayName":"NK cell electron microscopy","title":"NK cell electron microscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">NK cell electron microscopy</div><div class=\"cntnt\"><img style=\"width:432px; height:303px;\" src=\"images/ALLRG/76027_NK_cell_electron_micro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">NK cells (top) are distinguished from other lymphocytes by the presence of large cytoplasmic granules.</div><div class=\"graphic_footnotes\">NK: natural killer.</div><div id=\"graphicVersion\">Graphic 76027 Version 4.0</div></div></div>"},"76028":{"type":"graphic_table","displayName":"Beta-lactams against PRP","title":"Efficacy of higher concentrations of beta-lactams against penicillin-resistant pneumococci","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Efficacy of higher concentrations of beta-lactams against penicillin-resistant pneumococci</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">More effective</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Penicillins</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Penicillin, amoxicillin</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Piperacillin</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Cephalosporins</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle3_single\">Second generation</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent2\">Cefuroxime</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle3_single\">Third generation</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent2\">Cefotaxime</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent2\">Ceftriaxone</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent2\">Cefpodoxime</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle3_single\">Fourth generation</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent2\">Cefepime</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Carbapenems</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Imipenem-cilastatin</td></tr></tbody></table></td>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Less effective</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Penicillins</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Ticarcillin</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Cephalosporins</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle3_single\">First generation</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent2\">Cefazolin, cephalexin</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle3_single\">Second generation</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent2\">Cefaclor</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle3_single\">Third generation</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent2\">Ceftazidime</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent2\">Cefixime</td></tr></tbody></table></td>\n\n    </tr>\n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 76028 Version 1.0</div></div></div>"},"76029":{"type":"graphic_figure","displayName":"Hedgehog pathway","title":"Hedgehog signaling pathway in cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hedgehog signaling pathway in cancer</div><div class=\"cntnt\"><img style=\"width:433px; height:708px;\" src=\"images/ONC/76029_Hedgehog_pathway.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) In the absence of Hh ligand, Ptch1 inhibits surface localization of Smo and protein kinases phosphorylate Gli proteins, leading to an NH-terminal truncated form, which acts as a repressor of Hh target gene expression. Gli3 is the predominant repressor. Sufu also regulates the pathway by binding to Gli, both in the cytoplasm and in the nucleus, to prevent it from activating Hh target genes. Table, summary of genes implicated in cancer and potential treatment using Hh antagonists or Hh antibodies. B) Hh-mediated (Sonic, Indian, or Desert) inactivation of Ptch1 allows relocation of Smo to the tip of cilia, leading to downstream signaling events and the activation of the Gli proteins. Mutations in the pathway (*) or overexpression of the Hh ligand are highlighted (**) in (A) and (B) along with possible avenues of treatment using antibodies or small molecules (red arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Evangelista, M, Tlan, H, de Sauvage, FJ. The hedgehog signaling pathway in cancer. Clin Cancer Res 2006; 12:5924. Copyright &#169;2006 The American Association for Cancer Research.</div><div id=\"graphicVersion\">Graphic 76029 Version 1.0</div></div></div>"},"76030":{"type":"graphic_table","displayName":"R-ICE recipe","title":"Rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) chemotherapy for diffuse large B-cell lymphoma<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) chemotherapy for diffuse large B-cell lymphoma<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 14 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Rituximab</td> <td>375 mg/m<sup>2</sup> IV</td> <td>Dilute in normal saline (NS) or 5% dextrose in water (D5W) to a final concentration of 1 to 4 mg/mL. Initial infusion: Start at 50 mg/hour; escalate in 50 mg/hour increments every 30 minutes to a maximum of 400 mg/hour, as tolerated.<sup>[2]</sup> For subsequent infusions, administer 20% of the total dose over the first 30 minutes and the remaining 80% over 60 minutes, as tolerated. The 90-minute infusion schedule should NOT be used in patients who have clinically significant cardiovascular disease or have a circulating lymphocyte count &#8805;5000/mm<sup>3</sup>.</td> <td>Day minus 2 of cycle 1 (48 hours prior to initiation of cycle 1), then day 1 of cycles 1 to 3</td> </tr> <tr> <td>Ifosfamide</td> <td>5000 mg/m<sup>2</sup> continuous IV infusion</td> <td>Dilute in 0.9% sodium chloride injection or D5W to a final concentration of 0.6 to 20 mg/mL and infuse over 24 hours.</td> <td>Day 4</td> </tr> <tr> <td>Mesna*</td> <td>5000 mg/m<sup>2</sup> continuous IV infusion</td> <td>Add to ifosfamide bag and administer over 24 hours. Total concentration of mesna should not exceed 20 mg/mL.</td> <td>Day 4</td> </tr> <tr> <td>Carboplatin</td> <td>AUC<sup>&#182;</sup> = 5 mg/mL per min IV (maximum dose = 800 mg)</td> <td>Dilute in 250 mL 0.9% sodium chloride injection and administer over 30 minutes.</td> <td>Day 4</td> </tr> <tr class=\"divider_bottom\"> <td>Etoposide</td> <td>100 mg/m<sup>2</sup> IV daily</td> <td>Dilute in 500 mL 0.9% sodium chloride injection or D5W to final concentration &#60;0.4 mg/mL. Infuse over 30 to 60 minutes; if infused more rapidly, severe hypotension may occur.</td> <td>Days 3 to 5</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE (30 to 90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedicate with acetaminophen and diphenhydramine, with or without an H2 blocker, 30 minutes prior to at least the first and second infusions of rituximab.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF indicated.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Adjustment of initial etoposide and ifosfamide doses may be needed for preexisting renal or liver dysfunction.<sup>[3,4]</sup> Carboplatin dose is calculated based upon renal function; dose adjustment is not necessary for liver dysfunction.<sup>[5]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Dosing of anticancer agents in adults\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Hepatitis screening</strong></td> <td colspan=\"3\"> <ul> <li>Patients should be screened for hepatitis B and C prior to starting rituximab, and if positive, considered for hepatitis B prophylaxis. </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", \"Overview of the management of hepatitis B and case examples\", section on who should be tested and \"Hepatitis B virus reactivation associated with immunosuppressive therapy\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess basic metabolic panel (creatinine and electrolytes) daily during treatment and prior to each subsequent treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assay for liver function prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Dipstick urine for hematuria daily, on days 4 and 5. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Carriers of hepatitis B or C should be monitored for clinical and laboratory signs of active infection during and following completion of therapy. Rituximab should be discontinued if reactivation occurs. </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Delay treatment cycle until the absolute neutrophil count is &#62;1000/microL and platelet count is &#62;50,000/microL.<sup>[1]</sup> Dose reduction not indicated for intracycle hematologic toxicity. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony stimulating factors; CBC: complete blood count; GFR: glomerular filtration rate.<br />* Due to a longer half-life of ifosfamide and associated metabolites at higher doses, some references recommend continuation of mesna for 12 to 24 hours beyond completion of ifosfamide to reduce the risk of hemorrhagic cystitis. If necessary, oral mesna may be used at a dose twice that of IV mesna.<br />¶ AUC (area under the concentration × time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) × (GFR + 25). Refer to UpToDate topic on \"Dosing of anticancer agents in adults\".</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Kewalramani T, et al. Blood 2004; 103:3684.</LI>&#xD;&#xA;<LI>Rituximab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed October 23, 2012).</LI>&#xD;&#xA;<LI>Ifosfamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed October 23, 2012).</LI>&#xD;&#xA;<LI>Etoposide injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed October 23, 2012).</LI>&#xD;&#xA;<LI>Carboplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on October 23, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 76030 Version 23.0</div></div></div>"},"76031":{"type":"graphic_picture","displayName":"Duane syndrome type 1","title":"Duane syndrome of the left eye (type 1)","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Duane syndrome of the left eye (type 1)</div><div class=\"cntnt\"><img style=\"width:507px; height:349px;\" src=\"images/PEDS/76031_Duane_syndrome_type_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Notice the limitation of abduction. B) The very large up-shoot effect on attempted adduction. C) Upgaze is normal.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &#169;2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76031 Version 1.0</div></div></div>"},"76033":{"type":"graphic_picture","displayName":"Armpit stretch","title":"Armpit stretch","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Armpit stretch</div><div class=\"cntnt\"><img style=\"width:305px; height:335px;\" src=\"images/RHEUM/76033_Armpit_stretch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Use your good arm to lift the affected arm onto a shelf, a dresser, or any object about breast high. Gently bend at the knees, opening the arm pit. Try to push the arm up a little bit farther with each stretch. Perform sets of 10 to 20 stretches at each session.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 76033 Version 2.0</div></div></div>"},"76036":{"type":"graphic_table","displayName":"Causes of erythrocytosis","title":"Major causes of erythrocytosis (polycythemia)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of erythrocytosis (polycythemia)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Autonomous (inappropriate) increase of Epo - inappropriately high serum Epo</td> </tr> <tr> <td class=\"subtitle2_single\">Erythropoietin-producing neoplasms (most common)</td> </tr> <tr> <td class=\"indent1\">Renal cell carcinoma</td> </tr> <tr> <td class=\"indent1\">Hepatocellular carcinoma</td> </tr> <tr> <td class=\"indent1\">Cerebellar hemangioblastoma</td> </tr> <tr> <td class=\"indent1\">Pheochromocytoma</td> </tr> <tr> <td class=\"indent1\">Uterine fibroids</td> </tr> <tr> <td class=\"subtitle2_single\">Erythropoietin-producing renal lesions (eg, cysts, hydronephrosis, renal artery stenosis, <strong>distal renal tubular acidosis [rare]</strong>)</td> </tr> <tr> <td class=\"indent1\">Following renal transplantation (some cases are independent of erythropoietin)</td> </tr> <tr> <td class=\"subtitle1_single\">Appropriate increases in erythropoietin - appropriately high serum erythropoietin</td> </tr> <tr> <td class=\"subtitle2_single\">Hypoxemia secondary to:</td> </tr> <tr> <td class=\"indent1\">Chronic pulmonary disease</td> </tr> <tr> <td class=\"indent1\">Right-to-left cardiac shunts</td> </tr> <tr> <td class=\"indent1\">Sleep apnea</td> </tr> <tr> <td class=\"indent1\">Massive obesity (Pickwickian syndrome)</td> </tr> <tr> <td class=\"indent1\">High altitude</td> </tr> <tr> <td class=\"sublist2_start\">Red cell defects</td> </tr> <tr> <td class=\"sublist2\">Some cases of congenital methemoglobinemia</td> </tr> <tr> <td class=\"sublist2\">Chronic carbon monoxide poisoning (including heavy smoking)</td> </tr> <tr> <td class=\"sublist2\">Cobalt</td> </tr> <tr> <td class=\"subtitle1_single\">Germline and somatic mutational causes of polycythemia</td> </tr> <tr> <td class=\"indent1\">Polycythemia vera (JAK2 mutation)</td> </tr> <tr> <td class=\"indent1\">Activating mutations of the erythropoietin receptor (EPOR gene)</td> </tr> <tr> <td class=\"indent1\">Chuvash polycythemia (VHL gene mutation)</td> </tr> <tr> <td class=\"indent1\">Congenital methemoglobinemia</td> </tr> <tr> <td class=\"indent1\">Idiopathic familial polycythemia</td> </tr> <tr> <td class=\"indent1\">High oxygen affinity hemoglobins</td> </tr> <tr> <td class=\"indent1\">2,3 bisphosphoglycerate (BPG) mutase deficiency</td> </tr> <tr> <td class=\"indent1\">Other rare gene mutations (eg, PHD2, HIF2-alpha)</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous causes</td> </tr> <tr> <td class=\"indent1\">Use of androgens or anabolic steroids</td> </tr> <tr> <td class=\"indent1\">Diuretics (reduced plasma volume rather than erythrocytosis)</td> </tr> <tr> <td class=\"indent1\">Blood doping in athletes (ie, autologous blood transfusion)</td> </tr> <tr> <td class=\"indent1\">Self-injection of erythropoietin</td> </tr> <tr> <td class=\"indent1\">POEMS syndrome</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76036 Version 9.0</div></div></div>"},"76037":{"type":"graphic_table","displayName":"Survival cervical adenocarcinoma versus SCC","title":"Comparison of survival for cervical adenocarcinoma and squamous cell carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of survival for cervical adenocarcinoma and squamous cell carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Author, year<sup>[ref]</sup></td> <td class=\"subtitle1\" rowspan=\"2\">Number of patients (n)</td> <td class=\"subtitle1\" rowspan=\"2\">Treatment</td> <td class=\"subtitle1\" rowspan=\"2\">Stage</td> <td class=\"subtitle1\" colspan=\"2\">5-year survival (percent)</td> <td class=\"subtitle1\" rowspan=\"2\">p-Value</td> </tr> <tr> <td class=\"subtitle2\">AC</td> <td class=\"subtitle2\">SCC</td> </tr> <tr> <td rowspan=\"3\">Hopkins et al, 1991<sup>[1]</sup></td> <td rowspan=\"3\">959 (203 AC, 756 SCC)</td> <td rowspan=\"3\">Pelvic RT +/- radical hysterectomy, pelvic, and PA nodes for stage IB</td> <td>I</td> <td>60</td> <td>90</td> <td>&#60;0.0001</td> </tr> <tr> <td>II</td> <td>47</td> <td>62</td> <td>0.01</td> </tr> <tr> <td>III</td> <td>8</td> <td>36</td> <td>0.002</td> </tr> <tr class=\"divider_top\"> <td>Eifel et al, 1995<sup>[2]</sup></td> <td>1767 (229 AC, 1538 SCC)</td> <td>Pelvic RT +/- extrafascial hysterectomy</td> <td>IB</td> <td>72</td> <td>82</td> <td>&#60;0.01</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Chen et al, 1999<sup>[3]</sup></td> <td rowspan=\"5\">3678 (302 AC, 3376 SCC)</td> <td rowspan=\"2\">Stage IB-IIA: radical hysterectomy, pelvic nodes or RT</td> <td>Overall</td> <td>67</td> <td>81</td> <td>0.0009</td> </tr> <tr> <td>I</td> <td>76</td> <td>81</td> <td>0.0039</td> </tr> <tr> <td rowspan=\"3\">Stage IIB-IV: RT +/- CT</td> <td>II</td> <td>63</td> <td>75</td> <td>0.0103</td> </tr> <tr> <td>III</td> <td>29</td> <td>42</td> <td>&nbsp;</td> </tr> <tr> <td>IV</td> <td>0</td> <td>26</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td>Lai et al, 1999<sup>[4]</sup></td> <td>891 (134 AC, 757 SCC)</td> <td>Radical hysterectomy, pelvic nodes +/- adjuvant RT</td> <td>IB &#38; II</td> <td>74</td> <td>83</td> <td>0.0136</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Irie et al, 2000<sup>[5]</sup></td> <td rowspan=\"3\">255 (57 AC, 198 SCC)</td> <td rowspan=\"3\">Radical hysterectomy, pelvic nodes +/- adjuvant RT</td> <td>Overall</td> <td>78</td> <td>92</td> <td>0.0034</td> </tr> <tr> <td>IB</td> <td>96</td> <td>94</td> <td>NS</td> </tr> <tr> <td>II</td> <td>61</td> <td>90</td> <td>0.0007</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AC: adenocarcinoma; SCC: squamous cell carcinoma; RT: radiation therapy; CT: chemotherapy; PA: para-aortic; NS: not significant; ref: reference.</div><div class=\"graphic_reference\">References:<br> <ol> <li>Hopkins MP, Morley GW. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol 1991; 77:912. </li> <li>Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage 1B cervical carcinoma. Gynecol Oncol 1995; 59:38. </li> <li>Chen RJ, Lin YH, Chen CA, et al. Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan. Gynecol Oncol 1999; 73:184. </li> <li>Lai CH, Hsueh S, Hong JH, et al. Are adenocarcinomas and adenosquamous carcinomas different from squamous carcinomas in stage IB and II cervical cancer patients undergoing primary radical surgery? Int J Gynecol Cancer 1999; 9:28. </li> <li>Irie T, Kigawa J, Minagawa Y, et al. Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy. Eur J Surg Oncol 2000; 26:464. </li> </ol> <br> Reproduced from: Gien LT, Beauchemin MC, Thomas G. Adenocarcinoma: a unique cervical cancer. Gynecol Oncol 2010; 116:140. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 76037 Version 1.0</div></div></div>"},"76038":{"type":"graphic_figure","displayName":"Pelvic fractures","title":"Pelvic fractures","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Pelvic fractures</div><div class=\"cntnt\"><img style=\"width:514px; height:167px;\" src=\"images/SURG/76038_Unstable_pelvic_fx_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Rotationally unstable fracture. The symphysis pubis is separated and the anterior sacroiliac, sacrotuberous, and sacrospinous ligaments are disrupted.<br> (B) Vertically unstable fracture. The hemipelvis is displaced anteriorly and posteriorly through the symphysis pubis, and the sacroiliac joint ligaments are disrupted.<br> (C) Non-displaced fracture of the acetabulum.</div><div class=\"graphic_reference\">Reproduced with permission from: Smeltzer S, Bare B. Brunner and Suddarth's Textbook of Medical-Surgical Nursing, Ninth Edition. Philadelphia: Lippincott Williams &amp; Wilkins. Copyright &#169; 2000 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76038 Version 1.0</div></div></div>"},"76039":{"type":"graphic_figure","displayName":"Urethral anatomy","title":"Urethral anatomy","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Urethral anatomy</div><div class=\"cntnt\"><img style=\"width:539px; height:498px;\" src=\"images/SURG/76039_Urethral-anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The male urethra is divided into two major segments, the anterior urethra and the posterior urethra. From proximal to distal, the urethra is initially eccentrically placed toward the dorsum of the penis, becoming centrally located at the fossa navicularis. &#xD;&#xA;<UL>&#xD;&#xA;<LI>The anterior urethra begins at the meatus of the penis and includes the fossa navicularis, the pendulous urethra, and the bulbar urethra. The pendulous urethra is delineated from the bulbar urethra at the suspensory ligament of the penis. </LI>&#xD;&#xA;<LI>The posterior urethra includes the membranous urethra, the prostatic urethra, and the bladder neck. </LI></UL></div><div id=\"graphicVersion\">Graphic 76039 Version 3.0</div></div></div>"},"76040":{"type":"graphic_picture","displayName":"C3 glomerulonephritis IF","title":"Immunofluorescence microscopy in C3 glomerulonephritis","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Immunofluorescence microscopy in C3 glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:560px; height:463px;\" src=\"images/NEPH/76040_Immunofluoresce_C3_glom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence microscopy showing bright granular C3 staining on the mesangium and along capillary walls in a patient with C3 glomerulonephritis (40x).</div><div class=\"graphic_reference\">Provided by Dr. Sanjeev Sethi, Department of Laboratory Medicine and Pathology, Mayo Clinic.</div><div id=\"graphicVersion\">Graphic 76040 Version 4.0</div></div></div>"},"76041":{"type":"graphic_table","displayName":"NHLBI panel screening guidelines for pediatric dyslipidemia","title":"Pediatric dyslipidemia screening guidelines from the 2011 Expert Panel Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric dyslipidemia screening guidelines from the 2011 Expert Panel Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Birth to 2 years</td> </tr> <tr> <td>No lipid screening.</td> </tr> <tr> <td class=\"subtitle1_single\">2 to 8 years</td> </tr> <tr> <td>Selective screening using FLP two times*, based on a positive history of one of the following: <ul> <li>Parent, grandparent, aunt/uncle, or sibling with&nbsp;CHD (ie, myocardial infarction, angina, stroke, coronary artery bypass graft/stent/angioplasty) at &#60;55 years in males, &#60;65 years in females </li> <li>Parent with TC &#8805;240 mg/dL or known dyslipidemia </li> <li>Patient has diabetes, hypertension, BMI &#8805;95th percentile, or smokes cigarettes or is exposed to secondhand smoke </li> <li>Patient has a moderate- or high-risk medical condition associated with cardiovascular disease (ie, chronic kidney disease, recipient of a cardiac transplant, Kawasaki disease with current or regressed coronary artery disease, or chronic inflammatory disease) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">9 to 11 years</td> </tr> <tr> <td> <p>Universal screening with a nonfasting lipid screening using non-HDL cholesterol&nbsp;levels. </p> <p>Further evaluation (two FLP measurements*)&nbsp;is recommended with a positive result of either a nonfasting non-HDL cholesterol&nbsp;level &#8805;145 mg/dL, and HDL &#60;40 mg/dL, or a FLP with LDL cholesterol&nbsp;&#8805;130 mg/dL, non-HDL cholesterol&nbsp;&#8805;145 mg/dL, HDL cholesterol&nbsp;&#60;40 mg/dL, or TG &#8805;130 mg/dL.</p> </td> </tr> <tr> <td class=\"subtitle1_single\">12 to 16 years</td> </tr> <tr> <td>Universal screening <strong>not</strong> recommended because of normal changes in lipid levels during puberty, which decrease the sensitivity and specificity for predicting adult LDL cholesterol&nbsp;levels and increase false-negative results in this age group.</td> </tr> <tr> <td>Selective screening using FLP two times*, if new knowledge of one of the following: <ul> <li>Family history of&nbsp;CHD (ie, parent, grandparent, or aunt/uncle) </li> <li>Parent with TC &#8805;240 mg/dL or known dyslipidemia </li> <li>Patient has diabetes, hypertension, BMI &#8805;85th percentile, or smokes cigarettes </li> <li>Patient has a moderate- or high-risk medical condition associated with cardiovascular disease (ie, chronic kidney disease, recipient of a cardiac transplant, Kawasaki disease with current or regressed coronary artery disease, or chronic inflammatory disease) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">17 to 21 years</td> </tr> <tr> <td> <p>Universal screening once during this time period with a nonfasting lipid screening using non-HDL cholesterol&nbsp;levels.</p> <p>Further evaluation (two FLP measurements*) is recommended with a positive result of either a nonfasting non-HDL cholesterol&nbsp;level &#8805;145 mg/dL, and HDL &#60;40 mg/dL, or a FLP with LDL cholesterol&nbsp;&#8805;130 mg/dL, non-HDL cholesterol&nbsp;&#8805;145 mg/dL, HDL cholesterol&nbsp;&#60;40 mg/dL, or TG &#8805;130 mg/dL.</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NHLBI: National Heart, Lung, and Blood Institute; FLP: fasting lipid profile; CHD: coronary heart disease; BMI: body mass index; TC: total cholesterol; LDL: low-density lipoprotein; HDL: high-density lipoprotein; TG: triglycerides.<br />* Interval between FLP measurements: after&nbsp;two weeks, but within&nbsp;three months.</div><div class=\"graphic_reference\">Reproduced from: Daniels SR, Benuck I, Christakis DA, et al. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Full report, 2011. National Heart Lung and Blood Institute. Available at: <a href=\"http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>.</div><div id=\"graphicVersion\">Graphic 76041 Version 7.0</div></div></div>"},"76042":{"type":"graphic_picture","displayName":"Crohn disease capsule endoscopy","title":"Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crohn disease</div><div class=\"cntnt\"><img style=\"width:288px; height:288px;\" src=\"images/GAST/76042_Crohns_disease_capsule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small bowel ulceration as seen during capsule endoscopy.</div><div class=\"graphic_reference\">Courtesy of Given Imaging, Inc.</div><div id=\"graphicVersion\">Graphic 76042 Version 3.0</div></div></div>"},"76045":{"type":"graphic_table","displayName":"Drug and toxin associated odors","title":"Drug- and toxin-associated odors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug- and toxin-associated odors</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Odor</td>\n\n      <td class=\"subtitle1\">Agent(s)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acetone (fruity)</td>\n\n      <td>Ethanol, isopropyl alcohol, chloroform, salicylates</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bitter almonds</td>\n\n      <td>Cyanide</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Garlic</td>\n\n      <td>Arsenic, organophosphates, phosphorus, thallium, selenium</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mothballs</td>\n\n      <td>Naphthalene, paradichlorobenzene</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Kerosene (petroleum distillate)</td>\n\n      <td>Organophosphates, parathion</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Freshly mown hay</td>\n\n      <td>Phosgene</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Rotten eggs</td>\n\n      <td>Hydrogen sulfide</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Wintergreen</td>\n\n      <td>Methyl salicylate</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 76045 Version 3.0</div></div></div>"},"76046":{"type":"graphic_table","displayName":"Sarcoid organ involvement","title":"Number and percentage of patients with specified organ involvement","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Number and percentage of patients with specified organ involvement</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Organ involvement</td> <td class=\"subtitle1\">Number*</td> <td class=\"subtitle1\">Percent</td> </tr> <tr> <td>Lungs</td> <td>699</td> <td>95</td> </tr> <tr> <td>Skin<sup>&#182;</sup></td> <td>117</td> <td>15.9</td> </tr> <tr> <td>Lymph node</td> <td>112</td> <td>15.2</td> </tr> <tr> <td>Eye</td> <td>87</td> <td>11.8</td> </tr> <tr> <td>Liver</td> <td>85</td> <td>11.5</td> </tr> <tr> <td>Erythema nodosum</td> <td>61</td> <td>8.3</td> </tr> <tr> <td>Spleen</td> <td>49</td> <td>6.7</td> </tr> <tr> <td>Neurologic</td> <td>34</td> <td>4.6</td> </tr> <tr> <td>Parotid/salivary</td> <td>29</td> <td>3.9</td> </tr> <tr> <td>Bone marrow</td> <td>29</td> <td>3.9</td> </tr> <tr> <td>Calcium</td> <td>27</td> <td>3.7</td> </tr> <tr> <td>ENT</td> <td>22</td> <td>3</td> </tr> <tr> <td>Cardiac</td> <td>17</td> <td>2.3</td> </tr> <tr> <td>Renal</td> <td>5</td> <td>0.7</td> </tr> <tr> <td>Bone/joint</td> <td>4</td> <td>0.5</td> </tr> <tr> <td>Muscle</td> <td>3</td> <td>0.4</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ENT: ear, nose, and throat.<br />* Total n = 736.<br />¶ Excluding erythema nodosum.</div><div class=\"graphic_reference\">Reproduced with permission from: Baughman, RP, Teirstein, AS, Judson, MA, et al. Clinical characteristics of patients in case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885. Official Journal of the American Thoracic Society. Copyright &copy; 2001 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 76046 Version 3.0</div></div></div>"},"76047":{"type":"graphic_table","displayName":"Algorithm dx UCTD","title":"Algorithm for diagnosis of undifferentiated connective tissue diseases (UCTDs)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Algorithm for diagnosis of undifferentiated connective tissue diseases (UCTDs)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td colspan=\"4\"> <ul> <li>First, rule out osteoarthritis, bursitis/tendinitis and myofascial pain syndromes.</li> </ul> </td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\"> <ul> <li>Does the patient have clinical evidence for any of the following problems?</li> </ul> </td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">Persistent arthritis</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">Episodic arthritis</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">Muscle pain/weakness</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">Raynaud's phenomenon</td> </tr> <tr> <td colspan=\"4\"> <ul> <li>If \"NO,\" consider a diagnosis of possible fibromyalgia and follow.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul> <li>If \"YES,\" look for clinical, serological and other evidence for:</li> </ul> </td> </tr> <tr> <td class=\"subtitle1\">Persistent arthritis</td> <td class=\"subtitle1\">Episodic arthritis</td> <td class=\"subtitle1\">Muscle pain/weakness</td> <td class=\"subtitle1\">Raynaud's phenomenon</td> </tr> <tr> <td>Rheumatoid arthritis</td> <td>Gout</td> <td>Inflammatory myositis</td> <td>Primary Raynaud's (benign)</td> </tr> <tr> <td>Psoriatic arthritis</td> <td>Pseudogout</td> <td>Vasculitis</td> <td>Scleroderma/MCTD/SLE</td> </tr> <tr> <td>Reactive arthritis</td> <td>Viral arthritis</td> <td>Metabolic myopathy</td> <td>CREST</td> </tr> <tr> <td>Rheumatic fever</td> <td>Palindromic rheumatism</td> <td>Drug reaction (eg, statins)</td> <td>Myositis overlap</td> </tr> <tr> <td>SLE/MCTD</td> <td>Serum sickness</td> <td>Hypothyroidism</td> <td>Takayasu arteritis</td> </tr> <tr> <td>Drug-induced lupus</td> <td>Reactive arthritis</td> <td>Acromegaly</td> <td>Vasculitis</td> </tr> <tr> <td>Enteropathic arthritis</td> <td>Bacterial endocarditis</td> <td>Viral infection</td> <td>Thoracic outlet syndrome</td> </tr> <tr> <td>Ankylosing spondylitis</td> <td>Lyme disease</td> <td>Overuse syndrome</td> <td>Antiphospholipid syndrome</td> </tr> <tr> <td>Tophaceous gout</td> <td>Beh&#231;et's disease</td> <td>Osteomalacia</td> <td>Thromboangiitis obliterans</td> </tr> <tr> <td>Lyme disease</td> <td>Relapsing polychondritis</td> <td>Sarcoidosis</td> <td>Atheroembolic disease</td> </tr> <tr> <td>Acromegaly</td> <td>Sarcoidosis</td> <td>Polymyalgia rheumatica</td> <td>Cryoglobulinemia</td> </tr> <tr> <td>Hemochromatosis</td> <td>Sj&#246;gren's syndrome</td> <td>Sj&#246;gren's syndrome</td> <td>Bacterial endocarditis</td> </tr> <tr> <td>Sarcoidosis</td> <td>Malignancy</td> <td>Peripheral neuropathies</td> <td>Polycythemia vera</td> </tr> <tr> <td>Whipple's disease</td> <td rowspan=\"3\">&nbsp;</td> <td>Hyperparathyroidism</td> <td>Medication-induced*</td> </tr> <tr> <td>Polymyalgia rheumatica</td> <td rowspan=\"2\">&nbsp;</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td>Malignancy</td> </tr> <tr> <td colspan=\"4\"> <ul> <li>If a specific diagnosis can be made, manage as per contemporary treatment guidelines.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul> <li>If no specific diagnosis can be made, consider a diagnosis of a UCTD or overlap syndrome.</li> </ul> </td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\"> <ul> <li>Are any of the following features present?</li> </ul> </td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Clinical features</td> <td class=\"subtitle1\" colspan=\"2\">Autoantibodies</td> </tr> <tr> <td colspan=\"2\">Raynaud's phenomenon</td> <td colspan=\"2\">UI-RNP</td> </tr> <tr> <td colspan=\"2\">Proximal sclerodactyly</td> <td colspan=\"2\">U2-RNP</td> </tr> <tr> <td colspan=\"2\">Interstitial lung disease</td> <td colspan=\"2\">Fibrillarin</td> </tr> <tr> <td colspan=\"2\">Esophageal hypomotility</td> <td colspan=\"2\">Synthetases</td> </tr> <tr> <td colspan=\"2\">Trigeminal neuropathy</td> <td colspan=\"2\">PM/Scl</td> </tr> <tr> <td colspan=\"2\">Puffy hands</td> <td colspan=\"2\">RNA polymerases</td> </tr> <tr> <td rowspan=\"3\" colspan=\"2\">&nbsp;</td> <td colspan=\"2\">SRP</td> </tr> <tr> <td colspan=\"2\">Ku</td> </tr> <tr> <td colspan=\"2\">Th</td> </tr> <tr> <td colspan=\"4\"> <ul> <li>If \"YES,\" follow up as a potential overlap syndrome. If patient has Raynaud's phenomenon and systemic involvement in conjunction with persistent U1-RNP antibodies, the most likely diagnosis will turn out to be MCTD.</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SLE: systemic lupus erythematosus; MCTD: mixed connective tissue disease; CREST: calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia; UCTD: undifferentiated connective tissue disease.<br />* Drugs associated with Raynaud's phenomenon: Beta blockers, amphetamines, nicotine, bleomycin, vinblastine, clonidine, cisplatin, cocaine, cyclosporine, ergot, methysergide and vinyl chloride.</div><div class=\"graphic_reference\">Original figure modified for this publication. Bennett RM. Overlap Syndromes. Textbook of Rheumatology, 8th Edition, W.B. Saunders Co., Philadelphia 2009. Illustration used with the permission of Elsevier, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 76047 Version 4.0</div></div></div>"},"76048":{"type":"graphic_picture","displayName":"Corn - fifth toe","title":"Corn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Corn</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/76048_Corn_fifth_toe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A hyperkeratotic papule with a central &quot;core&quot; is present on the lateral fifth toe.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76048 Version 4.0</div></div></div>"},"76049":{"type":"graphic_table","displayName":"Chromosomal locations of T cell receptor genes","title":"Chromosomal locations of T cell receptor genes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chromosomal locations of T cell receptor genes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Locus </td> <td class=\"subtitle1\">Chromosome </td> </tr> <tr> <td>Alpha, delta</td> <td>14q11</td> </tr> <tr> <td>Beta</td> <td>7q35</td> </tr> <tr> <td>Gamma</td> <td>7p15</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76049 Version 3.0</div></div></div>"},"76051":{"type":"graphic_picture","displayName":"Chronic progressive external ophthalmoplegia","title":"Chronic progressive external ophthalmoplegia","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Chronic progressive external ophthalmoplegia</div><div class=\"cntnt\"><img style=\"width:584px; height:379px;\" src=\"images/NEURO/76051_Chrn_ext_ophthalmopleg_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient has profound ptosis and ophthalmoplegia in all directions of gaze.</div><div class=\"graphic_reference\">Courtesy of Michael S Lee, MD.</div><div id=\"graphicVersion\">Graphic 76051 Version 6.0</div></div></div>"},"76055":{"type":"graphic_figure","displayName":"Landmarks diagnosis Barretts","title":"Anatomic landmarks for the diagnosis of Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Anatomic landmarks for the diagnosis of Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:516px; height:433px;\" src=\"images/GAST/76055_GEJ_Z_separate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The squamocolumnar junction (SCJ or Z-line) is the visible line formed by the juxtaposition of squamous and columnar epithelia. The gastroesophageal junction (GEJ) is the imaginary line at which the esophagus ends and the stomach begins. The GEJ corresponds to the most proximal extent of the gastric folds. When the SCJ is located proximal to the GEJ, there is a columnar-lined segment of esophagus.</div><div class=\"graphic_reference\">Modified from: Spechler SJ. The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction. Gastroenterology 1999; 117:218.</div><div id=\"graphicVersion\">Graphic 76055 Version 8.0</div></div></div>"},"76058":{"type":"graphic_diagnosticimage","displayName":"Xray of distal clavicle fracture Type I","title":"Xray of distal clavicle fracture Type I","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Xray of distal clavicle fracture Type I</div><div class=\"cntnt\"><img style=\"width:432px; height:310px;\" src=\"images/EM/76058_Clav_fx_distal_type1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain radiograph shows a type I fracture of the distal clavicle with mild angulation. Intact ligaments hold the proximal fragment in normal position.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 76058 Version 2.0</div></div></div>"},"76059":{"type":"graphic_picture","displayName":"Finger volar splint","title":"Finger volar splint","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Finger volar splint</div><div class=\"cntnt\"><img style=\"width:468px; height:303px;\" src=\"images/EM/76059_Finger_volar_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 76059 Version 1.0</div></div></div>"},"76060":{"type":"graphic_table","displayName":"ADA DKA HHS water deficit","title":"Typical total body deficits of water and electrolytes in diabetic ketoacidosis and hyperosmolar hyperglycemic state*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical total body deficits of water and electrolytes in diabetic ketoacidosis and hyperosmolar hyperglycemic state*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">DKA</td> <td class=\"subtitle1\">HHS</td> </tr> <tr> <td><strong>Total water (L)</strong></td> <td>6</td> <td>9</td> </tr> <tr> <td><strong>Water (mL/kg<sup>&#182;</sup>)</strong></td> <td>100</td> <td>100&nbsp;to 200</td> </tr> <tr> <td><strong>Na+ (mEq/kg)</strong></td> <td>7 to 10</td> <td>5 to 13</td> </tr> <tr> <td><strong>Cl&ndash; (mEq/kg)</strong></td> <td>3 to 5</td> <td>5 to 15</td> </tr> <tr> <td><strong>K+ (mEq/kg)</strong></td> <td>3 to 5</td> <td>4 to 6</td> </tr> <tr> <td><strong>PO4 (mmol/kg)</strong></td> <td>5 to 7</td> <td>3 to 7</td> </tr> <tr> <td><strong>Mg++ (mEq/kg)</strong></td> <td>1 to 2</td> <td>1 to 2</td> </tr> <tr> <td><strong>Ca++ (mEq/kg)</strong></td> <td>1 to 2</td> <td>1 to 2</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Data are from Ennis et al (1994) and Kreisberg (1978).<br />¶ Per kilogram of body weight.</div><div class=\"graphic_reference\">Copyright &copy; 2006 American Diabetes Association From Diabetes Care Vol 29, Issue 12, 2006. Reprinted with permission from the American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 76060 Version 4.0</div></div></div>"},"76062":{"type":"graphic_diagnosticimage","displayName":"Actinomycosis CT","title":"Actinomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Actinomycosis</div><div class=\"cntnt\"><img style=\"width:368px; height:278px;\" src=\"images/GAST/76062_Actinomycosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed&nbsp;tomography (CT)&nbsp;of actinomycosis showing an ill-defined, heterogenous mass in the right lower quadrant. The streaks (arrowhead) inside the mass are composed of angulated tethering cords radiating from the core.</div><div class=\"graphic_reference\">Reproduced with permission from Yang SH, et al. Colonoscopy in abdominal actinomycosis. Gastrointest Endosc 2000; 51:236. Copyright © 2000 Mosby, Inc.</div><div id=\"graphicVersion\">Graphic 76062 Version 4.0</div></div></div>"},"76063":{"type":"graphic_table","displayName":"Causes of anal pruritus","title":"Causes of anal pruritus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of anal pruritus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Fecal soilage due to: </td> </tr> <tr> <td>Diarrhea or poorly formed stools of any cause</td> </tr> <tr> <td>Transient internal relaxation of the internal anal sphincter</td> </tr> <tr> <td>Poor hygiene</td> </tr> <tr> <td>Anatomic abnormalities making cleansing difficult (eg, prolapsed internal hemorrhoids, large external hemorrhoids)</td> </tr> <tr> <td class=\"subtitle1_single\">Dietary irritants </td> </tr> <tr> <td>Coffee</td> </tr> <tr> <td>Cola</td> </tr> <tr> <td>Beer</td> </tr> <tr> <td>Tomatoes</td> </tr> <tr> <td>Chocolate</td> </tr> <tr> <td>Tea</td> </tr> <tr> <td>Citrus fruits</td> </tr> <tr> <td class=\"subtitle1_single\">Anorectal diseases </td> </tr> <tr> <td>Abscesses</td> </tr> <tr> <td>Fissures</td> </tr> <tr> <td>Fistulas</td> </tr> <tr> <td>Malignancies (eg, squamous cell cancer)</td> </tr> <tr> <td class=\"subtitle1_single\">Dermatologic diseases </td> </tr> <tr> <td>Psoriasis</td> </tr> <tr> <td>Contact dermatitis</td> </tr> <tr> <td>Atopic dermatitis</td> </tr> <tr> <td>Hidradenitis suppurativa</td> </tr> <tr> <td>Paget's disease</td> </tr> <tr> <td class=\"subtitle1_single\">Infections </td> </tr> <tr> <td>Sexually transmitted diseases (condyloma, herpes, syphilis, gonorrhea)</td> </tr> <tr> <td>Bacterial infections (<em>Staphylococcus aureus</em>)</td> </tr> <tr> <td>Parasites (Pinworm, scabies)</td> </tr> <tr> <td>Fungal infections (particularly <em>Candida</em>)</td> </tr> <tr> <td class=\"subtitle1_single\">Psychological causes </td> </tr> <tr> <td class=\"subtitle1_single\">Other </td> </tr> <tr> <td>Chemotherapy</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76063 Version 2.0</div></div></div>"},"76064":{"type":"graphic_diagnosticimage","displayName":"Normal prostate on ultrasound","title":"Transverse view of normal prostate on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse view of normal prostate on ultrasound</div><div class=\"cntnt\"><img style=\"width:432px; height:297px;\" src=\"images/SURG/76064_Normal_prostate_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of RN Alheid.</div><div id=\"graphicVersion\">Graphic 76064 Version 2.0</div></div></div>"},"76065":{"type":"graphic_diagnosticimage","displayName":"Mallet finger with distal interphalangeal joint subluxation","title":"Mallet finger with distal interphalangeal joint subluxation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mallet finger with distal interphalangeal joint subluxation</div><div class=\"cntnt\"><img style=\"width:190px; height:396px;\" src=\"images/SURG/76065_Mallet_finger_DPIJ_sublux.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mallet fractures result from sudden forced flexion of an extended distal interphalangeal (DIP) joint, resulting in avulsion of the attachment of the extensor tendon. If subluxation of the DIP joint&nbsp;is present as shown here, the patient may need open reduction and should be referred to a hand surgeon within two to three days.</div><div id=\"graphicVersion\">Graphic 76065 Version 6.0</div></div></div>"},"76066":{"type":"graphic_figure","displayName":"Flow fraction and solute saturation","title":"Flow fraction and solute saturation in hemodialysis","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Flow fraction and solute saturation in hemodialysis</div><div class=\"cntnt\"><img style=\"width:534px; height:380px;\" src=\"images/NEPH/76066_Fall_urea_saturation.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data reproduced with permission from: NxStage Medical, Inc. Copyright &#169; 2012.</div><div id=\"graphicVersion\">Graphic 76066 Version 4.0</div></div></div>"},"76067":{"type":"graphic_picture","displayName":"Tinea pedis interdigital maceration","title":"Tinea pedis with interdigital maceration","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tinea pedis with interdigital maceration</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/76067_Tinea_pedis_interdig_macer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema and white, macerated skin between the toes in a patient with tinea pedis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" style=\"font-style: italic;\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76067 Version 6.0</div></div></div>"},"76068":{"type":"graphic_figure","displayName":"Survival stenting in diabetes","title":"Diabetics undergoing stenting have lower event-free survival","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diabetics undergoing stenting have lower event-free survival</div><div class=\"cntnt\"><img style=\"width:409px; height:283px;\" src=\"images/CARD/76068_Survival_stenting_in_diabet.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Compared to nondiabetic patients receiving a stent, diabetic patients undergoing stent placement have a lower one-year survival free of death, myocardial infarction, and target lesion revascularization (79 versus 73 percent, p &lt;0.001).</div><div class=\"graphic_reference\">Data from Elezi J, Kastrati A, Pachi S, et al. J Am Coll Cardiol 1998; 32:1866.</div><div id=\"graphicVersion\">Graphic 76068 Version 3.0</div></div></div>"},"76069":{"type":"graphic_picture","displayName":"Miliaria crystallina vesicles","title":"Miliaria crystallina","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Miliaria crystallina</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/76069_Miliaria_crystallina_vesicle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple&nbsp;small vesicles on the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76069 Version 2.0</div></div></div>"},"76071":{"type":"graphic_table","displayName":"Clinical manifestations of relapsing polychondritis","title":"Clinical manifestations of relapsing polychondritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of relapsing polychondritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical manifestation</td> <td class=\"subtitle1\"> <p>Present at disease onset</p> (percentage)</td> <td class=\"subtitle1\"> <p>Cumulative presence over disease course</p> (percentage)</td> </tr> <tr> <td>Auricular chondritis</td> <td>43</td> <td>89</td> </tr> <tr> <td>Arthritis</td> <td>32</td> <td>72</td> </tr> <tr> <td>Nasal chondritis</td> <td>21</td> <td>61</td> </tr> <tr> <td>Ocular inflammation</td> <td>18</td> <td>59</td> </tr> <tr> <td>Laryngotracheal symptoms</td> <td>23</td> <td>55</td> </tr> <tr> <td>Reduced hearing</td> <td>7</td> <td>40</td> </tr> <tr> <td class=\"sublist1_start\">Vestibular dysfunction*</td> <td>4</td> <td>28</td> </tr> <tr> <td class=\"sublist1_start\">Microhematuria<sup>&#182;</sup></td> <td class=\"sublist_other_start\">15</td> <td class=\"sublist_other_start\">26</td> </tr> <tr> <td class=\"sublist1_start\">Saddle nose*</td> <td class=\"sublist_other_start\">11</td> <td class=\"sublist_other_start\">25</td> </tr> <tr> <td class=\"sublist1_start\">Cutaneous*</td> <td class=\"sublist_other_start\">4</td> <td class=\"sublist_other_start\">25</td> </tr> <tr> <td class=\"sublist1_start\">Laryngotracheal stricture<sup>&#182;</sup></td> <td class=\"sublist_other_start\">15</td> <td class=\"sublist_other_start\">23</td> </tr> <tr> <td>Vasculitis*</td> <td>2</td> <td>14</td> </tr> <tr> <td>Elevated creatinine<sup>&#182;</sup></td> <td>7</td> <td>13</td> </tr> <tr> <td>Aortic or mitral regurgitation*</td> <td>0</td> <td>12</td> </tr> <tr> <td>Aneurysm<sup>&#182;</sup></td> <td>0</td> <td>4</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Data derived from three large case series and reviews, totaling 337 patients<SUP>[1-3]</SUP>.</div><div class=\"graphic_footnotes\">* Data incomplete or not reported in the study by McAdam et al<SUP>[1]</SUP>.<br />¶ Data only from the study by Michet et al<SUP>[2]</SUP>.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>McAdam LP, O'Hanlan MA, Bluestone R, et al. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore) 1976; 55:193.</LI>&#xD;&#xA;<LI>Michet CJ Jr, McKenna CH, Luthra HS, et al. Relapsing polychondritis: Survival and predictive role of early disease manifestations. Ann Intern Med 1986; 104:74.</LI>&#xD;&#xA;<LI>Trentham DE, Le CH. Relapsing polychondritis. Ann Intern Med 1998; 129:114.</LI></OL>Reproduced with permission from: Kent PD, Michet CJ, Luthra HS. Relapsing polychondritis. Curr Opin Rheumatol 2004; 16:56. Copyright © 2004 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 76071 Version 7.0</div></div></div>"},"76072":{"type":"graphic_picture","displayName":"Giant papillary conjunctivitis in contact lens wearer","title":"Giant papillary conjunctivitis on the upper tarsal conjunctiva","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Giant papillary conjunctivitis on the upper tarsal conjunctiva</div><div class=\"cntnt\"><img style=\"width:392px; height:260px;\" src=\"images/RHEUM/76072_GPC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Giant papillary conjunctivitis (GPC) formation on the upper tarsal conjunctiva of a patient from contact lens overwear. GPC can also be due to other prostheses or foreign objects, such as sutures, that abrade the surface of the conjunctiva.</div><div id=\"graphicVersion\">Graphic 76072 Version 2.0</div></div></div>"},"76073":{"type":"graphic_picture","displayName":"Laparoscopic vascular stapler","title":"Laparoscopic vascular stapler","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic vascular stapler</div><div class=\"cntnt\"><img style=\"width:319px; height:237px;\" src=\"images/SURG/76073_Vasc_stapler.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic vascular stapler applied to splenic artery proximal to splenic artery aneurysm.</div><div class=\"graphic_reference\">Courtesy of Jon Gould, MD</div><div id=\"graphicVersion\">Graphic 76073 Version 2.0</div></div></div>"},"76074":{"type":"graphic_figure","displayName":"Alternative port placement for appendectomy","title":"Alternative port placement for appendectomy*","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Alternative port placement for appendectomy*</div><div class=\"cntnt\"><img style=\"width:457px; height:587px;\" src=\"images/SURG/76074_Alternative_port_lap_appy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An open technique is used to enter the peritoneal cavity and place a 5 to 12 mm Hasson trocar at the umbilicus. The laparoscope is introduced through this port and two additional 5 mm ports are placed. As an alternative, the two 5 mm ports can be placed in the &quot;bikini line&quot;. The surgeon retracts the appendix using a grasper through a right lower quadrant port and dissects using the periumbilical port site (portrayed in red) while the assistant operates the laparoscope through a left lower quadrant port (portrayed in blue). The appendix is removed in a bag through the umbilical port.</div><div class=\"graphic_footnotes\">* Port placement and technique may vary amongst laparoscopic surgeons.</div><div id=\"graphicVersion\">Graphic 76074 Version 4.0</div></div></div>"},"76075":{"type":"graphic_figure","displayName":"Cutaneous sensory distribution of the ulnar nerve","title":"Cutaneous sensory distribution of the ulnar nerve","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Cutaneous sensory distribution of the ulnar nerve</div><div class=\"cntnt\"><img style=\"width:527px; height:343px;\" src=\"images/NEURO/76075_Cut_sens_dist_ulnar_ner_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This illustration show the cutaneous sensory distribution of the three major branches of the ulnar nerve.</div><div id=\"graphicVersion\">Graphic 76075 Version 3.0</div></div></div>"},"76077":{"type":"graphic_diagnosticimage","displayName":"Small field RT portal seminoma","title":"Limited or small field radiation portal for seminoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Limited or small field radiation portal for seminoma</div><div class=\"cntnt\"><img style=\"width:357px; height:334px;\" src=\"images/ONC/76077_Small_field_RT_portal_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small field or para-aortic lymph node (PALN)-only radiation therapy field for stage I seminoma.</div><div class=\"graphic_reference\">Courtesy of Clair Beard, MD.</div><div id=\"graphicVersion\">Graphic 76077 Version 5.0</div></div></div>"},"76078":{"type":"graphic_table","displayName":"WHO classification anal cancer","title":"WHO classification of anal cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO classification of anal cancer</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Anal canal</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Squamous cell (cloacogenic) carcinoma</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Large cell keratinizing</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Large cell nonkeratinizing (transitional) </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Basaloid</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Adenocarcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Rectal type</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Of anal glands</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Within anorectal fistula</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Small cell carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Undifferentiated</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Anal margin</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Squamous cell carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Giant condyloma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Basal cell carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Others</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bowen's disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Paget's disease</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 76078 Version 1.0</div></div></div>"},"76079":{"type":"graphic_picture","displayName":"Cholesteatoma pars flaccida","title":"Acquired cholesteatoma of the pars flaccida with chronic purulent drainage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acquired cholesteatoma of the pars flaccida with chronic purulent drainage</div><div class=\"cntnt\"><img style=\"width:324px; height:324px;\" src=\"images/PEDS/76079_Cholesteatomaparsflaccida.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acquired cholesteatoma of the pars flaccida. This lesion presented with chronic purulent drainage and a white mass behind the drum.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 76079 Version 2.0</div></div></div>"},"76080":{"type":"graphic_table","displayName":"Causes of delayed closure of the anterior fontanelle","title":"Causes of delayed closure of the anterior fontanelle","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of delayed closure of the anterior fontanelle</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n   <tr>\n   <td class=\"container\"><table cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Common causes\n   </td>\n   </tr>\n   <tr>\n   <td>Normal variation</td>\n   </tr>\n   <tr>\n   <td>Congenital hypothyroidism</td>\n   </tr>\n   <tr>\n   <td>Primary megalencephaly</td>\n   </tr>\n   <tr>\n   <td>Increased intracranial pressure (of any etiology)</td>\n   </tr>\n   <tr>\n   <td>Down syndrome</td>\n   </tr>\n   <tr>\n   <td>Rickets</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Skeletal disorders\n   </td>\n   </tr>\n   <tr>\n   <td>Achondroplasia*</td>\n   </tr>\n   <tr>\n   <td>Osteogenesis imperfecta*</td>\n   </tr>\n   <tr>\n   <td>Cleidocranial dysostosis*</td>\n   </tr>\n   <tr>\n   <td>Apert syndrome*</td>\n   </tr>\n   <tr>\n   <td>Campomelic dysplasia</td>\n   </tr>\n   <tr>\n   <td>Otopalatodigital syndrome, Type II</td>\n   </tr>\n   <tr>\n   <td>Achondrogenesis-hypochondrogenesis, Type II</td>\n   </tr>\n   <tr>\n   <td>Acrocallosal syndrome</td>\n   </tr>\n   <tr>\n   <td>Antley-Bixler syndrome</td>\n   </tr>\n   <tr>\n   <td>Hypophosphatasia*</td>\n   </tr>\n   <tr>\n   <td>Pycnodysostosis*</td>\n   </tr>\n   <tr>\n   <td>Schinzel-Giedion syndrome</td>\n   </tr>\n   <tr>\n   <td>Kenny syndrome*</td>\n   </tr>\n   <tr>\n   <td>Lenz-Majewski hyperostosis*</td>\n   </tr>\n   <tr>\n   <td>Stanesco dysostosis</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Chromosomal abnormalities\n   </td>\n   </tr>\n   <tr>\n   <td>Down syndrome*</td>\n   </tr>\n   <tr>\n   <td>Trisomy 13*</td>\n   </tr>\n   <tr>\n   <td>Trisomy 18*</td>\n   </tr>\n   </table></td>\n   <td class=\"container\"><table cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Endocrine disorders\n   </td>\n   </tr>\n   <tr>\n   <td>Hypothyroidism*</td>\n   </tr>\n   <tr>\n   <td>Rickets*</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Drugs/toxins\n   </td>\n   </tr>\n   <tr>\n   <td>Fetal hydantoin syndrome</td>\n   </tr>\n   <tr>\n   <td>Aminopterin-induced malformation</td>\n   </tr>\n   <tr>\n   <td>Aluminum toxicity</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Dysmorphogenetic syndromes\n   </td>\n   </tr>\n   <tr>\n   <td>Russell-Silver syndrome*</td>\n   </tr>\n   <tr>\n   <td>Rubinstein-Taybi syndrome*</td>\n   </tr>\n   <tr>\n   <td>Hallermann-Streiff syndrome* (Oculomandibulofacial syndrome)</td>\n   </tr>\n   <tr>\n   <td>Zellweger syndrome* (cerebrohepatorenal syndrome)</td>\n   </tr>\n   <tr>\n   <td>Robinow syndrome*</td>\n   </tr>\n   <tr>\n   <td>Cutis laxa*</td>\n   </tr>\n   <tr>\n   <td>Progeria</td>\n   </tr>\n   <tr>\n   <td>VATER association*</td>\n   </tr>\n   <tr>\n   <td>Aase syndrome</td>\n   </tr>\n   <tr>\n   <td>Melnick-Needles syndrome</td>\n   </tr>\n   <tr>\n   <td>Conradi-Hunermann syndrome</td>\n   </tr>\n   <tr>\n   <td>Otopalatodigital syndrome</td>\n   </tr>\n   <tr>\n   <td>Saethre-Chotzen syndrome</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Miscellaneous\n   </td>\n   </tr>\n   <tr>\n   <td>Primary megalencephaly</td>\n   </tr>\n   <tr>\n   <td>Malnutrition*</td>\n   </tr>\n   <tr>\n   <td>Congenital syphilis*</td>\n   </tr>\n   </table></td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=51480&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Delayed_closure_ant_fontane.htm</title></head></div><div class=\"graphic_footnotes\">* Also associated with an enlarged fontanelle.</div><div class=\"graphic_reference\">Data from: <br>Tunnessen, WW. Delayed closure of the anterior fontanelle. In: Signs and Symptoms in Pediatrics, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.192.<br>Tunnessen, WW. Enlarged anterior fontanelle. In: Signs and Symptoms in Pediatrics, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.187.</div><div id=\"graphicVersion\">Graphic 76080 Version 2.0</div></div></div>"},"76081":{"type":"graphic_table","displayName":"LD history","title":"Important elements of the history for students with learning failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important elements of the history for students with learning failure</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Potential significance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">History of the learning problem</td> </tr> <tr> <td class=\"indent1\">When did the family first notice learning problems in the child? Is the child learning successfully now or still struggling?</td> <td>Persistent learning problems over time are more highly associated with LD than a learning problem of recent onset; LD can first manifest at any time throughout the primary and elementary school years but usually manifests in the primary school years</td> </tr> <tr> <td class=\"indent1\">What helps the child learn more successfully? (eg, small group instruction; 1:1 instruction, etc)</td> <td>Greater success in small groups as opposed to the general classroom may be related to LD or may be related to other factors such as a language disorder or weak executive skills</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">School performance</td> </tr> <tr> <td class=\"indent1\">What are the child's grades?</td> <td>Past or current poor academic achievement is a significant risk factor for LD</td> </tr> <tr> <td class=\"indent1\">Can the child complete homework independently?</td> <td>Inability to complete homework independently, especially after grade one, can indicate LD</td> </tr> <tr> <td class=\"indent1\">Did the child receive any early intervention or special education services?</td> <td>Past early intervention or special education services are a significant risk factor for LD, regardless of the type of service that was offered and regardless of whether the child was found to be no longer eligible for services</td> </tr> <tr> <td class=\"indent1\">Did the child's teachers provide any indication that they were concerned about the child's educational progress?</td> <td>Not all teachers can identify LD specifically, and not all teachers have access to a student support team to facilitate identification of LD; however, teacher observations of learning failure is a sensitive indicator of LD</td> </tr> <tr> <td class=\"indent1\">Past grade retention</td> <td>Past grade retention is a significant risk factor for LD</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">School attendance</td> </tr> <tr> <td class=\"indent1\">Does the child attend school regularly, now and in the past?</td> <td>Past school absences have a significant impact upon learning success and can mimic LD or be due to LD</td> </tr> <tr> <td class=\"indent1\">Does the child have a history of school avoidance?</td> <td>School avoidance may be due to perceived lack of competence because of LD and may also lead to school absences, aggravating learning problems</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Current psychiatric or behavioral conditions</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Mental health conditions often occur with LD and are a risk factor for LD</td> </tr> <tr> <td class=\"indent1\">Ability to focus and sustain attention to complete tasks of the daily routine; participate in social activities; and/or complete homework independently</td> <td>Symptoms of inattention are associated with attention deficit hyperactivity disorder, which is highly comorbid with LD; LD can also cause inattention during academic tasks</td> </tr> <tr> <td class=\"indent1\">Capacity to regulate anxiety, eg, separation anxiety when leaving the home to go to school or elsewhere; other symptoms of anxiety</td> <td>Symptoms of anxiety are a risk factor for LD, either as a comorbid condition or as a result of LD</td> </tr> <tr> <td class=\"indent1\">Capacity for managing frustration (waiting his/her turn in a game; capacity to self-soothe when angry)</td> <td>Symptoms of difficulty regulating anger are a risk factor for behavior disorders, which are highly comorbid with LD; low frustration tolerance for school activities specifically is a significant risk factor for LD</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Medical history</td> </tr> <tr> <td class=\"indent1\">Prenatal health problems; prenatal exposure to medications, toxins (alcohol, nicotine, etc) or infection</td> <td>Past neurologic insults are a risk factor for learning problems in general and for LD</td> </tr> <tr> <td class=\"indent1\">Perinatal course and complications</td> <td>Perinatal complications are a risk factor for learning problems in general and for LD</td> </tr> <tr> <td class=\"indent1\">Gestational age; birth weight</td> <td>Prematurity is a risk factor for learning problems in general and for LD</td> </tr> <tr> <td class=\"indent1\">Past illnesses, especially affecting the CNS</td> <td>Past neurologic insults are a risk factor for learning problems in general and for LD</td> </tr> <tr> <td class=\"indent1\">Past lead exposure</td> <td>Lead exposure is associated with lower cognitive potential</td> </tr> <tr> <td class=\"indent1\">Past or current medications</td> <td>Medications may interfere with CNS functioning and may be associated with learning failure</td> </tr> <tr> <td class=\"indent1\">Current neurologic symptoms to suggest seizures</td> <td>Seizures can interfere with learning</td> </tr> <tr> <td class=\"indent1\">Current sleeping habits</td> <td>Poor sleeping habits may interfere with learning success</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Developmental history</td> </tr> <tr> <td class=\"indent1\">Age-appropriate attainment of gross motor skills</td> <td>Motor problems are related to cerebral palsy and other neurologic conditions, which are comorbid with learning failure in general and may be associated with LD</td> </tr> <tr> <td class=\"indent1\">Age-appropriate attainment of language skills</td> <td>Language problems are highly comorbid with LD</td> </tr> <tr> <td class=\"indent1\">Age-appropriate attainment of adaptive skills such as personal care, toileting</td> <td>Age-appropriate attainment of adaptive skills requires general cognitive skills, as well as attention regulation skills; poor adaptive function may be associated with learning failure and with LD</td> </tr> <tr> <td class=\"indent1\">Attainment of social and play skills (ability to play successfully with same-age peers without parent supervision; capacity for friendships)</td> <td>Social skills may be delayed as a primary problem (eg, autism spectrum disorder) or may be due to perceived lack of self-confidence due to LD</td> </tr> <tr> <td class=\"indent1\">Able to participate in community activities such as sports teams or other recreational activities</td> <td>Motor, adaptive, and social skills are required for success in community activities; LD is associated with lower success in these areas</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Family history</td> </tr> <tr> <td class=\"indent1\">Do any first- or second-degree relatives have learning problems?</td> <td>LD is often inherited</td> </tr> <tr> <td class=\"indent1\">Do any first- or second-degree relatives have mental health or developmental conditions such as anxiety, depression, attention problems, learning problems, etc?</td> <td>Mental health conditions often occur with LD and are a risk factor for LD</td> </tr> <tr> <td class=\"indent1\">What are the parents' or family's current reading habits?</td> <td>The history of current reading habits can serve as a proxy for an unidentified reading disability</td> </tr> <tr> <td class=\"indent1\">How far did the parents take their education?</td> <td>Poor educational achievement is related to LD</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Social history</td> </tr> <tr> <td class=\"indent1\">Current parent employment status</td> <td>Current parental employment status may be related to the parents' success at school and maybe an indicator of LD</td> </tr> <tr> <td class=\"indent1\">Past abuse or neglect</td> <td>Past abuse or neglect is a significant risk factor for poor educational achievement in general and may be related to LD, regardless of current social status</td> </tr> <tr> <td class=\"indent1\">Past or current homelessness</td> <td>Past homelessness is a significant risk factor for poor educational achievement in general and may be related to LD, regardless of current living circumstances</td> </tr> <tr> <td class=\"indent1\">Past or current parental illnesses in family members</td> <td>Past illnesses in the family is a risk factor for poor educational achievement, for both social and heritable reasons</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Poor educational achievement may occur because of LD, weak language skills, weak executive skills, or lower overall cognitive potential. All of the risk factors listed above are associated with learning failure and strengthen the case for requesting an evaluation for LD or other causes of learning failure.</div><div class=\"graphic_footnotes\">LD: learning disability; CNS: central nervous system.</div><div id=\"graphicVersion\">Graphic 76081 Version 8.0</div></div></div>"},"76084":{"type":"graphic_picture","displayName":"Chordoma Light","title":"Chordoma","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Chordoma</div><div class=\"cntnt\"><img style=\"width:515px; height:231px;\" src=\"images/ONC/76084_Chordoma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low and high power light micrographs of a skull base chordoma. The tumor cells have vesicular nuclei and abundant vacuolated, soap bubble-like cytoplasm (physaliphorous cells) that contains glycogen (PAS positive) or mucin.</div><div class=\"graphic_reference\">Courtesy of Silloo B Kapadia, MD.</div><div id=\"graphicVersion\">Graphic 76084 Version 1.0</div></div></div>"},"76087":{"type":"graphic_algorithm","displayName":"Acute treatment of moderate asthma in children","title":"Management of moderate asthma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management of moderate asthma</div><div class=\"cntnt\"><img style=\"width:428px; height:434px;\" src=\"images/PEDS/76087_Acute_Rx_moderate_asthma_ch.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MDI: metered-dose inhaler; IM: intramuscular.<br />* Consider IM methylprednisolone or IM dexamethasone if the child vomits prednisone or dexamethasone.</div><div class=\"graphic_reference\">Courtesy of Richard Scarfone, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 76087 Version 5.0</div></div></div>"},"76089":{"type":"graphic_picture","displayName":"Hepatic VOD Reticulum","title":"Sinusoidal obstruction syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sinusoidal obstruction syndrome</div><div class=\"cntnt\"><img style=\"width:365px; height:252px;\" src=\"images/HEME/76089_Hepatic_VOD_Reticulum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of a reticulin stain of a liver biopsy from a patient with sinusoidal obstruction syndrome. There is prominent perivenular fibrosis (stained in black, arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Negrin RS, Blume KG. Bone marrow and peripheral blood progenitor cell transplantation. In: Leukemia, 6th ed, Henderson ES, Lister TA, Greaves ME (Eds), WB Saunders, Philadelphia, 1996. p.389.</div><div id=\"graphicVersion\">Graphic 76089 Version 2.0</div></div></div>"},"76095":{"type":"graphic_figure","displayName":"History physical exam A","title":"History and physical examination","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">History and physical examination</div><div class=\"cntnt\"><img style=\"width:497px; height:600px;\" src=\"images/OBGYN/76095_History_phys_exam_A_edt.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 76095 Version 3.0</div></div></div>"},"76097":{"type":"graphic_movie","displayName":"Ultrasound biceps contraction and relaxation","title":"Ultrasound biceps contraction and relaxation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound biceps contraction and relaxation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/NEURO/76097_USbicepscontrelaxconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:215px; height:372px;\" src=\"images/NEURO/76097_USbicepscontractrelax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an axial real-time image of the biceps (B) over the mid humerus (H); note a thin layer of subcutaneous tissue (S). The elbow is initially extended, and then gently flexed to 90 degrees; a slow full isometric contraction of the biceps follows, with repeated cycles of isometric relaxation and contraction. Note the shifting of fascicles as the muscle contracts and bulges, significantly increasing the diameter of the muscle belly.</div><div class=\"graphic_reference\">Courtesy of Francis O Walker, MD.</div><div id=\"graphicVersion\">Graphic 76097 Version 3.0</div></div></div>"},"76098":{"type":"graphic_picture","displayName":"Resisted thumb opposition","title":"Resisted thumb opposition","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Resisted thumb opposition</div><div class=\"cntnt\"><img style=\"width:432px; height:264px;\" src=\"images/EM/76098_Resisted_thumb_opp_final.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the photograph above, the clinician is trying to disrupt the circle formed by the patient's fingertip and opposing thumb-tip.</div><div id=\"graphicVersion\">Graphic 76098 Version 1.0</div></div></div>"},"76099":{"type":"graphic_figure","displayName":"Z-track technique","title":"Z-track technique for needle insertion during paracentesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Z-track technique for needle insertion during paracentesis</div><div class=\"cntnt\"><img style=\"width:371px; height:529px;\" src=\"images/GAST/76099_Z-track-technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A: Relative locations where the needle will enter the skin and the peritoneal cavity. <BR>B: The skin is pulled down, and the needle is then advanced in 5 mm increments, pulling the plunger&nbsp;back a few millimeters with each advancement to see if any blood or ascitic fluid&nbsp;is aspirated. <BR>C: The skin is released, returning the skin and peritoneal cavity entry sites to their original positions.</div><div id=\"graphicVersion\">Graphic 76099 Version 3.0</div></div></div>"},"76100":{"type":"graphic_picture","displayName":"Paraphimosis","title":"Paraphimosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paraphimosis</div><div class=\"cntnt\"><img style=\"width:433px; height:186px;\" src=\"images/EM/76100_Paraphimosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paraphimosis caused by excessive retraction of a physiologic phimosis in a male infant. Note the marked swelling at the coronal sulcus and the flaccid penile shaft.</div><div class=\"graphic_reference\">Reproduced with permission from: Waseem M, Devas G. Photo Quiz: Pediatrics. Resident &amp; Staff Physician, 2007; 53(6). Copyright &copy;2007 Ascend Media Healthcare.</div><div id=\"graphicVersion\">Graphic 76100 Version 3.0</div></div></div>"},"76101":{"type":"graphic_table","displayName":"Blood glucose level diary","title":"Blood glucose level diary","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Blood glucose level diary</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Time</td> <td class=\"subtitle1\">Blood glucose level, mg/dL</td> </tr> <tr> <td>4 to 5 AM</td> <td>117 to 201</td> </tr> <tr> <td>7 AM</td> <td>44 to 223; frequently below 90</td> </tr> <tr> <td>12 PM</td> <td>48 to 197</td> </tr> <tr> <td>3 PM</td> <td>39 to 266</td> </tr> <tr> <td>6 PM</td> <td>41 to 297</td> </tr> <tr> <td>11 PM</td> <td>49 to 239</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76101 Version 3.0</div></div></div>"},"76102":{"type":"graphic_figure","displayName":"Scheme thymic T cell development","title":"Scheme of thymic T cell development in alpha-beta T cells","html":"<div class=\"graphic\"><div style=\"width: 696px\" class=\"figure\"><div class=\"ttl\">Scheme of thymic T cell development in alpha-beta T cells</div><div class=\"cntnt\"><img style=\"width:676px; height:288px;\" src=\"images/RHEUM/76102_Scheme_thymic_Tcell_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of T cell development in the thymus. The various stages of maturation include the DN stages (1, 2, 3, and 4), DP stage, and SP stage. The lower part of the figure indicates TCR2 rearrangements which correspond to each stage. The upper part of the figure demonstrates some of the receptors expressed at each stage of differentiation.</div><div class=\"graphic_footnotes\">BM: bone marrow; c-kit: a proto-oncogene, also called mast stem cell growth factor receptor; CD: cluster of differentiation; NK: natural killer; TCR: T cell receptor; DN: double negative; IL: interleukin; DP: double positive; SP: single positive; TCR2: T cell receptor type 2 or T cell receptor alpha-beta.</div><div id=\"graphicVersion\">Graphic 76102 Version 10.0</div></div></div>"},"76104":{"type":"graphic_picture","displayName":"Spiral enteroscopy overtube","title":"Spiral enteroscopy overtube","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spiral enteroscopy overtube</div><div class=\"cntnt\"><img style=\"width:362px; height:200px;\" src=\"images/GAST/76104_Spiral_enteroscopy_overtube.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endo-Ease Discovery SB&#174; overtube for small bowel enteroscopy.</div><div class=\"graphic_reference\">Reproduced with permission from: Spirus Medical, Inc. Copyright &#169; 2010. All rights reserved.</div><div id=\"graphicVersion\">Graphic 76104 Version 2.0</div></div></div>"},"76105":{"type":"graphic_algorithm","displayName":"Diagnostic algorithm for HCC","title":"Algorithm for investigation of small nodules found on screening in patients at risk for hepatocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Algorithm for investigation of small nodules found on screening in patients at risk for hepatocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:529px; height:421px;\" src=\"images/GAST/76105_HCC_algo_edt3.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; HCC: hepatocellular carcinoma; MDCT: multidetector CT scan; MRI: magnetic resonance imaging; US: ultrasound.</div><div class=\"graphic_reference\">Reproduced with permission from: Bruix J, Sherman M. Management of Hepatocellular Carcinoma: An Update. Hepatology 2010. Copyright &#169; 2010 John Wiley &amp; Sons.</div><div id=\"graphicVersion\">Graphic 76105 Version 5.0</div></div></div>"},"76106":{"type":"graphic_table","displayName":"Methods to quantify gene expression","title":"Comparison of methods to quantify gene expression","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of methods to quantify gene expression</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Amount of starting RNA required</td> <td class=\"subtitle1\">Sensitivity of test</td> <td class=\"subtitle1\">Analytic requirements</td> <td class=\"subtitle1\">Information obtained from the test</td> <td class=\"subtitle1\">Number of targets</td> <td class=\"subtitle1\">Relative cost</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td rowspan=\"4\">Northern blot</td> <td rowspan=\"4\">High</td> <td rowspan=\"4\">Low</td> <td rowspan=\"4\">Low</td> <td rowspan=\"4\">Presence and size of RNA of interest</td> <td rowspan=\"4\">Few</td> <td rowspan=\"4\">Low</td> <td rowspan=\"4\">Straightforward</td> <td>Risk of RNA degradation</td> </tr> <tr> <td>Radioactivity use</td> </tr> <tr> <td>Lower sensitivity</td> </tr> <tr> <td>Higher starting quantity of RNA</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Ribonuclease protection assay</td> <td rowspan=\"2\">High</td> <td rowspan=\"2\">Moderate</td> <td rowspan=\"2\">Low</td> <td rowspan=\"2\">Presence and size of RNA of interest</td> <td rowspan=\"2\">Few</td> <td rowspan=\"2\">Low</td> <td>Higher specificity for the gene</td> <td>Complex protocol</td> </tr> <tr> <td>Better sensitivity</td> <td>Radioactivity use</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">In-situ hybridization</td> <td rowspan=\"2\">High</td> <td rowspan=\"2\">Low to moderate</td> <td rowspan=\"2\">Low</td> <td rowspan=\"2\">Presence and spatial localization of RNA of interest</td> <td rowspan=\"2\">Few</td> <td rowspan=\"2\">Low</td> <td rowspan=\"2\">Spatial localization in a tissue section or cell</td> <td>Low sensitivity</td> </tr> <tr> <td>Qualitative, not quantitative</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Spotted cDNA arrays</td> <td rowspan=\"2\">Moderate</td> <td rowspan=\"2\">Moderate to high</td> <td rowspan=\"2\">Moderate to high</td> <td rowspan=\"2\">Relative gene expression between two conditions</td> <td rowspan=\"2\">Several hundred</td> <td rowspan=\"2\">Moderate</td> <td>Simultaneous detection of hundreds of genes</td> <td rowspan=\"2\">Limited reproducibility</td> </tr> <tr> <td>Direct comparison of two samples</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Oligonucleotide arrays</td> <td rowspan=\"2\">Low to moderate</td> <td rowspan=\"2\">Moderate to high</td> <td rowspan=\"2\">Moderate to high</td> <td rowspan=\"2\">Relative gene expression</td> <td rowspan=\"2\">Thousands</td> <td rowspan=\"2\">Moderate</td> <td>Simultaneous detection of thousands of genes</td> <td>Analysis limited to known genes</td> </tr> <tr> <td>Higher resolution than older methods</td> <td>Decreased sensitivity for lowly expressed transcripts</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">RT-PCR</td> <td rowspan=\"2\">Low</td> <td rowspan=\"2\">High</td> <td rowspan=\"2\">Low to moderate</td> <td rowspan=\"2\">Relative gene expression</td> <td rowspan=\"2\">Few to several hundred</td> <td rowspan=\"2\">Low</td> <td>Straightforward protocol</td> <td rowspan=\"2\">Needs careful primer selection</td> </tr> <tr> <td>Higher sensitivity</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Transcriptome sequencing</td> <td rowspan=\"4\">Low to moderate</td> <td rowspan=\"4\">High</td> <td rowspan=\"4\">Very high</td> <td rowspan=\"4\">Digital counts of each RNA molecule (as measure of gene expression) with excellent dynamic range</td> <td rowspan=\"4\">Unlimited</td> <td rowspan=\"4\">High</td> <td>Higher resolution than microarrays</td> <td>High cost</td> </tr> <tr> <td>Large dynamic range, can detect low abundance transcripts</td> <td>Low throughput</td> </tr> <tr> <td>Detects novel transcripts</td> <td>Large storage space needed for data</td> </tr> <tr> <td>Can identify polymorphisms within a sequence</td> <td>Intensive computational analysis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76106 Version 2.0</div></div></div>"},"76107":{"type":"graphic_table","displayName":"TST vs IGRA comparison","title":"A comparison of tuberculin skin tests and interferon-gamma release assays","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">A comparison of tuberculin skin tests and interferon-gamma release assays</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">TST</td> <td class=\"subtitle1\">IGRAs</td> </tr> <tr> <td><strong>Advantages</strong></td> <td> <p>TST does not require equipment and can be done without a laboratory. It is less expensive than for IGRAs (but greater personnel time is required).</p> <p>Longitudinal studies have demonstrated the predictive value of TST, and randomized trials show that LTBI therapy is&nbsp;much more&nbsp;effective in those who are TST positive than TST negative.</p> </td> <td> <p>IGRA does not require follow-up visit to complete the testing process (but follow-up visits may be needed for LTBI therapy).</p> <p>IGRA does not give false-positive results because of prior BCG vaccination.</p> </td> </tr> <tr class=\"divider_top\"> <td><strong>Disadvantages</strong></td> <td> <p>TST requires an intra-dermal injection and a subsequent follow-up visit with trained staff to interpret results in 48 to 72 hours.</p> <p>TST may give false-positive results because of prior BCG vaccination or sensitization to nontuberculous mycobacteria.</p> <p>TST may give false-negative results because of immunosuppression (eg, HIV or active TB), natural waning of immunity, and technical limitations (including reader variability).</p> <p>Serial TST interpretation is complicated by potential boosting, although this can be minimized through initial two-step testing.</p> <p>TST can cause adverse reactions (skin blistering and ulceration); these are rare.</p> </td> <td> <p>IGRA requires a blood draw, laboratory equipment, and technical expertise for specimen collection, processing, and assay. Reagent costs are substantially higher than costs of TST.</p> <p>IGRA test results are available within 24 hours at the earliest.</p> <p>IGRA may give false-negative results because of immunosuppression (eg, HIV or active TB) and technical variability.</p> <p>Interpretation of serial IGRA is complicated by frequent conversions and spontaneous&nbsp;reversions and by lack of consensus on optimum thresholds for conversions.</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TST: tuberculin skin test; IGRA: interferon-gamma release assay; HIV: human immunodeficiency virus; LTBI: latent tuberculosis infection; BCG: Bacillus Calmette-Guerin.</div><div id=\"graphicVersion\">Graphic 76107 Version 4.0</div></div></div>"},"76108":{"type":"graphic_table","displayName":"Comparison between EME and EIEE","title":"Comparison of early myoclonic encephalopathy (EME) and early infantile epileptic encephalopathy (EIEE)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of early myoclonic encephalopathy (EME) and early infantile epileptic encephalopathy (EIEE)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">EME</td> <td class=\"subtitle1\">EIEE</td> </tr> <tr> <td><strong>Age of onset</strong></td> <td>Neonatal period</td> <td>Within first three months</td> </tr> <tr> <td><strong>Neurologic status at onset</strong></td> <td>Abnormal at birth or at seizure onset</td> <td>Always abnormal, even prior to seizure onset</td> </tr> <tr> <td><strong>Characteristic seizure type</strong></td> <td>Erratic or fragmentary myoclonus</td> <td>Tonic spasm</td> </tr> <tr> <td><strong>Additional seizure types</strong></td> <td> <p>Massive myoclonus</p> <p>Simple partial seizures</p> Infantile spasms (tonic)</td> <td> <p>Focal motor seizures</p> <p>Hemiconvulsions</p> Generalized seizures</td> </tr> <tr> <td><strong>Background EEG</strong></td> <td>Suppression-burst</td> <td>Suppression-burst</td> </tr> <tr> <td><strong>Etiology</strong></td> <td> <p>Inborn errors of metabolism</p> <p>Genetic</p> Unknown</td> <td> <p>Cerebral dysgenesis</p> <p>Anoxia</p> <p>Genetic</p> <p>Unknown</p> </td> </tr> <tr> <td><strong>Natural course</strong></td> <td>Progressive impairment</td> <td>Static impairment</td> </tr> <tr> <td><strong>Incidence of death</strong></td> <td>Very high, occurring in infancy</td> <td>High, occurring in infancy, childhood or adolescence</td> </tr> <tr> <td><strong>Status of survivors</strong></td> <td>Vegetative state</td> <td> <p>Severe mental retardation</p> Quadriplegia and bedridden</td> </tr> <tr> <td><strong>Long-term seizure evolution</strong></td> <td>Infantile spasms</td> <td> <p>West syndrome</p> Lennox-Gastaut</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Based upon data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Aicardi J. Epileptic encephalopathies of early childhood. Curr Opin Neurol Neurosurg 1992; 5:344.</li>&#xD;&#xA;    <li>Ohtahara S, Yamatogi Y. Epileptic encephalopathies in early infancy with suppression-burst. J Clin Neurophysiol. 2003; 20:398.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 76108 Version 5.0</div></div></div>"},"76109":{"type":"graphic_figure","displayName":"First branchial arch","title":"First branchial arch derivatives","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">First branchial arch derivatives</div><div class=\"cntnt\"><img style=\"width:364px; height:384px;\" src=\"images/PEDS/76109_First_branchial_arch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arch dermal mesenchyme forms mandible (MN), maxilla (MX), zygomatic temporal bone (Z), and squamous temporal bone (ST) through direct ossification. First arch cartilage derivatives include the malleus (M); incus (I) alisphenoid (greater wing of sphenoid); and small fibrous core in mandible, which is called Meckel's cartilage (MC).</div><div id=\"graphicVersion\">Graphic 76109 Version 3.0</div></div></div>"},"76110":{"type":"graphic_picture","displayName":"Mature cataract 2","title":"Mature cataract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mature cataract</div><div class=\"cntnt\"><img style=\"width:396px; height:272px;\" src=\"images/PEDS/76110_Mature_cataract_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mature cataract with complete opacification of the lens.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd ed. Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76110 Version 2.0</div></div></div>"},"76111":{"type":"graphic_table","displayName":"Procedure for sucrose analgesia","title":"Procedure for sucrose analgesia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Procedure for sucrose analgesia</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n\r\n\r\n  <tbody>\r\n\r\n\r\n\r\n    <tr>\r\n\r\n\r\n      <td class=\"subtitle1_single\">Indications</td>\r\n\r\n\r\n    </tr>\r\n\r\n\r\n    <tr>\r\n\r\n\r\n      <td>1. Painful procedure such as venipuncture or lumbar puncture</td>\r\n\r\n\r\n    </tr>\r\n\r\n\r\n    <tr>\r\n\r\n\r\n      <td>2. Age < 6 months</td>\r\n\r\n\r\n    </tr>\r\n\r\n\r\n    <tr>\r\n\r\n\r\n      <td class=\"subtitle1_single\">Contraindications</td>\r\n\r\n\r\n    </tr>\r\n\r\n\r\n    <tr>\r\n\r\n\r\n      <td>Infant is restricted from oral intake</td>\r\n\r\n\r\n    </tr>\r\n\r\n\r\n    <tr>\r\n\r\n\r\n      <td class=\"subtitle1_single\">Procedure</td>\r\n\r\n\r\n    </tr>\r\n\r\n\r\n    <tr>\r\n\r\n\r\n      <td>1. Use a 25 percent sucrose solution</td>\r\n\r\n\r\n    </tr>\r\n\r\n\r\n    <tr>\r\n\r\n\r\n      <td>2. Administer 2 mL, perferably by allowing the infant to suck on a pacifier, or with a syringe, 1 mL in each cheek</td>\r\n\r\n\r\n    </tr>\r\n\r\n\r\n    <tr>\r\n\r\n\r\n      <td>3. Administer no more than 2 minutes before beginning painful procedure</td>\r\n\r\n\r\n    </tr>\r\n\r\n\r\n    <tr>\r\n\r\n\r\n      <td>4. May repeat the dose but not to exceed two doses in one hour</td>\r\n\r\n\r\n    </tr>\r\n\r\n\r\n  \r\n  </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 76111 Version 1.0</div></div></div>"},"76112":{"type":"graphic_picture","displayName":"Tube patency","title":"Tympanostomy tube patency","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Tympanostomy tube patency</div><div class=\"cntnt\"><img style=\"width:473px; height:488px;\" src=\"images/PEDS/76112_Tubepatency.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proper function of a tympanostomy tube is assured if it is seen to span the eardrum, its lumen is unobstructed, and no middle ear effusion is present. Panel A above depicts a tube that is in place and patent. Panel B depicts a tube that is in place, but occluded. Panel C depicts a tube that is in place and patent, but appears to have extruded.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 93, Pages 924-9, Copyright © 1994 by the AAP.</div><div id=\"graphicVersion\">Graphic 76112 Version 13.0</div></div></div>"},"76113":{"type":"graphic_picture","displayName":"Eosinophilic fasciitis biopsy 2","title":"Eosinophilic fasciitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eosinophilic fasciitis</div><div class=\"cntnt\"><img style=\"width:432px; height:289px;\" src=\"images/RHEUM/76113_Eosinophilic_fasciitis_bi1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This high-power view of a hematoxylin and eosin-stained skin biopsy from a patient with eosinophilic fasciitis shows marked accumulation of eosinophils in close proximity to collagen bundles in the fascia.</div><div class=\"graphic_reference\">Courtesy of John Varga, MD.</div><div id=\"graphicVersion\">Graphic 76113 Version 2.0</div></div></div>"},"76114":{"type":"graphic_figure","displayName":"Mutations entry inhibitors","title":"Mutations in the envelope gene associated with resistance to entry inhibitors","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Mutations in the envelope gene associated with resistance to entry inhibitors</div><div class=\"cntnt\"><img style=\"width:610px; height:260px;\" src=\"images/ID/76114_Mutations_entry_inhib_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted with permission from: the International AIDS Society-USA. Johnson VA, Brun-Vézinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, Schapiro JM, and Richman DD. Update of the Drug Resistance Mutations in HIV-1: December 2010. Topics in HIV Medicine 2010; 18(5):156-163. Updated information (and thorough explanatory notes) are available at <a href=\"http://www.iasusa.org/\" target=\"_blank\">www.iasusa.org</a>.</div><div id=\"graphicVersion\">Graphic 76114 Version 9.0</div></div></div>"},"76115":{"type":"graphic_movie","displayName":"Parasternal long axis color Doppler echo AR","title":"Parasternal long axis echocardiogram with color Doppler showing aortic regurgitation and a dilated aortic root","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parasternal long axis echocardiogram with color Doppler showing aortic regurgitation and a dilated aortic root</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/76115_laxcdarsconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:249px; height:446px;\" src=\"images/CARD/76115_laxcdars.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parasternal long axis view with color Doppler demonstrates severe aortic regurgitation associated with marked dilatation of the aortic root.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 76115 Version 3.0</div></div></div>"},"76117":{"type":"graphic_figure","displayName":"CW Doppler from LA in MR","title":"Continuous wave Doppler in mitral regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Continuous wave Doppler in mitral regurgitation</div><div class=\"cntnt\"><img style=\"width:381px; height:259px;\" src=\"images/CARD/76117_CW_Doppler_from_LA_in_MR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The continuous wave Doppler of mitral regurgitation, recorded from the left atrium, shows a jet with a symmetrical shape, suggesting that a significant v-wave in the left atrium is unlikely; however, the jet is dense with a well defined envelope and the early onset of regurgitant flow (arrow), suggesting a moderate degree of regurgitation.</div><div id=\"graphicVersion\">Graphic 76117 Version 1.0</div></div></div>"},"76120":{"type":"graphic_table","displayName":"PedNIHSS items","title":"Pediatric National Institutes of Health Stroke Scale (PedNIHSS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric National Institutes of Health Stroke Scale (PedNIHSS)</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td colspan=\"2\">PedNIHSS INSTRUCTIONS: Administer stroke scale items in the order listed. Follow directions provided for each exam item. Scores should reflect what the patient does, not what the clinician thinks the patient can do. <em><strong>MODIFICATIONS FOR CHILDREN: Modifications to testing instructions from the adult version for use in children are shown in bold italic with each item where appropriate. Items with no modifications should be administered and scored with children in the same manner as for adults.</strong></em></td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td class=\"subtitle1\">Item# and instructions</td>\r\n            <td class=\"subtitle1\">Scale definition and scoring guide</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">1a. Level of consciousness:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">The investigator must choose a response, even if a full evaluation is prevented by such obstacles as an endotracheal tube, language barrier, orotracheal trauma/bandages. A 3 is scored only if the patient makes no movement (other than reflexive posturing) in response to noxious stimulation.</td>\r\n            <td>\r\n            <p>0 = Alert; keenly responsive.</p>\r\n            <p>1 = Not alert, but arousable by minor stimulation to obey, answer, or respond.</p>\r\n            <p>2 = Not alert, requires repeated stimulation to attend, or is obtunded and requires strong or painful stimulation to make movements (not stereotyped).</p>\r\n            <p>3 = Responds only with reflex motor or autonomic effects or totally unresponsive, flaccid, areflexic.</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">1b. LOC questions:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">The patient is asked the month and his/her age. The answer must be correct - there is no partial credit for being close. Aphasic and stuporous patients who do not comprehend the questions will score 2. Patients unable to speak because of endotracheal intubation, orotracheal trauma, severe dysarthria from any cause, language barrier or any other problem not secondary to aphasia are given a 1. It is important that only the initial answer be graded and that the examiner not \"help\" the patient with verbal or non-verbal cues. <em><strong>Modified for children, age 2 years and up. A familiar Family Member must be present for this item: Ask the child \"how old are you?\" Or \"How many years old are you?\" for question number one. Give credit if the child states the correct age, or shows the correct number of fingers for his/her age. For the second question, ask the child \"where is XX?\", XX referring to the name of the parent or other familiar family member present. Use the name for that person which the child typically uses, eg, \"mommy\". Give credit if the child correctly points to or gazes purposefully in the direction of the family member.</strong></em></td>\r\n            <td>\r\n            <p>0 = Answers both questions correctly.</p>\r\n            <p>1 = Answers one question correctly.</p>\r\n            <p>2 = Answers neither question correctly.</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">1c. LOC commands:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">The patient is asked to open and close the eyes and then to grip and release the non-paretic hand. <em><strong>For children one may substitute the command to grip the hand with the command \"show me your nose\" or \"touch your nose\".</strong></em> Substitute another one step command if the hands cannot be used. Credit is given if an unequivocal attempt is made but not completed due to weakness. If the patient does not respond to command, the task should be demonstrated to them (pantomime) and score the result (ie, follows none, one or two commands). Patients with trauma, amputation, or other physical impediments should be given suitable one-step commands. Only the first attempt is scored.</td>\r\n            <td>\r\n            <p>0 = Performs both tasks correctly.</p>\r\n            <p>1 = Performs one task correctly.</p>\r\n            <p>2 = Performs neither task correctly.</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">2. Best gaze:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Only horizontal eye movements will be tested. Voluntary or reflexive (oculocephalic) eye movements will be scored but caloric testing is not done. If the patient has a conjugate deviation of the eyes that can be overcome by voluntary or reflexive activity, the score will be 1. If a patient has an isolated peripheral nerve paresis (CN III, IV or VI) score a 1. Gaze is testable in all aphasic patients. Patients with ocular trauma, bandages, pre-existing blindness or other disorder of visual acuity or fields should be tested with reflexive movements and a choice made by the investigator. Establishing eye contact and then moving about the patient from side to side will occasionally clarify the presence of a partial gaze palsy.</td>\r\n            <td>\r\n            <p>0 = Normal.</p>\r\n            <p>1 = Partial gaze palsy. This score is given when gaze is abnormal in one or both eyes, but where forced deviation or total gaze paresis are not present.</p>\r\n            <p>2 = Forced deviation, or total gaze paresis not overcome by the oculocephalic maneuver.</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">3. Visual:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Visual fields (upper and lower quadrants) are tested by confrontation, using finger counting <em><strong>(for children &#62;6 years)</strong></em> or visual threat <em><strong>(for children age 2 to 6 years)</strong></em> as appropriate. Patient must be encouraged, but if they look at the side of the moving fingers appropriately, this can be scored as normal. If there is unilateral blindness or enucleation, visual fields in the remaining eye are scored. Score 1 only if a clear-cut asymmetry, including quadrantanopia is found. If patient is blind from any cause score 3. Double simultaneous stimulation is performed at this point. If there is extinction patient receives a 1 and the results are used to answer question 11.</td>\r\n            <td>\r\n            <p>0 = No visual loss.</p>\r\n            <p>1 = Partial hemianopia.</p>\r\n            <p>2 = Complete hemianopia.</p>\r\n            <p>3 = Bilateral hemianopia (blind including cortical blindness).</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">4. Facial palsy:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Ask, or use pantomime to encourage the patient to show teeth or raise eyebrows and close eyes. Score symmetry of grimace in response to noxious stimuli in the poorly responsive or non-comprehending patient. If facial trauma/bandages, orotracheal tube, tape or other physical barrier obscures the face, these should be removed to the extent possible.</td>\r\n            <td>\r\n            <p>0 = Normal symmetrical movement.</p>\r\n            <p>1 = Minor paralysis (flattened nasolabial fold, asymmetry on smiling).</p>\r\n            <p>2 = Partial paralysis (total or near total paralysis of lower face).</p>\r\n            <p>3 = Complete paralysis of one or both sides (absence of facial movement in the upper and lower face).</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">5 &#38; 6. Motor arm and leg:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" rowspan=\"2\">The limb is placed in the appropriate position: extend the arms (palms down) 90 degrees (if sitting) or 45 degrees (if supine) and the leg 30 degrees (always tested supine). Drift is scored if the arm falls before 10 seconds or the leg before 5 seconds. <em><strong>For children too immature to follow precise directions or uncooperative for any reason, power in each limb should be graded by observation of spontaneous or elicited movement according to the same grading scheme, excluding the time limits.</strong></em> The aphasic patient is encouraged using urgency in the voice and pantomime but not noxious stimulation. Each limb is tested in turn, beginning with the non-paretic arm. Only in the case of amputation or joint fusion at the shoulder or hip, <em><strong>or immobilization by an IV board,</strong></em> may the score be \"9\" and the examiner must clearly write the explanation for scoring as a \"9\". Score each limb separately.</td>\r\n            <td>\r\n            <p><strong>5a. Left arm</strong><br />\r\n            <strong>5b. Right arm</strong></p>\r\n            <p>0 = No drift, limb holds 90 (or 45) degrees for full 10 seconds.</p>\r\n            <p>1 = Drift, limb holds 90 (or 45) degrees, but drifts down before full 10 seconds; does not hit bed or other support.</p>\r\n            <p>2 = Some effort against gravity, limb cannot get to or maintain (if cued) 90 (or 45) degrees, drifts down to bed, but has some effort against gravity.</p>\r\n            <p>3 = No effort against gravity, limb falls.</p>\r\n            <p>4 = No movement.</p>\r\n            <p>9 = Amputation, joint fusion explain.</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td>\r\n            <p><strong>6a. Left leg</strong><br />\r\n            <strong>6b. Right leg</strong></p>\r\n            <p>0 = No drift, leg holds 30 degrees position for full 5 seconds.</p>\r\n            <p>1 = Drift, leg falls by the end of the 5 second period but does not hit bed.</p>\r\n            <p>2 = Some effort against gravity; leg falls to bed by 5 seconds, but has some effort against gravity.</p>\r\n            <p>3 = No effort against gravity, leg falls to bed immediately.</p>\r\n            <p>4 = No movement.</p>\r\n            <p>9 = Amputation, joint fusion explain.</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">7. Limb ataxia:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">This item is aimed at finding evidence of a unilateral cerebellar lesion. Test with eyes open. In case of visual defect, insure testing is done in intact visual field. The finger-nose-finger and heel-shin tests are performed on both sides, and ataxia is scored only if present out of proportion to weakness. <em><strong>In children, substitute this task with reaching for a toy for the upper extremity, and kicking a toy or the examiner's hand, in children too young (&#60;5 years) or otherwise uncooperative for the standard exam item.</strong></em> Ataxia is absent in the patient who cannot understand or is paralyzed. Only in the case of amputation or joint fusion may the item be scored \"9\", and the examiner must clearly write the explanation for not scoring. In case of blindness test by touching nose from extended arm position.</td>\r\n            <td>\r\n            <p>0 = Absent.</p>\r\n            <p>1 = Present in one limb.</p>\r\n            <p>2 = Present in two limbs.</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">8. Sensory:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Sensation or grimace to pin prick when tested, or withdrawal from noxious stimulus in the obtunded or aphasic patient. <em><strong>For children too young or otherwise uncooperative for reporting gradations of sensory loss, observe for any behavioral response to pin prick, and score it according to the same scoring scheme as a \"normal\" response, \"mildly diminished\" or \"severely diminished\" response.</strong></em> Only sensory loss attributed to stroke is scored as abnormal and the examiner should test as many body areas [arms (not hands), legs, trunk, face] as needed to accurately check for hemisensory loss. A score of 2, \"severe or total,\" should only be given when a severe or total loss of sensation can be clearly demonstrated. Stuporous and aphasic patients will therefore probably score 1 or 0.</td>\r\n            <td>\r\n            <p>0 = Normal; no sensory loss.</p>\r\n            <p>1 = Mild to moderate sensory loss; patient feels pinprick is less sharp or is dull on the affected side; or there is a loss of superficial pain with pinprick but patient is aware he/she is being touched.</p>\r\n            <p>2 = Severe to total sensory loss; patient is not aware of being touched in the face, arm, and leg.</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">9. Best language:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">A great deal of information about comprehension will be obtained during the preceding sections of the examination. <em><strong>For children age 6 years and up with normal language development before onset of stroke: The patient is asked to describe what is happening in the attached picture, to name the items on the attached naming sheet, to repeat words from the attached list, and to read from the attached list of sentences (see Table S1&nbsp;\"Language testing items\"&nbsp;below, and see&nbsp;separate figures for&nbsp;Cookie theft picture, Picture naming for PedNIHSS, and Reading&nbsp;for PedNIHSS).</strong></em> Comprehension is judged from responses here as well as to all of the commands in the preceding general neurological exam. If visual loss interferes with the tests, ask the patient to identify objects placed in the hand, repeat, and produce speech. The intubated patient should be asked to write. The patient in coma (question 1a = 3) will arbitrarily score 3 on this item. The examiner must choose a score in the patient with stupor or limited cooperation but a score of 3 should be used only if the patient is mute and follows no one step commands. <em><strong>For children age 2 yrs to 6 yrs (or older children with premorbid language skills &#60;6 yr level), score this item based on observations of language comprehension and speech during the examination.</strong></em> The patient with brain stem stroke who has bilateral loss of sensation is scored 2. If the patient does not respond and is quadriplegic score 2. Patients in coma (item 1a = 3) are arbitrarily given a 2 on this item.</td>\r\n            <td>\r\n            <p>0 = No aphasia, normal.</p>\r\n            <p>1 = Mild to moderate aphasia; some obvious loss of fluency or facility of comprehension, without significant limitation on ideas expressed or form of expression. Reduction of speech and/or comprehension, however, makes conversation about provided material difficult or impossible. For example in conversation about provided materials examiner can identify picture or naming card from patient's response.</p>\r\n            <p>2 = Severe aphasia; all communication is through fragmentary expression; great need for inference, questioning, and guessing by the listener. Range of information that can be exchanged is limited; listener carries burden of communication. Examiner cannot identify materials provided from patient response.</p>\r\n            <p>3 = Mute, global aphasia; no usable speech or auditory comprehension.</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">10. Dysarthria:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">If patient is thought to be normal an adequate sample of speech must be obtained by asking patient to read or repeat words from the attached list. If the patient has severe aphasia, the clarity of articulation of spontaneous speech can be rated. Only if the patient is intubated or has other physical barrier to producing speech, may the item be scored \"9\", and the examiner must clearly write an explanation for not scoring. Do not tell the patient why he/she is being tested.</td>\r\n            <td>\r\n            <p>0 = Normal.</p>\r\n            <p>1 = Mild to moderate; patient slurs at least some words and, at worst, can be understood with some difficulty.</p>\r\n            <p>2 = Severe; patient's speech is so slurred as to be unintelligible in the absence of or out of proportion to any dysphasia, or is mute/anarthric.</p>\r\n            <p>9 = Intubated or other physical barrier, explain.</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">11. Extinction and inattention (formerly neglect):</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Sufficient information to identify neglect may be obtained during the prior testing. If the patient has a severe visual loss preventing visual double simultaneous stimulation, and the cutaneous stimuli are normal, the score is normal. If the patient has aphasia but does appear to attend to both sides, the score is normal. The presence of visual spatial neglect or anosognosia may also be taken as evidence of abnormality. Since the abnormality is scored only if present, the item is never untestable.</td>\r\n            <td>\r\n            <p>0 = No abnormality.</p>\r\n            <p>1 = Visual, tactile, auditory, spatial, or personal inattention or extinction to bilateral simultaneous stimulation in one of the sensory modalities.</p>\r\n            <p>2 = Profound hemi-inattention or hemi-inattention to more than one modality. Does not recognize own hand or orients to only one side of space.</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1\" colspan=\"2\">Table S1. Language testing items for PedNIHSS:</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"2\">Repetition</td>\r\n            <td>Each of 4 word-repetition tasks is presented:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">\r\n            <p>a. Stop</p>\r\n            <p>b. Stop and go</p>\r\n            <p>c. If it rains we play inside</p>\r\n            <p>d. The President lives in Washington</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Reading</td>\r\n            <td>Each of 3 items is presented for the child to read (see separate&nbsp;\"Reading items figure&nbsp;for PedNIHSS\"). Adjust expectations according to child's age/school level.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Name</td>\r\n            <td>Pictures are presented of a clock, pencil, skateboard, shirt, baseball, and bicycle (see separate&nbsp;\"Picture naming figure for PedNIHSS\").</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Fluency and word finding</td>\r\n            <td>The Cookie theft picture&nbsp;is presented and the child is asked to describe what he/she sees (see separate&nbsp;\"Cookie theft picture for NIHSS and PedNIHSS\").</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Ichord RN, Bastian R, Abraham L, et al. Interrater reliability of the Pediatric National Institutes of Health Stroke Scale (PedNIHSS) in a multicenter study. Stroke 2011; 42:613. Copyright &#169; 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76120 Version 1.0</div></div></div>"},"76124":{"type":"graphic_table","displayName":"Types of Mullerian anomalies","title":"Classification of Müllerian anomalies according to the American Fertility Society classification system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of M&#252;llerian anomalies according to the American Fertility Society classification system</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Type I: \"M&#252;llerian\" agenesis or hypoplasia\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A. Vaginal (uterus may be normal or exhibit a variety of malformations)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>B. Cervical</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>C. Fundal</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>D. Tubal</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>E. Combined</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Type II: Unicornuate uterus\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A1a. Communicating (endometrial cavity present)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A1b. Noncommunicating (endometrial cavity present)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A2. Horn without endometrial cavity</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>B. No rudimentary horn</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Type III: Uterus didelphys\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Type IV: Uterus bicornuate\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A. Complete (division down to internal os)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>B. Partial</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>C. Arcuate</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Type V: Septate uterus\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A. Complete (septum to internal os)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>B. Partial</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Type VI: Diethylstibestrol-related anomalies\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A. T-shaped uterus</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>B. T-shaped with dilated horns</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Reproduced with permission from: American Fertility Society (AFS).<br>The American Fertility Society classifications of adnexal adhesions,distal tubal occlusion secondary to tubal ligation, tubal pregnancies, M&#252;llerian anomalies and intrauterine adhesions. Fertil Steril 1988;49:944. Copyright &#169; 1988 American Society for Reproductive Medicine.</div><div id=\"graphicVersion\">Graphic 76124 Version 2.0</div></div></div>"},"76125":{"type":"graphic_picture","displayName":"T rich large B cell NHL","title":"T-cell rich large B-cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">T-cell rich large B-cell lymphoma</div><div class=\"cntnt\"><img style=\"width:453px; height:288px;\" src=\"images/HEME/76125_T_rich_large_B_cell_NHL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: this field shows a mixture of isolated, mildly atypical large lymphoid cells (red arrows) in a background of small lymphocytes (black arrows). The large cells stain positively for the B-cell marker CD20 (right upper panel), while the small lymphocytes stain positively for the T-cell marker CD45RO (right lower panel).</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 76125 Version 1.0</div></div></div>"},"76126":{"type":"graphic_table","displayName":"Pound tables 2003","title":"Updated metastasis-free survival at 3, 5, and 7 years after a postprostatectomy biochemical (PSA) failure in 321 men","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Updated metastasis-free survival at 3, 5, and 7 years after a postprostatectomy biochemical (PSA) failure in 321 men</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle1_left\">Gleason score</td>\n\t\t\t\t<td colspan=\"4\">5-7</td>\n\t\t\t\t<td colspan=\"4\">8-10</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle1_left\">Years to recur</td>\n\t\t\t\t<td colspan=\"2\">&#62;2 yr</td>\n\t\t\t\t<td colspan=\"2\">&#8804;2 yr</td>\n\t\t\t\t<td colspan=\"2\">&#62;2 yr</td>\n\t\t\t\t<td colspan=\"2\">&#8804;2 yr</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle1_left\">PSADT, months*</td>\n\t\t\t\t<td>&#62;10</td>\n\t\t\t\t<td>&#8804;10</td>\n\t\t\t\t<td>&#62;10</td>\n\t\t\t\t<td>&#8804;10</td>\n\t\t\t\t<td>&#62;10</td>\n\t\t\t\t<td>&#8804;10</td>\n\t\t\t\t<td>&#62;10</td>\n\t\t\t\t<td>&#8804;10</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle1_left\">3 years</td>\n\t\t\t\t<td>92</td>\n\t\t\t\t<td>66</td>\n\t\t\t\t<td>99</td>\n\t\t\t\t<td>60</td>\n\t\t\t\t<td>84</td>\n\t\t\t\t<td>57</td>\n\t\t\t\t<td>N/A</td>\n\t\t\t\t<td>52</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle1_left\">5 years</td>\n\t\t\t\t<td>92</td>\n\t\t\t\t<td>34</td>\n\t\t\t\t<td>83</td>\n\t\t\t\t<td>24</td>\n\t\t\t\t<td>72</td>\n\t\t\t\t<td>36</td>\n\t\t\t\t<td>N/A</td>\n\t\t\t\t<td>27</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle1_left\">7 years</td>\n\t\t\t\t<td>84</td>\n\t\t\t\t<td>27</td>\n\t\t\t\t<td>75</td>\n\t\t\t\t<td>6</td>\n\t\t\t\t<td>57</td>\n\t\t\t\t<td>24</td>\n\t\t\t\t<td>N/A</td>\n\t\t\t\t<td>7</td>\n\t\t\t</tr>\n\t</table></div><div class=\"graphic_footnotes\">PSA: prostate specific antigen; PSADT: PSA doubling time, months; N/A: not available. </div><div class=\"graphic_reference\">Data from: Eisenberger, MA, et al. Proc ASCO 2003; 22:380a (abstract 1527).</div><div id=\"graphicVersion\">Graphic 76126 Version 1.0</div></div></div>"},"76127":{"type":"graphic_picture","displayName":"Phytophotodermatitis","title":"Phytophotodermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Phytophotodermatitis</div><div class=\"cntnt\"><img style=\"width:292px; height:339px;\" src=\"images/PEDS/76127_Phytophotodermatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This burn-like skin lesion occurs when sunlight interacts with photosensitizing compounds found in certain fruits or vegetables (eg, limes, lemons, figs, parsnips, celery). The pattern of lesion corresponds to the contact (eg, streaks from dripping juice, handprints from adults handling the sensitizing material and then the child), or around the hands and mouth after the child handles or ingests the agent.</div><div class=\"graphic_reference\">Courtesy of Erin E Endom, MD.</div><div id=\"graphicVersion\">Graphic 76127 Version 1.0</div></div></div>"},"76129":{"type":"graphic_figure","displayName":"Tracheal anatomy","title":"Anatomy of the trachea","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Anatomy of the trachea</div><div class=\"cntnt\"><img style=\"width:500px; height:408px;\" src=\"images/PULM/76129_Tracheal_anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 76129 Version 2.0</div></div></div>"},"76130":{"type":"graphic_picture","displayName":"Pathology of granuloma annulare - palisading granuloma periphery","title":"Pathology of granuloma annulare (H&E 400x)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathology of granuloma annulare (H&amp;E 400x)</div><div class=\"cntnt\"><img style=\"width:425px; height:316px;\" src=\"images/DERM/76130_Multinucleated_giant_cell.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This necrobiotic granuloma demonstrates a center of necrobiosis to the right, a rim of lymphocytes and histiocytes at the center, and a multinucleated giant cell at the left of the specimen (H&amp;E 400x).</div><div id=\"graphicVersion\">Graphic 76130 Version 2.0</div></div></div>"},"76131":{"type":"graphic_figure","displayName":"Time course of osmotic demyelination syndrome","title":"Delayed appearance of osmotic demyelination and relowering of the serum sodium","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Delayed appearance of osmotic demyelination and relowering of the serum sodium</div><div class=\"cntnt\"><img style=\"width:535px; height:366px;\" src=\"images/NEPH/76131_Time_course_of_ODS_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Neurologic symptoms of osmotic demyelination syndrome (ODS) typically occur two to six days after correction of the hyponatremia. In this patient, severe hyponatremia was corrected too quickly (23 mEq/L in 48 hours), and coma developed two days later. The serum sodium was quickly relowered and then slowly corrected. Neurologic symptoms improved, which may have been due to relowering of the serum sodium or may have represented spontaneous resolution.</div><div class=\"graphic_footnotes\">sNa: serum sodium.</div><div class=\"graphic_reference\">Reproduced with permission from: Oya S, Tsutsumi K, Ueki K, Kirino T. Reinduction of hyponatremia to treat central pontine myelinolysis. Neurology 2001; 57:1931. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76131 Version 15.0</div></div></div>"},"76132":{"type":"graphic_movie","displayName":"Mitral stenosis parasternal long axis","title":"Mitral stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/76132_mstpalaxconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:260px; height:439px;\" src=\"images/CARD/76132_mstpalax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parasternal long axis view from a 2-D echocardiogram shows limited mobility and doming of the mitral valve (MV), particularly the posterior leaflet, as a result of mitral stenosis. There is also left atrial enlargement.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 76132 Version 2.0</div></div></div>"},"76135":{"type":"graphic_table","displayName":"Consensus statement ov ca","title":"Ovarian cancer symptoms consensus statement","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ovarian cancer symptoms consensus statement</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Historically, ovarian cancer was called the \"silent killer\" because symptoms were not thought to develop until the chance of cure was poor. However, studies have shown that this term is untrue and that the following symptoms are much more likely to occur in women with ovarian cancer than in women in the general population. <strong>These symptoms include</strong><sup>[1,2]</sup>:</td> </tr> <tr> <td class=\"sublist1\">&#8226; Bloating</td> </tr> <tr> <td class=\"sublist1\">&#8226; Pelvic or abdominal pain</td> </tr> <tr> <td class=\"sublist1\">&#8226; Difficulty eating or feeling full quickly</td> </tr> <tr> <td class=\"sublist1\">&#8226; Urinary symptoms (urgency or frequency)</td> </tr> <tr> <td>Women with ovarian cancer report that symptoms are persistent and represent a change from normal for their bodies. The frequency and/or number of such symptoms are key factors in the diagnosis of ovarian cancer<sup>[3]</sup>. Several studies show that even early stage ovarian cancer can produce these symptoms<sup>[2-6]</sup>.</td> </tr> <tr> <td>Women who have these symptoms almost daily for more than a few weeks should see their doctor, preferably a gynecologist. Prompt medical evaluation may lead to detection at the earliest possible stage of the disease. Early stage diagnosis is associated with an improved prognosis.</td> </tr> <tr> <td>Several other symptoms have been commonly reported by women with ovarian cancer<sup>[2-5]</sup>. These symptoms include fatigue, indigestion, back pain, pain with intercourse, constipation, and menstrual irregularities. However, these other symptoms are not as useful in identifying ovarian cancer, because they are also found in equal frequency in women in the general population who do not have ovarian cancer<sup>[1]</sup>.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Gynecologic Cancer Foundation (<A style=\"FONT-STYLE: italic\" href=\"http://www.wcn.org/\">www.wcn.org</A>).<BR>1. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care. JAMA 2004; 291:2705. Level II-2.<BR>2. Olson SH, Mignone L, Nakaraseive C, et al. Symptoms of ovarian cancer. Obstet Gynecol 2001; 98:212. Level II-2.<BR>3. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis: results of a national ovarian cancer survey. Cancer 2000; 89:2068. Level III.<BR>4. Vine MF, Ness RB, Calingaert B, et al. Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor. Gynecol Oncol 2001; 83:466. Level III.<BR>5. Yawn BP, Barrette BA, Wollan PC. Ovarian cancer: the neglected diagnosis. Mayo Clin Proc 2004; 79:1277. Level III.<BR>6. Goff BA, Mandel L, Drescher CW, et al. Development of an ovarian cancer symptom index. Cancer 2007; 109:221. Level II-2.</div><div id=\"graphicVersion\">Graphic 76135 Version 3.0</div></div></div>"},"76136":{"type":"graphic_picture","displayName":"Velamentous cord insertion twin pregnancy","title":"Velamentous cord insertion","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Velamentous cord insertion</div><div class=\"cntnt\"><img style=\"width:499px; height:318px;\" src=\"images/OBGYN/76136_Velamentous_cord3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diamnionic, monochorionic twin placenta with the intervening amnion rolled in the center. Notice the haphazard vascularization (large arrow). The velamentous cord insertion (small arrow) of the smaller twin of this discordant pair is not an unusual finding in monochorionic twins.</div><div class=\"graphic_reference\">Reproduced with permission from: Mhairi G. MacDonald, Mary M. K. Seshia, et al. Avery's Neonatology Pathophysiology &amp; Management of the Newborn, 6th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright &#169; 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76136 Version 2.0</div></div></div>"},"76139":{"type":"graphic_diagnosticimage","displayName":"Tubal recanalization c","title":"Tubal recanalization C","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Tubal recanalization C</div><div class=\"cntnt\"><img style=\"width:499px; height:331px;\" src=\"images/OBGYN/76139_Tubal_recanalization_c.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Widely patent both fallopian tubes (arrows) shown with free spillage of contrast medium into the pelvic intraperitoneal space following the fallopian tube recanalization.</div><div id=\"graphicVersion\">Graphic 76139 Version 2.0</div></div></div>"},"76140":{"type":"graphic_table","displayName":"Management of immunosuppression in skin cancer","title":"Expert consensus on the management of immunosuppression for specific skin cancer scenarios","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Expert consensus on the management of immunosuppression for specific skin cancer scenarios</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\" colspan=\"2\">Skin cancer scenario*</td> <td class=\"subtitle1\" colspan=\"3\">Level of reduction of immunosuppression to consider<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2\">Kidney allograft</td> <td class=\"subtitle2\">Heart allograft</td> <td class=\"subtitle2\">Liver allograft</td> </tr> <tr> <td>1.</td> <td>No history of actinic keratosis or skin cancer</td> <td>None<sup>&#9674;</sup></td> <td>None<sup>&#9674;</sup></td> <td>None<sup>&#9674;</sup></td> </tr> <tr> <td>2.</td> <td> <p>History of actinic keratosis</p> <ul> <li>No risk of mortality </li> <li>Marker for increased skin cancer risk in future </li> </ul> </td> <td>None</td> <td>None<sup>&#9674;</sup></td> <td>None<sup>&#9674;</sup></td> </tr> <tr> <td>3.</td> <td> <p>History of &#8804;1 NMSC per year</p> <ul> <li>Negligible risk of mortality, &#8804;1 minor surgical procedure per year </li> <li>Patients handle this with ease </li> <li>Warning sign of possible future skin cancers </li> </ul> </td> <td>Mild</td> <td>None</td> <td>Mild<sup>&#9674;</sup></td> </tr> <tr> <td>4.</td> <td> <p>History of&nbsp;two to five&nbsp;NMSCs per year</p> <ul> <li>Zero to five&nbsp;percent risk of mortality over&nbsp;three years, minor-moderate surgical procedure&nbsp;two to five times per year </li> <li>Patients can usually handle this, but it starts to bother them </li> <li>Likelihood of numerous future skin cancers </li> </ul> </td> <td>Mild<sup>&#9674;</sup></td> <td>Mild</td> <td>Mild</td> </tr> <tr> <td>5.</td> <td> <p>History of 6 to 10 NMSCs per year</p> <ul> <li>One&nbsp;percent risk of mortality over&nbsp;three years, minor-moderate surgical procedure 6 to 10 times per year </li> <li>Patients can usually handle this, but it bothers them </li> <li>High likelihood of numerous future skin cancers </li> </ul> </td> <td>Mild<sup>&#9674;</sup></td> <td>Mild<sup>&#9674;</sup></td> <td>Mild</td> </tr> <tr> <td>6.</td> <td> <p>History of 11 to 25 NMSCs per year</p> <ul> <li>Two&nbsp;percent risk of mortality over&nbsp;three years, minor-moderate surgical procedure 11 to 25 times per year </li> <li>This level of morbidity causes moderate distress and moderate disfigurement, depression may begin </li> <li>High likelihood of severe future skin cancers </li> </ul> </td> <td>Mild<sup>&#9674;</sup></td> <td>Mild<sup>&#9674;</sup></td> <td>Mild</td> </tr> <tr> <td>7.</td> <td> <p>History of &#62;25 NMSCs per year</p> <ul> <li>Five&nbsp;percent risk of mortality over&nbsp;three years, moderate-severe surgical procedure &#62;25 times per year </li> <li>This level of morbidity causes severe distress and disfigurement </li> <li>Patients question whether transplant was worth it; depression is common </li> <li>High likelihood of severe and possibly life-threatening future skin cancers </li> </ul> </td> <td>Moderate</td> <td>Mild</td> <td>Moderate</td> </tr> <tr> <td>8.</td> <td> <p>Individual high-risk skin cancer:&nbsp;1 percent mortality over&nbsp;three years</p> <ul> <li>Average-risk SCC </li> <li>Cutaneous and oral KS </li> <li>Stage IA melanoma<sup>&#167;</sup> </li> </ul> </td> <td>Mild<sup>&#9674;</sup></td> <td>None</td> <td>Mild</td> </tr> <tr> <td>9. </td> <td> <p>Individual high-risk skin cancer:&nbsp;5 percent mortality over&nbsp;three years</p> <ul> <li>Moderate-risk SCC </li> <li>Stage IB melanoma<sup>&#167;</sup> </li> </ul> </td> <td>Mild</td> <td>Mild</td> <td>Mild</td> </tr> <tr> <td>10.</td> <td> <p>Individual high-risk skin cancer: 10 percent mortality over&nbsp;three years</p> <ul> <li>High-risk SCC </li> <li>Early Merkel cell carcinoma </li> <li>Stage IIA melanoma<sup>&#167;</sup> </li> </ul> </td> <td>Moderate</td> <td>Mild</td> <td>Moderate</td> </tr> <tr> <td>11.</td> <td> <p>Individual high-risk skin cancer: 25 percent mortality over&nbsp;three years</p> <ul> <li>Very high-risk SCC </li> <li>Stage IIB melanoma<sup>&#167;</sup> </li> </ul> </td> <td>Moderate</td> <td>Mild</td> <td>Moderate</td> </tr> <tr> <td>12.</td> <td> <p>Individual high-risk skin cancer: 50 percent mortality over&nbsp;three years</p> <ul> <li>Metastatic SCC </li> <li>Stage IIC/III melanoma<sup>&#167;</sup> </li> <li>Aggressive Merkel cell carcinoma </li> <li>Visceral KS </li> </ul> </td> <td>Severe<sup>&#9674;</sup></td> <td>Moderate</td> <td>Moderate</td> </tr> <tr> <td>13.</td> <td> <p>Individual high-risk skin cancer: 90 percent mortality over&nbsp;three years</p> <ul> <li>Untreatable metastatic SCC </li> <li>Stage IV melanoma<sup>&#167;</sup> </li> <li>Metastatic Merkel cell carcinoma </li> </ul> </td> <td>Severe<sup>&#9674;</sup></td> <td>Severe</td> <td>Severe</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NMSC: nonmelanoma skin cancer; SCC: squamous cell carcinoma; KS: Kaposi's sarcoma.<br />* Estimates of mortality risk are derived from data in immunocompetent patients; risk may be higher in immunosuppressed patients.<br />Δ Appropriate level of reduction of immunosuppression should be individualized on the basis of specific patient- and tumor-related data.<br /><FONT class=lozenge>◊</FONT> Unanimous opinion.<br />§ Melanoma staging derived from the American Joint Commission on Cancer.</div><div class=\"graphic_reference\">Otley CC, Berg D, Ulrich C, et al. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Br J Dermatol 2006; 154:395. Copyright © 2006. Reproduced with permission of John Wiley &amp; Sons, Inc.</div><div id=\"graphicVersion\">Graphic 76140 Version 4.0</div></div></div>"},"76141":{"type":"graphic_picture","displayName":"Cutaneous findings of Stevens-Johnson syndrome","title":"Stevens-Johnson syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Stevens-Johnson syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/EM/76141_CutanStevensJohnsyndrPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vesicles and bullae are characteristic cutaneous findings in Stevens-Johnson syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76141 Version 6.0</div></div></div>"},"76142":{"type":"graphic_picture","displayName":"Chronic bullous disease of childhood 2","title":"Chronic bullous disease of childhood","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Chronic bullous disease of childhood</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/76142_Chronic_bull_dis_child_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76142 Version 1.0</div></div></div>"},"76143":{"type":"graphic_picture","displayName":"Choosing the proper size pediatric mask","title":"Choosing the proper size pediatric mask","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Choosing the proper size pediatric mask</div><div class=\"cntnt\"><img style=\"width:526px; height:475px;\" src=\"images/EM/76143_Mask_size_pediatric.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The correct size mask is the smallest size that completely covers the child's nose and mouth (photos on left), without covering the eyes or overlapping the chin (photos on right).</div><div id=\"graphicVersion\">Graphic 76143 Version 5.0</div></div></div>"},"76145":{"type":"graphic_picture","displayName":"GAVE Light","title":"Gastric antral vascular ectasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric antral vascular ectasia</div><div class=\"cntnt\"><img style=\"width:393px; height:262px;\" src=\"images/GAST/76145_GAVE_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of gastric antral vascular ectasia shows vascular ectasia, spindle cell proliferation, and fibrohyalinosis.</div><div class=\"graphic_reference\">Courtesy of Rome Jutabha, MD and Dennis M Jensen, MD.</div><div id=\"graphicVersion\">Graphic 76145 Version 1.0</div></div></div>"},"76146":{"type":"graphic_picture","displayName":"Body lice in clothing","title":"Body lice in clothing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Body lice in clothing</div><div class=\"cntnt\"><img style=\"width:402px; height:251px;\" src=\"images/PC/76146_Body_lice_in_clothing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Body lice nits tend to concentrate along the seams of clothing.</div><div class=\"graphic_reference\">Photo courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 76146 Version 1.0</div></div></div>"},"76147":{"type":"graphic_picture","displayName":"Palpation lateral femoral condyle","title":"Palpation of the lateral femoral condyle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palpation of the lateral femoral condyle</div><div class=\"cntnt\"><img style=\"width:373px; height:274px;\" src=\"images/EM/76147_Palpation_lat_femoral_condy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palpation of the lateral femoral condyle is performed to assess the integrity of the iliotibial band, a broad, thick fascia that is the distal portion of the tensor fascia lata and the vastus lateralis fascia. It crosses the prominence of the lateral femoral condyle to attach primarily at the proximal tibia and blends with the lateral patellar retinaculum near the lateral joint line. The lateral femoral condyle is palpated 1 inch above the joint line.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 76147 Version 3.0</div></div></div>"},"76148":{"type":"graphic_table","displayName":"Topical antifungal agents","title":"Topical antifungal agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Topical antifungal agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">How supplied*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Azoles<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Clotrimazole<sup>&#916;</sup></td> <td rowspan=\"3\">Twice per day</td> <td>Cream 1%</td> </tr> <tr> <td>Ointment 1%</td> </tr> <tr> <td>Solution 1%</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Econazole</td> <td rowspan=\"2\">Once per day (twice per day for candidiasis)</td> <td>Cream 1%</td> </tr> <tr> <td>Foam 1%</td> </tr> <tr> <td class=\"indent1\">Efinaconazole<sup>&#9674;</sup></td> <td>Once per day</td> <td>Solution 10%</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Ketoconazole</td> <td rowspan=\"4\">Once per day (shampoo is usually one use)</td> <td>Cream 2%</td> </tr> <tr> <td>Shampoo&nbsp;2% (1% shampoo is available over-the-counter)</td> </tr> <tr> <td>Gel 2%</td> </tr> <tr> <td>Foam 2%</td> </tr> <tr> <td class=\"indent1\">Luliconazole</td> <td>Once per day</td> <td>Cream 1%</td> </tr> <tr> <td class=\"indent1\" rowspan=\"7\">Miconazole<sup>&#916;</sup></td> <td rowspan=\"7\">Twice per day</td> <td>Cream 2%</td> </tr> <tr> <td>Ointment 2%</td> </tr> <tr> <td>Solution 2%</td> </tr> <tr> <td>Lotion 2%</td> </tr> <tr> <td>Powder 2%</td> </tr> <tr> <td>Aerosol solution 2%</td> </tr> <tr> <td>Aerosol powder 2%</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Oxiconazole</td> <td rowspan=\"2\">Once to twice per day</td> <td>Cream 1%</td> </tr> <tr> <td>Lotion 1%</td> </tr> <tr> <td class=\"indent1\">Sertaconazole</td> <td>Twice per day</td> <td>Cream 2%</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Sulconazole</td> <td class=\"divider_bottom\" rowspan=\"2\">Once or twice per day</td> <td>Cream 1%</td> </tr> <tr class=\"divider_bottom\"> <td>Solution 1%</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Allylamines<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Naftifine</td> <td rowspan=\"4\">Once per day (cream), twice per day (gel)</td> <td>Cream 1%</td> </tr> <tr> <td>Cream 2%</td> </tr> <tr> <td>Gel 1%</td> </tr> <tr> <td>Gel 2%</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">Terbinafine<sup>&#916;</sup></td> <td class=\"divider_bottom\" rowspan=\"3\">Once to twice per day</td> <td>Cream 1%</td> </tr> <tr> <td>Gel 1%</td> </tr> <tr class=\"divider_bottom\"> <td>Spray solution 1%</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Benzylamine<sup>&#167;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Butenafine<sup>&#916;</sup></td> <td>Once per day (twice per day for tinea pedis)</td> <td>Cream 1%</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Polyene: Treats <em>Candida</em> infections only</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">Nystatin</td> <td class=\"divider_bottom\" rowspan=\"3\">Two to three times per day</td> <td>Cream 100,000 units/gram</td> </tr> <tr> <td>Ointment 100,000 units/gram</td> </tr> <tr class=\"divider_bottom\"> <td>Powder 100,000 units/gram</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Other</td> </tr> <tr> <td class=\"indent1\" rowspan=\"5\">Ciclopirox<sup>&#165;</sup></td> <td rowspan=\"5\">Twice per day</td> <td>Cream 0.77%</td> </tr> <tr> <td>Gel 0.77%</td> </tr> <tr> <td>Suspension 0.77%</td> </tr> <tr> <td>Shampoo 1%</td> </tr> <tr> <td>Solution 8%</td> </tr> <tr> <td class=\"indent1\" rowspan=\"6\">Tolnaftate<sup>&#916;</sup><sup>&#135;</sup></td> <td rowspan=\"6\">Twice per day</td> <td>Cream 1%</td> </tr> <tr> <td>Powder 1%</td> </tr> <tr> <td class=\"sublist1_start\">Aerosol:</td> </tr> <tr> <td class=\"sublist1\">Liquid 1%</td> </tr> <tr> <td class=\"sublist1\">Powder 1%</td> </tr> <tr> <td>Solution 1%</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Preparations available in United States and some other countries.<br />¶ Azoles have activity against dermatophytes, tinea versicolor, and <EM>Candida</EM>. Sulconazole, oxiconazole, and luliconazole may be less effective for <EM>Candida</EM> infection than other azoles.<br />Δ Available in over-the-counter (nonprescription) preparations in the United States and some other countries.<br /><FONT class=lozenge>◊</FONT> Indicated for onychomycosis.<br />§ Can treat <EM>Candida</EM> in addition to dermatophytes and tinea versicolor but may be less effective than azoles and ciclopirox for <EM>Candida</EM> infection.<br />¥ Treats dermatophytes, tinea versicolor, and <EM>Candida</EM>.<br />‡ Does not treat <EM>Candida</EM>; less effective than other options for dermatophytes.</div><div class=\"graphic_reference\">Prepared with data from: US Food &amp; Drug Administration (FDA) approved product information. US National Library of Medicine. (Available online at: <A href=\"http://dailymed.nlm.nih.gov/dailymed/about.cfm\" target=_blank>http://dailymed.nlm.nih.gov/dailymed/about.cfm</A>).</div><div id=\"graphicVersion\">Graphic 76148 Version 11.0</div></div></div>"},"76149":{"type":"graphic_table","displayName":"Definitions of sepsis","title":"Definitions of systemic inflammatory response syndrome (SIRS) and different degrees of severity of sepsis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions of systemic inflammatory response syndrome (SIRS) and different degrees of severity of sepsis</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Condition\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Description\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Systemic inflammatory response syndrome</td>\r\n  \r\n   <td>Two or more of the following conditions: temperature &#62;38.5&#176;C or &#60;35.0&#176;C; heart rate of &#62;90 beats/min; respiratory rate of &#62;20 breaths/min or PaCO<sub>2</sub> of &#60;32 mm Hg; and WBC count of &#62;12,000 cells/mL, &#60;4000 cells/mL, or &#62;10 percent immature (band) forms</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Sepsis</td>\r\n  \r\n   <td>SIRS in response to documented infection (culture or Gram stain of blood, sputum, urine, or normally sterile body fluid positive for pathogenic microorganism; or focus of infection identified by visual inspection, eg, ruptured bowel with free air or bowel contents found in abdomen at surgery, wound with purulent discharge)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Severe sepsis</td>\r\n  \r\n   <td>Sepsis and at least one of the following signs of organ hypoperfusion or organ dysfunction: areas of mottled skin; capillary refilling of &#8805;3 s; urinary output of &#60;0.5 mL/kg for at least 1 h or renal replacement therapy; lactate &#62;2 mmol/L; abrupt change in mental status or abnormal EEG findings; platelet count of &#60;100,000 cells/mL or disseminated intravascular coagulation; acute lung injury/ARDS; and cardiac dysfunction (echocardiography)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Septic shock</td>\r\n  \r\n   <td>Severe sepsis and one of the following conditions: systemic mean BP of &#60;60 mm Hg (&#60;80 mm Hg if previous hypertension) after 20 to 30 mL/kg starch or 40 to 60 mL/kg saline solution, or PCWP between 12 and 20 mm Hg; and need for dopamine of &#62;5 mcg/kg/min, or norepinephrine or epinephrine of &#60;0.25 mcg/kg/min to maintain mean BP at &#62;60 mm Hg (80 mm Hg if previous hypertension)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Refractory septic shock</td>\r\n  \r\n   <td>Need for dopamine at &#62;15 mcg/kg/min, or norepinephrine or epinephrine at &#62;0.25 mcg/kg/min to maintain mean BP at &#62;60 mm Hg (80 mm Hg if previous hypertension)</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">14.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=64221&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Definitions_of_sepsis.htm</title></head></div><div class=\"graphic_footnotes\">WBC count: white blood cell count; BP: blood pressure.</div><div class=\"graphic_reference\">Data from: Annane, D, Bellissant, E, Cavaillon, JM. Septic shock. Lancet 2005; 365:63.</div><div id=\"graphicVersion\">Graphic 76149 Version 1.0</div></div></div>"},"76150":{"type":"graphic_diagnosticimage","displayName":"Neurofibrosarcoma CT","title":"Neurofibrosarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neurofibrosarcoma</div><div class=\"cntnt\"><img style=\"width:403px; height:252px;\" src=\"images/PULM/76150_Neurofibrosarcoma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows sharply defined metastases from an axillary neurofibrosarcoma in a patient with scoliosis and a surgical spinal fusion.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 76150 Version 3.0</div></div></div>"},"76152":{"type":"graphic_picture","displayName":"Botryomycosis lesion","title":"Botryomycosis lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Botryomycosis lesion</div><div class=\"cntnt\"><img style=\"width:396px; height:334px;\" src=\"images/ID/76152_Botryomycosis_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lesion on the left knee.</div><div class=\"graphic_reference\">Reproduced with permission from: Magauran CE, Oethinger M, Armstrong WS. Photo Quiz: A marble under the skin. Clin Infect Dis 2008; 47:1579. Copyright ©2008 University of Chicago Press.</div><div class=\"contractual\"><br/><a href=\"http://www.journals.uchicago.edu/\">http://www.journals.uchicago.edu/</a></div><div id=\"graphicVersion\">Graphic 76152 Version 2.0</div></div></div>"},"76153":{"type":"graphic_figure","displayName":"Metabolism of glucose","title":"Metabolism of glucose","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Metabolism of glucose</div><div class=\"cntnt\"><img style=\"width:543px; height:438px;\" src=\"images/ID/76153_Metabolism_of_glucose.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simplified schedule demonstrates the aerobic metabolism of glucose, lactate and triglycerides in the mitochondrion, with a central role for OXPHOS (oxidative phosphorylation) system. When this system is blocked (dotted line), accumulation of lactate and triglycerides occurs, while formation of ketonic bodies increases.</div><div class=\"graphic_reference\">Courtesy of Kees Brinkman, MD.</div><div id=\"graphicVersion\">Graphic 76153 Version 2.0</div></div></div>"},"76154":{"type":"graphic_waveform","displayName":"ECG digoxin toxicity in AF 2","title":"Single-lead electrocardiogram (ECG) showing atrial fibrillation with an accelerated junctional pacemaker","html":"<div class=\"graphic normal\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Single-lead electrocardiogram (ECG) showing atrial fibrillation with an accelerated junctional pacemaker</div><div class=\"cntnt\"><img style=\"width:536px; height:79px;\" src=\"images/CARD/76154_Digitalis_toxicity_in_AF_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 4 electrocardiograms in this sequence demonstrate increasing severity of digoxin toxicity in a patient with atrial fibrillation.<br />In this strip, the R-R intervals are constant, as the ventricles are controlled by an accelerated junctional pacemaker, resulting in a regular tachycardia at 115 beats per minute. Physical examination at this time might lead to the erroneous diagnosis of a regular sinus mechanism.</div><div class=\"graphic_reference\">The four electrocardiograms are adapted from: Childers R, Med Clin North Am 1976; 60:3.</div><div id=\"graphicVersion\">Graphic 76154 Version 6.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"76155":{"type":"graphic_picture","displayName":"Prostate cancer glands light","title":"Prostate adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prostate adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:369px; height:277px;\" src=\"images/ONC/76155_Prostate_cancer_glands_ligh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power photomicrograph of an hematoxylin- and eosin-stained sample of prostate cancer, demonstrating that the malignant glandular structures of the adenocarcinoma (arrows) are smaller in size to the benign glandular structures (arrowheads).</div><div class=\"graphic_reference\">Courtesy of Ximing Yang, MD.</div><div id=\"graphicVersion\">Graphic 76155 Version 2.0</div></div></div>"},"76157":{"type":"graphic_figure","displayName":"Glucose use brain v nonbrain","title":"Glucose use by the brain versus other tissues","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Glucose use by the brain versus other tissues</div><div class=\"cntnt\"><img style=\"width:545px; height:316px;\" src=\"images/PEDS/76157_Glucose_use_brain_v_nonbrai.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Estimated percentage of glucose rate of disappearance (Rd) used by brain and non-brain tissue from infancy to adulthood (n=141). The tissue data points represent the mean values for subjects with body weights, in kg, of 0.5-1.0, 1.1-2.0, 2.1-3.0, 3.1-4.0, 4.1-5.0, 5.1-10, 10.1-15, 15.1-20.0, 20.1-30.0, 30.1-40.0, 40.1-50.0, 50.1-60.0, 60.1-70, and 70.1-95.0, respectively.</div><div class=\"graphic_reference\">Data from Haymond, MW, Sunehag, A, Endocrinol Metab Clin North Am 1999; 28:663.</div><div id=\"graphicVersion\">Graphic 76157 Version 1.0</div></div></div>"},"76159":{"type":"graphic_diagnosticimage","displayName":"Pancreatic cancer MRI","title":"Pancreatic cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic cancer</div><div class=\"cntnt\"><img style=\"width:361px; height:305px;\" src=\"images/GAST/76159_Pancreatic_cancer_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance imaging from a patient with pancreatic cancer. The pancreatic duct has patent portions (arrows) but is partially occluded by tumor (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Michael L Steer, MD.</div><div id=\"graphicVersion\">Graphic 76159 Version 3.0</div></div></div>"},"76160":{"type":"graphic_picture","displayName":"Unraveled suture material","title":"Endoscopic view of unraveled suture material in a patient with a gastric bypass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic view of unraveled suture material in a patient with a gastric bypass</div><div class=\"cntnt\"><img style=\"width:400px; height:344px;\" src=\"images/GAST/76160_Unraveled_suture_material.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Unraveled suture material associated with marginal ulceration after gastric bypass.</div><div class=\"graphic_reference\">Courtesy of Christopher S Huang, MD.</div><div id=\"graphicVersion\">Graphic 76160 Version 3.0</div></div></div>"},"76161":{"type":"graphic_picture","displayName":"Palpating the plantar fascia","title":"Palpating the plantar fascia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palpating the plantar fascia</div><div class=\"cntnt\"><img style=\"width:363px; height:282px;\" src=\"images/RHEUM/76161_Palpating_the_plantar_fasci.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The toes are grasped and dorsiflexed with one hand, while the other hand palpates the plantar aspect of the foot, particularly the bands compressing the plantar fascia.</div><div class=\"graphic_reference\">Courtesy of Robert P Sheon, MD.</div><div id=\"graphicVersion\">Graphic 76161 Version 2.0</div></div></div>"},"76162":{"type":"graphic_picture","displayName":"Necrolytic migratory erythema perioral","title":"Necrolytic migratory erythema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Necrolytic migratory erythema</div><div class=\"cntnt\"><img style=\"width:432px; height:499px;\" src=\"images/DERM/76162_Necrolytic_migratory_erythema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perioral erythematous plaques, erosions, and crusts.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76162 Version 4.0</div></div></div>"},"76163":{"type":"graphic_diagnosticimage","displayName":"Retracted internal anal sphincter","title":"Endoanal ultrasound showing a retracted internal anal sphincter","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Endoanal ultrasound showing a retracted internal anal sphincter</div><div class=\"cntnt\"><img style=\"width:473px; height:444px;\" src=\"images/OBGYN/76163_Retr_int_anal_sphincter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The solid line represents the retracted internal anal sphincter.</div><div id=\"graphicVersion\">Graphic 76163 Version 3.0</div></div></div>"},"76164":{"type":"graphic_figure","displayName":"Glucose and insulin concentrations after prolonged fast","title":"Plasma glucose and insulin concentrations after a prolonged fast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plasma glucose and insulin concentrations after a prolonged fast</div><div class=\"cntnt\"><img style=\"width:420px; height:396px;\" src=\"images/ENDO/76164_Glucos_insulin_prolong_fast.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation between plasma glucose and insulin concentrations in normal subjects and patients with insulinoma after a prolonged fast.</div><div class=\"graphic_reference\">Data from: Service FJ. Diagnostic approach to adults with hypoglycemic disorders. Endocrinol Metab Clin North Am 1999; 28:519.</div><div id=\"graphicVersion\">Graphic 76164 Version 2.0</div></div></div>"},"76165":{"type":"graphic_table","displayName":"Tanner stages of male puberty","title":"Tanner stages of puberty in normal adolescent boys","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tanner stages of puberty in normal adolescent boys</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Stage of puberty</td> <td class=\"subtitle1\">Age (mean &#177; SD)</td> <td class=\"subtitle1\">Genitalia</td> <td class=\"subtitle1\">Serum testosterone (ng/dL)</td> </tr> <tr> <td>1</td> <td>&nbsp;</td> <td>Prepubertal</td> <td>87</td> </tr> <tr> <td>2</td> <td>11.6&#177;1.1</td> <td>Beginning enlargement of scrotum and testes; change in texture and reddening of scrotal skin</td> <td>251</td> </tr> <tr> <td>3</td> <td>12.9&#177;1.0</td> <td>Beginning growth of the penis, mainly in length; further growth of testes and scrotum</td> <td>336</td> </tr> <tr> <td>4</td> <td>13.8&#177;1.0</td> <td>Further growth of penis in length and breadth; further darkening of scrotal skin</td> <td>525</td> </tr> <tr> <td>5</td> <td>14.9&#177;1.1</td> <td>Adult size genitalia</td> <td>571</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SD: standard deviation.</div><div class=\"graphic_reference\">Description of genitalia from: Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970; 45:13; serum testosterone concentrations from Lee PA, Jaffe RB, Midgely AR Jr. Serum gonadotropin, testosterone and prolactin concentrations throughout puberty in boys: a longitudinal study. J Clin Endocrinol Metab 1974; 39:664.</div><div id=\"graphicVersion\">Graphic 76165 Version 4.0</div></div></div>"},"76166":{"type":"graphic_table","displayName":"Clinical features malabsorption","title":"Signs and symptoms of intestinal malabsorption","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms of intestinal malabsorption</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Malabsorption of</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Laboratory findings</td> </tr> <tr> <td>Calories</td> <td>Weight loss with normal appetite</td> <td>&nbsp;</td> </tr> <tr> <td>Fat</td> <td>Pale and voluminous stool, diarrhea without flatulence, steatorrhea</td> <td>Fractional fat excretion (% of dietary fat not absorbed) &#62;6%</td> </tr> <tr> <td>Protein</td> <td>Edema, muscle atrophy, amenorrhea</td> <td>Hypoalbuminemia, hypoproteinemia</td> </tr> <tr> <td>Carbohydrates</td> <td>Watery diarrhea, flatulence, acidic stool pH, milk intolerance, stool osmotic gap</td> <td>Increased breath hydrogen</td> </tr> <tr> <td>Vitamin B12</td> <td>Anemia, subacute combined degeneration of the spinal cord (early symptoms are paresthesias and ataxia associated with loss of vibration and position sense)</td> <td>Macrocytic anemia, vitamin B12 decreased, abnormal Schilling test, serum methylmalonic acid and homocysteine increased</td> </tr> <tr> <td>Folic acid</td> <td>Anemia</td> <td>Macrocytic anemia, serum and RBC folate decreased, serum homocysteine increased</td> </tr> <tr> <td>Vitamin B, general</td> <td>Cheilosis, painless glossitis, acrodermatitis, angular stomatitis</td> <td>&nbsp;</td> </tr> <tr> <td>Iron</td> <td>Microcytic anemia, glossitis, pagophagia</td> <td>Serum iron and ferritin decreased, total iron binding capacity increased</td> </tr> <tr> <td>Calcium and vitamin D</td> <td>Paresthesia, tetany, pathologic fractures due to osteomalacia, positive Chvostek and Trousseau signs</td> <td>Hypocalcemia, serum alkaline phosphatase increased, abnormal bone densitometry</td> </tr> <tr> <td>Vitamin A</td> <td>Follicular hyperkeratosis, night blindness</td> <td>Serum retinol decreased</td> </tr> <tr> <td>Vitamin K</td> <td>Hematoma, bleeding disorders</td> <td>Prolonged prothrombin time, vitamin K-dependent coagulation factors decreased</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RBC: red blood cell.</div><div id=\"graphicVersion\">Graphic 76166 Version 9.0</div></div></div>"},"76168":{"type":"graphic_picture","displayName":"Passive painful arc maneuver","title":"Passive painful arc maneuver","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Passive painful arc maneuver</div><div class=\"cntnt\"><img style=\"width:432px; height:367px;\" src=\"images/EM/76168_Passive_painful_arc_maneuve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This maneuver, when combined with subacromial space tenderness, assesses the degree of impingement. One hand is placed atop the acromion and one hand grasps the proximal forearm. The patient is asked to relax the shoulder. The arm is carefully raised (without the help of the patient!) while simultaneously preventing the patient from shrugging. Note whether the patient guards by shrugging as the maneuver is performed.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 76168 Version 3.0</div></div></div>"},"76169":{"type":"graphic_picture","displayName":"Tinea cruris buttocks","title":"Tinea cruris, involvement of buttocks","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tinea cruris, involvement of buttocks</div><div class=\"cntnt\"><img style=\"width:396px; height:285px;\" src=\"images/PC/76169_Tinea_cruris_buttocks.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient with tinea cruris exhibited extension of disease to the buttocks and gluteal cleft.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76169 Version 1.0</div></div></div>"},"76171":{"type":"graphic_diagnosticimage","displayName":"Cystic hygroma CXR I","title":"Cystic hygroma in newborn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystic hygroma in newborn</div><div class=\"cntnt\"><img style=\"width:432px; height:272px;\" src=\"images/PULM/76171_Cystic_hygroma_CXR_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph shows a large mass involving the chest wall of the left hemithorax.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 76171 Version 2.0</div></div></div>"},"76172":{"type":"graphic_figure","displayName":"NYHA LVEF outcome MV surgery","title":"Survival after mitral valve surgery is better for patients in NYHA class I/II independent of LVEF","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Survival after mitral valve surgery is better for patients in NYHA class I/II independent of LVEF</div><div class=\"cntnt\"><img style=\"width:504px; height:278px;\" src=\"images/CARD/76172_NYHA_LVEF_outcome_MV_surger.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long-term patient survival after mitral valve surgery for chronic mitral regurgitation is better in those in NYHA class I/II compared to those in class III/IV at the time of surgery. The benefit is independent of the left ventricular ejection fraction (LVEF).</div><div class=\"graphic_reference\">Data from Tribouilloy CM, Enriquez-Sarano M, Schaff, HV et al. Circulation 1999; 99:400.</div><div id=\"graphicVersion\">Graphic 76172 Version 2.0</div></div></div>"},"76173":{"type":"graphic_table","displayName":"B pertussis virulence factors","title":"Biologically active substances and virulence factors of <EM>Bordetella pertussis</EM>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Biologically active substances and virulence factors of <EM>Bordetella pertussis</EM></div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Adhesion molecules</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Filamentous hemagglutinin*</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Pertactin*</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Pertussis toxin</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Fimbriae</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Tracheal colonization factor</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Toxins</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Tracheal cytotoxin*</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Pertussis toxin*</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Adenylate cyclase toxin</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Dermonecrotic toxin</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Lipopolysaccharide</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Factors that interfere with phagocytic function</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Adenylate cyclase toxin*</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Pertussis toxin*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">8.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=29204&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>B_pertussis_virulence_facto.htm</title></head></div><div class=\"graphic_footnotes\">* In vitro and in vivo data suggest this factor plays a major role.</div><div class=\"graphic_reference\">Adapted from references [2-7].</div><div id=\"graphicVersion\">Graphic 76173 Version 3.0</div></div></div>"},"76174":{"type":"graphic_picture","displayName":"Millet seeds","title":"Comparative size of millet seeds","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comparative size of millet seeds</div><div class=\"cntnt\"><img style=\"width:432px; height:306px;\" src=\"images/ID/76174_Millet_seeds.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Millet seeds from which the name miliary tuberculosis derives compared to the size of a dime (right) and a centimeter scale (left). These correspond to the approximate size of miliary lesions seen on chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Nesli Basgoz, MD.</div><div id=\"graphicVersion\">Graphic 76174 Version 1.0</div></div></div>"},"76175":{"type":"graphic_movie","displayName":"Chromoendoscopy","title":"Chromoendoscopy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chromoendoscopy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/76175_chromoendoscopyconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:312px; height:329px;\" src=\"images/CARD/76175_chromoendoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spray catheter used for chromendoscopy.</div><div class=\"graphic_reference\">Courtesy of Marcia I Canto, MD, MHS.</div><div id=\"graphicVersion\">Graphic 76175 Version 2.0</div></div></div>"},"76176":{"type":"graphic_figure","displayName":"Depression mortality after MI","title":"Depression after a myocardial infarction predicts mortality","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Depression after a myocardial infarction predicts mortality</div><div class=\"cntnt\"><img style=\"width:389px; height:309px;\" src=\"images/CARD/76176_Depressionmortalityafter.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 887 patients, baseline depression was measured by the Beck Depression Inventory (BDI); those with a higher level of depression (BDI ≥10) had a higher one year mortality than those with a lower level of depression. Although the relationship between mortality and depression decreased with increasing levels of perceived social support (PSS), social support was not directly related to survival.</div><div class=\"graphic_reference\">Data from Frasure-Smith, N, Lesperance, F, Gravel, G, et al, Circulation 2000; 101:1919.</div><div id=\"graphicVersion\">Graphic 76176 Version 2.0</div></div></div>"},"76177":{"type":"graphic_picture","displayName":"Adipose tissue invasion","title":"Invasion of the adipose tissue","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Invasion of the adipose tissue</div><div class=\"cntnt\"><img style=\"width:504px; height:381px;\" src=\"images/ONC/76177_Adipose_tissue_invasion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urothelial carcinoma invading perivesical adipose tissue (pT3).</div><div id=\"graphicVersion\">Graphic 76177 Version 1.0</div></div></div>"},"76178":{"type":"graphic_table","displayName":"Prognosis RMS by primary site","title":"Prognosis of nonmetastatic rhabdomyosarcoma according to site of primary tumor from two different clinical trials","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prognosis of nonmetastatic rhabdomyosarcoma according to site of primary tumor from two different clinical trials</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Site of primary tumor</td> <td class=\"subtitle1\" colspan=\"4\">Five year rates, percent</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">MMT-89</td> <td class=\"subtitle2\" colspan=\"2\">IRS-IV</td> </tr> <tr> <td class=\"subtitle3\">OS</td> <td class=\"subtitle3\">EFS</td> <td class=\"subtitle3\">OS</td> <td class=\"subtitle3\">EFS</td> </tr> <tr> <td>Orbit</td> <td>85</td> <td>53</td> <td>100</td> <td>93</td> </tr> <tr> <td>Genitourinary (not bladder or prostate)</td> <td>94</td> <td>82</td> <td>90</td> <td>83</td> </tr> <tr> <td>Genitourinary (bladder or prostate)</td> <td>80</td> <td>64</td> <td>86</td> <td>79</td> </tr> <tr> <td>Head and neck (nonparameningeal)</td> <td>64</td> <td>35</td> <td>89</td> <td>83</td> </tr> <tr> <td>Head and neck (parameningeal) &#60;3 years of age</td> <td>59</td> <td>33</td> <td>64</td> <td>60</td> </tr> <tr> <td>Head and neck (parameningeal) &#8805;3 years of age</td> <td>65</td> <td>62</td> <td>78</td> <td>73</td> </tr> <tr> <td>Limbs</td> <td>46</td> <td>35</td> <td>71</td> <td>64</td> </tr> <tr> <td>Other</td> <td>63</td> <td>54</td> <td>81</td> <td>77</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MMT-89: International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study-89; IRS-IV: Intergroup Rhabdomyosarcoma Study Group IV protocol; OS: overall survival; EFS: event-free survival.</div><div class=\"graphic_reference\">Data from: Donaldson SS, Anderson JR. Rhabdomyosarcoma: many similarities, a few philosophical differences. J Clin Oncol 2005; 23:2586.</div><div id=\"graphicVersion\">Graphic 76178 Version 5.0</div></div></div>"},"76180":{"type":"graphic_figure","displayName":"Free hand needle knife 1","title":"Free-hand needle-knife papillotomy","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Free-hand needle-knife papillotomy</div><div class=\"cntnt\"><img style=\"width:516px; height:481px;\" src=\"images/GAST/76180_Free_hand_needle_knife_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Martin L Freeman, MD.</div><div id=\"graphicVersion\">Graphic 76180 Version 4.0</div></div></div>"},"76182":{"type":"graphic_diagnosticimage","displayName":"HRCT giant bulla","title":"HRCT giant bulla","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">HRCT giant bulla</div><div class=\"cntnt\"><img style=\"width:369px; height:300px;\" src=\"images/PULM/76182_HRCT_giant_bulla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HRCT image of a giant bulla with adjacent area of compressed pulmonary parenchyma (see arrow).</div><div class=\"graphic_footnotes\">HRCT: high resolution computed tomography.</div><div class=\"graphic_reference\">Courtesy of Fernando J. Martinez, MD, MS.</div><div id=\"graphicVersion\">Graphic 76182 Version 3.0</div></div></div>"},"76183":{"type":"graphic_waveform","displayName":"Normal ECG","title":"Normal ECG","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"76184":{"type":"graphic_picture","displayName":"Lupus pernio - nasal tip","title":"Lupus pernio in sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lupus pernio in sarcoidosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/76184_Lupus_pernio_nasal_tip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous to violaceous plaque is present on the nose of this patient with cutaneous sarcoidosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76184 Version 3.0</div></div></div>"},"76185":{"type":"graphic_figure","displayName":"Component separation technique plane of dissection","title":"Component separation technique plane of dissection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Component separation technique plane of dissection</div><div class=\"cntnt\"><img style=\"width:442px; height:507px;\" src=\"images/SURG/76185_CST-plane-of-dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the plane of dissection between the external oblique muscle and internal oblique muscle for performing the component separation technique.</div><div id=\"graphicVersion\">Graphic 76185 Version 3.0</div></div></div>"},"76186":{"type":"graphic_table","displayName":"SJS/TEN risk HLA type","title":"Human leukocyte antigen types associated with an increased risk of Stevens-Johnson syndrome/toxic epidermal necrolysis induced by specific drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Human leukocyte antigen&nbsp;types associated with an increased risk of Stevens-Johnson syndrome/toxic epidermal necrolysis induced by specific drugs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug type yielding increased risk of SJS/TEN</td> <td class=\"subtitle1\">HLA type</td> </tr> <tr> <td>Sulfonamides</td> <td>HLA-A29, HLA-B12, HLA-DR7</td> </tr> <tr> <td>Oxicam&nbsp;NSAIDs</td> <td>HLA-A2, HLA-B12</td> </tr> <tr> <td>Carbamazepine</td> <td>HLA-B*15:02</td> </tr> <tr> <td>Allopurinol</td> <td>HLA-B*58:01</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis; HLA: human leukocyte antigen; NSAIDs: nonsteroidal anti-inflammatory drugs.</div><div id=\"graphicVersion\">Graphic 76186 Version 12.0</div></div></div>"},"76188":{"type":"graphic_picture","displayName":"Avulsed incisors","title":"Avulsed incisors","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Avulsed incisors</div><div class=\"cntnt\"><img style=\"width:432px; height:379px;\" src=\"images/PEDS/76188_Avulsed_incisors.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Avulsed permanent teeth should be handled by the crown (arrows) to prevent damage to the periodontal ligament.</div><div class=\"graphic_reference\">Courtesy of Dennis J McTigue, MD.</div><div id=\"graphicVersion\">Graphic 76188 Version 1.0</div></div></div>"},"76190":{"type":"graphic_picture","displayName":"Pediculosis corporis","title":"Pediculosis corporis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pediculosis corporis</div><div class=\"cntnt\"><img style=\"width:256px; height:392px;\" src=\"images/DERM/76190_Pediculosis_corporis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Body lice infestation of long duration can lead to hyperpigmentation and excoriations. Lesions tend to be concentrated in areas where clothing seams contact the skin.</div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 76190 Version 2.0</div></div></div>"},"76193":{"type":"graphic_diagnosticimage","displayName":"CT versus EUS","title":"Radial echoendoscope demonstrating a 360-degree image of malignant appearing mediastinal lymph nodes","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Radial echoendoscope demonstrating a 360-degree image of malignant appearing mediastinal lymph nodes</div><div class=\"cntnt\"><img style=\"width:489px; height:189px;\" src=\"images/PULM/76193_CT_versus_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Computed tomography (CT) lymph nodes. B) Endoscopic ultrasound (EUS) radial view.</div><div id=\"graphicVersion\">Graphic 76193 Version 3.0</div></div></div>"},"76194":{"type":"graphic_picture","displayName":"Scleral tuberculosis","title":"Scleral tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scleral tuberculosis</div><div class=\"cntnt\"><img style=\"width:360px; height:234px;\" src=\"images/ID/76194_Scleral_tuberculosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multinodular scleral mass in the left eye.</div><div class=\"graphic_reference\">Reproduced with permission from: Saini JS, Sharma A, Pillai P. Trop Geogr Med 1988; 40:350.</div><div id=\"graphicVersion\">Graphic 76194 Version 2.0</div></div></div>"},"76195":{"type":"graphic_diagnosticimage","displayName":"Medullary sponge kidney CT","title":"Calcifications in medullary sponge kidney","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcifications in medullary sponge kidney</div><div class=\"cntnt\"><img style=\"width:342px; height:288px;\" src=\"images/NEPH/76195_Medullary_sponge_kidney_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan demonstrates bilateral calcifications at the corticomedullary junction in both kidneys as is typically seen with medullary sponge kidney. There is an absence of interstitial calcifications as may be seen with nephrocalcinosis.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 76195 Version 3.0</div></div></div>"},"76196":{"type":"graphic_table","displayName":"Americans with Disabilities Act PI","title":"Americans with Disabilities Act (ADA)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Americans with Disabilities Act (ADA)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Title I of the <strong>Americans with Disabilities Act of 1990</strong>, which took effect on July 26, 1992, prohibits private employers, state and local governments, employment agencies, and labor unions from discriminating against qualified individuals with disabilities in job application procedures; hiring; firing; advancement; compensation; job training; and other terms, conditions, and privileges of employment. An individual with a disability is a person who:</td> </tr> <tr> <td class=\"sublist1\">Has a physical or mental impairment that substantially limits one or more major life activities</td> </tr> <tr> <td class=\"sublist1\">Has a record of such an impairment</td> </tr> <tr> <td class=\"sublist1\">Is regarded as having such an impairment</td> </tr> <tr> <td class=\"sublist1_start\">A qualified employee or applicant with a disability is an individual who, with or without reasonable accommodation, can perform the essential functions of the job in question. Reasonable accommodation may include, but is not limited to:</td> </tr> <tr> <td class=\"sublist1\">Making existing facilities used by employees readily accessible to and usable by persons with disabilities</td> </tr> <tr> <td class=\"sublist1\">Job restructuring</td> </tr> <tr> <td class=\"sublist1\">Modifying work schedules </td> </tr> <tr> <td class=\"sublist1\">Reassignment to a vacant position</td> </tr> <tr> <td class=\"sublist1\">Acquiring or modifying equipment or devices </td> </tr> <tr> <td class=\"sublist1\">Adjusting or modifying examinations, training materials, or policies and providing qualified readers or interpreters</td> </tr> <tr> <td>An employer is required to make an accommodation to the known disability of a qualified applicant or employee if it would not impose an \"undue hardship\" on the operation of the employer's business. Undue hardship is defined as an action requiring significant difficulty or expense when considered in light of factors, such as an employer's size, financial resources, and the nature and structure of its operation.</td> </tr> <tr> <td>An employer is not required to lower quality or production standards to make an accommodation nor is an employer obligated to provide personal use items, such as glasses or hearing aids.</td> </tr> <tr> <td class=\"subtitle1_single\">Medical examinations and inquiries</td> </tr> <tr> <td>Employers may not ask job applicants about the existence, nature, or severity of a disability. Applicants may be asked about their ability to perform specific job functions. A job offer may be conditioned on the results of a medical examination but only if the examination is required for all entering employees in similar jobs. Medical examinations of employees must be job related and consistent with the employer's business needs.</td> </tr> <tr> <td class=\"subtitle1_single\">Drug and alcohol abuse</td> </tr> <tr> <td>Employees and applicants currently engaging in the illegal use of drugs are not covered by the ADA when an employer acts on the basis of such use. Tests for illegal drugs are not subject to the ADA's restrictions on medical examinations. Employers may hold illegal drug users and alcoholics to the same performance standards as other employees.</td> </tr> <tr> <td class=\"subtitle1_single\">Equal Employment Opportunity Commission (EEOC) enforcement of the ADA</td> </tr> <tr> <td>The US EEOC issued regulations to enforce the provisions of Title I of the ADA on July 26, 1991. The provisions originally took effect on July 26, 1992 and covered employers with 25 or more employees. On July 26, 1994, the threshold dropped to include employers with 15 or more employees.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76196 Version 2.0</div></div></div>"},"76198":{"type":"graphic_table","displayName":"Pediatric signs of dehydration","title":"Physical findings of volume depletion in infants and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical findings of volume depletion in infants and children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Finding</td> <td class=\"subtitle1\">Mild<br /> (3 to 5%)</td> <td class=\"subtitle1\">Moderate<br /> (6 to 9%)</td> <td class=\"subtitle1\">Severe<br /> (&#8805;10%)</td> </tr> <tr> <td>Pulse</td> <td>Full, normal rate</td> <td>Rapid</td> <td>Rapid and weak <strong>or </strong>absent</td> </tr> <tr> <td>Systolic pressure</td> <td>Normal</td> <td>Normal to low</td> <td>Low</td> </tr> <tr> <td>Respirations</td> <td>Normal</td> <td>Deep, rate may be increased</td> <td>Deep, tachypnea <strong>or </strong>decreased to absent</td> </tr> <tr> <td>Buccal mucosa</td> <td>Tacky or slightly dry</td> <td>Dry</td> <td>Parched</td> </tr> <tr> <td>Anterior fontanelle</td> <td>Normal</td> <td>Sunken</td> <td>Markedly sunken</td> </tr> <tr> <td>Eyes</td> <td>Normal</td> <td>Sunken</td> <td>Markedly sunken</td> </tr> <tr> <td>Skin turgor</td> <td>Normal</td> <td>Reduced</td> <td>Tenting</td> </tr> <tr> <td>Skin</td> <td>Normal</td> <td>Cool</td> <td>Cool, mottled, acrocyanosis</td> </tr> <tr> <td>Urine output</td> <td>Normal or mildly reduced</td> <td>Markedly reduced</td> <td>Anuria</td> </tr> <tr> <td>Systemic signs</td> <td>Increased thirst</td> <td>Listlessness, irritability</td> <td>Grunting, lethargy, coma</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76198 Version 7.0</div></div></div>"},"76199":{"type":"graphic_table","displayName":"Survival estimates cancer","title":"Summary of studies comparing physicians' estimated survival to patients' actual survival","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of studies comparing physicians' estimated survival to patients' actual survival</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Investigator</td> <td class=\"subtitle1\">Median estimated survival, weeks</td> <td class=\"subtitle1\">Median actual survival, weeks</td> <td class=\"subtitle1\">Estimated survival/ actual survival</td> </tr> <tr> <td>Parkes 1972</td> <td>4.5*</td> <td>2*</td> <td>1.8</td> </tr> <tr> <td>Evans 1985</td> <td>NR</td> <td>NR</td> <td>3.2<sup>&#182;</sup></td> </tr> <tr> <td>Heyse-Moore 1987</td> <td>8</td> <td>2</td> <td>4</td> </tr> <tr> <td>Forster 1988</td> <td>7<sup>&#916;</sup></td> <td>3.5</td> <td>2</td> </tr> <tr> <td>Maltoni 1994</td> <td>6</td> <td>5</td> <td>1.2</td> </tr> <tr> <td>Maltoni 1995</td> <td>6</td> <td>4.6</td> <td>1.3</td> </tr> <tr> <td>Oxenham 1998</td> <td>3</td> <td>2.1</td> <td>1.4</td> </tr> <tr> <td>Maltoni 1999</td> <td>6</td> <td>4.7</td> <td>1.3</td> </tr> <tr> <td>Christakis 2000</td> <td>NR</td> <td>3.4</td> <td>5.3<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NR: not reported.<br />* Values estimated from graph in paper.<br />¶ Ratio of mean estimated survival/mean survival.<br />Δ 7 weeks calculated through statement in paper that survival was overestimated by 3.4 weeks on average.</div><div id=\"graphicVersion\">Graphic 76199 Version 3.0</div></div></div>"},"76200":{"type":"graphic_picture","displayName":"Inverse psoriasis groin","title":"Inverse psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inverse psoriasis</div><div class=\"cntnt\"><img style=\"width:396px; height:264px;\" src=\"images/DERM/76200_Inverse_psoriasis_groin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous plaques involve the inguinal area in this patient with inverse psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76200 Version 3.0</div></div></div>"},"76201":{"type":"graphic_diagnosticimage","displayName":"Stereotactic radiosurgery II","title":"Stereotactic radiosurgery for Cushing's disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stereotactic radiosurgery for Cushing's disease</div><div class=\"cntnt\"><img style=\"width:300px; height:324px;\" src=\"images/ENDO/76201_Stereotactic_radiosurgery1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial section CT image through the sella turcica and pituitary gland of the patient shown in the previous figure. The magnification of the image is considerably greater; the anterior aspect of the image is at the top. The brown areas represent brain or other tissue; the black areas represent air-filled sinuses (eg, the space above and to the left of center is the sphenoid sinus, and the optic foramina are visible angling anterolaterally toward each upper corner of the image); the white areas represent bone (eg, the band below the pituitary gland, which has been artificially colored red and outlined in black, represent the posterior clinoid processes). A computer-assisted stereotactic &quot;photon knife&quot; treatment plan is superimposed on the CT image; it employs two isocenters of 15 Gy radiation delivered by a linear accelerator, one in each half of the anterior pituitary. Each concentric circle is an isorad 1 Gy less than the next inner circle. The cavernous sinuses will receive about 8 cGy of radiation.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 76201 Version 3.0</div></div></div>"},"76203":{"type":"graphic_figure","displayName":"Anorectic drugs aortic regurg","title":"Anorectic drugs produce mild to moderate aortic regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anorectic drugs produce mild to moderate aortic regurgitation</div><div class=\"cntnt\"><img style=\"width:363px; height:310px;\" src=\"images/CARD/76203_Anorecticdrugsaorticregu.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When the echocardiograms from 257 patients receiving anorectic drugs were compared&nbsp;with 239 control patients, there was a significant increase in the incidence of trace to moderate aortic regurgitation among those using anorectic drugs.</div><div class=\"graphic_reference\">Data from Khan MA, Herzog CA, St Peter JV, et al. N Engl J Med 1998; 339:713.</div><div id=\"graphicVersion\">Graphic 76203 Version 2.0</div></div></div>"},"76204":{"type":"graphic_diagnosticimage","displayName":"Idiopathic pulm fibrosis PA","title":"Idiopathic pulmonary fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Idiopathic pulmonary fibrosis</div><div class=\"cntnt\"><img style=\"width:360px; height:353px;\" src=\"images/PULM/76204_Idiopathic_pulm_fibrosis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows diffuse, coarse reticular opacities involving all compartments of both lungs. Dilatation of both central pulmonary arteries indicates pulmonary arterial hypertension and cor pulmonale. Traction bronchiectasis contributes to the cystic and tubular lucencies. The lung volumes are preserved.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 76204 Version 3.0</div></div></div>"},"76206":{"type":"graphic_figure","displayName":"Sliding hernia repair","title":"Sliding hernia repair","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Sliding hernia repair</div><div class=\"cntnt\"><img style=\"width:541px; height:619px;\" src=\"images/SURG/76206_Sliding_hernia_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) The hernia sac is opened, exposing the intraperitoneal serosa-covered surface of the sliding sigmoid colon. <BR>B) The peritoneal portion of the sac is trimmed, leaving a cuff of peritoneum attached to the sigmoid colon, which can be everted for approximation across the extraperitoneal mesenteric area.<BR>C) The opposing leaves of the peritoneal cuff are sutured together from apex to internal ring.<BR>D) The newly peritonealized sigmoid colon is returned to the abdominal cavity allowing for closure of the neck of the peritoneal component of the sac.</div><div id=\"graphicVersion\">Graphic 76206 Version 2.0</div></div></div>"},"76207":{"type":"graphic_picture","displayName":"Little brown mushrooms ","title":"Little brown mushrooms or backyard mushrooms: Lepiota naucina","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Little brown mushrooms or backyard mushrooms: Lepiota naucina</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/EM/76207_Lepiota_naucina.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One of the many types of &quot;little brown mushrooms&quot; found growing in backyards. Lepiota naucina are edible. These mushrooms are sometimes confused with Amanita virosa (and other Amanita species) resulting in severe toxicity.</div><div class=\"graphic_reference\">Courtesy of Paul Dengler. Identification by William Hollenbaugh.</div><div id=\"graphicVersion\">Graphic 76207 Version 3.0</div></div></div>"},"76208":{"type":"graphic_picture","displayName":"Actinic keratosis histopathology","title":"Actinic keratosis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Actinic keratosis</div><div class=\"cntnt\"><img style=\"width:540px; height:364px;\" src=\"images/DERM/76208_Actinic_keratosis_histopath.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Partial thickness epidermal dysplasia, solar collagen degeneration, and mild lymphocytic inflammation in the superficial dermis.</div><div id=\"graphicVersion\">Graphic 76208 Version 2.0</div></div></div>"},"76209":{"type":"graphic_picture","displayName":"Canker sore PI","title":"Canker sores","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Canker sores</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PI/76209_Canker_sore_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Canker sores are open sores that are white or yellow in the middle, and red around the edges. This person has canker sores on the inside of the mouth.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76209 Version 4.0</div></div></div>"},"76214":{"type":"graphic_picture","displayName":"Atopic derm infantile PI","title":"Atopic dermatitis in infants","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atopic dermatitis in infants</div><div class=\"cntnt\"><img style=\"width:327px; height:419px;\" src=\"images/PI/76214_Atopic_derm_infantile_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In infants with atopic dermatitis, the face often turns red and&nbsp;forms tiny blisters,&nbsp;scales, and crusts. The trunk and arms can have similar symptoms, but those areas are usually less severely affected. That's because babies have an easier time scratching their face than other parts of their body, and scratching worsens the symptoms. This baby is squeezing the skin on his chest to relieve the intense itching.</div><div class=\"graphic_reference\">Reproduced with permission from: Fitzpatrick, TB, Johnson, RA, Wolff, K, et al (Eds). Color Atlas and Synopsis of Clinical Dermatology, 3rd ed, McGraw-Hill, New York, 1997. Copyright © McGraw-Hill.</div><div id=\"graphicVersion\">Graphic 76214 Version 5.0</div></div></div>"},"76215":{"type":"graphic_diagnosticimage","displayName":"Biliary atresia type 2","title":"Biliary atresia type 2","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Biliary atresia type 2</div><div class=\"cntnt\"><img style=\"width:473px; height:390px;\" src=\"images/PEDS/76215_Biliary_atresia_type_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biliary atresia type 2. Visualization of a narrow and irregular distal common bile duct. Normal cystic duct and gallbladder.</div><div class=\"graphic_reference\">Reproduced with permission from: Guelrud M, Carr-Locke DL, Fox VL. ERCP in Pediatric Practice: Diagnosis and Treatment. Isis Medical Media, London 1997. Copyright © 1997 Taylor and Francis.</div><div id=\"graphicVersion\">Graphic 76215 Version 10.0</div></div></div>"},"76216":{"type":"graphic_picture","displayName":"Granuloma annulare hand","title":"Granuloma annulare","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Granuloma annulare</div><div class=\"cntnt\"><img style=\"width:432px; height:362px;\" src=\"images/DERM/76216_Granuloma_annulare_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This granuloma annulare lesion is an erythematous, nonscaly, annular plaque.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76216 Version 3.0</div></div></div>"},"76217":{"type":"graphic_table","displayName":"Differential diagnosis of posterior heel or calf pain ","title":"Differential diagnosis of posterior heel or calf pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of posterior heel or calf pain</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td>Ankle sprain</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1_start\">Stress fracture </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Calcaneal </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Tibial </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Tendinopathy of ankle tendons other than Achilles</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Posterior impingement syndrome</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Severs lesion (calcaneal apophysitis in adolescents)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Accessory soleus muscle</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Osteoarthritis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1_start\">Neuropathy </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Peripheral </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Tarsal tunnel syndrome </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Vascular claudication</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Deep venous thrombosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Rheumatologic disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Cellulitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Abscess</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Osteomyelitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Bone cyst</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Malignancy</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Hematoma</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 76217 Version 2.0</div></div></div>"},"76219":{"type":"graphic_table","displayName":"IPS Hodgkin lymphoma","title":"The International Prognostic Score for Hodgkin lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The International Prognostic Score for Hodgkin lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td colspan=\"3\">One point is given for each of the characteristics below present in the patient, for a total score ranging from zero to seven</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Serum albumin &#60;4 g/dL</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Hemoglobin &#60;10.5 g/dL</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Male gender</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Age &#62;45 years</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Stage IV disease</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">White blood cell count &#8805;15,000/microL</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\">Absolute lymphocyte count &#60;600/microL and/or &#60;8 percent of the total white blood cell count</td> </tr> <tr> <td colspan=\"3\">When applied to an initial group of 5141 patients with advanced Hodgkin lymphoma treated prior to 1992 with combination chemotherapy with or without radiation therapy, five-year overall survival (OS) and freedom from progression (FFP) rates according to score were as follows<sup>[1]</sup>:</td> </tr> <tr> <td class=\"subtitle2\">Score</td> <td class=\"subtitle2\">Five-year FFP, percent</td> <td class=\"subtitle2\">Five-year OS, percent</td> </tr> <tr> <td class=\"centered\">0</td> <td class=\"centered\">84</td> <td class=\"centered\">89</td> </tr> <tr> <td class=\"centered\">1</td> <td class=\"centered\">77</td> <td class=\"centered\">90</td> </tr> <tr> <td class=\"centered\">2</td> <td class=\"centered\">67</td> <td class=\"centered\">81</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">60</td> <td class=\"centered\">78</td> </tr> <tr> <td class=\"centered\">4</td> <td class=\"centered\">51</td> <td class=\"centered\">61</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">5 or more</td> <td class=\"centered\">42</td> <td class=\"centered\">56</td> </tr> <tr> <td colspan=\"3\">When applied to 740 patients with advanced Hodgkin lymphoma treated with curative intent with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) from 1980 to 2010, five-year OS and FFP rates according to score were as follows<sup>[2]</sup>:</td> </tr> <tr> <td class=\"subtitle2\">Score</td> <td class=\"subtitle2\">Five-year FFP, percent</td> <td class=\"subtitle2\">Five-year OS, percent</td> </tr> <tr> <td class=\"centered\">0</td> <td class=\"centered\">88</td> <td class=\"centered\">98</td> </tr> <tr> <td class=\"centered\">1</td> <td class=\"centered\">84</td> <td class=\"centered\">97</td> </tr> <tr> <td class=\"centered\">2</td> <td class=\"centered\">80</td> <td class=\"centered\">91</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">74</td> <td class=\"centered\">88</td> </tr> <tr> <td class=\"centered\">4</td> <td class=\"centered\">67</td> <td class=\"centered\">85</td> </tr> <tr> <td class=\"centered\">5 or more</td> <td class=\"centered\">62</td> <td class=\"centered\">67</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506.</li>&#xD;&#xA;    <li>Moccia AA, Donaldson J, Chhanabhai M, et al. International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era. J Clin Oncol 2012; 30:3383.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 76219 Version 5.0</div></div></div>"},"76220":{"type":"graphic_table","displayName":"Risk factors ICH warfarin","title":"Risk factors for intracerebral hemorrhage during warfarin anticoagulation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for intracerebral hemorrhage during warfarin anticoagulation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Firmly established risk factors</td>\n</tr>\n\n<tr>\n<td>Advancing age (especially &#62;75 years)</td>\n</tr>\n\t\n<tr>\n<td>Hypertension (especially systolic blood pressure &#62;160 mmHg)</td>\n</tr>\n\n<tr>\n<td>History of cerebrovascular disease</td>\n</tr>\n\n<tr>\n<td>Intensity of anticoagulation</td>\n</tr>\n\n<tr>\n<td class=\"subtitle1_single\">Possible risk factors</td>\n</tr>\n\n<tr>\n<td>Concomitant use of aspirin</td>\n</tr>\n\n<tr>\n<td>Cerebral amyloid angiopathy</td>\n</tr>\n\n<tr>\n<td>Asian or Mexican-American ethnicity</td>\n</tr>\n\n<tr>\n<td>Tobacco smoking</td>\n</tr>\n\n<tr>\n<td>Heavy alcohol consumption</td>\n</tr>\n\n<tr>\n<td class=\"subtitle1_single\">Imaging and genetic markers</td>\n</tr>\n\n<tr>\n<td>Leukoaraiosis detected by brain CT/MRI</td>\n</tr>\n\n<tr>\n<td>Microbleeds by T2*-weighted MRI</td>\n</tr>\n\n<tr>\n<td>APOE epsilon II or IV genotype</td>\n</tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">7.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">4/24/2007 - permission requested to LWW. sending to Terrence to make.mt 4/24/2007 - granted.mt 4/25/2008--Requested renewal (JD). 6/6/2008--Renewal granted (JD). 5/30/2009--Renewal granted via Rightslink (JD). 6/6/2010--Renewal granted via Rightslink (JD).</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=26564&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Risk_factors_ICH_warfarin.htm</title></head></div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: Recent data and ideas. Stroke 2005; 36:1588. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76220 Version 9.0</div></div></div>"},"76221":{"type":"graphic_table","displayName":"Suicide method by gender","title":"Percentage of fatal and nonfatal suicide attempts among persons aged ≤17 years, by sex, age group, and method used - Oregon,1988-1993","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Percentage of fatal and nonfatal suicide attempts among persons aged &le;17 years, by sex, age group, and method used - Oregon,1988-1993</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"10\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Method</td> <td class=\"subtitle1\" colspan=\"7\">Nonfatal attempts</td> <td class=\"subtitle1\" rowspan=\"3\">Percent fatal attempts<sup>&#182;</sup>, n=124</td> <td class=\"subtitle1\" rowspan=\"3\">Percent attempts resulting in death<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Total attempts</td> <td class=\"subtitle2\" colspan=\"2\">Sex, percent</td> <td class=\"subtitle2\" colspan=\"3\">Age group, years</td> </tr> <tr> <td class=\"subtitle3\">Number</td> <td class=\"subtitle3\">Percent</td> <td class=\"subtitle3\">Male, n=726</td> <td class=\"subtitle3\">Female, n=3057</td> <td class=\"subtitle3\">&#60;12, n=1821</td> <td class=\"subtitle3\">13-14, n=1029</td> <td class=\"subtitle3\">15-17, n=2572</td> </tr> <tr> <td>Poisoning, drugs</td> <td>2857</td> <td>75.5</td> <td>57.4</td> <td>79.8</td> <td>75.3</td> <td>77.5</td> <td>74.8</td> <td>9.7</td> <td>0.4</td> </tr> <tr> <td>Poisoning, solids and liquids</td> <td>174</td> <td>4.6</td> <td>6.6</td> <td>4</td> <td>6</td> <td>5.5</td> <td>4.1</td> <td>0.8</td> <td>0.6</td> </tr> <tr> <td>Poisoning, gas</td> <td>8</td> <td>0.2</td> <td>1</td> <td>0.1</td> <td>0</td> <td>0.3</td> <td>0.2</td> <td>4</td> <td>35.7</td> </tr> <tr> <td>Suffocation/ hanging</td> <td>91</td> <td>2.4</td> <td>7</td> <td>1.3</td> <td>8.2</td> <td>2.1</td> <td>2.1</td> <td>18.5</td> <td>20.2</td> </tr> <tr> <td>Drowning</td> <td>4</td> <td>0.1</td> <td>0.4</td> <td>0.1</td> <td>0</td> <td>0.1</td> <td>0.2</td> <td>-</td> <td>-</td> </tr> <tr> <td>Using firearms</td> <td>23</td> <td>0.6</td> <td>2.6</td> <td>0.2</td> <td>0</td> <td>0.6</td> <td>0.8</td> <td>63.7</td> <td>78.2</td> </tr> <tr> <td>Cutting/ piercing</td> <td>421</td> <td>11.1</td> <td>16.3</td> <td>9.9</td> <td>7.1</td> <td>9.9</td> <td>11.9</td> <td>-</td> <td>-</td> </tr> <tr> <td>Jumping from a high place</td> <td>23</td> <td>0.6</td> <td>1.7</td> <td>0.3</td> <td>-</td> <td>0.5</td> <td>0.7</td> <td>-</td> <td>-</td> </tr> <tr class=\"divider_bottom\"> <td>Other<sup>&#9674;</sup></td> <td>182</td> <td>4.8</td> <td>7</td> <td>4.2</td> <td>3.3</td> <td>3.6</td> <td>5.3</td> <td>3.2</td> <td>2.2</td> </tr> <tr> <td>Total</td> <td>3783</td> <td>100</td> <td>100</td> <td>100</td> <td>100</td> <td>100</td> <td>100</td> <td>100</td> <td>3.2</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Source: Oregon Adolescent Suicide Attempt Data System.<br />¶ Source: Oregon death certificate data.<br />Δ Calculated by dividing the number of fatal attempts in a category by the total number of attempts in that category.<br /><FONT class=lozenge>◊</FONT> Includes attempts by multiple methods.</div><div class=\"graphic_reference\">Adapted from MMWR Morb Mortal Wkly Rep 1995; 44:312.</div><div id=\"graphicVersion\">Graphic 76221 Version 2.0</div></div></div>"},"76223":{"type":"graphic_picture","displayName":"Oral aphthae in Behçet's syndrome","title":"Oral aphthae in Behçet's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral aphthae in Behçet's syndrome</div><div class=\"cntnt\"><img style=\"width:233px; height:155px;\" src=\"images/RHEUM/76223_Oral_aphthae_Behcets_edt_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple painful oral aphthae in a patient with Behçet's syndrome.</div><div class=\"graphic_reference\">Courtesy of Samuel Moschella, MD.</div><div id=\"graphicVersion\">Graphic 76223 Version 4.0</div></div></div>"},"76224":{"type":"graphic_figure","displayName":"Medial approach to open repair of popliteal aneurysm","title":"Medial approach to open repair of popliteal aneurysm","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Medial approach to open repair of popliteal aneurysm</div><div class=\"cntnt\"><img style=\"width:507px; height:692px;\" src=\"images/SURG/76224_Pop_repair_medial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right lower extremity popliteal artery&nbsp;aneurysm repair: With the medial approach, the popliteal artery aneurysm is left in-situ and bypassed using a segment of saphenous vein. The incision (dotted black line) is made along the medial leg (A). The popliteal artery aneurysm&nbsp;is ligated proximal and distal to the aneurysm to exclude it from the circulation (B).&nbsp;The vein graft can be tunnelled subcutaneously along the medial aspect of the knee or positioned adjacent the popliteal artery (inset) depending upon the extent of the bypass, patient anatomy, and operator preference (C).</div><div id=\"graphicVersion\">Graphic 76224 Version 3.0</div></div></div>"},"76225":{"type":"graphic_picture","displayName":"PXE neck","title":"Pseudoxanthoma elasticum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudoxanthoma elasticum</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/76225_PXE_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous, confluent yellow papules are present on the neck of this patient with pseudoxanthoma elasticum.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76225 Version 3.0</div></div></div>"},"76226":{"type":"graphic_waveform","displayName":"ECG sinus rhythm WPW","title":"12-lead electrocardiogram (ECG) of a patient in sinus rhythm with Wolff-Parkinson-White (WPW) pattern","html":"<div class=\"graphic normal\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) of a patient in sinus rhythm with Wolff-Parkinson-White (WPW) pattern</div><div class=\"cntnt\"><img style=\"width:541px; height:304px;\" src=\"images/CARD/76226_SinusECGWPW.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nearly full preexcitation is manifest in normal sinus rhythm on the 12-lead ECG in this patient with a short accessory pathway refractory period. The ventricular complex in preexcitation is a fusion of the impulse that preexcites the ventricles due to rapid conduction through an accessory pathway and of the impulse that takes the usual route through the atrioventricular (AV) node; this fusion creates the delta wave that is characteristic of Wolff-Parkinson-White ECG pattern.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 76226 Version 7.0</div></div><div style=\"width: 466px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:466px; height:324px;\" src=\"images/CARD/58149_Sinusrhythm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal sinus rhythm at a rate of 71 beats/minute, a P wave axis of 45°, and a PR interval of 0.15 seconds.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram.</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 58149 Version 4.0</div></div></div>"},"76227":{"type":"graphic_table","displayName":"Ancillary testing in MS","title":"Ancillary testing in multiple sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ancillary testing in multiple sclerosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Percent abnormal in patients with multiple sclerosis</td> </tr> <tr> <td>Visual evoked responses</td> <td class=\"centered\">50 to 90</td> </tr> <tr> <td>Brainstem auditory evoked responses</td> <td class=\"centered\">20 to 55</td> </tr> <tr> <td>Somatosensory evoked potentials</td> <td class=\"centered\">50</td> </tr> <tr> <td>Cerebrospinal fluid oligoclonal banding</td> <td class=\"centered\">85 to 95</td> </tr> <tr> <td>Cerebrospinal fluid IgG index</td> <td class=\"centered\">75</td> </tr> <tr> <td>Brain MRI</td> <td class=\"centered\">70 to 95</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Giesser BS. Diagnosis of multiple sclerosis. Neurol Clin 2011; 29:381.</li>&#xD;&#xA;    <li>Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry 2013; 84:909.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 76227 Version 4.0</div></div></div>"},"76228":{"type":"graphic_table","displayName":"Mode of transmission of HIV in adolescents","title":"Modes of transmission of HIV in 13- to 19-year-olds, United States, 2010","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modes of transmission of HIV in 13- to 19-year-olds, United States, 2010</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Mode of transmission</td> <td class=\"subtitle1\">Females</td> <td class=\"subtitle1\">Males</td> </tr> <tr> <td>Heterosexual contact*</td> <td>84&nbsp;percent</td> <td>3&nbsp;percent</td> </tr> <tr> <td>Male-to-male sexual contact (MSM)</td> <td>NA</td> <td>93&nbsp;percent</td> </tr> <tr> <td>Injection drug use (IDU)</td> <td>6&nbsp;percent</td> <td>1&nbsp;percent</td> </tr> <tr> <td>MSM + IDU</td> <td>NA</td> <td>2&nbsp;percent</td> </tr> <tr> <td>Other<sup>&#182;</sup></td> <td>10 percent</td> <td>1 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; NA: not applicable.<br />* Heterosexual contact with a person known to have or to be at high risk for HIV infection.<br />¶ Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.</div><div class=\"graphic_reference\">Adapted from: Centers for Disease Control and Prevention. HIV surveillance in adolescents and young adults. Available at: <A href=\"http://www.cdc.gov/hiv/pdf/statistics_surveillance_adolescents.pdf\">http://www.cdc.gov/hiv/pdf/statistics_surveillance_adolescents.pdf</A>. Accessed on July 7, 2015.</div><div id=\"graphicVersion\">Graphic 76228 Version 5.0</div></div></div>"},"76229":{"type":"graphic_table","displayName":"Presenting symptoms lung ca","title":"Symptoms of lung cancer in over 3500 patients at presentation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms of lung cancer in over 3500 patients at presentation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Symptom</td>\n<td class=\"subtitle1\">Patients (percent)</td>\n</tr>\n\n<tr>\n<td>Cough</td>\n<td>45-74</td>\n</tr>\n\t\n<tr>\n<td>Weight loss</td>\n<td>46-68</td>\n</tr>\n\n<tr>\n<td>Dyspnea</td>\n<td>37-58</td>\n</tr>\n\n<tr>\n<td>Chest pain</td>\n<td>27-49</td>\n</tr>\n\n<tr>\n<td>Hemoptysis</td>\n<td>27-29</td>\n</tr>\n\n<tr>\n<td>Bone pain</td>\n<td>20-21</td>\n</tr>\n\n<tr>\n<td>Hoarseness</td>\n<td>8-18</td>\n</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Modified from: Hyde, L, Hyde, CI. Chest 1974; 65:299-306 and Chute CG, et al. Cancer 1985; 56:2107-2111.</div><div id=\"graphicVersion\">Graphic 76229 Version 1.0</div></div></div>"},"76230":{"type":"graphic_diagnosticimage","displayName":"Pulmonary artery sarcoma","title":"Osteogenic sarcoma of the pulmonary artery","html":"<div class=\"graphic\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Osteogenic sarcoma of the pulmonary artery</div><div class=\"cntnt\"><img style=\"width:656px; height:526px;\" src=\"images/PULM/76230_Pulmonary_artery_sarcoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph (above left) shows a left hilar mass and multiple bilateral calcified pulmonary nodules. The pulmonary arteriogram (above right) shows obstruction of the left pulmonary artery and a filling defect in the right pulmonary artery. The CT scan (bottom) demonstrates ossified tumor in the left pulmonary artery (arrow), and in the periphery of the left lung.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 76230 Version 3.0</div></div></div>"},"76232":{"type":"graphic_figure","displayName":"Spironolactone in heart failure","title":"Spironolactone reduces mortality in heart failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spironolactone reduces mortality in heart failure</div><div class=\"cntnt\"><img style=\"width:387px; height:346px;\" src=\"images/CARD/76232_Spironolactone_in_heart_fai.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier analysis of survival among 1663 patients with advanced heart failure in the RALES trial shows that spironolactone reduces mortality by 30 percent (35 versus 46 percent for placebo, p&lt;0.001).</div><div class=\"graphic_reference\">Data from: Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709.</div><div id=\"graphicVersion\">Graphic 76232 Version 3.0</div></div></div>"},"76233":{"type":"graphic_figure","displayName":"MCFONTZL classification system","title":"MCFONTZL classification system","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MCFONTZL classification system</div><div class=\"cntnt\"><img style=\"width:432px; height:560px;\" src=\"images/EM/76233_MCFONTZL_class_system_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">R: right; C: center; L: left; F: forehead; T: temple; O: orbit; Z: zygoma (cheek); N: nose; M: maxilla; L: lip (Up: upper; Lo: lower); Ch: chin.</div><div class=\"graphic_reference\">Reproduced with permission from: Lee R, Gamble WB, Robertson B, Manson PN. The MCFONTZL classification system for soft-tissue injuries to the face. Plast Reconstr Surg 1999; 103:1150. Copyright © 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76233 Version 6.0</div></div></div>"},"76234":{"type":"graphic_picture","displayName":"Acanthosis nigricans in groin","title":"Acanthosis nigricans","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acanthosis nigricans</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/76234_Acanthosis_nigricans_groin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented, velvety plaques are present in the groin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76234 Version 3.0</div></div></div>"},"76235":{"type":"graphic_table","displayName":"Initial hx endometriosis adoles","title":"Initial history","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial history</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Characteristics of the pain: Location (diffuse or localized, if so where?), onset sudden or gradual, constant or intermittent, magnitude, timing, duration, quality (sharp or dull), radiation, relationship to various activities (physical, sexual, physiologic, menses)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Is pain associated with symptoms such as dysuria, urinary frequency, nausea, vomiting, chills, fever, backache or other musculoskeletal pain, or change in bowel habits?</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Past medical/surgical history with attention to symptoms suspicious for, diagnosis of, and therapy for endometriosis or pelvic inflammatory disease (PID), gastrointestinal (GI) or genitourinary (GU) problems, infection, musculoskeletal problems, or psychiatric conditions. Any previous diagnostic tests or treatments for pain?</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Menstrual, contraceptive, sexual, and gynecologic history</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Is there a history of sexual or substance abuse?</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Family history of relevant clinical conditions</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>How does pain interfere with daily activities?</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Does anything make the pain better or worse?</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Adapted from Gambone, JC, Mittman, BS, Munro, MG, et al. Fertil Steril 2002; 78:961.</div><div id=\"graphicVersion\">Graphic 76235 Version 1.0</div></div></div>"},"76236":{"type":"graphic_table","displayName":"Lab tests in iron deficiency","title":"Laboratory tests in iron deficiency of increasing severity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory tests in iron deficiency of increasing severity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Normal</td> <td class=\"subtitle1\">Iron deficiency without anemia</td> <td class=\"subtitle1\">Iron deficiency with mild anemia</td> <td class=\"subtitle1\">Severe iron deficiency with severe anemia</td> </tr> <tr> <td>Marrow reticuloendothelial iron</td> <td><strong>2+ to 3+</strong></td> <td><strong>None</strong></td> <td>None</td> <td>None</td> </tr> <tr> <td>Serum iron (Fe), mcg/dL</td> <td>60 to 150</td> <td>60 to 150</td> <td><strong>&#60;60</strong></td> <td><strong>&#60;40</strong></td> </tr> <tr> <td>Serum iron (Fe), microM/L</td> <td>10.7 to 26.7</td> <td>10.7 to 26.7</td> <td><strong>&#60;10.7</strong></td> <td><strong>&#60;7.1</strong></td> </tr> <tr> <td>Total iron-binding capacity (transferrin, TIBC), mcg/dL</td> <td>300 to 360</td> <td>300 to 390</td> <td>350 to 400</td> <td><strong>&#62;410</strong></td> </tr> <tr> <td>Total iron binding capacity, microM/L</td> <td>53.7 to 64.4</td> <td>53.7 to 69.8</td> <td>62.6 to 71.6</td> <td><strong>&#62;73.4</strong></td> </tr> <tr> <td>Transferrin saturation (Fe/TIBC), percent</td> <td>20 to 50</td> <td>30</td> <td><strong>&#60;15</strong></td> <td>&#60;10</td> </tr> <tr> <td>Hemoglobin, g/dL</td> <td><strong>Normal</strong></td> <td><strong>Normal</strong></td> <td><strong>9 to 12</strong></td> <td><strong>6 to 7</strong></td> </tr> <tr> <td>Hemoglobin, g/L</td> <td><strong>Normal</strong></td> <td><strong>Normal</strong></td> <td><strong>90 to 120</strong></td> <td><strong>60 to 70</strong></td> </tr> <tr> <td>Red cell morphology</td> <td>Normal</td> <td>Normal</td> <td>Normal or slight hypochromia</td> <td>Hypochromia and microcytosis</td> </tr> <tr> <td>Plasma or serum ferritin, ng/mL or microg/L</td> <td>40 to 200</td> <td><strong>&#60;40</strong></td> <td>&#60;20</td> <td>&#60;10</td> </tr> <tr> <td>Plasma or serum ferritin, picoM/L</td> <td>89.9 to 449</td> <td><strong>&#60;89.9</strong></td> <td>&#60;45</td> <td>&#60;22.5</td> </tr> <tr> <td>Erythrocyte protoporphyrin, ng/mL RBC</td> <td>30 to 70</td> <td>30 to 70</td> <td><strong>&#62;100</strong></td> <td>100 to 200</td> </tr> <tr> <td>Other tissue changes</td> <td>None</td> <td>None</td> <td>None</td> <td>Nail and epithelial changes</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: Test results outlined in bold type are the ones most likely to define the various stages of iron deficiency. Thus, the presence or absence of iron stores (marrow reticuloendothelial iron) in a non-anemic patient serves to distinguish normal subjects from those with iron deficiency without anemia, respectively.</div><div id=\"graphicVersion\">Graphic 76236 Version 8.0</div></div></div>"},"76237":{"type":"graphic_picture","displayName":"Neers test for shoulder impingement","title":"Neer test  for shoulder impingement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neer test  for shoulder impingement</div><div class=\"cntnt\"><img style=\"width:399px; height:504px;\" src=\"images/EM/76237_Neer_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The \"passive painful arc maneuver\" shown above involves passively flexing the glenohumeral joint while simultaneously preventing shoulder shrugging. The test is often referred to as the Neer test, and is used to assess shoulder impingement.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD, J Bryan Dixon, MD, and David Kruse, MD.</div><div id=\"graphicVersion\">Graphic 76237 Version 5.0</div></div></div>"},"76239":{"type":"graphic_picture","displayName":"Benign macrofollicular thyroid lesion low-power view","title":"Benign macrofollicular thyroid lesion: Findings on fine-needle aspirate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Benign macrofollicular thyroid lesion: Findings on fine-needle aspirate</div><div class=\"cntnt\"><img style=\"width:360px; height:238px;\" src=\"images/ENDO/76239_Macrofollicular_lesion_FN1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power view of a fine-needle aspirate of a thyroid nodule showing an intact macrofollicle (a) and a macrofollicle that has been broken apart by the biopsy forming a flat sheet (b). At this power, the cells appear uniform in size and are not crowded. Not shown, but commonly present in macrofollicular lesions are areas of cystic degeneration, cellular debris, and hemosiderin-laden macrophages.</div><div id=\"graphicVersion\">Graphic 76239 Version 6.0</div></div></div>"},"76240":{"type":"graphic_table","displayName":"Lab eval liver granulomas","title":"Suggested laboratory evaluation in patients with granulomas on liver biopsy*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested laboratory evaluation in patients with granulomas on liver biopsy*</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Chest film</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Tuberculin skin test</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Serum angiotensin converting enzyme concentration</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Blood cultures (bacteria, fungi, mycobacteria)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Serologies (HIV, Brucella, syphilis, Coxiella, etc.)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Serum antimitochondrial antibodies</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Serum IgM concentration</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acid-fast and fungal stains on liver biopsy</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Specific testing should consider clinical symptoms, travel history.</div><div id=\"graphicVersion\">Graphic 76240 Version 1.0</div></div></div>"},"76242":{"type":"graphic_table","displayName":"Supporting and nonsupporting features dx MSA","title":"Supporting and non-supporting features for a diagnosis of multiple system atrophy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Supporting and non-supporting features for a diagnosis of multiple system atrophy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Supporting features</td> </tr> <tr> <td class=\"indent1\">Orofacial dystonia</td> </tr> <tr> <td class=\"indent1\">Disproportionate antecollis</td> </tr> <tr> <td class=\"indent1\">Camptocormia (severe anterior flexion of the spine) and/or Pisa syndrome (severe lateral flexion of the spine)</td> </tr> <tr> <td class=\"indent1\">Contractures of hands or feet</td> </tr> <tr> <td class=\"indent1\">Inspiratory sighs</td> </tr> <tr> <td class=\"indent1\">Severe dysphonia</td> </tr> <tr> <td class=\"indent1\">Severe dysarthria</td> </tr> <tr> <td class=\"indent1\">New or increased snoring</td> </tr> <tr> <td class=\"indent1\">Cold hands and feet</td> </tr> <tr> <td class=\"indent1\">Pathologic laughter or crying</td> </tr> <tr> <td class=\"indent1\">Jerky, myoclonic postural/action tremor</td> </tr> <tr> <td class=\"subtitle2_left\">Non-supporting features</td> </tr> <tr> <td class=\"indent1\">Classic pill-rolling rest tremor</td> </tr> <tr> <td class=\"indent1\">Clinically significant neuropathy</td> </tr> <tr> <td class=\"indent1\">Hallucinations not induced by drugs</td> </tr> <tr> <td class=\"indent1\">Onset after age 75 years</td> </tr> <tr> <td class=\"indent1\">Family history of ataxia or parkinsonism</td> </tr> <tr> <td class=\"indent1\">Dementia (on DSM-IV)</td> </tr> <tr> <td class=\"indent1\">White matter lesions suggesting multiple sclerosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.</div><div class=\"graphic_reference\">Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71:670.</div><div id=\"graphicVersion\">Graphic 76242 Version 2.0</div></div></div>"},"76244":{"type":"graphic_picture","displayName":"Ganglioneuroma","title":"Ganglioneuroma","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Ganglioneuroma</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/PEDS/76244_Ganglioneuroma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ganglioneuroma is predominantly composed of Schwannian cells studded with maturing or fully mature ganglion cells.</div><div class=\"graphic_reference\">Courtesy of MJ Hicks, MD.</div><div id=\"graphicVersion\">Graphic 76244 Version 1.0</div></div></div>"},"76246":{"type":"graphic_picture","displayName":"Gastric ulcer with adherent clot","title":"Gastric ulcer with adherent clot","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Gastric ulcer with adherent clot</div><div class=\"cntnt\"><img style=\"width:480px; height:374px;\" src=\"images/GAST/76246_Gastric_ulcer_clot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper endoscopy showing a gastric ulcer with an adherent clot (Forrest classification IIb).</div><div class=\"graphic_reference\">Courtesy of Rome Jutabha, MD.</div><div id=\"graphicVersion\">Graphic 76246 Version 1.0</div></div></div>"},"76247":{"type":"graphic_picture","displayName":"Alopecia areata white hair","title":"Alopecia areata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alopecia areata</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/76247_Alopecia_areata_white_hair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patchy alopecia areata on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76247 Version 6.0</div></div></div>"},"76248":{"type":"graphic_figure","displayName":"Thyroid nodule PI","title":"Thyroid nodule","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Thyroid nodule</div><div class=\"cntnt\"><img style=\"width:505px; height:482px;\" src=\"images/PI/76248_Thyroid_nodule_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a thyroid nodule on the left side of the thyroid. Thyroid nodules feel round or oval-shaped and differ from the surrounding normal thyroid tissue. A person may have one or more thyroid nodules.</div><div id=\"graphicVersion\">Graphic 76248 Version 4.0</div></div></div>"},"76249":{"type":"graphic_figure","displayName":"GI reflux off and on acid suppressive therapy","title":"Gastroesophageal reflux in the postprandial period off and on acid suppressive therapy","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Gastroesophageal reflux in the postprandial period off and on acid suppressive therapy</div><div class=\"cntnt\"><img style=\"width:511px; height:504px;\" src=\"images/GAST/76249_GI_reflux_acid_suppressive.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The total number of reflux episodes remains unchanged while the number of acid reflux episodes decreases and the number of non-acid reflux episodes increases on therapy. This indicates that proton pump inhibitor (PPI) therapy only changes the composition of the postprandial refluxate without affecting the total number of reflux episodes.</div><div class=\"graphic_reference\">Data from: Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophagel impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120:1599.</div><div id=\"graphicVersion\">Graphic 76249 Version 3.0</div></div></div>"},"76251":{"type":"graphic_table","displayName":"Diagnostic criteria EGPA (Churg-Strauss)","title":"Diagnostic criteria for eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">American College of Rheumatology criteria*</td> <td class=\"subtitle1\">Lanham criteria<sup>&#182;</sup></td> </tr> <tr> <td>Asthma (a history of wheezing or the finding of diffuse high-pitched wheezes on expiration)</td> <td>Asthma</td> </tr> <tr> <td>Eosinophilia &#62;10 percent on differential white blood cell count</td> <td>Eosinophilia &#62;1500 cells/microL</td> </tr> <tr> <td>Mononeuropathy (including multiplex) or polyneuropathy</td> <td>Systemic vasculitis involving two or more extrapulmonary organs</td> </tr> <tr> <td>Migratory or transient pulmonary opacities detected radiographically</td> <td>&nbsp;</td> </tr> <tr> <td>Paranasal sinus abnormality</td> <td>&nbsp;</td> </tr> <tr> <td>Biopsy containing a blood vessel showing the accumulation of eosinophils in extravascular areas</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Four of the six criteria needed and biopsy evidence of vasculitis.<br />&para; All three criteria needed.</div><div id=\"graphicVersion\">Graphic 76251 Version 5.0</div></div></div>"},"76252":{"type":"graphic_figure","displayName":"Noncontact map fascicular tachy","title":"Noncontact endocardial map of fascicular tachycardia","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Noncontact endocardial map of fascicular tachycardia</div><div class=\"cntnt\"><img style=\"width:553px; height:252px;\" src=\"images/CARD/76252_Noncontactmapfasciculart.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During tachycardia, the fascicular activation sequence is altered; panel A shows that activation begins near the left ventricular apex (red arrow) and panel B shows that activation (red arrow) propagates toward His bundle (white arrow). This rapid retrograde fascicular activation is closely followed by ventricular activation, seen as a white area in panel C. The relative delay in right ventricular activation produces a QRS complex with right bundle branch block pattern in ECG lead I.</div><div class=\"graphic_reference\">With permission from: Peters NS, Jackman WM, Schilling RJ, et al. Circulation 1997; 95:1658.</div><div id=\"graphicVersion\">Graphic 76252 Version 3.0</div></div></div>"},"76253":{"type":"graphic_table","displayName":"Clinical manifestations of cystic fibrosis","title":"Clinical manifestations of cystic fibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of cystic fibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Pulmonary manifestations</td> </tr> <tr> <td class=\"indent1\">Chronic productive cough</td> </tr> <tr> <td class=\"indent1\">Sinusitis</td> </tr> <tr> <td class=\"indent1\">Bronchiolitis/asthma</td> </tr> <tr> <td class=\"indent1\">Pseudomonas aeruginosa colonization of the respiratory tract</td> </tr> <tr> <td class=\"indent1\">Staphylococcal colonization of the respiratory tract</td> </tr> <tr> <td class=\"indent1\">Bronchiectasis</td> </tr> <tr> <td class=\"indent1\">Digital clubbing</td> </tr> <tr> <td class=\"indent1\">Atypical mycobacterial infection</td> </tr> <tr> <td class=\"indent1\">Allergic bronchopulmonary aspergillosis</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal manifestations</td> </tr> <tr> <td class=\"indent1\">Pancreatic insufficiency</td> </tr> <tr> <td class=\"indent1\">Distal intestinal obstruction syndrome (DIOS)</td> </tr> <tr> <td class=\"indent1\">Meconium ileus</td> </tr> <tr> <td class=\"indent1\">Cystic fibrosis-related diabetes (CFRD)</td> </tr> <tr> <td class=\"indent1\">Vitamin deficiencies</td> </tr> <tr> <td class=\"indent1\">Recurrent pancreatitis</td> </tr> <tr> <td class=\"indent1\">Prolonged neonatal jaundice</td> </tr> <tr> <td class=\"indent1\">Biliary cirrhosis with portal hypertension</td> </tr> <tr> <td class=\"indent1\">Dermatitis resembling acrodermatitis enteropathica, with fatty acid and zinc deficiency</td> </tr> <tr> <td class=\"indent1\">Rectal prolapse</td> </tr> <tr> <td class=\"indent1\">Volvulus in fetal life</td> </tr> <tr> <td class=\"subtitle1_single\">Genitourinary</td> </tr> <tr> <td class=\"indent1\">Bilateral absence of vas deferens</td> </tr> <tr> <td class=\"indent1\">Male infertility</td> </tr> <tr> <td class=\"indent1\">Reduced female fertility</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Hypochloremic, hyponatremic alkalosis</td> </tr> <tr> <td class=\"indent1\">Pseudotumor cerebri</td> </tr> <tr> <td class=\"indent1\">Osteoporosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76253 Version 3.0</div></div></div>"},"76254":{"type":"graphic_table","displayName":"Indications and contraindications laparoscopic cholecystectomy","title":"Indications and contraindications for laparoscopic cholecystectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications and contraindications for laparoscopic cholecystectomy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n  <tr>\n    <td class=\"subtitle1_single\">Indications</td>\n  </tr>\n  <tr>\n    <td class=\"sublist1_start\">Symptomatic cholelithiasis</td>\n  </tr>\n  <tr>\n    <td class=\"sublist1\">Biliary colic, acute cholecystitis, gallstone pancreatitis</td>\n  </tr>\n  <tr>\n    <td class=\"sublist1_start\">Asymptomatic cholelithiasis in select cases</td>\n  </tr>\n  <tr>\n    <td class=\"sublist1\">Sickle cell, TPN, immunosuppression</td>\n  </tr>\n  <tr>\n    <td>Acalculous cholecystitis</td>\n  </tr>\n  <tr>\n    <td>Gallbladder dyskinesia</td>\n  </tr>\n  <tr>\n    <td>Large gallbladder polyps</td>\n  </tr>\n  <tr>\n    <td>Porcelain gallbladder</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle1_single\">Contraindications</td>\n  </tr>\n  <tr>\n    <td class=\"sublist1_start\">Absolute</td>\n  </tr>\n  <tr>\n    <td class=\"sublist1\">Inability to tolerate general anesthesia, peritonitis with hemodynamic compromise, refractory coagulopathy, gallbladder cancer</td>\n  </tr>\n  <tr>\n    <td class=\"sublist1_start\">Relative</td>\n  </tr>\n  <tr>\n    <td class=\"sublist1\">Previous abdominal surgery, pregnancy, morbid obesity, cholangitis, severe comorbidities</td>\n  </tr>\n\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 76254 Version 2.0</div></div></div>"},"76259":{"type":"graphic_figure","displayName":"C reactive protein and serum amyloid A predict risk after MI","title":"C reactive protein and serum amyloid A predict risk after myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">C reactive protein and serum amyloid A predict risk after myocardial infarction</div><div class=\"cntnt\"><img style=\"width:373px; height:467px;\" src=\"images/CARD/76259_CRP_amyloid_A_risk_post_MI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the CARE trial of 782 patients with a recent myocardial infarction, patients with serum concentrations of C-reactive protein or amyloid A in the highest quintile had a significantly greater risk for a recurrent fatal or nonfatal cardiac event compared to those with values in the lowest quintile.</div><div class=\"graphic_footnotes\">*p = 0.02.</div><div class=\"graphic_reference\">Data from Ridker PM, Rifai N, Pfeffer MA, et al, for the Cholesterol and Recurrent Events (CARE) Investigators, Circulation 1998; 98:839.</div><div id=\"graphicVersion\">Graphic 76259 Version 3.0</div></div></div>"},"76260":{"type":"graphic_picture","displayName":"Micrograph neurothekeoma","title":"Micrograph neurothekeoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Micrograph neurothekeoma</div><div class=\"cntnt\"><img style=\"width:287px; height:435px;\" src=\"images/NEURO/76260_Micrographneurothekeoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This photomicrograph shows a neurothekeoma of the pretibial region. Neurothekeomas are variably myxoid, moderately cellular neoplasms lacking either Schwann or perineurial cell differentiation. They are distinguished from nerve sheath myxomas by virtue of their increased cellularity and reduced myxoid background. H&amp;E, x100. <br />(B) This is a higher-power photomicrograph demonstrating a cluster of tumor cells, which are variably spindle shaped or epithelioid in appearance. H&amp;E, x400.</div><div class=\"graphic_reference\">Courtesy of John E Donahue, MD.</div><div id=\"graphicVersion\">Graphic 76260 Version 3.0</div></div></div>"},"76262":{"type":"graphic_picture","displayName":"Cirrhosis trichrome Light","title":"Cirrhosis on needle biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cirrhosis on needle biopsy</div><div class=\"cntnt\"><img style=\"width:396px; height:261px;\" src=\"images/GAST/76262_Cirrhosis_trichrome_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Needle biopsy of the liver (40x) of a 61-year-old female with obesity, diabetes, and hyperlipidemia referred for evaluation of chronically elevated serum aminotransferases. Trichrome stain demonstrates bridging fibrosis (blue staining), peri-portal inflammatory infiltrates and marked steatosis. These findings are consistent with cirrhosis secondary to NASH.</div><div class=\"graphic_reference\">Courtesy of Jeremy Ditelberg, MD.</div><div id=\"graphicVersion\">Graphic 76262 Version 1.0</div></div></div>"},"76263":{"type":"graphic_figure","displayName":"Optimal surveillance Barretts","title":"Optimal surveillance intervals in Barrett's esophagus (example data for cost-effectiveness analysis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Optimal surveillance intervals in Barrett's esophagus (example data for cost-effectiveness analysis)</div><div class=\"cntnt\"><img style=\"width:318px; height:304px;\" src=\"images/GAST/76263_Optimal_surveillance_Barret.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Depiction of the optimal endoscopic surveillance intervals in patients with Barrett's esophagus according to the annual incidence of esophageal cancer. More frequent surveillance is associated with increased quality-adjusted life expectancy as the incidence of esophageal cancer increases. In populations with a low incidence of esophageal adenocarcinoma (less than 0.2 percent), not performing surveillance endoscopy produced the optimal quality-adjusted life expectancy. In contrast, annual surveillance (gray area) was optimal in populations with a high incidence of esophageal adenocarcinoma (more than 2 percent). These data were derived from a decision analysis using a Markov model.</div><div class=\"graphic_reference\">Data from: Provenzale D, et al, Am J Gastroenterol 1999; 94:2043.</div><div id=\"graphicVersion\">Graphic 76263 Version 3.0</div></div></div>"},"76264":{"type":"graphic_table","displayName":"DBA versus TEC","title":"Differential diagnosis of acquired pure red cell aplasia in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of acquired pure red cell aplasia in children</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">&nbsp;</td>\r\n                    <td class=\"subtitle1\">Diamond-Blackfan anemia</td>\r\n                    <td class=\"subtitle1\">Transient erythroblastopenia of childhood</td>\r\n                </tr>\r\n                <tr>\r\n                    <td><strong>Age at diagnosis</strong></td>\r\n                    <td>90 percent &#60;1 year</td>\r\n                    <td>80 percent from one to four years</td>\r\n                </tr>\r\n                <tr class=\"divider_top\">\r\n                    <td><strong>Male:Female</strong></td>\r\n                    <td>1.1</td>\r\n                    <td>1.2</td>\r\n                </tr>\r\n                <tr class=\"divider_top\">\r\n                    <td><strong>Etiology</strong></td>\r\n                    <td>Constitutional</td>\r\n                    <td>Acquired</td>\r\n                </tr>\r\n                <tr class=\"divider_top\">\r\n                    <td><strong>Antecedent history</strong></td>\r\n                    <td>None</td>\r\n                    <td>Viral illness</td>\r\n                </tr>\r\n                <tr class=\"divider_top\">\r\n                    <td><strong>Body height</strong></td>\r\n                    <td>50 percent below standard</td>\r\n                    <td>Normal</td>\r\n                </tr>\r\n                <tr class=\"divider_top\">\r\n                    <td><strong>Congenital anomalies</strong></td>\r\n                    <td>35 percent have one or more anomaly</td>\r\n                    <td>Absent</td>\r\n                </tr>\r\n                <tr class=\"divider_top\">\r\n                    <td class=\"subtitle2_left\" colspan=\"3\">Laboratory values</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Hemoglobin</td>\r\n                    <td>2 to 6 g/dL at diagnosis</td>\r\n                    <td>3 to 9 g/dL at diagnosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">White cell count</td>\r\n                    <td>Normal </td>\r\n                    <td>Normal to decreased</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Platelet count</td>\r\n                    <td>Usually normal (80 percent of patients have platelets &#62;400,000/microL)</td>\r\n                    <td>Normal to elevated</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist2_start\" colspan=\"3\">MCV increased:</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\">At diagnosis</td>\r\n                    <td>Yes, 30 percent</td>\r\n                    <td>No</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\">During recovery</td>\r\n                    <td>Yes, 100 percent</td>\r\n                    <td>Yes</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\">During remission</td>\r\n                    <td>Yes, 100 percent</td>\r\n                    <td>No</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist2_start\" colspan=\"3\">Hemoglobin F increased:</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\">At diagnosis</td>\r\n                    <td>Yes, 100 percent</td>\r\n                    <td>No</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\">During recovery</td>\r\n                    <td>Yes, 100 percent</td>\r\n                    <td>Yes</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\">During remission</td>\r\n                    <td>Yes, 85 percent</td>\r\n                    <td>No</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">eADA activity</td>\r\n                    <td>Elevated</td>\r\n                    <td>Normal</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">i RBC antigen</td>\r\n                    <td>Present</td>\r\n                    <td>Absent</td>\r\n                </tr>\r\n                <tr class=\"divider_top\">\r\n                    <td><strong>Course</strong></td>\r\n                    <td>Prolonged transfusion support or steroid therapy</td>\r\n                    <td>Spontaneous recovery within weeks to months</td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">7</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=25162&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_footnotes\">MCV: mean corpuscular volume; eADA: erythrocyte adenosine deaminase; i RBC antigen: red blood cell i antigen.</div><div class=\"graphic_reference\">Data from: <br /><OL>&#xD;&#xA;<LI>Alter BP, Young NS. The Bone Marrow Failure Syndromes. In: Nathan and Oski's Hematology of Infancy and Childhood, Nathan DG, Orkin SH (Eds), WB Saunders, 1998, p.237.</LI>&#xD;&#xA;<LI>Oski FA, Pediatr Rev 1982; 4:25.</LI>&#xD;&#xA;<LI>Gerrits GP, van Oostrom CG, de Vaan GA, Bakkeren JA, Eur J Pediatr 1984; 142:266.</LI>&#xD;&#xA;<LI>Vlachos A, et al. Diagnosing and treating Diamond Blackfan anemia: results of an international clinical consensus conference. Br J Hematol 2008; 142:859.</LI></OL></div><div id=\"graphicVersion\">Graphic 76264 Version 10.0</div></div></div>"},"76266":{"type":"graphic_table","displayName":"US guidelines - surgery for native valve endocarditis","title":"ACC/AHA guideline summary: Surgery for native valve endocarditis ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA guideline summary: Surgery for native valve endocarditis </div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Class I - There is evidence and/or general agreement that surgery is indicated in patients with NVE with one of the following:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; Valve stenosis or regurgitation leading to heart failure.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; Aortic or mitral regurgitation with hemodynamic evidence of elevated left ventricular end-diastolic or atrial pressures such as premature closure of the mitral valve with aortic regurgitation, rapid decelerating mitral regurgitation signal by continuous wave Doppler (v-wave cutoff sign), or moderate to severe pulmonary hypertension.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; IE due to fungal or other highly resistant organisms.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; Complications such as heart block, annular or aortic abscess, or destructive penetrating lesions such as fistula from the sinus of Valsalva to the right or left atrium or right ventricle, mitral leaflet perforation with IE of the aortic valve, or infection in annulus fibrosis.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Class IIa - The weight of evidence or opinion is in favor of the usefulness of surgery in patients with NVE who develop the following:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; Recurrent emboli and persistent vegetations despite appropriate antibiotic therapy.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Class IIb - The weight of evidence or opinion is less well established for the usefulness of surgery in patients with NVE who develop the following:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; Mobile vegetations larger than 10 mm with or without emboli.</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">ACC: American College of Cardiology;&nbsp;AHA: American Heart Association; NVE: native valve endocarditis; IE: infective endocarditis.</div><div class=\"graphic_reference\">Data from: Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients withvalvular heart disease. A report of the American College ofCardiology/American Heart Association Task Force on Practice Guidelines(Writing committee to revise the 1998 guidelines for the management ofpatients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.</div><div id=\"graphicVersion\">Graphic 76266 Version 6.0</div></div></div>"},"76267":{"type":"graphic_diagnosticimage","displayName":"CT with free air from perforated ulcer","title":"Perforated duodenal ulcer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perforated duodenal ulcer</div><div class=\"cntnt\"><img style=\"width:432px; height:373px;\" src=\"images/GAST/76267_CT_free_air_perforat_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic scan showing free air in the anterior peritoneal space (white arrows), in the ligamentum venosum (black arrow), and in the hepatogastric ligament (small black arrow) resulting from a perforation of a duodenal peptic ulcer.</div><div class=\"graphic_reference\">Courtesy of Jonathan B Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 76267 Version 3.0</div></div></div>"},"76268":{"type":"graphic_picture","displayName":"Jessner lymphocytic infiltration of the skin","title":"Jessner's lymphocytic infiltration of the skin","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Jessner's lymphocytic infiltration of the skin</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/76268_Jessner_lymphocytic_infil.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular erythematous plaques are present on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76268 Version 3.0</div></div></div>"},"76269":{"type":"graphic_picture","displayName":"Roseola rash PI","title":"Roseola rash","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Roseola rash</div><div class=\"cntnt\"><img style=\"width:515px; height:276px;\" src=\"images/PI/76269_Roseola_rash_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The roseola rash starts as the fever goes away. It shows up first on the neck, chest, and belly and then spreads to the arms, legs, and face.</div><div class=\"graphic_reference\">Courtesy of Michael Brady, MD.</div><div id=\"graphicVersion\">Graphic 76269 Version 1.0</div></div></div>"},"76270":{"type":"graphic_figure","displayName":"VISA A questionnaire","title":"The VISA-A questionnaire: An index of the severity of Achilles tendinopathy","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">The VISA-A questionnaire: An index of the severity of Achilles tendinopathy</div><div class=\"cntnt\"><img style=\"width:566px; height:792px;\" src=\"images/EM/76270_VISA_A_questionnaire.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Robinson, JM, Cook, JL, Purdam, C, et al. The VISA-A questionnaire: a valid and reliable index of the clinical severity of Achilles tendinopathy. Br J Sports Med 2001; 35:335. Copyright &#169; 2002 BMJ Publishing Group Ltd.</div><div id=\"graphicVersion\">Graphic 76270 Version 2.0</div></div></div>"},"76272":{"type":"graphic_diagnosticimage","displayName":"Gastric hernia simulating pneumothorax","title":"Gastric hernia simulating pneumothorax","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric hernia simulating pneumothorax</div><div class=\"cntnt\"><img style=\"width:360px; height:364px;\" src=\"images/PULM/76272_Hernia_mimicking_ptx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph demonstrates a herniated, gas-filled stomach through a rent in the left hemidiaphragm, mimicking a left-sided tension pneumothorax.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 76272 Version 4.0</div></div></div>"},"76273":{"type":"graphic_figure","displayName":"Pleural fluid venous pressure","title":"Pleural fluid formation with increased systemic venous pressure","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Pleural fluid formation with increased systemic venous pressure</div><div class=\"cntnt\"><img style=\"width:464px; height:298px;\" src=\"images/PULM/76273_Pleural_fluid_venous_pressu.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of pleural fluid formation with increased venous pressure. An elevation in systemic venous pressure both increases filtration from the parietal pleural microvessels (the intercostal arteries, solid arrows) and decreases lymphatic drainage into the venous system (dashed open&nbsp;arrow). Filtration from visceral pleural microvessels (the bronchial arteries) is unaffected (dashed solid arrows).&nbsp;In comparison, an elevation in pulmonary venous pressure would&nbsp;increase filtration from the visceral pleural microvessels.</div><div id=\"graphicVersion\">Graphic 76273 Version 2.0</div></div></div>"},"76274":{"type":"graphic_figure","displayName":"B and T cells and Ab production","title":"Cellular interactions resulting in antibody production","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cellular interactions resulting in antibody production</div><div class=\"cntnt\"><img style=\"width:341px; height:381px;\" src=\"images/RHEUM/76274_B_and_T_cells_and_Ab_produc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the multiple cellular interactions required for antibody production. As shown by the differently colored boxes at the top of the figure, antigens may consist of multiple possible epitopes. After the polypeptide antigen is processed intracellularly by an antigen presenting cell, a small peptide fragment (orange box) is presented to a Th1 cell (blue cell). The T cell responds to the peptide by releasing cytokines which stimulates a cognate specific B cell (green cell) to produce antibodies to the peptide fragment.</div><div id=\"graphicVersion\">Graphic 76274 Version 1.0</div></div></div>"},"76276":{"type":"graphic_picture","displayName":"Zephyr Endobronchial Valve end view","title":"Zephyr® Endobronchial Valve, end view","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Zephyr&#174; Endobronchial Valve, end view</div><div class=\"cntnt\"><img style=\"width:452px; height:262px;\" src=\"images/PULM/76276_Zephyr_Endobr_Valv_end_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Views of the Zephyr&#174; Endobronchial Valve vents showing an open valve during expiration (panel A) and a closed valve during inspiration (panel B).</div><div class=\"graphic_reference\">Reproduced with permission from: Strange, C, Herth, FJ, Kovitz, KL, et al. Design of the Endobronchial Valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reduction. BMC Pulm Med 2007; 7:10. Copyright &#169; 2010 BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 76276 Version 3.0</div></div></div>"},"76277":{"type":"graphic_algorithm","displayName":"Management of a large parapneumonic effusion in children","title":"Approach to the management of pneumonia with a moderate or large parapneumonic effusion in children","html":"<div class=\"graphic\"><div style=\"width: 670px\" class=\"figure\"><div class=\"ttl\">Approach to the management of pneumonia with a moderate or large parapneumonic effusion in children</div><div class=\"cntnt\"><img style=\"width:650px; height:750px;\" src=\"images/PEDS/76277_Appr_parapneum_effus_2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computerized tomography; IV: intravenous; VATS: video-assisted thoracoscopic surgery.<br />* A small effusion is defined as &lt;1 cm on a lateral decubitus radiograph, or one that opacifies less than one-fourth of the hemithorax<sup>[1]</sup>.<br />&para; Ultrasonography is generally preferred over CT for evaluation and monitoring of pleural effusions. CT should be reserved for complicated cases in which further characterization of parenchymal disease is needed, or ultrasonography is inadequate<sup>[2]</sup>.<br />&Delta; An alternative to chest tube placement for patients who are clinically stable is a trial of empirically selected intravenous antibiotics for 24 to 72 hours.<br /><span class=\"lozenge\">&loz;</span> Whenever thoracentesis or drainage is performed, the fluid should be cultured and IV antibiotics started; the choice of antibiotics should be reevaluated depending on culture results.<br />&sect; If a chest tube is placed, small-bore tubes (&lt;14F) should be used when possible, even for loculated effusions. Small-bore chest tubes are effective with fibrinolytics and cause less discomfort to the patient<sup>[2]</sup>.<br />&yen; For initial treatment of a complicated effusion, most experts agree that either pleural drainage with fibrinolytics or VATS is a reasonable first step. The choice may be influenced by available expertise, cost considerations, and patient preferences.<br />&Dagger; Patients who fail to improve after VATS may require open thoracotomy to remove the pleural rind and evacuate pyogenic material (\"decortication\").<br />&dagger; Antibiotics may be changed from IV to oral route when the child has been afebrile for two to five days.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.</li>&#xD;&#xA;    <li>Islam S, Calkins CM, Goldin AB, et al. The diagnosis and management of empyema in children: a comprehensive review from the APSA Outcomes and Clinical Trials Committee. J Pediatr Surg 2012; 47:2101.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 76277 Version 7.0</div></div></div>"},"76278":{"type":"graphic_picture","displayName":"Diffuse optic atrophy","title":"Diffuse optic atrophy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse optic atrophy</div><div class=\"cntnt\"><img style=\"width:288px; height:428px;\" src=\"images/PEDS/76278_Diffuse_optic_atrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Top: diffuse optic atrophy. Bottom: fellow eye with normal disc color.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 76278 Version 1.0</div></div></div>"},"76279":{"type":"graphic_picture","displayName":"Nasolacrimal duct probing","title":"Nasolacrimal duct probing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nasolacrimal duct probing</div><div class=\"cntnt\"><img style=\"width:360px; height:387px;\" src=\"images/PEDS/76279_Nasolacrimal_duct_probing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A small probe is introduced into the punctum and advanced through the lacrimal drainage system until it abuts the obstruction.</div><div class=\"graphic_reference\">Adapted with permission from: Paysse EA, Coats DK, Cassidy M. Refinements Volume III/Number 2. San Francisco: American Academy of Opthalmology, 1999.</div><div id=\"graphicVersion\">Graphic 76279 Version 3.0</div></div></div>"},"76280":{"type":"graphic_waveform","displayName":"Intermediate case 6","title":"Intermediate case 6","html":"<div class=\"graphic normal\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Intermediate case 6</div><div class=\"cntnt\"><img style=\"width:464px; height:101px;\" src=\"images/CARD/76280_Intermediate_case_6.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 76280 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"76281":{"type":"graphic_figure","displayName":"Third nerve anatomy","title":"Third nerve anatomy","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Third nerve anatomy</div><div class=\"cntnt\"><img style=\"width:485px; height:504px;\" src=\"images/PEDS/76281_Third_nerve_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The third cranial nerve begins as a nucleus in the midbrain. The fascicle of the third nerve leaves the nucleus and passes ventrally near important structures in the midbrain (eg, red nucleus, corticospinal tract). It then enters the subarachnoid space, passes into the lateral wall of the cavernous sinus, and finally divides into superior and inferior branches as it enters the superior orbital fissure in the orbit. The pupil fibers are shown; the innervation to individual muscles (superior rectus, inferior rectus, medial rectus, and inferior oblique) are not shown.</div><div id=\"graphicVersion\">Graphic 76281 Version 1.0</div></div></div>"},"76282":{"type":"graphic_picture","displayName":"Gingival abnormalities in scurvy","title":"Gingival abnormalities in scurvy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gingival abnormalities in scurvy</div><div class=\"cntnt\"><img style=\"width:432px; height:298px;\" src=\"images/PC/76282_Gingival_abnormalities.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The gingival swelling and dusky color just above two of the teeth indicate hemorrhage into the gums of this patient with poor dentition. The gingival abnormalities of scurvy occur only in the presence of teeth, which presumably provide portals of entry for microbes into the gums. One hypothesis suggests that vitamin C deficiency impairs neutrophil-mediated killing of bacteria, leading to chronic gingivitis, which is then complicated by bleeding from the fragile vessels characteristic of scurvy.</div><div class=\"graphic_reference\">Reproduced with permission from: Hirschmann JV, Raugi GJ. Adult scurvy. J Am Acad Dermatol 1999; 41:895. Copyright ©1999 Elsevier.</div><div id=\"graphicVersion\">Graphic 76282 Version 3.0</div></div></div>"},"76283":{"type":"graphic_diagnosticimage","displayName":"TEE transverse view of aortic rupture ","title":"Transesophageal echocardiography transverse view of aortic rupture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiography transverse view of aortic rupture</div><div class=\"cntnt\"><img style=\"width:385px; height:288px;\" src=\"images/CARD/76283_Aortic_rupture_TEE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transesophageal echocardiography transverse view of traumatic subadventitial rupture of the aortic isthmus. There is a thick and highly mobile medial flap associated with a localized deformity of the anterolateral aortic wall due to the acute formation of a pseudoaneurysm (small arrow). The flap is thicker than the intimal flap seen with aortic dissection, since the entire depth of the intima and media are involved with aortic rupture.</div><div class=\"graphic_reference\">Courtesy of P Vignon, MD and RM Lang, MD.</div><div id=\"graphicVersion\">Graphic 76283 Version 3.0</div></div></div>"},"76286":{"type":"graphic_picture","displayName":"Skin lesion HIV P marneffei","title":"Skin lesions in an HIV-infected patient with <em>Penicillium marneffei</em> infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin lesions in an HIV-infected patient with <em>Penicillium marneffei</em> infection</div><div class=\"cntnt\"><img style=\"width:396px; height:300px;\" src=\"images/ID/76286_Skin_lesion_HIV_P_marneffei.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drs. Khuanchai Supparatpinyo and Thira Sirisanthana.</div><div id=\"graphicVersion\">Graphic 76286 Version 1.0</div></div></div>"},"76287":{"type":"graphic_movie","displayName":"Pericardial effusion parasternal long axis echocardiogram","title":"Pericardial effusion","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pericardial effusion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/76287_palaxpefconv.mp4\" style=\"width:324px;height:236px\"></div><img style=\"width:242px; height:374px;\" src=\"images/CARD/76287_palaxpef.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parasternal long axis view from a 2-D echocardiogram shows a moderate sized anterior and posterior pericardial effusion which also extends behind the left atrium. There is no evidence for tamponade. The interventricular septum and posterior left ventricular (LV) wall are hypertrophied.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 76287 Version 2.0</div></div></div>"},"76289":{"type":"graphic_table","displayName":"Allergen avoidance restaurants","title":"Potential allergen avoidance pitfalls in restaurant meals","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential allergen avoidance pitfalls in restaurant meals</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td>Shared food preparation (blender, pan, fryer, grill, etc)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cross contact of primary food with allergen (eg, vanilla ice cream previously contacted with peanut ice cream from prior scoop, vegetable tray containing walnut from a prior spill)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Poor communication between consumer and chef</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Hidden or \"secret ingredients\" (allergen in sauces, powder forms)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cross contact during serving (buffet, preparation trays, garnish, spills)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Addition of allergen after final preparation (added butter, etc)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Removal of ingredient with residual allergen (removing nuts from a salad)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Foods prepared in advance and ingredients unknown </td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Allergen used without notion of \"ingredient\" (peanut butter to seal an egg roll, nuts for decoration)</td>\n\t\t\t\t</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 76289 Version 2.0</div></div></div>"},"76290":{"type":"graphic_diagnosticimage","displayName":"Juvenile Tillaux fx","title":"Juvenile Tillaux fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Juvenile Tillaux fracture</div><div class=\"cntnt\"><img style=\"width:288px; height:292px;\" src=\"images/EM/76290_JuvenileTillauxfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tillaux fracture of the distal tibia. The medial aspect of the epiphysis is closing. The fracture line runs vertically through the epiphysis (black arrow) and then laterally along the open and slightly widened physis (white arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Baskin M. Trauma: Extremeties. In: Atlas of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Baskin M (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 76290 Version 11.0</div></div></div>"},"76293":{"type":"graphic_table","displayName":"Donor infections and lung transplant","title":"Donor infections limiting transplant","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Donor infections limiting transplant</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Donors should not be used routinely upon evidence of: </td> </tr> <tr> <td>Gram-negative bacteremia</td> </tr> <tr> <td>Mycobacterial infections of the chest</td> </tr> <tr> <td>Invasive fungal diseases</td> </tr> <tr> <td>Hepatitis B surface antigen-positivity</td> </tr> <tr> <td>HIV/AIDS</td> </tr> <tr> <td>Creutzfeldt-Jakob disease</td> </tr> <tr> <td>West Nile virus</td> </tr> <tr> <td>Severe acute respiratory syndrome (SARS)</td> </tr> <tr> <td class=\"subtitle1_single\">Donors may be used with caution upon evidence of: </td> </tr> <tr> <td>Gram-positive bacteremia</td> </tr> <tr> <td>Mycobacterial infections outside the chest</td> </tr> <tr> <td>Fungal airway colonization</td> </tr> <tr> <td>Hepatitis B core antibody</td> </tr> <tr> <td>Hepatitis C</td> </tr> <tr> <td>Herpesviruses (HHV 6-8, simplex, varicella)</td> </tr> <tr> <td>Cytomegalovirus</td> </tr> <tr> <td>Epstein-Barr virus (high risk if donor<sup>+</sup>/recipient<sup>-</sup>)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; AIDS: acquired immunodeficiency syndrome; HHV: human herpes virus.</div><div class=\"graphic_reference\">Reproduced with permission from: Garrity, ER, Jr., Boettcher, H, Gabbay, E. Donor infection: an opinion on lung donor utilization. J Heart Lung Transplant 2005; 24:791. Copyright © 2005 The International Society for Heart and Lung Transplantation.</div><div id=\"graphicVersion\">Graphic 76293 Version 2.0</div></div></div>"},"76294":{"type":"graphic_figure","displayName":"Peyronie's disease deformity","title":"Peyronie's disease deformity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peyronie's disease deformity</div><div class=\"cntnt\"><img style=\"width:418px; height:448px;\" src=\"images/SURG/76294_PD_deformity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peyronie's disease is an acquired, localized fibrotic disorder of the tunica albuginea causing penile deformity.</div><div class=\"graphic_reference\">Reproduced with permission from: Porth, CM. Pathophysiology Concepts of Altered Health States, Seventh Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76294 Version 4.0</div></div></div>"},"76295":{"type":"graphic_table","displayName":"Pancreatic organ injury scale","title":"Pancreatic organ injury scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pancreatic organ injury scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"25%\"></colgroup><colgroup span=\"3\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade*</td> <td class=\"subtitle1\">Injury type</td> <td class=\"subtitle1\">Injury description<sup>&#182;</sup></td> <td class=\"subtitle1\">ICD-9</td> <td class=\"subtitle1\">AIS-85</td> <td class=\"subtitle1\">AIS-90</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">I</td> <td>Hematoma</td> <td>Minor contusion without duct injury</td> <td class=\"divider_bottom\" rowspan=\"2\">863.81-863.84</td> <td>2</td> <td>2</td> </tr> <tr class=\"divider_bottom\"> <td>Laceration</td> <td>Superficial laceration without duct injury</td> <td>2</td> <td>2</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">II</td> <td>Hematoma</td> <td>Major contusion without duct injury or tissue loss</td> <td class=\"divider_bottom\" rowspan=\"2\">863.81-863.84</td> <td>3</td> <td>2</td> </tr> <tr class=\"divider_bottom\"> <td>Laceration</td> <td>Major laceration without duct injury or tissue loss</td> <td>3</td> <td>3</td> </tr> <tr class=\"divider_bottom\"> <td>III</td> <td>Laceration</td> <td>Distal transection or parenchymal injury with duct injury</td> <td>863.92-863.94</td> <td>3</td> <td>3</td> </tr> <tr class=\"divider_bottom\"> <td>IV</td> <td>Laceration</td> <td>Proximal<sup>&#916;</sup> transection or parenchymal injury involving ampulla</td> <td>863.91</td> <td>3</td> <td>4</td> </tr> <tr> <td>V</td> <td>Laceration</td> <td>Massive disruption of pancreatic head</td> <td>863.91</td> <td>5</td> <td>5</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Advance one grade for multiple injuries to the same organ.<br />¶ Based on most accurate assessment at autopsy, laparotomy, or radiologic study.<br />Δ Proximal pancreas is to the patients' right of the superior mesenteric vein.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore EE, Cogbill TH, Malangoni MA, et al. Organ injury scalin, II: Pancreas, duodenum, small bowel, colon, and rectum. J Trauma 1990; 30: 1427. Copyright &copy; 1990 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76295 Version 10.0</div></div></div>"},"76296":{"type":"graphic_picture","displayName":"Confluent and reticulated papillomatosis - chest","title":"Confluent and reticulated papillomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Confluent and reticulated papillomatosis</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/76296_Confl_retic_papill_chest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reticulated, hyperpigmented patches and thin plaques with mild scale are present on the chest and inframammary areas.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76296 Version 3.0</div></div></div>"},"76298":{"type":"graphic_picture","displayName":"Chronic GVHD - range of motion","title":"Chronic graft-versus-host disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic graft-versus-host disease</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/76298_Chronic_GVHD_range_motion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Deep sclerosis leading to joint contractures limited the ability to extend the fingers in this patient with chronic GVHD (&quot;prayer sign&quot;). The overlying skin appears normal.</div><div id=\"graphicVersion\">Graphic 76298 Version 1.0</div></div></div>"},"76299":{"type":"graphic_table","displayName":"Normal uterine dimensions on ultrasound examination","title":"Normal uterine dimensions on ultrasound examination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal uterine dimensions on ultrasound examination</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Parameter</td> <td class=\"subtitle1\">Nullipara</td> <td class=\"subtitle1\">Primipara</td> <td class=\"subtitle1\">Multipara</td> <td class=\"subtitle1\">Menopausal &#8804;5 years</td> <td class=\"subtitle1\">Menopausal &#62;5 years</td> </tr> <tr> <td>Uterine length (cm)</td> <td>7.3 (0.8)</td> <td>8.3 (0.8)</td> <td>9.2 (0.8)</td> <td>6.7 (0.7)</td> <td>5.6 (0.9)</td> </tr> <tr> <td>Corpus width (cm)</td> <td>4.0 (0.6)</td> <td>4.6 (0.5)</td> <td>5.1 (0.5)</td> <td>3.6 (0.5)</td> <td>3.1 (0.5)</td> </tr> <tr> <td>Corpus height (cm)</td> <td>3.2 (0.5)</td> <td>3.9 (0.5)</td> <td>4.3 (0.6)</td> <td>3.1 (0.4)</td> <td>2.5 (0.4)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The mean and standard deviation () for uterine length, width, and height in premenopausal women (nulliparas, primiparas, multiparas) and menopausal women (less than or equal to five years of menopause, and greater than five years of menopause) without uterine or ovarian pathology. These dimensions represent the outer dimensions of the uterus, not the inner dimensions (ie, dimensions of the endometrial cavity).</div><div class=\"graphic_reference\">Data from: Merz E, Miric-Tesanic D, Bahlmann F, Weber G, Wellek S. Sonographic size of uterus and ovaries in pre- and post-menopausal women. Ultrasound Obstet Gynecol 1996; 7:38.</div><div id=\"graphicVersion\">Graphic 76299 Version 4.0</div></div></div>"},"76300":{"type":"graphic_table","displayName":"FOLFIRI regimen","title":"FOLFIRI chemotherapy for gastrointestinal cancer<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">FOLFIRI chemotherapy for gastrointestinal cancer<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 14 days.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Irinotecan</strong></td> <td>180* mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL 5 percent dextrose in water (D5W)<sup>&#916;</sup> and administer over 90 minutes (can be administered concurrently with leucovorin via y-site connection).</td> <td>Day 1</td> </tr> <tr> <td><strong>Leucovorin</strong><sup>&#9674;</sup></td> <td>400 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL D5W and administer over two hours.</td> <td>Day 1</td> </tr> <tr> <td><strong>Fluorouracil (FU)</strong></td> <td>400 mg/m<sup>2</sup> IV</td> <td>Slow intravenous push over five minutes (administer immediately after leucovorin).</td> <td>Day 1</td> </tr> <tr> <td><strong>Fluorouracil (FU)</strong></td> <td>2400<sup>&#167;</sup> mg/m<sup>2</sup> IV</td> <td>Dilute in 500 to 1000 mL D5W and administer over 46 hours (begin immediately after FU bolus). To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL normal saline.</td> <td>Day 1</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> MODERATE. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> There is no standard premedication regimen for prophylaxis of infusion reactions.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Primary prophylaxis with granulocyte colony stimulating factors is not justified (estimated risk of febrile neutropenia approximately 6 percent<sup>[1]</sup>). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> A lower starting dose of FU and irinotecan may be needed for patients with liver impairment. A lower starting dose of irinotecan may be needed for patients with severe renal impairment. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Diarrhea:</strong> Irinotecan is associated with early and late diarrhea, both of which may be severe. For patients who develop abdominal cramps and/or diarrhea within 24 hours of treatment, administer atropine (0.3 to 0.6 mg IV) and premedicate with atropine during later cycles. Patients must be instructed in the early use of loperamide as a treatment for late diarrhea. <strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Obtain CBC with differential and platelet count prior to each treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess electrolytes and liver and renal function prior to each treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Patients who develop diarrhea should be closely monitored and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) provided as needed. Do not retreat until resolution of diarrhea for at least 24 hours without anti-diarrheal medication.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose alterations for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Delay treatment until absolute neutrophil count is &#62;1500 cells/microL and the platelet count is &#62;100,000/microL. United States Prescribing Information suggests irinotecan dose reduction for grade 3 or worse hematologic toxicity during a prior cycle<sup>[2]</sup>. A different approach is used by some clinicians. If treatment is delayed for two weeks or delayed for one week on two separate occasions, the day 1 FU bolus is eliminated. With the second occurrence, reduce the FU infusion dose by 20 percent and reduce irinotecan dose to 150 mg/m<sup>2</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Diarrhea:</strong> Withhold treatment until resolution of diarrhea for at least 24 hours off antidiarrheal medications. Reduce irinotecan dose for patients with grade 2 or worse diarrhea during a prior treatment cycle<sup>[2]</sup>. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Other toxicity:</strong> Hold treatment until less than or equal to grade 1, if grade 2; hold treatment until less than or equal to grade 2, if grade 3 or 4<sup>[2]</sup>. Withhold FU for grade 2 or worse diarrhea, and restart at a lower dose after complete resolution<sup>[3]</sup>. Reduce irinotecan dose for patients with grade 3 or worse other non-hematologic toxicities during a prior treatment cycle<sup>[2]</sup>. For grade 3 mucositis, eliminate FU bolus dose; prophylactic ice chips may be beneficial. Refer to UpToDate topic on \"Oral toxicity associated with chemotherapy\".</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count.<br /><SPAN style=\"COLOR: black\">* A lower initial starting dose of irinotecan may be considered for patients with poor performance status, prior pelvic or abdominal radiotherapy, or increased bilirubin levels<SUP>[2]</SUP>. Whether a reduced starting dose is needed in patients who are homozygous for the UGT 1A1*28 allele (Gilbert's syndrome) and whether testing for this allele should be carried out prior to starting irinotecan is controversial. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</SPAN><br />Δ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br /><FONT class=lozenge>◊</FONT> Leucovorin dose is given for d,l-racemic mixture<SUP>[4]</SUP>. Use half the dose for LEVOleucovorin (l-leucovorin).<br />§ If there is no grade 1 or worse toxicity 1 in cycles 1 and 2, some clinicians increase the dose to 3000 mg/m<SUP>2</SUP> starting with cycle 3<SUP>[1]</SUP>.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Tournigand C, et al. J Clin Oncol 2004; 22:229. </LI>&#xD;&#xA;<LI>Irinotecan hydrochloride injection.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016). </LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016).</LI>&#xD;&#xA;<LI>Leucovorin calcium injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016). </LI></OL></div><div id=\"graphicVersion\">Graphic 76300 Version 28.0</div></div></div>"},"76301":{"type":"graphic_table","displayName":"Histology gallbladder cancer","title":"Common histologic types of gallbladder cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common histologic types of gallbladder cancer</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Tumor type*</td>\n\n      <td class=\"subtitle1\">Percent of total</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Adenocarcinoma</td>\n\n      <td>76</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Papillary</td>\n\n      <td>6</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mucinous</td>\n\n      <td>5</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Adenosquamous</td>\n\n      <td>4</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Squamous</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Oat cell</td>\n\n      <td>0.5</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Nonspecified</td>\n\n      <td>8</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=46408&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Histology_gallbladder_cance.htm</title></head></div><div class=\"graphic_footnotes\">* Data collected from 3038 patients treated between 1977 and 1986. Two-year survival for papillary type was 47%. For tumors limited to the gallbladder, five-year survival was 32%.</div><div class=\"graphic_reference\">Modified from Henson, DE. Cancer 1992; 70:713.</div><div id=\"graphicVersion\">Graphic 76301 Version 2.0</div></div></div>"},"76303":{"type":"graphic_figure","displayName":"Refractive error astigmatic eye","title":"Refractive error: An uncorrected astigmatic eye","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Refractive error: An uncorrected astigmatic eye</div><div class=\"cntnt\"><img style=\"width:507px; height:171px;\" src=\"images/PC/76303_Astigmatic_eye.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The refractive power of the eye is different in different meridians. Light rays can never be brought to a single point, and objects will appear blurry at any distance. The circle of least confusion is demonstrated on the retina.</div><div class=\"graphic_reference\">Reproduced with permission from Yanoff M, Duker JS. Ophthalmology, Mosby 1999. Copyright © 1999 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 76303 Version 2.0</div></div></div>"},"76304":{"type":"graphic_picture","displayName":"Periaerolar abscess ","title":"Periareolar abscess","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Periareolar abscess</div><div class=\"cntnt\"><img style=\"width:504px; height:202px;\" src=\"images/PC/76304_Non_lactational_abscess_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Periareolar abscess. Large incisions are not necessary for the drainage of a breast abscess.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 76304 Version 3.0</div></div></div>"},"76308":{"type":"graphic_diagnosticimage","displayName":"Continuous wave Doppler across the aortic valve","title":"Continuous wave Doppler across the aortic valve in a patient with aortic stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Continuous wave Doppler across the aortic valve in a patient with aortic stenosis</div><div class=\"cntnt\"><img style=\"width:296px; height:260px;\" src=\"images/CARD/76308_Continuous_wave_Doppler_AV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During simultaneous imaging from an anteriorly angulated apical five chamber view (panel A), continuous wave Doppler sampling is performed along the beam represented by the solid line passing through the aortic valve. The peak velocity from this view was the highest obtained from multiple sites and was 3.45 meter/sec or a transvalvular gradient of 48 mmHg (= 3.45 x 3.45 x 4) (panel B).</div><div id=\"graphicVersion\">Graphic 76308 Version 5.0</div></div></div>"},"76309":{"type":"graphic_picture","displayName":"Paraganglioma Light","title":"Paraganglioma","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Paraganglioma</div><div class=\"cntnt\"><img style=\"width:509px; height:227px;\" src=\"images/ONC/76309_Paraganglioma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power and high power light micrographs showing round and polygonal epithelioid cells arranged in a trabecular pattern.</div><div class=\"graphic_reference\">Courtesy of Silloo B Kapadia, MD.</div><div id=\"graphicVersion\">Graphic 76309 Version 1.0</div></div></div>"},"76310":{"type":"graphic_table","displayName":"A1C and blood sugar PI","title":"A1C level and average blood sugar","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">A1C level and average blood sugar</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">If your A1C level is (percent):</td> <td class=\"subtitle1\" colspan=\"2\">That means your average blood sugar level during the past&nbsp;two to&nbsp;three months was:</td> </tr> <tr> <td class=\"subtitle2\">If you live <em>within the United States</em>, use these values. Your blood sugar is measured in milligrams/deciliter (mg/dL).</td> <td class=\"subtitle2\">If you live <em>outside the United States</em>, use these values. Your blood sugar is measured in millimoles/liter (mmol/L).</td> </tr> <tr> <td>5</td> <td>97</td> <td>5.4</td> </tr> <tr> <td>6</td> <td>126</td> <td>7</td> </tr> <tr> <td>7</td> <td>154</td> <td>8.6</td> </tr> <tr> <td>8</td> <td>183</td> <td>10.2</td> </tr> <tr> <td>9</td> <td>212</td> <td>11.8</td> </tr> <tr> <td>10</td> <td>240</td> <td>13.3</td> </tr> <tr> <td>11</td> <td>269</td> <td>15</td> </tr> <tr> <td>12</td> <td>298</td> <td>16.5</td> </tr> <tr> <td>13</td> <td>326</td> <td>18.1</td> </tr> <tr> <td>14</td> <td>355</td> <td>19.7</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The A1C blood test tells you what your average blood sugar level has been for the past&nbsp;two to&nbsp;three months. This table lists which A1C levels go with which average blood sugar levels. Blood sugar is measured differently within the United States than it is in most other countries. The column in the middle is for people in the United States. The column on the right is for people who live outside the United States.</div><div class=\"graphic_footnotes\">A1C: glycated hemoglobin.</div><div id=\"graphicVersion\">Graphic 76310 Version 3.0</div></div></div>"},"76311":{"type":"graphic_picture","displayName":"IgG4 immunoperoxidase stain of chronic sclerosing sialadenitis","title":"IgG4 immunoperoxidase stain of chronic sclerosing sialadenitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">IgG4 immunoperoxidase stain of chronic sclerosing sialadenitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/76311_IgG4_immunoperox_scler_sial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic sclerosing sialadenitis (Küttner's tumor) with large numbers of IgG4-positive plasma cells (IgG4 immunoperoxidase stain).</div><div class=\"graphic_reference\">Reproduced with permission from: Geyer J, Deshpande V. IgG4-associated sialadenitis. Curr Opinion Rheum 2011; 23:95. Copyright © 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76311 Version 6.0</div></div></div>"},"76312":{"type":"graphic_table","displayName":"Cetuximab monotherapy colorectal cancer","title":"Cetuximab monotherapy for metastatic, K-ras wild type colorectal cancer<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cetuximab monotherapy for metastatic, K-ras wild type colorectal cancer<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> Weekly. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Cetuximab</td> <td>400 mg/m<sup>2</sup> IV</td> <td>The appropriate dose should be withdrawn from the vials (supplied in a concentration of 2 mg/mL) and aseptically transferred into an empty sterile IV bag without further dilution. The initial dose should be infused over 120 minutes.*<sup>&#182;</sup></td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Cetuximab</td> <td>250 mg/m<sup>2</sup> IV</td> <td>If Day 1 is tolerated, subsequent doses may be administered over 60 minutes.</td> <td>Weekly, beginning day 8<sup>&#916;</sup></td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>LOW (&#60;30% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedication with diphenhydramine with or without a glucocorticoid at least prior to the first infusion.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess basic metabolic panel (including creatinine, magnesium, calcium, and potassium) prior to each dose. </li> <li>Monitor serum calcium, magnesium, and potassium levels weekly for eight weeks after completion of therapy.<sup>[2]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for skin rash. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dematologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Severe dermatologic reactions, such as acneiform rash, require delayed administration of cetuximab and/or dose reduction. </li> <li>Refer to UpToDate topic on \"Acneiform eruption secondary to epidermal growth factor receptor (EGFR) inhibitors\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous.<br />* Cetuximab should be administered with an infusion or syringe pump, using a low protein-binding 0.22 micron in line filter. Do not shake or dilute. Flush line with normal saline.<br />¶ A slower infusion rate should be considered in areas with a high incidence of infusion reactions (such as the southeast United States). Refer to UpToDate topic on \"Infusion reactions to the therapeutic monoclonal antibodies used in cancer therapy\".<br />Δ Results from a nonrandomized phase II trial<SUP>[3]</SUP> and a multicenter retrospective analysis<SUP>[4]</SUP> suggest that cetuximab at a dose of 500 mg/m<SUP>2</SUP> every two weeks results in similar plasma concentrations and single-agent activity as does weekly dosing.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Jonker DJ, et al. N Engl J Med 2007; 357:2040.</LI>&#xD;&#xA;<LI>Cetuximab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 14, 2012).</LI>&#xD;&#xA;<LI>Pfeiffer P, et al. Ann Oncol 2008; 19:1141.</LI>&#xD;&#xA;<LI>Bouchahda M, et al. Med Oncol 2011; 28 Suppl 1:253.</LI></OL></div><div id=\"graphicVersion\">Graphic 76312 Version 10.0</div></div></div>"},"76313":{"type":"graphic_table","displayName":"PBL levels","title":"Patterns of peripheral blood lymphocyte levels","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patterns of peripheral blood lymphocyte levels</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Defective protein </td> <td class=\"subtitle1\">CD4 </td> <td class=\"subtitle1\">CD8 </td> <td class=\"subtitle1\">B cell</td> <td class=\"subtitle1\">NK cell</td> </tr> <tr> <td>RAG1/RAG2</td> <td>&#8595;</td> <td>&#8595;</td> <td>&#8595;</td> <td>NL</td> </tr> <tr> <td>MHCII</td> <td>&#8595;</td> <td>NL</td> <td>NL</td> <td>NL</td> </tr> <tr> <td>CD3 delta</td> <td>&#8595;</td> <td>&#8595;</td> <td>NL/&#8593;</td> <td>NL/&#8593;</td> </tr> <tr> <td>CD3 gamma</td> <td>&#8595;</td> <td>&#8595;</td> <td>NL</td> <td>NL</td> </tr> <tr> <td>CD3 epsilon</td> <td>&#8595;</td> <td>&#8595;</td> <td>NL</td> <td>NL</td> </tr> <tr> <td>CD3 zeta</td> <td>&#8595;</td> <td>&#8595;/NL</td> <td>NL</td> <td>NL</td> </tr> <tr> <td>p56lck</td> <td>&#8595;</td> <td>NL/&#8593;</td> <td>NL</td> <td>NL</td> </tr> <tr> <td>ZAP-70</td> <td>NL/&#8593;</td> <td>&#8595;</td> <td>NL</td> <td>&#8595;/NL</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CD4: cluster of differentiation 4; CD8: cluster of differentiation 8; NK: natural killer; RAG: recombinase-activating gene; MHCII: major histocompatibility complex II; CD3: cluster of differentiation 3; p56lck: lymphocyte-specific protein-tyrosine kinase; ZAP-70: zeta-chain-associated protein kinase 70 kilodalton; NL: normal.</div><div id=\"graphicVersion\">Graphic 76313 Version 2.0</div></div></div>"},"76314":{"type":"graphic_table","displayName":"Causes of refractory peptic ulcer disease","title":"Causes of refractory peptic ulcer disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of refractory peptic ulcer disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Persisting <em>H. pylori</em> infection</td> </tr> <tr> <td>Poor compliance with treatment</td> </tr> <tr> <td>Resistant organism</td> </tr> <tr> <td>Inadequate <em>H. pylori</em> regimen</td> </tr> <tr> <td class=\"sublist1_start\">Unrecognized <em>H. pylori</em> infection:</td> </tr> <tr> <td class=\"sublist1\">False negative <em>H. pylori</em> testing</td> </tr> <tr> <td class=\"sublist1\">Skipped or inadequate testing</td> </tr> <tr> <td class=\"subtitle1_single\">Ulcers related to nonsteroidal anti-inflammatory drugs (NSAIDs)</td> </tr> <tr> <td>Continued NSAID use</td> </tr> <tr> <td>Undiscovered NSAID use</td> </tr> <tr> <td>Poor response to co-therapy with a proton pump inhibitor (PPI)&nbsp;or histamine 2 receptor antagonist (H2RA)</td> </tr> <tr> <td class=\"subtitle1_single\">Other mechanisms</td> </tr> <tr> <td class=\"sublist1_start\">Impaired healing:</td> </tr> <tr> <td class=\"sublist1\">Cigarette smoking</td> </tr> <tr> <td class=\"sublist1_start\">Inadequate inhibition of acid secretion:</td> </tr> <tr> <td class=\"sublist1\">Poor compliance with treatment</td> </tr> <tr> <td class=\"sublist1\">Pharmacologic resistance or tolerance to&nbsp;H2RAs </td> </tr> <tr> <td class=\"sublist1\">Pharmacologic resistance to PPIs</td> </tr> <tr> <td class=\"sublist1\">Rapid metabolism (inactivation) of PPIs </td> </tr> <tr> <td class=\"sublist1_start\">Hypersecretory states:</td> </tr> <tr> <td class=\"sublist1\">Gastrinoma</td> </tr> <tr> <td class=\"sublist1\">Antral G cell hyperfunction</td> </tr> <tr> <td class=\"sublist1\">Idiopathic hypersecretory duodenal ulcer</td> </tr> <tr> <td class=\"sublist1_start\">Co-therapies:</td> </tr> <tr> <td class=\"sublist1\">Glucocorticoids (especially when given with NSAIDs)</td> </tr> <tr> <td class=\"sublist1\">Cytotoxic drugs</td> </tr> <tr> <td class=\"sublist1\">Other drugs, such as methamphetamine or cocaine use</td> </tr> <tr> <td class=\"sublist1_start\">Uncommon causes:</td> </tr> <tr> <td class=\"sublist1\">Cancer</td> </tr> <tr> <td class=\"sublist1\">Crohn disease</td> </tr> <tr> <td class=\"sublist1\">Infections other than <em>H. pylori</em></td> </tr> <tr> <td class=\"sublist1\">Eosinophilic, inflammatory, infiltrative&nbsp;conditions</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><EM>H. pylori</EM>: <EM innerHtml>Helicobacter pylori</EM><EM>.</EM></div><div id=\"graphicVersion\">Graphic 76314 Version 8.0</div></div></div>"},"76316":{"type":"graphic_figure","displayName":"Schematic LV free wall accessory pathways","title":"Schematic showing anatomic locations of accessory pathways in the left ventricular (LV) free wall","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic showing anatomic locations of accessory pathways in the left ventricular (LV) free wall</div><div class=\"cntnt\"><img style=\"width:345px; height:350px;\" src=\"images/CARD/76316_Anatomic_location_acc_path.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal cross section of the free wall of the left ventricle at the level of the atrioventricular (AV) groove. The accessory pathways are present in the AV groove fat pad at variable depths in relation to the mitral annulus and the epicardium overlying the AV groove.</div><div id=\"graphicVersion\">Graphic 76316 Version 2.0</div></div></div>"},"76317":{"type":"graphic_picture","displayName":"Development of mammary gland","title":"Development of mammary gland","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Development of mammary gland</div><div class=\"cntnt\"><img style=\"width:403px; height:254px;\" src=\"images/PEDS/76317_Development_of_mammary_glan.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Lothar Hennighausen.</div><div id=\"graphicVersion\">Graphic 76317 Version 2.0</div></div></div>"},"76318":{"type":"graphic_figure","displayName":"Heart rate in mitral stenosis","title":"Effect of heart rate on mitral valve gradient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of heart rate on mitral valve gradient</div><div class=\"cntnt\"><img style=\"width:433px; height:333px;\" src=\"images/CARD/76318_Heart_rate_in_mitral_stenos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simultaneously recorded pressures from the left atrium (LA) and left ventricle (LV) in a patient with mitral stenosis who has a persistent diastolic gradient (shaded areas) across the mitral valve. Top panel: When the RR interval is shorter, the mean pressure gradient is greater and the mitral valve area smaller. Bottom panel: A long RR interval results in a gradual equilibration of the LA and LV pressures and the mean gradient is smaller. There is no pressure gradient present by the end of diastole.</div><div class=\"graphic_reference\">Adapted from Kern, MJ (Ed). Hemodynamic Rounds: Interpretation of Cardiac Pathophysiology from Pressure Waveform Analysis. Wiley-Liss, New York, 1993.</div><div id=\"graphicVersion\">Graphic 76318 Version 2.0</div></div></div>"},"76319":{"type":"graphic_table","displayName":"Indications pacing modes I","title":"Indications for different pacing modes - I","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for different pacing modes - I</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"subtitle1\">Mode</td>\n\n\t\t\t<td class=\"subtitle1\">Generally agreed upon indications</td>\n\n\t\t\t<td class=\"subtitle1\">Controversial indications</td>\n\n\t\t\t<td class=\"subtitle1\">Contraindicated</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>VVI</td>\n\n\t\t\t<td>Atrial fibrillation with symptomatic bradycardia in the chronotropically competent patient</td>\n\n\t\t\t<td>Symptomatic bradycardia in the patient with associated terminal illness or other medical conditions from which recovery is not anticipated and pacing is life-sustaining only</td>\n\n\t\t\t<td><p>Patients with known pacemaker syndrome or hemodynamic deterioration with ventricular pacing at the time of implant</p>\n\n\t\t\t<p>\n\t\t\tChronotropic incompetent patient who will benefit from rate response</p>\n\t\n\t\t\t<p>\n\t\t\tPatients with hemodynamic need for dual-chamber pacing</p></td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>VVIR</td>\n\n\t\t\t<td>Fixed atrial arrhythmias (atrial fibrillation or flutter) with symptomatic bradycardia in the chronotropically incompetent patient</td>\n\n\t\t\t<td>As for VVI</td>\n\n\t\t\t<td>As for VVI</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>AAI</td>\n\n\t\t\t<td>Symptomatic bradycardia as a result of sinus node dysfunction in the otherwise chronotropically competent patient and when AV conduction can be proven normal</td>\n\n\t\t\t<td>&nbsp;</td>\n\n\t\t\t<td><p>Sinus node dysfunction with associated AV block either demonstrated spontaneously or during pre-implant testing</p>\n\t\t\t<p>\n\t\t\tWhen adequate atrial sensing cannot be attained</p></td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>AAIR</td>\n\n\t\t\t<td>Symptomatic bradycardia as a result of sinus node dysfunction in the otherwise chronotropically incompetent patient and when AV conduction can be proven normal</td>\n\n\t\t\t<td>&nbsp;</td>\n\n\t\t\t<td>As for AAI</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 76319 Version 1.0</div></div></div>"},"76321":{"type":"graphic_diagnosticimage","displayName":"Non Hodgkins lymphoma PA","title":"Non-Hodgkin's lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Non-Hodgkin's lymphoma</div><div class=\"cntnt\"><img style=\"width:358px; height:343px;\" src=\"images/PULM/76321_Non_Hodgkins_lymphoma_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Non-Hodgkin's lymphoma involving the right upper lobe and the right middle lobe. Chest radiograph shows large opacities due to bilobar consolidation. The patient had undergone an open lung biopsy.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 76321 Version 3.0</div></div></div>"},"76323":{"type":"graphic_picture","displayName":"Bacillary angiomatosis in HIV","title":"Bacillary angiomatous lesions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bacillary angiomatous lesions</div><div class=\"cntnt\"><img style=\"width:360px; height:251px;\" src=\"images/ID/76323_Bacillary_angiomatosis_in_H.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The small papule with a smooth, reddish, glistening and obviously vascular appearance is more typical than the larger lesion, which is hyperkeratotic, drier, and polypoid. Courtesy of Leonard N Slater, MD.</div><div class=\"graphic_reference\">Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds), Williams and Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 76323 Version 5.0</div></div></div>"},"76324":{"type":"graphic_table","displayName":"CSF analysis in CNS infections","title":"Typical cerebrospinal fluid findings in central nervous system infections*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical cerebrospinal fluid findings in central nervous system infections*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Glucose (mg/dL)</td> <td class=\"subtitle1\" colspan=\"2\">Protein (mg/dL)</td> <td class=\"subtitle1\" colspan=\"3\">Total white blood cell count (cells/microL)</td> </tr> <tr> <td class=\"subtitle2\">&#60;10<sup>&#182;</sup></td> <td class=\"subtitle2\">10 to 40<sup>&#916;</sup></td> <td class=\"subtitle2\">100 to 500<sup>&#9674;</sup></td> <td class=\"subtitle2\">50 to 300<sup>&#167;</sup></td> <td class=\"subtitle2\">&#62;1000</td> <td class=\"subtitle2\">100 to 1000</td> <td class=\"subtitle2\">5 to 100</td> </tr> <tr class=\"divider_bottom\"> <td><strong>More common</strong></td> <td>Bacterial meningitis</td> <td>Bacterial meningitis</td> <td>Bacterial meningitis</td> <td> <p>Viral meningitis</p> <p>Nervous system Lyme disease (neuroborreliosis)</p> <p>Neurosyphilis</p> TB meningitis<sup>&#165;</sup></td> <td>Bacterial meningitis</td> <td> <p>Bacterial or viral meningitis</p> TB meningitis</td> <td> <p>Early bacterial meningitis</p> <p>Viral meningitis</p> <p>Neurosyphilis</p> TB meningitis</td> </tr> <tr> <td><strong>Less common</strong></td> <td> <p>TB meningitis</p> Fungal meningitis</td> <td> <p>Neurosyphilis</p> Some viral infections (such as mumps and LCMV)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Some cases of mumps and LCMV</td> <td>Encephalitis</td> <td>Encephalitis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TB: tuberculosis; LCMV: lymphocytic choriomeningitis virus.<br />* It is important to note that the spectrum of cerebrospinal fluid values in bacterial meningitis is so wide that the absence of one or more of these findings is of little value. Refer to the UpToDate topic reviews on bacterial meningitis for additional details.<br />¶ &lt;0.6 mmol/L.<br />Δ&nbsp;0.6 to 2.2 mmol/L.<br />◊&nbsp;1 to 5&nbsp;g/L.<br />§&nbsp;0.5 to&nbsp;3 g/L.<br />¥&nbsp;Cerebrospinal fluid&nbsp;protein concentrations may be higher in some patients with tuberculous meningitis; concentrations &gt;500 mg/dL are an indication of blood-brain barrier disruption or increased intracerebral production of immunoglobulins, and extremely high concentrations, in the range of 2 to 6 g/dL, may be found in association with subarachnoid block.</div><div id=\"graphicVersion\">Graphic 76324 Version 9.0</div></div></div>"},"76326":{"type":"graphic_movie","displayName":"TEE aortic plaque","title":"Aortic plaque","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic plaque</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/76326_teeaoplaconv.mp4\" style=\"width:383px;height:276px\"></div><img style=\"width:225px; height:259px;\" src=\"images/CARD/76326_teeaopla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram show a large, mobile aortic plaque (arrow).</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 76326 Version 2.0</div></div></div>"},"76328":{"type":"graphic_picture","displayName":"Grade I infiltrating ductal carcinoma of the breast","title":"Grade I infiltrating ductal carcinoma of the breast","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Grade I infiltrating ductal carcinoma of the breast</div><div class=\"cntnt\"><img style=\"width:584px; height:239px;\" src=\"images/ONC/76328_Grade_1_breast_ca_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Low power view of a well differentiated infiltrating ductal carcinoma shows tumor cells which infiltrate the stroma as solid nests and glands.<br />(Panel B) High power view demonstrates relatively uniform nuclei with no evidence of mitotic activity.</div><div class=\"graphic_reference\">Courtesy of Stuart Schnitt, MD.</div><div id=\"graphicVersion\">Graphic 76328 Version 4.0</div></div></div>"},"76329":{"type":"graphic_figure","displayName":"Anatomy of the oropharynx","title":"Anatomy of the oropharynx","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the oropharynx</div><div class=\"cntnt\"><img style=\"width:413px; height:469px;\" src=\"images/EM/76329_Oropharynx_anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 76329 Version 2.0</div></div></div>"},"76330":{"type":"graphic_picture","displayName":"Toe plate","title":"Toe platform extension of cast used in the treatment of great toe fractures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Toe platform extension of cast used in the treatment of great toe fractures</div><div class=\"cntnt\"><img style=\"width:432px; height:388px;\" src=\"images/EM/76330_Toe_plate.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Eiff, PE, Hatch, RL, Calmbach, WL. Fracture Management for Primary Care, 2nd ed, Saunders, New York, 2003. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 76330 Version 1.0</div></div></div>"},"76331":{"type":"graphic_figure","displayName":"Ig light chain gene rearrangement","title":"Immunoglobulin light chain gene rearrangement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunoglobulin light chain gene rearrangement</div><div class=\"cntnt\"><img style=\"width:448px; height:241px;\" src=\"images/ALLRG/76331_Transcript_Ig_light.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Bona C, Bonilla FA. Textbook of Immunology, 2nd ed. Harwood Academic Publishers GmbH, Amsterdam 1996. Copyright © 1996 Overseas Publishers Association, NV. Permission granted by Gordon and Breach Publishers.</div><div id=\"graphicVersion\">Graphic 76331 Version 3.0</div></div></div>"},"76332":{"type":"graphic_picture","displayName":"Continuous lesions UC Endosc","title":"Continuous involvement of colonic lesions in ulcerative colitis","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Continuous involvement of colonic lesions in ulcerative colitis</div><div class=\"cntnt\"><img style=\"width:525px; height:180px;\" src=\"images/GAST/76332_Continuous_lesions_UC_Endos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In contrast to Crohn disease, lower endoscopy in ulcerative colitis shows continuous and circumferential involvement, with no normal areas of mucosa.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 76332 Version 3.0</div></div></div>"},"76333":{"type":"graphic_diagnosticimage","displayName":"Subchorionic hematoma","title":"Distinction between subchorionic hematoma and unfused amnion in patient with vaginal bleeding at 13 weeks' gestational age","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distinction between subchorionic hematoma and unfused amnion in patient with vaginal bleeding at 13 weeks' gestational age</div><div class=\"cntnt\"><img style=\"width:339px; height:324px;\" src=\"images/OBGYN/76333_Subchorionic_hematoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transabdominal sagittal sonogram of uterus reveals subchorionic hematoma (H) extending posteriorly around chorion (arrows) and lifting edge of anterior placenta (P). Appearance should not be confused with that of unfused amnion. Amnion is the thin membrane continuous along anterior placental edge, but limited by umbilical cord insertion; subchorionic bleeding leads to edge of placenta.</div><div class=\"graphic_reference\">Reproduced with permission from Trop, I, Levine, D. Hemorrage During Pregnancy: Sonography and MR Imaging. AJR Am J Roentgenol 2001; 176:607. Copyright 2001 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 76333 Version 2.0</div></div></div>"},"76335":{"type":"graphic_table","displayName":"Clinical features of spasmus nutans","title":"Features distinguishing spasmus nutans from congenital nystagmus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features distinguishing spasmus nutans from congenital nystagmus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Congenital nystagmus</td> <td class=\"subtitle1\">Spasmus nutans</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Features of nystagmus</td> </tr> <tr> <td class=\"indent1\">Waveform</td> <td>Often mixed with jerk</td> <td>Strictly pendular</td> </tr> <tr> <td class=\"indent1\">Amplitude</td> <td>Large, always &#62;3&#176;</td> <td>Small, often &#60;3&#176;</td> </tr> <tr> <td class=\"indent1\">Amplitude asymmetry</td> <td>Minimal (&#60;25 percent)</td> <td>&#62;25 percent</td> </tr> <tr> <td class=\"indent1\">Frequency</td> <td>Slow, &#60;7Hz</td> <td>Fast, &#62;7Hz</td> </tr> <tr> <td class=\"indent1\">Phase relationship</td> <td>Conjugate</td> <td>Dysconjugate</td> </tr> <tr> <td class=\"indent1\">Duration</td> <td>Constant</td> <td>Intermittent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Other features</td> </tr> <tr> <td class=\"indent1\">Age at onset</td> <td>&#60;6 months</td> <td>&#62;6 months</td> </tr> <tr> <td class=\"indent1\">Associated strabismus/amblyopia</td> <td>&nbsp;</td> <td>More frequent</td> </tr> <tr> <td class=\"indent1\">Head nodding</td> <td>&nbsp;</td> <td>Larger and more frequent</td> </tr> <tr> <td class=\"indent1\">Horizontal OKR</td> <td>Absent or inverted</td> <td>Normal</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Gottlob I, Zubcov A, Catalano RA, et al. Ophthalmology 1990; 97:1166.</div><div id=\"graphicVersion\">Graphic 76335 Version 3.0</div></div></div>"},"76337":{"type":"graphic_diagnosticimage","displayName":"TB chest radiograph 3","title":"Imaging of cavitary lesions in tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Imaging of cavitary lesions in tuberculosis</div><div class=\"cntnt\"><img style=\"width:514px; height:385px;\" src=\"images/ID/76337_TB_chest_radiograph_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph (A) and computed tomography (CT) scan (B), the latter of which more clearly demonstrates two cavitary lesions. A repeated CT scan (C) showed improvement after&nbsp;one month of treatment in a young woman with primary multidrug-resistant tuberculosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Gorbach SL, Bartlett JG, et al. Infectious Diseases. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76337 Version 3.0</div></div></div>"},"76338":{"type":"graphic_picture","displayName":"Lichen planus - oral Wickham striae","title":"Oral lichen planus - Wickham's striae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral lichen planus - Wickham's striae</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/76338_Lich_plan_oral_Wick_striae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lacy white plaques (Wickham's striae) are present on the buccal mucosa.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76338 Version 4.0</div></div></div>"},"76339":{"type":"graphic_picture","displayName":"Mouth frown","title":"Mouth frown","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Mouth frown</div><div class=\"cntnt\"><img style=\"width:502px; height:347px;\" src=\"images/DERM/76339_Mouth_frown_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A downward turn of the corners of the mouth at rest (mouth frown) can occur as a normal feature of aging.</div><div id=\"graphicVersion\">Graphic 76339 Version 2.0</div></div></div>"},"76340":{"type":"graphic_movie","displayName":"AR as heard at the second right intercostal space","title":"Phonocardiogram of aortic regurgitation as heard at the second right intercostal space","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Phonocardiogram of aortic regurgitation as heard at the second right intercostal space</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/76340_aor2ricsconv.mp4\" style=\"width:382px;height:440px\"></div><img style=\"width:389px; height:221px;\" src=\"images/CARD/76340_aor2rics.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Carotid artery pulse tracing and phonocardiogram of aortic regurgitation as heard at the second right intercostal space. S1 (mitral and tricuspid valve closure) is followed by a systolic ejection murmur due to the large stroke volume seen in aortic regurgitation. After S2 (aortic and pulmonic valve closure), there is a faint and short diastolic \"blowing\" murmur of aortic regurgitation.</div><div class=\"graphic_reference\">Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.</div><div id=\"graphicVersion\">Graphic 76340 Version 4.0</div></div></div>"},"76342":{"type":"graphic_table","displayName":"Causes of seizures in older patients","title":"Causes of seizures and epilepsy in elderly patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of seizures and epilepsy in elderly patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Relative proportion (percent)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Acute seizures</td> </tr> <tr> <td class=\"indent1\">Acute stroke</td> <td class=\"centered\">50</td> </tr> <tr> <td class=\"indent1\">Metabolic encephalopathy</td> <td class=\"centered\">6-30</td> </tr> <tr> <td class=\"indent1\">Drugs</td> <td class=\"centered\">10</td> </tr> <tr> <td class=\"indent1\">Others (trauma, infections)</td> <td class=\"centered\">5-20</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Epilepsy</td> </tr> <tr> <td class=\"indent1\">Cerebrovascular disease</td> <td class=\"centered\">30-50</td> </tr> <tr> <td class=\"indent1\">Dementia</td> <td class=\"centered\">9-17</td> </tr> <tr> <td class=\"indent1\">Others (tumors, trauma)</td> <td class=\"centered\">5-15</td> </tr> <tr> <td class=\"indent1\">Unknown</td> <td class=\"centered\">30-50</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76342 Version 4.0</div></div></div>"},"76343":{"type":"graphic_table","displayName":"Differential diagnosis of limp in children","title":"Abnormalities causing limp in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Abnormalities causing limp in children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Osseous</td> </tr> <tr> <td>Osteomyelitis</td> </tr> <tr> <td class=\"sublist1_start\">Fractures</td> </tr> <tr> <td class=\"sublist1\">Salter-Harris</td> </tr> <tr> <td class=\"sublist1\">Toddler's: tibia, calcaneus, cuboid</td> </tr> <tr> <td class=\"sublist1\">Stress</td> </tr> <tr> <td class=\"sublist1\">Incomplete: buckle, greenstick</td> </tr> <tr> <td class=\"sublist1\">Complete</td> </tr> <tr> <td class=\"sublist1\">Plastic</td> </tr> <tr> <td class=\"sublist1\">Avulsion: pelvic, tibial tuberosity, patellar sleeve</td> </tr> <tr> <td class=\"sublist1\">Child abuse: traumatic periostitis, metaphyseal-epiphyseal fracture</td> </tr> <tr> <td class=\"sublist1_start\">Osteochondrosis and apophysitis (affected bone)</td> </tr> <tr> <td class=\"sublist1\">Sinding-Larsen-Johansson disease (inferior patella)</td> </tr> <tr> <td class=\"sublist1\">K&#246;hler disease (navicular bone of the foot)</td> </tr> <tr> <td class=\"sublist1\">Sever disease (calcaneus)</td> </tr> <tr> <td class=\"sublist1\">Freiberg disease (head of the 2nd metatarsal)</td> </tr> <tr> <td class=\"sublist1\">Osgood-Schlatter disease (tibial tuberosity)</td> </tr> <tr> <td class=\"sublist1\">Iselin disease (base of the 5th metatarsal)</td> </tr> <tr> <td class=\"sublist1\">Buschke disease (medial cuneiform)&nbsp;</td> </tr> <tr> <td>Vasoocclusive crisis of sickle cell disease</td> </tr> <tr> <td>Slipped capital femoral epiphysis</td> </tr> <tr> <td>Legg-Calv&#233;-Perthes disease</td> </tr> <tr> <td class=\"sublist1_start\">Tumors</td> </tr> <tr> <td class=\"sublist1\">Leukemia</td> </tr> <tr> <td class=\"sublist1\">Spinal cord tumor</td> </tr> <tr> <td class=\"sublist1\">Metastatic neuroblastoma</td> </tr> <tr> <td class=\"sublist1\">Osteogenic sarcoma</td> </tr> <tr> <td class=\"sublist1\">Ewings sarcoma</td> </tr> <tr> <td class=\"sublist1\">Osteoid osteoma</td> </tr> <tr> <td class=\"subtitle1_single\">Articular</td> </tr> <tr> <td>Transient synovitis of the hip</td> </tr> <tr> <td>Septic arthritis</td> </tr> <tr> <td>Osteochodritis dissecans</td> </tr> <tr> <td>Acute rheumatic fever</td> </tr> <tr> <td>Juvenile idiopathic arthritis</td> </tr> <tr> <td>Henoch-Sch&#246;nlein purpura</td> </tr> <tr> <td>Serum sickness</td> </tr> <tr> <td>Discitis</td> </tr> <tr> <td>Developmental dysplasia of the hip</td> </tr> <tr> <td>Chrodomalacia of the patella</td> </tr> <tr> <td>Hemarthrosis&nbsp;(causes include&nbsp;trauma, hemophilia, and pigmented villonodular synovitis)</td> </tr> <tr> <td>Lyme disease</td> </tr> <tr> <td>Systemic lupus erythematosis</td> </tr> <tr> <td>Patellar dislocation</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Soft tissue</td> </tr> <tr> <td>Contusion</td> </tr> <tr> <td>Muscle strain</td> </tr> <tr> <td>Sprain</td> </tr> <tr> <td>Tendonitis</td> </tr> <tr> <td>Viral myositis</td> </tr> <tr> <td>Foreign body</td> </tr> <tr> <td>Benign hypermobility syndrome</td> </tr> <tr> <td>Intramuscular vaccination</td> </tr> <tr> <td>Bursitis</td> </tr> <tr> <td>Cellulitis</td> </tr> <tr> <td>Baker's cyst rupture</td> </tr> <tr> <td>Soft tissue abscess</td> </tr> <tr> <td>Pyomyositis</td> </tr> <tr> <td>Insect envenomation</td> </tr> <tr> <td>Bunion</td> </tr> <tr> <td>Ingrown toenail</td> </tr> <tr> <td>Plantar warts</td> </tr> <tr> <td>Myositis ossificans</td> </tr> <tr> <td class=\"subtitle1_single\">Neurological</td> </tr> <tr> <td>Cerebral palsy</td> </tr> <tr> <td>Peripheral neuropathy</td> </tr> <tr> <td>Meningitis</td> </tr> <tr> <td>Epidural abscess of the spine</td> </tr> <tr> <td>Complex regional pain syndrome (reflex sympathetic dystrophy)</td> </tr> <tr> <td>Spinal cord tumor</td> </tr> <tr> <td class=\"subtitle1_single\">Intra-abdominal</td> </tr> <tr> <td>Appendicitis</td> </tr> <tr> <td>Pelvic inflammatory disease</td> </tr> <tr> <td>Pelvic abscess</td> </tr> <tr> <td>Psoas abscess</td> </tr> <tr> <td>Perirectal abscess</td> </tr> <tr> <td>Iliac adenitis</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td>Conversion disorder</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76343 Version 6.0</div></div></div>"},"76344":{"type":"graphic_table","displayName":"Eval acute asthma attack","title":"Formal evaluation of asthma exacerbation severity in the urgent or emergency care setting","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Formal evaluation of asthma exacerbation severity in the urgent or emergency care setting</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Mild</td> <td class=\"subtitle1\">Moderate</td> <td class=\"subtitle1\">Severe</td> <td class=\"subtitle1\">Subset: Respiratory arrest imminent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Symptoms </td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Breathlessness</td> <td>While walking</td> <td>While at rest (infant - softer, shorter cry, difficulty feeding)</td> <td>While at rest (infant - stops feeding)</td> <td>&nbsp;</td> </tr> <tr> <td>Can lie down</td> <td>Prefers sitting</td> <td>Sits upright </td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Talks in</td> <td>Sentences</td> <td>Phrases</td> <td>Words </td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Alertness</td> <td>May be agitated</td> <td>Usually agitated*</td> <td>Usually agitated*</td> <td>Drowsy or confused </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Signs </td> </tr> <tr> <td class=\"indent1\" rowspan=\"7\">Respiratory rate</td> <td rowspan=\"7\">Increased</td> <td>Increased</td> <td>Often &#62;30/minute </td> <td rowspan=\"7\">Poor respiratory effort, appears exhausted</td> </tr> <tr> <td colspan=\"2\"><strong>Guide to rates of breathing in awake children: </strong></td> </tr> <tr> <td class=\"sublist1_start\">Age</td> <td>Normal rate </td> </tr> <tr> <td class=\"sublist1\">&#60;2 months</td> <td class=\"sublist_other\">&#60;60/minute </td> </tr> <tr> <td class=\"sublist1\">2 to 12 months</td> <td class=\"sublist_other\">&#60;50/minute</td> </tr> <tr> <td class=\"sublist1\">1 to 5 years</td> <td class=\"sublist_other\">&#60;40/minute </td> </tr> <tr> <td class=\"sublist1\">6 to 8 years</td> <td class=\"sublist_other\">&#60;30/minute</td> </tr> <tr> <td class=\"indent1\">Use of accessory muscles; suprasternal retractions</td> <td>Usually not</td> <td>Commonly</td> <td>Usually</td> <td>Paradoxical thoracoabdominal movement </td> </tr> <tr> <td class=\"indent1\">Wheeze</td> <td>Moderate, often only end expiratory</td> <td>Loud; throughout exhalation</td> <td>Usually loud; throughout inhalation and exhalation</td> <td>Absence of wheeze (silent chest)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"6\">Pulse/minute</td> <td rowspan=\"6\">&#60;100</td> <td>100 to 120</td> <td>&#62;120</td> <td rowspan=\"6\">Bradycardia </td> </tr> <tr> <td colspan=\"2\"><strong>Guide to normal pulse rates in children: </strong></td> </tr> <tr> <td class=\"sublist1_start\">Age</td> <td>Normal rate </td> </tr> <tr> <td class=\"sublist1\">2 to 12 months</td> <td class=\"sublist_other\">&#60;160/minute </td> </tr> <tr> <td class=\"sublist1\">1 to 2 years</td> <td class=\"sublist_other\">&#60;120/minute </td> </tr> <tr> <td class=\"sublist1\">2 to 8 years</td> <td class=\"sublist_other\">&#60;110/minute</td> </tr> <tr> <td class=\"indent1\">Pulsus paradoxus</td> <td>Absent to&nbsp;&#60;10 mmHg</td> <td> <p>May be present </p> <p>10 to 25 mmHg</p> </td> <td>Often present <p>&#62;25 mmHg (adult)</p> <p>20 to 40 mmHg (child)</p> </td> <td>Absence suggests respiratory muscle fatigue </td> </tr> <tr> <td class=\"indent1\">Other</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Cyanosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Functional assessment </td> </tr> <tr> <td class=\"indent1\">PEF percent predicted or percent personal best</td> <td>&#8805;70%</td> <td>Approximately 40 to 69% or response to inhaled beta-agonists lasts &#60;2 hours</td> <td>&#60;40%</td> <td> <p>&#60;25%</p> <p>Note: PEF testing may not be needed in very severe attacks </p> </td> </tr> <tr> <td class=\"indent1\">PaO<sub>2</sub> (in room air)</td> <td>Normal (test not usually necessary)</td> <td>&#8805;60 mmHg (test not usually necessary)</td> <td>&#60;60 mmHg: possible cyanosis </td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">PCO<sub>2</sub></td> <td>&#60;42 mmHg (test not usually necessary)</td> <td>&#60;42 mmHg (test not usually necessary)</td> <td>&#8805;42 mmHg: possible respiratory failure </td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">SpO<sub>2</sub> percent (in room&nbsp;air) at sea level</td> <td>&#62;95% (test not usually necessary)</td> <td>90 to 95% (test not usually necessary)</td> <td>&#60;90%</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"4\">Hypercapnia (hypoventilation) develops more readily in young children than in adults and adolescents.</td> </tr> <tr> <td class=\"indent1\">&nbsp;BP</td> <td colspan=\"4\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>Notes:</STRONG><br />- The presence of several parameters, but not necessarily all, indicates the general classification of the exacerbation. <br />- Many of these parameters have not been systematically studied, especially as they correlate with each other. Thus, they serve only as general guides (Cham et al 2002; Chey et al 1999; Gorelick et al 2004b; Karras et al 2000; Kelly et al 2002b and 2004; Keogh et al 2001; McCarren et al 2000; Rodrigo and Rodrigo 1998b; Rodrigo et al 2004; Smith et al 2002). <br />- The emotional impact of asthma symptoms on the patient and family is variable, but must be recognized and addressed and can affect approaches to treatment and follow-up (Ritz et al 2000; Strunk and Mrazek 1986; von Leupoldt and Dahme 2005).</div><div class=\"graphic_footnotes\">PaO<SUB>2</SUB>: arterial oxygen pressure; PCO<SUB>2</SUB>: partial pressure of carbon dioxide; PEF: peak expiratory flow; SpO<SUB>2</SUB>: oxygen saturation; BP: blood pressure.<br />* Some children with an acute severe asthma exacerbation do not appear agitated.</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 76344 Version 7.0</div></div></div>"},"76345":{"type":"graphic_table","displayName":"HBV immunoprophylaxis for infants with BW 2 kg or more","title":"Recommended schedule of hepatitis B immunoprophylaxis for term infants and preterm infants with birth weight ≥2 kg","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended schedule of hepatitis B immunoprophylaxis for term infants and preterm infants with birth weight ≥2 kg</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Maternal HBsAg status</td> <td class=\"subtitle1\" colspan=\"2\">Single-antigen vaccine*</td> <td class=\"subtitle1\" colspan=\"2\">Single antigen*&nbsp;plus combination vaccine</td> </tr> <tr> <td class=\"subtitle2\">Dose</td> <td class=\"subtitle2\">Age</td> <td class=\"subtitle2\">Dose</td> <td class=\"subtitle2\">Age</td> </tr> <tr> <td rowspan=\"5\">Positive<sup>&#182;</sup></td> <td>1</td> <td>Birth (&#8804;12 hours)*</td> <td>1</td> <td>Birth (&#8804;12 hours)*</td> </tr> <tr> <td>HBIG<sup>&#916;</sup></td> <td>Birth (&#8804;12 hours)</td> <td>HBIG<sup>&#916;</sup></td> <td>Birth (&#8804;12 hours)</td> </tr> <tr> <td>2</td> <td>1 to 2 months*</td> <td>2</td> <td>2 months</td> </tr> <tr> <td>3</td> <td>6 months<sup>&#9674;&#167;</sup></td> <td>3</td> <td>4 months</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>4</td> <td>6 months<sup>&#9674;&#167;</sup></td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Unknown<sup>&#165;</sup></td> <td>1</td> <td>Birth (&#8804;12 hours)*</td> <td>1</td> <td>Birth (&#8804;12 hours)*</td> </tr> <tr> <td>2</td> <td>1 to 2 months*</td> <td>2</td> <td>2 months</td> </tr> <tr> <td>3</td> <td>6 months<sup>&#9674;</sup></td> <td>3</td> <td>4 months</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>4</td> <td>6 months<sup>&#9674;</sup></td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Negative</td> <td>1</td> <td>Birth (&#8804;24 hours)*</td> <td>1</td> <td>Birth (&#8804;24 hours)*</td> </tr> <tr> <td>2</td> <td>1 to 2 months*</td> <td>2</td> <td>2 months</td> </tr> <tr> <td>3</td> <td>6 to 18 months<sup>&#9674;</sup></td> <td>3</td> <td>4 months</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>4</td> <td>6 months<sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen; HBIG: hepatitis B immune globulin; anti-HBs: antibody to HBsAg.<br />* Single-antigen vaccines (ie, Recombivax HB or Engerix-B) should be used for the birth dose. Combination vaccines (eg, Pediarix) cannot be administered at birth or before age 6 weeks.<br />¶ Infants born to HBsAg-positive mothers should receive immunoprophylaxis as recommended whether or not their mother received antiviral therapy during the third trimester.<br />Δ HBIG&nbsp;(0.5 mL) administered intramuscularly&nbsp;at a separate site (ie, different leg)&nbsp;from vaccine.&nbsp;<br />◊ The final dose in the vaccine series should not be administered before age 24 weeks (164 days).<br />§&nbsp;These infants should be tested for&nbsp;anti-HBs and HBsAg at age 9 to&nbsp;12 months or 1 to 2 months after the last dose of hepatitis B vaccine. Testing should not be performed before age&nbsp;9 months nor within 4 weeks of the most recent vaccine dose. <br />¥ Mothers should have blood drawn and tested for HBsAg as soon as possible after admission for delivery; if the mother is found to be HBsAg positive, the infant should receive HBIG as soon as possible but no later than age&nbsp;7 days.</div><div class=\"graphic_reference\">Adapted&nbsp;from: Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018; 67:1.</div><div id=\"graphicVersion\">Graphic 76345 Version 15.0</div></div></div>"},"76346":{"type":"graphic_picture","displayName":"DIF of linear IgA bullous dermatosis","title":"Direct immunofluorescence microscopy of linear IgA bullous dermatosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Direct immunofluorescence microscopy of linear IgA bullous dermatosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/76346_DIF_line_IgA_bull_dermat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A linear band of fluorescence representing deposition of IgA along the basement membrane zone is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76346 Version 3.0</div></div></div>"},"76347":{"type":"graphic_diagnosticimage","displayName":"Ascariasis - abdominal film 2","title":"Ascariasis - abdominal film 2","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ascariasis - abdominal film 2</div><div class=\"cntnt\"><img style=\"width:285px; height:403px;\" src=\"images/ID/76347_Ascariasis_abdomen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A barium follow-through demonstrates a large number of parasitic worms in the jejunum with tram-track appearance.</div><div class=\"graphic_reference\">Reproduced with permission from: Shrivastav A, Pal J. Medical image. Ascaris lumbricoides. N Z Med J 2008; 121:126. Copyright &copy; 2008 New Zealand Medical Association.</div><div id=\"graphicVersion\">Graphic 76347 Version 2.0</div></div></div>"},"76348":{"type":"graphic_table","displayName":"Features of IPSID lymphomas","title":"Clinical features of the different types of small intestinal lymphomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of the different types of small intestinal lymphomas</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Feature</td>\n<td class=\"subtitle1\">IPSID-associated lymphoma</td>\n<td class=\"subtitle1\">Non-IPSID-associated lymphoma</td>\n</tr>\n<tr>\n<td>Median age</td>\n<td>25 years</td>\n<td>37 years</td>\n</tr>\n<tr>\n<td>Gender</td>\n<td>Primarily males</td>\n<td>Slight male predominance</td>\n</tr>\n<tr>\n<td>Symptoms and signs</td>\n<td colspan=\"1\" rowspan=\"1\">Abdominal pain<br />Chronic diarrhea<br />Malabsorption<br />Severe weight loss<br />Clubbing<br />Ankle edema</td>\n<td colspan=\"1\" rowspan=\"1\">Abdominal pain<br />Palpable abdominal mass<br />Bleeding<br />Intestinal obstruction<br />Intestinal perforation</td>\n</tr>\n\n\n\n\n\n<tr>\n<td>Paraprotein</td>\n<td>Usually present</td>\n<td>Usually absent</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_lgnd\">IPSID: Immunoproliferative small intestinal disease</div><div class=\"graphic_reference\">Adapted from: Salem, P, El-Hashimi, L, Allam, C, et al, Cancer 1987; 59:1670.</div><div id=\"graphicVersion\">Graphic 76348 Version 2.0</div></div></div>"},"76349":{"type":"graphic_picture","displayName":"Laparoscopy surgery instruments","title":"Laparoscopic instruments","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic instruments</div><div class=\"cntnt\"><img style=\"width:381px; height:266px;\" src=\"images/OBGYN/76349_Laparoscopy_surgery_instrum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These instruments are used for grasping, biopsy, and manipulation of tissue.</div><div id=\"graphicVersion\">Graphic 76349 Version 1.0</div></div></div>"},"76350":{"type":"graphic_diagnosticimage","displayName":"Vascular malformation 9AB","title":"A 40-year-old woman (G0) who presented with history of three days of intermittent profuse vaginal bleeding","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">A 40-year-old woman (G0) who presented with history of three days of intermittent profuse vaginal bleeding</div><div class=\"cntnt\"><img style=\"width:550px; height:589px;\" src=\"images/OBGYN/76350_Vascular_malformation_9AB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Ultrasound of the pelvis demonstrates hypoechoic regions (arrows).<br />(B) Duplex color Doppler ultrasound shows a hypervascular lesion within the fundus that measures 2.6x2.3x1.3 cms, consistent with arteriovenous fistula or malformation. She was s/p TAB at 14 weeks, 5 months.</div><div id=\"graphicVersion\">Graphic 76350 Version 3.0</div></div></div>"},"76352":{"type":"graphic_figure","displayName":"Tricyclic ECG changes B","title":"Electrocardiographic changes associated with tricyclic antidepressant overdose","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Electrocardiographic changes associated with tricyclic antidepressant overdose</div><div class=\"cntnt\"><img style=\"width:524px; height:350px;\" src=\"images/PULM/76352_Tricyclic_ECG_changes_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following treatment with sodium bicarbonate, the intraventricular conduction delay resolves, and the QRS complex duration and morphology return to normal.</div><div id=\"graphicVersion\">Graphic 76352 Version 1.0</div></div></div>"},"76354":{"type":"graphic_table","displayName":"Neonatal blood pressures and potential treatment parameters","title":"Neonatal blood pressures and potential treatment parameters","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neonatal blood pressures and potential treatment parameters</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Post-conceptual age</td> <td class=\"subtitle1\">50th percentile</td> <td class=\"subtitle1\">95th percentile</td> <td class=\"subtitle1\">99th percentile</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">44 weeks</td> </tr> <tr> <td class=\"indent1\">SBP</td> <td>88</td> <td>105</td> <td>110</td> </tr> <tr> <td class=\"indent1\">DBP</td> <td>50</td> <td>68</td> <td>73</td> </tr> <tr> <td class=\"indent1\"><strong>MAP</strong></td> <td><strong>63</strong></td> <td><strong>80</strong></td> <td><strong>85</strong></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">42 weeks</td> </tr> <tr> <td class=\"indent1\">SBP</td> <td>85</td> <td>98</td> <td>102</td> </tr> <tr> <td class=\"indent1\">DBP</td> <td>50</td> <td>65</td> <td>70</td> </tr> <tr> <td class=\"indent1\"><strong>MAP</strong></td> <td><strong>62</strong></td> <td><strong>76</strong></td> <td><strong>81</strong></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">40 weeks</td> </tr> <tr> <td class=\"indent1\">SBP</td> <td>80</td> <td>95</td> <td>100</td> </tr> <tr> <td class=\"indent1\">DBP</td> <td>50</td> <td>65</td> <td>70</td> </tr> <tr> <td class=\"indent1\"><strong>MAP</strong></td> <td><strong>60</strong></td> <td><strong>75</strong></td> <td><strong>80</strong></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">38 weeks</td> </tr> <tr> <td class=\"indent1\">SBP</td> <td>77</td> <td>92</td> <td>97</td> </tr> <tr> <td class=\"indent1\">DBP</td> <td>50</td> <td>65</td> <td>70</td> </tr> <tr> <td class=\"indent1\"><strong>MAP</strong></td> <td><strong>59</strong></td> <td><strong>74</strong></td> <td><strong>79</strong></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">36 weeks</td> </tr> <tr> <td class=\"indent1\">SBP</td> <td>72</td> <td>87</td> <td>92</td> </tr> <tr> <td class=\"indent1\">DBP</td> <td>50</td> <td>65</td> <td>70</td> </tr> <tr> <td class=\"indent1\"><strong>MAP</strong></td> <td><strong>57</strong></td> <td><strong>72</strong></td> <td><strong>77</strong></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">34 weeks</td> </tr> <tr> <td class=\"indent1\">SBP</td> <td>70</td> <td>85</td> <td>90</td> </tr> <tr> <td class=\"indent1\">DBP</td> <td>40</td> <td>55</td> <td>60</td> </tr> <tr> <td class=\"indent1\"><strong>MAP</strong></td> <td><strong>50</strong></td> <td><strong>65</strong></td> <td><strong>70</strong></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">32 weeks</td> </tr> <tr> <td class=\"indent1\">SBP</td> <td>68</td> <td>83</td> <td>88</td> </tr> <tr> <td class=\"indent1\">DBP</td> <td>40</td> <td>55</td> <td>60</td> </tr> <tr> <td class=\"indent1\"><strong>MAP</strong></td> <td><strong>49</strong></td> <td><strong>64</strong></td> <td><strong>69</strong></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">30 weeks</td> </tr> <tr> <td class=\"indent1\">SBP</td> <td>65</td> <td>80</td> <td>85</td> </tr> <tr> <td class=\"indent1\">DBP</td> <td>40</td> <td>55</td> <td>60</td> </tr> <tr> <td class=\"indent1\"><strong>MAP</strong></td> <td><strong>48</strong></td> <td><strong>63</strong></td> <td><strong>68</strong></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">28 weeks</td> </tr> <tr> <td class=\"indent1\">SBP</td> <td>60</td> <td>75</td> <td>80</td> </tr> <tr> <td class=\"indent1\">DBP</td> <td>38</td> <td>50</td> <td>54</td> </tr> <tr> <td class=\"indent1\"><strong>MAP</strong></td> <td><strong>45</strong></td> <td><strong>58</strong></td> <td><strong>63</strong></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">26 weeks</td> </tr> <tr> <td class=\"indent1\">SBP</td> <td>55</td> <td>72</td> <td>77</td> </tr> <tr> <td class=\"indent1\">DBP</td> <td>30</td> <td>50</td> <td>56</td> </tr> <tr> <td class=\"indent1\"><strong>MAP</strong></td> <td><strong>38</strong></td> <td><strong>57</strong></td> <td><strong>63</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table provides estimated values for blood pressures after two weeks of age in infants from 26 to 44 weeks post-conceptual age. The 95th and 99th percentile values are intended to serve as a reference to identify infants with persistent hypertension that may require treatment.</div><div class=\"graphic_footnotes\">SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure.</div><div class=\"graphic_reference\">Reproduced from: Dionne JM, Abitbol CL, Flynn JT. Hypertension in infancy: diagnosis, management, and outcome. Pediatr Nephrol 2011 with kind permission from Springer Science + Business Media B.V. Copyright © 2011. This table includes the changes published in the correction: Pediatr Nephol 2012; 27:159.</div><div id=\"graphicVersion\">Graphic 76354 Version 11.0</div></div></div>"},"76356":{"type":"graphic_picture","displayName":"Lymphangitis of the hand and arm","title":"Lymphangitis of the hand and arm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphangitis of the hand and arm</div><div class=\"cntnt\"><img style=\"width:360px; height:540px;\" src=\"images/SURG/76356_Lymphangitis_hand_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymphangitis is an infection of the lymphatics characterized by a distal nidus and erythematous streaks that spread proximally up the arm. Note the red streak extending proximally from the ring finger.</div><div id=\"graphicVersion\">Graphic 76356 Version 3.0</div></div></div>"},"76359":{"type":"graphic_table","displayName":"Clinical features of central versus peripheral vertigo","title":"Clinical features of central versus peripheral vertigo","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of central versus peripheral vertigo</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Peripheral</td> <td class=\"subtitle1\">Central</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Nystagmus</td> </tr> <tr> <td class=\"indent1\">Direction</td> <td>Unidirectional, fast component toward the normal ear; never reverses direction</td> <td>Sometimes reverses direction when patient looks in the direction of slow component</td> </tr> <tr> <td class=\"indent1\">Type</td> <td>Horizontal with a torsional component, never purely torsional or vertical</td> <td>Can be any direction</td> </tr> <tr> <td class=\"indent1\">Effect of visual fixation</td> <td>Suppressed</td> <td>Not suppressed</td> </tr> <tr> <td><strong>Other neurologic signs</strong></td> <td>Absent</td> <td>Often present</td> </tr> <tr> <td><strong>Postural instability</strong></td> <td>Unidirectional instability, walking preserved</td> <td>Severe instability, patient often falls when walking</td> </tr> <tr> <td><strong>Deafness or tinnitus</strong></td> <td>May be present</td> <td>Absent</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76359 Version 4.0</div></div></div>"},"76360":{"type":"graphic_picture","displayName":"Cook Gianturco Z stent","title":"Single Cook-Gianturco Z-stent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Single Cook-Gianturco Z-stent</div><div class=\"cntnt\"><img style=\"width:270px; height:214px;\" src=\"images/PULM/76360_Cook_Gianturco_Z_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown fully expanded, it can be compressed into a narrow cylinder prior to bronchoscopic deployment.</div><div id=\"graphicVersion\">Graphic 76360 Version 2.0</div></div></div>"},"76363":{"type":"graphic_figure","displayName":"BP response to TZ diuretics","title":"Determinants of hypotensive response to thiazide diuretic","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Determinants of hypotensive response to thiazide diuretic</div><div class=\"cntnt\"><img style=\"width:329px; height:228px;\" src=\"images/NEPH/76363_BP_response_to_TZ_diuretics.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sequential changes in vascular resistance in nonresponders (blue squares) and responders (red circles) to the hypotensive effect of a thiazide diuretic in patients with primary hypertension (formerly called \"essential\" hypertension). Although both groups had an initial diuresis and reduction in plasma volume, there was no significant fall in blood pressure in the nonresponders due to a rise in vascular resistance mediated in part by increased production of angiotensin II. In comparison, vascular resistance fell over time in the responders via an unknown mechanism.</div><div class=\"graphic_reference\">Data from Van Brummelen, P, Man in't Veld, AJ, Schalekamp, MA, Clin Pharmacol Ther 1980; 27:328.</div><div id=\"graphicVersion\">Graphic 76363 Version 2.0</div></div></div>"},"76364":{"type":"graphic_waveform","displayName":"ECG SA nodal reentrant tachycardia","title":"Single-lead electrocardiogram (ECG) showing sinoatrial (SA) nodal reentrant tachycardia","html":"<div class=\"graphic normal\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Single-lead electrocardiogram (ECG) showing sinoatrial (SA) nodal reentrant tachycardia</div><div class=\"cntnt\"><img style=\"width:451px; height:85px;\" src=\"images/CARD/76364_SA_nodal_reentrant_tach_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram showing SA nodal reentrant tachycardia. The first three beats are normal sinus beats at a rate of about 107 beats/min; the fourth beat is an atrial premature beat that is followed by a return to sinus rhythm. The eighth beat (arrow) represents the sudden onset of SA nodal reentrant tachycardia at a rate of about 145 beats/min. Since the P waves are similar to the sinus beats, the diagnosis is suggested only by the abrupt onset of the tachycardia.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 76364 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"76365":{"type":"graphic_table","displayName":"Cyanide sources","title":"Sources of cyanide","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sources of cyanide</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Industrial exposures</td>\n</tr>\n<tr>\n<td>Plastics production</td>\n</tr>\n<tr>\n<td>Photography</td>\n</tr>\n<tr>\n<td>Fumigation</td>\n</tr>\n<tr>\n<td>Pesticides/ Rodenticides</td>\n</tr>\n<tr>\n<td>Synthetic rubber production</td>\n</tr>\n<tr>\n<td>Fertilizer production</td>\n</tr>\n<tr>\n<td>Metal polish</td>\n</tr>\n<tr>\n<td>Hair removal from hides</td>\n</tr>\n<tr>\n<td>Electroplating</td>\n</tr>\n<tr>\n<td>Metallurgy</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Plants and fruits</td>\n</tr>\n<tr>\n<td>Bamboo sprout</td>\n</tr>\n<tr>\n<td>Macadamia nuts</td>\n</tr>\n<tr>\n<td>Hydrangea</td>\n</tr>\n<tr>\n<td>Rosaceae family (plum, peach, pear, apple, bitter almond, cherry)</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Miscellaneous</td>\n</tr>\n<tr>\n<td>Cigarette smoking</td>\n</tr>\n<tr>\n<td>Phencyclidine synthesis</td>\n</tr>\n<tr>\n<td>Artificial nail glue remover</td>\n</tr>\n<tr>\n<td>Product tampering</td>\n</tr>\n<tr>\n<td>Suicide/ Terrorist attack</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Drugs</td>\n</tr>\n<tr>\n<td>Sodium Nitroprusside</td>\n</tr>\n<tr>\n<td>Laetrile</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Combustion</td>\n</tr>\n<tr>\n<td>Wool</td>\n</tr>\n<tr>\n<td>Silk</td>\n</tr>\n<tr>\n<td>Polyurethanes</td>\n</tr>\n<tr>\n<td>Polyacrylonitriles</td>\n</tr>\n<tr>\n<td>Nylon</td>\n</tr>\n<tr>\n<td>Melamine resins</td>\n</tr>\n<tr>\n<td>Plastics</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 76365 Version 1.0</div></div></div>"},"76366":{"type":"graphic_table","displayName":"Antithyroid drug comparisons","title":"Antithyroid drug comparisons","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antithyroid drug comparisons</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Factor</td> <td class=\"subtitle1\">Propylthiouracil</td> <td class=\"subtitle1\">Methimazole</td> </tr> <tr> <td>Response time</td> <td>Slower</td> <td>Faster</td> </tr> <tr> <td>Toxicity</td> <td>Dose-related hepatitis, vasculitis</td> <td>Dose-related, rare side-effects less common</td> </tr> <tr> <td>Compliance</td> <td>Worse</td> <td>Better</td> </tr> <tr> <td>Cost (per 100 tablets)</td> <td>$100 for&nbsp;50 mg tablet</td> <td>$77 for&nbsp;10 mg tablet</td> </tr> <tr> <td>Effect on radioiodine outcome</td> <td>Decreases effect</td> <td>Possible effect</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">$: US dollars.</div><div class=\"graphic_reference\">Adapted with permission from: Cooper DC. Antithyroid drugs in the management of patients with Graves' disease: An evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab 2003; 88:3474. http://jcem.endojournals.org/. Copyright © 2003 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 76366 Version 10.0</div></div></div>"},"76369":{"type":"graphic_figure","displayName":"Milex incontinence ring pessary","title":"Milex incontinence vaginal ring","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Milex incontinence vaginal ring</div><div class=\"cntnt\"><img style=\"width:417px; height:324px;\" src=\"images/OBGYN/76369_Milex_incontinence_ring_pes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ball portion of the pessary lies below the urethrovesical junction.</div><div class=\"graphic_reference\">Courtesy of Milex Products, Inc., Chicago, IL.</div><div id=\"graphicVersion\">Graphic 76369 Version 2.0</div></div></div>"},"76370":{"type":"graphic_table","displayName":"Epid clin types KS","title":"Epidemiologic and clinical types of Kaposi sarcoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epidemiologic and clinical types of Kaposi sarcoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Predominant risk groups</td> <td class=\"subtitle1\">Cutaneous presentation</td> <td class=\"subtitle1\">Visceral involvement</td> <td class=\"subtitle1\">Clinical course</td> </tr> <tr class=\"divider_bottom\"> <td>Classic (sporadic)</td> <td> <p>~3:1 male:female ratio</p> <p>Age &#62;60</p> Mediterranean or Central/Eastern European Origin; Middle East</td> <td>Distal lower extremities</td> <td>Uncommon</td> <td>Usually indolent; rarely aggressive &#38; disseminated</td> </tr> <tr class=\"divider_bottom\"> <td>Endemic (African)</td> <td> <p>Male adults</p> <p>Children of both sexes</p> Equatorial Africa</td> <td>Various (may be similar to classic or more locally aggressive); lower extremity lymphedema in adults; cutaneous disease often absent in children</td> <td> <p>Internal organs involved in a subset of adult patients</p> Common (lymph nodes and viscera) in children</td> <td> <p>Indolent to locally invasive in adults</p> <p>Occasional rapid progression with visceral disease in adults</p> Aggressive in children</td> </tr> <tr class=\"divider_bottom\"> <td>Iatrogenic (immunosuppression-related)</td> <td> <p>Exogenous immunosuppression, esp. solid organ transplant</p> <p>Older patients (&#62;50)</p> Use of cyclosporin A</td> <td>Distal lower extremities; may be disseminated</td> <td>Relatively common</td> <td> <p>May regress with modification of immunosuppression</p> May be aggressive</td> </tr> <tr> <td>AIDS-associated</td> <td> <p>Men who have sex with men (developed countries)</p> Heterosexual men &#38; women (Africa)</td> <td>Localized or disseminated</td> <td>Common with poor HIV control</td> <td> <p>Aggressive or indolent</p> May regress with effective HIV treatment</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76370 Version 3.0</div></div></div>"},"76373":{"type":"graphic_table","displayName":"Laboratory findings inborn errors of metabolism","title":"Distinguishing biochemical findings of inborn errors of metabolism*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinguishing biochemical findings of inborn errors of metabolism*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Findings</td> <td class=\"subtitle1\">Maple syrup urine disease</td> <td class=\"subtitle1\">Organic acidemias</td> <td class=\"subtitle1\">Urea cycle defects</td> <td class=\"subtitle1\">Disorders of carbohydrate metabolism</td> <td class=\"subtitle1\">Fatty acid oxidation disorders</td> <td class=\"subtitle1\">Mitochondrial disorders</td> <td class=\"subtitle1\">Peroxisomal disorders</td> <td class=\"subtitle1\">Lysosomal storage disorders</td> </tr> <tr> <td>Metabolic acidosis</td> <td>&#177;</td> <td>++</td> <td>-</td> <td>&#177;</td> <td>&#177;</td> <td>&#177;</td> <td>-</td> <td>-</td> </tr> <tr> <td>Respiratory alkalosis</td> <td>-</td> <td>-</td> <td>+</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Hyperammonemia</td> <td>&#177;</td> <td>+</td> <td>++</td> <td>-</td> <td>&#177;</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Hypoglycemia</td> <td>&#177;</td> <td>&#177;</td> <td>-</td> <td>+</td> <td>+</td> <td>&#177;</td> <td>-</td> <td>-</td> </tr> <tr> <td>Ketones</td> <td>A/H</td> <td>H</td> <td>A</td> <td>A/H</td> <td>A/L</td> <td>A/H</td> <td>A</td> <td>A</td> </tr> <tr> <td>Lactic acidosis</td> <td>&#177;</td> <td>&#177;</td> <td>-</td> <td>+</td> <td>&#177;</td> <td>++</td> <td>-</td> <td>-</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">-: usually absent; ±: sometimes present; +: usually present; ++: always present; A: appropriate; H: inappropriately high; L: inappropriately low.<br />* Within disease categories, not all diseases have all findings; for disorders with episodic decompensation clinical and laboratory findings may be present only during acute crisis; for progressive disorders, findings may not be present early in the course of disease.</div><div class=\"graphic_reference\">Adapted from: Weiner DL. Metabolic Emergencies. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.1193.</div><div id=\"graphicVersion\">Graphic 76373 Version 6.0</div></div></div>"},"76376":{"type":"graphic_figure","displayName":"Menstrual calendar","title":"Menstrual record chart","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Menstrual record chart</div><div class=\"cntnt\"><img style=\"width:521px; height:335px;\" src=\"images/OBGYN/76376_Menstrual_calendar.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 76376 Version 1.0</div></div></div>"},"76377":{"type":"graphic_waveform","displayName":"Advanced case 7 with answer","title":"Acute/evolving infero-postero-lateral myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Acute/evolving infero-postero-lateral myocardial infarction</div><div class=\"cntnt\"><img style=\"width:540px; height:264px;\" src=\"images/CARD/76377_Advancedcase7withanswer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram showing the major features of an inferior (Q waves, ST elevations, and T wave inversions in II, III, and aVF), posterior (tall R waves in V1 and V2), and lateral (T wave inversions in V4 to V6) myocardial infarction.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76377 Version 3.0</div></div></div>"},"76378":{"type":"graphic_picture","displayName":"Lymph node Hodgkin lymphoma","title":"Lymph node in Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymph node in Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:312px; height:288px;\" src=\"images/HEME/76378_Lymph_node_Hodgkin_lymphoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cut section of a lymph node from a patient with the nodular sclerosis subtype of Hodgkin lymphoma shows distinct separation into nodules by fibrous bands.</div><div class=\"graphic_reference\">From Warnke RA, Weiss LM, Chan JK, et al. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 76378 Version 2.0</div></div></div>"},"76379":{"type":"graphic_table","displayName":"Signs and symptoms of spinal cord injury","title":"Symptoms and signs of traumatic cervical spinal cord injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms and signs of traumatic cervical spinal cord injury</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Altered mental status</td>\n\n</tr>\n<tr>\n<td>Abnormal motor examination</td>\n\n</tr>\n<tr>\n<td>Abnormal sensory examination</td>\n\n</tr>\n<tr>\n<td>Abnormal or absent reflexes</td>\n\n</tr>\n<tr>\n<td>Paralysis</td>\n\n</tr>\n<tr>\n<td>Neck pain at rest or with isometric neck motion</td>\n\n</tr>\n\n<tr>\n<td>Decreased cervical range of motion</td>\n\n</tr>\n<tr>\n<td>Posterior midline cervical tenderness</td>\n\n</tr><tr><td>Muscle spasm of cervical muscles</td></tr><tr><td>Bilateral symptoms</td></tr><tr><td>Lower extremity symptoms</td></tr><tr><td>Hypotension with bradycardia (neurogenic shock)</td></tr><tr><td>Diaphragmatic breathing without retractions</td></tr><tr><td>Autonomic hyperreflexia</td></tr><tr><td>Hypothermia or hyperthermia</td></tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 76379 Version 2.0</div></div></div>"},"76382":{"type":"graphic_diagnosticimage","displayName":"Fetal anal atresia with rectovaginal fistula ","title":"Prenatal ultrasound and magnetic resonance images of anal atresia with rectovaginal fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound and magnetic resonance images of anal atresia with rectovaginal fistula</div><div class=\"cntnt\"><img style=\"width:377px; height:577px;\" src=\"images/OBGYN/76382_Anal_atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Ultrasound. Coronal view of the abdomen at 22 weeks of gestation shows the fluid-filled rectosigmoid colon containing intraluminal calcifications.<br />(B and C) Magnetic resonance imaging. Coronal and sagittal T2w images of the fetal abdomen confirm the presence of fluid within the distal rectosigmoid coursing posterior and inferior to the&nbsp;bladder base.</div><div class=\"graphic_reference\">Courtesy of Dorothy I Bulas, MD.</div><div id=\"graphicVersion\">Graphic 76382 Version 5.0</div></div></div>"},"76383":{"type":"graphic_picture","displayName":"Lichen planus wrists fair skin","title":"Lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen planus</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/76383_Lich_plan_wrists_fair_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Violaceous, polygonal papules are present on the ventral wrists.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76383 Version 4.0</div></div></div>"},"76384":{"type":"graphic_algorithm","displayName":"Balanoposthitis algorithm","title":"Evaluation algorithm for balanoposthitis","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Evaluation algorithm for balanoposthitis</div><div class=\"cntnt\"><img style=\"width:542px; height:638px;\" src=\"images/EM/76384_Balanoposthitis_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with refractory balanoposthitis, recurrence, or scarring with phimosis warrant referral to a pediatric urologist.</div><div class=\"graphic_footnotes\">Rx: treatment; STD: sexually transmitted disease.<br>* Presumptive treatment without specific testing for infectious pathogens is appropriate in young boys (&lt;6 years of age).</div><div id=\"graphicVersion\">Graphic 76384 Version 1.0</div></div></div>"},"76385":{"type":"graphic_figure","displayName":"Short-acting nifedipine in CHD","title":"Association of high-dose short-acting nifedipine with increased mortality","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Association of high-dose short-acting nifedipine with increased mortality</div><div class=\"cntnt\"><img style=\"width:481px; height:248px;\" src=\"images/NEPH/76385_Short_acting_nifedipine_in.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relative risk of mortality in patients with underlying coronary heart disease (CHD) treated with a short-acting preparation of oral nifedipine. Doses of 80 mg/day and above were associated with a relative risk of mortality of 2.83.</div><div class=\"graphic_reference\">Data from Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92:1326.</div><div id=\"graphicVersion\">Graphic 76385 Version 5.0</div></div></div>"},"76388":{"type":"graphic_picture","displayName":"Variant histologies merkel cell","title":"Histologic variants of Merkel cell skin cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic variants of Merkel cell skin cancer</div><div class=\"cntnt\"><img style=\"width:230px; height:459px;\" src=\"images/ONC/76388_Variant_histologies_merkel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power photomicrographs of hematoxylin and eosin-stained sections of a skin biopsy showing three different histologic variants of skin Merkel cell cancer (MCC). Top panel: intermediate variant of MCC with vesicular, basophilic nuclei containing prominent nucleoli and multiple mitoses. Middle panel: small-cell variant, histologically indistinguishable from bronchial small-cell carcinoma. Lower panel: trabecular variant, which is rare and normally only seen as a small component of a mixed type of MCC.</div><div class=\"graphic_reference\">Reproduced with permission from: Mosby-Wolfe, Times Mirror International Medical Publishers, from: McKee PH, Pathology of the skin, 2nd ed, 1996. Copyright © 1996 Harcourt Publishers Ltd.</div><div id=\"graphicVersion\">Graphic 76388 Version 2.0</div></div></div>"},"76390":{"type":"graphic_figure","displayName":"Generation of ECG","title":"Generation of the normal electrocardiogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Generation of the normal electrocardiogram</div><div class=\"cntnt\"><img style=\"width:406px; height:181px;\" src=\"images/CARD/76390_Generation_of_ECG.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation between cardiac depolarization, ventricular repolarization, and the appearance of the normal electrocardiogram, including the P wave, QRS complex, ST segment, and T wave. The PR interval can be prolonged by disease from the atria to the Purkinje fibers (steps 2 to 4). The SA node is not seen on the surface ECG due to its small mass; its activity is inferred from the P wave, which reflects atrial activation.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram.</div><div class=\"graphic_reference\">Data from Arnsdorf MA, in: Electrophysiology of the Heart. Electrocardiography II: Applied Theory, Part 1, American Physiological Society, Bethesda 1978.</div><div id=\"graphicVersion\">Graphic 76390 Version 3.0</div></div></div>"},"76391":{"type":"graphic_figure","displayName":"Penis anatomy","title":"Anatomy of the penis","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Anatomy of the penis</div><div class=\"cntnt\"><img style=\"width:507px; height:580px;\" src=\"images/EM/76391_Penis_anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 76391 Version 3.0</div></div></div>"},"76393":{"type":"graphic_diagnosticimage","displayName":"Mediastinal lymphoma x ray","title":"Mediastinal lymphoma chest radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mediastinal lymphoma chest radiograph</div><div class=\"cntnt\"><img style=\"width:390px; height:523px;\" src=\"images/HEME/76393_Mediastinal_lymphoma_x_ray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PA (upper panel) and lateral (lower panel) radiographs of a patient with a large right-sided mediastinal mass (arrows). The biopsy was consistent with diffuse large B-cell non-Hodgkin's lymphoma.</div><div class=\"graphic_footnotes\">PA: posteroanterior. </div><div class=\"graphic_reference\">Courtesy of Arnold S Freedman, MD, Jonathan W Friedberg, MD, and Pam DePiro, MD.</div><div id=\"graphicVersion\">Graphic 76393 Version 4.0</div></div></div>"},"76394":{"type":"graphic_table","displayName":"HPV high and low risk types","title":"Human papillomavirus: High and low risk types for causing cervical cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Human papillomavirus: High and low risk types for causing cervical cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">High-risk (oncogenic or cancer-associated) types</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Common types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 69, 82</p> </td> </tr> <tr> <td class=\"subtitle1_single\">Low-risk (non-oncogenic) types</td> </tr> <tr> <td class=\"indent1\"> <p>Common types: 6, 11, 40, 42, 43, 44, 54, 61, 72, 81</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Centers for Disease Control and Prevention. National Cancer Institute Factsheet. Human papillomavirus and cancer: Questions and answers. Available at: www.cancer.gov/cancertopics/factsheet/Risk/HPV (Accessed on June 11, 2012).</div><div id=\"graphicVersion\">Graphic 76394 Version 5.0</div></div></div>"},"76396":{"type":"graphic_figure","displayName":"Gender determination PI","title":"Gender determination","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Gender determination</div><div class=\"cntnt\"><img style=\"width:529px; height:491px;\" src=\"images/PI/76396_Gender_determination_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the process of reproduction, a male's sperm and woman's egg each contributes one sex chromosome. A child's gender (male or female) is determined by the chromosome that the male parent contributes. Females have XX sex chromosomes. Males have XY sex chromosomes. A male infant results if the male contributes his Y chromosome while a female infant results if he contributes his X chromosome.</div><div id=\"graphicVersion\">Graphic 76396 Version 3.0</div></div></div>"},"76397":{"type":"graphic_table","displayName":"VTE risk in pregnancy by thrombophilia","title":"Risk of venous thromboembolism in pregnancy with different thrombophilias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk of venous thromboembolism in pregnancy with different thrombophilias</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"5\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Prevalence in general population (percent)</td> <td class=\"subtitle1\">VTE risk per pregnancy (women with <em>no history of VTE</em>) (percent)</td> <td class=\"subtitle1\">VTE risk per pregnancy (women with <em>previous history of VTE</em>) (percent)</td> <td class=\"subtitle1\">Percentage of all VTE in pregnancy</td> <td class=\"subtitle1\">Reference</td> </tr> <tr> <td><strong>Factor V Leiden heterozygote</strong></td> <td>1 to 15</td> <td>0.5 to 1.2</td> <td>10</td> <td>40</td> <td>1-4</td> </tr> <tr> <td><strong>Factor V Leiden homozygote</strong></td> <td>&#60;1</td> <td>4</td> <td>17</td> <td>2</td> <td>1-4</td> </tr> <tr> <td><strong>Prothrombin gene heterozygote</strong></td> <td>2 to 5</td> <td>&#60;0.5</td> <td>&#62;10</td> <td>17</td> <td>1-4</td> </tr> <tr> <td><strong>Prothrombin gene homozygote</strong></td> <td>&#60;1</td> <td>2 to 4</td> <td>&#62;17</td> <td>0.5</td> <td>1-4</td> </tr> <tr> <td><strong>Factor V Leiden/prothrombin double heterozygote</strong></td> <td>&#60;1</td> <td>4 to 5</td> <td>&#62;20</td> <td>1 to 3</td> <td>1-4</td> </tr> <tr> <td><strong>Antithrombin deficiency</strong></td> <td>0.02</td> <td>3 to 7</td> <td>40</td> <td>1</td> <td>1, 5, 6</td> </tr> <tr> <td><strong>Protein C deficiency</strong></td> <td>0.2 to 0.4</td> <td>0.1 to 0.8</td> <td>4 to 17</td> <td>14</td> <td>1, 5, 7</td> </tr> <tr> <td><strong>Protein S deficiency</strong></td> <td>0.03 to 0.13</td> <td>0.1</td> <td>0 to 22</td> <td>3</td> <td>1, 8-10</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">VTE: venous thromboembolism.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet 2001; 109:369-84. (Level III) </LI>&#xD;&#xA;<LI>Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342:374-80. (Level II-3) </LI>&#xD;&#xA;<LI>Zotz RB, Gerhardt A, Scharf RE. Inherited thrombophilia and gestational venous thromboembolism. Best Pract Res Clin Haematol 2003; 16:243-59. (Level III) </LI>&#xD;&#xA;<LI>Haverkate F, Samama M. Familial dysfibrinogenaemia and thrombophilia. Report on a study of the SSC Subcommittee on fibrinogen. Thromb Haemost 1995; 73:151-61. (Level II-2) </LI>&#xD;&#xA;<LI>Carraro P. Guidelines for the laboratory investigation of inherited thrombophilias. Recommendations for the first level clinical laboratories. European Communities Confederation of Clinical Chemistry and Laboratory Medicine, Working Group on Guidelines for Investigation of Disease. Clin Chem Lab Med 2003; 41:382-91. (Level III) </LI>&#xD;&#xA;<LI>Friederich PW, Sanson BJ, Simioni P, Zanardi S, Huisman MV, Kindt I, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor deficient women: implications for prophylaxis [published errata appear in Ann Intern Med 1997; 127:1138; Ann Intern Med 1997; 126:835]. Ann Intern Med 1996; 125:955-60. (Level II-2) </LI>&#xD;&#xA;<LI>Vossen CY, Preston FE, Conard J, Fontcuberta J, Makris M, van der Meer FJ, et al. Hereditary thrombophilia and fetal loss: a prospective follow-up study. J Thromb Haemost 2004; 2:592-6. (Level II-2) </LI>&#xD;&#xA;<LI>Paidas MJ, Ku DH, Lee MJ, Manish S, Thurston A, Lockwood CJ, et al. Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications. J Thromb Haemost 2005; 3:497-501. (Level II-3) </LI>&#xD;&#xA;<LI>Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol. 2001; 113:636-41. (Level II-3) </LI>&#xD;&#xA;<LI>Goodwin AJ, Rosendaal FR, Kottke-Marchant K, Bovill EG. A review of the technical, diagnostic, and epidemiologic considerations for protein S assays. Arch Pathol Lab Med 2002; 126:1349-66. (Level III)</LI></OL>Reprinted with permission from Thromboembolism in pregnancy. Practice Bulletin No. 138. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013; 122:706-17. Copyright © 2013.</div><div id=\"graphicVersion\">Graphic 76397 Version 19.0</div></div></div>"},"76398":{"type":"graphic_picture","displayName":"Nasogastric tube placement","title":"Nasogastric tube placement","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Nasogastric tube placement</div><div class=\"cntnt\"><img style=\"width:500px; height:581px;\" src=\"images/SURG/76398_NG_tube_placement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Lubricate the nasogastric (NG) tube and offer the patient a cup or glass of water with a straw (unless contraindicated). Place the tube into one of the nares, gently advance the tube but stop before it reaches the nasopharynx. Direct the patient to sip and swallow as the tube is advanced which helps pass the tube into the esophagus. If water is not being used, ask the patient to swallow.<br> (B) Once the tube is in place, aspirate using a suction tip syringe and examine the aspirate. It should have a typical gastric fluid appearance (grassy green, clear and colorless with mucus shreds, or brown). If needed, place a small amount on the pH test strip; the pH should be &#8804;5.0. Alternatively, instill about 15-20 cc warm water and then aspirate. If the tube is in good position, at least 1/2 of the fluid should be returned.<br> (C) Secure the NG tube to the patient's nose with hypoallergenic tape (or an NG tube holder). If the patient's skin is oily, wipe the bridge of the nose with an alcohol pad and allow to dry. Split one end of the tape up the center about 1 1/2 inches. Make tabs on the split ends (by folding the sticky sides together). Apply the unsplit tape end on the patient's nose so the split in the tape starts about 1/2 to 1 1/2 inches from the tip of the nose. Crisscross the tabbed ends around the tube. Apply another piece of tape over the bridge of the nose to secure the tube.</div><div class=\"graphic_reference\">Reproduced with permission from: Springhouse. Lippincott's Visual Encyclopedia of Clinical Skills. Philadelphia: Wolters Kluwer Health, 2009. Copyright &#169; 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76398 Version 2.0</div></div></div>"},"76400":{"type":"graphic_table","displayName":"Herbal medicine hepatotoxicity","title":"Some of the herbal supplements associated with hepatic injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some of the herbal supplements associated with hepatic injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Product</td> <td class=\"subtitle1\">Other names/toxins</td> <td class=\"subtitle1\">Clinical manifestations</td> <td class=\"subtitle1\">Pathologic findings</td> </tr> <tr> <td rowspan=\"4\">Chaparral leaf</td> <td><em>Laurie tridentata</em></td> <td rowspan=\"4\">ALT 10 to 20x normal; AST 7 to 10x normal; elevated bilirubin and prothrombin time; reversible; dose dependent</td> <td rowspan=\"4\">Acute and chronic liver injury: portal inflammation with bile duct proliferation; lobular necrosis and collapse</td> </tr> <tr> <td>\"Creosote bush\"</td> </tr> <tr> <td>\"Grease wood\"</td> </tr> <tr> <td>Nordi-hydroguaiaretic acid (HDGA)</td> </tr> <tr> <td rowspan=\"2\">Jin Bu Huan</td> <td><em>Lycopodium serratum</em></td> <td rowspan=\"2\">ALT/AST 10 to 20x normal; elevated bilirubin and prothrombin time; reversible</td> <td rowspan=\"2\">Acute and chronic liver injury: focal hepatic necrosis; eosinophilia; steatosis; bridging fibrosis and necrosis</td> </tr> <tr> <td>Levo-tetrahydropalmatine</td> </tr> <tr> <td rowspan=\"2\">Germander</td> <td><em>Teucrium chamaedrys</em></td> <td rowspan=\"2\">ALT/AST 5 to 10x normal; elevated bilirubin; reversible</td> <td rowspan=\"2\">Acute and chronic liver injury: hepatocellular necrosis; portal inflammation; fibrosis</td> </tr> <tr> <td><em>Teucrium polium</em></td> </tr> <tr> <td>Kava</td> <td><em>Piper methysticum</em> rhizoma</td> <td>ALT/AST 10 to 20X normal; elevated bilirubin, prothrombin time; can be fatal</td> <td>Hepatic necrosis; cholestasis, lobular hepatitis</td> </tr> <tr> <td>Mistletoe</td> <td><em>Viscum album</em></td> <td>ALT/AST 5 to 10x normal; elevated bilirubin; reversible</td> <td>Acute and chronic hepatitis: hepatocellular injury</td> </tr> <tr> <td>Skullcap</td> <td><em>Scutellaria</em> spp</td> <td>ALT/AST 5 to 10x normal; elevated bilirubin; reversible</td> <td>Acute hepatitis; hepatocellular injury</td> </tr> <tr> <td rowspan=\"12\">Toxic alkaloids</td> <td><em>Symphytum</em> (Comfrey)</td> <td rowspan=\"12\">ALT/AST 3 to 10x normal; elevated bilirubin; generally reversible; can be fatal; dose dependent</td> <td rowspan=\"12\">Hepatic venoocclusive disease; acute inflammation</td> </tr> <tr> <td><em>Senecio</em> spp</td> </tr> <tr> <td><em>Crotalaria</em> spp</td> </tr> <tr> <td><em>Heliotropium</em> spp</td> </tr> <tr> <td>Mat&#233; (Paraquay) tea</td> </tr> <tr> <td>Ackee Fruit</td> </tr> <tr> <td><em>Atractylis gummifera</em></td> </tr> <tr> <td><em>Callilepsis laureola</em></td> </tr> <tr> <td><em>Cassia angustifolia</em> (<em>Senna</em>)</td> </tr> <tr> <td>Cocaine (<em>Erythroxylon coca</em>)</td> </tr> <tr> <td><em>Sassafras albidum</em></td> </tr> <tr> <td><em>Borago officinalis</em></td> </tr> <tr> <td rowspan=\"4\">Pennyroyal&nbsp;&nbsp;</td> <td>Squawmint oil</td> <td rowspan=\"4\">ALT/AST 10 to 20x normal; associated with renal failure</td> <td rowspan=\"4\">Acute liver injury related to depletion of hepatic glutathione</td> </tr> <tr> <td><em>Hedeoma pulegoides</em></td> </tr> <tr> <td><em>Mentha pulegium</em></td> </tr> <tr> <td>Toxic terpenes, especially isopropylidene</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Bashir RM,&nbsp;Lewis JH. Gastroenterol Clin North Am 1995; 24:957.</div><div id=\"graphicVersion\">Graphic 76400 Version 4.0</div></div></div>"},"76402":{"type":"graphic_table","displayName":"Etiology of chronic meningitis","title":"Potential causes of chronic meningitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential causes of chronic meningitis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td class=\"subtitle2_single\">Mycobacterial</td> </tr> <tr> <td class=\"indent1\"><em>Mycobacterium tuberculosis</em></td> </tr> <tr> <td class=\"subtitle2_single\">Spirochetal</td> </tr> <tr> <td class=\"indent1\"><em>Borrelia burgdorferi</em></td> </tr> <tr> <td class=\"indent1\"><em>Treponema pallidum</em></td> </tr> <tr> <td class=\"indent1\"><em>Leptospira</em></td> </tr> <tr> <td class=\"subtitle2_single\">Bacterial</td> </tr> <tr> <td class=\"indent1\"><em>Brucella</em></td> </tr> <tr> <td class=\"indent1\"><em>Francisella tularensis</em></td> </tr> <tr> <td class=\"indent1\"><em>Actinomyces</em></td> </tr> <tr> <td class=\"indent1\"><em>Listeria</em></td> </tr> <tr> <td class=\"indent1\"><em>Ehrlichia chaffeensis</em></td> </tr> <tr> <td class=\"indent1\"><em>Nocardia</em></td> </tr> <tr> <td class=\"indent1\">Whipple's disease</td> </tr> <tr> <td class=\"subtitle2_single\">Viral</td> </tr> <tr> <td class=\"indent1\">Human immunodeficiency virus</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr virus</td> </tr> <tr> <td class=\"indent1\">Human T cell lymphotrophic virus I and II</td> </tr> <tr> <td class=\"indent1\">Enterovirus</td> </tr> <tr> <td class=\"indent1\">Herpes simplex virus</td> </tr> <tr> <td class=\"indent1\">Varicella-zoster virus</td> </tr> <tr> <td class=\"indent1\">Cache Valley virus</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infections (continued)</td> </tr> <tr> <td class=\"subtitle2_single\">Fungal</td> </tr> <tr> <td class=\"indent1\"><em>Cryptococcus</em></td> </tr> <tr> <td class=\"indent1\"><em>Sporothrix</em></td> </tr> <tr> <td class=\"indent1\"><em>Histoplasma</em></td> </tr> <tr> <td class=\"indent1\"><em>Blastomyces</em></td> </tr> <tr> <td class=\"indent1\"><em>Coccidioides</em></td> </tr> <tr> <td class=\"indent1\">Other (eg, <em>Scedosporium apiospermum</em>, <em>Paracoccidioides</em>, dematiaceous molds)</td> </tr> <tr> <td class=\"subtitle2_single\">Parasitic</td> </tr> <tr> <td class=\"indent1\"><em>Taenia solium</em> (cysticercosis)</td> </tr> <tr> <td class=\"indent1\"><em>Angiostrongylus</em></td> </tr> <tr> <td class=\"indent1\"><em>Schistosoma</em></td> </tr> <tr> <td class=\"indent1\"><em>Toxoplasma</em></td> </tr> <tr> <td class=\"indent1\"><em>Acanthamoeba</em></td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Noninfectious conditions</td> </tr> <tr> <td>Neoplastic</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td>Beh&#231;et's disease</td> </tr> <tr> <td>Fabry disease</td> </tr> <tr> <td>Central nervous system vasculitis</td> </tr> <tr> <td>Vogt-Koyanagi-Harada disease</td> </tr> <tr> <td>Chemical or drug-induced meningitis</td> </tr> <tr> <td>Idiopathic (up to one-third of cases)</td> </tr> <tr> <td class=\"subtitle2_left\">Drugs</td> </tr> <tr> <td class=\"indent1\">Nonsteroidal anti-inflammatory drugs</td> </tr> <tr> <td class=\"indent1\">Intravenous immunoglobulin</td> </tr> <tr> <td class=\"indent1\">Intrathecal agents</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76402 Version 10.0</div></div></div>"},"76403":{"type":"graphic_table","displayName":"Risk of healthcare personnel acquiring pathogens","title":"Risk of acquisition of bloodborne pathogens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk of acquisition of bloodborne pathogens</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">HBV</td> <td class=\"subtitle1\">HCV</td> <td class=\"subtitle1\">HIV</td> </tr> <tr> <td>Seroprevalance, general population</td> <td>0.42 percent (95 percent CI, 0.32-0.55)</td> <td>1.8 percent (95 percent CI, 1.5-2.3)</td> <td>0.31-0.42 percent</td> </tr> <tr> <td>Seroprevalance in healthcare providers compared to general population</td> <td>Increased in the past</td> <td>Similar</td> <td>Similar</td> </tr> <tr> <td>Viral particles/mL of serum or plasma</td> <td>10<sup>2</sup>-10<sup>8</sup></td> <td>1-&#62;10<sup>6</sup></td> <td>1-10<sup>7</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Risk of infection by mode of exposure</td> </tr> <tr> <td class=\"indent1\">Percutaneous</td> <td>6-30 percent</td> <td>1.8 percent (range, 0-7 percent)</td> <td>0.3 percent (95 percent CI, 0.2-0.5)</td> </tr> <tr> <td class=\"indent1\">Mucosal</td> <td>Risk not quantified, transmission documented</td> <td>Risk not quantified, transmission documented</td> <td>0.09 percent (95 percent CI, 0.006-0.5)</td> </tr> <tr> <td class=\"indent1\">Nonintact skin</td> <td>Risk not quantified, transmission not documented</td> <td>Risk not quantified, transmission not documented</td> <td>&#60;0.1 percent, risk not completely quantified</td> </tr> <tr> <td class=\"indent1\">Human bite</td> <td>Risk not quantified, transmission documented</td> <td>Risk not quantified, transmission documented</td> <td>Risk not quantified, transmission documented</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Infective material leading to HCW infection</td> </tr> <tr> <td class=\"indent1\">Documented</td> <td>Blood, blood products</td> <td>Blood, immunoglobulin preparations</td> <td>Blood, blood products, bloody fluids</td> </tr> <tr> <td class=\"indent1\">Possible</td> <td>Semen, vaginal fluid, bloody fluids, saliva</td> <td>Bloody products, bloody fluids, semen, vaginal fluid</td> <td>Semen, vaginal fluid, cerebrospinal fluid, breast milk, exudates, serosal fluids, amniotic fluid, saliva (during dental exams)</td> </tr> <tr> <td class=\"indent1\">Unlikely</td> <td>Urine, feces</td> <td>Saliva, urine, feces</td> <td>Saliva, urine, feces</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of David Weber, MD, MPH.</div><div id=\"graphicVersion\">Graphic 76403 Version 2.0</div></div></div>"},"76406":{"type":"graphic_algorithm","displayName":"Management of mesenteric venous thrombosis","title":"Management of mesenteric venous thrombosis","html":"<div class=\"graphic\"><div style=\"width: 652px\" class=\"figure\"><div class=\"ttl\">Management of mesenteric venous thrombosis</div><div class=\"cntnt\"><img style=\"width:632px; height:576px;\" src=\"images/SURG/76406_Mng_msntrc_vns_thrmb.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography.<br />* Diagnosis is typically made on CT angiography.<br />&para; In uncomplicated cases, symptoms typically resolve steadily over time.<br />&Delta; Imaging may include magnetic resonance venography.<br /><span class=\"lozenge\">&loz;</span> If thrombolysis is contraindicated, continue anticoagulation.<br />&sect; Portal embolectomy is uncommonly performed.</div><div id=\"graphicVersion\">Graphic 76406 Version 4.0</div></div></div>"},"76407":{"type":"graphic_table","displayName":"Psychosocial burden present thalassemia","title":"Psychosocial burden of thalassemia in the present","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Psychosocial burden of thalassemia in the present</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Better physical appearance</td>\n\n    </tr>\n\n    <tr>\n      <td>Pubertal growth and sexual development </td>\n    </tr>\n    <tr>\n      <td>Schooling </td>\n    </tr>\n    <tr>\n      <td>Working</td>\n    </tr>\n    <tr>\n      <td>Establishing relationships</td>\n    </tr>\n    <tr>\n      <td>Getting married </td>\n    </tr>\n    <tr>\n      <td>Raising a family </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1_start\">Low compliance with treatment for large number of patients</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1\">Living for today</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Denial/anxiety/hostility</td>\n    </tr>\n    <tr>\n\n      <td class=\"subtitle1_single\">Prospects</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Oral chelators</td>\n\n    </tr>\n    <tr>\n      <td>HbF inducers </td>\n    </tr>\n    <tr>\n      <td>Bone marrow transplantation</td>\n    </tr>\n    <tr>\n      <td>Gene therapy</td>\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Data from: Politis C. The psychosocial impact of chronic illness. Ann N Y Acad Sci 1998; 850:349.</div><div id=\"graphicVersion\">Graphic 76407 Version 2.0</div></div></div>"},"76408":{"type":"graphic_movie","displayName":"Supracristal VSD subcostal 2D and color","title":"Supracristal VSD subcostal 2D and color","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Supracristal VSD subcostal 2D and color</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/76408_SupracrVSDsubcostmovie.mp4\" style=\"width:496px;height:384px\"></div><img style=\"width:546px; height:396px;\" src=\"images/CARD/76408_SupracrVSDsubcostposter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The proximity of the defect to the pulmonary valve can be appreciated. Color flow mapping shows antegrade flow across the mitral valve (red), flow into the left ventricular outflow tract (blue), and across the defect into the right ventricle.</div><div class=\"graphic_footnotes\">PA: pulmonary artery; RV: right ventricle; IVS: trabecular portion of the intraventricular septum; LVOT: left ventricular outflow tract; LA: left atrium; LV: left ventricle.</div><div id=\"graphicVersion\">Graphic 76408 Version 2.0</div></div></div>"},"76409":{"type":"graphic_figure","displayName":"Anisakiasis life cycle","title":"Anisakiasis life cycle","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Anisakiasis life cycle</div><div class=\"cntnt\"><img style=\"width:515px; height:586px;\" src=\"images/ID/76409_Anisakiasis_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adult stages of <em>Anisakis simplex</em> or <em>Pseudoterranova decipiens</em> reside in the stomach of marine mammals, where they are embedded in the mucosa, in clusters. Unembryonated eggs produced by adult females are passed in the feces of marine mammals <strong>(1)</strong>. The eggs become embryonated in water, and first-stage larvae are formed in the eggs. The larvae molt, becoming second-stage larvae <strong>(2a)</strong>, and after the larvae hatch from the eggs, they become free-swimming <strong>(2b)</strong>. Larvae released from the eggs are ingested by crustaceans <strong>(3)</strong>. The ingested larvae develop into third-stage larvae that are infective to fish and squid <strong>(4)</strong>. The larvae migrate from the intestine to the tissues in the peritoneal cavity and grow up to 3 cm in length. Upon the host's death, larvae migrate to the muscle tissues, and through predation, the larvae are transferred from fish to fish. Fish and squid maintain third-stage larvae that are infective to humans and marine mammals <strong>(5)</strong>. When fish or squid containing third-stage larvae are ingested by marine mammals, the larvae molt twice and develop into adult worms. The adult females produce eggs that are shed by marine mammals <strong>(6)</strong>. Humans become infected by eating raw or undercooked infected marine fish <strong>(7)</strong>. After ingestion, the anisakid larvae penetrate the gastric and intestinal mucosa, causing the symptoms of anisakiasis.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Anisakiasis. Available at: <a href=\"http://www.cdc.gov/dpdx/anisakiasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/anisakiasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 76409 Version 4.0</div></div></div>"},"76410":{"type":"graphic_table","displayName":"Multiple keratoacanthoma clinical variants","title":"Clinical variants of multiple keratoacanthomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical variants of multiple keratoacanthomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Characteristics</td> <td class=\"subtitle1\">Genetic features</td> </tr> <tr> <td>Generalized eruptive keratoacanthomas of Grzybowski</td> <td> <p>Presents in&nbsp;fifth to&nbsp;seventh&nbsp;decade</p> <p>Multiple follicular-based papules and ulcerated nodules</p> <p>100s to 1000s of lesions</p> <p>Predilection for the trunk, extremities, and inner mouth</p> <p>Disfigurement due to facial lesions (ectropion)</p> <p>Individual lesions spontaneously regress with scar formation</p> </td> <td>Sporadic disorder</td> </tr> <tr class=\"divider_top\"> <td>Multiple self-healing squamous epithelioma (Ferguson-Smith disease)</td> <td> <p>Present in&nbsp;second to&nbsp;third decade; mean age of 25</p> <p>Multiple reddish macules that develop into papules and nodules that resemble solitary keratoacanthoma</p> <p>Single lesion to 100s in number</p> <p>Predilection for sites of trauma and sun-exposed areas, face, arms</p> <p>Individual lesions involute spontaneously, but lesions may recur throughout life</p> </td> <td> <p>Autosomal dominant</p> <p>Loss of function mutations in <em>TGFBR1</em> gene</p> <p>Increased in patients with Scottish ancestry</p> </td> </tr> <tr class=\"divider_top\"> <td>Multiple familial keratoacanthoma of Witten and Zak</td> <td> <p>Clinical features of both generalized eruptive keratoacanthomas of Grzybowski and multiple self-healing squamous epithelioma</p> <p>Larger lesions that tend to ulcerate</p> <p>Locally destructive</p> </td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td>Muir-Torre syndrome</td> <td> <p>May occur in both young and&nbsp;older patients</p> <p>Multiple keratoacanthomas</p> <p>Sebaceous tumors</p> <p>Visceral malignancies (genitourinary and gastrointestinal)</p> </td> <td> <p>Autosomal dominant</p> <p>Defect in mismatch repair gene (<em>MSH2</em> or <em>MLH1</em>)</p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76410 Version 4.0</div></div></div>"},"76411":{"type":"graphic_picture","displayName":"Necrobiosis lipoidica 4","title":"Necrobiosis lipoidica","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Necrobiosis lipoidica</div><div class=\"cntnt\"><img style=\"width:351px; height:474px;\" src=\"images/DERM/76411_Necrobiosis_lipoidica_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow-red or yellow-brown plaques with atrophy and telangiectasias are consistent with necrobiosis lipoidica.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76411 Version 1.0</div></div></div>"},"76412":{"type":"graphic_diagnosticimage","displayName":"Sellar mass MRI II","title":"Sellar mass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sellar mass</div><div class=\"cntnt\"><img style=\"width:425px; height:206px;\" src=\"images/ENDO/76412_Sellar_mass_MRI_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The MRI on the left shows, in sagittal view, a very large pituitary adenoma elevating the optic chiasm (arrow). The MRI on the right shows a sellar mass of similar size, which has a much brighter signal than the mass on the left (arrow). The reason for the brighter signal could have been hemorrhage into a pituitary adenoma but, in this case, was found surgically to be fluid in a craniopharyngioma.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Peter J Snyder, MD.</div><div id=\"graphicVersion\">Graphic 76412 Version 4.0</div></div></div>"},"76413":{"type":"graphic_diagnosticimage","displayName":"Cystic lesion calcification","title":"Solid pseudopapillary neoplasm of the pancreas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Solid pseudopapillary neoplasm of the pancreas</div><div class=\"cntnt\"><img style=\"width:400px; height:285px;\" src=\"images/GAST/76413_Cystic_lesion_calcification.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incidental finding of a 4 cm solid pseudopapillary neoplasm with peripheral calcification in the pancreatic tail of a young woman.</div><div class=\"graphic_reference\">Courtesy of Kevin McGrath, MD, and Asif Khalid, MD.</div><div id=\"graphicVersion\">Graphic 76413 Version 3.0</div></div></div>"},"76416":{"type":"graphic_diagnosticimage","displayName":"Transverse metacarpal shaft fracture","title":"Proximal transverse metacarpal shaft fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proximal transverse metacarpal shaft fracture</div><div class=\"cntnt\"><img style=\"width:360px; height:325px;\" src=\"images/EM/76416_Metacarpal_shaft_fx_transve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This oblique radiograph shows a proximal transverse fracture of the&nbsp;second metacarpal shaft.</div><div class=\"graphic_reference\">Courtesy of Josh Bloom, MD, MPH.</div><div id=\"graphicVersion\">Graphic 76416 Version 2.0</div></div></div>"},"76417":{"type":"graphic_figure","displayName":"Feeding jejunostomy","title":"Feeding jejunostomy","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Feeding jejunostomy</div><div class=\"cntnt\"><img style=\"width:503px; height:629px;\" src=\"images/SURG/76417_Feeding_jejunostomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A jejunal feeding tube is placed approximately 20 cm distal to the Roux-en-Y entero-enterostomy, with a Stamm type jejunostomy, secured with a double purse-string suture of 3-0 absorbable suture and then anchored to the anterior abdominal wall.</div><div id=\"graphicVersion\">Graphic 76417 Version 2.0</div></div></div>"},"76418":{"type":"graphic_figure","displayName":"LV and aortic pressures - two methods","title":"LV and aortic pressures - two methods","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">LV and aortic pressures - two methods</div><div class=\"cntnt\"><img style=\"width:497px; height:387px;\" src=\"images/CARD/76418_LVaorticpresstwomethods.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">LV and aortic pressures.<br />(A) Two high fidelity pressure transducers on single catheter across aortic valve. Note normal LV diastolic waveform with early diastolic pressure as lowest point with slow increase in pressure across diastole \"a\" wave after atrial contraction.<br />(B) Fluid filled LV catheter and femoral sheath pressures. Note ringing artifact of fluid filled systems. Note overshoot of femoral artery pressure and delay in upstroke from central to peripheral location.</div><div class=\"graphic_footnotes\">LV: left ventricular.</div><div id=\"graphicVersion\">Graphic 76418 Version 3.0</div></div></div>"},"76420":{"type":"graphic_table","displayName":"History for hypertensive child or adolescent","title":"History in the child or adolescent with elevated blood pressure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">History in the child or adolescent with elevated blood pressure</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">History</td> <td class=\"subtitle1\">Possible cause of hypertension</td> </tr> <tr> <td>CNS: Head trauma, headache, visual disturbance, lethargy, seizures, tremors, morning vomiting</td> <td>Elevated intracranial pressure</td> </tr> <tr> <td rowspan=\"2\">Hearing: Hearing loss</td> <td>Renal disease (ie, Alport syndrome)</td> </tr> <tr> <td>Lead poisoning</td> </tr> <tr> <td>Cardiovascular: Palpitations, irregular pulse</td> <td>Catecholamine excess</td> </tr> <tr> <td>Renal: Edema; history of UTI or unexplained fever, abnormal urine color, enuresis, flank pain, dysuria</td> <td>Reflux nephropathy</td> </tr> <tr> <td rowspan=\"3\">Skin: Rash, sweating, pallor</td> <td>Catecholamine excess</td> </tr> <tr> <td>Thyroid dysfunction</td> </tr> <tr> <td>Renal vasculitis</td> </tr> <tr> <td>Respiratory: Epistaxis; difficulty breathing</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"2\">Recent medical history: Recent pharyngitis or impetigo, exposure to sources of enterohemorrhagic E. coli</td> <td>Post-infectious glomerulonephritis</td> </tr> <tr> <td>Hemolytic uremic syndrome</td> </tr> <tr> <td>Medications: Sympathomimetics, oral contraceptives, corticosteroids</td> <td>Side effect of medication</td> </tr> <tr> <td>Substance use: Cocaine, amphetamines, anabolic steroids, phencyclidine, ephedra-containing alternative medications, caffeine</td> <td>Drug-mediated effects</td> </tr> <tr> <td>Family history: Hypertension, early MI, diabetes, stroke</td> <td>Essential hypertension</td> </tr> <tr> <td>Sexual history: Post-menarchal female actively engaged in sexual intercourse</td> <td>Preeclampsia</td> </tr> <tr> <td>Neonatal history: Use of umbilical artery catheters</td> <td>Reno-vascular hypertension</td> </tr> <tr> <td>Growth history: Excessive weight gain or loss, change in growth percentiles</td> <td>Obesity, thyroid dysfunction</td> </tr> <tr> <td>Dietary history: Types and amount of food ingested; salt craving</td> <td>Obesity, essential hypertension</td> </tr> <tr> <td>Social history: Stress factors at home and school</td> <td>Stress</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76420 Version 4.0</div></div></div>"},"76421":{"type":"graphic_picture","displayName":"Retrocuspid papilla","title":"Retrocuspid papilla","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retrocuspid papilla</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/PEDS/76421_Retrocuspid_papilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A retrocuspid papilla in a seven-year-old child. Note the firm, round papule on the attached gingiva lingual to the mandibular canine.</div><div class=\"graphic_reference\">Reproduced with permission from: Delaney JE, Keels MA. Pediatric oral pathology. Soft tissue and periodontal conditions. Pediatr Clin North Am 2000; 47:1125. Copyright &copy; 2000 WB Saunders.</div><div id=\"graphicVersion\">Graphic 76421 Version 4.0</div></div></div>"},"76422":{"type":"graphic_table","displayName":"Etiology of chest pain","title":"Causes of nonemergent chest pain in Michigan Research Network (MIRNET) primary care practices","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of nonemergent chest pain in Michigan Research Network (MIRNET) primary care practices</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Cause</td> <td class=\"subtitle1\">Prevalence, percent</td> </tr> <tr> <td>Musculoskeletal, including costochondritis</td> <td>36</td> </tr> <tr> <td>Gastrointestinal</td> <td>19</td> </tr> <tr> <td class=\"sublist1_start\">Cardiac </td> <td class=\"sublist_other_start\">16*</td> </tr> <tr> <td class=\"indent1 sublist1\">Stable angina</td> <td class=\"sublist_other\">10.5</td> </tr> <tr> <td class=\"indent1 sublist1\">Unstable angina or myocardial infarction</td> <td class=\"sublist_other\">1.5</td> </tr> <tr> <td class=\"indent1 sublist1\">Other cardiac</td> <td class=\"sublist_other\">3.8</td> </tr> <tr> <td>Psychiatric</td> <td>8</td> </tr> <tr> <td>Pulmonary</td> <td>5</td> </tr> <tr> <td>Other/unknown</td> <td>16</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* As high as 50% in older populations.</div><div class=\"graphic_reference\">Adapted from Klinkman MS, Stevens D, Gorenflo DW. J Fam Pract 1994; 38:345.</div><div id=\"graphicVersion\">Graphic 76422 Version 3.0</div></div></div>"},"76424":{"type":"graphic_picture","displayName":"Strangulated hernia","title":"Strangulated hernia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Strangulated hernia</div><div class=\"cntnt\"><img style=\"width:237px; height:360px;\" src=\"images/PC/76424_Strangulated_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scrotal swelling is seen in a patient with a strangulated indirect inguinal hernia.</div><div class=\"graphic_reference\">Reproduced with permission from Lawrence B Stack, MD.</div><div id=\"graphicVersion\">Graphic 76424 Version 1.0</div></div></div>"},"76425":{"type":"graphic_table","displayName":"Avoiding false positive TBNA","title":"Recommendations to avoid false positive results during lung cancer staging","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations to avoid false positive results during lung cancer staging</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>The fiberoptic bronchoscope should not be connected to the suction apparatus until all TBNA samples have been obtained. The area of interest should be washed with saline or lidocaine, if it is covered with secretions, before needle insertion.</td>\n</tr>\n<tr>\n<td>The TBNA procedure should be performed prior to airway examination or acquisition of other samples.</td>\n</tr>\n<tr>\n<td>Lymph nodes denoting worse prognosis should be aspirated first, ie, N3 before N2 and N2 before N1, using the same needle, in patients with multiple sites of nodal involvement.</td>\n</tr>\n<tr>\n<td>Suction should be released prior to needle withdrawal from the lymph node.</td>\n</tr>\n<tr>\n<td>Histology specimens should be obtained when appropriate.</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research-Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.</div><div id=\"graphicVersion\">Graphic 76425 Version 1.0</div></div></div>"},"76427":{"type":"graphic_figure","displayName":"SPECT scan in brain death","title":"HMPAO-Tc99m SPECT in brain death","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">HMPAO-Tc99m SPECT in brain death</div><div class=\"cntnt\"><img style=\"width:508px; height:364px;\" src=\"images/NEURO/76427_Hollow_skull_phenomenon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">99mTc-labeled hexamethylpropyleneamineoxime (HMPAO), and subsequent imaging with single photon emission computed tomographic (SPECT) brain scintigraphy.<br />The top figures show anterior posterior and lateral views of a normal scan with uptake in the brain. The bottom figures (same sequence) show lack of brain perfusion and the \"empty light bulb\" and \"hot nose\" signs.</div><div class=\"graphic_reference\">Courtesy of G Bryan Young, MD.</div><div id=\"graphicVersion\">Graphic 76427 Version 4.0</div></div></div>"},"76428":{"type":"graphic_diagnosticimage","displayName":"MRI ventriculomegaly atrophy versus NPH","title":"MRI ventriculomegaly atrophy versus NPH","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">MRI ventriculomegaly atrophy versus NPH</div><div class=\"cntnt\"><img style=\"width:508px; height:295px;\" src=\"images/NEURO/76428_Ventriculomegaly_vs_atrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial T2-weighted image at level of lateral ventricles in a patient with Alzheimer disease demonstrates increased size of the ventricular system in proportion to sulcal dilatation, consistent with brain parenchymal volume loss.<br />(B) Axial T2-weighted image at level of lateral ventricles in a patient with normal pressure hydrocephalus shows ventricular dilatation out of proportion to the sulci.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; NPH: normal pressure hydrocephalus. </div><div id=\"graphicVersion\">Graphic 76428 Version 4.0</div></div></div>"},"76429":{"type":"graphic_diagnosticimage","displayName":"Intraop SLN mapping radioactive","title":"Mapping the area of radioactivity during a sentinel node imaging procedure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mapping the area of radioactivity during a sentinel node imaging procedure</div><div class=\"cntnt\"><img style=\"width:400px; height:355px;\" src=\"images/ONC/76429_Intraop_SLN_mapping_radioac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Images derived from the use of the gamma camera to detect foci of radioactive uptake after injection of radiocolloid. The images on the left show the tracer activity in the injection sites and nodes. The corresponding images on the right are obtained by waving a sheet source of radioactivity behind the patient to produce a body (and lung) outline for reference.</div><div class=\"graphic_reference\">Courtesy of Kevin Donohoe, MD.</div><div id=\"graphicVersion\">Graphic 76429 Version 2.0</div></div></div>"},"76430":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image of embryo in gestational sac ","title":"Measurement of embryo in gestational sac","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Measurement of embryo in gestational sac</div><div class=\"cntnt\"><img style=\"width:452px; height:515px;\" src=\"images/PI/76430_Gestational_sac_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image of an early gestational sac demonstrating the early embryo. Calipers are placed at both ends of the embryo measuring the longest length from the &quot;crown to the rump,&quot; giving the crownrump length. This measurement is used for dating the pregnancy. Surrounding the embryo is the developing amnion as shown by the hyperechoic circular line.</div><div class=\"graphic_reference\">Courtesy of Thomas Shipp, MD.</div><div id=\"graphicVersion\">Graphic 76430 Version 3.0</div></div></div>"},"76431":{"type":"graphic_picture","displayName":"Bulging AOM","title":"Bulging acute otitis media","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bulging acute otitis media</div><div class=\"cntnt\"><img style=\"width:324px; height:324px;\" src=\"images/PEDS/76431_Bulging_AOM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Occasionally, bulging otitis media can mimic a cholesteatoma.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 76431 Version 1.0</div></div></div>"},"76433":{"type":"graphic_picture","displayName":"Ascaris ovum in stool","title":"<em>Ascaris lumbricoides</em> in stool","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Ascaris lumbricoides</em> in stool</div><div class=\"cntnt\"><img style=\"width:359px; height:240px;\" src=\"images/ID/76433_Ascaris_ovum_in_stool.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wet mount of stool (x400) showing the ovum of <EM>Ascaris lumbricoides</EM>.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 76433 Version 2.0</div></div></div>"},"76434":{"type":"graphic_table","displayName":"Eosinophil-associated diseases","title":"Eosinophil-associated diseases and disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Eosinophil-associated diseases and disorders</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Allergic diseases</td> </tr> <tr> <td>Atopic and related diseases</td> </tr> <tr> <td>Medication-related eosinophilias</td> </tr> <tr> <td class=\"subtitle1_single\">Infectious diseases</td> </tr> <tr> <td>Parasitic infections, mostly with helminths</td> </tr> <tr> <td>Specific fungal infections</td> </tr> <tr> <td>Other infections (infrequent)</td> </tr> <tr> <td class=\"subtitle1_single\">Hematologic and neoplastic disorders</td> </tr> <tr> <td>Hypereosinophilic syndromes</td> </tr> <tr> <td>Leukemia</td> </tr> <tr> <td>Lymphomas</td> </tr> <tr> <td>Tumor-associated</td> </tr> <tr> <td>Mastocytosis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Diseases with specific organ involvement</td> </tr> <tr> <td>Skin and subcutaneous diseases</td> </tr> <tr> <td>Pulmonary diseases</td> </tr> <tr> <td>Gastrointestinal diseases</td> </tr> <tr> <td>Neurologic diseases</td> </tr> <tr> <td>Rheumatologic diseases</td> </tr> <tr> <td>Cardiac diseases</td> </tr> <tr> <td>Renal diseases</td> </tr> <tr> <td class=\"subtitle1_single\">Immunologic reactions</td> </tr> <tr> <td>Specific immune deficiency diseases</td> </tr> <tr> <td>Transplant rejection</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine</td> </tr> <tr> <td>Hypoadrenalism</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76434 Version 3.0</div></div></div>"},"76438":{"type":"graphic_picture","displayName":"Pill esophagitis CPC Endosc","title":"Medication-induced esophagitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Medication-induced esophagitis</div><div class=\"cntnt\"><img style=\"width:252px; height:262px;\" src=\"images/GAST/76438_Pill_esophagitis_CPC_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy revealed superficial ulcerations with bleeding localized in the proximal esophagus at the level of the aortic arch. The mid and distal esophageal mucosa appeared normal.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD and Kenneth Falchuk, MD.</div><div id=\"graphicVersion\">Graphic 76438 Version 3.0</div></div></div>"},"76439":{"type":"graphic_figure","displayName":"Long and short stimulat cycles","title":"Examples of different approaches to ovarian stimulation used in IVF programs","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Examples of different approaches to ovarian stimulation used in IVF programs</div><div class=\"cntnt\"><img style=\"width:542px; height:504px;\" src=\"images/OBGYN/76439_Long_and_short_stimulat_cyc.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">gnRHa: gonadotropin releasing hormone agonist analogues; hMG: human menopausal gonadotropin; FSH: follicle stimulating hormone; hCG: human chorionic gonadotropin.</div><div class=\"graphic_reference\">Adapted from Barbieri, RL. Assisted Reproduction. In Reproductive Endocrinology, 4th edition, Yen, SSC, Jaffe, RB, Barbieri, RL (eds), Saunders, Philadelphia, 1999, p 603.</div><div id=\"graphicVersion\">Graphic 76439 Version 1.0</div></div></div>"},"76440":{"type":"graphic_picture","displayName":"Bidirectional Doppler","title":"Bidirectional Doppler","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Bidirectional Doppler</div><div class=\"cntnt\"><img style=\"width:540px; height:360px;\" src=\"images/SURG/76440_Bi_directional_Doppler.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Summit Doppler Systems, Inc.</div><div id=\"graphicVersion\">Graphic 76440 Version 2.0</div></div></div>"},"76441":{"type":"graphic_diagnosticimage","displayName":"TEE 4 chamber view","title":"Four-chamber transesophageal echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Four-chamber transesophageal echocardiogram</div><div class=\"cntnt\"><img style=\"width:490px; height:215px;\" src=\"images/CARD/76441_TEE_4_chamber_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Horizontal (0°) imaging of the heart at 32 cm from the incisors (panel A) demonstrates the four-chamber view. Well seen are the body of the left atrium (LA), mitral valve (MV), foreshortened left ventricle (LV), right atrium (RA), tricuspid valve (TV), foreshortened right ventricle (RV), and Eustachian valve (EV). In panel B the probe is at a slightly more proximal location (28 cm from the incisors); seen are the LA, LV, RV, anterior (AML) and posterior mitral valve leaflets (PML), interventricular septum, left ventricular outflow tract (LVOT), aorta (Ao), and aortic valve (AoV). The LV is often foreshortened and the true apex is generally not seen in this orientation.</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 76441 Version 2.0</div></div></div>"},"76442":{"type":"graphic_picture","displayName":"Cronkhite-Canada syndrome","title":"Cronkhite-Canada syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cronkhite-Canada syndrome</div><div class=\"cntnt\"><img style=\"width:400px; height:262px;\" src=\"images/GAST/76442_Cronkhite_Canada_syndr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Onychodystrophy in the case patient.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Sweetser S, Alexander GL, Boardman LA. A case of Cronkhite-Canada syndrome presenting with adenomatous and inflammatory colon polyps. Nat Rev Gastroenterol Hepatol 2010; 7:460. Copyright &#169; 2010.</div><div id=\"graphicVersion\">Graphic 76442 Version 2.0</div></div></div>"},"76443":{"type":"graphic_picture","displayName":"Juvenile plantar dermatosis 2","title":"Juvenile plantar dermatosis 2","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Juvenile plantar dermatosis 2</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/76443_Juveplantdermatosis2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shiny and cracked appearance of the plantar skin in a child with juvenile plantar dermatosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76443 Version 5.0</div></div></div>"},"76444":{"type":"graphic_picture","displayName":"Straight leg raise exercise","title":"Straight leg raises","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Straight leg raises</div><div class=\"cntnt\"><img style=\"width:432px; height:231px;\" src=\"images/SM/76444_Straight_leg_raise_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lie on a bed or the floor. Bend the \"good\" knee and&nbsp;place the foot on the floor. Keep the injured leg straight. On the injured side, tighten the quadriceps, keep the&nbsp;knee straight, and lift the leg about 18 inches (45 cm)&nbsp;off the floor. Slowly lower the leg back to the bed or floor.&nbsp;</div><div id=\"graphicVersion\">Graphic 76444 Version 5.0</div></div></div>"},"76445":{"type":"graphic_table","displayName":"Risk factors for osteoporosis","title":"Clinical risk factors for fracture","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical risk factors for fracture</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Advancing age</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Previous fracture</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Glucocorticoid therapy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Parental history of hip fracture</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Low body weight</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Current cigarette smoking</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Excessive alcohol consumption</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Rheumatoid arthritis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Secondary osteoporosis (eg, hypogonadism or premature menopause, malabsorption, chronic liver disease, inflammatory bowel disease)</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">4.00000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=15950&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Risk_factors_osteoporos.htm</title></head></div><div class=\"graphic_reference\">Data from: Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005; 16:581.</div><div id=\"graphicVersion\">Graphic 76445 Version 3.0</div></div></div>"},"76446":{"type":"graphic_figure","displayName":"Pacemaker algorithm rate adaptive","title":"Simplified pacemaker algorithm for use with rate adaptive pacemakers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Simplified pacemaker algorithm for use with rate adaptive pacemakers</div><div class=\"cntnt\"><img style=\"width:387px; height:138px;\" src=\"images/CARD/76446_Pacemaker_algorithm_adaptiv.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simplified algorithm for the choice of pacemaker mode assuming that a rate-responsive pacemaker (DDDR or VVIR) will be used.</div><div class=\"graphic_reference\">Courtesy of MD McGoon, MD.</div><div id=\"graphicVersion\">Graphic 76446 Version 2.0</div></div></div>"},"76447":{"type":"graphic_table","displayName":"AS clinical assessment","title":"Assessment of disease impact in ankylosing spondylitis in clinical practice","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment of disease impact in ankylosing spondylitis in clinical practice</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Domain</td> <td class=\"subtitle1\">Instrument</td> </tr> <tr> <td>Function</td> <td>BASFI, http://www.spondylitis.org</td> </tr> <tr> <td>Pain</td> <td>VAS, last week, spinal pain, at night, caused by AS and VAS, last week, peripheral joint pain caused by AS</td> </tr> <tr> <td>Spinal mobility</td> <td>Chest expansion, modified Sch&#246;ber index, and occiput-to-wall distance</td> </tr> <tr> <td>Patient global</td> <td>VAS, last week</td> </tr> <tr> <td>Stiffness</td> <td>Duration of morning stiffness, spine, last week</td> </tr> <tr> <td>Peripheral joints and entheses</td> <td>Number of swollen joints (44 joint count) validated enthesis index*</td> </tr> <tr> <td>Acute phase reactants</td> <td>ESR or CRP</td> </tr> <tr> <td>Fatigue</td> <td>VAS</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BASFI: Bath ankylosing spondylitis functional index; VAS: visual analog scale (0&nbsp;to 100 mm); ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.</div><div class=\"graphic_reference\">* Braun, J, Pham, T, Sieper, J, et al. Ann Rheum Dis 62:127, 2003.</div><div id=\"graphicVersion\">Graphic 76447 Version 3.0</div></div></div>"},"76448":{"type":"graphic_picture","displayName":"Muscle biopsy dermatomyositis","title":"Perivascular inflammation in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Perivascular inflammation in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:484px; height:324px;\" src=\"images/RHEUM/76448_Muscle_biopsy_dermatomyosit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin and eosin stain (20x) of a muscle biopsy from a patient with dermatomyositis showing perivascular and perimysial inflammation, as well as perifascicular necrosis.</div><div class=\"graphic_reference\">Courtesy of William W Pendlebury, MD.</div><div id=\"graphicVersion\">Graphic 76448 Version 1.0</div></div></div>"},"76449":{"type":"graphic_diagnosticimage","displayName":"CT lumbar hernia","title":"CT lumbar hernia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT lumbar hernia</div><div class=\"cntnt\"><img style=\"width:372px; height:294px;\" src=\"images/SURG/76449_CT_lumbar_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomogram of a left-sided lumbar hernia following nephrectomy for renal cell cancer.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Mulholland, MW, Lillemoe, KD. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76449 Version 5.0</div></div></div>"},"76450":{"type":"graphic_figure","displayName":"Enterocele examination","title":"Pelvic examination technique for enterocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pelvic examination technique for enterocele</div><div class=\"cntnt\"><img style=\"width:418px; height:416px;\" src=\"images/OBGYN/76450_Enterocele_examination.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rectovaginal examination, standing - An enterocele is detected during standing rectovaginal examination by palpating small bowel between thumb and index finger.</div><div class=\"graphic_reference\">Reproduced with permission from: LifeART. Copyright &#169; 2010 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 76450 Version 1.0</div></div></div>"},"76451":{"type":"graphic_table","displayName":"Predictors of spontaneous closure of enterocutaneous fistulas","title":"Predictors of spontaneous closure of enterocutaneous fistulas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predictors of spontaneous closure of enterocutaneous fistulas</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Factor</td> <td class=\"subtitle1\">Likely to close</td> <td class=\"subtitle1\">Unlikely to close</td> </tr> <tr> <td>Anatomical location</td> <td> <ul> <li>Oropharyngeal</li> <li>Esophageal</li> <li>Duodenal stump</li> <li>Lateral duodenal</li> <li>Pancreaticobiliary</li> <li>Jejunal</li> </ul> </td> <td> <ul> <li>Gastric</li> <li>Ligament of Treitz</li> <li>Ileal</li> </ul> </td> </tr> <tr> <td>Tract length</td> <td>&#62;2 cm</td> <td>&#60;2 cm</td> </tr> <tr> <td>Defect size</td> <td>&#60;1 cm<sup>2</sup></td> <td>&#62;1 cm<sup>2</sup></td> </tr> <tr> <td>Fistula output</td> <td>Decreasing</td> <td>Stable or increasing</td> </tr> <tr> <td>Surrounding bowel</td> <td>Healthy</td> <td> <ul> <li>Distal obstruction or stricture</li> <li>Abscess</li> <li>Active inflammation</li> <li>Bowel discontinuity</li> </ul> </td> </tr> <tr> <td>Etiology</td> <td> <ul> <li>Appendicitis</li> <li>Diverticulitis</li> <li>Postoperative</li> </ul> </td> <td> <ul> <li>Crohn disease</li> <li>Malignancy</li> <li>Radiation</li> <li>Foreign body (mesh)</li> </ul> </td> </tr> <tr> <td>Nutritional status</td> <td>Well-nourished</td> <td>Malnourished</td> </tr> <tr> <td>Sepsis</td> <td>Absent</td> <td>Present</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">20.0000000000000</mso:Specialty>\r\n<mso:Publishable_Version msdt:dt=\"string\">0</mso:Publishable_Version>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=91437&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Predictors_of_spontaneous_closure.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from: Fischer JE, Evenson AR. Gastrointestinal-cutaneous fistulae. In: Mastery of Surgery, Fischer JE (Ed), Lippincott Williams &amp; Wilkins 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 76451 Version 8.0</div></div></div>"},"76452":{"type":"graphic_diagnosticimage","displayName":"IVUS diffuse coronary disease","title":"Coronary artery disease is a diffuse process","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coronary artery disease is a diffuse process</div><div class=\"cntnt\"><img style=\"width:153px; height:269px;\" src=\"images/CARD/76452_IVUS_diffuse_coronary_disea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With contrast angiography a stenosis, assumed to be the result of plaque, is seen relative to the normal looking reference segment. Although the rest of the vessel appears to be normal, intracoronary ultrasound demonstrates the presence of a moderate amount of plaque.</div><div class=\"graphic_reference\">Reproduced with permission from Yock P, Fitzgerald P, Popp R. Science and Medicine 1995; 2:68.</div><div id=\"graphicVersion\">Graphic 76452 Version 3.0</div></div></div>"},"76454":{"type":"graphic_figure","displayName":"Spondylolisthesis","title":"Spondylolisthesis","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Spondylolisthesis</div><div class=\"cntnt\"><img style=\"width:525px; height:293px;\" src=\"images/PC/76454_Spondylolithesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dotted line follows posterior vertebral margins of L5 and the sacrum.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF II. Clinical Oriented Anatomy, Fourth Edition. Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright © 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76454 Version 4.0</div></div></div>"},"76455":{"type":"graphic_table","displayName":"Benefits transtracheal O2","title":"Potential benefits of transtracheal oxygen","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential benefits of transtracheal oxygen</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Physiologic benefit</td>\n<td class=\"subtitle1\">Mechanism</td>\n</tr>\n<tr>\n<td>Decrease in dead space</td>\n<td>O2 from catheter enters the trachea lower in the airways, decreasing dead space.</td>\n</tr>\n<tr>\n<td>Decrease in total inspired minute ventilation </td>\n<td>Due to flow from the catheter, less gas is inspired at the mouth, reducing work of breathing.</td>\n</tr>\n<tr>\n<td>Increase in CO2 elimination efficiency</td>\n<td>Fresh gas flowing from the catheter flushes the area proximal to the catheter tip during expiration, reducing the amount of CO2 that returns to the alveoli with the next inspiratory cycle. In addition, gas exiting the catheter tip at high velocity generates turbulence that enhances gas mixing distal to the catheter tip, increasing CO2 washout. As a consequence, PaCO2 remains unchanged despite a decrease in total inspired minute ventilation.</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 76455 Version 1.0</div></div></div>"},"76456":{"type":"graphic_table","displayName":"Chemotherapy infusion reaction types","title":"Characteristics and differentiation of infusion reactions to chemotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics and differentiation of infusion reactions to chemotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Symptoms and signs of mast cell/basophil-mediated infusion reactions</td> <td class=\"subtitle1\">Symptoms and signs of cytokine-mediated infusion reactions</td> </tr> <tr> <td>Flushing</td> <td>Flushing</td> </tr> <tr> <td>Itching</td> <td>Itching</td> </tr> <tr> <td>Urticaria and/or angioedema</td> <td>Rash (various)</td> </tr> <tr> <td>Dyspnea or chest tightness</td> <td>Dyspnea or chest discomfort</td> </tr> <tr> <td>Tongue, uvula, laryngeal edema, stridor</td> <td>Rarely pulmonary infiltrates</td> </tr> <tr> <td>Hypoxemia</td> <td>Hypoxemia</td> </tr> <tr> <td>Cough, wheeze</td> <td>Nausea, vomiting and/or diarrhea</td> </tr> <tr> <td>Nausea, vomiting, abdominal cramping and/or diarrhea</td> <td>Back or abdominal pain</td> </tr> <tr> <td>Hypotension, tachycardia (rarely bradycardia)</td> <td>Alterations in heart rate or blood pressure </td> </tr> <tr> <td>Sense of impending doom, dizziness and/or syncope</td> <td>Dizziness and/or syncope</td> </tr> <tr> <td>Fever (rare)</td> <td>Fever</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76456 Version 3.0</div></div></div>"},"76458":{"type":"graphic_table","displayName":"High fiber diet sample menu PI","title":"Sample menu for a high-fiber diet for children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sample menu for a high-fiber diet for children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Sample menu for a 7- to 10-year-old child, with approximate fiber content*<br /> (estimated fiber requirement for this age group: 25 to 31 grams per day)</td> </tr> <tr> <td class=\"subtitle2_single\">Breakfast (6.5 grams fiber)</td> </tr> <tr> <td class=\"indent1\">1 cup instant oatmeal (2 grams fiber)*<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">1 slice whole-grain toast (1.5 grams fiber)</td> </tr> <tr> <td class=\"indent1\">1 teaspoon margarine or butter</td> </tr> <tr> <td class=\"indent1\">1 cup strawberries (3 grams fiber)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">8 ounces skim milk</td> </tr> <tr> <td class=\"subtitle2_single\">Lunch (10 grams fiber)</td> </tr> <tr> <td class=\"indent1\">Turkey sandwich on whole-grain bread (3 grams fiber)</td> </tr> <tr> <td class=\"indent1\">1 teaspoon mustard</td> </tr> <tr> <td class=\"indent1\">1 ounce whole-grain chips (2 grams fiber)</td> </tr> <tr> <td class=\"indent1\">1 medium apple (3 grams fiber)</td> </tr> <tr> <td class=\"indent1\">8 baby carrots (2 grams fiber)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bottled water</td> </tr> <tr> <td class=\"subtitle2_single\">Snack 1 (3 grams fiber)</td> </tr> <tr> <td class=\"indent1\">4 fig bar cookies (3 grams fiber)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">8 ounces skim milk</td> </tr> <tr> <td class=\"subtitle2_single\">Dinner (8.5 grams fiber)</td> </tr> <tr> <td class=\"indent1\">3 ounces pork tenderloin</td> </tr> <tr> <td class=\"indent1\">&#189; cup mashed sweet potatoes (4 grams fiber)</td> </tr> <tr> <td class=\"indent1\">&#189; cup green beans (1.5 grams fiber)</td> </tr> <tr> <td class=\"indent1\">&#188; cup baked beans (3 grams fiber)</td> </tr> <tr> <td class=\"indent1\">2 teaspoons margarine or butter</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">8 ounces skim milk</td> </tr> <tr> <td class=\"subtitle2_single\">Snack 2</td> </tr> <tr> <td class=\"indent1\">&#189; cup vanilla bean ice cream</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Reflects insoluble fiber, which is the most relevant type of fiber for prevention and treatment of constipation. Soluble fiber has different health benefits.<br />&para; Some \"high fiber\" forms of instant oatmeal contain up to 10 grams of fiber. However, most of this additional fiber is soluble, which may not be as valuable as insoluble fiber for prevention and treatment of constipation.</div><div id=\"graphicVersion\">Graphic 76458 Version 6.0</div></div></div>"},"76459":{"type":"graphic_picture","displayName":"Botryoid rhabdomyosarcoma","title":"Botryoid rhabdomyosarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Botryoid rhabdomyosarcoma</div><div class=\"cntnt\"><img style=\"width:351px; height:468px;\" src=\"images/PEDS/76459_Botryoidrhabdomyosarcoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Botryoid variant of embryonal rhabdomyosarcoma involving the nasal cavity with overlying intact respiratory mucosa. Subepithelial dense aggregates of rhabdomyoblasts (the so-called \"cambrium\" layer) are characteristic (H&amp;E, 200x original magnification).</div><div class=\"graphic_footnotes\">H&amp;E: hematoxylin and eosin. </div><div id=\"graphicVersion\">Graphic 76459 Version 2.0</div></div></div>"},"76460":{"type":"graphic_table","displayName":"DKA rapid overview child","title":"Rapid overview of the initial evaluation and treatment of moderate to severe diabetic ketoacidosis (DKA) in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid overview of the initial evaluation and treatment of moderate to severe diabetic ketoacidosis (DKA) in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Definition of diabetic ketoacidosis (DKA): hyperglycemia (blood glucose of &#8805;200 mg/dL (11 mmol/L) and metabolic acidosis (venous pH &#60;7.30 and/or serum bicarbonate &#60;15 mEq/L), resulting in hyperosmolality and volume depletion</td> </tr> <tr> <td class=\"subtitle1_single\">Evaluation: assessment of severity </td> </tr> <tr> <td class=\"indent1\">Degree of dehydration - Patients with DKA are usually more dehydrated than suggested by the clinical examination. For moderate to severe DKA, initial fluid management is based on assuming 7 to 10 percent fluid deficit at presentation. </td> </tr> <tr> <td class=\"indent1\">Initial laboratory testing should include, at a minimum: serum testing for glucose, electrolytes, creatinine and urea nitrogen, blood gases, hematocrit, hemoglobin A1C, venous pH, and&nbsp;routine urinalysis. </td> </tr> <tr> <td class=\"indent1\">Neurologic status: Patients with abnormal mental status may have cerebral edema (see complications below). </td> </tr> <tr> <td class=\"subtitle1_single\">Management </td> </tr> <tr> <td class=\"sublist2_start\">Fluids: </td> </tr> <tr> <td class=\"sublist2\">Initial bolus of 10 mL/kg (up to a maximum volume of 1000 mL) of an isotonic solution should be given over one hour. A second bolus may be infused over the next hour for patients with compromised circulation. </td> </tr> <tr> <td class=\"sublist2\">20 mL/kg boluses may be used for the patient with DKA in shock. Hypovolemic shock is a rare occurrence in DKA, and should prompt evaluation for other&nbsp;causes, such as sepsis. </td> </tr> <tr> <td class=\"sublist2\">Following initial fluid resuscitation, replace deficit over the next 48 hours. This fluid should be given no more rapidly than 1.5 to 2 times the maintenance rate during the first 24 hours. Use an isotonic solution for the first 4 to 6 hours, then switch to half normal saline solution. </td> </tr> <tr> <td class=\"sublist2\">Urinary losses should not be replaced. </td> </tr> <tr> <td class=\"sublist2_start\">Electrolytes: </td> </tr> <tr> <td class=\"sublist2\">Sodium: Serum sodium levels are generally low and should rise as fluid deficit, hyperglycemia, and acidosis are corrected. Failure of the serum sodium to rise appropriately may be an early sign that the patient is at risk for cerebral edema. </td> </tr> <tr> <td class=\"sublist2\">Potassium: Regardless of the initial measured level of serum potassium, patients with DKA have a total body potassium deficit. Therapy with fluids and insulin will lower potassium. Therefore, potassium should be immediately added to intravenous fluid for patients who are hypokalemic. If the patient is normokalemic, potassium replacement should begin with the start of insulin therapy (eg, adding 40 meq/L of potassium to the IV solution). For patients who are hyperkalemic, potassium replacement should be initiated when the serum potassium falls to normal. </td> </tr> <tr> <td class=\"indent1\">Insulin: After the initial fluid bolus, begin a continuous insulin infusion at 0.05 to 0.1 units/kg per hour. Mix 50 units of regular insulin in 50 mL normal saline (such that 1 mL of the infusion provides 1 unit of insulin). Do not give an initial bolus of insulin. </td> </tr> <tr> <td class=\"indent1\">Glucose: Blood glucose falls rapidly during the initial volume expansion, but after that should not fall faster than 90 mg/dL (5 mmol/L) per hour. Add 5 percent dextrose solution when blood glucose falls to 300 mg/dL (17 mmol/L). Add dextrose sooner if level is dropping too quickly. It may be necessary to use a higher concentration (10 to 12.5 percent dextrose) to prevent hypoglycemia while continuing to infuse insulin to correct metabolic acidosis. </td> </tr> <tr> <td class=\"subtitle1_single\">Monitoring </td> </tr> <tr> <td class=\"indent1\">Record hourly vital signs and neurologic status, as well as fluid intake (intravenous and oral) and losses. </td> </tr> <tr> <td class=\"indent1\">Measure blood glucose, electrolytes, and venous pH hourly for the first three to four hours. Continue to monitor blood glucose hourly. Electrolytes and venous pH may subsequently be measured every two hours. </td> </tr> <tr> <td class=\"subtitle1_single\">Complications </td> </tr> <tr> <td class=\"indent1\">Cerebral edema: The risk for cerebral edema is increased with young age, and with greater degree of acidosis or dehydration at presentation. </td> </tr> <tr> <td class=\"indent1\">Monitor neurologic status carefully. Initiate treatment with 0.5-1 g/kg of mannitol as soon as cerebral edema is suspected. Reduce rate of fluid and support oxygenation and ventilation. </td> </tr> <tr> <td class=\"indent1\">Venous thrombosis: Avoid placing a central line. </td> </tr> <tr> <td class=\"indent1\">Aspiration (as the result of altered mental status and vomiting): Consider placing nasogastric tube in children with these symptoms. </td> </tr> <tr> <td class=\"indent1\">Cardiac arrhythmia (as the result of hypo- or hyperkalemia) </td> </tr> <tr> <td class=\"indent1\">Pancreatic enzyme elevations are common in DKA and do not generally reflect pancreatitis. The laboratory abnormality generally corrects with treatment of the DKA. </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76460 Version 5.0</div></div></div>"},"76461":{"type":"graphic_table","displayName":"High fiber diet guidelines","title":"Guidelines for a high fiber diet for children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for a high fiber diet for children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Why we need fiber</td> </tr> <tr> <td class=\"indent1\">Fiber helps children and adults have regular bowel movements and helps prevent constipation and other health problems. Dietary fiber helps keep the bowel and digestive tract healthy and enhances feelings of fullness after eating.</td> </tr> <tr> <td class=\"subtitle1_single\">How much fiber is needed</td> </tr> <tr> <td class=\"indent1\"> <p>For prevention of constipation, a practical target for fiber intake is the child's age plus 5 to 10 grams per day.<sup>[1]</sup> Giving more than this fiber goal has no proven benefit for management of constipation in children.<sup>[2]</sup></p> <p>Somewhat higher targets for fiber intake (14 grams/1000 kcals in the diet) have been recommended by the Institute of Medicine.<sup>[3]</sup> For children, this translates to an intake of about 20 grams/day in early childhood, rising to 29 grams/day for adolescent girls and young women, and 38 grams/day for adolescent boys and young men.</p> To find out the number of grams of fiber in a certain food, read the label, or see the foods listed in this table. High fiber foods contain 3 or more grams of fiber per serving.</td> </tr> <tr> <td class=\"subtitle1_single\">How to help your child eat more fiber</td> </tr> <tr> <td class=\"sublist2_start\">A high fiber diet should be a balanced diet with foods from all the food groups. The most common sources of fiber are whole grain breads and cereals, legumes and nuts, fruits, and vegetables. Include these in your child's balanced diet:</td> </tr> <tr> <td class=\"sublist2\">Offer your child a variety of high fiber foods during the day rather than giving only one or two high fiber foods.</td> </tr> <tr> <td class=\"sublist2\">Mix a high fiber cereal with a cereal your child likes.</td> </tr> <tr> <td class=\"sublist2\">Use whole wheat bread or white bread with added fiber, brown rice, whole wheat crackers, bran muffins, barley, bran cereals, or oatmeal. Use less refined white flour breads, cereals, and other starches.</td> </tr> <tr> <td class=\"sublist2\">Offer raw vegetables, such as carrots, jicama, or cherry tomatoes for snacks and with meals. Offer a salad with dark green lettuce each day.</td> </tr> <tr> <td class=\"sublist2\">Offer fresh fruits with the skin on. Prunes and pears act as natural laxatives because they contain sorbitol.</td> </tr> <tr> <td class=\"sublist2\">If needed, offer a moderate amount (4 to 8 ounces) of sorbitol-containing juice (prune, apple, or pear juice) each day. However, remember that fresh fruit has more fiber than juice.</td> </tr> <tr> <td class=\"sublist2\">Offer snacks that have fiber, like granola bars, fruit bars, fig cookies, or popcorn (after age 3 years).</td> </tr> <tr> <td class=\"sublist2\">Help your child develop a taste for bran. Try to include 2 to 4 tablespoons of some form of bran each day.</td> </tr> <tr> <td class=\"sublist2\">Add nuts or seeds to breads and salads, or use them as a snack. This is not recommended for children younger than three years.</td> </tr> <tr> <td class=\"sublist2\">Read labels on foods, and look for foods with 3 or more grams of fiber per serving. Have your child eat 3 or more servings each day of breads and cereals made from whole grains and bran. Have your child eat 5 or more servings of vegetables and fruits, including beans. It is important to increase water in the diet when you increase fiber.</td> </tr> <tr> <td class=\"subtitle1_single\">Preventing constipation</td> </tr> <tr> <td class=\"indent1\">If your child is constipated, follow the dietary guidelines above. Also, encourage your child to drink at least 4 to 8 cups (32 to 64 ounces) of fluid per day, preferably water, low-fat milk, and low-sugar decaffeinated beverages. A moderate amount of apple, prune, or pear juice also can be helpful for preventing constipation in some children.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Williams CL, Bollella M, Wynder EL. A new recommendation for dietary fiber in childhood. Pediatrics 1995; 96:985.</li>&#xD;&#xA;    <li>Tabbers MM, DiLorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr 2014; 58:258.</li>&#xD;&#xA;    <li>Dietary Guidelines for Americans 2005. US Department of Health and Human Services. Available at: www.health.gov/dietaryguidelines/pubs.htm.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 76461 Version 8.0</div></div></div>"},"76465":{"type":"graphic_table","displayName":"Kurtzke disability status scale","title":"Kurtzke disability status scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Kurtzke disability status scale</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>1. No disability and minimal neurologic signs</td>\n</tr>\n<tr>\n<td>2. Minimal disability (eg, slight weakness or stiffness, mild gait or visual disturbance)</td>\n</tr>\n<tr>\n<td>3. Moderate disability (eg, monoparesis, mild hemiparesis, moderate ataxia, disturbing sensory loss, prominent urinary or eye symptom, or combination of lesser dysfunction</td>\n</tr>\n<tr>\n<td>4. Relatively severe disability but fully ambulatory without aid, self sufficient and able to be up around 12 hours/day, does not prevent the ability to work or carry on normal living activities, excluding sexual dysfunction</td>\n</tr>\n<tr>\n<td>5. Disability is severe enough to preclude working, maximal motor function involves walking unaided up to 500 meters</td>\n</tr>\n<tr>\n<td>6. Needs assistance with walking (eg, cane, crutches, or braces)</td>\n</tr>\n<tr>\n<td>7. Restricted to a wheelchair but able to wheel oneself and enter and leave chair without assistance</td>\n</tr>\n<tr>\n<td>8. Restricted to bed or chair, retains many self care functions and has effective use of arms</td>\n</tr>\n<tr>\n<td>9. Helpless and bedridden</td>\n</tr>\n<tr>\n<td>10. Death due to multiple sclerosis (from respiratory paralysis, coma, following repeated or prolonged epileptic seizures)</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 76465 Version 1.0</div></div></div>"},"76466":{"type":"graphic_figure","displayName":"Early coronary atherosclerosis","title":"Fatty streak","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fatty streak</div><div class=\"cntnt\"><img style=\"width:284px; height:324px;\" src=\"images/CARD/76466_Early_coronary_atherosclero.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cross-section of a human coronary artery demonstrates the early atherosclerotic changes of a fatty streak with thickening of the intima (short arrow) and a soft lipid core (long arrow).</div><div class=\"graphic_reference\">Courtesy of Charles E Rackley, MD.</div><div id=\"graphicVersion\">Graphic 76466 Version 1.0</div></div></div>"},"76467":{"type":"graphic_figure","displayName":"MCA peak velocity","title":"MCA peak velocity","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">MCA peak velocity</div><div class=\"cntnt\"><img style=\"width:502px; height:370px;\" src=\"images/OBGYN/76467_MCA_peak_velocity_ed1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MCA: middle cerebral artery; MoMs: multiples of the median.</div><div class=\"graphic_reference\">Data from: Mari G, for the Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. N Engl J Med 2000; 342:9.</div><div id=\"graphicVersion\">Graphic 76467 Version 3.0</div></div></div>"},"76468":{"type":"graphic_table","displayName":"Early vs late diver comps","title":"Early versus late complications in continent urinary diversions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Early versus late complications in continent urinary diversions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Complication type</td> <td class=\"subtitle1\">Early (within 30 days)</td> <td class=\"subtitle1\">Percent</td> <td class=\"subtitle1\">Long term (30 days to death)</td> <td class=\"subtitle1\">Percent</td> </tr> <tr> <td rowspan=\"4\">Reservoir-related</td> <td>Urinary leak</td> <td>1.8-10</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Pyelonephritis</td> <td>0.9-13</td> <td>Pyelonephritis</td> <td>3-10</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Upper tract calculi</td> <td>3</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Pouch calculi</td> <td>5-35</td> </tr> <tr> <td rowspan=\"3\">Anastomosis-related</td> <td>Ureteral obstruction</td> <td>0-6.3</td> <td>Ureteral obstruction/stricture</td> <td>2-30</td> </tr> <tr> <td>Urethral or stomal stricture</td> <td>2-14.3</td> <td>Renal deterioration</td> <td>0.4-10.5</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Ureteral reflux</td> <td>&#60;2</td> </tr> <tr> <td rowspan=\"2\">Bowel-related</td> <td>Fecal leak</td> <td>1-2</td> <td>Metabolic abnormalities</td> <td>15-50</td> </tr> <tr> <td>Prolonged ileus</td> <td>2-11</td> <td>Bowel obstruction</td> <td>4-8</td> </tr> <tr> <td rowspan=\"5\">Other</td> <td>Wound infection</td> <td>5</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Wound dehiscence</td> <td>5</td> <td>Wound hernia</td> <td>0-10</td> </tr> <tr> <td>Deep venous thrombosis</td> <td>2-2.7</td> <td>Deep venous thrombosis</td> <td>0-6.3</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Loss of continence mechanism</td> <td>15-20</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Hypercontinence (male versus&nbsp;female)</td> <td>3-9 versus&nbsp;10-50</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76468 Version 2.0</div></div></div>"},"76469":{"type":"graphic_table","displayName":"Repeat prost bx high grade PIN","title":"Results of repeat prostate biopsy in men with isolated high grade PIN","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Results of repeat prostate biopsy in men with isolated high grade PIN</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author</td> <td class=\"subtitle1\">Year</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Number with cancer</td> <td class=\"subtitle1\">Percent with cancer</td> </tr> <tr> <td>Brawer, MK, et al.</td> <td>1991</td> <td>10</td> <td>10</td> <td>100</td> </tr> <tr> <td>Berner, A, et al.</td> <td>1993</td> <td>37</td> <td>14</td> <td>38</td> </tr> <tr> <td>Weinstein, MH, et al.</td> <td>1993</td> <td>19</td> <td>10</td> <td>53</td> </tr> <tr> <td>Davidson, D, et al.</td> <td>1995</td> <td>212</td> <td>74</td> <td>35</td> </tr> <tr> <td>Keetch, DW, et al.</td> <td>1995</td> <td>37</td> <td>19</td> <td>51</td> </tr> <tr> <td>Raviv, G, at al.</td> <td>1996</td> <td>48</td> <td>23</td> <td>48</td> </tr> <tr> <td>Langer, JE, et al.</td> <td>1996</td> <td>53</td> <td>15</td> <td>28</td> </tr> <tr> <td>O'Dowd, GJ, et al.</td> <td>2000</td> <td>3030</td> <td>697</td> <td>23</td> </tr> <tr> <td>Lefkowitz, GK, et al.</td> <td>2001</td> <td>43</td> <td>1</td> <td>2.3*</td> </tr> <tr> <td>Goeman, L et al.</td> <td>2003</td> <td>63</td> <td>17</td> <td>27</td> </tr> <tr> <td>Moore, C, et al.</td> <td>2005</td> <td>31</td> <td>1</td> <td>3.2<sup>&#182;</sup></td> </tr> <tr> <td>Gokden, N, et al.</td> <td>2005</td> <td>190</td> <td>25</td> <td>13.2</td> </tr> <tr> <td>Herawi, M; et al.</td> <td>2006</td> <td>791</td> <td>139</td> <td>18</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* 12 cores on initial biopsy.<br />¶ 10 cores on initial biopsy.</div><div id=\"graphicVersion\">Graphic 76469 Version 2.0</div></div></div>"},"76470":{"type":"graphic_algorithm","displayName":"Algorithm for nonhealing pressure ulcer management","title":"Algorithm for nonhealing pressure ulcer management","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Algorithm for nonhealing pressure ulcer management</div><div class=\"cntnt\"><img style=\"width:596px; height:467px;\" src=\"images/ID/76470_Management_of_pressure_ulce.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 76470 Version 4.0</div></div></div>"},"76471":{"type":"graphic_figure","displayName":"Hyponatremia demyelination","title":"Course of osmotic demyelination in hyponatremia","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Course of osmotic demyelination in hyponatremia</div><div class=\"cntnt\"><img style=\"width:483px; height:262px;\" src=\"images/NEPH/76471_Hyponatremia_demyelination.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clinical course in seven previously healthy women show developed postoperative hyponatremia and seizures presumably due to cerebral edema. Rapid correction of the plasma sodium concentration was associated with late deterioration into coma or a permanent vegetative state that may have been due to osmotic demyelination.</div><div class=\"graphic_reference\">Data from: Arieff AI. N Engl J Med 1986; 314:1529.</div><div id=\"graphicVersion\">Graphic 76471 Version 2.0</div></div></div>"},"76472":{"type":"graphic_picture","displayName":"Crescentic GN Light High II","title":"Light micrograph showing crescentic glomerulonephritis II","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph showing crescentic glomerulonephritis II</div><div class=\"cntnt\"><img style=\"width:378px; height:259px;\" src=\"images/NEPH/76472_RPGN_Light_High_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power light micrograph showing an active hypercellular crescent containing fibrin, which has a bright red appearance (long arrow). Note that the severe inflammatory injury has led to fragmentation of the glomerular tuft (short arrow) and to creation of a rent in the capsule (double arrow).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 76472 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"76474":{"type":"graphic_table","displayName":"Nongastrointestinal manifestations of celiac disease in children","title":"Nongastrointestinal manifestations of celiac disease in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nongastrointestinal manifestations of celiac disease in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Growth and development</td> </tr> <tr> <td class=\"sublist1\">Short stature</td> </tr> <tr> <td class=\"sublist1\">Delayed puberty</td> </tr> <tr> <td class=\"sublist1_start\">Neurologic and behavioral symptoms</td> </tr> <tr> <td class=\"sublist1\">Hypotonia</td> </tr> <tr> <td class=\"sublist1\">Developmental delay</td> </tr> <tr> <td class=\"sublist1\">Learning disorders</td> </tr> <tr> <td class=\"sublist1\">Headache</td> </tr> <tr> <td class=\"sublist1\">Cerebellar ataxia</td> </tr> <tr> <td class=\"sublist1\">Epilepsy</td> </tr> <tr> <td>Liver disease&nbsp;</td> </tr> <tr> <td>Iron deficiency&nbsp;</td> </tr> <tr> <td>Skin&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Dermatitis herpetiformis</td> </tr> <tr> <td class=\"sublist1\">Others (refer to&nbsp;table of skin disorders associated with celiac disease)&nbsp;</td> </tr> <tr> <td>Dental enamel defects</td> </tr> <tr> <td>Metabolic bone disease</td> </tr> <tr> <td>Arthritis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76474 Version 6.0</div></div></div>"},"76475":{"type":"graphic_table","displayName":"Muscle relaxants chronic pain","title":"Muscle relaxants for chronic pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Muscle relaxants for chronic pain</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Drug</td>\r\n                    <td class=\"subtitle1\">Dose</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Cyclobenzaprine</td>\r\n                    <td>10 mg&nbsp;three times daily&nbsp;(10 to 40 mg/day)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Carisoprodol (Soma)</td>\r\n                    <td>350 mg three times daily</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Baclofen (Lioresal)</td>\r\n                    <td>5 mg once a day, titrated gradually to 5 to 10 mg three times daily</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Methocarbamol (Robaxin)</td>\r\n                    <td>1500 mg four times daily</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 76475 Version 2.0</div></div></div>"},"76476":{"type":"graphic_table","displayName":"Diff dx diabetic neuropathy","title":"Differential diagnosis of diabetic neuropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of diabetic neuropathy</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n   <tr>\n   <td class=\"container\"><table cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Distal symmetrical polyneuropathy\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_single\">\n   Metabolic\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Uremia\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Folic acid/cyanocobalamin deficiency\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Hypothyroidism\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Acute intermittent porphyria\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_single\">\n   Toxic\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Alcohol\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Heavy metals (lead, mercury, arsenic)\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Industrial hydrocarbons\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Various drugs\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_single\">\n   Infectious or inflammatory\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Sarcoidosis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Leprosy\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Periarteritis nodosa\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Other connective tissue diseases (eg, systemic lupus erythematosus)\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_single\">\n   Other\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Dysproteinemias and paraproteinemias\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Paraneoplastic syndrome\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Leukemias and lymphomas\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Amyloidosis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Hereditary neuropathies\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Pains and paresthesias without neurologic deficit\n   </td>\n   </tr>\n   <tr>\n   <td>Early small fiber sensory neuropathy</td>\n   </tr>\n   <tr>\n   <td>Psychophysiologic disorder (eg, severe depression, hysteria)</td>\n   </tr>\n   </table></td>\n   <td class=\"container\"><table cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Autonomic neuropathy\n   </td>\n   </tr>\n   <tr>\n   <td>Shy-Drager syndrome (Multiple system atrophy with predominant autonomic failure)</td>\n   </tr>\n   <tr>\n   <td>Riley-Day syndrome (Familial dysautonomia)</td>\n   </tr>\n   <tr>\n   <td>Idiopathic orthostatic hypotension</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Diffuse motor neuropathy without sensory deficit\n   </td>\n   </tr>\n   <tr>\n   <td>Guillain-Barre syndrome</td>\n   </tr>\n   <tr>\n   <td>Primary myopathies</td>\n   </tr>\n   <tr>\n   <td>Myasthenia gravis</td>\n   </tr>\n   <tr>\n   <td>Heavy metal toxicity</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Femoral neuropathy (sacral plexopathy)\n   </td>\n   </tr>\n   <tr>\n   <td>Degenerative spinal disc disease</td>\n   </tr>\n   <tr>\n   <td>Intrinsic spinal cord mass lesion</td>\n   </tr>\n   <tr>\n   <td>Cauda equina lesions</td>\n   </tr>\n   <tr>\n   <td>Coagulopathies</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Cranial neuropathy\n   </td>\n   </tr>\n   <tr>\n   <td>Carotid aneurysm</td>\n   </tr>\n   <tr>\n   <td>Intracranial mass</td>\n   </tr>\n   <tr>\n   <td>Intracranial hypertension</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Mononeuropathy multiplex\n   </td>\n   </tr>\n   <tr>\n   <td>Vasculidities</td>\n   </tr>\n   <tr>\n   <td>Amyloidosis</td>\n   </tr>\n   <tr>\n   <td>Hypothyroidism</td>\n   </tr>\n   <tr>\n   <td>Acromegaly</td>\n   </tr>\n   <tr>\n   <td>Coagulopathies</td>\n   </tr>\n   </table></td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Adapted with permission from Greene, DA, Feldman, EL, Stevens, MJ, et al. Diabetic neuropathy. In: Ellenberg and Rifkin's Diabetes Mellitus, 5th ed, 1996. Copyright Appleton &amp; Lange.</div><div id=\"graphicVersion\">Graphic 76476 Version 3.0</div></div></div>"},"76479":{"type":"graphic_picture","displayName":"Bladder endometriosis resection","title":"Bladder endometriosis: Resection of nodule","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Bladder endometriosis: Resection of nodule</div><div class=\"cntnt\"><img style=\"width:498px; height:381px;\" src=\"images/OBGYN/76479_Bladder_endometriosis_resec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Laparoscopic excision of the endometriotic nodule. The bladder catheter is visible inside the bladder.<br />(B) Laparoscopic closure of the bladder.<br />(C) Laparoscopic ties at the end of the procedure.</div><div id=\"graphicVersion\">Graphic 76479 Version 2.0</div></div></div>"},"76480":{"type":"graphic_picture","displayName":"Actinic keratoses treated with 5-fluorouracil","title":"Inflammatory response during treatment of actinic keratoses with topical 5-fluorouracil","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Inflammatory response during treatment of actinic keratoses with topical 5-fluorouracil</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/76480_Actinic_keratoses_5FU.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous inflamed scaly patches are present on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76480 Version 4.0</div></div></div>"},"76481":{"type":"graphic_diagnosticimage","displayName":"TEE mitral valve vegetations","title":"Transesophageal echocardiogram (TEE) showing vegetations on the mitral valve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiogram (TEE) showing vegetations on the mitral valve</div><div class=\"cntnt\"><img style=\"width:175px; height:219px;\" src=\"images/CARD/76481_TEE_MV_vegetations.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bulky vegetations on the mitral valve as seen on transesophageal echocardiography in the four-chamber view transverse plane.</div><div id=\"graphicVersion\">Graphic 76481 Version 3.0</div></div></div>"},"76482":{"type":"graphic_figure","displayName":"Blood supply of the pelvis","title":"Blood supply of the pelvis","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Blood supply of the pelvis</div><div class=\"cntnt\"><img style=\"width:534px; height:558px;\" src=\"images/SURG/76482_Blood-supply-of-the-pelvis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 76482 Version 1.0</div></div></div>"},"76483":{"type":"graphic_table","displayName":"Approach to establishing the cause of acute pancreatitis","title":"Approach to establishing the cause of acute pancreatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to establishing the cause of acute pancreatitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical profile</td> <td class=\"subtitle1\">Suspected cause</td> <td class=\"subtitle1\">Confirmatory testing</td> </tr> <tr class=\"divider_bottom\"> <td>Prior episodes of biliary colic and/or cholangitis, increased serum ALT and/or bilirubin during episode</td> <td>Gallstones</td> <td>Abdominal ultrasound. If ultrasound is negative and clinical suspicion is high, additional testing should be considered with MRCP/EUS to rule out choledocholithiasis.</td> </tr> <tr class=\"divider_bottom\"> <td>Long history (usually 10 to 20 years) of alcohol abuse</td> <td>Alcohol</td> <td>Plain film/CT scan for pancreatic calcification; blood glucose for diabetes; 72 hour fecal fat for steatorrhea; exclude other causes of acute pancreatitis</td> </tr> <tr class=\"divider_bottom\"> <td>Medication known to cause acute pancreatitis (particularly Class I and II drugs) and no other cause for pancreatitis</td> <td>Drug-induced pancreatitis</td> <td>Withdrawal of offending drug and look for resolution</td> </tr> <tr class=\"divider_bottom\"> <td>Child with family history of pancreatitis</td> <td>Familial hypertriglyceridemia or hereditary chronic pancreatitis</td> <td>Serum triglyceride concentration and genetic testing, respectively</td> </tr> <tr class=\"divider_bottom\"> <td>Adult with milky serum</td> <td>Hypertriglyceridemia</td> <td>Serum triglyceride concentration</td> </tr> <tr class=\"divider_bottom\"> <td>Recent ERCP, surgery or abdominal trauma</td> <td>Posttraumatic/post procedure</td> <td>Temporal relationship to event</td> </tr> <tr class=\"divider_bottom\"> <td>Hemorrhagic shock, recent vascular surgery, angiography, coronary artery bypass graft</td> <td>Vascular</td> <td>Temporal relationship to event; evidence of ischemic or atheroembolic injury to other organs; tissue biopsy may show evidence of atheroembolism and urine eosinophils</td> </tr> <tr class=\"divider_bottom\"> <td>Recurrent pancreatitis with hypercalcemia</td> <td>Hypercalcemia</td> <td>Hypercalcemia is an unusual cause of acute pancreatitis; exclude other causes first</td> </tr> <tr> <td>Hypertension, proteinuria, mononeuropathy, skin lesions</td> <td>Polyarteritis nodosa</td> <td>Biopsy of muscle, skin or nerve, angiography, ANCA</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALT: alanine aminotransferase; ERCP: endoscopic retrograde cholangiopancreatography; EUS: endoscopic ultrasound; MRCP: magnetic resonance cholangiopancreatography; CT: computed tomography; DDI: didanosine; ACE: angiotensin converting enzyme; ANCA: antineutrophil cytoplasmic antibody.</div><div id=\"graphicVersion\">Graphic 76483 Version 8.0</div></div></div>"},"76485":{"type":"graphic_diagnosticimage","displayName":"Color flow Doppler MR I","title":"Color flow Doppler of mitral regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Color flow Doppler of mitral regurgitation</div><div class=\"cntnt\"><img style=\"width:389px; height:267px;\" src=\"images/CARD/76485_ColorflowDopplerMRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A shows an apical four-chamber view with color flow Doppler of mild mitral regurgitation (MR); mild tricuspid regurgitation (TR) is also present. The regurgitant jets have a mosaic of color because their high velocities are represented by an aliased signal; they begin with a very narrow point of origin at the valve, remain narrow, and penetrate only partially into the left atrial (LA) cavity. These are characteristics of mild regurgitant lesions. In panel B, the size of the MR jet at the site of origin is wider, the jet reaches the posterior LA wall, and blood begins to accelerate before reaching the valve; these are characteristics of moderate to severe MR. In panel C, the jet is even wider, almost filling the LA, and it reaches the posterior LA wall and enters the pulmonary veins. Panel D is from a patient with rheumatic MR and a giant LA; proper gain settings show marked spontaneous echo contrast (D1). With slightly lower gain setting, spontaneous echo contrast is artifactually not seen (D2). Panel D3 shows a narrow jet of trivial mitral regurgitation (MR); spontaneous echo contrast does not develop when MR is moderate or severe.</div><div class=\"graphic_footnotes\">RA and LA: right and left atria; LV and RV: left and right ventricles.</div><div id=\"graphicVersion\">Graphic 76485 Version 3.0</div></div></div>"},"76488":{"type":"graphic_figure","displayName":"Carbohydrate profiles in IDDM","title":"Carbohydrate intake profiles in different patients","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Carbohydrate intake profiles in different patients</div><div class=\"cntnt\"><img style=\"width:507px; height:195px;\" src=\"images/ENDO/76488_Carbohydrate_profiles_in_ID.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Carbohydrate intake (each column represents one meal or snack and each box represents 15 g) throughout the day in two patients with excellent glycemic control. The more active, younger man (right panel) takes in more carbohydrate, but both patients maintain a relatively constant profile each day (not shown).</div><div class=\"graphic_footnotes\">HbA1c: glycated hemoglobin, A1C.</div><div id=\"graphicVersion\">Graphic 76488 Version 2.0</div></div></div>"},"76491":{"type":"graphic_table","displayName":"Antibiotics for the initial treatment of AOM in children","title":"Systemic antibiotics used for the initial treatment of acute otitis media in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Systemic antibiotics used&nbsp;for the initial treatment of&nbsp;acute otitis media in children</div><div class=\"cntnt\"><table cellspacing=\"0\"> <colgroup width=\"25%\" span=\"4\" /> <tbody> <tr> <td class=\"subtitle1\">Antibiotic</td> <td class=\"subtitle1\">Route</td> <td class=\"subtitle1\">Dose/duration</td> <td class=\"subtitle1\">Maximum daily dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">First-line agents</td> </tr> <tr> <td class=\"indent1\">Amoxicillin</td> <td>Oral</td> <td> <ul> <li>Children &#60;2 years: 90 mg/kg per day in two doses for 10 days </li> <li>Children &#8805;2 years: 90 mg/kg per day in two doses for 5 to 7 days </li> </ul> </td> <td>3 g/day</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Amoxicillin-clavulanate*<sup>&#182;</sup></td> <td>Oral</td> <td> <ul> <li>Children &#60;2 years: 90 mg/kg per day in two doses for 10 days </li> <li>Children &#8805;2 years: 90 mg/kg per day in two doses for 5 to 7 days </li> </ul> </td> <td>3 g/day (amoxicillin component)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Alternatives for children with mild or remote allergy to penicillins (ie, without anaphylaxis, bronchospasm, or angioedema)</td> </tr> <tr> <td class=\"indent1\">Cefdinir</td> <td>Oral</td> <td>14 mg/kg per day in one or two doses for 10 days</td> <td>600 mg/day</td> </tr> <tr> <td class=\"indent1\">Cefpodoxime</td> <td>Oral</td> <td>10 mg/kg per day in two doses for 10 days</td> <td>400 mg/day</td> </tr> <tr> <td class=\"indent1\">Cefuroxime suspension<sup>&#182;</sup><sup>&#916;</sup></td> <td>Oral</td> <td>30 mg/kg per day in two doses for 10 days</td> <td>1 g/day</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ceftriaxone<sup>&#182;</sup></td> <td>Intramuscular or intravenous</td> <td>50 mg/kg per day for 1 to 3 days</td> <td>1 g/day</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Alternatives for children with severe reaction<sup>&#9674;</sup> to beta-lactams including cephalosporins</td> </tr> <tr> <td class=\"indent1\">Azithromycin</td> <td>Oral</td> <td>10 mg/kg once on day 1, then 5 mg/kg once per day on days 2 through 5</td> <td>500 mg/day on day one; 250 mg/day on days 2 through 5</td> </tr> <tr> <td class=\"indent1\">Clarithromycin<sup>&#167;</sup></td> <td>Oral</td> <td>15 mg/kg per day in two doses for 10 days</td> <td>1 g/day</td> </tr> <tr> <td class=\"indent1\">Clindamycin</td> <td>Oral</td> <td> <ul> <li>Mild to moderate infection<sup>&#165;</sup>: 10 to 25 mg/kg per day in three doses for 10 days </li> <li>Severe infection<sup>&#165;</sup>: 30 to 40 mg/kg per day in three doses for 10 days </li> </ul> </td> <td>1.8 g/day</td> </tr> <tr> <td class=\"indent1\">Erythromycin-sulfisoxazole (not available in the United States)</td> <td>Oral</td> <td>50 mg/kg (erythromycin component) per day in three to four doses <span style=\"color: black;\">for 10 days</span></td> <td>2 g/day (erythromycin component)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><SPAN style=\"COLOR: black\">AOM: acute otitis media.</SPAN><SPAN style=\"COLOR: black\"><br />* For children who have received a beta-lactam antibiotic (eg, penicillins, cephalosporins) in the previous 30 days or have concomitant purulent conjunctivitis or have a history of recurrent otitis media unresponsive to amoxicillin.<br />¶ Frequently used if amoxicillin fails.<br />Δ For children who can swallow tablets whole and weigh &gt;17 kg, may use cefuroxime tablets; the dose is 250 mg twice daily.<br /><FONT class=lozenge>◊</FONT> Severe reactions include anaphylaxis, angioedema, bronchospasm, urticaria where skin testing is unavailable or contraindicated (eg, for serious cutaneous reaction), and serious delayed reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, hemolytic anemia).<br />§ Infrequently used because of drug interactions. <br />¥ Mild to moderate AOM is characterized by mild pain, ear&nbsp;pain &lt;48&nbsp;hours, and temperature &lt;39°C (102.2°F).&nbsp;Severe AOM is characterized by moderate to severe pain, ear pain ≥48 hours, or temperature ≥39°C (102.2°F). </SPAN>&nbsp;</div><div id=\"graphicVersion\">Graphic 76491 Version 11.0</div></div></div>"},"76492":{"type":"graphic_table","displayName":"Lab findings in miliary TB","title":"Laboratory findings in patients with miliary tuberculosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory findings in patients with miliary tuberculosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Laboratory finding</td>\n<td class=\"subtitle1\">Maartens, 1990</td>\n<td class=\"subtitle1\">Kim, 1990</td>\n<td class=\"subtitle1\">Munt, 1971</td>\n<td class=\"subtitle1\">Proudfoot, 1969</td>\n</tr>\n<tr>\n<td>Anemia</td>\n<td>52*</td>\n<td>38</td>\n<td>58</td>\n<td>12</td>\n</tr>\n<tr>\n<td>Leukopenia</td>\n<td>15</td>\n<td>&nbsp;</td>\n<td>25</td>\n<td>12</td>\n</tr>\n<tr>\n<td>Leukocytosis or left shift</td>\n<td>14</td>\n<td>61</td>\n<td>11</td>\n<td>1</td>\n</tr>\n<tr>\n<td>Thrombocytopenia</td>\n<td>23</td>\n<td>7</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>Thrombocytosis</td>\n<td>24</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>Hyponatremia</td>\n<td>78</td>\n<td>68</td>\n<td>29</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>Elevated alkaline phosphatase</td>\n<td>83</td>\n<td>&nbsp;</td>\n<td>34</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>Transaminitis</td>\n<td>42</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>Hyperbilirubinemia</td>\n<td>15</td>\n<td>8</td>\n<td>24</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>Elevated ESR &#62;50</td>\n<td>68</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>97</td>\n</tr>\n<tr>\n<td>Hypoxemia (pO2 &#60;60)</td>\n<td>40</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>Sterile pyuria</td>\n<td>32</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">8.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=31342&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Lab_findings_in_miliary_TB.htm</title></head></div><div class=\"graphic_footnotes\">ESR: erythrocyte sedimentation rate.<br />* Numbers are percentages.</div><div class=\"graphic_reference\">Courtesy of Nesli Basgoz, MD.</div><div id=\"graphicVersion\">Graphic 76492 Version 2.0</div></div></div>"},"76493":{"type":"graphic_table","displayName":"Criteria CIM","title":"Suggested diagnostic research criteria for critical illness myopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested diagnostic research criteria for critical illness myopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major diagnostic features</td> </tr> <tr> <td>1. Sensory nerve amplitudes &#62;80 percent of the lower limit of normal in two or more nerves</td> </tr> <tr> <td>2. Needle EMG with short-duration, low-amplitude MUPs with early or normal full recruitment, with or without fibrillation potentials</td> </tr> <tr> <td>3. Absence of a decremental response on repetitive nerve stimulation</td> </tr> <tr> <td>4. Muscle histopathologic findings of myopathy with myosin loss</td> </tr> <tr> <td class=\"subtitle1_single\">Supportive features</td> </tr> <tr> <td>1. Motor amplitudes &#60;80 percent lower limit of normal in two or more nerves without conduction block</td> </tr> <tr> <td>2. Elevated serum CK (best assessed in the first week of illness)</td> </tr> <tr> <td>3. Demonstration of muscle inexcitability</td> </tr> <tr> <td>4. Prolonged compound muscle action potential durations</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">By definition, patients are or were critically ill, and weakness should have started after onset of critical illness. For a <EM>definite diagnosis of critical illness myopathy</EM>, patients should have all four major features and one or more supportive features. For <EM>probable critical illness myopathy</EM>, patients should have any three major features and one or more supportive feature. For <EM>possible critical illness myopathy</EM>, patients should have either major features 1 and 3, or 2 and 3, and one or more supportive feature.</div><div class=\"graphic_footnotes\">EMG: electromyography; MUPs: motor unit potentials; CK: creatine kinase.</div><div id=\"graphicVersion\">Graphic 76493 Version 2.0</div></div></div>"},"76494":{"type":"graphic_picture","displayName":"Hemostats applied to foreskin","title":"Hemostats applied to foreskin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemostats applied to foreskin</div><div class=\"cntnt\"><img style=\"width:432px; height:283px;\" src=\"images/OBGYN/76494_Hemostats_applied_to_foresk.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of David G Weismiller, MD.</div><div id=\"graphicVersion\">Graphic 76494 Version 1.0</div></div></div>"},"76495":{"type":"graphic_figure","displayName":"SEER CRC incid mort","title":"SEER Incidence and mortality rate of invasive colorectal cancer according to age in the SEER database (2002-2006)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">SEER Incidence and mortality rate of invasive colorectal cancer according to age in the SEER database (2002-2006)</div><div class=\"cntnt\"><img style=\"width:377px; height:278px;\" src=\"images/ONC/76495_SEER_CRC_incid_mort.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SEER: Surveillance, Epidemiology and End Results.</div><div class=\"graphic_reference\">Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009.</div><div id=\"graphicVersion\">Graphic 76495 Version 1.0</div></div></div>"},"76497":{"type":"graphic_waveform","displayName":"ECG ST-T changes with LVH tutorial","title":"Left ventricular hypertrophy (LVH) with strain pattern","html":"<div class=\"graphic normal\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Left ventricular hypertrophy (LVH) with strain pattern</div><div class=\"cntnt\"><img style=\"width:530px; height:232px;\" src=\"images/CARD/76497_STTchangesLVHtutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ST-T wave abnormalities secondary to LVH (often termed \"strain\") are most often seen in the anterolateral leads (eg, I, aVL, V4-V6). Typical abnormalitites include a horizontal or downsloping ST segment and T wave inversions. In some cases, there is concavity to the ST segment, which has a final downward turn that blends into an inverted T wave.</div><div id=\"graphicVersion\">Graphic 76497 Version 6.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"76499":{"type":"graphic_table","displayName":"Antimicrobial prophylaxis for cardiac surgery","title":"Antimicrobial prophylaxis for cardiac surgery in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial prophylaxis for cardiac surgery in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nature of operation</td> <td class=\"subtitle1\">Common pathogens</td> <td class=\"subtitle1\">Recommended antimicrobials</td> <td class=\"subtitle1\">Usual adult dose*</td> <td class=\"subtitle1\">Redose interval<sup>&#182;</sup></td> </tr> <tr> <td rowspan=\"4\">Cardiac procedures: coronary artery bypass, cardiac device insertion procedures (eg, pacemaker implantation), placement of ventricular assist devices</td> <td rowspan=\"4\"><em>Staphylococcus aureus</em>, <em>S. epidermidis</em></td> <td>Cefazolin</td> <td> <p>&#60;120 kg: 2 g IV</p> &#8805;120 kg: 3 g IV</td> <td>4 hours</td> </tr> <tr> <td><strong>OR</strong> cefuroxime</td> <td>1.5 g IV</td> <td>4 hours<sup>&#916;</sup></td> </tr> <tr> <td><strong>OR</strong> vancomycin<sup>&#9674;</sup></td> <td>15 mg/kg IV (max 2 g)</td> <td>N/A</td> </tr> <tr> <td><strong>OR</strong> clindamycin</td> <td>900 mg IV</td> <td>6 hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">IV: intravenous.</div><div class=\"graphic_footnotes\">* Parenteral prophylactic antimicrobials can be given as a single IV dose begun within 60 minutes before the procedure. If vancomycin is used, the infusion should be started within 60 to 120 minutes before the initial incision to have adequate tissue levels at the time of incision and to minimize the possibility of an infusion reaction close to the time of induction of anesthesia.<br />¶&nbsp;For prolonged procedures (&gt;3 hours) or those with major blood loss or in patients with extensive burns, additional intraoperative doses should be given at intervals one to two times the half-life of the drug for the duration of the procedure in patients with normal renal function.<br />Δ Some experts recommend an additional dose when patients are removed from bypass during open-heart surgery.<br /><FONT class=lozenge>◊</FONT> Use of vancomycin is appropriate in hospitals in which methicillin-resistant <EM>S. aureus</EM> (MRSA) and <EM>S. epidermidis</EM> are a frequent cause of postoperative wound infection, in patients previously colonized with MRSA or for those who are allergic to penicillins or cephalosporins. Rapid IV administration may cause hypotension, which could be especially dangerous during induction of anesthesia. Even when the drug is given over 60 minutes, hypotension may occur; treatment with diphenhydramine and further slowing of the infusion rate may be helpful. For procedures in which enteric gram-negative bacilli are common pathogens, many experts would add another drug such as an aminoglycoside (gentamicin 5 mg/kg IV), aztreonam (2 g IV), or a fluoroquinolone (ciprofloxacin 400 mg IV or levofloxacin 500 mg IV).</div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>Antimicrobial prophylaxis for surgery. Med Lett Drugs Ther 2016; 58:63.</LI>&#xD;&#xA;<LI>Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt) 2013; 14:73.</LI></OL></div><div id=\"graphicVersion\">Graphic 76499 Version 14.0</div></div></div>"},"76500":{"type":"graphic_figure","displayName":"Celiac ganglia intervention","title":"Celiac ganglia intervention","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Celiac ganglia intervention</div><div class=\"cntnt\"><img style=\"width:442px; height:298px;\" src=\"images/GAST/76500_Celiac_ganglia_intervention.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An artist's rendition of endosonography-guided celiac ganglia intervention. Celiac ganglia neurolysis is demonstrated with the needle tip positioned within a ganglion.</div><div class=\"graphic_reference\">Courtesy of Mike King. Copyrighted and used with permission of Mayo Foundation for Medical Education and Research.</div><div id=\"graphicVersion\">Graphic 76500 Version 9.0</div></div></div>"},"76502":{"type":"graphic_table","displayName":"Muscle tone in colic PI","title":"Symptoms of increased muscle tone in babies with colic","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms of increased muscle tone in babies with colic</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>The baby's face is red, and the skin around the mouth is pale.</td> </tr> <tr> <td>The belly is bulging and hard.</td> </tr> <tr> <td>The legs are drawn into the belly, and the feet are cold. (The legs can also be straight out when the baby cries especially hard.)</td> </tr> <tr> <td>The fingers are clenched shut.</td> </tr> <tr> <td>The arms are stiff, tight, and straight. (The elbows can also be bent.)</td> </tr> <tr> <td>The back is arched.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Lester BM. Colic and Excessive Crying. Report of the 105th Ross Conference on Pediatric Research, Lester BM, Barr RG (Eds), Ross Products Division, Columbus, OH, 1997. p.18.</div><div id=\"graphicVersion\">Graphic 76502 Version 7.0</div></div></div>"},"76503":{"type":"graphic_waveform","displayName":"Intermediate case 15","title":"Intermediate case 15","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Intermediate case 15</div><div class=\"cntnt\"><img style=\"width:540px; height:98px;\" src=\"images/CARD/76503_Intermediate_case_15.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 76503 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"76504":{"type":"graphic_picture","displayName":"Grover's disease","title":"Grover's disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Grover's disease</div><div class=\"cntnt\"><img style=\"width:432px; height:280px;\" src=\"images/PC/76504_Grovers_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical appearance of scattered pruritic, erythematous papules and papulovesicles on the trunk.</div><div class=\"graphic_reference\">Courtesy of Whitney High, MD.</div><div id=\"graphicVersion\">Graphic 76504 Version 2.0</div></div></div>"},"76505":{"type":"graphic_form","displayName":"Asthma peak flow daily diary II","title":"Asthma peak flow daily diary","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Asthma peak flow daily diary</div><div class=\"cntnt\"><img style=\"width:609px; height:792px;\" src=\"images/PULM/76505_Asthma_daily_diary_II.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: Woolcock Institute of Medical Research, 2006.</div><div id=\"graphicVersion\">Graphic 76505 Version 2.0</div></div></div>"},"76506":{"type":"graphic_table","displayName":"Categories of synovial fluid","title":"Categories of synovial fluid based upon clinical and laboratory findings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Categories of synovial fluid based upon clinical and laboratory findings</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Measure </td> <td class=\"subtitle1\">Normal </td> <td class=\"subtitle1\">Noninflammatory </td> <td class=\"subtitle1\">Inflammatory </td> <td class=\"subtitle1\">Septic </td> <td class=\"subtitle1\">Hemorrhagic </td> </tr> <tr> <td>Volume, mL (knee)</td> <td>&#60;3.5</td> <td>Often &#62;3.5</td> <td>Often &#62;3.5</td> <td>Often &#62;3.5</td> <td>Usually &#62;3.5</td> </tr> <tr> <td>Clarity</td> <td>Transparent</td> <td>Transparent</td> <td>Translucent-opaque</td> <td>Opaque</td> <td>Bloody</td> </tr> <tr> <td>Color</td> <td>Clear</td> <td>Yellow</td> <td>Yellow</td> <td>Yellow</td> <td>Red</td> </tr> <tr> <td>Viscosity</td> <td>High</td> <td>High</td> <td>Low</td> <td>Variable</td> <td>Variable</td> </tr> <tr> <td>White blood cell, per mm<sup>3</sup></td> <td>&#60;200</td> <td>0 to 2000</td> <td>&#62;2000*</td> <td>&#62;20,000*</td> <td>Variable</td> </tr> <tr> <td>Polymorphonuclear leukocytes, percent</td> <td>&#60;25</td> <td>&#60;25</td> <td>&#8805;50</td> <td>&#8805;75</td> <td>50 to 75</td> </tr> <tr> <td>Culture</td> <td>Negative</td> <td>Negative</td> <td>Negative</td> <td>Often positive</td> <td>Negative</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Inflammatory arthritis may include septic arthritis. Septic arthritis is typically associated with synovial fluid&nbsp;white blood cell&nbsp;counts &gt;20,000, but lower counts may be observed, especially for arthritis due to disseminated gonococcal infection.</div><div id=\"graphicVersion\">Graphic 76506 Version 9.0</div></div></div>"},"76507":{"type":"graphic_figure","displayName":"ARF lateral view anorectal fistulas","title":"Anorectal fistulas, lateral view","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Anorectal fistulas, lateral view</div><div class=\"cntnt\"><img style=\"width:463px; height:507px;\" src=\"images/SURG/76507_ARF lateral view anal rectal fistulas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this lateral view of anorectal fistulas, a superficial fistula has been included. It is not a component of the original Parks' classification. This figure also illustrates the potential pathways of transsphincteric fistulas.</div><div id=\"graphicVersion\">Graphic 76507 Version 4.0</div></div></div>"},"76513":{"type":"graphic_table","displayName":"Dyspnea signs","title":"Dyspnea signs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dyspnea signs</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Physical examination finding </td>\r\n                    <td class=\"subtitle1\">Clinical significance </td>\r\n                    <td class=\"subtitle1\">Possible diagnosis </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Absent/diminished breath sounds</td>\r\n                    <td>Decreased air movement</td>\r\n                    <td>\r\n                    <p>COPD</p>\r\n                    <p>Severe asthma</p>\r\n                    <p>Pneumothorax</p>\r\n                    <p>Tension pneumothorax</p>\r\n                    <p>Hemothorax</p>\r\n                    </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Accessory muscle use</td>\r\n                    <td>Muscle weakness, fatigue</td>\r\n                    <td>\r\n                    <p>Respiratory failure</p>\r\n                    <p>Severe COPD</p>\r\n                    <p>Severe asthma</p>\r\n                    </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Expiratory/mixed stridor</td>\r\n                    <td>Air flow obstruction below vocal cords</td>\r\n                    <td>\r\n                    <p>Croup</p>\r\n                    <p>Foreign body</p>\r\n                    <p>Bacterial tracheitis</p>\r\n                    </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Inspiratory stridor</td>\r\n                    <td>Air flow obstruction above vocal cords</td>\r\n                    <td>\r\n                    <p>Foreign body</p>\r\n                    <p>Epiglottitis</p>\r\n                    <p>Angioedema</p>\r\n                    </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Hyperventilation</td>\r\n                    <td>&nbsp;</td>\r\n                    <td>\r\n                    <p>Acidosis</p>\r\n                    <p>Sepsis</p>\r\n                    <p>Salicylate poisoning</p>\r\n                    <p>Anxiety</p>\r\n                    </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>JVD with clear lungs</td>\r\n                    <td>Right heart failure</td>\r\n                    <td>\r\n                    <p>Cardiac tamponade</p>\r\n                    <p>Pulmonary embolism</p>\r\n                    </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>JVD with crackles</td>\r\n                    <td>Right and left heart failure</td>\r\n                    <td>\r\n                    <p>ADHF </p>\r\n                    <p>ARDS</p>\r\n                    </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Heart murmur</td>\r\n                    <td>Valvular disease</td>\r\n                    <td>Valvular dysfunction</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Hepatojugular reflux</td>\r\n                    <td>Right heart failure</td>\r\n                    <td>ADHF</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Pulsus paradoxus</td>\r\n                    <td>Poor right heart filling</td>\r\n                    <td>\r\n                    <p>Right heart failure</p>\r\n                    <p>Pulmonary embolism</p>\r\n                    <p>Cardiogenic shock</p>\r\n                    <p>Pericardial tamponade</p>\r\n                    <p>Asthma exacerbation</p>\r\n                    </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Crackles (Rales)</td>\r\n                    <td>Interalveolar fluid</td>\r\n                    <td>\r\n                    <p>ADHF</p>\r\n                    <p>ARDS</p>\r\n                    <p>Pneumonia</p>\r\n                    </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Wheezes</td>\r\n                    <td>Obstruction below trachea</td>\r\n                    <td>\r\n                    <p>Asthma exacerbation</p>\r\n                    <p>Foreign body</p>\r\n                    <p>ADHF</p>\r\n                    <p>COPD</p>\r\n                    </td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_lgnd\">ADHF: Acute decompensated heart failure; ARDS: Acute respiratory distress syndrome; COPD: Chronic obstructive pulmonary disease; JVD: Jugular venous distension;</div><div id=\"graphicVersion\">Graphic 76513 Version 2.0</div></div></div>"},"76514":{"type":"graphic_diagnosticimage","displayName":"Esophageal web on barium swallow","title":"Esophageal web on barium swallow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal web on barium swallow</div><div class=\"cntnt\"><img style=\"width:204px; height:348px;\" src=\"images/GAST/76514_Esophageal_web_Ba_swallow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This modified barium swallow, obtained in a 45-year-old man with dysphagia, demonstrates an asymmetric esophageal web arising from the right side of the upper esophagus (arrow).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 76514 Version 4.0</div></div></div>"},"76515":{"type":"graphic_figure","displayName":"Identifying ureter at hysterectomy","title":"Identification of the ureter during hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Identification of the ureter during hysterectomy</div><div class=\"cntnt\"><img style=\"width:477px; height:317px;\" src=\"images/OBGYN/76515_Identifyingureterathyste.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ureter is located on the medial leaf of the broad ligament and courses under the uterine artery. Prior to any surgical manipulation, it usually lies 2 cm lateral to the uterus, but may be nearer. The ureter must be identified before clamping and cutting the uterine artery to avoid injury.</div><div id=\"graphicVersion\">Graphic 76515 Version 4.0</div></div></div>"},"76516":{"type":"graphic_table","displayName":"Classification NCPH","title":"Classification of noncirrhotic portal hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of noncirrhotic portal hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Prehepatic</td> </tr> <tr> <td class=\"indent1\">Portal vein thrombosis</td> </tr> <tr> <td class=\"indent1\">Splenic vein thrombosis</td> </tr> <tr> <td class=\"indent1\">Splanchnic arteriovenous fistula</td> </tr> <tr> <td class=\"indent1\">Splenomegaly (eg, from lymphoma, Gaucher's disease*)</td> </tr> <tr> <td class=\"subtitle1_single\">Intrahepatic</td> </tr> <tr> <td class=\"subtitle2_single\">Presinusoidal</td> </tr> <tr> <td class=\"indent1\">Schistosomiasis*</td> </tr> <tr> <td class=\"indent1\">Idiopathic noncirrhotic portal hypertension (including nodular regenerative hyperplasia)</td> </tr> <tr> <td class=\"indent1\">Primary biliary cholangitis</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis*</td> </tr> <tr> <td class=\"indent1\">Congenital hepatic fibrosis</td> </tr> <tr> <td class=\"indent1\">Primary sclerosing cholangitis</td> </tr> <tr> <td class=\"indent1\">Hepatic arteriopetal fistula</td> </tr> <tr> <td class=\"indent1\">Adult polycystic liver disease</td> </tr> <tr> <td class=\"indent1\">Arteriovenous fistulas</td> </tr> <tr> <td class=\"indent1\">Autoimmune cholangiopathy</td> </tr> <tr> <td class=\"indent1\">Vinyl chloride toxicity*</td> </tr> <tr> <td class=\"indent1\">Neoplastic occlusion of the intrahepatic portal vein</td> </tr> <tr> <td class=\"indent1\">Mineral oil granuloma*</td> </tr> <tr> <td class=\"subtitle2_single\">Sinusoidal</td> </tr> <tr> <td class=\"indent1\">Arsenic poisoning</td> </tr> <tr> <td class=\"indent1\">Vinyl chloride toxicity*</td> </tr> <tr> <td class=\"indent1\">Drugs (eg, amiodarone, methotrexate)</td> </tr> <tr> <td class=\"indent1\">Alcoholic liver disease*</td> </tr> <tr> <td class=\"indent1\">Nonalcoholic fatty liver disease</td> </tr> <tr> <td class=\"indent1\">Gaucher's disease*</td> </tr> <tr> <td class=\"indent1\">Zellweger syndrome</td> </tr> <tr> <td class=\"indent1\">Viral hepatitis</td> </tr> <tr> <td class=\"indent1\">Chronic Q fever</td> </tr> <tr> <td class=\"indent1\">Schistosomiasis*</td> </tr> <tr> <td class=\"indent1\">Amyloid or light-chain deposition in the space of Disse</td> </tr> <tr> <td class=\"indent1\">Acute hepatic injury</td> </tr> <tr> <td class=\"indent1\">Mastocytosis</td> </tr> <tr> <td class=\"indent1\">Agnogenic myeloid metaplasia</td> </tr> <tr> <td class=\"indent1\">Acute fatty liver of pregnancy</td> </tr> <tr> <td class=\"subtitle2_single\">Postsinusoidal</td> </tr> <tr> <td class=\"indent1\">Sinusoidal obstruction syndrome (venoocclusive disease)</td> </tr> <tr> <td class=\"indent1\">Budd-Chiari syndrome*</td> </tr> <tr> <td class=\"indent1\">Alcoholic liver disease*</td> </tr> <tr> <td class=\"indent1\">Chronic radiation injury</td> </tr> <tr> <td class=\"indent1\">Vitamin A toxicity</td> </tr> <tr> <td class=\"indent1\">Epithelioid hemangioendothelioma</td> </tr> <tr> <td class=\"indent1\">Angiosarcoma</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis*</td> </tr> <tr> <td class=\"indent1\"><em>Mycobacterium avium</em> or <em>M. intracellulare </em>infection</td> </tr> <tr> <td class=\"indent1\">Mineral oil granuloma*</td> </tr> <tr> <td class=\"subtitle1_single\">Posthepatic</td> </tr> <tr> <td class=\"indent1\">IVC obstruction (eg, Budd-Chiari syndrome*)</td> </tr> <tr> <td class=\"indent1\">Cardiac disease (constrictive pericarditis, restrictive cardiomyopathy)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IVC: inferior vena cava.<br />* May cause noncirrhotic portal hypertension via several mechanisms.</div><div class=\"graphic_reference\">Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology 2011; 54:1071.</div><div id=\"graphicVersion\">Graphic 76516 Version 4.0</div></div></div>"},"76521":{"type":"graphic_diagnosticimage","displayName":"Coronary artery dissection IVUS","title":"Coronary artery dissection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coronary artery dissection</div><div class=\"cntnt\"><img style=\"width:386px; height:222px;\" src=\"images/CARD/76521_Coronary_artery_dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After the placement of a stent in the right coronary artery there is an area of haziness, distal to the stent, seen by angiography (left panel). With intracoronary ultrasound, a dissection flap is seen protruding into the lumen of the coronary artery (right panel).</div><div class=\"graphic_reference\">Reproduced with permission from Ziada KM, Tuzcu EM, De Franco AC, et al. Am J Cardiol 1997; 80:116.</div><div id=\"graphicVersion\">Graphic 76521 Version 4.0</div></div></div>"},"76522":{"type":"graphic_table","displayName":"Prevalence antithyroid Ab","title":"Estimated prevalence of antithyroid antibodies (in percent)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated prevalence of antithyroid antibodies (in percent)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Group</td> <td class=\"subtitle1\">Anti-TSHR Ab</td> <td class=\"subtitle1\">Anti-Tg Ab</td> <td class=\"subtitle1\">Anti-TPO Ab</td> </tr> <tr> <td>General population</td> <td>0</td> <td>5 to 20</td> <td>8 to 27</td> </tr> <tr> <td>Graves' disease</td> <td>80 to 95</td> <td>50 to 70</td> <td>50 to 80</td> </tr> <tr> <td>Autoimmune thyroiditis</td> <td>10 to 20</td> <td>80 to 90</td> <td>90 to 100</td> </tr> <tr> <td>Relatives of patients with autoimmune thyroiditis</td> <td>0</td> <td>30 to 50</td> <td>30 to 50</td> </tr> <tr> <td>Type 1 diabetes</td> <td>0</td> <td>30 to 40</td> <td>30 to 40</td> </tr> <tr> <td>Pregnant women</td> <td>0</td> <td>about 14</td> <td>about 14</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Anti-TSHR Ab: anti-thyroid-stimulating hormone&nbsp;receptor antibodies; anti-Tg Ab: anti-thyroglobulin antibodies; anti-TPO Ab: anti-thyroid peroxidase antibodies.</div><div id=\"graphicVersion\">Graphic 76522 Version 3.0</div></div></div>"},"76523":{"type":"graphic_table","displayName":"ASC-US triage based on age","title":"Performance of HPV DNA testing versus repeat thin layer cytology in triage of women with ASC-US for colposcopic evaluation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Performance of HPV DNA testing versus repeat thin layer cytology in triage of women with ASC-US for colposcopic evaluation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Triage strategy</td> <td class=\"subtitle1\">Percent sensitivity for detection of CIN 3 or higher (95% CI)</td> <td class=\"subtitle1\">Percent women referred for colposcopy (95% CI)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Age 23 to 28 years</td> </tr> <tr> <td class=\"indent1\">HPV testing</td> <td>96 (91 to 100)</td> <td>65 (62 to 69)</td> </tr> <tr> <td class=\"indent1\">Repeat cytology for ASC-US</td> <td>88 (79 to 97)</td> <td>64 (60 to 68)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Age &#8805;29 years</td> </tr> <tr> <td class=\"indent1\">HPV testing</td> <td>94 (86 to 100)</td> <td>31 (28 to 34)</td> </tr> <tr> <td class=\"indent1\">Repeat cytology for ASC-US</td> <td>91 (81 to 100)</td> <td>50 (47 to 54)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">All ages</td> </tr> <tr> <td class=\"indent1\">HPV testing</td> <td>96 (93 to 100)</td> <td>54 (52 to 56)</td> </tr> <tr> <td class=\"indent1\">Repeat cytology for ASC-US</td> <td>86 (80 to 92)</td> <td>59 (57 to 61)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HPV: human papillomavirus; ASC-US: atypical squamous cells of unknown significance; CI: confidence interval.</div><div class=\"graphic_reference\">Adapted from: Sherman ME, Schiffman M, Cox JT. J Natl Cancer Inst 2002; 94:102.</div><div id=\"graphicVersion\">Graphic 76523 Version 4.0</div></div></div>"},"76524":{"type":"graphic_figure","displayName":"Uterus didelphys and hemivagina","title":"Uterus didelphys with obstructed hemivagina with ipsolateral renal agenesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterus didelphys with obstructed hemivagina with ipsolateral renal agenesis</div><div class=\"cntnt\"><img style=\"width:278px; height:387px;\" src=\"images/OBGYN/76524_Uterusdidelphysandhemiva.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 76524 Version 14.0</div></div></div>"},"76526":{"type":"graphic_picture","displayName":"Erythema induratum of Bazin","title":"Erythema induratum of Bazin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema induratum of Bazin</div><div class=\"cntnt\"><img style=\"width:338px; height:306px;\" src=\"images/DERM/76526_Eryth_indur_Bazin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An ulcerated nodule and multiple scars are present on the lower legs of this patient with erythema&nbsp;induratum of Bazin.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. M Ramam, New Delhi.</div><div id=\"graphicVersion\">Graphic 76526 Version 2.0</div></div></div>"},"76527":{"type":"graphic_picture","displayName":"Triangular alopecia","title":"Temporal triangular alopecia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Temporal triangular alopecia</div><div class=\"cntnt\"><img style=\"width:432px; height:402px;\" src=\"images/DERM/76527_Triangular_alopecia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This healthy five-year-old boy was evaluated for congenital symmetric oval to triangular temporal patches of alopecia. There were scattered vellus hairs within the patches.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 76527 Version 6.0</div></div></div>"},"76528":{"type":"graphic_figure","displayName":"Linkage disequilibrium","title":"Linkage disequilibrium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Linkage disequilibrium</div><div class=\"cntnt\"><img style=\"width:433px; height:198px;\" src=\"images/ALLRG/76528_Linkage_disequilibrium.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this hypothetical example, the A1 and B1 alleles are more often found on the same chromosome than would be anticipated by chance alone. The same is true for the A2 and B2 alleles. Consequently, there is a deficiency of A1 B2 and A2 B1 haplotypes. This discrepancy between the observed and expected haplotype frequencies is linkage disequilibrium.</div><div id=\"graphicVersion\">Graphic 76528 Version 1.0</div></div></div>"},"76529":{"type":"graphic_figure","displayName":"Polistes species","title":"Polistes species","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Polistes species</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ALLRG/76529_Polistes_species.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.</div><div id=\"graphicVersion\">Graphic 76529 Version 2.0</div></div></div>"},"76530":{"type":"graphic_figure","displayName":"Percutaneous transtracheal ventilation Y connector","title":"Percutaneous transtracheal ventilation via Y-connector or oxygen tubing side port","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Percutaneous transtracheal ventilation via Y-connector or oxygen tubing side port</div><div class=\"cntnt\"><img style=\"width:263px; height:516px;\" src=\"images/EM/76530_PTVYconnector.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PTV setups utilizing a Y-connector and oxygen tubing with a cut side port.</div><div class=\"graphic_reference\">Reproduced with permission from: Mittal MK, Baren JM. Percutaneous Transtracheal Ventilation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 76530 Version 11.0</div></div></div>"},"76531":{"type":"graphic_picture","displayName":"Short arm cast","title":"Applying a short arm cast","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Applying a short arm cast</div><div class=\"cntnt\"><img style=\"width:463px; height:597px;\" src=\"images/EM/76531_Shortarmcast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: The casting position is maintained and the stockinette (optional) is applied.<br />Panels B and C: Cast padding (Webril) is wrapped distal to proximal, overlapping by half each turn.<br />Panel D:Fiberglass or plaster rolls are similarly wrapped distal to proximal.<br />Panel E: The fiberglass or plaster is smoothed using the palms and thenar eminences (not the fingers).<br />Panels F and G:The ends of the stockinette are folded over to provide smooth ends for the cast.<br />Panel H:Positioning of the extremity is maintained until the cast is hardened.</div><div class=\"graphic_reference\">Reproduced with permission from: Bachman DT. Short arm and short leg casts. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippinicott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 76531 Version 12.0</div></div></div>"},"76532":{"type":"graphic_diagnosticimage","displayName":"NSCLC bone met PETCT","title":"Bone metastasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone metastasis</div><div class=\"cntnt\"><img style=\"width:396px; height:289px;\" src=\"images/PULM/76532_NSCLC_bone_met_PETCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PET-CT showing two foci of hypermetabolic activity in a lumbar vertebral body in a 76-year-old woman with metastatic adenocarcinoma of the lung.</div><div class=\"graphic_footnotes\">PET-CT: positron emission tomography-computed tomography.</div><div id=\"graphicVersion\">Graphic 76532 Version 3.0</div></div></div>"},"76535":{"type":"graphic_picture","displayName":"Bullard rigid fiberoptic laryngoscope","title":"Bullard rigid fiberoptic laryngoscope","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bullard rigid fiberoptic laryngoscope</div><div class=\"cntnt\"><img style=\"width:252px; height:324px;\" src=\"images/EM/76535_Bull_rig_fiber_laryngoscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Bullard laryngoscope is available in three sizes as shown from top to bottom: infant, pediatric, and adult. It is most useful when intubating patients with limited mouth opening or neck mobility and in those with predicted difficult airways due to poor visualization.</div><div class=\"graphic_reference\">Image courtesy of Olympus America Inc.</div><div id=\"graphicVersion\">Graphic 76535 Version 1.0</div></div></div>"},"76536":{"type":"graphic_figure","displayName":"IHC data about ER neg rate","title":"Immunohistochemistry data about ER-negative rate from the Intermountain Healthcare Study","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Immunohistochemistry data about ER-negative rate from the Intermountain Healthcare Study</div><div class=\"cntnt\"><img style=\"width:498px; height:373px;\" src=\"images/ONC/76536_IHCdataERnegrateedt3.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ER: estrogen receptor.</div><div class=\"graphic_reference\">Based on data from: Nkoy FL, Hammond ME, Rees W, et al. Arch Pathol Lab Med 2010; 134:606.</div><div id=\"graphicVersion\">Graphic 76536 Version 2.0</div></div></div>"},"76537":{"type":"graphic_table","displayName":"HCT survival according to Pesaro risk class","title":"Survival according to Pesaro risk class in patients with beta thalassemia major who underwent HCT in the 1980s and 1990s","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Survival according to Pesaro risk class in patients with beta thalassemia major who underwent HCT in the 1980s and 1990s</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Risk class</td> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Transplant-related mortality<br /> (%)</td> <td class=\"subtitle1\">Survival<br /> (%)</td> <td class=\"subtitle1\">Thalassemia-free survival<br /> (%)</td> </tr> <tr> <td>Low (Class I)</td> <td>Bu 14 + Cy 200</td> <td class=\"centered\">6</td> <td class=\"centered\">94</td> <td class=\"centered\">87</td> </tr> <tr> <td>Intermediate (Class II)</td> <td>Bu 14 + Cy 200</td> <td class=\"centered\">15</td> <td class=\"centered\">84</td> <td class=\"centered\">81</td> </tr> <tr> <td>High (Class III; transplant performed prior to 1990)</td> <td>Bu 14 + Cy 200</td> <td class=\"centered\">47</td> <td class=\"centered\">50</td> <td class=\"centered\">47</td> </tr> <tr> <td>High (Class III; transplant performed after 1990)</td> <td>Bu 14 + Cy 120 to 160</td> <td class=\"centered\">18</td> <td class=\"centered\">79</td> <td class=\"centered\">58</td> </tr> <tr> <td>Adult</td> <td>Bu 14 + Cy 120 to 160</td> <td class=\"centered\">34</td> <td class=\"centered\">66</td> <td class=\"centered\">62</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Risk categories&nbsp;are defined according to&nbsp;the Pesaro classification. Refer to UpToDate for details regarding HCT for thalassemia.<br /></div><div class=\"graphic_footnotes\">HCT: hematopoietic cell transplantation; Bu: busulfan; Cy: cyclophosphamide.</div><div class=\"graphic_reference\">Prepared with data from:<br /><OL>&#xD;&#xA;<LI>Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990; 322:417.</LI>&#xD;&#xA;<LI>Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993; 329:840.</LI>&#xD;&#xA;<LI>Lucarelli G, Clift RA, Galimberti M, et al. Marrow transplantation for patients with thalassemia: Results in class 3 patients. Blood 1996; 87:2082.</LI>&#xD;&#xA;<LI>Lucarelli G, Clift RA, Galimberti M, et al. Bone marrow transplantation in adult thalassemic patients. Blood 1999; 93:1164.</LI></OL></div><div id=\"graphicVersion\">Graphic 76537 Version 5.0</div></div></div>"},"76538":{"type":"graphic_picture","displayName":"Child with classic presentation of acute epiglottitis","title":"Child with classic presentation of acute epiglottitis","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Child with classic presentation of acute epiglottitis</div><div class=\"cntnt\"><img style=\"width:455px; height:362px;\" src=\"images/PEDS/76538_Epiglottitis_classic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This four-year-old girl has epiglottitis caused by <em>Haemophilus influenzae</em> type b.<br />(A) She prefers to sit and appears anxious.<br />(B) The child assumes the characteristic sniffing position to maximize the patency of her airway.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig W, Baskin MN. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76538 Version 4.0</div></div></div>"},"76541":{"type":"graphic_algorithm","displayName":"Diagnostic approach to back pain in patients with cancer","title":"Diagnostic approach to back pain in patients with cancer","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to back pain in patients with cancer</div><div class=\"cntnt\"><img style=\"width:505px; height:458px;\" src=\"images/ONC/76541_Dgnstc_app_bck_pn_ptnt_cncr.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IV: intravenous; MRI: magnetic resonance imaging; XRT: radiation therapy; CSF: cerebrospinal fluid.<br />* Combined computed tomography (CT) and myelogram may be used in place of MRI if MRI is unavailable or contraindicated.</div><div id=\"graphicVersion\">Graphic 76541 Version 3.0</div></div></div>"},"76542":{"type":"graphic_picture","displayName":"Bronchiolitis obliterans II","title":"Bronchiolitis obliterans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchiolitis obliterans</div><div class=\"cntnt\"><img style=\"width:360px; height:238px;\" src=\"images/PULM/76542_Bronchiolitis_obliterans_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchiolitis obliterans in chronic lung transplant rejection. Photomicrograph of chronic lung transplant rejection showing granulation tissue within the lumen of a small airway.</div><div class=\"graphic_reference\">Courtesy of L Kobzik, MD.</div><div id=\"graphicVersion\">Graphic 76542 Version 1.0</div></div></div>"},"76543":{"type":"graphic_table","displayName":"LTOT indications","title":"Indications for long-term oxygen therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for long-term oxygen therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">General indications</td> </tr> <tr> <td>PaO<sub>2</sub> &#8804;55 mmHg (7.32 kPa) or SaO<sub>2</sub> &#8804;88 percent</td> </tr> <tr> <td class=\"subtitle1_single\">In the presence of cor pulmonale</td> </tr> <tr> <td>PaO<sub>2</sub> &#8804;59 mmHg (7.85 kPa) or SaO<sub>2</sub> &#8804;89 percent</td> </tr> <tr> <td>EKG evidence of P pulmonale</td> </tr> <tr> <td>Hematocrit &#62;55 percent</td> </tr> <tr> <td>Clinical evidence of right heart failure</td> </tr> <tr> <td class=\"subtitle1_single\">Specific situations</td> </tr> <tr> <td>PaO<sub>2</sub> &#8805;60 mmHg (7.98 kPa) or SaO<sub>2</sub> &#8805;90 percent with lung disease and other clinical needs such as sleep apnea with nocturnal desaturation not corrected by CPAP.</td> </tr> <tr> <td>If the patient meets criteria at rest, O<sub>2</sub> should also be prescribed during sleep and exercise, and appropriately titrated.</td> </tr> <tr> <td>If the patient is normoxemic at rest but desaturates during exercise (PaO<sub>2</sub> &#8804;55 mmHg [7.32 kPa]), O<sub>2</sub> is generally prescribed for use during exercise. For patients who desaturate (PaO<sub>2</sub> &#8804;55 mmHg [7.32 kPa]) during sleep, further evaluation with polysomnography may be indicated to assess for sleep-disordered breathing.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76543 Version 3.0</div></div></div>"},"76544":{"type":"graphic_diagnosticimage","displayName":"MRI diabetic amyotrophy","title":"MRI findings in diabetic lumbar plexopathy","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">MRI findings in diabetic lumbar plexopathy</div><div class=\"cntnt\"><img style=\"width:500px; height:569px;\" src=\"images/NEURO/76544_MRI_diabetic_amyotrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MR neurography coronal images show increased caliber and T2 signal (A, B) and abnormal T1 contrast enhancement (C, D) of the right L3 nerve (short thin arrow), L4 nerve (long thin arrow), proximal portion of the femoral nerve (short thick arrow), and right obturator nerve (arrowheads).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Cianfoni A, Luigetti M, Media F, et al. Teaching NeuroImage: MRI of diabetic lumbar plexopathy treated with local steroid injection. Neurology 2009; 72:e32. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76544 Version 12.0</div></div></div>"},"76545":{"type":"graphic_diagnosticimage","displayName":"Overdistended bladder mimicking placenta previa","title":"Overdistended bladder mimicking placenta previa","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Overdistended bladder mimicking placenta previa</div><div class=\"cntnt\"><img style=\"width:504px; height:380px;\" src=\"images/OBGYN/76545_Overdistended_bladder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transabdominal study shows an over-distended bladder giving the appearance of a previa in a patient with&nbsp;NO placenta previa. An over-distended bladder can compress the anterior lower uterine segment against the posterior lower uterine segment, thereby mimicking placenta previa. The arrow points to the cervical os.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 76545 Version 3.0</div></div></div>"},"76546":{"type":"graphic_diagnosticimage","displayName":"TTTS5","title":"TTTS5","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">TTTS5</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/OBGYN/76546_TTTS5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal view of the recipient twin at approximately 25 weeks of gestation. The fetal head is&nbsp;to the right and the fetal buttocks are&nbsp;to the left. Arrow&nbsp;points to&nbsp;fetal ascites indicating the presence of hydrops (Quintero Stage IV TTTS).</div><div class=\"graphic_reference\">Courtesy of Kenneth J Moise, Jr, MD &amp; Anthony Johnson, DO.</div><div id=\"graphicVersion\">Graphic 76546 Version 3.0</div></div></div>"},"76547":{"type":"graphic_table","displayName":"Nonpharm intervent refract gastroparesis","title":"Nonpharmacologic interventions for refractory gastroparesis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonpharmacologic interventions for refractory gastroparesis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Available procedures</td> <td class=\"subtitle1\">Purpose</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr class=\"divider_bottom\"> <td>Nasogastric tube</td> <td> <p>Blind</p> Radiologic (under fluoroscopy)</td> <td> <p>Decompression</p> Access for feeding or medications</td> <td> <p>Ease of placement</p> <p>Simple procedure</p> Low cost</td> <td> <p>Easily displaced/removed</p> <p>Short-term use only</p> <p>Discomfort</p> <p>Source of infection</p> <p>Risk of tube blockage</p> Potentially increased reflux, aspiration of feeds</td> </tr> <tr class=\"divider_bottom\"> <td>Gastrostomy tube</td> <td> <p>Surgical</p> <p>Radiologic</p> Percutaneous endoscopic</td> <td> <p>Decompression</p> Feeding</td> <td> <p>Superior for decompression</p> <p>Moderate ease of placement</p> <p>Bolus feeding may occasionally be possible by gastrostomy tube alone</p> Potentially long term</td> <td> <p>Questionable value for nutritional support without jejunal tube placement</p> <p>Source of infection</p> <p>Risk of tube blockage</p> High risk of reflux, aspiration of feeds</td> </tr> <tr class=\"divider_bottom\"> <td>Jejunostomy tube (direct)</td> <td> <p>Surgical</p> <p>Radiologic</p> Percutaneous endoscopic</td> <td>Feeding</td> <td> <p>Superior for nutritional purposes</p> Potential for long-term use</td> <td> <p>Source of infection</p> <p>Risk of tube blockage</p> <p>Requires enteral infusion pump for nutrition</p> Does not provide for gastric decompression</td> </tr> <tr class=\"divider_bottom\"> <td>Jejunostomy tube (trans-gastric)</td> <td> <p>Radiologic</p> Percutaneous endoscopic</td> <td>Biluminal enteral tube with separate gastric and jejunal ports</td> <td> <p>Single tube</p> <p>Single procedure for two tubes</p> <p>Single stoma/abdominal</p> Can accomplish decompression and feedings through different ports of the same tube</td> <td> <p>Risk of migration of jejunal tube into stomach</p> <p>Reflux of feeds into stomach</p> <p>Source of infection</p> <p>Risk of tube blockage (especially jejunal port)</p> Technically somewhat more difficult to place the jejunal tube</td> </tr> <tr class=\"divider_bottom\"> <td>Separate gastrostomy and jejunostomy tubes</td> <td> <p>Radiologic</p> Percutaneous endoscopic</td> <td> <p>Decompression</p> Feeding</td> <td> <p>Two separate simultaneously working tubes</p> <p>Decreased risk of reflux, aspiration of feeds</p> Provides gastric decompression</td> <td> <p>Longer, more difficult procedure</p> <p>Higher cost due to two procedures</p> <p>Higher risk of infection due to two stomas/wounds</p> Risk of tube blockage</td> </tr> <tr class=\"divider_bottom\"> <td>Gastrojejunostomy with or without percutaneous jejunostomy (open versus laparoscopic)</td> <td>Surgical</td> <td>Surgical bypass for decompression and feeding</td> <td> <p>Drainage by gravity</p> <p>Potentially permanent</p> Most useful in gastric outlet obstruction syndrome</td> <td> <p>Increased morbidity of surgery</p> <p>Needs careful patient selection</p> <p>Gastroparesis, if significant, may not be alleviated and may require jejunal tube placement regardless</p> <p>Higher cost of procedure</p> High expertise required for the procedure</td> </tr> <tr> <td>Gastric electrical stimulation</td> <td>Surgical</td> <td> <p>Feeding</p> Enteral passage of secretions</td> <td> <p>Physiologic</p> <p>Potentially eliminates the need for enteral feeding</p> <p>No foreign body on body surface (tubes)</p> Decreased risk of infection</td> <td> <p>More expertise required</p> <p>Cost of procedure and device</p> Unknown benefit for MG (currently, gastric electric stimulation is not used in MG and is still controversial in gastroparesis. Patients are required to have a life expectancy of &#62;6 years).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MG: malignant gastroparesis.</div><div class=\"graphic_reference\">Reproduced with permission from: Donthireddy K, Ailawadhi S, Nasser E, et al. Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol 2007; 5:355. Illustrations used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 76547 Version 5.0</div></div></div>"},"76548":{"type":"graphic_table","displayName":"PEFG regimen pancreatic cancer","title":"PEFG regimen for metastatic pancreaticobiliary cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PEFG regimen for metastatic pancreaticobiliary cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Agent </td> <td class=\"subtitle1\">Dose </td> </tr> <tr> <td>Cisplatin</td> <td>40 mg/m<sup>2</sup> day 1 every 28 days</td> </tr> <tr> <td>Epirubicin</td> <td>40 mg/m<sup>2</sup> day 1 every 28 days</td> </tr> <tr> <td>5-FU</td> <td>200 mg/m<sup>2</sup>/day by continuous infusion days 1 to 28</td> </tr> <tr> <td>Gemcitabine</td> <td>600 mg/m<sup>2</sup> over one hour on days 1, 8 every 28 days</td> </tr> </tbody></table></div><div class=\"graphic_reference\">1. Reni M, et al. J Clin Oncol 2001; 19:2679.<BR>2. Cereda S, et al. Cancer 2010; 116:2208.</div><div id=\"graphicVersion\">Graphic 76548 Version 3.0</div></div></div>"},"76549":{"type":"graphic_table","displayName":"Antiseptics umbilical cord","title":"Antiseptic topical cord care agents and rare associated complications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antiseptic topical cord care agents and rare associated complications</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Rare complication</td> </tr> <tr> <td>1 percent basic fuchsine</td> <td>None</td> </tr> <tr> <td>Bacitracin</td> <td>None</td> </tr> <tr> <td>Colloid silver-benzyl-peroxide</td> <td>None</td> </tr> <tr> <td>Micronized green clay powder</td> <td>None</td> </tr> <tr> <td>Chlorhexidine</td> <td>Slight delay in cord separation</td> </tr> <tr> <td>Hexachlorophene</td> <td>Spongiform myelinopathy</td> </tr> <tr> <td>Isopropyl alcohol</td> <td>Percutaneous toxicity, central nervous system depression, skin necrosis</td> </tr> <tr> <td>Neomycin</td> <td>Neural deafness</td> </tr> <tr> <td>Povidone-iodine</td> <td>Transient hypothyroxinemia, hypothyroidism</td> </tr> <tr> <td>Salicylic acid</td> <td>Metabolic acidosis</td> </tr> <tr> <td>Silver sulfadiazine</td> <td>Kernicterus (sulfa)</td> </tr> <tr> <td>Triple dye</td> <td>Carcinogenicity</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Roberts J. Drug Therapy in Infants. Philadelphia, PA. WB Saunders 1984. p.341.</li>&#xD;&#xA;    <li>Rosenkranz HS, et al. Br Med J 1971; 3:702.</li>&#xD;&#xA;    <li>Lin CP, et al. Eur J Pediatr 1994; 153:756.</li>&#xD;&#xA;    <li>Pyati SP, et al. J Pediatr 1977; 91:825.</li>&#xD;&#xA;    <li>Payne CM, et al. Lancet 1992; 340:126.</li>&#xD;&#xA;    <li>Pezzati M, et al. Biol Neonate 2002; 81:38.</li>&#xD;&#xA;    <li>Siegfried EC, et al. J Perinatol 1999; 19:31.</li>&#xD;&#xA;    <li>Rutter N. Clin Perinatol 1987; 14:911.</li>&#xD;&#xA;    <li>West DP, et al. J Invest Dermatol 1981; 76:147.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 76549 Version 4.0</div></div></div>"},"76550":{"type":"graphic_diagnosticimage","displayName":"Mirizzi syndrome ERCP","title":"Mirizzi syndrome seen on endoscopic retrograde cholangiopancreatography (ERCP)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mirizzi syndrome seen on endoscopic retrograde cholangiopancreatography (ERCP)</div><div class=\"cntnt\"><img style=\"width:206px; height:288px;\" src=\"images/GAST/76550_Mirizzi_syndrome_ERCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography in a patient with obstructive jaundice and Mirizzi syndrome shows an impacted stone in the distal cystic duct which is obstructing the common hepatic duct by extrinsic compression (arrow).</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 76550 Version 3.0</div></div></div>"},"76555":{"type":"graphic_table","displayName":"SFG rickettsioses symptoms","title":"Symptoms of spotted fever group rickettsioses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms of spotted fever group rickettsioses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Disease (Bacterium responsible)</td> <td class=\"subtitle1\" colspan=\"3\">Percent of patients with</td> <td class=\"subtitle1\" rowspan=\"2\">Multiple eschars</td> <td class=\"subtitle1\" rowspan=\"2\">Enlarged local nodes</td> <td class=\"subtitle1\" rowspan=\"2\">Patients with purpuric rash (percent)</td> </tr> <tr> <td class=\"subtitle2\">Rash</td> <td class=\"subtitle2\">Headache</td> <td class=\"subtitle2\">Eschar</td> </tr> <tr> <td>Rocky Mountain spotted fever (R. rickettsii)</td> <td>90</td> <td>80</td> <td>0</td> <td>No</td> <td>No</td> <td>45</td> </tr> <tr> <td>Mediterranean spotted fever (R. conorii)</td> <td>97</td> <td>56</td> <td>72</td> <td>Very rare</td> <td>Rare</td> <td>10</td> </tr> <tr> <td>Siberian tick typhus (R. sibirica)</td> <td>100</td> <td>100</td> <td>77</td> <td>No</td> <td>Yes</td> <td>No</td> </tr> <tr> <td>Rickettsialpox (R. akari)</td> <td>100*</td> <td>100</td> <td>83</td> <td>Yes</td> <td>Yes</td> <td>No</td> </tr> <tr> <td>Queensland tick typhus (R. australis)</td> <td>100*</td> <td>&nbsp;</td> <td>65</td> <td>No</td> <td>Yes</td> <td>&nbsp;</td> </tr> <tr> <td>Japanese spotted fever (R. japonica)</td> <td>100</td> <td>22</td> <td>48</td> <td>No</td> <td>No</td> <td>No</td> </tr> <tr> <td>African tick bite fever (R. africae)</td> <td>30*</td> <td>Yes</td> <td>100</td> <td>Yes</td> <td>Yes</td> <td>No</td> </tr> <tr> <td>Flinders Island spotted fever (R. honei)</td> <td>85</td> <td>73</td> <td>25</td> <td>No</td> <td>Yes</td> <td>8</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*&nbsp;Vesicular</div><div class=\"graphic_reference\">Data from Raoult D, Roux V. Rickettsioses as paradigms of new or emerging infectious diseases. Clin Microbiol Rev 1997; 10:694.</div><div id=\"graphicVersion\">Graphic 76555 Version 2.0</div></div></div>"},"76556":{"type":"graphic_figure","displayName":"Open cystectomy ab","title":"Open ovarian cystectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Open ovarian cystectomy</div><div class=\"cntnt\"><img style=\"width:324px; height:413px;\" src=\"images/OBGYN/76556_Open_cystectomy_ab.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A thin incision is made in the axis of the ovary over its most dependent area. (B) The back of the knife handle is used to separate the cyst wall from the ovarian cortex.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 76556 Version 4.0</div></div></div>"},"76557":{"type":"graphic_picture","displayName":"Plasma cell leukemia","title":"Plasma cell leukemia (PCL)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plasma cell leukemia (PCL)</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/HEME/76557_Plasma_cell_leukemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The peripheral blood smear of patients with plasma cell leukemia demonstrates a leukocytosis with circulating plasma cells. By definition, the absolute plasma cell count must exceed 2000/microL or 20 percent of the peripheral white blood cell count. The morphological features of plasma cells can differ depending upon their maturity. Mature plasma cells are oval with abundant basophilic cytoplasm. The nucleus is round and eccentrically located with a marked perinuclear hof, or cytoplasmic clearing. The nucleus contains &quot;clock-face&quot; or &quot;spoke wheel&quot; chromatin without nucleoli. Immature plasma cells have dispersed nuclear chromatin, prominent nucleoli and a high nuclear to cytoplasmic ratio.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson, SC, PhD. Anderson's Atlas of Hematology. Copyright 2003, Wolters Kluwer Health/Lippincott Williams &amp; Wilkins. Copyright ©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76557 Version 2.0</div></div></div>"},"76558":{"type":"graphic_algorithm","displayName":"Clinical testing for pemphigoid","title":"Clinical testing algorithm for bullous pemphigoid and mucous membrane pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 633px\" class=\"figure\"><div class=\"ttl\">Clinical testing algorithm for bullous pemphigoid and mucous membrane pemphigoid</div><div class=\"cntnt\"><img style=\"width:613px; height:739px;\" src=\"images/DERM/76558_Clinicaltestpemphigoid.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thin dashed lines represent negative. Larger dashed lines represent specimen tests. Solid lines represent positive.</div><div class=\"graphic_footnotes\">BMZ: basement membrane zone; DIF: direct immunofluorescence; ELISA: enzyme-linked immunosorbent assay; H&amp;E: hematoxylin and eosin histology stain; IIF: indirect immunofluorescence.</div><div id=\"graphicVersion\">Graphic 76558 Version 5.0</div></div></div>"},"76559":{"type":"graphic_algorithm","displayName":"Emergency department sedation of ventilated adults","title":"Emergency department sedation of ventilated adults","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Emergency department sedation of ventilated adults</div><div class=\"cntnt\"><img style=\"width:575px; height:620px;\" src=\"images/EM/76559_Algorithm_for_ED_sedation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is a general guideline for the use of analgesics and sedatives. Refer to the text for clinical and pharmacologic issues that dictate optimal drug selection, recommended assessment scales, and precautions for patient monitoring. Doses are approximate for a 70-kg adult.</div><div class=\"graphic_footnotes\">IVP: intravenous push.<br>* Numeric rating scale or other pain scale.<br>• Riker Sedation-Agitation Scale or other sedation scale.<br>Δ Confusion Assessment Method for the ICU.</div><div class=\"graphic_reference\">Adapted from: Jacobi, J, Fraser, GL, Coursin, DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002; 30:119. Official Journal of the Society of Critical Care Medicine, Copyright © 2002 Society of Critical Care Medicine.</div><div id=\"graphicVersion\">Graphic 76559 Version 2.0</div></div></div>"},"76560":{"type":"graphic_table","displayName":"History ill appearing infant","title":"Linking history and diagnosis in the ill-appearing infant","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Linking history and diagnosis in the ill-appearing infant</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">History</td> <td class=\"subtitle1\">Associated diagnosis or diagnoses</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Fever </li> </ul> </td> <td> <ul> <li>Bacterial or viral infection </li> <li>Child abuse with intracranial bleeding </li> <li>Bowel perforation from an underlying surgical condition* </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Mother with genital lesions </li> </ul> </td> <td> <ul> <li>Herpes simplex virus infection </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Coma or seizures developing shortly after transition from breast to formula feeding </li> </ul> </td> <td> <ul> <li>Inborn errors of metabolism<sup>&#182;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Cough </li> </ul> </td> <td> <ul> <li>Pneumonia </li> <li>Bronchiolitis<sup>&#916;</sup> </li> <li>Pertussis<sup>&#916;</sup> </li> <li>Congenital heart disease with heart failure </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Cyanosis, tachypnea, and/or diaphoresis with feeding </li> </ul> </td> <td> <ul> <li>Congenital heart disease </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Afebrile, breastfed baby with decreased feeding, constipation, floppiness, and progressive weakness </li> </ul> </td> <td> <ul> <li>Infant botulism </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Bilious vomiting </li> </ul> </td> <td> <ul> <li>Bowel obstruction due to surgical conditions* </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Projectile nonbilious vomiting </li> </ul> </td> <td> <ul> <li>Pyloric stenosis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Abdominal distension with infrequent or no stooling </li> </ul> </td> <td> <ul> <li>Bowel obstruction due to surgical conditions* </li> <li>Hirschsprung disease </li> <li>Meconium ileus from cystic fibrosis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Not using an extremity </li> </ul> </td> <td> <ul> <li>Child abuse with a long bone fracture </li> <li>Osteomyelitis (fever typically present) </li> <li>Septic arthritis (fever typically present) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Unusual urine odor </li> </ul> </td> <td> <ul> <li>Inborn errors of metabolism<sup>&#182;</sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Surgical conditions in ill-appearing young infants that may cause bowel perforation included intestinal malrotation with volvulus, congenital aganglionic megacolon (Hirschsprung disease), incarcerated hernia, necrotizing enterocolitis, and neonatal appendicitis.<br />¶ Refer to UpToDate topics on and graphics on inborn errors of metabolism for more specific features.<br />Δ Young infants may present with apnea before respiratory symptoms or signs are prominent.</div><div id=\"graphicVersion\">Graphic 76560 Version 5.0</div></div></div>"},"76564":{"type":"graphic_figure","displayName":"Bimodal distribution of organ failure in pancreatitis","title":"Bimodal distribution of organ failure in pancreatitis","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Bimodal distribution of organ failure in pancreatitis</div><div class=\"cntnt\"><img style=\"width:480px; height:258px;\" src=\"images/SURG/76564_Bimod_distr_org_fail_pancr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bimodal distribution of organ failure in severe acute pancreatitis showing the early organ failure attributable to systemic inflammatory response syndrome and the liberation of inflammatory cytokines and the late organ failure predominately attributable to infection in necrosis and sepsis.</div><div id=\"graphicVersion\">Graphic 76564 Version 2.0</div></div></div>"},"76565":{"type":"graphic_picture","displayName":"Syringohydromyelia","title":"External appearances of hydromyelic and normal embryos","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">External appearances of hydromyelic and normal embryos</div><div class=\"cntnt\"><img style=\"width:542px; height:539px;\" src=\"images/PEDS/76565_Syringohydromyelia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Frontal view of an embryo with a hydromyelic change at the level of lower limb buds (arrowhead).<br> (B) A closer view of the caudal part of the same embryo, showing the dilated neural tube.<br> (C) The caudal part of a normal embryo at the same stage of development.<br> (D, E) Caudal views of embryos with the dilated caudal neural tube at a slightly later stage of development.<br> (F) The caudal part of a normal embryo in the same stage of development.</div><div class=\"graphic_reference\">Reproduced from: Ikenouchi J, Uwabe C, Nakatsu T, et al. Embryonic hydromyelia: cystic dilation of the lumbosacral neural tube in human embryos. Acta Neuropathol 2002; 103:248, with kind permission from Springer Science + Business Media B.V. Copyright © 2002.</div><div id=\"graphicVersion\">Graphic 76565 Version 5.0</div></div></div>"},"76566":{"type":"graphic_picture","displayName":"Dyskeratosis congenita","title":"Clinical features of dyskeratosis congenita","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Clinical features of dyskeratosis congenita</div><div class=\"cntnt\"><img style=\"width:494px; height:514px;\" src=\"images/PEDS/76566_Dyskeratosis_congenita.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photographs showing the classical mucocutaneous features of dyskeratosis congenita: (A) tongue leucoplakia, (B) nail dystrophy, (C and D) reticular skin pigmentation.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76566 Version 3.0</div></div></div>"},"76568":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound image of umbilical cord pseudocyst","title":"Prenatal ultrasound image of umbilical cord pseudocyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound image of umbilical cord pseudocyst</div><div class=\"cntnt\"><img style=\"width:331px; height:514px;\" src=\"images/OBGYN/76568_US_umbil_cord_pseudocyst2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Multiple umbilical cord pseudocysts in a fetus with trisomy 18.<br> (Panel B) Color Doppler imaging depicts the vascular component of the umbilical cord.</div><div id=\"graphicVersion\">Graphic 76568 Version 2.0</div></div></div>"},"76569":{"type":"graphic_picture","displayName":"Purpura annularis telangiectodes","title":"Purpura annularis telangiectodes (Majocchi's disease)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Purpura annularis telangiectodes (Majocchi's disease)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/76569_Purp_annular_telan_Majocchi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular purpuric patches are present on the leg.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76569 Version 2.0</div></div></div>"},"76570":{"type":"graphic_diagnosticimage","displayName":"RML RLL atelectasis-I","title":"Frontal chest radiograph demonstrates combined atelectasis of the right middle and lower lobes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Frontal chest radiograph demonstrates combined atelectasis of the right middle and lower lobes</div><div class=\"cntnt\"><img style=\"width:432px; height:432px;\" src=\"images/PULM/76570_RML_RLL_atelectasis-I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The minor fissure (arrowhead) forms an interface with the hyperexpanded right upper lobe. The right heart border, right hemidiaphragm and the descending right pulmonary artery are obscured. Arrows denote the major fissure and the asterisk marks the upper triangle sign.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 76570 Version 3.0</div></div></div>"},"76571":{"type":"graphic_diagnosticimage","displayName":"Sequestration CXR III","title":"Intralobar sequestration right lower lobe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intralobar sequestration right lower lobe</div><div class=\"cntnt\"><img style=\"width:360px; height:393px;\" src=\"images/PULM/76571_Sequestration_CXR_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph shows a mass at the right base, which obscures the right hemidiaphragm.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 76571 Version 2.0</div></div></div>"},"76572":{"type":"graphic_figure","displayName":"Platelet adhesion and aggregation","title":"Platelet adhesion and aggregation","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Platelet adhesion and aggregation</div><div class=\"cntnt\"><img style=\"width:482px; height:219px;\" src=\"images/CARD/76572_Platelet_adherence_wall_inj.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Platelet adherence at a site of vessel wall injury is mediated by von Willebrand factor (vWF) via its interaction with platelet surface receptor glycoprotein (GP) Ib/IX. Platelet aggregation requires fibrinogen (Fgn) bridging that occurs at the GP IIb/IIIa receptor.</div><div id=\"graphicVersion\">Graphic 76572 Version 2.0</div></div></div>"},"76573":{"type":"graphic_picture","displayName":"Lichen sclerosis et atrophicus","title":"Lichen sclerosis et atrophicus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen sclerosis et atrophicus</div><div class=\"cntnt\"><img style=\"width:322px; height:324px;\" src=\"images/RHEUM/76573_Lichen_sclerosis_et_atrophi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White atrophic plaque with a violaceous border that is characteristic of lichen sclerosis et atrophicus.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 76573 Version 1.0</div></div></div>"},"76574":{"type":"graphic_diagnosticimage","displayName":"Mesenteric swirl","title":"Mesenteric swirl","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mesenteric swirl</div><div class=\"cntnt\"><img style=\"width:360px; height:276px;\" src=\"images/SURG/76574_Mesenteric_swirl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is a 39-year-old woman presenting with abdominal pain following gastric bypass surgery. The patient was diagnosed with an internal hernia through the mesenteric defect at the enteroenterostomy.<br />The enhanced transverse CT scan through mesentery shows swirled appearance of mesenteric vessels (arrows) in superior mesenteric artery region. Associated mild mesenteric edema appears as increased attenuation of mesenteric fat.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Lockhart ME, Tessler FN, Canon C, et al. Internal hernia after gastric bypass: Sensitivity and specificity of seven CT signs with surgical correlation and controls. Am J Roentgenol 2007; 188:745. Reprinted with permission from: the American Journal of Roentgenology. Copyright &copy; 2007 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 76574 Version 17.0</div></div></div>"},"76575":{"type":"graphic_diagnosticimage","displayName":"Breast MRI of contralateral breast cancer","title":"Breast MRI of contralateral breast cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Breast MRI of contralateral breast cancer</div><div class=\"cntnt\"><img style=\"width:259px; height:586px;\" src=\"images/SURG/76575_Breast_MRI_contr_br_cx_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Breast MRI can be used to diagnose contralateral disease in newly diagnosed breast cancer patients. This series depicts a patient with right breast cancer detected on mammography.<br />(A) Architectural distortion was detected in the right breast on screening mammography.<br />(B) Ultrasound demonstrated a solid mass on the right and biopsy under ultrasound-guidance confirmed invasive ductal carcinoma.<br />(C) Preoperative MRI confirmed the biopsy clip within the proven cancer in the right breast.<br />(D) MRI also showed a suspicious lesion in the left breast that was not seen on mammography.<br />(E) Second look ultrasound revealed an irregular solid mass on the left and subsequent biopsy showed an invasive ductal cancer, confirming contralateral disease.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 76575 Version 7.0</div></div></div>"},"76576":{"type":"graphic_figure","displayName":"Nutrition label PI","title":"Nutrition label: Counting carbohydrates","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">Nutrition label: Counting carbohydrates</div><div class=\"cntnt\"><img style=\"width:579px; height:487px;\" src=\"images/PI/76576_Nutrition_label_PI_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To figure out the \"carb count\" in 1 serving (1 cup), start with the number of grams of total carbohydrates (46 grams), then subtract the number of grams of dietary fiber (7 grams). In this example, the carb count is <STRONG>39 grams</STRONG>. Use this number when counting carbs for your insulin dose.</div><div id=\"graphicVersion\">Graphic 76576 Version 6.0</div></div></div>"},"76577":{"type":"graphic_figure","displayName":"Upper body weight routine","title":"Upper body weight routine","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Upper body weight routine</div><div class=\"cntnt\"><img style=\"width:549px; height:186px;\" src=\"images/PC/76577_Upper_body_weight_routine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Curls/palms up.<br />(B) Reverse curls/palms down.<br />(C) Bent knee over rows.<br />(D) Tricep kick-backs.<br />(E) Side lift.<br />(F) Military press.</div><div id=\"graphicVersion\">Graphic 76577 Version 3.0</div></div></div>"},"76579":{"type":"graphic_table","displayName":"Dyspnea patient questionnaire","title":"Dyspnea questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dyspnea questionnaire</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Please select up to three phrases that best describe your breathing discomfort. If you choose more than one phrase, please also note the phrase that most closely describes the sensation you feel. If none of these phrases applies, please write in your own description of your breathing discomfort.</td>\n</tr>\n<tr>\n<td>My breathing is shallow.</td>\n</tr>\n<tr>\n<td>I feel an urge to breathe more.</td>\n</tr>\n<tr>\n<td>My chest is constricted.</td>\n</tr>\n<tr>\n<td>My breathing requires effort.</td>\n</tr>\n<tr>\n<td>I feel a hunger for more air.</td>\n</tr>\n<tr>\n<td>I feel out of breath.</td>\n</tr>\n<tr>\n<td>I cannot get enough air.</td>\n</tr>\n<tr>\n<td>My breath does not go in all the way.</td>\n</tr>\n<tr>\n<td>My chest feels tight.</td>\n</tr>\n<tr>\n<td>My breathing requires work.</td>\n</tr>\n<tr>\n<td>I feel that I am smothering/suffocating.</td>\n</tr>\n<tr>\n<td>I feel that I cannot get a deep breath.</td>\n</tr>\n<tr>\n<td>I feel that I am breathing more.</td>\n</tr>\n<tr>\n<td>My breath does not go out all the way.</td>\n</tr>\n<tr>\n<td>My breathing is heavy.</td>\n</tr>\n<tr>\n<td>Other descriptions:</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 76579 Version 1.0</div></div></div>"},"76580":{"type":"graphic_picture","displayName":"KS invasion of bronchial wall","title":"Endobronchial Kaposi sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endobronchial Kaposi sarcoma</div><div class=\"cntnt\"><img style=\"width:332px; height:246px;\" src=\"images/PULM/76580_KS_invasion_of_bronchial_wa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph shows dark, hemorrhagic Kaposi sarcoma tissue (arrow) lining and invading the bronchial mucosa.</div><div class=\"graphic_reference\">From Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.</div><div id=\"graphicVersion\">Graphic 76580 Version 2.0</div></div></div>"},"76582":{"type":"graphic_figure","displayName":"Hypospadias 2 stage repair 1","title":"Stage one of two-stage hypospadias repair","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Stage one of two-stage hypospadias repair</div><div class=\"cntnt\"><img style=\"width:516px; height:660px;\" src=\"images/PEDS/76582_Hypospadias2stagerepair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The first stage includes correction of penile curvature and transfer of dorsal foreskin to the ventral aspect of the penis. <br />(A) Scrotal hypospadias with penile curvature. <br />(B) Initial dissection removing ventral tethering urethral plate tissue. <br />(C) Penile straightening with dorsal plication. <br />(D) Confirmation of a straight penis with artificial saline erection. <br />(E) In select cases, part of urethral plate can be preserved. <br />(F) The dorsal skin is split and wrapped to the ventrum. <br />(G) First stage complete with temporary catheter in the urethral meatus at the penile scrotal junction.</div><div class=\"graphic_reference\">Figure modified from TTMed (Timely Topics in Medicine)-Urology USA. Copyright © 2009 Prous Science S.A.U. or its licensors. All rights reserved.</div><div id=\"graphicVersion\">Graphic 76582 Version 3.0</div></div></div>"},"76583":{"type":"graphic_table","displayName":"Inotropic drugs","title":"Drugs with inotropic and vasopressive effects used for management of a potential pediatric organ donor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs with inotropic and vasopressive effects used for management of a potential pediatric organ donor</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td> <p><strong>Milrinone</strong></p> <p>&nbsp;</p> </td> <td>0.25 to 0.75 micrograms/kg per minute IV</td> <td> <p>Loading dose: 50 micrograms/kg</p> <p>Hypotension can occur</p> </td> </tr> <tr> <td><strong>Dopamine</strong></td> <td>2 to 20 micrograms/kg per minute IV</td> <td>Titrate to desired blood pressure</td> </tr> <tr> <td> <p><strong>Dobutamine</strong></p> <p>&nbsp;</p> </td> <td>2 to 20 micrograms/kg per minute IV</td> <td>Titrate to desired blood pressure</td> </tr> <tr> <td><strong>Epinephrine</strong></td> <td>0.1 to 1 micrograms/kg per minute IV</td> <td>Titrate to desired blood pressure</td> </tr> <tr> <td> <p><strong>Norepinephrine</strong></p> <p>&nbsp;</p> </td> <td>0.05 to 2 micrograms/kg per minute IV</td> <td>Titrate to desired blood pressure</td> </tr> <tr> <td> <p><strong>Phenylephrine</strong></p> <p>&nbsp;</p> </td> <td>0.1 to 0.5 micrograms/kg per minute IV</td> <td> <p>Bolus: 5 to 20 micrograms/kg</p> <p>Titrate to desired blood pressure</p> </td> </tr> <tr> <td> <p><strong>Vasopressin</strong></p> <p>&nbsp;</p> </td> <td> <p>0.3 to 2 <strong>milli</strong>units/kg per minute IV</p> <p><strong>Note: Dosing is different for treatment of diabetes insipidus</strong></p> </td> <td> <p>Limited data in children</p> <p>Not recommended as first-line therapy</p> <p>Titrate to desired blood pressure</p> </td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">Inotropic agents are used for low cardiac output states to improve end organ perfusion. These agents should be titrated to maintain a normal blood pressure for age. Blood pressure alone does not indicate adequate tissue perfusion. Serum biomarkers such as lactate should be followed as inotropic support is titrated.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: Intravenous</div><div class=\"graphic_reference\">Reproduced with permission from: Nakagawa, TA. Pediatric donor management guidelines. NATCO, The Organization for Transplant Professionals, 2008. p.5.</div><div id=\"graphicVersion\">Graphic 76583 Version 4.0</div></div></div>"},"76584":{"type":"graphic_form","displayName":"Parent questionnaire C","title":"Questionnaire for parents (continued)","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Questionnaire for parents (continued)</div><div class=\"cntnt\"><img style=\"width:495px; height:657px;\" src=\"images/PEDS/76584_Parent_questionnaire_C.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Speech-Language Pathology Department, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 76584 Version 2.0</div></div></div>"},"76585":{"type":"graphic_table","displayName":"Signs symptoms lead toxicity","title":"Signs and symptoms of lead toxicity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms of lead toxicity</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Lowest exposure: Impaired abilities (patients may be asymptomatic)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Decreased learning and memory</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Decreased verbal ability</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Early signs of hyperactivity or ADHD</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lowered IQ</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Impaired speech and hearing functions</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Low exposure\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Myalgia or paresthesia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Mild fatigue</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Irritability</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lethargy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Occasional abdominal discomfort</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Moderate exposure\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Arthralgia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>General fatigue</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Difficulty concentrating</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Muscular exhaustibility</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Tremor</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Headache</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Diffuse abdominal pain</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Vomiting</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Weight loss</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Constipation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   High exposure\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Paresis or paralysis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Encephalopathy\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   May abruptly lead to seizures, changesin consciousness, coma, and death\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lead line (blue-black) on gingival tissue</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Colic (intermittent, severe abdominal cramps)</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=55902&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Signs_symptoms_lead_toxicit.htm</title></head></div><div class=\"graphic_reference\">Reproduced from: Environmental Health and Medicine Education. Lead Toxicity: How should patients exposed to lead be evaluated? Agency for Toxic Substances &amp; Disease Registry. Available at: <A spellcheck=true href=\"http://www.atsdr.cdc.gov/csem/csem.asp?csem=7&amp;po=11\"target=_blank>http://www.atsdr.cdc.gov/csem/csem.asp?csem=7&amp;po=11</A>.</div><div id=\"graphicVersion\">Graphic 76585 Version 2.0</div></div></div>"},"76586":{"type":"graphic_table","displayName":"Amount of topical medications","title":"Amount of topical medication for adult use","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Amount of topical medication for adult use</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Twice daily/One week</td> <td class=\"subtitle1\">Three times daily/Two weeks</td> <td class=\"subtitle1\">Twice daily/Four weeks</td> </tr> <tr> <td>Face and neck</td> <td>15 g</td> <td>45 g</td> <td>60 g</td> </tr> <tr> <td>Trunk</td> <td>60 g</td> <td>180 g</td> <td>240 g</td> </tr> <tr> <td>One arm</td> <td>15 g</td> <td>45 g</td> <td>60 g</td> </tr> <tr> <td>One leg</td> <td>30 g</td> <td>90 g</td> <td>120 g</td> </tr> <tr> <td>Hands and feet</td> <td>15 g</td> <td>45 g</td> <td>60 g</td> </tr> <tr> <td>Body</td> <td>180 g</td> <td>0.75 to 1 kg</td> <td>1.25 to 2 kg</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For children use one-third to one-half these amounts.</div><div class=\"graphic_reference\">Adapted from: Goldstein BG, Goldstein AO, Practical Dermatology 2nd ed, Mosby-Year Book, Inc, St. Louis, MO, 1997.</div><div id=\"graphicVersion\">Graphic 76586 Version 5.0</div></div></div>"},"76587":{"type":"graphic_figure","displayName":"Axon terminal and synapse","title":"The axon terminal and the synapse","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">The axon terminal and the synapse</div><div class=\"cntnt\"><img style=\"width:490px; height:458px;\" src=\"images/PC/76587_Axon_terminal_and_synapse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axon terminals form synapses with the dendrites or somata of other neurons. When a nerve impulse arrives in the presynaptic axon terminal, neurotransmitter molecules are released from synaptic vesicles into the synaptic cleft. Neurotransmitter then binds to specific receptor proteins, causing the generation of electrical or chemical signals in the postsynaptic cell.</div><div class=\"graphic_reference\">Reproduced with permission from: Bear MF, Connors BW, and Parasido, MA. Neuroscience - Exploring the Brain, 2nd ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &#169;2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76587 Version 1.0</div></div></div>"},"76588":{"type":"graphic_picture","displayName":"NI secretory endometrium","title":"Secretory endometrium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Secretory endometrium</div><div class=\"cntnt\"><img style=\"width:360px; height:288px;\" src=\"images/OBGYN/76588_NI_secretory_endometrium.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note tortuous glands, subnuclear vacuoles, without glandular crowding.</div><div class=\"graphic_reference\">Courtesy of Russell S Vang, MD.</div><div id=\"graphicVersion\">Graphic 76588 Version 1.0</div></div></div>"},"76589":{"type":"graphic_table","displayName":"Umbilical cord length","title":"Normal umbilical cord length","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal umbilical cord length</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Gestation, weeks</td>\n<td class=\"subtitle1\">Length, cm</td>\n</tr>\n<tr>\n<td>20</td>\n<td>32 +/- 9</td>\n</tr>\n<tr>\n<td>24</td>\n<td>40 +/- 10</td>\n</tr>\n<tr>\n<td>28</td>\n<td>45 +/- 10</td>\n</tr>\n<tr>\n<td>32</td>\n<td>50 +/- 12</td>\n</tr>\n<tr>\n<td>36</td>\n<td>56 +/- 13</td>\n</tr>\n<tr>\n<td>38</td>\n<td>57 +/- 13</td>\n</tr>\n<tr>\n<td>40</td>\n<td>60 +/- 13</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=44935&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Umbilical_cord_length.htm</title></head></div><div class=\"graphic_reference\">Data from: Naeye RL. Umbilical cord length: clinical significance. J Pediatr 1985; 107:278. </div><div id=\"graphicVersion\">Graphic 76589 Version 2.0</div></div></div>"},"76591":{"type":"graphic_table","displayName":"Hodgkin classification","title":"Classification of Hodgkin lymphomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of Hodgkin lymphomas</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Jackson and Parker\n   </td>\n   <td  class=\"subtitle1\">\n   Lukes and Butler\n   </td>\n   <td  class=\"subtitle1\">\n   Rye Conference\n   </td>\n   <td  class=\"subtitle1\">\n   R.E.A.L. Classification\n   </td>\n   <td  class=\"subtitle1\">\n   World Health Organization (WHO) Classification\n   </td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Paragranuloma\n   </td>\n   <td>Lymphocytic and/or histiocytic, nodular</td>\n   <td>Lymphocyte predominance</td>\n   <td>Nodular lymphocyte predominance</td>\n   <td>Nodular lymphocyte predominant HL</td>\n   </tr>\n   <tr>\n   <td>Lymphocytic and/or histiocytic, diffuse</td>\n   <td>&nbsp;</td>\n   <td>Classical Lymphocyte-rich HL*</td>\n   <td>Lymphocyte-rich classical HL</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Granuloma\n   </td>\n   <td>Nodular sclerosis</td>\n   <td>Nodular sclerosis</td>\n   <td>Classical Nodular sclerosis HL</td>\n   <td>Nodular sclerosis classical HL</td>\n   </tr>\n   <tr>\n   <td>Mixed cellularity</td>\n   <td>Mixed cellularity</td>\n   <td>Classical Mixed cellularity HL</td>\n   <td>Mixed cellularity classical HL</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Sarcoma\n   </td>\n   <td>Diffuse fibrosis</td>\n   <td>Lymphocyte depletion</td>\n   <td>Classical Lymphocyte depletion HL</td>\n   <td>Lymphocyte depleted classical HL</td>\n   </tr>\n   <tr>\n   <td>Reticular</td>\n   <td>&nbsp;</td>\n   <td>&nbsp;</td>\n   <td>&nbsp;</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">HL: Hodgkin lymphoma.<br>* Includes some L&amp;H nodular cases.</div><div id=\"graphicVersion\">Graphic 76591 Version 1.0</div></div></div>"},"76593":{"type":"graphic_table","displayName":"Causes of facial palsy","title":"Causes of facial palsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of facial palsy</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Idiopathic</td> </tr> <tr> <td class=\"indent1\">Bell's palsy</td> </tr> <tr> <td class=\"indent1\">Melkersson-Rosenthal syndrome (recurrent alternating facial palsy, furrowed tongue, faciolabial edema)</td> </tr> <tr> <td class=\"subtitle1_single\">Congenital</td> </tr> <tr> <td class=\"indent1\">Traumatic</td> </tr> <tr> <td class=\"indent1\">Myotonic dystrophy</td> </tr> <tr> <td class=\"indent1\">Moebius syndrome</td> </tr> <tr> <td class=\"indent1\">Hereditary congenital facial paresis 1</td> </tr> <tr> <td class=\"indent1\">Hereditary congenital facial paresis 2</td> </tr> <tr> <td class=\"indent1\">Hereditary hypertrophic neuropathy</td> </tr> <tr> <td class=\"indent1\">Hemifacial microsomia</td> </tr> <tr> <td class=\"indent1\">Poland syndrome</td> </tr> <tr> <td class=\"indent1\">Teratogenesis</td> </tr> <tr> <td class=\"indent1\">Osteopetrosis</td> </tr> <tr> <td class=\"indent1\">Sclerosing bone dysplasias</td> </tr> <tr> <td class=\"indent1\">Trisomy 13, trisomy 18</td> </tr> <tr> <td class=\"indent1\">Branchio-oto-renal syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Trauma</td> </tr> <tr> <td class=\"indent1\">Basal skull fracture</td> </tr> <tr> <td class=\"indent1\">Penetrating injury to middle ear</td> </tr> <tr> <td class=\"indent1\">Lightning</td> </tr> <tr> <td class=\"indent1\">Barotrauma</td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic</td> </tr> <tr> <td class=\"indent1\">Opercular syndrome (cortical lesion in facial motor area)</td> </tr> <tr> <td class=\"indent1\">Millard-Gubler syndrome</td> </tr> <tr> <td class=\"indent1\">Amyloid neuropathy</td> </tr> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td class=\"indent1\">External otitis</td> </tr> <tr> <td class=\"indent1\">Otitis media</td> </tr> <tr> <td class=\"indent1\">Mastoiditis</td> </tr> <tr> <td class=\"indent1\">Chickenpox</td> </tr> <tr> <td class=\"indent1\">Diphtheria</td> </tr> <tr> <td class=\"indent1\">Herpes zoster cephalicus (Ramsey Hunt syndrome)</td> </tr> <tr> <td class=\"indent1\">Encephalitis</td> </tr> <tr> <td class=\"indent1\">Poliomyelitis (type 1)</td> </tr> <tr> <td class=\"indent1\">Mumps</td> </tr> <tr> <td class=\"indent1\">Mononucleosis</td> </tr> <tr> <td class=\"indent1\">Leprosy</td> </tr> <tr> <td class=\"indent1\">Influenza</td> </tr> <tr> <td class=\"indent1\">Coxsackievirus</td> </tr> <tr> <td class=\"indent1\">Malaria</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> </tr> <tr> <td class=\"indent1\">Tetanus</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"indent1\">Botulism</td> </tr> <tr> <td class=\"indent1\">Acute hemorrhagic conjunctivitis (enterovirus 70)</td> </tr> <tr> <td class=\"indent1\">Gnathostomiasis</td> </tr> <tr> <td class=\"indent1\">Mucormycosis</td> </tr> <tr> <td class=\"indent1\">Lyme disease</td> </tr> <tr> <td class=\"indent1\">Cat scratch</td> </tr> <tr> <td class=\"indent1\">HIV</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Metabolic</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> </tr> <tr> <td class=\"indent1\">Hyperthyroidism</td> </tr> <tr> <td class=\"indent1\">Pregnancy</td> </tr> <tr> <td class=\"indent1\">Hypertension</td> </tr> <tr> <td class=\"indent1\">Vitamin A deficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Neoplastic</td> </tr> <tr> <td class=\"indent1\">Benign lesions of parotid</td> </tr> <tr> <td class=\"indent1\">Cholesteatoma</td> </tr> <tr> <td class=\"indent1\">Seventh nerve tumor</td> </tr> <tr> <td class=\"indent1\">Glomus jugulare tumor</td> </tr> <tr> <td class=\"indent1\">Leukemia</td> </tr> <tr> <td class=\"indent1\">Meningioma</td> </tr> <tr> <td class=\"indent1\">Hemangioblastoma</td> </tr> <tr> <td class=\"indent1\">Sarcoma</td> </tr> <tr> <td class=\"indent1\">Carcinoma (invading or metastatic)</td> </tr> <tr> <td class=\"indent1\">Hemangioma of tympanum</td> </tr> <tr> <td class=\"indent1\">Hydradenoma (external canal)</td> </tr> <tr> <td class=\"indent1\">Schwannoma</td> </tr> <tr> <td class=\"indent1\">Teratoma</td> </tr> <tr> <td class=\"indent1\">Langerhans cell histiocytosis</td> </tr> <tr> <td class=\"indent1\">Fibrous dysplasia</td> </tr> <tr> <td class=\"indent1\">Neurofibromatosis</td> </tr> <tr> <td class=\"subtitle1_single\">Vascular</td> </tr> <tr> <td class=\"indent1\">Anomalous sigmoid sinus</td> </tr> <tr> <td class=\"indent1\">Carotid artery aneurysm</td> </tr> <tr> <td class=\"subtitle1_single\">Toxic</td> </tr> <tr> <td class=\"indent1\">Thalidomide</td> </tr> <tr> <td class=\"indent1\">Ethylene glycol</td> </tr> <tr> <td class=\"indent1\">Alcoholism</td> </tr> <tr> <td class=\"indent1\">Arsenic intoxication</td> </tr> <tr> <td class=\"indent1\">Carbon monoxide</td> </tr> <tr> <td class=\"subtitle1_single\">Iatrogenic</td> </tr> <tr> <td class=\"indent1\">Mandibular block anesthesia</td> </tr> <tr> <td class=\"indent1\">Antitetanus serum</td> </tr> <tr> <td class=\"indent1\">Vaccine treatment for rabies</td> </tr> <tr> <td class=\"indent1\">Postimmunization</td> </tr> <tr> <td class=\"indent1\">Parotid surgery</td> </tr> <tr> <td class=\"indent1\">Mastoid surgery</td> </tr> <tr> <td class=\"indent1\">Posttonsillectomy and adenoidectomy</td> </tr> <tr> <td class=\"indent1\">Iontophoresis (local anesthesia)</td> </tr> <tr> <td class=\"indent1\">Embolization</td> </tr> <tr> <td class=\"indent1\">Dental</td> </tr> <tr> <td class=\"subtitle1_single\">Autoimmune syndrome</td> </tr> <tr> <td class=\"indent1\">Temporal arteritis</td> </tr> <tr> <td class=\"indent1\">Thrombotic thrombocytopenic purpura</td> </tr> <tr> <td class=\"indent1\">Periarteritis nodosa</td> </tr> <tr> <td class=\"indent1\">Guillain-Barr&#233; syndrome</td> </tr> <tr> <td class=\"indent1\">Multiple sclerosis</td> </tr> <tr> <td class=\"indent1\">Myasthenia gravis</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Jackson C, von Doersten P. The facial nerve. Current trends in diagnosis, treatment, and rehabilitation. Med Clin North Am 1999; 83:179.</li>&#xD;&#xA;    <li>Shapiro N, Cunningham MJ, Parikh S, et al. Congenital unilateral facial paralysis. Pediatrics 1996; 97:261.</li>&#xD;&#xA;    <li><a href=\"http://www.ncbi.nlm.nih.gov/omim\" target=\"_blank\">Online Mendelian Inheritance in Man</a>.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 76593 Version 6.0</div></div></div>"},"76594":{"type":"graphic_movie","displayName":"Short axis echo 1 HCM","title":"Parasternal short axis echocardiogram in a patient with hypertrophic cardiomyopathy (HCM)","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parasternal short axis echocardiogram in a patient with hypertrophic cardiomyopathy (HCM)</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/76594_shax1hcmconv.mp4\" style=\"width:360px;height:272px\"></div><img style=\"width:360px; height:256px;\" src=\"images/CARD/76594_shax1hcm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short axis view from a two-dimensional echocardiogram shows marked asymmetric hypertrophy of the posterior left ventricular wall and the papillary muscles. During systole, there is near obliteration of the left ventricular cavity.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 76594 Version 4.0</div></div></div>"},"76597":{"type":"graphic_figure","displayName":"Protein filtration in FGS","title":"Mechanism of proteinuria in FGS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mechanism of proteinuria in FGS</div><div class=\"cntnt\"><img style=\"width:413px; height:328px;\" src=\"images/NEPH/76597_Protein_filtration_in_FGS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dextran sieving profiles in patients with heavy proteinuria and the nephrotic syndrome due to focal glomerulosclerosis (FGS). A fractional dextran clearance of 1 represents complete filtration. Patients with FGS have decreased clearance of smaller dextrans, but increased clearance of dextrans with a radius above 52 Å, suggesting an increased number of larger pores.</div><div class=\"graphic_reference\">Data from Guasch A, Hashimoto H, Sibley RK, et al. Am J Physiol 1991; 260:F728.</div><div id=\"graphicVersion\">Graphic 76597 Version 2.0</div></div></div>"},"76598":{"type":"graphic_figure","displayName":"Breech extraction of a fetus originally in transverse lie","title":"Breech extraction of a fetus originally in transverse lie","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Breech extraction of a fetus originally in transverse lie</div><div class=\"cntnt\"><img style=\"width:393px; height:489px;\" src=\"images/OBGYN/76598_Breech_extraction_of_a_fetus_originally_in_transverse_lie.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After external version from transverse lie to breech, the fetus is extracted in the breech presentation by the operator, while the assistant continuously holds the fetus in longitudinal position.</div><div id=\"graphicVersion\">Graphic 76598 Version 4.0</div></div></div>"},"76600":{"type":"graphic_picture","displayName":"Agar colonies P marneffei","title":"Colonies of <em>Penicillium marneffei</em> mycelia after incubating at 25°C on Sabouraud dextrose agar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colonies of <em>Penicillium marneffei</em> mycelia after incubating at 25&#176;C on Sabouraud dextrose agar</div><div class=\"cntnt\"><img style=\"width:396px; height:315px;\" src=\"images/ID/76600_Agar_colonies_P_marneffei.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drs. Khuanchai Supparatpinyo and Thira Sirisanthana.</div><div id=\"graphicVersion\">Graphic 76600 Version 1.0</div></div></div>"},"76601":{"type":"graphic_movie","displayName":"Mitral valve prolapse bileaflet four chamber echocardiogram","title":"Mitral valve prolapse","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral valve prolapse</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/76601_4chmvpbiconv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:245px; height:433px;\" src=\"images/CARD/76601_4chmvpbi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four chamber view from a 2-D echocardiogram shows mild prolapse of both anterior and posterior leaflets of the mitral valve. The leaflets are thickened and show redundancy. The left atrium and ventricle are slightly dilated, suggesting the presence of mitral regurgitation.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 76601 Version 3.0</div></div></div>"},"76602":{"type":"graphic_picture","displayName":"BRAO cholesterol plaque","title":"Cholesterol plaque embolus causing branch retinal artery occlusion","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Cholesterol plaque embolus causing branch retinal artery occlusion</div><div class=\"cntnt\"><img style=\"width:516px; height:169px;\" src=\"images/NEURO/76602_BRAO_cholesterol_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Cholesterol plaque in a branch retinal artery. B) The cholesterol plaque has moved through the retinal circulation and is no longer visible.</div><div id=\"graphicVersion\">Graphic 76602 Version 2.0</div></div></div>"},"76604":{"type":"graphic_table","displayName":"Differential diagnosis of acquired torticollis in children","title":"Differential diagnosis of acquired torticollis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of acquired torticollis in children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Trauma</td> </tr> <tr> <td class=\"indent1\">C1-C2 subluxation</td> </tr> <tr> <td class=\"indent1\">C1-C2 dislocation</td> </tr> <tr> <td class=\"indent1\">Clavicle fracture</td> </tr> <tr> <td class=\"indent1\">Cervical spine fracture</td> </tr> <tr> <td class=\"indent1\">Muscle injury</td> </tr> <tr> <td class=\"indent1\">Ligamentous injury</td> </tr> <tr> <td class=\"indent1\">Spinal epidural hematoma</td> </tr> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td class=\"indent1\">Upper respiratory infection</td> </tr> <tr> <td class=\"indent1\">Cervical adenitis</td> </tr> <tr> <td class=\"indent1\">Pharyngitis</td> </tr> <tr> <td class=\"indent1\">Retropharyngeal abscess</td> </tr> <tr> <td class=\"indent1\">Upper lobe pneumonia</td> </tr> <tr> <td class=\"indent1\">Cervical osteomyelitis</td> </tr> <tr> <td class=\"indent1\">Cervical diskitis</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"indent1\">Lemierre syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Tumors</td> </tr> <tr> <td class=\"indent1\">Posterior fossa</td> </tr> <tr> <td class=\"indent1\">Intraspinal</td> </tr> <tr> <td class=\"indent1\">Osteoid osteoma</td> </tr> <tr> <td class=\"indent1\">Eosinophilic granuloma</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Neurogenic</td> </tr> <tr> <td class=\"indent1\">Myasthenia gravis</td> </tr> <tr> <td class=\"indent1\">Poliomyelitis</td> </tr> <tr> <td class=\"indent1\">Dystonia</td> </tr> <tr> <td class=\"indent1\">Kernicterus</td> </tr> <tr> <td class=\"indent1\">Huntington chorea</td> </tr> <tr> <td class=\"indent1\">Wilson disease</td> </tr> <tr> <td class=\"indent1\">Neuritis of spinal accessory nerve</td> </tr> <tr> <td class=\"subtitle1_single\">Ocular</td> </tr> <tr> <td class=\"indent1\">Superior oblique palsy</td> </tr> <tr> <td class=\"indent1\">Congenital nystagmus</td> </tr> <tr> <td class=\"indent1\">Refractive errors</td> </tr> <tr> <td class=\"indent1\">Strabismus</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Myositis or fibromyositis</td> </tr> <tr> <td class=\"indent1\">Gastroesophageal reflux</td> </tr> <tr> <td class=\"indent1\">Juvenile idiopathic arthritis</td> </tr> <tr> <td class=\"indent1\">Spasmus nutans</td> </tr> <tr> <td class=\"indent1\">Benign paryoxysmal torticollis</td> </tr> <tr> <td class=\"indent1\">Drug-induced</td> </tr> <tr> <td class=\"indent1\">Ligamentous laxity</td> </tr> <tr> <td class=\"indent1\">Functional torticollis</td> </tr> <tr> <td class=\"indent1\">Polymyositis</td> </tr> <tr> <td class=\"indent1\">Calcification of the intervertebral disks</td> </tr> <tr> <td class=\"indent1\">Idiopathic intracranial hypertension (pseudotumor cerebri)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Torticollis. In: Signs and symptoms in pediatrics, 3rd ed, Tunnessen WW, Roberts KB (Eds), Lippincott, Williams and Wilkins, Philadelphia, 1999. p.353.</div><div id=\"graphicVersion\">Graphic 76604 Version 6.0</div></div></div>"},"76605":{"type":"graphic_figure","displayName":"Holter monitor PI","title":"Holter monitor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Holter monitor</div><div class=\"cntnt\"><img style=\"width:322px; height:494px;\" src=\"images/PI/76605_Holter_monitor_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">People with possible heart problems are sometimes asked to wear a device called a Holter monitor for 1 or 2 days. The device measures the electrical activity in the heart. It helps doctors pinpoint heart rhythm problems. You will have \"electrodes\" stuck to your chest that are connected to wires leading to the monitor. These electrodes tell the monitor how often your heart beats and if it has a normal rhythm. While you have a Holter monitor on, you should do your normal activities but keep the electrodes, wires, and device dry. Some people have an abnormal heart rhythm only during certain activities or certain times of the day.</div><div id=\"graphicVersion\">Graphic 76605 Version 8.0</div></div></div>"},"76606":{"type":"graphic_table","displayName":"Vitamins PN preterm infant","title":"Suggested intakes of vitamins for premature infants receiving parenteral nutrition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested intakes of vitamins for premature infants receiving parenteral nutrition</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Vitamin</td> <td class=\"subtitle1\">Current regimen based upon pediatric multivitamin formulation*<br /> (unit/kg/day)</td> <td class=\"subtitle1\">Estimate based upon the needs of premature infants<br /> (unit/kg/day)</td> <td class=\"subtitle1\">Maximum not to exceed term infant<br /> (unit/day)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Fat-soluble vitamins</td> </tr> <tr> <td class=\"indent1\">A (microg)<sup>&#182;</sup></td> <td class=\"centered\">280</td> <td class=\"centered\">500</td> <td class=\"centered\">700</td> </tr> <tr> <td class=\"indent1\">E (mg)<sup>&#916;</sup></td> <td class=\"centered\">2.8</td> <td class=\"centered\">2.8</td> <td class=\"centered\">7</td> </tr> <tr> <td class=\"indent1\">K (microg)</td> <td class=\"centered\">80</td> <td class=\"centered\">80</td> <td class=\"centered\">200</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">D (microg)<sup>&#9674;</sup></td> <td class=\"centered\">4</td> <td class=\"centered\">4</td> <td class=\"centered\">10</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Water-soluble vitamins</td> </tr> <tr> <td class=\"indent1\">C, Ascorbic acid (mg)</td> <td class=\"centered\">32</td> <td class=\"centered\">25</td> <td class=\"centered\">80</td> </tr> <tr> <td class=\"indent1\">B1, Thiamin (mg)</td> <td class=\"centered\">0.48</td> <td class=\"centered\">0.35</td> <td class=\"centered\">1.2</td> </tr> <tr> <td class=\"indent1\">B2, Riboflavin (mg)</td> <td class=\"centered\">0.56</td> <td class=\"centered\">0.15</td> <td class=\"centered\">1.4</td> </tr> <tr> <td class=\"indent1\">B6, Pyridoxine (mg)</td> <td class=\"centered\">0.4</td> <td class=\"centered\">0.18</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Niacin (mg)</td> <td class=\"centered\">6.8</td> <td class=\"centered\">6.8</td> <td class=\"centered\">17</td> </tr> <tr> <td class=\"indent1\">Pantothenate (mg)</td> <td class=\"centered\">2</td> <td class=\"centered\">2</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"indent1\">Biotin (microg)</td> <td class=\"centered\">8</td> <td class=\"centered\">6</td> <td class=\"centered\">20</td> </tr> <tr> <td class=\"indent1\">Folate (microg)</td> <td class=\"centered\">56</td> <td class=\"centered\">56</td> <td class=\"centered\">140</td> </tr> <tr> <td class=\"indent1\">Vitamin B12 (microg)</td> <td class=\"centered\">0.4</td> <td class=\"centered\">0.3</td> <td class=\"centered\">1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Regimen based upon using 40 percent of a vial of MVI-Pediatric (Mayne Pharma (USA), Inc, Paramus, NJ) per kg body weight or 2 mL/kg/day. Infuvite Pediatric (Sandoz Canada Inc, Boucherville, Quebec, Canada) has composition similar to MVI-Pediatric, with the following exceptions (per 5 mL): aluminum (4.2 versus 0.2 microg) and polysorbate 20 (0 versus 0.8 mg), in Infuvite versus MVI-Pediatric, respectively.<br />¶ 1 microg retinol = 3.33 int. unit vitamin A = 6 microg <SUB>β</SUB>-carotene = 1.83 microg retinyl palmitate = 1 retinol equivalent (RE).<br />Δ 1 mg α-tocopherol = 1 int. unit vitamin E.<br /><FONT class=lozenge>◊</FONT> 1 microg vitamin D (cholecalciferol) = 40 int. unit vitamin D (cholecalciferol).</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Schanler RJ. The low birth weight infant: Perinatal nutrition. In: Nutrition in Pediatrics: Basic Science and Clinical Applications, Walker WA, Watkins JB (Eds), B.C. Decker Inc., Hamilton, Ontario, Canada 1996. p.387.</li>&#xD;&#xA;    <li>Greene HL, Hambidge KM, Schanler RJ, Tsang RC. Guidelines for the use of vitamins, trace elements, calcium, magnesium, and phosphorus in infants and children receiving total parenteral nutrition: report of the Subcommittee on Pediatric Parenteral Nutrient Requirements from the Committee on Clinical Practice Issues of The American Society for Clinical Nutrition. Am J Clin Nutr 1988; 48:1324.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 76606 Version 5.0</div></div></div>"},"76607":{"type":"graphic_picture","displayName":"Exophthalmos trauma","title":"Exophthalmos from trauma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Exophthalmos from trauma</div><div class=\"cntnt\"><img style=\"width:396px; height:321px;\" src=\"images/EM/76607_Exophthalmos_trauma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retrobulbar hemorrhage causing dramatic proptosis and subconjunctival hemorrhage after a fist strike in a man on warfarin.</div><div class=\"graphic_reference\">Reproduced with permission from: Harwood-Nuss, A, Wolfson, AB, et al. The Clinical Practice of Emergency Medicine, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76607 Version 2.0</div></div></div>"},"76609":{"type":"graphic_figure","displayName":"Prepubertal vaginal examination using a Killian nasal speculum ","title":"Vaginal examination of patient under anesthesia, using a Killian nasal speculum with fiberoptic light","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Vaginal examination of patient under anesthesia, using a Killian nasal speculum with fiberoptic light</div><div class=\"cntnt\"><img style=\"width:481px; height:338px;\" src=\"images/PEDS/76609_Killian_nasal_speculum.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 76609 Version 2.0</div></div></div>"},"76610":{"type":"graphic_diagnosticimage","displayName":"Peripheral lung abscesses CT","title":"Lung abscesses","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lung abscesses</div><div class=\"cntnt\"><img style=\"width:378px; height:262px;\" src=\"images/ID/76610_Peripheral_lung_abscesses_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest&nbsp;computed tomography&nbsp;in a patient with hematogenous lung infection due to<EM> Staphylococcus aureu</EM>s. There are multiple peripheral abscesses in both lung fields. The infection arose from a contaminated Hickman catheter.</div><div class=\"graphic_reference\">Courtesy of Jay Fishman, MD.</div><div id=\"graphicVersion\">Graphic 76610 Version 3.0</div></div></div>"},"76612":{"type":"graphic_diagnosticimage","displayName":"Norml umbilical cord insertion color doppler","title":"Color Doppler image of a normal umbilical cord insertion site","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Color Doppler image of a normal umbilical cord insertion site</div><div class=\"cntnt\"><img style=\"width:289px; height:239px;\" src=\"images/OBGYN/76612_Norml_cord_insert_color_dop.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 76612 Version 3.0</div></div></div>"},"76615":{"type":"graphic_table","displayName":"Commonly missed conditions","title":"Commonly missed conditions in patients with intellectual disability","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly missed conditions in patients with intellectual disability</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Psychiatric disorders</td> </tr> <tr> <td>Depression</td> </tr> <tr> <td>Schizophrenia</td> </tr> <tr> <td>Bipolar affective disorder</td> </tr> <tr> <td>Anxiety disorders</td> </tr> <tr> <td>Post-traumatic stress disorder</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal disorders</td> </tr> <tr> <td>Constipation/atonic bowel</td> </tr> <tr> <td>Bowel obstruction</td> </tr> <tr> <td>Reflux oesophagitis</td> </tr> <tr> <td><em>Helicobacter pylori</em> infection</td> </tr> <tr> <td class=\"subtitle1_single\">Undescended testis/hypogonadism</td> </tr> <tr> <td class=\"subtitle1_single\">Unrecognized pain or infection</td> </tr> <tr> <td>Dental pathology</td> </tr> <tr> <td>Chest infection</td> </tr> <tr> <td>Urinary tract infection</td> </tr> <tr> <td class=\"subtitle1_single\">Medication issues</td> </tr> <tr> <td>Overuse of tranquilizers</td> </tr> <tr> <td>Unrecognized side effects of medication</td> </tr> <tr> <td class=\"subtitle1_single\">Epilepsy management</td> </tr> <tr> <td>Inadequate review of anticonvulsant medication</td> </tr> <tr> <td>Failure to consider medication interactions and toxicity</td> </tr> <tr> <td class=\"subtitle1_single\">Sensory impairment</td> </tr> <tr> <td>Hearing impairment</td> </tr> <tr> <td>Visual impairment</td> </tr> <tr> <td>Ear and eye pathology</td> </tr> <tr> <td class=\"subtitle1_single\">Health maintenance activities</td> </tr> <tr> <td>Immunization</td> </tr> <tr> <td>Screening for infectious conditions including hepatitis B</td> </tr> <tr> <td>Nutritional assessment (exclude malnutrition and obesity)</td> </tr> <tr> <td>Breast checks and Pap tests</td> </tr> <tr> <td>Blood pressure and skin checks</td> </tr> <tr> <td>Screening for osteoporosis and vitamin D deficiency where appropriate</td> </tr> <tr> <td>Physical activity assessment</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Lennox N, Eastgate G. Adults with intellectual disability and the GP. Aust Fam Physician 2004; 33:601. Copyright to Australian Family Physician. Reproduced with permission. Permission to reproduce must be sought from the publisher, The Royal Australian College of General Practitioners.</div><div id=\"graphicVersion\">Graphic 76615 Version 9.0</div></div></div>"},"76617":{"type":"graphic_figure","displayName":"Structure sulfasalazine 5 ASA","title":"Structures of sulfasalazine, mesalamine, and olsalazine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Structures of sulfasalazine, mesalamine, and olsalazine</div><div class=\"cntnt\"><img style=\"width:357px; height:250px;\" src=\"images/GAST/76617_Structure_sulfasalazine_5_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sulfasalazine is a composite molecule composed of 5-ASA linked by an azo bond to sulfapyridine. Mesalamine is the 5-ASA moiety alone, while olsalazine consists of two 5-ASA molecules joined by an azo bond.</div><div class=\"graphic_footnotes\">5-ASA: 5-aminosalicylic acid.</div><div id=\"graphicVersion\">Graphic 76617 Version 2.0</div></div></div>"},"76618":{"type":"graphic_picture","displayName":"APL hypergranular variant","title":"Hypergranular variant of acute promyelocytic leukemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypergranular variant of acute promyelocytic leukemia</div><div class=\"cntnt\"><img style=\"width:371px; height:252px;\" src=\"images/HEME/76618_APL_hypergranular_variant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The malignant promyelocytes in the more common &quot;hypergranular&quot; variant of acute promyelocytic leukemia (APL) have characteristic large reddish-blue or dark purple granules in the cytoplasm. The nucleus is often folded, indented, or dumb-bell shaped.</div><div class=\"graphic_reference\">Courtesy of Richard A Larson, MD.</div><div id=\"graphicVersion\">Graphic 76618 Version 2.0</div></div></div>"},"76619":{"type":"graphic_table","displayName":"ILD associated BAL neutrophilia","title":"Interstitial lung disease associated with BAL neutrophilia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interstitial lung disease associated with BAL neutrophilia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Idiopathic pulmonary fibrosis (15 to 40 percent) </td> </tr> <tr> <td>Cryptogenic organizing pneumonia (40 to 70 percent)</td> </tr> <tr> <td class=\"sublist1_start\">Inorganic dust diseases </td> </tr> <tr> <td class=\"sublist1\">Asbestosis </td> </tr> <tr> <td class=\"sublist1\">Silicosis </td> </tr> <tr> <td>Cigarette smoking (&#60;10 percent)</td> </tr> <tr> <td>Pulmonary Langerhans cell histiocytosis (Histiocytosis X)</td> </tr> <tr> <td>Hypersensitivity pneumonitis (acute)</td> </tr> <tr> <td>Sarcoidosis (advanced)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BAL: bronchoalveolar lavage.</div><div id=\"graphicVersion\">Graphic 76619 Version 2.0</div></div></div>"},"76620":{"type":"graphic_picture","displayName":"Sq ca lung in situ bronch","title":"Squamous carcinoma in situ of the lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Squamous carcinoma in situ of the lung</div><div class=\"cntnt\"><img style=\"width:396px; height:396px;\" src=\"images/PULM/76620_Sq_ca_lung_in_situ_bronch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchoscopic image showing a focal area of mucosal erythema and elevation at the entrance to the superior segment of the right lower lobe; biopsy showed carcinoma in situ.</div><div id=\"graphicVersion\">Graphic 76620 Version 3.0</div></div></div>"},"76621":{"type":"graphic_picture","displayName":"Erythema nodosum - legs","title":"Erythema nodosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema nodosum</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/76621_Erythema_nodosum_legs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous nodules are present on the legs.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76621 Version 3.0</div></div></div>"},"76624":{"type":"graphic_figure","displayName":"Tillaux anatomy","title":"Tillaux fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tillaux fracture</div><div class=\"cntnt\"><img style=\"width:354px; height:549px;\" src=\"images/EM/76624_Tillaux_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Juvenile Tillaux fracture. Mechanism of injury, the anteroinferior tibiofibular ligament avulses a fragment of the medial epiphysis corresponding to the portion of the physis that is still open (top, anterior view; bottom, inferior view).</div><div class=\"graphic_reference\">Redrawn with permission from: Cummings, RJ. Distal tibial and fibular fractures. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty, JH, Kasser, JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76624 Version 1.0</div></div></div>"},"76626":{"type":"graphic_figure","displayName":"Schematic CVVHDF pre-filter","title":"Schematic of CVVHDF with pre-filter infusion of replacement fluid","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Schematic of CVVHDF with pre-filter infusion of replacement fluid</div><div class=\"cntnt\"><img style=\"width:520px; height:279px;\" src=\"images/NEPH/76626_Schematic_CVVHDF_Prefilter.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CVVHDF: continuous venovenous hemodiafiltration.</div><div id=\"graphicVersion\">Graphic 76626 Version 3.0</div></div></div>"},"76627":{"type":"graphic_table","displayName":"Back pain generating tissue","title":"Tissues in the low back that can generate pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tissues in the low back that can generate pain</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"sublist1_start\">External Tissues</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">&#8226; Skin</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">&#8226; Subcutaneous tissue</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">&#8226; Fat</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Joints</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">&#8226; Capsules of facet and sacroiliac joints</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Ligaments</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">&#8226; Longitudinal spinal</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">&#8226; Posterior interspinous</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">&#8226; Sacroiliac</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">&#8226; Ligamentum flavum (minimal pain fiber innervation)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Periosteum</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">&#8226; Vertebral bodies and arches</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Dura mater</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Epidural fibro-adipose tissue</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Annulus fibrosus</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Arterioles</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">&#8226; Of spinal and sacroiliac joints</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">&#8226; Of vertebral cancellous bone</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Veins</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">&#8226; Epidural</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">&#8226; Paravertebral</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Paravertebral muscles</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">&#8226; Pain fibers in perivascular connective tissues</td>\n\t  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Courtesy of Kerry Levin, MD.</div><div id=\"graphicVersion\">Graphic 76627 Version 1.0</div></div></div>"},"76630":{"type":"graphic_table","displayName":"Components of newborn screening programs","title":"Commonly included components of state newborn screening programs for conditions that cause intellectual disability","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly included components of state newborn screening programs for conditions that cause intellectual disability</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Clinical syndrome</td> <td class=\"subtitle1\">Treatment</td> </tr> <tr> <td>Biotinidase deficiency</td> <td>Seizures, skin disorders, hearing loss, ID, death</td> <td>Daily biotin</td> </tr> <tr> <td>Congenital hypothyroidism</td> <td>Impaired growth and intellectual development</td> <td>Thyroid hormone replacement</td> </tr> <tr> <td>Galactosemia</td> <td>Cataracts, cirrhosis, ID, fatal sepsis</td> <td>Eliminate lactose, use soy for newborn sepsis evaluation</td> </tr> <tr> <td>Homocystinuria</td> <td>ID, osteoporosis, thromboembolic disease</td> <td>Dietary restrictions, supplemental medicines</td> </tr> <tr> <td>Maple syrup urine disease</td> <td>Feeding problems, vomiting, death; severe ID</td> <td>Branched-chain amino acids/dietary restrictions</td> </tr> <tr> <td>Phenylketonuria</td> <td>ID, seizures, eczema</td> <td>Phenylalanine-restricted diet</td> </tr> <tr> <td>Congenital toxoplasmosis</td> <td>Hydrocephalus, ID, splenomegaly, ascites</td> <td>One year of regimented antibiotics, infectious disease consult</td> </tr> <tr> <td>Newborn hearing screen</td> <td>Global delay in cognitive and social development</td> <td> <p>Hearing aids</p> Special Education</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ID: intellectual disability.</div><div id=\"graphicVersion\">Graphic 76630 Version 5.0</div></div></div>"},"76631":{"type":"graphic_algorithm","displayName":"Traumatic shock initial management algorithm","title":"Traumatic shock: Initial management","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traumatic shock: Initial management</div><div class=\"cntnt\"><img style=\"width:322px; height:468px;\" src=\"images/EM/76631_Traumashockinitalgoed2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IV: intravenous; IO: intraosseous; FAST: Focused Assessment with Sonography in Trauma; CXR: chest x-ray; C-spine: cervical spine.</div><div id=\"graphicVersion\">Graphic 76631 Version 4.0</div></div></div>"},"76634":{"type":"graphic_picture","displayName":"Snare extract billie club","title":"Snare extraction of the Billie club","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Snare extraction of the Billie club</div><div class=\"cntnt\"><img style=\"width:432px; height:297px;\" src=\"images/GAST/76634_Snare_extract_billie_club.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Picture demonstrating the Billie club following successful transanal extraction. The colonoscope is also visible.</div><div class=\"graphic_reference\">Courtesy of Justin A Maykel, MD.</div><div id=\"graphicVersion\">Graphic 76634 Version 1.0</div></div></div>"},"76635":{"type":"graphic_picture","displayName":"AML FAB M5B maturation","title":"Acute monocytic leukemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute monocytic leukemia</div><div class=\"cntnt\"><img style=\"width:419px; height:288px;\" src=\"images/HEME/76635_AML_FAB_M5B_maturation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow smear from a patient with acute monocytic leukemia with maturation (FAB M5B). This field shows a range of maturation of monocytic cells. (Wright-Giemsa stain).</div><div class=\"graphic_reference\">From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 76635 Version 1.0</div></div></div>"},"76636":{"type":"graphic_picture","displayName":"Telogen effluvium","title":"Telogen effluvium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Telogen effluvium</div><div class=\"cntnt\"><img style=\"width:432px; height:285px;\" src=\"images/PC/76636_Telogen_effluvium.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Telogen effluvium is characterized by diffuse hair loss. Hair loss is often most noticeable in the temporal region.</div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 76636 Version 2.0</div></div></div>"},"76637":{"type":"graphic_diagnosticimage","displayName":"Exaggerated CCL view","title":"Exaggerated craniocaudal (XCCL) view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Exaggerated craniocaudal (XCCL) view</div><div class=\"cntnt\"><img style=\"width:420px; height:425px;\" src=\"images/PC/76637_XCCL_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The XCCL view (Panel A) includes the more posterior and lateral breast tissue than the standard CC view (Panel B).</div><div class=\"graphic_footnotes\">XCCL: exaggerated craniocaudal; CC: craniocaudal.</div><div id=\"graphicVersion\">Graphic 76637 Version 2.0</div></div></div>"},"76640":{"type":"graphic_picture","displayName":"Nordic lower starting position","title":"Nordic lower: Starting position","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nordic lower: Starting position</div><div class=\"cntnt\"><img style=\"width:351px; height:468px;\" src=\"images/EM/76640_Nordic_lower_start_posit_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Nordic lower exercise strengthens the hamstring muscles and many other muscles of the posterior kinetic chain. Maintain the thighs and torso in a straight line throughout the exercise.</div><div class=\"graphic_reference\">Courtesy of Karl Fields, MD; Spencer Copland, MD; and John Tipton, MD.</div><div id=\"graphicVersion\">Graphic 76640 Version 2.0</div></div></div>"},"76641":{"type":"graphic_table","displayName":"Autoimmune blistering diseases","title":"Autoimmune mucocutaneous blistering diseases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Autoimmune mucocutaneous blistering diseases</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Pemphigoid</td> </tr> <tr> <td class=\"sublist1\">Bullous pemphigoid</td> </tr> <tr> <td class=\"sublist1\">Mucous membrane pemphigoid</td> </tr> <tr> <td class=\"sublist1\">Pemphigoid gestationis</td> </tr> <tr> <td class=\"sublist1\">Anti-laminin 332 pemphigoid (anti-epiligrin cicatricial pemphigoid)</td> </tr> <tr> <td class=\"sublist1\">Anti-p200 pemphigoid (anti-laminin gamma-1 pemphigoid)</td> </tr> <tr> <td class=\"sublist1\">Other pemphigoid variants</td> </tr> <tr> <td class=\"sublist1_start\">Linear IgA disease</td> </tr> <tr> <td class=\"sublist1\">Linear IgA bullous dermatosis</td> </tr> <tr> <td class=\"sublist1\">Chronic bullous disease of childhood</td> </tr> <tr> <td class=\"sublist1_start\">Pemphigus</td> </tr> <tr> <td class=\"sublist1\">Pemphigus vulgaris</td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Pemphigus vegetans </li> <li>Pemphigus herpetiformis </li> </ul> </td> </tr> <tr> <td class=\"sublist1\">Pemphigus foliaceus</td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Pemphigus erythematosus </li> <li>Fogo selvagem </li> </ul> </td> </tr> <tr> <td class=\"sublist1\">Paraneoplastic pemphigus</td> </tr> <tr> <td class=\"sublist1\">IgA pemphigus</td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Subcorneal pustular dermatosis </li> <li>Intraepidermal neutrophilic IgA dermatosis </li> </ul> </td> </tr> <tr> <td>Bullous lupus erythematosus</td> </tr> <tr> <td>Dermatitis herpetiformis</td> </tr> <tr> <td>Epidermolysis bullosa acquisita</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgA: immunoglobulin A.</div><div id=\"graphicVersion\">Graphic 76641 Version 5.0</div></div></div>"},"76642":{"type":"graphic_table","displayName":"Causes of noncompliance","title":"Factors that reduce compliance to antihypertensive therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors that reduce compliance to antihypertensive therapy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Patient and disease characteristics</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Asymptomatic</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Chronic condition</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Condition suppressed, not cured</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>No immediate consequences of stopping therapy</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Social isolation</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Disrupted home situation</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Psychiatric illness</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Treatment characteristics</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Long duration of therapy</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Complicated regimens</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Expensive medications</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Side effects of medications</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Multiple behavioral modifications</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Lack of specific appointment times</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Long waiting time in office</td>\n\n\n    </tr>\n\n\n  \n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 76642 Version 1.0</div></div></div>"},"76644":{"type":"graphic_picture","displayName":"Skin biopsy NSF CD34 cells I","title":"High power image showing immunohistochemical staining for CD34 of a skin biopsy from a patient with nephrogenic systemic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">High power image showing immunohistochemical staining for CD34 of a skin biopsy from a patient with nephrogenic systemic fibrosis</div><div class=\"cntnt\"><img style=\"width:432px; height:293px;\" src=\"images/NEPH/76644_Skin_biopsy_NSF_CD34_cells.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A high magnification image with immunohistochemical staining reveals abundant elongated cells that express the cell surface antigen CD34 (brown) and produce the protein procollagen I (magenta). This combination of findings identifies the cells as circulating fibrocytes.</div><div class=\"graphic_reference\">With permission from: Shawn E Cowper, MD.</div><div id=\"graphicVersion\">Graphic 76644 Version 3.0</div></div></div>"},"76645":{"type":"graphic_table","displayName":"Aneurysm risk in CN3 palsy","title":"Risk of aneurysm based on internal and external dysfunction of the third nerve","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk of aneurysm based on internal and external dysfunction of the third nerve</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Internal and external dysfunction</td>\n\t\t\t\t\t<td class=\"subtitle1\">Risk of aneurysm</td>\n\t\t\t\t\t<td class=\"subtitle1\">Recommendation</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">Complete internal dysfunction (\"pupil blown\") </td>\n\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">With complete external dysfunction</td>\n\t\t\t\t\t<td>Highest</td>\n\t\t\t\t\t<td>MRI/MRA (CTA) catheter angiogram</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">With incomplete external dysfunction</td>\n\t\t\t\t\t<td>Highest</td>\n\t\t\t\t\t<td>MRI/MRA (CTA) catheter angiogram</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Without external dysfunction</td>\n\t\t\t\t\t<td>Minimal</td>\n\t\t\t\t\t<td>No imaging</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">Incomplete internal dysfunction (\"partial pupil\")</td>\n\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">With complete external dysfunction</td>\n\t\t\t\t\t<td>Uncertain, probably low</td>\n\t\t\t\t\t<td>MRI/MRA (CTA) consider catheter angiogram</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">With incomplete external dysfunction</td>\n\t\t\t\t\t<td>Uncertain, minimal</td>\n\t\t\t\t\t<td>MRI/MRA (CTA) consider catheter angiogram</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Without external dysfunction</td>\n\t\t\t\t\t<td>Minimal</td>\n\t\t\t\t\t<td>No imaging</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">No internal dysfunction (\"pupil not involved\")</td>\n\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">With complete external dysfunction</td>\n\t\t\t\t\t<td>Low if isolated</td>\n\t\t\t\t\t<td>Observe</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">With incomplete external dysfunction</td>\n\t\t\t\t\t<td>Uncertain</td>\n\t\t\t\t\t<td>MRI/MRA (CTA) consider catheter angiogram</td>\n\t\t\t\t</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">MRA: magnetic resonance angiography; MRI: magnetic resonance imaging; CTA: computed tomography angiography.</div><div id=\"graphicVersion\">Graphic 76645 Version 1.0</div></div></div>"},"76646":{"type":"graphic_figure","displayName":"2nd trimester AFP levels ","title":"Second trimester alpha-fetoprotein (AFP) levels ","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Second trimester alpha-fetoprotein (AFP) levels </div><div class=\"cntnt\"><img style=\"width:516px; height:493px;\" src=\"images/OBGYN/76646_2triAFPlvlsgestatnlage.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Median maternal serum levels in unaffected pregnancies calculated from in-house data at Women and Infants Hospital, Providence, Rhode Island. These data are representative and not intended or appropriate for use in other laboratories.</div><div class=\"graphic_footnotes\">IU: international units.</div><div class=\"graphic_reference\">Courtesy of Glenn E Palomaki, PhD.</div><div id=\"graphicVersion\">Graphic 76646 Version 2.0</div></div></div>"},"76648":{"type":"graphic_figure","displayName":"Hand-sewn ileocolic anastomosis - two layer closur anterior wall","title":"Hand-sewn ileocolic anastomosis - two layer closure anterior wall","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hand-sewn ileocolic anastomosis - two layer closure anterior wall</div><div class=\"cntnt\"><img style=\"width:265px; height:244px;\" src=\"images/SURG/76648_Hand-sewn-anast-ant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Connell sutures are used on the anterior wall of the anastomosis between the ileum and colon.</div><div id=\"graphicVersion\">Graphic 76648 Version 2.0</div></div></div>"},"76649":{"type":"graphic_picture","displayName":"Erythema multiforme elbow","title":"Erythema multiforme","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema multiforme</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/76649_Erythema_multiforme_elbow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This child with erythema multiforme has multiple erythematous plaques and some vesicles on the elbows. A few true target lesions are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76649 Version 4.0</div></div></div>"},"76650":{"type":"graphic_table","displayName":"Burkitt therapy CALGB 9251","title":"Intensive treatment for Burkitt leukemia/lymphoma: CALGB 9251 (revised*)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intensive treatment for Burkitt leukemia/lymphoma: CALGB 9251 (revised*)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cycle 1<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide: 200 mg/m<sup>2</sup> IV per day on days 1 through 5</td> </tr> <tr> <td class=\"indent1\">Prednisone: 60 mg/m<sup>2</sup> PO per day on days 1 through 7</td> </tr> <tr> <td class=\"subtitle1_single\">Cycles 2, 4, and 6<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Ifosfamide: 800 mg/m<sup>2</sup> over one hour IV per day on days 1 through 5</td> </tr> <tr> <td class=\"indent1\">Mesna: 200 mg/m<sup>2</sup> IV per day on days 1 through 5 at 0, 4, and 8 hours after ifosfamide</td> </tr> <tr> <td class=\"indent1\">Methotrexate: 150 mg/m<sup>2</sup> IV over 30 minutes on day 1, then 1.35 g/m<sup>2</sup> IV over the next 23.5 hours, for a total dose of 1.5 g/m<sup>2</sup></td> </tr> <tr> <td class=\"indent1\">Leucovorin: 50 mg/m<sup>2</sup> IV 36 hours after initiation of methotrexate, then 15 mg/m<sup>2</sup> every 6 hours until serum methotrexate concentration &#60;0.05 micromolar</td> </tr> <tr> <td class=\"indent1\">Vincristine: 2 mg IV push on day 1</td> </tr> <tr> <td class=\"indent1\">Cytarabine: 150 mg/m<sup>2</sup> per day by continuous IV infusion on days 4 and 5</td> </tr> <tr> <td class=\"indent1\">Etoposide: 80 mg/m<sup>2</sup> per day IV over one hour on days 4 and 5</td> </tr> <tr> <td class=\"indent1\">Dexamethasone: 10 mg/m<sup>2</sup> PO per day on days 1 through 5</td> </tr> <tr> <td class=\"subtitle1_single\">Cycles 3, 5, and 7</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide: 200 mg/m<sup>2</sup> per day IV on days 1 through 5</td> </tr> <tr> <td class=\"indent1\">Methotrexate: 150 mg/m<sup>2</sup> IV over 30 minutes on day 1, then 1.35 g/m<sup>2</sup> IV over the next 23.5 hours, for a total dose of 1.5 g/m<sup>2</sup></td> </tr> <tr> <td class=\"indent1\">Leucovorin: 50 mg/m<sup>2</sup> IV 36 hours after initiation of methotrexate, then 15 mg/m<sup>2</sup> every 6 hours until serum methotrexate concentration &#60;0.05 micromolar</td> </tr> <tr> <td class=\"indent1\">Vincristine: 2 mg IV push on day 1</td> </tr> <tr> <td class=\"indent1\">Doxorubicin: 25 mg/m<sup>2</sup> per day by IV bolus on days 4 and 5</td> </tr> <tr> <td class=\"indent1\">Dexamethasone: 10 mg/m<sup>2</sup> PO per day on days 1 through 5</td> </tr> <tr> <td class=\"subtitle1_single\">Intrathecal chemotherapy with cycles 2 through 7 (amended)</td> </tr> <tr> <td class=\"indent1\">Methotrexate: 15 mg IT on day 1</td> </tr> <tr> <td class=\"indent1\">Cytarabine: 40 mg IT on day 1</td> </tr> <tr> <td class=\"indent1\">Hydrocortisone: 50 mg IT on day 1</td> </tr> <tr> <td class=\"subtitle1_single\">Cranial irradiation (amended)</td> </tr> <tr> <td class=\"indent1\">2400 cGy administered in 12 fractions after chemotherapy for cycle 7 completed, only for patients who had prior bone marrow involvement at the time of presentation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CALGB: Cancer and Leukemia Group B; IV: intravenously; PO: by mouth; IT: intrathecal injection.<br />* Revised protocol as given to Cohort 2 of the study in order to reduce the incidence and severity of neurotoxicity.<br />¶ All cycles are repeated at 21-day intervals except cycle 1, which lasts 7 days.</div><div class=\"graphic_reference\">Modified from: Lee, EJ, et al. J Clin Oncol 2001; 19:4014 and Rizzieri, DA, et al. Cancer 2004; 100:1438.</div><div id=\"graphicVersion\">Graphic 76650 Version 4.0</div></div></div>"},"76651":{"type":"graphic_table","displayName":"Normal testicular size","title":"Normal testicular length and volume, by age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal testicular length and volume, by age</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age, years</td> <td class=\"subtitle1\">Length, cm (mean &#177; SD)</td> <td class=\"subtitle1\">Volume, mL (approximate)</td> </tr> <tr> <td>&#60; 2 </td> <td>1.4 &#177; 0.4</td> <td>&nbsp;</td> </tr> <tr> <td>2 - 4 </td> <td>1.2 &#177; 0.2</td> <td>&nbsp;</td> </tr> <tr> <td>4 - 6</td> <td>1.5 &#177; 0.6</td> <td>1</td> </tr> <tr> <td>6 - 8</td> <td>1.8 &#177; 0.3</td> <td>&nbsp;</td> </tr> <tr> <td>8 - 10</td> <td>2.0 &#177; 0.5</td> <td>2</td> </tr> <tr> <td>10 - 12</td> <td>2.7 &#177; 0.7</td> <td>5</td> </tr> <tr> <td>12 - 14</td> <td>3.4 &#177; 0.8</td> <td>10</td> </tr> <tr> <td>14 - 16</td> <td>4.1 &#177; 1.0</td> <td>20</td> </tr> <tr> <td>16 - 18</td> <td>5.0 &#177; 0.5</td> <td>29</td> </tr> <tr> <td>18 - 20</td> <td>5.0 &#177; 0.3</td> <td>29</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Keefer JR. Endocrinology. In: Harriet Lane Handbook, 15th ed, Siberry GK, Iannone R (Eds), Mosby, St. Louis 2000. p.227.</div><div id=\"graphicVersion\">Graphic 76651 Version 3.0</div></div></div>"},"76652":{"type":"graphic_waveform","displayName":"ECG Lown-Ganong-Levine syndrome tutorial","title":"Electrocardiogram (ECG) showing Lown-Ganong-Levine syndrome","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) showing Lown-Ganong-Levine syndrome</div><div class=\"cntnt\"><img style=\"width:512px; height:152px;\" src=\"images/CARD/76652_LGL_syndrome_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This syndrome is characterized by a short PR interval (&lt;0.12 seconds) and a normal QRS complex due to rapid atrioventricular conduction.</div><div id=\"graphicVersion\">Graphic 76652 Version 3.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"76654":{"type":"graphic_picture","displayName":"Upper papillae in VKC","title":"Upper tarsal signs in vernal keratoconjunctivitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Upper tarsal signs in vernal keratoconjunctivitis</div><div class=\"cntnt\"><img style=\"width:397px; height:256px;\" src=\"images/RHEUM/76654_VKC_upper_tarsal_signs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With vernal keratoconjunctivitis (VKC), the upper papillae may assume a &quot;cobblestone&quot; appearance. Visualization of these changes requires everting the upper lids.</div><div id=\"graphicVersion\">Graphic 76654 Version 2.0</div></div></div>"},"76655":{"type":"graphic_diagnosticimage","displayName":"Abdominal CT scan showing superior mesenteric artery syndrome","title":"Abdominal CT scan showing superior mesenteric artery syndrome","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Abdominal CT scan showing superior mesenteric artery syndrome</div><div class=\"cntnt\"><img style=\"width:550px; height:288px;\" src=\"images/SURG/76655_Abd_CT_scan_mesen_art_syn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography of the abdomen with intravenous contrast showing a narrowed angle between the superior mesenteric artery and the aorta measuring eight degrees.</div><div class=\"graphic_reference\">Reproduced from: Abu-Zidan FM, Hefny AF, Saadeldinn YA, El-Ashaal YI. Sonographic findings of superior mesenteric artery syndrome causing massive gastric dilatation in a young healthy girl. Singapore Med J 2010; 51:e184. Copyright © 2010 Singapore Medical Association.</div><div id=\"graphicVersion\">Graphic 76655 Version 2.0</div></div></div>"},"76656":{"type":"graphic_table","displayName":"AAST Organ Injury Scales for stomach or intestinal injury","title":"AAST Organ Injury Scales for stomach, small intestine, colon, and rectum","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">AAST Organ Injury Scales for stomach, small intestine, colon, and rectum</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Injured structure</td> <td class=\"subtitle1\">AAST grade*</td> <td class=\"subtitle1\">Characteristics of injury</td> <td class=\"subtitle1\">AIS-90 score</td> </tr> <tr> <td rowspan=\"5\">Stomach</td> <td class=\"centered\">I</td> <td>Intramural hematoma &#60;3 cm; partial-thickness laceration</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"centered\">II</td> <td>Intramural hematoma &#8805;3 cm; small (&#60;3 cm) laceration</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"centered\">III</td> <td>Large (&#62;3 cm) laceration</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"centered\">IV</td> <td>Large laceration involving vessels on greater or lesser curvature</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"centered\">V</td> <td>Extensive (&#62;50 percent) rupture; stomach devascularized</td> <td class=\"centered\">4</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Small bowel</td> <td class=\"centered\">I</td> <td>Contusion or hematoma without devascularization; partial-thickness laceration</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"centered\">II</td> <td>Small (&#60;50 percent of circumference) laceration</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"centered\">III</td> <td>Large (&#8805;50 percent of circumference) laceration without transection</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"centered\">IV</td> <td>Transection</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">V</td> <td>Transection with segmental tissue loss; devascularized segment</td> <td class=\"centered\">4</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Colon</td> <td class=\"centered\">I</td> <td>Contusion or hematoma; partial-thickness laceration</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"centered\">II</td> <td>Small (&#60;50 percent of circumference) laceration</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"centered\">III</td> <td>Large (&#8805;50 percent of circumference) laceration</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"centered\">IV</td> <td>Transection</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">V</td> <td>Transection with tissue loss; devascularized segment</td> <td class=\"centered\">4</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Rectosigmoid and rectum</td> <td class=\"centered\">I</td> <td>Contusion or hematoma; partial-thickness laceration</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"centered\">II</td> <td>Small (&#60;50 percent of circumference) laceration</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"centered\">III</td> <td>Large (&#8805;50 percent of circumference) laceration</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">IV</td> <td>Full-thickness laceration with perineal extension</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"centered\">V</td> <td>Devascularized segment</td> <td class=\"centered\">5</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">20</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=96984&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">AAST: American Association for the Surgery of Trauma; GE: gastroesophageal.<br />* Advance one grade for multiple injuries up to grade III.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Moore EE, Jurkovich GJ, Knudson MM, et al. Organ injury scaling. VI: Extrahepatic biliary, esophagus, stomach, vulva, vagina, uterus (nonpregnant), uterus (pregnant), fallopian tube, and ovary. J Trauma 1995; 39:1069.</LI>&#xD;&#xA;<LI>Moore EE, Cogbill TH, Malangoni MA, et al. Organ injury scaling, II: Pancreas, duodenum, small bowel, colon, and rectum. J Trauma 1990; 30:1427.</LI></OL></div><div id=\"graphicVersion\">Graphic 76656 Version 3.0</div></div></div>"},"76657":{"type":"graphic_table","displayName":"Viral skin infections after OLT","title":"Viral skin infections after liver transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Viral skin infections after liver transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Virus</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Cytomegalovirus</td> <td>Uncommon, indicates strong immunosuppression. Mucocutaneous lesions are polymorphic: vesicles, necrotic lesions, oral or genital ulcerations.</td> </tr> <tr> <td>Epstein-Barr virus</td> <td>Responsible for oral hairy leukoplakia. Sign of a strong immunosuppression.</td> </tr> <tr> <td>Herpes simplex</td> <td>Frequent. Reactivation can occur in the days following the transplantation or years later. Sometimes unusual presentations: skin necrosis, ulceration, pseudo-tumoral vegetations. Primary infection via the graft is possible.</td> </tr> <tr> <td>Herpes zoster</td> <td>Reactivation occurs in about 20 percent of the patients with a liver graft. Necrotic or hemorrhagic pustules that can be limited to a dermatome or have a generalized distribution. Should be considered as a life-threatening complication. Can trigger unexpected complications such as pancreatitis. Like generalized shingles, varicella is a dermatologic emergency given the risk of visceral dissemination: meningoencephalitis, fulminant pneumopathy, and diffuse intravascular coagulopathy.</td> </tr> <tr> <td>Molluscum contagiosum</td> <td>Due to a poxvirus infection. Multiple and often large lesions found on the scalp, beard, axillae, and groin. Biopsies are necessary to differentiate them from verrucae, sebaceous hyperplasia, and cryptococcosis.</td> </tr> <tr> <td>Papillomavirus</td> <td>Verrucea appear two to three years after the transplantation and continue to grow and multiply over the years. More than 80 percent of the recipients of a liver graft have verrucea vulgaris or genital warts five years after transplantation. They are particularly frequent in patients with a strong immunosuppression. Papillomavirus lesions in the anogenital region increase the risk of a squamous cell carcinoma by a factor of 100. In the context of transplantation, the specific types of papillomaviruses lose their tissue specificity. Papillomaviruses type 6 and 11 have been found in verrucae vulgaris. Conversion to sirolimus may be a useful strategy for recalcitrant cutaneous viral warts<sup>[1]</sup>.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference:<br /><ol>&#xD;&#xA;    <li>Dharancy S, Catteau B, Mortier L, et al. Conversion to sirolimus: a useful strategy for recalcitrant cutaneous viral warts in liver transplant recipient. Liver Transpl 2006; 12:1883.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 76657 Version 3.0</div></div></div>"},"76660":{"type":"graphic_figure","displayName":"ACST use of medical treatments","title":"Use of medical treatments in the Asymptomatic Carotid Surgery Trial","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Use of medical treatments in the Asymptomatic Carotid Surgery Trial</div><div class=\"cntnt\"><img style=\"width:508px; height:330px;\" src=\"images/NEURO/76660_ACST_medical_rx_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The use of lipid lowering drugs rose dramatically over the 10-year course of patient enrollment, from 17 percent in earlier randomization (1993 to 1996) to 58 percent in later randomization (2000 to 2003). Patient numbers reflect year of randomization.</div><div class=\"graphic_reference\">Reproduced with permission from: MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004; 363:1491. Copyright &copy; 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 76660 Version 5.0</div></div></div>"},"76661":{"type":"graphic_table","displayName":"Rotating fluids protocol","title":"Rotating fluids protocol","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rotating fluids protocol</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Maternal plasma glucose</td> <td class=\"subtitle1\">Intravenous insulin (units/hour)*<sup>[1]</sup></td> <td class=\"subtitle1\">Intravenous solution</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">\"Rotating fluids.\" For use in women with gestational diabetes. This protocol should not be used in women with type 1 or type 2 diabetes mellitus.</td> </tr> <tr> <td class=\"indent1\">&#8804;100 mg/dL (5.6 mmol/L)</td> <td>Hold</td> <td>D5NS at 125 mL/hour to achieve CBG of 100 mg/dL (5.6 mmol/L)</td> </tr> <tr> <td class=\"indent1\">101 to 140 mg/dL (5.6 to 7.8 mmol/L)</td> <td>Hold</td> <td>Lacted Ringers or normal saline at 125 mL/hour to achieve CBG of 100 mg/dL (5.6 mmol/L)</td> </tr> <tr> <td class=\"indent1\">&#62;140 mg/dL (7.8 mmol/L)</td> <td>Short- or rapid-acting insulin infusion titrated to achieve CBG of 100 mg/dL (5.6 mmol/L)</td> <td>Lacted Ringers or normal saline at 125 mL/hour to achieve CBG of 100 mg/dL (5.6 mmol/L)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CBG: capillary blood glucose; D5NS: 5 percent dextrose normal saline.<br />* Mix 25 units regular insulin in 250 mL normal saline (1 unit:10 mL).</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Jovanovic L, Peterson CM. Management of the pregnant, insulin-dependent diabetic woman. Diabetes Care 1980; 3:63.</li>&#xD;&#xA;</ol>&#xD;&#xA;Data from: Rosenberg VA, Eglinton GS, Rauch ER, Skupski DW. Intrapartum maternal glycemic control in women with insulin requiring diabetes: a randomized clinical trial of rotating fluids versus insulin drip. Am J Obstet Gynecol 2006; 195:1095.</div><div id=\"graphicVersion\">Graphic 76661 Version 12.0</div></div></div>"},"76662":{"type":"graphic_figure","displayName":"Components of a long bone","title":"Components of a long bone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Components of a long bone</div><div class=\"cntnt\"><img style=\"width:333px; height:499px;\" src=\"images/PEDS/76662_Components_of_a_long_bone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This illustration depicts the major components of a long bone.</div><div id=\"graphicVersion\">Graphic 76662 Version 2.0</div></div></div>"},"76663":{"type":"graphic_figure","displayName":"Patient position for femoral vascular access","title":"Patient position for femoral vascular access","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Patient position for femoral vascular access</div><div class=\"cntnt\"><img style=\"width:536px; height:254px;\" src=\"images/EM/76663_Patpositfemvascaccess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hip should be flexed and externally rotated and a towel roll placed to facilitate an easy approach to the femoral vessels.</div><div class=\"graphic_reference\">Reproduced with permission from: Torrey SB, Saladino RA. Arterial puncture and catheterization. In: Textbook of Pediatric Emergency Procedures, 2nd Edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 76663 Version 6.0</div></div></div>"},"76664":{"type":"graphic_picture","displayName":"Hairy tongue","title":"Hairy tongue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hairy tongue</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/76664_Hairy_tongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow to black elongated papillae are present on the dorsal tongue. This case occurred in association with antibiotic therapy.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76664 Version 4.0</div></div></div>"},"76665":{"type":"graphic_picture","displayName":"Tarantula","title":"Tarantula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tarantula</div><div class=\"cntnt\"><img style=\"width:432px; height:317px;\" src=\"images/EM/76665_Tarantula.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Richard S Vetter, MS.</div><div id=\"graphicVersion\">Graphic 76665 Version 1.0</div></div></div>"},"76666":{"type":"graphic_picture","displayName":"Beta thalassemia intermedia","title":"Peripheral blood smear in beta thalassemia intermedia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral blood smear in beta thalassemia intermedia</div><div class=\"cntnt\"><img style=\"width:446px; height:288px;\" src=\"images/HEME/76666_Betathalassemiaintermedia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral smear from a patient with beta thalassemia intermedia postsplenectomy. This field shows target cells, hypochromic cells, microcytic cells, red cell fragments, red cells with bizarre shapes, and a single nucleated red cell (arrow).</div><div class=\"graphic_reference\">Courtesy of Stanley Schrier, MD.</div><div id=\"graphicVersion\">Graphic 76666 Version 3.0</div></div></div>"},"76669":{"type":"graphic_figure","displayName":"Stepwise asthma Rx 0 to 4 years","title":"Stepwise approach for managing asthma in children 0 to 4 years of age","html":"<div class=\"graphic\"><div style=\"width: 636px\" class=\"figure\"><div class=\"ttl\">Stepwise approach for managing asthma in children 0 to 4 years of age</div><div class=\"cntnt\"><img style=\"width:616px; height:543px;\" src=\"images/PULM/76669_Stepwise_asthma_0_to_4_yrs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The stepwise approach is meant to assist, not replace, the clinical decision making required to meet individual patient needs. If alternative treatment is used and response is inadequate, discontinue it and use the preferred treatment before stepping up. If clear benefit is not observed within four to six weeks and patient/family medication technique and adherence are satisfactory, consider adjusting therapy or alternative diagnosis. Studies on children zero to four years of age are limited. Step 2 preferred therapy is based on evidence A. All other recommendations are based on expert opinion and extrapolation from studies in older children.<br /><strong>Alphabetical order is used when more than one treatment option is listed within either preferred or alternative therapy.</strong></div><div class=\"graphic_footnotes\">SABA: inhaled short-acting beta<sub>2 </sub>agonist; PRN: \"as needed\"; LABA: inhaled long-acting beta<sub>2 </sub>agonist.</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 76669 Version 12.0</div></div></div>"},"76670":{"type":"graphic_picture","displayName":"Factitial dermatitis","title":"Factitial ulcerations","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Factitial ulcerations</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/76670_Factitial_dermatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulcerations created by the patient. Note their geometric appearance. The patient had a severe psychiatric disorder.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76670 Version 1.0</div></div></div>"},"76671":{"type":"graphic_picture","displayName":"Immune thrombocytopenia - ITP","title":"Immune thrombocytopenia (ITP)","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Immune thrombocytopenia (ITP)</div><div class=\"cntnt\"><img style=\"width:468px; height:352px;\" src=\"images/DERM/76671_Idiopathic_thrombo_purpura.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Petechiae are present on the legs of this patient with immune thrombocytopenia (ITP).</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76671 Version 4.0</div></div></div>"},"76672":{"type":"graphic_table","displayName":"Rapid response team staffing","title":"Rapid response team staffing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid response team staffing</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Physician-led<sup>[1]</sup></td> <td class=\"subtitle1\">Non-physician-led<sup>[2]</sup></td> <td class=\"subtitle1\">Primary team-led<sup>[3]</sup></td> </tr> <tr> <td rowspan=\"7\"><strong>Team members</strong></td> <td>Intensivist (leader)</td> <td>Physician assistant (leader)</td> <td>Patient's primary resident (leader)</td> </tr> <tr> <td>Critical care nurse</td> <td>Critical care nurse</td> <td>Patient's primary nurse</td> </tr> <tr> <td>Floor nurse</td> <td>Respiratory care</td> <td>Senior nurse</td> </tr> <tr> <td>Anesthesia</td> <td>Intensivist (as needed)</td> <td>Respiratory care (as needed)</td> </tr> <tr> <td>Respiratory care</td> <td>Hospitalist (as needed)</td> <td>Other providers (as needed)</td> </tr> <tr> <td>Physician for chest compressions</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Physician for procedures</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>DeVita MA, Braithwaite RS, Mahidhara R, et al. Use of medical emergency team responses to reduce hospital cardiopulmonary arrests. Qual Saf Health Care 2004; 13:251. </li>&#xD;&#xA;    <li>Dacey, et al. The effect of a rapid response team on major clinical outcome measures in a community hospital. Crit Care Med 2007; 35:2076. </li>&#xD;&#xA;    <li>Howell MD, Ngo L, Folcarelli P, et al. Sustained effectiveness of a primary-team based rapid response system. Crit Care Med 2012; 40:2562.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 76672 Version 4.0</div></div></div>"},"76673":{"type":"graphic_algorithm","displayName":"Subtype evaluation primary aldosteronism","title":"Subtype evaluation of primary aldosteronism","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Subtype evaluation of primary aldosteronism</div><div class=\"cntnt\"><img style=\"width:514px; height:444px;\" src=\"images/ENDO/76673_Subtype_eval_prim_aldo_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">See text for details.</div><div class=\"graphic_footnotes\">APA: aldosterone-producing adenoma; AVS: adrenal venous sampling; CT: computed tomography; GRA: glucocorticoid-remediable aldosteronism; IHA: idiopathic hyperaldosteronism; PAH: primary adrenal hyperplasia.</div><div class=\"graphic_reference\">Data from: Young WF Jr, Hogan MJ. Renin-independent hypermineralocorticoidism. Trends Endocrinol Metab 1994; 5:97.</div><div id=\"graphicVersion\">Graphic 76673 Version 10.0</div></div></div>"},"76674":{"type":"graphic_table","displayName":"Late cardiovasc death preeclamp","title":"Deaths from cardiovascular causes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Deaths from cardiovascular causes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Population</td> <td class=\"subtitle1\">Relative hazard rate (95% CI)</td> </tr> <tr> <td>No preeclampsia, term delivery</td> <td>1</td> </tr> <tr> <td>No preeclampsia, preterm delivery</td> <td>2.95 (2.12-4.11)</td> </tr> <tr> <td>Preeclampsia, term delivery</td> <td>1.65 (1.01-2.70)</td> </tr> <tr> <td>Preeclampsia, preterm delivery</td> <td>8.12 (4.31-15.33)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 2001; 323:1213.</div><div id=\"graphicVersion\">Graphic 76674 Version 4.0</div></div></div>"},"76676":{"type":"graphic_table","displayName":"CF nutrition monitor","title":"Nutritional assessment during routine care at a Cystic Fibrosis center","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nutritional assessment during routine care at a Cystic Fibrosis center</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp; </td> <td class=\"subtitle1\">At diagnosis </td> <td class=\"subtitle1\">Every 3 months, from birth to 24 months </td> <td class=\"subtitle1\">Every 3 months </td> <td class=\"subtitle1\">Annually </td> </tr> <tr> <td>Head circumference</td> <td>X*</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Weight (to 0.1 kg)</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td>Length (to 0.1 cm)</td> <td>X*</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Height (to 0.1 cm)</td> <td>X</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td>Weight for length (birth to 24 mo)</td> <td>X*</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>BMI percentile (24 mo to adult)</td> <td>X</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td>Biological parents' height<sup>&#182;</sup></td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Pubertal status, female</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X<sup>&#916;</sup></td> </tr> <tr> <td>Pubertal status, male</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X<sup>&#9674;</sup></td> </tr> <tr> <td>24-hour diet recall</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> </tr> <tr> <td>Nutritional supplement intake<sup>&#167;</sup></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> </tr> <tr> <td>Anticipatory dietary and feeding behavior guidance</td> <td>&nbsp;</td> <td>X<sup>&#165;</sup></td> <td>X<sup>&#165;</sup></td> <td>X</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MAC: Mid-arm circumference; TSF: Triceps skinfold.<br />* If less than 24 months of age at diagnosis.<br />¶&nbsp;Record in cm and gender-specific height percentile; note patient's target height percentile on all growth charts.<br />Δ&nbsp;Starting at age 9 years, annual pubertal self-assessment form (patient, or parent and patient) or physician examination for breast and pubic hair, Tanner stage determination; annual question as to menarchal status. Record month and year of menarche on all growth charts.<br />◊&nbsp;Starting at age 10 years, annual pubertal self-assessment form (patient, or parent and patient) or physician examination for genital development and pubic hair, Tanner stage determination.<br />§&nbsp;A review of enzymes, vitamins, minerals, oral or enteral formulas; herbal, botanical, and other Complimentary and Alternative Medicine products.<br />¥&nbsp;Routine surveillance may be done informally by other team members, but the center dietitian should perform the&nbsp;annual assessment and&nbsp;monitoring visits (every 3 months)&nbsp;in the first 2 years of life and for patients at nutritional risk.</div><div class=\"graphic_reference\">Modified with permission from: Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002; 35:246. Copyright © 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76676 Version 12.0</div></div></div>"},"76678":{"type":"graphic_figure","displayName":"Musculoskeletal screen 3","title":"The pGALS musculoskeletal screen (continued)","html":"<div class=\"graphic\"><div style=\"width: 609px\" class=\"figure\"><div class=\"ttl\">The pGALS musculoskeletal screen (continued)</div><div class=\"cntnt\"><img style=\"width:589px; height:715px;\" src=\"images/PEDS/76678_Musculoskeletal_screen_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">pGALS: pediatric Gait Arms Legs Spine.</div><div class=\"graphic_reference\">Reproduced with permission from: Foster HE, Jandial S. pGALS - A Screening Examination of the Musculoskeletal System in School-Aged Children. Reports on the Rheumatic Diseases (Series 5), Hands On 15. Arthritis Research Campaign; 2008 June. Copyright &copy; 2008 Arthritis Research Campaign.</div><div id=\"graphicVersion\">Graphic 76678 Version 3.0</div></div></div>"},"76679":{"type":"graphic_diagnosticimage","displayName":"Adrenal hyperplasia CT","title":"Adrenal hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adrenal hyperplasia</div><div class=\"cntnt\"><img style=\"width:318px; height:288px;\" src=\"images/ENDO/76679_Adrenal_hyperplasia_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced CT through the upper abdomen of a 72-year-old woman demonstrates uniform enlargement of the left adrenal gland (arrow), which is maintaining its shape; similar enlargement was present in the right adrenal gland (not shown). These findings are consistent with bilateral adrenal hyperplasia.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 76679 Version 4.0</div></div></div>"},"76680":{"type":"graphic_picture","displayName":"Celiac disease light","title":"Celiac disease","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Celiac disease</div><div class=\"cntnt\"><img style=\"width:390px; height:259px;\" src=\"images/GAST/76680_Celiac_disease_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a small bowel biopsy from a patient with celiac disease. The mucosa is flat with complete loss of the normal villous architecture.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 76680 Version 2.0</div></div><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Normal small intestine</div><div class=\"cntnt\"><img style=\"width:517px; height:168px;\" src=\"images/GAST/63225_Normal_small_bowel_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low (left) and high (right) power views of the normal villous architecture of the small intestine. The high power view shows the enterocytes and interspersed goblet cells (arrows).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 63225 Version 1.0</div></div></div>"},"76681":{"type":"graphic_picture","displayName":"Radical stepwise ER Endosc","title":"Radical stepwise mucosal resection in a patient with esophageal cancer","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Radical stepwise mucosal resection in a patient with esophageal cancer</div><div class=\"cntnt\"><img style=\"width:553px; height:247px;\" src=\"images/GAST/76681_Radical_stepwise_EMR_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 2 cm long segment of Barrett's esophagus is visible with a raised area subsequently found to correspond to a mucosal cancer (panels A to C). Electrocoagulation markers were placed to delineate the lesion (panel D) after which it was resected with the cap technique (panel E). A bleeding site was treated by placement of a hemoclip (panel F). Histologic evaluation of the resection specimen showed a mucosal cancer. The patient subsequently underwent stepwise complete resection of the residual Barrett's epithelium (panel G) resulting in complete neosquamous reepithelialization (panel H).</div><div class=\"graphic_reference\">Reproduced with permission from: www.Barrett.nl. Copyright &copy; Amsterdam Esophageal Research Foundation.</div><div id=\"graphicVersion\">Graphic 76681 Version 5.0</div></div></div>"},"76682":{"type":"graphic_table","displayName":"Types of germ cell neoplasms","title":"Classification of ovarian germ cell neoplasms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of ovarian germ cell neoplasms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Dysgerminoma</td> </tr> <tr> <td>Yolk sac tumor (endodermal sinus tumor)</td> </tr> <tr> <td>Embryonal carcinoma</td> </tr> <tr> <td>Polyembryoma</td> </tr> <tr> <td>Choriocarcinoma</td> </tr> <tr> <td class=\"sublist1_start\">Teratoma </td> </tr> <tr> <td class=\"sublist1\">Immature (solid, cystic, both) </td> </tr> <tr> <td class=\"sublist1\">Mature </td> </tr> <tr> <td class=\"sublist2\">Solid </td> </tr> <tr> <td class=\"sublist2\">Cystic </td> </tr> <tr> <td class=\"sublist3\">Mature cystic teratoma (dermoid cyst) </td> </tr> <tr> <td class=\"sublist3\">Mature cystic teratoma (dermoid cyst) with malignant transformation </td> </tr> <tr> <td class=\"sublist1\">Monodermal </td> </tr> <tr> <td class=\"sublist2\">Struma ovarii </td> </tr> <tr> <td class=\"sublist2\">Carcinoid </td> </tr> <tr> <td class=\"sublist2\">Struma ovarii and carcinoid </td> </tr> <tr> <td>Mixed forms</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76682 Version 3.0</div></div></div>"},"76683":{"type":"graphic_diagnosticimage","displayName":"Tracheal bronchus II","title":"Tracheal bronchus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheal bronchus</div><div class=\"cntnt\"><img style=\"width:360px; height:255px;\" src=\"images/PULM/76683_Tracheal_bronchus_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan shows a thin accessory right bronchus, originating from the right lateral aspect of the lower trachea at or below the level of the azygous vein arch. This is an incidental finding.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 76683 Version 2.0</div></div></div>"},"76684":{"type":"graphic_table","displayName":"Indications for urinary bladder catheters","title":"Indications for urinary bladder catheters","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for urinary bladder catheters</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"52%\"></colgroup><colgroup span=\"4\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Indications</td> <td class=\"subtitle1\" colspan=\"4\">Type of catheter</td> </tr> <tr> <td class=\"subtitle2\">Indwelling urethral</td> <td class=\"subtitle2\">Intermittent urethral</td> <td class=\"subtitle2\">Suprapubic</td> <td class=\"subtitle2\">Condom</td> </tr> <tr class=\"divider_bottom\"> <td>Urinary retention</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> </tr> <tr class=\"divider_bottom\"> <td>Hourly urine output monitoring in critically ill patient</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> </tr> <tr class=\"divider_bottom\"> <td>Daily urine output monitoring for fluid management or diagnostic test</td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">N</td> <td class=\"centered\">Y</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"5\">Intra- and postoperative monitoring:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Patients undergoing prolonged duration of surgery </li> </ul> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Patients requiring large-volume infusions or diuretics </li> </ul> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Patients requiring intraoperative monitoring of urinary output </li> </ul> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Patients with urinary incontinence </li> </ul> </td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> </tr> <tr class=\"divider_bottom\"> <td>Post-prostate, bladder, or gynecologic surgery*</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> </tr> <tr class=\"divider_bottom\"> <td>Hematuria with clots</td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> </tr> <tr class=\"divider_bottom\"> <td>Prolonged immobilization</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> </tr> <tr class=\"divider_bottom\"> <td>Urinary incontinence in patients who fail behavioral and pharmacological therapy and incontinence pads</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> <td class=\"centered\">N</td> <td class=\"centered\">Y</td> </tr> <tr class=\"divider_bottom\"> <td>Neurogenic bladder/spinal cord patients</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> </tr> <tr class=\"divider_bottom\"> <td>Assist in healing of open sacral or perineal wounds in incontinent patients</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> </tr> <tr> <td>Improve comfort for end-of-life care</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> <td class=\"centered\">Y</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* After a transurethral resection of the prostate (TURP), intermittent urethral catheterization is not appropriate within the first seven postoperative days.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Gould CV, Umscheid CA, Agarwal RK, et al. Guideline for the prevention of catheter-associated urinary tract infections 2008. Department of Health and Human Services. Centers for Disease Control and Prevention.</li>&#xD;&#xA;    <li>Meddings J, Saint S, Fowler KE, et al. The Ann Arbor Criteria for Appropriate Urinary Catheter Use in Hospitalized Medical Patients: Results Obtained by Using the RAND/UCLA Appropriateness Method. Ann Intern Med 2015; 162:S1.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 76684 Version 6.0</div></div></div>"},"76685":{"type":"graphic_figure","displayName":"Langers lines of the abdomen","title":"Langers lines of the abdomen","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Langers lines of the abdomen</div><div class=\"cntnt\"><img style=\"width:456px; height:679px;\" src=\"images/SURG/76685_Langers_lines_abdomen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Langer's lines are lines of skin tension. Because these lines are predominantly horizontal in the abdomen, transverse incisions generate less tension in the skin.</div><div id=\"graphicVersion\">Graphic 76685 Version 2.0</div></div></div>"},"76686":{"type":"graphic_picture","displayName":"Pseudofolliculitis barbae - hair loop","title":"Pseudofolliculitis barbae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudofolliculitis barbae</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/76686_Pseudofol_barbae_hair_loop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pseudofolliculitis barbae. A loop of hair exiting and entering the skin is visible at the site of the erythematous papule.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76686 Version 4.0</div></div></div>"},"76687":{"type":"graphic_figure","displayName":"Guide for lateral cervical spine x-ray","title":"Guide for lateral cervical spine x-ray","html":"<div class=\"graphic\"><div style=\"width: 692px\" class=\"figure\"><div class=\"ttl\">Guide for lateral cervical spine x-ray</div><div class=\"cntnt\"><img style=\"width:672px; height:683px;\" src=\"images/EM/76687_Guide_lat_cerv_spine_xrayPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Mower WR, Hoffman JR, Mahadevan SV. Cervical spine fractures. In: Harwood-Nuss Clinical Practice of Emergency Medicine, 5th ed, Wolfson AB (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 76687 Version 5.0</div></div></div>"},"76689":{"type":"graphic_table","displayName":"Pregnancy loss rates after selective termination","title":"Pregnancy loss rates after selective termination by starting number, finishing number, and by number of fetuses reduced","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pregnancy loss rates after selective termination by starting number, finishing number, and by number of fetuses reduced</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Loss rates, percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Starting number (n)</td> </tr> <tr> <td class=\"indent1\">2 (164)</td> <td>2.4</td> </tr> <tr> <td class=\"indent1\">&#8805;3 (36)</td> <td>11.1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Finishing number</td> </tr> <tr> <td class=\"indent1\">1 (170)</td> <td>3.8</td> </tr> <tr> <td class=\"indent1\">&#8805;2 (30)</td> <td>3.3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Number of fetuses reduced</td> </tr> <tr> <td class=\"indent1\">1 (193)</td> <td>2.6</td> </tr> <tr> <td class=\"indent1\">2 (7)</td> <td>42.9</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Stone J, Eddleman K, Lynch L, Berkowitz RL. A single center experience with 1000 consecutive cases of multifetal pregnancy reduction. Am J Obstet Gynecol 2002; 187:1163. Copyright &copy; 2002 Elsevier.</div><div id=\"graphicVersion\">Graphic 76689 Version 3.0</div></div></div>"},"76691":{"type":"graphic_table","displayName":"Progn ampullary CA","title":"Five-year survival in a series of 1301 patients with ampullary cancer reported to the SEER* registry between 1988 and 2003","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Five-year survival in a series of 1301 patients with ampullary cancer reported to the SEER* registry between 1988 and 2003</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\" rowspan=\"2\">\r\n  \r\n   Stage at presentation\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\" rowspan=\"2\">\r\n  \r\n   N\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\" colspan=\"2\">\r\n  \r\n   Five-year survival percent\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   OS\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   CSS\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ia</td>\r\n  \r\n   <td>218</td>\r\n  \r\n   <td>60</td>\r\n  \r\n   <td>74</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ib</td>\r\n  \r\n   <td>255</td>\r\n  \r\n   <td>57</td>\r\n  \r\n   <td>66</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>IIa</td>\r\n  \r\n   <td>252</td>\r\n  \r\n   <td>30</td>\r\n  \r\n   <td>41</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>IIb</td>\r\n  \r\n   <td>483</td>\r\n  \r\n   <td>22</td>\r\n  \r\n   <td>30</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>III</td>\r\n  \r\n   <td>38</td>\r\n  \r\n   <td>27</td>\r\n  \r\n   <td>34</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>IV</td>\r\n  \r\n   <td>15</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"4\">\r\n  \r\n   N stage\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   N0\r\n  \r\n   </td>\r\n  \r\n   <td>518</td>\r\n  \r\n   <td>48</td>\r\n  \r\n   <td>59</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   N1\r\n  \r\n   </td>\r\n  \r\n   <td>749</td>\r\n  \r\n   <td>21</td>\r\n  \r\n   <td>28</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">OS: overall survival; CSS: cause-specific survival.<br> * SEER: Surveillance, Epidemiology and End Results database of the National Cancer Institute.</div><div class=\"graphic_reference\">Modified from: O'Connell, et al. Ann Surg Oncol 2008; 15:1820.</div><div id=\"graphicVersion\">Graphic 76691 Version 1.0</div></div></div>"},"76692":{"type":"graphic_diagnosticimage","displayName":"CPAM type 1 chest x-ray","title":"Chest radiographs of a type 1 congenital pulmonary airway malformation (CPAM)*","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Chest radiographs of a type 1 congenital pulmonary airway malformation (CPAM)*</div><div class=\"cntnt\"><img style=\"width:528px; height:270px;\" src=\"images/PEDS/76692_CCAM_type_1_chest_x-ray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiographs (posterior-anterior and lateral views) showing a type 1 congenital pulmonary airway malformation (CPAM) in the right upper lobe. The large cystic lesion was an incidental finding on a film of a one-year-old child who ingested a coin. The coin is visible on both views, lodged in the esophagus.</div><div class=\"graphic_footnotes\">*CPAM was previously known as congenital cystic adenomatoid malformation (CCAM).</div><div class=\"graphic_reference\">Courtesy of Christopher M Oermann, MD.</div><div id=\"graphicVersion\">Graphic 76692 Version 4.0</div></div></div>"},"76693":{"type":"graphic_picture","displayName":"Clitoromegaly2","title":"Clitoromegaly ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clitoromegaly </div><div class=\"cntnt\"><img style=\"width:263px; height:390px;\" src=\"images/PEDS/76693_Clitoromegaly2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clitoral enlargement in an infant with a 46,XX karyotype.</div><div class=\"graphic_reference\">Reproduced with permission from: Clark DA. Atlas of Neonatology - A companion to Disease of the Newborn, 1st ed. WB Saunders Co., Philadelphia 2000. Copyright &#169; 2000 Elsevier.</div><div id=\"graphicVersion\">Graphic 76693 Version 4.0</div></div></div>"},"76694":{"type":"graphic_diagnosticimage","displayName":"MRI of boy with ADEM","title":"Brain and spine MRI of a 7 year old boy with acute disseminated encephalomyelitis (ADEM)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain and spine MRI of a 7 year old boy with acute disseminated encephalomyelitis (ADEM)</div><div class=\"cntnt\"><img style=\"width:431px; height:384px;\" src=\"images/PEDS/76694_MRI_7_yr_old_ADEM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial T2-weighted magnetic resonance imaging (MRI)&nbsp;of the brain&nbsp;show relatively symmetric high signal intensity in the deep gray matter, including bilateral thalami (panel A). There is also high T2 signal within the left aspect of the pons (panel B). Sagittal T2-weighted MRI of the cervical spine demonstrates expansion/swelling and high signal intensity within the spinal cord (panel C), and corresponding axial T2-weighted MRI reveal that the high signal is mostly posterior (panel D). One month later, T2-weighted axial images demonstrate resolution of the findings in the deep gray matter (panel E) and pons (panel F).</div><div class=\"graphic_reference\">Courtesy of Eric D Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 76694 Version 5.0</div></div></div>"},"76695":{"type":"graphic_figure","displayName":"Anterior and posterior columns of acetabulum","title":"Anterior and posterior columns of acetabulum","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Anterior and posterior columns of acetabulum</div><div class=\"cntnt\"><img style=\"width:549px; height:341px;\" src=\"images/EM/76695_Acetabulum_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Matta, JM. Surgical Treatment of Acetabular Fractures. In: Skeletal Trauma: Basic Science, Management, and Reconstruction, Browner, BD, Jupiter, JB, Levine, AM, Trafton, PG (Eds), Saunders, Philadelphia 2003. p.1110-12. Illustrations used with permission of Elsevier Inc. All rights reserved. Copyright &#169;2003 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 76695 Version 2.0</div></div></div>"},"76698":{"type":"graphic_figure","displayName":"Ureter and uterine artery","title":"Identification of the ureter and ligating the uterine artery during hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Identification of the ureter and ligating the uterine artery during hysterectomy</div><div class=\"cntnt\"><img style=\"width:430px; height:304px;\" src=\"images/OBGYN/76698_Ureter_and_uterine_artery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With sharp dissection, the ureter is dissected free of its soft tissue attachments from its point of entry into the pelvis to its insertion into the bladder. The uterine artery is then identified, divided at its origin, and reflected medially. Identification of the uterine artery can be facilitated by placing downward tension on the superior vesical artery on the ipsilateral side. This causes all of the branches of the internal iliac artery to be tensed and makes them more readily identified.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 76698 Version 3.0</div></div></div>"},"76699":{"type":"graphic_table","displayName":"Tracheostomy versus intubation","title":"Advantages and disadvantages of tracheostomy versus tracheal intubation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of tracheostomy versus tracheal intubation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Tracheostomy</td> <td class=\"subtitle1\">Intubation</td> </tr> <tr> <td>Advantages</td> <td> <p>Ease of replacement (once tract has formed)</p> <p>Speech, mobility, and swallowing enhanced</p> <p>Patient can be nursed outside of ICU</p> <p>Ease of suctioning</p> <p>Patient comfort</p> </td> <td> <p>Rapid insertion by skilled consultant in most settings</p> <p>Lack of need for surgical procedure (risk, expense)</p> <p>Lack of stomal complications</p> </td> </tr> <tr> <td>Disadvantages</td> <td> <p>Complications at cuff site</p> <p>Stomal complications</p> <p>Possible contribution to ultimate laryngeal injury </p> <p>Tracheo-innominate artery fistula formation</p> <p>Possible increase in pulmonary infections</p> <p>Access to mediastinum by infectious agents after local surgery</p> <p>High mortality for inadvertent decannulation before tract formation</p> </td> <td> <p>Complications at cuff site</p> <p>Laryngeal complications</p> <p>Replacement requires skill at all times</p> <p>Generally requires ICU level supervision</p> <p>Injuries at nose or mouth</p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76699 Version 2.0</div></div></div>"},"76700":{"type":"graphic_figure","displayName":"Gastric erosion","title":"Band erosion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Band erosion</div><div class=\"cntnt\"><img style=\"width:378px; height:454px;\" src=\"images/SURG/76700_Band_erosion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Band erosion through the wall of the stomach is thought to occur as a result of either gastric wall ischemia from an excessively tight band, mechanical trauma related to the band buckle or thermal trauma from electrosurgical energy sources used during band placement.</div><div class=\"graphic_reference\">Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury, Connecticut 2010. Copyright &#169; 2010 Cine-Med.</div><div id=\"graphicVersion\">Graphic 76700 Version 4.0</div></div></div>"},"76701":{"type":"graphic_figure","displayName":"Lumbar plexus","title":"Lumbar plexus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lumbar plexus</div><div class=\"cntnt\"><img style=\"width:429px; height:411px;\" src=\"images/SURG/76701_Lumbar_plexus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lumbar plexus is formed by the ventral rami of the lumbar nerve roots and supplies the muscular and cutaneous innervation to the lower extremity.</div><div class=\"graphic_footnotes\">n.: nerve.</div><div id=\"graphicVersion\">Graphic 76701 Version 3.0</div></div></div>"},"76702":{"type":"graphic_diagnosticimage","displayName":"Juvenile angiofibroma","title":"Axial CT and endoscopic nasal view of a juvenile angiofibroma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Axial CT and endoscopic nasal view of a juvenile angiofibroma</div><div class=\"cntnt\"><img style=\"width:267px; height:514px;\" src=\"images/EM/76702_Juvenile_angiofibroma_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This juvenile angiofibroma was a cause of repeated epistaxis in this teenage boy. Axial computed tomography with contrast shows a vascular mass arising from the pterygopalatine fossa and filling the nasopharynx (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 76702 Version 4.0</div></div></div>"},"76703":{"type":"graphic_figure","displayName":"Endoscopic component separation technique rectus muscle release","title":"Endoscopic component separation technique rectus muscle release","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic component separation technique rectus muscle release</div><div class=\"cntnt\"><img style=\"width:351px; height:328px;\" src=\"images/SURG/76703_ECST-rectus-muscle-release.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The skin and subcutaneous tissue flaps are carefully dissected from the rectus sheath for no more than 1 to 2 cm, taking special care to avoid disruption of the perforating vessels from the anterior surface of the rectus muscle.</div><div class=\"graphic_reference\">Lowe JB, Garza JR, Bowman JL, et al. Endoscopically assisted &quot;components separation&quot; for closure of abdominal wall defects. Plast Reconstr Surg 2000; 105:720.</div><div id=\"graphicVersion\">Graphic 76703 Version 4.0</div></div></div>"},"76706":{"type":"graphic_picture","displayName":"Lymphedema stageII AB","title":"Lymphedema stage II","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Lymphedema stage II</div><div class=\"cntnt\"><img style=\"width:512px; height:408px;\" src=\"images/ONC/76706_Lymphedema_stageII_AB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stage II lymphedema. A) Left upper extremity. B) Right lower extremity.</div><div class=\"graphic_reference\">Courtesy of Tammy Mondry, DPT, MSRS, CLT-LANA.</div><div id=\"graphicVersion\">Graphic 76706 Version 2.0</div></div></div>"},"76707":{"type":"graphic_table","displayName":"Non onc indic MTX","title":"Non-oncologic conditions for which methotrexate is prescribed*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Non-oncologic conditions for which methotrexate is prescribed*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Rheumalogic disorders</td> </tr> <tr> <td>Rheumatoid arthritis</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Granulomatosis with polyangiitis (Wegener's) and other vasculitides</td> </tr> <tr> <td>Eosinophilic fasciitis</td> </tr> <tr> <td>Systemic sclerosis</td> </tr> <tr> <td>Inflammatory myopathies (dermatomyositis/polymyositis)</td> </tr> <tr> <td>Juvenile inflammatory arthritis</td> </tr> <tr> <td class=\"subtitle1_single\">Dermatologic disorders</td> </tr> <tr> <td>Psoriasis</td> </tr> <tr> <td>Hidradenitis suppurativa</td> </tr> <tr> <td class=\"subtitle1_single\">Gastroenterologic disorders</td> </tr> <tr> <td>Primary biliary cirrhosis</td> </tr> <tr> <td>Crohn's disease</td> </tr> <tr> <td>Autoimmune hepatitis</td> </tr> <tr> <td>Granulomatosis hepatitis</td> </tr> <tr> <td class=\"subtitle1_single\">Obstetrics/gynecology disorders</td> </tr> <tr> <td>Placenta accreta</td> </tr> <tr> <td>Ectopic pregnancy</td> </tr> <tr> <td>Medical termination of pregnancy</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td>Graft-versus-host disease</td> </tr> <tr> <td>Multiple sclerosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Not an inclusive list.</div><div id=\"graphicVersion\">Graphic 76707 Version 3.0</div></div></div>"},"76708":{"type":"graphic_figure","displayName":"Pathways endothelial cell","title":"The pathways within the endothelial cell that contribute to renal cell carcinoma progression","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">The pathways within the endothelial cell that contribute to renal cell carcinoma progression</div><div class=\"cntnt\"><img style=\"width:539px; height:421px;\" src=\"images/ONC/76708_Pathways_endothelial_cell.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vascular endothelial growth factor (VEGF) binds to its receptors inducing vascular growth. Several agents block VEGF either by binding to it (antibodies), blocking receptor signaling (small molecules), or by blocking at several steps inside the endothelial cell.</div><div class=\"graphic_reference\">Reproduced with permission from: Atkins M. Nephrology Forum: Management of advanced renal cancer. Kidney Int 2005; 67:2069. Copyright © 2005 Blackwell Publishing.</div><div id=\"graphicVersion\">Graphic 76708 Version 4.0</div></div></div>"},"76709":{"type":"graphic_diagnosticimage","displayName":"MRI basal ganglia capsular infarct","title":"Diffusion-weighted MRI of basal ganglia and capsular infarction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffusion-weighted MRI of basal ganglia and capsular infarction</div><div class=\"cntnt\"><img style=\"width:290px; height:351px;\" src=\"images/PEDS/76709_Basal_ganglia_capsular_infa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffusion MRI (axial view) showing a right basal ganglia and capsular high intensity lesion consistent with acute infarction (arrow).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 76709 Version 5.0</div></div></div>"},"76710":{"type":"graphic_table","displayName":"Causes postinf GN","title":"Bacterial and viral agents associated with post-infectious glomerulonephritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bacterial and viral agents associated with post-infectious glomerulonephritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Bacterial infections</td> </tr> <tr> <td>Skin or throat (Streptococcus group A)</td> </tr> <tr> <td>Endocarditis (Staphylococcus aureus, Streptococcus viridans)</td> </tr> <tr> <td>Visceral abcess (Staphylococcus aureus, E. coli, Pseudomonas, Proteus mirabilis)</td> </tr> <tr> <td>Shunt nephritis (Staphylococcus aureus, Staphylococcus albus, Streptococcus viridans)</td> </tr> <tr> <td>Pneumonia (Diplococcus pneumoniae, Mycoplasma)</td> </tr> <tr> <td>Typhoid fever (Salmonella typhi)</td> </tr> <tr> <td class=\"subtitle1_single\">Viral infections</td> </tr> <tr> <td>Epstein Barr virus</td> </tr> <tr> <td>Parvovirus B19</td> </tr> <tr> <td>Varicella</td> </tr> <tr> <td>Cytomegalovirus infection</td> </tr> <tr> <td>Coxsackie</td> </tr> <tr> <td>Rubella</td> </tr> <tr> <td>Mumps</td> </tr> <tr> <td>Hepatitis B</td> </tr> <tr> <td class=\"subtitle1_single\">Parasitic infections</td> </tr> <tr> <td>Schistosoma mansoni</td> </tr> <tr> <td>Plasmodium falciparum</td> </tr> <tr> <td>Toxoplasma gondii</td> </tr> <tr> <td>Filaria</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Original figure modified for this publication. Reproduced with permission from: Niaudet P. Nephritic Syndrome. In: Comprehensive Pediatric Nephrology, Geary DF, Schaefer F (Eds), Mosby, Philadelphia 2008. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 76710 Version 3.0</div></div></div>"},"76711":{"type":"graphic_algorithm","displayName":"Universal airway management algorithm","title":"Universal emergency airway algorithm©","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Universal emergency airway algorithm©</div><div class=\"cntnt\"><img style=\"width:365px; height:302px;\" src=\"images/EM/76711_Universalairwayalgo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm demonstrates how the emergency airway algorithms work together.</div><div class=\"graphic_reference\">Reproduced with permission from: The Difficult Airway Course®: Emergency and Brown III CA, Walls RM. The Emergency Airway Algorithms. In: The Walls Manual of Emergency Airway Management, 5th ed, Brown III CA, Sakles JC, Mick NW (Eds), Wolters Kluwer, Philadelphia 2018. Copyright © 2018 Wolters Kluwer.</div><div id=\"graphicVersion\">Graphic 76711 Version 14.0</div></div></div>"},"76712":{"type":"graphic_diagnosticimage","displayName":"Benign gastric ulcer UGI","title":"Gastric ulcer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric ulcer</div><div class=\"cntnt\"><img style=\"width:309px; height:252px;\" src=\"images/GAST/76712_Benign_gastric_ulcer_UGI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image from an upper gastrointestinal (GI) series demonstrates a small ulcer crater (arrow) with smooth folds radiating into the center of the ulcer. This feature suggests benignity, which was confirmed by biopsy. The patient responded to conventional antiulcer therapy.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 76712 Version 3.0</div></div></div>"},"76713":{"type":"graphic_table","displayName":"Clinical uses of somatostatin","title":"Clnical uses of the long-acting somatostatin receptor agonists","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clnical uses of the long-acting somatostatin receptor agonists</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Tumors\n   </td>\n   </tr>\n   <tr>\n   <td>Acromegaly</td>\n   </tr>\n   <tr>\n   <td>Thyrotropinoma</td>\n   </tr>\n   <tr>\n   <td>ACTH-secreting tumors</td>\n   </tr>\n   <tr>\n   <td>Zollinger-Ellison syndrome</td>\n   </tr>\n   <tr>\n   <td>Carcinoid syndrome</td>\n   </tr>\n   <tr>\n   <td>VIPoma (Verner Morisson/pancreatic cholera/watery diarrhea, hypokalemia, achlorhydria)</td>\n   </tr>\n   <tr>\n   <td>Glucagonoma</td>\n   </tr>\n   <tr>\n   <td>Insulinoma</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Other therapeutic uses\n   </td>\n   </tr>\n   <tr>\n   <td>HIV-associated diarrhea</td>\n   </tr>\n   <tr>\n   <td>Portal hypertension</td>\n   </tr>\n   <tr>\n   <td>Pancreatic fistula</td>\n   </tr>\n   <tr>\n   <td>Enteric fistula</td>\n   </tr>\n   <tr>\n   <td>Secretory diarrhea</td>\n   </tr>\n   <tr>\n   <td>Chemotherapy induced diarrhea</td>\n   </tr>\n   <tr>\n   <td>Diabetic diarrhea</td>\n   </tr>\n   <tr>\n   <td>Radiation induced diarrhea</td>\n   </tr>\n   <tr>\n   <td>Short bowel syndrome</td>\n   </tr>\n   <tr>\n   <td>Graft-versus-host disease related diarrhea</td>\n   </tr>\n   <tr>\n   <td>Diabetic retinopathy</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 76713 Version 1.0</div></div></div>"},"76715":{"type":"graphic_picture","displayName":"Parastomal hernia","title":"Parastomal hernia","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Parastomal hernia</div><div class=\"cntnt\"><img style=\"width:516px; height:254px;\" src=\"images/SURG/76715_Parastomal_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) An anterior view of a large paracolostomy hernia. Note the skin breakdown in the peristomal area where the appliance would be placed. This commonly occurs due to the pressure required to maintain the appliance in place against a large parastomal hernia.<br />(B) A lateral view of a large paracolostomy hernia.</div><div class=\"graphic_reference\">Courtesy of Robert Cima, MD</div><div id=\"graphicVersion\">Graphic 76715 Version 3.0</div></div></div>"},"76716":{"type":"graphic_picture","displayName":"Ankle fracture after resolution of CRPS","title":"Ankle fracture after resolution of complex regional pain syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ankle fracture after resolution of complex regional pain syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/EM/76716_Ankle_frac_after_res_CRPS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CRPS, 28 days after injury. The patient responded to gabapentin, early motion, tactile stimulation, and lumbar sympathetic nerve block. This photo (taken four days after a lumbar sympathetic nerve block and five days after the photo &quot;Ankle fracture complicated by complex regional pain syndrome&quot;) shows improvement in the swelling and skin changes. The patient recovered fully after three months of treatment.</div><div class=\"graphic_reference\">Courtesy of Scott M Koehler, MD.</div><div id=\"graphicVersion\">Graphic 76716 Version 4.0</div></div></div>"},"76717":{"type":"graphic_figure","displayName":"Superficial fibular (peroneal) nerve","title":"Normal and variant anatomy of the superficial fibular (peroneal) nerve","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Normal and variant anatomy of the superficial fibular (peroneal) nerve</div><div class=\"cntnt\"><img style=\"width:535px; height:673px;\" src=\"images/SURG/76717_Superficial_fibular_nerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The superficial fibular (peroneal) nerve (in yellow) branches from the common fibular (peroneal) nerve at or below the proximal fibular head. The nerve descends in its 'normal' course (A) in the lateral compartment adjacent the intermuscular septum (in blue) of the anterior and lateral compartments. Between 27 and 43 percent of patients have the superficial fibular (peroneal) in either the anterior compartment (B) or both the anterior and the lateral compartments (C) of the leg. The superficial fibular (peroneal) nerve has also been found in close proximity to the septum that separates the anterior from the lateral compartment (D).</div><div class=\"graphic_reference\">Redrawn based on information from: Adkison DP, Bosse MJ, Gaccione DR, Gabriel KR. Anatomical variations in the course of the superficial peroneal nerve. J Bone Joint Surg Am 1991; 73:112.</div><div id=\"graphicVersion\">Graphic 76717 Version 6.0</div></div></div>"},"76718":{"type":"graphic_movie","displayName":"Ultrasound persistent median artery","title":"Ultrasound persistent median artery","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound persistent median artery</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/NEURO/76718_USpersistmedianartconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:514px; height:253px;\" src=\"images/NEURO/76718_USpersistmedartery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a real-time axial image of the median nerve (N) at the wrist in a healthy subject with a persistent median artery (A). Note that the nerve and artery are in the same fibrous tissue sheath, as they move together with piano-playing movements of the fingers. The pulsations of the artery are apparent on B-mode and the presence of Doppler signal further confirms pulsatile flow through this structure.</div><div class=\"graphic_reference\">Courtesy of Francis O Walker, MD.</div><div id=\"graphicVersion\">Graphic 76718 Version 2.0</div></div></div>"},"76719":{"type":"graphic_table","displayName":"Pharmacologic treatment and prevention of high altitude illness","title":"Pharmacologic treatment and prevention of high altitude illness (HAI)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacologic treatment and prevention of high altitude illness (HAI)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Preferred agent</td> <td class=\"subtitle1\">Alternatives</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>AMS/HACE</strong></td> <td>Prevention*</td> <td><strong>Acetazolamide:</strong> 125 mg orally every 12 hours<br /> <p>Children: 2.5 mg/kg (maximum single dose: 125 mg) orally every 12 hours<sup>&#165;</sup></p> Duration: start day before ascent and continue 2-3 days at maximum altitude; may use once at night thereafter to improve sleep</td> <td><strong>Dexamethasone:</strong> 2 mg orally every 6 hours or 4 mg orally every 12 hours<br /> <p>Children: Acetazolamide preferred, do not use for prophylaxis</p> Duration: start day of ascent and continue 2-3 days at maximum altitude, but for no more than 7 days total </td> </tr> <tr> <td>Treatment mild AMS<sup>&#182;</sup></td> <td><strong>Acetazolamide:</strong> 125 to 250 mg orally every 12 hours<br /> <p>Children: 2.5 mg/kg (maximum single dose: 250 mg) orally every 12 hours<sup>&#165;</sup></p> Duration: continue for 24 hours after symptoms resolve or descent accomplished</td> <td><strong>Dexamethasone:</strong> 2 to 4 mg orally every 6 hours<br /> <p>Children: 0.15 mg/kg orally every 6 hours(maximum single dose: 4 mg)</p> Duration: continue until 24 hours after symptoms resolve or descent completed, but not longer than 7 days total</td> </tr> <tr> <td>Treatment moderate to severe AMS</td> <td><strong>Dexamethasone:<sup></sup></strong><sup>&#916;</sup><sup><span style=\"font-family: Calibri;\"> </span></sup>4 mg orally every 6 hours<br /> <p>Children: 0.15 mg/kg orally (maximum single dose: 4 mg) every 6 hours</p> Duration: continue until 24 hours after symptoms resolve or descent completed, but not longer than 7 days total</td> <td><strong>Acetazolamide:</strong> 125 to 250 mg orally every 12 hours<br /> <p>Children: 2.5 mg/kg (maximum single dose: 250 mg) orally every 12 hours<sup>&#165;</sup></p> Duration: continue for 24 hours after symptoms resolve or descent accomplished</td> </tr> <tr class=\"divider_bottom\"> <td>HACE treatment</td> <td><strong>Dexamethasone:<sup></sup></strong><sup>&#916;</sup> 8 to 10&nbsp;mg orally /IM/IV once, then 4 mg orally/IM/IV every 6 hours<br /> <p>Children: 0.15 mg/kg every 6 hours (maximum single dose: 4 mg)</p> Duration: continue until 24 hours after symptoms resolve or descent completed, but not longer than 7 days total</td> <td><strong>Acetazolamide:</strong> 250 mg orally every 12 hours, may use as adjunct with dexamethasone; NOT for monotherapy<br /> <p>Children: 2.5 mg/kg (maximum single dose: 250 mg) orally every 12 hours<sup>&#165;</sup></p> Duration: continue until 24 hours after symptoms resolve or descent accomplished</td> </tr> <tr> <td rowspan=\"2\"><strong>HAPE</strong></td> <td>HAPE prevention*</td> <td><strong>Nifedipine:</strong> 60 mg extended-release orally divided daily (30 mg orally every 12 hrs; or 20 mg orally every 8 hours).<sup>&#9674;</sup> <p>Children: 0.5 mg/kg (maximum single dose: 20 mg) extended-release orally every 8 hours<sup><span style=\"font-size: 13px;\">&#9674;</span></sup></p> Duration: start day before ascent and continue for 3-5 days at maximum altitude</td> <td> <p>Further research is needed before the medications listed below can be recommended for routine use:</p> <p><strong>Tadalafil:</strong> 10 mg orally every 12 hours; start day of ascent and continue 3-5 days at maximum altitude</p> <p><strong>Sildenafil:</strong> 50 mg orally every 8 hours; start day of ascent and continue 3-5 days at maximum altitude</p> <p><strong>Dexamethasone:</strong> 8 mg orally every 12 hours; start day of ascent and continue 48-72 hours at maximum altitude</p> <strong>Acetazolamide:</strong> 125 to 250 mg orally every 12 hours; start day before ascent and continue 48-72 hours at maximum altitude</td> </tr> <tr> <td>HAPE treatment<sup>&#167;</sup></td> <td><strong>Nifedipine:</strong> 60 mg extended-release orally divided daily (30 mg orally every 12 hours; or 20 mg orally every 8 hours).<sup><span style=\"font-size: 13px;\">&#9674;</span></sup> <p>Children: 0.5 mg/kg (maximum single dose: 20 mg) extended-release orally every 8 hours<sup><span style=\"font-size: 13px;\">&#9674;</span></sup></p> <p>Duration: continue until descent completed, symptoms resolved and SpO2 normal for altitude</p> </td> <td> <p>Further research is needed before the medications listed below can be recommended for routine use in HAPE treatment:</p> <p><strong>Tadalafil:</strong> 10 mg orally every 12 hours</p> <p><strong>Sildenafil:</strong> 50 mg orally every 8 hours</p> Duration: continue until descent completed, symptoms resolved and SpO2 normal for altitude</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AMS: acute mountain sickness; HACE: high altitude cerebral edema; HAPE: high altitude pulmonary edema; IM: intramuscular; NSAID: nonsteroidal antiinflammatory drug<br />* Gradual ascent profile is primary method of prevention. Reserve pharmacologic prophylaxis for all patients at high risk and selected patients at moderate risk of developing HAI according to criteria listed in the separate table. Provision of rescue medications is a reasonable alternative. Refer to accompanying text.<br />¶ May not require pharmacologic treatment. Rest, halt ascent, and symptomatic treatment (eg, acetaminophen or NSAID for headache and ondansetron for nausea/vomiting) may be sufficient. Refer to accompanying text.<br />Δ Treatment with dexamethasone alleviates symptoms of AMS/HACE&nbsp; but does not improve acclimatization. Dexamethasone is not a substitute for immediate descent in HACE.<br />◊ In United States the lowest strength extended-release nifedipine oral preparation available is 30 mg. In some other countries, 10 and 20 mg extended-release preparations&nbsp;are&nbsp;available.&nbsp;<br />§&nbsp;May not require any pharmacologic intervention. In proper setting, rest and supplemental oxygen may be sufficient. Refer to accompanying&nbsp;text.<br />¥ For immediate administration in children,&nbsp;a liquid acetazolamide solution can be made by crushing a 125 mg or 250 mg tablet and suspending it in cherry, chocolate, or other flavored syrup to hide the bitter taste. A flavored oral suspension useful in patients who cannot swallow pills or for measurement of doses used in smaller children (eg &lt;125 mg) can also be compounded by a pharmacy. Detail is available in the acetazolamide pediatric drug monograph.</div><div class=\"graphic_reference\">Courtesy of Scott Gallagher, MD and Peter Hackett, MD with additional data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Luks A, McIntosh S, Grissom CK, et al. Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness. Wilderness Environ Med 2010; 21:146.</LI>&#xD;&#xA;<LI>Pollard A, Niermeyer S, Barry P, et al. Children at High Altitude: An International Consensus, Statement by an Ad Hoc Committee of the International Society for Mountain Medicine, March 12, 2001. High Altitude Medicine &amp; Biology. Volume 2, Number 3, 2001. Mary Ann Liebert, Inc. Pages 389-403.</LI></OL></div><div id=\"graphicVersion\">Graphic 76719 Version 12.0</div></div></div>"},"76720":{"type":"graphic_picture","displayName":"Seborrheic keratosis temple","title":"Seborrheic keratosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seborrheic keratosis</div><div class=\"cntnt\"><img style=\"width:360px; height:229px;\" src=\"images/DERM/76720_Seborrheic_keratosis_temple.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Seborrheic keratosis on the right temple of a 57-year-old man with verrucous (wart-like) texture and dark-brown coloration.</div><div id=\"graphicVersion\">Graphic 76720 Version 1.0</div></div></div>"},"76722":{"type":"graphic_table","displayName":"mCRC severe chemo tox","title":"Incidence of severe chemotherapy toxicity by age in trials of metastatic colorectal cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of severe chemotherapy toxicity by age in trials of metastatic colorectal cancer</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\" rowspan=\"2\">\r\n  \r\n   Author\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\" rowspan=\"2\">\r\n  \r\n   Regimen\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\" colspan=\"2\">\r\n  \r\n   Neutropenia\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\" colspan=\"2\">\r\n  \r\n   Thrombocytopenia\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\" colspan=\"2\">\r\n  \r\n   Mucositis\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\" colspan=\"2\">\r\n  \r\n   Diarrhea\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   &#60;70 yrs, percent\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   &#8805;70 yrs, percent\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   &#60;70 yrs, percent\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   &#8805;70 yrs, percent\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   &#60;70 yrs, percent\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   &#8805;70 yrs, percent\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   &#60;70 yrs, percent\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   &#8805;70 yrs, percent\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   Sargent, D; 2001\r\n  \r\n   </td>\r\n  \r\n   <td>5-FU/LV</td>\r\n  \r\n   <td>4</td>\r\n  \r\n   <td>8</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>11</td>\r\n  \r\n   <td>15</td>\r\n  \r\n   <td>15</td>\r\n  \r\n   <td>15</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>5-FU/Lev</td>\r\n  \r\n   <td>17</td>\r\n  \r\n   <td>31</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>5</td>\r\n  \r\n   <td>9</td>\r\n  \r\n   <td>9</td>\r\n  \r\n   <td>11</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   Folprecht, G; 2006\r\n  \r\n   </td>\r\n  \r\n   <td>5-FU</td>\r\n  \r\n   <td>27</td>\r\n  \r\n   <td>37</td>\r\n  \r\n   <td>1</td>\r\n  \r\n   <td>1</td>\r\n  \r\n   <td>6</td>\r\n  \r\n   <td>8</td>\r\n  \r\n   <td>20</td>\r\n  \r\n   <td>23</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Irinotecan/5-FU</td>\r\n  \r\n   <td>35</td>\r\n  \r\n   <td>39</td>\r\n  \r\n   <td>1</td>\r\n  \r\n   <td>2</td>\r\n  \r\n   <td>3</td>\r\n  \r\n   <td>9</td>\r\n  \r\n   <td>28</td>\r\n  \r\n   <td>34</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Goldberg, R; 2006</td>\r\n  \r\n   <td>FOLFOX</td>\r\n  \r\n   <td>43</td>\r\n  \r\n   <td>49</td>\r\n  \r\n   <td>2</td>\r\n  \r\n   <td>5</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>11</td>\r\n  \r\n   <td>13</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Arkenau, H; 2008</td>\r\n  \r\n   <td>FOLFOX or CAPOX</td>\r\n  \r\n   <td>6</td>\r\n  \r\n   <td>9</td>\r\n  \r\n   <td>1</td>\r\n  \r\n   <td>4</td>\r\n  \r\n   <td>2</td>\r\n  \r\n   <td>2</td>\r\n  \r\n   <td>12</td>\r\n  \r\n   <td>21</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   Sastre, J; 2009\r\n  \r\n   </td>\r\n  \r\n   <td>CAPOX</td>\r\n  \r\n   <td>5</td>\r\n  \r\n   <td>12</td>\r\n  \r\n   <td>3</td>\r\n  \r\n   <td>3</td>\r\n  \r\n   <td>2</td>\r\n  \r\n   <td>3</td>\r\n  \r\n   <td>8</td>\r\n  \r\n   <td>25</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>FOLFOX</td>\r\n  \r\n   <td>12</td>\r\n  \r\n   <td>6</td>\r\n  \r\n   <td>4</td>\r\n  \r\n   <td>2</td>\r\n  \r\n   <td>4</td>\r\n  \r\n   <td>4</td>\r\n  \r\n   <td>21</td>\r\n  \r\n   <td>33</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   Jackson, N; 2009\r\n  \r\n   </td>\r\n  \r\n   <td>FOLFIRI, mIFL, CAPIRI</td>\r\n  \r\n   <td>37</td>\r\n  \r\n   <td>46</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>26</td>\r\n  \r\n   <td>30</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>FOLFIRI, mIFL + bevacizumab</td>\r\n  \r\n   <td>36</td>\r\n  \r\n   <td>55</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>23</td>\r\n  \r\n   <td>20</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">5-FU: 5-fluorouracil; LV: leucovorin; FOLFOX: infusional 5-flourouracil, leucovorin, oxalipltin; NR: not reported.</div><div id=\"graphicVersion\">Graphic 76722 Version 1.0</div></div></div>"},"76723":{"type":"graphic_table","displayName":"Neuroendocrine neoplasms","title":"Adult neoplasms with neuroendocrine differentiation and a known primary site","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adult neoplasms with neuroendocrine differentiation and a known primary site</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Indolent biology</td> <td class=\"subtitle1\">Aggressive biology</td> </tr> <tr> <td> <p>Well-differentiated neuroendocrine tumor (carcinoid, atypical carcinoid, many primary sites)</p> <p>Well-differentiated pancreatic neuroendocrine tumor (islet cell tumor)</p> <p>Medullary carcinoma of the&nbsp;thyroid</p> <p>Paraganglioma</p> <p>Pheochromocytoma</p> </td> <td> <p>Small cell and large cell neuroendocrine lung cancer</p> <p>High-grade poorly-differentiated&nbsp;neuroendocrine carcinoma (small cell and large cell types, many primary sites)*</p> <p>Extrapulmonary small cell carcinoma (many primary sites)</p> <p>Merkel cell tumor of the skin</p> <p>Neuroblastoma</p> <p>&nbsp;</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* A subset of high-grade neuroendocrine carcinomas has morphology consistent with a well-differentiated tumor but high proliferative activity (high-grade well-differentiated neuroendocrine tumor). These neoplasms have biologic behavior that is intermediate between an indolent and aggressive natural history.</div><div class=\"graphic_reference\">Reproduced with modifications from: Greco FA, Hainsworth JD. Cancer of Unknown Primary site. In: Cancer: Principles and Practice of Oncology 8th edition, DeVita VT, Lawrence TS, Rosenberg SA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76723 Version 13.0</div></div></div>"},"76725":{"type":"graphic_picture","displayName":"Bilateral vocal fold paralysis","title":"Bilateral vocal fold paralysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral vocal fold paralysis</div><div class=\"cntnt\"><img style=\"width:366px; height:280px;\" src=\"images/PEDS/76725_Bilateral_vocal_fold_paraly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Because of the relative closed position of the vocal folds, the voice can be preserved and the airway protected against aspiration; however, respiratory difficulties, stridor, and distress are the typical presenting signs.</div><div class=\"graphic_footnotes\">E: epiglottis; G: glottis; vf: vocal folds.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 76725 Version 2.0</div></div></div>"},"76726":{"type":"graphic_table","displayName":"Causes of neonatal seizures","title":"Etiologies of neonatal seizures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologies of neonatal seizures</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Acute</td> </tr> <tr> <td class=\"indent1\">Acute neonatal encephalopathy (includes classic hypoxic-ischemic encephalopathy, both ante- and intrapartum)</td> </tr> <tr> <td class=\"indent1\">Arterial ischemic stroke</td> </tr> <tr> <td class=\"indent1\">Sinovenous thrombosis</td> </tr> <tr> <td class=\"indent1\">Extracorporeal membrane oxygenation</td> </tr> <tr> <td class=\"indent1\">Congenital heart disease</td> </tr> <tr> <td class=\"indent1\">Vein of Galen malformation</td> </tr> <tr> <td class=\"indent1\">Giant arteriovenous malformation</td> </tr> <tr> <td class=\"indent1\">Hypertensive encephalopathy</td> </tr> <tr> <td class=\"indent1\">Intracranial hemorrhage (subdural subarachnoid, intraventricular, intraparenchymal)</td> </tr> <tr> <td class=\"indent1\">Trauma (intrapartum and nonaccidental)</td> </tr> <tr> <td class=\"indent1\">Infections (sepsis, meningitis, encephalitis)</td> </tr> <tr> <td class=\"indent1\">Transient, simple metabolic disorders</td> </tr> <tr> <td class=\"indent1\">Inborn errors of metabolism (including pyridoxine dependent seizures)</td> </tr> <tr> <td class=\"indent1\">Intoxication</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Chronic</td> </tr> <tr> <td class=\"indent1\">Isolated cerebral dysgenesis, eg, lissencephaly, hemimegalencephaly</td> </tr> <tr> <td class=\"indent1\">Cerebral dysgenesis associated with inborn errors of metabolism</td> </tr> <tr> <td class=\"indent1\">Chronic infection (TORCH [toxoplasmosis, other infections, rubella, cytomegalovirus, and herpes simplex] syndromes)</td> </tr> <tr> <td class=\"sublist2_start\">Neurocutaneous syndromes</td> </tr> <tr> <td class=\"sublist2\">Incontinentia pigmenti (Bloch Sulzberger syndrome)</td> </tr> <tr> <td class=\"sublist2\">Hypomelanosis of Ito</td> </tr> <tr> <td class=\"sublist2\">Sturge-Weber syndrome</td> </tr> <tr> <td class=\"sublist2\">Tuberous sclerosis</td> </tr> <tr> <td class=\"sublist2\">Linear sebaceous nevus (epidermal nevus syndrome)</td> </tr> <tr> <td class=\"sublist2_start\">Specific very early onset epilepsy syndromes</td> </tr> <tr> <td class=\"sublist2\">Fifth-day fits (benign neonatal seizures)</td> </tr> <tr> <td class=\"sublist2\">Benign familial neonatal seizures</td> </tr> <tr> <td class=\"sublist2\">Early myoclonic encephalopathy</td> </tr> <tr> <td class=\"sublist2\">Early infantile epileptic encephalopathy</td> </tr> <tr> <td class=\"sublist2\"><em>KCNQ2</em> encephalopathy&nbsp;</td> </tr> <tr> <td class=\"sublist2\"><em>SCN2A</em> encephalopathy&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Migrating partial seizures of infancy</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Chapman KE, Mizrahi EM, Clancy RR. Neonatal seizures. In: Wyllie's Treatment of Epilepsy: Principles and Practice, 5th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 76726 Version 14.0</div></div></div>"},"76728":{"type":"graphic_picture","displayName":"Chron pancreatitis H and E","title":"Chronic pancreatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic pancreatitis</div><div class=\"cntnt\"><img style=\"width:432px; height:321px;\" src=\"images/GAST/76728_Chron_pancreatitis_H_and_E.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">H and E stained section of pancreas from a patient with chronic pancreatitis. Pancreatic biopsy showing extensive fibrosis, chronic inflammation, residual ductal structures, and a residual islet. There is no acinar tissue remaining.</div><div class=\"graphic_reference\">Courtesy of Larry Brown, MD.</div><div id=\"graphicVersion\">Graphic 76728 Version 2.0</div></div></div>"},"76729":{"type":"graphic_picture","displayName":"Pseudopolyps IBD Endosc","title":"Colonic pseudopolyps in inflammatory bowel disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colonic pseudopolyps in inflammatory bowel disease</div><div class=\"cntnt\"><img style=\"width:210px; height:200px;\" src=\"images/GAST/76729_Pseudopolyps_IBD_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy of pseudopolyps; these lesions are not specific to ulcerative colitis, although they are more common in this disorder than in Crohn disease.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 76729 Version 3.0</div></div></div>"},"76730":{"type":"graphic_figure","displayName":"Secretin tissue distribution","title":"Location of secretin-producing cells throughout the gastrointestinal tract","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Location of secretin-producing cells throughout the gastrointestinal tract</div><div class=\"cntnt\"><img style=\"width:481px; height:276px;\" src=\"images/GAST/76730_Secretin_tissue_distributio.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 76730 Version 1.0</div></div></div>"},"76731":{"type":"graphic_figure","displayName":"Hunt-Lawrence pouch for esophagojejunostomy","title":"Hunt-Lawrence pouch for esophagojejunostomy","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Hunt-Lawrence pouch for esophagojejunostomy</div><div class=\"cntnt\"><img style=\"width:539px; height:579px;\" src=\"images/SURG/76731_Pouch_reconstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To construct the Hunt-Lawrence pouch, the distal portion of the afferent limb measuring 20 cm in length is brought up posteriorly to the colon. The GIA stapler is used to perform a side-to-side anastomosis at the antimesenteric border of the bowel. The EEA device is then used for the anastomosis between the pouch and the esophagus. The completed pouch should measure approximately 20 cm in length. The Roux-en-Y is constructed approximately 20 cm below the pouch to reestablish intestinal continuity.</div><div id=\"graphicVersion\">Graphic 76731 Version 5.0</div></div></div>"},"76733":{"type":"graphic_figure","displayName":"Coronary steal physiology","title":"Coronary steal physiology","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Coronary steal physiology</div><div class=\"cntnt\"><img style=\"width:510px; height:506px;\" src=\"images/SURG/76733_Coronary-steal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In coronary-subclavian steal, severe stenosis or occlusion of the left subclavian artery proximal to the origin of a left internal mammary-to-coronary artery bypass graft may cause &quot;steal&quot; from the coronary graft to maintain perfusion to the arm via the left subclavian artery during upper extremity exercise.</div><div id=\"graphicVersion\">Graphic 76733 Version 3.0</div></div></div>"},"76734":{"type":"graphic_table","displayName":"Lipids - Standard vs SI units","title":"Cholesterol and triglyceride measurements in the United States and elsewhere","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cholesterol and triglyceride measurements in the United States and elsewhere</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\"> <p>Measurement used within the United States<br /> Milligrams/deciliter (mg/dL)</p> </td> <td class=\"subtitle1\"> <p>Measurement used most places outside the United States<br /> Millimoles/liter (mmol/Liter)</p> </td> </tr> <tr> <td class=\"subtitle2\">Level to aim for</td> <td class=\"subtitle2\">Level to aim for</td> </tr> <tr> <td><strong>Total cholesterol</strong></td> <td>Below 200</td> <td>Below 5.17</td> </tr> <tr> <td><strong>LDL cholesterol</strong></td> <td>Below 130&nbsp;&ndash; or much lower if at risk of heart attack and stroke</td> <td>Below 3.36&nbsp;&ndash; or much lower if at risk of heart attack and stroke</td> </tr> <tr> <td><strong>HDL cholesterol</strong></td> <td>Above 60</td> <td>Above 1.55</td> </tr> <tr> <td><strong>Triglycerides</strong></td> <td>Below 150</td> <td>Below 1.7</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Cholesterol is measured differently in the United States than it is in most other countries. This table shows values used within and outside the United States. It includes the cholesterol and triglyceride levels that most people who do not have heart disease should aim for.</div><div id=\"graphicVersion\">Graphic 76734 Version 3.0</div></div></div>"},"76735":{"type":"graphic_figure","displayName":"Eye anatomy PI","title":"Common eye disorders","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Common eye disorders</div><div class=\"cntnt\"><img style=\"width:537px; height:360px;\" src=\"images/PI/76735_Eye-anatomy-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vision loss can be caused by different problems in the eye:<br /><ul>&#xD;&#xA;    <li>Presbyopia makes it hard for the lens to focus </li>&#xD;&#xA;    <li>Cataracts make the lens cloudy </li>&#xD;&#xA;    <li>Glaucoma damages the optic nerve </li>&#xD;&#xA;    <li>Macular degeneration damages the macula, the part of the eye that allows you to see fine detail </li>&#xD;&#xA;    <li>Diabetic retinopathy damages the blood vessels in the retina, the part of the eye that receives visual images and sends these images to the brain </li>&#xD;&#xA;</ul></div><div id=\"graphicVersion\">Graphic 76735 Version 5.0</div></div></div>"},"76736":{"type":"graphic_table","displayName":"Help paying for your medicines PI","title":"Help paying for your medicines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Help paying for your medicines</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">These websites provide information about different programs to help you pay for your medicines</td> </tr> <tr> <td><strong>Benefits Checkup (National Council on Aging):</strong> This website gives people lists of services and programs for which they can apply. The lists include programs to help pay for medicines, but also programs that don't have to do with health care directly. For example, this site has information on finding housing, getting food stamps, and finding elder care. You can search for all types of programs at once or target your search to find a specific kind of service. <ul> <li>Website: <a href=\"http://www.benefitscheckup.org/\" target=\"_blank\">www.benefitscheckup.org</a> </li> <li>Phone: <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-800-677-1116</span></li> </ul> </td> </tr> <tr> <td><strong>Needymeds:</strong> This is an independent non-profit organization that provides information about patient assistance from drug companies and the government. The site also offers people a discount card that they can use on prescriptions if they have no insurance or choose not to use their insurance. This card is especially useful in paying for medicines after you reach the Medicare&nbsp;coverage gap&nbsp;and Medicare is no longer paying for your prescriptions. (You reach the coverage gap, sometimes called the \"donut hole,\"&nbsp;once you and your plan spend a certain amount of money for covered drugs. After that,&nbsp;you have to pay more for your prescriptions up to a certain amount.) <ul> <li>General website: <a href=\"http://www.needymeds.org/\" target=\"_blank\">www.needymeds.org</a> </li> <li>Website with state health insurance assistance program (SHIP) information:&nbsp;<a href=\"http://www.needymeds.org/inclusions/ship.htm\" target=\"_blank\">www.needymeds.org/inclusions/ship.htm</a> </li> </ul> </td> </tr> <tr> <td><strong>Partnership for Prescription Assistance:</strong> This program is run by drug companies and their trade group. It is only for people who do not have prescription drug coverage. The site helps people find programs that will get them medicines for free or for a reduced cost. <ul> <li>Website: <a href=\"http://www.pparx.org/\" target=\"_blank\">www.pparx.org</a> </li> <li>Phone: <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-888-4PPA-NOW </span>(<span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-888-477-2669</span>) </li> </ul> </td> </tr> <tr> <td><strong>Rx Assist:</strong> This website lets you enter the name of a medicine or the name of a drug company to find programs that can help you get that medicine or medicines made by that company at a reduced cost. In many cases, the online applications for those programs are included. <ul> <li>Website: <a href=\"http://rxassist.org/patients\" target=\"_blank\">http://rxassist.org/patients </a></li> <li>Phone: <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-401-729-3284</span></li> </ul> </td> </tr> <tr> <td><strong>Rx Outreach:</strong> This website offers medicines and diabetic treatment supplies at a reduced cost to people who make less than a certain amount of money each year. <ul> <li>Website: <a href=\"http://www.rxoutreach.org/\" target=\"_blank\">www.rxoutreach.org</a> </li> <li>Phone: <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-800-769-3880</span></li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76736 Version 5.0</div></div></div>"},"76737":{"type":"graphic_table","displayName":"Babesia Lyme coinfection","title":"Coinfection with babesiosis and Lyme borreliosis by area and year","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Coinfection with babesiosis and Lyme borreliosis by area and year</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Region </td> <td class=\"subtitle1\">Timeframe </td> <td class=\"subtitle1\">Prevalence </td> </tr> <tr> <td rowspan=\"2\">Block Island </td> <td>May through September, 1990 to 1994<sup>[1]</sup></td> <td>Among 97 individuals with antibodies to <em>Babesia burgdorferi </em>identified by serosurvey, 14 percent also had antibodies to <em>Babesia microti</em>. Among 206 patients diagnosed with Lyme disease, 11 percent also experienced mild babesiosis.</td> </tr> <tr> <td>May through September, 1997 to 2000<sup>[2]</sup></td> <td>Among 76 patients with Lyme disease, 22 percent also experienced mild babesiosis.</td> </tr> <tr> <td rowspan=\"2\">Connecticut </td> <td>1986 to 1989<sup>[3]</sup></td> <td>Among 735 residents who were seropositive for <em>B. burgdorferi</em>, 9.5 percent also had antibodies against <em>B. microti.</em></td> </tr> <tr> <td>May through September, 1997 to 2000<sup>[2]</sup></td> <td>Among 20 patients diagnosed with Lyme disease, 50 percent also presented with symptoms of mild babesiosis.</td> </tr> <tr> <td rowspan=\"2\">Eastern Long Island </td> <td>1985<sup>[4]</sup></td> <td>Among Lyme disease patients from areas endemic for both Lyme disease and babesiosis, 66 percent also had antibodies to <em>B. microti.</em></td> </tr> <tr> <td>1988 to 2001<sup>[5]</sup></td> <td>Among 34 patients hospitalized for severe babesiosis, 53 percent were seropositive for <em>B. burgdorferi.</em></td> </tr> <tr> <td>Nantucket Island</td> <td>May through September, 1997 to 2000<sup>[2]</sup></td> <td>Among 65 patients diagnosed with Lyme disease, 58 percent also presented with symptoms of mild babesiosis.</td> </tr> <tr> <td rowspan=\"2\">New York State </td> <td>1982 to 1991<sup>[6]</sup></td> <td>Among 136 patients diagnosed with babesiosis, 23 percent experienced clinical Lyme disease.</td> </tr> <tr> <td>1982 to 1993<sup>[7]</sup></td> <td>Among 139 hospitalized for severe babesiosis, 12 percent had a history of Lyme disease.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:</P>&#xD;&#xA;<OL>&#xD;&#xA;<LI>Krause, PJ, Telford, SR, 3rd, Spielman, A, et al. Concurrent Lyme disease and babesiosis. Evidence for increased severity and duration of illness. JAMA 1996; 275:1657.</LI>&#xD;&#xA;<LI>Krause, PJ, McKay, K, Thompson, CA, et al. Disease-specific diagnosis of coinfecting tickborne zoonoses: babesiosis, human granulocytic ehrlichiosis, and Lyme disease. Clin Infect Dis 2002; 34:1184.</LI>&#xD;&#xA;<LI>Krause, PJ, Telford SR, 3rd, Ryan, R, et al. Geographical and temporal distribution of babesial infection in Connecticut. J Clin Microbiol 1991; 29:1.</LI>&#xD;&#xA;<LI>Benach, JL, Coleman, JL, Habicht, GS, et al. Serological evidence for simultaneous occurrences of Lyme disease and babesiosis. J Infect Dis 1985; 152:473.</LI>&#xD;&#xA;<LI>Hatcher, JC, Greenberg, PD, Antique, J, Jimenez-Lucho, VE. Severe babesiosis in Long Island: review of 34 cases and their complications. Clin Infect Dis 2001; 32:1117.</LI>&#xD;&#xA;<LI>Meldrum, SC, Birkhead, GS, White, DJ, et al. Human babesiosis in New York State: an epidemiological description of 136 cases. Clin Infect Dis 1992; 15:1019.</LI>&#xD;&#xA;<LI>White, DJ, Talarico, J, Chang, HG, et al. Human babesiosis in New York State: Review of 139 hospitalized cases and analysis of prognostic factors. Arch Intern Med 1998; 158:2149.</LI></OL></div><div id=\"graphicVersion\">Graphic 76737 Version 3.0</div></div></div>"},"76738":{"type":"graphic_table","displayName":"Prev CVP cath infection","title":"Prevention of infection with central venous catheters*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevention of infection with central venous catheters*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Replacement and relocation of catheter</td> </tr> <tr> <td class=\"indent1\">Do not routinely replace central venous catheters solely for the purpose of reducing the incidence of infection (including peripherally inserted, non-tunneled, or tunneled catheters and implantable devices).</td> </tr> <tr> <td class=\"subtitle1_single\">Replacement of catheter-site dressing</td> </tr> <tr> <td class=\"indent1\">Replace dressing when the catheter is removed or replaced, the dressing becomes damp, loosened, or soiled, or inspection of the site is necessary.</td> </tr> <tr> <td class=\"indent1\">Replace gauze dressing every two days, and transparent dressings every seven days on short-term catheters.</td> </tr> <tr> <td class=\"indent1\">Replace dressing no more than once per week until the insertion site is healed on long-term catheters. The necessity for dressing on well-healed exit sites of long-term culled and tunneled CVC is an unresolved issue.</td> </tr> <tr> <td class=\"subtitle1_single\">Replacement of administration sets</td> </tr> <tr> <td class=\"indent1\">Replace administration sets, including secondary sets and add-on devices, no more frequently than at 96-hour intervals, unless clinically indicated.</td> </tr> <tr> <td class=\"indent1\">Replace tubing used to administer blood, blood products, or lipid emulsions within 24 hours of initiating the infusion. <strong>No recommendation<sup>&#182;</sup></strong> for replacement of tubing used for intermittent infusions.</td> </tr> <tr> <td class=\"indent1\">Replace tubing used to administer propofol infusions every 6 or 12 hours, depending on its use.</td> </tr> <tr> <td class=\"subtitle1_single\">Hang time for parenteral fluids</td> </tr> <tr> <td class=\"indent1\">Complete infusion of lipids or lipid-containing parenteral nutrition fluids (eg, 3-in-1 solutions) within 24 hours of hanging the fluid. When lipid emulsions are given alone, complete the infusion within 12 hours of hanging the emulsion.</td> </tr> <tr> <td class=\"indent1\">Complete infusion of blood or blood products within four hours of hanging the blood.</td> </tr> <tr> <td class=\"indent1\"><strong>No recommendation<sup>&#182;</sup></strong> for parenteral nutrition fluids.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Includes non-tunneled catheters, tunneled catheters, and totally implanted devices.<br />¶ No recommendation is made when there is insufficient data in the literature.</div><div id=\"graphicVersion\">Graphic 76738 Version 4.0</div></div></div>"},"76739":{"type":"graphic_picture","displayName":"Postinfectious GN EM","title":"Electron micrograph of postinfectious glomerulonephritis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of postinfectious glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:393px; height:249px;\" src=\"images/NEPH/76739_Postinfectious_GN_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph shows subepithelial deposits (D) with a semilunar, hump-shaped appearance in postinfectious glomerulonephritis. The humps sit on top of the glomerular basement membrane (GBM). A neutrophil is attached to the denuded GBM, contributing to the glomerular inflammation. Neutrophil attraction requires the initial presence of subepithelial immune deposits so that complement chemoattractants have access to the systemic circulation.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 76739 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"76740":{"type":"graphic_picture","displayName":"Fetal membrane roll","title":"The fetal membranes are rolled around the tips of a pair of forceps","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The fetal membranes are rolled around the tips of a pair of forceps</div><div class=\"cntnt\"><img style=\"width:390px; height:262px;\" src=\"images/OBGYN/76740_Fetal_membrane_roll.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 76740 Version 2.0</div></div></div>"},"76742":{"type":"graphic_table","displayName":"Framingham ATPIII score women","title":"Framingham/ATP III point scores in women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Framingham/ATP III point scores in women</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age, years</td> <td class=\"subtitle1\">Points</td> <td class=\"subtitle1\" colspan=\"4\">&nbsp;</td> </tr> <tr> <td>20 to 34</td> <td>-7</td> <td rowspan=\"10\" colspan=\"4\">&nbsp;</td> </tr> <tr> <td>35 to 39</td> <td>-3</td> </tr> <tr> <td>40 to 44</td> <td>0</td> </tr> <tr> <td>45 to 49</td> <td>3</td> </tr> <tr> <td>50 to 54</td> <td>6</td> </tr> <tr> <td>55 to 59</td> <td>8</td> </tr> <tr> <td>60 to 64</td> <td>10</td> </tr> <tr> <td>65 to 69</td> <td>12</td> </tr> <tr> <td>70 to 74</td> <td>14</td> </tr> <tr> <td>75 to 79</td> <td>16</td> </tr> <tr> <td class=\"subtitle1\">Total cholesterol, mg/dL (mmol/L)</td> <td class=\"subtitle1\">Age 20 to 39</td> <td class=\"subtitle1\">Age 40 to 49</td> <td class=\"subtitle1\">Age 50 to 59</td> <td class=\"subtitle1\">Age 60 to 69</td> <td class=\"subtitle1\">Age 70 to 79</td> </tr> <tr> <td>&#60;160 (3.4)</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>160 to 199 (3.4 to 5.15)</td> <td>4</td> <td>3</td> <td>2</td> <td>1</td> <td>1</td> </tr> <tr> <td>200 to 239 (5.17 to 6.18)</td> <td>8</td> <td>6</td> <td>4</td> <td>2</td> <td>1</td> </tr> <tr> <td>240 to 279 (6.2 to 7.21)</td> <td>11</td> <td>8</td> <td>5</td> <td>3</td> <td>2</td> </tr> <tr> <td>&#8805;280 (7.24)</td> <td>13</td> <td>10</td> <td>7</td> <td>4</td> <td>2</td> </tr> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Age 20 to 39</td> <td class=\"subtitle1\">Age 40 to 49</td> <td class=\"subtitle1\">Age 50 to 59</td> <td class=\"subtitle1\">Age 60 to 69</td> <td class=\"subtitle1\">Age 70 to 79</td> </tr> <tr> <td>Nonsmoker</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>Smoker</td> <td>9</td> <td>7</td> <td>4</td> <td>2</td> <td>1</td> </tr> <tr> <td class=\"subtitle1\">HDL cholesterol, mg/dL (mmol/L)</td> <td class=\"subtitle1\">Points</td> <td class=\"subtitle1\" colspan=\"4\">&nbsp;</td> </tr> <tr> <td>&#8805;60 (1.55)</td> <td>-1</td> <td rowspan=\"4\" colspan=\"4\">&nbsp;</td> </tr> <tr> <td>50 to 59 (1.29 to 1.53)</td> <td>0</td> </tr> <tr> <td>40 to 49 (1.03 to 1.27)</td> <td>1</td> </tr> <tr> <td>&#60;40 (1.03)</td> <td>2</td> </tr> <tr> <td class=\"subtitle1\">Systolic blood pressure, mmHg</td> <td class=\"subtitle1\">Untreated</td> <td class=\"subtitle1\">Treated</td> <td class=\"subtitle1\" colspan=\"3\">&nbsp;</td> </tr> <tr> <td>&#60;120</td> <td>0</td> <td>0</td> <td rowspan=\"5\" colspan=\"3\">&nbsp;</td> </tr> <tr> <td>120 to 129</td> <td>1</td> <td>3</td> </tr> <tr> <td>130 to 139</td> <td>2</td> <td>4</td> </tr> <tr> <td>140 to 159</td> <td>3</td> <td>5</td> </tr> <tr> <td>&#8805;160</td> <td>4</td> <td>6</td> </tr> <tr> <td class=\"subtitle1\">Point total</td> <td class=\"subtitle1\">10-year risk, percent</td> <td class=\"subtitle1\">Point total</td> <td class=\"subtitle1\">10-year risk, percent</td> <td class=\"subtitle1\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td>&#60;9</td> <td>&#60;1</td> <td>17</td> <td>5</td> <td rowspan=\"9\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td>9</td> <td>1</td> <td>18</td> <td>6</td> </tr> <tr> <td>10</td> <td>1</td> <td>19</td> <td>8</td> </tr> <tr> <td>11</td> <td>1</td> <td>20</td> <td>11</td> </tr> <tr> <td>12</td> <td>1</td> <td>21</td> <td>14</td> </tr> <tr> <td>13</td> <td>2</td> <td>22</td> <td>17</td> </tr> <tr> <td>14</td> <td>2</td> <td>23</td> <td>22</td> </tr> <tr> <td>15</td> <td>3</td> <td>24</td> <td>27</td> </tr> <tr> <td>16</td> <td>4</td> <td>&#8805;25</td> <td>&#8805;30</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: These risk estimates for the development of coronary heart disease (CHD) do not account for all important cardiovascular risk factors. Not included are diabetes mellitus (which is considered a CHD equivalent), family history of CHD, alcohol intake, and the serum C-reactive protein concentration. The point total is determined in each category, and the 10-year risk determined in the bottom row.</div><div class=\"graphic_footnotes\">CHD: coronary heart disease.</div><div class=\"graphic_reference\">Adapted from Adult Treatment Panel III at http://www.nhlbi.nih.gov/.</div><div id=\"graphicVersion\">Graphic 76742 Version 3.0</div></div></div>"},"76743":{"type":"graphic_table","displayName":"Characteristic features of congenital infections","title":"Clinical manifestations that are suggestive of specific congenital infections in the neonate","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations that are suggestive of specific congenital infections in the neonate</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Congenital toxoplasmosis</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Intracranial calcifications (diffuse) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hydrocephalus </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Chorioretinitis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Otherwise unexplained mononuclear CSF pleocytosis or elevated CSF protein </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Congenital syphilis</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Skeletal abnormalities (osteochondritis and periostitis) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Pseudoparalysis </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Persistent rhinitis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Maculopapular rash (particularly on palms and soles or in diaper area) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Congenital rubella</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cataracts, congenital glaucoma, pigmentary retinopathy </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Congenital heart disease (most commonly patent ductus arteriosus or peripheral pulmonary artery stenosis) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Radiolucent bone disease </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Sensorineural hearing loss </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Congenital cytomegalovirus</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Thrombocytopenia </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Periventricular intracranial calcifications </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Microcephaly </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hepatosplenomegaly </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Sensorineural hearing loss </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Herpes simplex virus</td> </tr> <tr> <td class=\"indent1\">Perinatally acquired HSV infection</td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Mucocutaneous vesicles </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>CSF pleocytosis </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Thrombocytopenia </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Elevated liver transaminases </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Conjunctivitis or keratoconjuctivitis </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\">Congenital (in utero) HSV infection (rare)</td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Skin vesicles, ulcerations, or scarring </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Eye abnormalities (eg, micro-ophthalmia) </li> </ul> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <ul> <li>Brain abnormalities (eg, hydranencephaly, microcephaly) </li> </ul> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Congenital varicella</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cicatricial or vesicular skin lesions </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Microcephaly </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Congenital Zika syndrome</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Microcephaly </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Intracranial calcifications </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Arthrogryposis </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hypertonia/spasticity </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Ocular abnormalities </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Sensorineural hearing loss </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; HSV: herpes simplex virus.</div><div id=\"graphicVersion\">Graphic 76743 Version 9.0</div></div></div>"},"76747":{"type":"graphic_table","displayName":"Administering positive pressure","title":"Advantages and disadvantages of the different methods for administering positive airway pressure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of the different methods for administering positive airway pressure</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1\">Mode of positive pressure ventilation</td>\n\n\n      <td class=\"subtitle1\">Advantages</td>\n\n\n      <td class=\"subtitle1\">Disadvantages</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"1\" rowspan=\"2\">CPAP</td>\n\n\n      <td>Inexpensive</td>\n\n\n      <td colspan=\"1\" rowspan=\"2\">Lack of inspiratory pressure support</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n\n      <td>Widely available</td>\n\n\n      \n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"1\" rowspan=\"3\">Bi-level</td>\n\n\n      <td>Widely available</td>\n\n\n      <td colspan=\"1\" rowspan=\"3\">Tidal volume may may be limited by patient-related factors</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n\n      <td>Can provide inspiratory pressure support to augment tidal volume</td>\n\n\n      \n\n\n    </tr>\n\n\n    <tr>\n\n\n\n      <td>Leak tolerant</td>\n\n\n      \n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"1\" rowspan=\"4\">Volume-cycled</td>\n\n\n      <td colspan=\"1\" rowspan=\"4\">Can set specific respiratory parameters</td>\n\n\n      <td>More expensive</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n\n      \n\n\n      <td>Less widely available</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n\n      \n\n\n      <td> Less well-tolerated than pressure support devices</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n\n      \n\n\n      <td>Leaks lead to loss of tidal volume</td>\n\n\n    </tr>\n\n\n  \n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 76747 Version 2.0</div></div></div>"},"76748":{"type":"graphic_picture","displayName":"Silicoproteinosis pathology","title":"Acute silicosis (silicoproteinosis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute silicosis (silicoproteinosis)</div><div class=\"cntnt\"><img style=\"width:429px; height:277px;\" src=\"images/PULM/76748_Silicoproteinosis_path.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is prominent alveolar filling with eosinophilic proteinaceous material. Mild interstitial thickening is also present.</div><div class=\"graphic_reference\">Courtesy of Dr. J Parker.</div><div id=\"graphicVersion\">Graphic 76748 Version 3.0</div></div></div>"},"76749":{"type":"graphic_figure","displayName":"Structure of immunoglobulin family of adhesion proteins","title":"Structure of immunoglobulin family of adhesion proteins","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Structure of immunoglobulin family of adhesion proteins</div><div class=\"cntnt\"><img style=\"width:531px; height:318px;\" src=\"images/RHEUM/76749_Structure_of_adhesion_prote.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The defining structural characteristic of the immunoglobulin superfamily of molecules is a variable number of intramolecular loops linked by disulfide bonds. The molecules of this family, which play a role in leukocyte-endothelial adhesion, are ICAM-1, ICAM-2, and VCAM-1. ICAM-1 has five extracellular domains, ICAM-2 has two domains, and VCAM-1 can have either six or seven domains due to alternate splicing.</div><div class=\"graphic_footnotes\">ICAM: intracellular adhesion molecule; VCAM: vascular cell adhesion molecule.</div><div id=\"graphicVersion\">Graphic 76749 Version 3.0</div></div></div>"},"76750":{"type":"graphic_picture","displayName":"Peau d orange chin","title":"Peau d'orange chin","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Peau d'orange chin</div><div class=\"cntnt\"><img style=\"width:502px; height:325px;\" src=\"images/DERM/76750_Peau_dorange_chin_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peau d'orange chin is characterized by the appearance of multiple dimples on the chin during contraction of the mentalis muscle.</div><div id=\"graphicVersion\">Graphic 76750 Version 3.0</div></div></div>"},"76753":{"type":"graphic_table","displayName":"Differential diagnosis of MS","title":"Differential diagnosis of multiple sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of multiple sclerosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Inflammatory disease</td> </tr> <tr> <td>Acute disseminated encephalomyelitis</td> </tr> <tr> <td>Beh&#231;et disease</td> </tr> <tr> <td>Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS)</td> </tr> <tr> <td>Clinically isolated syndromes suggestive of multiple sclerosis</td> </tr> <tr> <td>Granulomatosis angiitis</td> </tr> <tr> <td>Neuromyelitis optica (Devic disease)</td> </tr> <tr> <td>Paraneoplastic encephalomyelopathies</td> </tr> <tr> <td>Polyarteritis nodosa</td> </tr> <tr> <td>Sj&#246;gren syndrome</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td class=\"subtitle1_single\">Infectious disease</td> </tr> <tr> <td>Human immunodeficiency virus</td> </tr> <tr> <td>Lyme neuroborreliosis</td> </tr> <tr> <td>Neurosyphilis</td> </tr> <tr> <td>Progressive multifocal leukoencephalopathy</td> </tr> <tr> <td>Tropical spastic paraparesis</td> </tr> <tr> <td class=\"subtitle1_single\">Genetic disease</td> </tr> <tr> <td>Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)</td> </tr> <tr> <td class=\"subtitle1_single\">Granulomatous disease</td> </tr> <tr> <td>Lymphomatoid granulomatosis</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td class=\"subtitle1_single\">Disease of myelin</td> </tr> <tr> <td>Adrenoleukodystrophy</td> </tr> <tr> <td>Adult metachromatic leukodystrophy</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td>Arnold-Chiari malformation</td> </tr> <tr> <td>Compressive spinal cord lesions</td> </tr> <tr> <td>Vascular malformations</td> </tr> <tr> <td>Vitamin B12 deficiency</td> </tr> <tr> <td>Spinocerebellar disorders</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76753 Version 5.0</div></div></div>"},"76754":{"type":"graphic_picture","displayName":"Photo birth 3","title":"Delivery sequence from crowning through birth of the newborn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Delivery sequence from crowning through birth of the newborn</div><div class=\"cntnt\"><img style=\"width:432px; height:309px;\" src=\"images/OBGYN/76754_Photo_birth_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright &#169;2009.</div><div id=\"graphicVersion\">Graphic 76754 Version 1.0</div></div></div>"},"76755":{"type":"graphic_table","displayName":"RT postmastectomy local recur","title":"Results of treatment for isolated postmastectomy chest wall recurrence","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Results of treatment for isolated postmastectomy chest wall recurrence</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\" rowspan=\"2\">\r\n  \r\n   Author; year\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\" rowspan=\"2\">\r\n  \r\n   n\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\" rowspan=\"2\">\r\n  \r\n   Median follow-up, months\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\" rowspan=\"2\">\r\n  \r\n   Local control, percent\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\" colspan=\"2\">\r\n  \r\n   FFDM\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\" colspan=\"2\">\r\n  \r\n   OS\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   5 years\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   10 years\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   5 years\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   10 years\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Aberizk, WJ; 1986</td>\r\n  \r\n   <td>90</td>\r\n  \r\n   <td>81</td>\r\n  \r\n   <td>35 (10-yr)</td>\r\n  \r\n   <td>30</td>\r\n  \r\n   <td>7</td>\r\n  \r\n   <td>50</td>\r\n  \r\n   <td>26</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Deutsch, M; 1986</td>\r\n  \r\n   <td>107</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>45 (5-yr)</td>\r\n  \r\n   <td>35 (RFS)</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>35</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Mendenhall, N; 1988</td>\r\n  \r\n   <td>47</td>\r\n  \r\n   <td>24 (min)</td>\r\n  \r\n   <td>61 (10-yr)</td>\r\n  \r\n   <td>41</td>\r\n  \r\n   <td>17</td>\r\n  \r\n   <td>50</td>\r\n  \r\n   <td>34</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Halverson, K; 1990</td>\r\n  \r\n   <td>224</td>\r\n  \r\n   <td>46</td>\r\n  \r\n   <td>57 (5-yr)</td>\r\n  \r\n   <td>25 (RFS)</td>\r\n  \r\n   <td>15</td>\r\n  \r\n   <td>43</td>\r\n  \r\n   <td>26</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Schwaibold, F; 1991</td>\r\n  \r\n   <td>128</td>\r\n  \r\n   <td>33</td>\r\n  \r\n   <td>43 (5-yr)</td>\r\n  \r\n   <td>24</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>49</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   Borner, M; 1994\r\n  \r\n   </td>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   167\r\n  \r\n   </td>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   76\r\n  \r\n   </td>\r\n  \r\n   <td>RT alone: 65 (5-yr)</td>\r\n  \r\n   <td>36</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>76</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>RT + Tam: 88 (5-yr)</td>\r\n  \r\n   <td>59</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>74</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hsi, R; 1998</td>\r\n  \r\n   <td>18</td>\r\n  \r\n   <td>100</td>\r\n  \r\n   <td>86 (10-yr)</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>42 (RFS)</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>72</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>van Tienhoven, G; 1999</td>\r\n  \r\n   <td>67</td>\r\n  \r\n   <td>74</td>\r\n  \r\n   <td>62 (5-yr)</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>58</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ballo, M; 1999</td>\r\n  \r\n   <td>148</td>\r\n  \r\n   <td>78</td>\r\n  \r\n   <td>\t<p>68 (5-yr)</p>\r\n\t<p> \t55 (10-yr)</p>\r\n</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>50</td>\r\n  \r\n   <td>35</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   Haylock, B; 2000\r\n  \r\n   </td>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   120\r\n  \r\n   </td>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   24\r\n  \r\n   </td>\r\n  \r\n   <td>RT alone: 66 (10-yr)</td>\r\n  \r\n   <td>60</td>\r\n  \r\n   <td>45</td>\r\n  \r\n   <td>74</td>\r\n  \r\n   <td>50</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>RT + chemo: 58 (10-yr)</td>\r\n  \r\n   <td>75</td>\r\n  \r\n   <td>49</td>\r\n  \r\n   <td>82</td>\r\n  \r\n   <td>62</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Haffty, B; 2004</td>\r\n  \r\n   <td>113</td>\r\n  \r\n   <td>121</td>\r\n  \r\n   <td>79 (10-yr)</td>\r\n  \r\n   <td>49</td>\r\n  \r\n   <td>40</td>\r\n  \r\n   <td>46</td>\r\n  \r\n   <td>28</td>\r\n  \r\n   </tr>\r\n\r\n   <tr>\r\n  \r\n   <td>Kuo, S; 2008</td>\r\n  \r\n   <td>115</td>\r\n  \r\n   <td>46</td>\r\n  \r\n   <td>83</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>79</td>\r\n  \r\n   <td>59</td>\r\n  \r\n   </tr>\r\n\r\n </table></div><div class=\"graphic_footnotes\">FFDM: freedom from distant metastases; OS: overall survival; RT: radiation therapy; Tam: tamoxifen; chemo: systemic chemotherapy; min: minimum; RFS: relapse-free survival; NR: not reported.</div><div id=\"graphicVersion\">Graphic 76755 Version 1.0</div></div></div>"},"76756":{"type":"graphic_table","displayName":"Cutaneous syndrome","title":"The cutaneous syndrome in occult spinal dysraphism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The cutaneous syndrome in occult spinal dysraphism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Patch of hyperkeratosis</td> </tr> <tr> <td>Patch of hypertrichosis</td> </tr> <tr> <td>Patch of hyperpigmentation</td> </tr> <tr> <td>Patch of epidermal atrophy (may be tender)</td> </tr> <tr> <td>Subcutaneous mass (lipoma or neurofibroma)</td> </tr> <tr> <td>Capillary hemangioma or cutaneous angioma</td> </tr> <tr> <td>Dorsal dermal sinus</td> </tr> <tr> <td>Sacrococcygeal pit</td> </tr> <tr> <td>Sacrococcygeal dimple</td> </tr> <tr> <td>Caudal cutaneous appendage (true tail or pseudotail)</td> </tr> <tr> <td>Isolated deviation of the intergluteal fold</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Chaouki Khoury, MD, MS.</div><div id=\"graphicVersion\">Graphic 76756 Version 3.0</div></div></div>"},"76757":{"type":"graphic_picture","displayName":"Stimson technique for shoulder reduction","title":"Stimson technique for reduction of shoulder dislocation ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stimson technique for reduction of shoulder dislocation </div><div class=\"cntnt\"><img style=\"width:432px; height:322px;\" src=\"images/EM/76757_Shoulder_reduct_Stimson.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is placed prone on the stretcher with the affected shoulder hanging off the edge. Weights (10-15 lbs) are fastened to the wrist to provide gentle, constant traction.</div><div class=\"graphic_reference\">Courtesy of Scott Sherman, MD</div><div id=\"graphicVersion\">Graphic 76757 Version 2.0</div></div></div>"},"76761":{"type":"graphic_figure","displayName":"Anatomy carotid sinus","title":"Anatomy of the carotid sinus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the carotid sinus</div><div class=\"cntnt\"><img style=\"width:396px; height:428px;\" src=\"images/CARD/76761_Anatomy_carotid_sinus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Peter J Zimetbaum, MD and Daniel Frisch, MD.</div><div id=\"graphicVersion\">Graphic 76761 Version 1.0</div></div></div>"},"76762":{"type":"graphic_table","displayName":"Causes drug induced acne","title":"Major causes of drug-induced acne","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of drug-induced acne</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n  <tr>\n    <td>Glucocorticoids</td>\n  </tr>\n  <tr>\n    <td>Phenytoin</td>\n  </tr>\n  <tr>\n    <td>Lithium</td>\n  </tr>\n  <tr>\n    <td>Isoniazid</td>\n  </tr>\n  <tr>\n    <td>Epidermal growth factor receptor inhibitors</td>\n  </tr>\n  <tr>\n    <td>Iodides</td>\n  </tr>\n  <tr>\n    <td>Bromides</td>\n  </tr>\n  <tr>\n    <td>Androgens</td>\n  </tr>\n  <tr>\n    <td>Corticotropin</td>\n  </tr>\n  <tr>\n    <td>Cyclosporine</td>\n  </tr>\n  <tr>\n    <td>Disulfiram</td>\n  </tr>\n  <tr>\n    <td>Psoralens</td>\n  </tr>\n  <tr>\n    <td>Thiourea</td>\n  </tr>\n  <tr>\n    <td>Vitamins B2, B6, and B12</td>\n  </tr>\n  <tr>\n    <td>Azathioprine</td>\n  </tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 76762 Version 2.0</div></div></div>"},"76766":{"type":"graphic_figure","displayName":"Vulvar varicosities","title":"Vulvar varicosities","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Vulvar varicosities</div><div class=\"cntnt\"><img style=\"width:503px; height:569px;\" src=\"images/OBGYN/76766_Vulvar varicosities.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vulvar varicosities appear as purple-blue distensible folds in the vaginal mucosa and labia or as a grape-like cluster of veins (&quot;bag of worms&quot;) in the enlarged vulva.</div><div class=\"graphic_reference\"><span style=\"font-family:monaco;color:#0000ff;font-size:12pt;text-decoration:underline\"></span></div><div id=\"graphicVersion\">Graphic 76766 Version 2.0</div></div></div>"},"76767":{"type":"graphic_picture","displayName":"Autoimmune pancreatitis patient with IgG4 immunostaining","title":"Autoimmune pancreatitis patient with IgG4 immunostaining","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Autoimmune pancreatitis patient with IgG4 immunostaining</div><div class=\"cntnt\"><img style=\"width:361px; height:583px;\" src=\"images/RHEUM/76767_Autoimm_pancr_IgG4_immunost.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histological findings for the pancreas in an autoimmune pancreatitis patient showing (A) dense lymphoplasmacytic infiltration and storiform fibrosis (HE staining), and (B) abundant infiltration of IgG4-positive plasma cells (IgG4 immunostaining).</div><div class=\"graphic_reference\">Reproduced with permission from: Takuma K, Kamisawa T, Igarashi Y. Autoimmune pancreatitis and IgG4-related sclerosing cholangitis. Curr Opinion Rheum 2011; 23:80. Copyright © 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76767 Version 5.0</div></div></div>"},"76768":{"type":"graphic_diagnosticimage","displayName":"Gastroschisis 1","title":"Classic prenatal ultrasound image of gastroschisis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Classic prenatal ultrasound image of gastroschisis</div><div class=\"cntnt\"><img style=\"width:331px; height:331px;\" src=\"images/OBGYN/76768_Gastroschisis1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image is taken at the level of the cord insertion site. The cord insertion appears normal; echolucent vessels can be seen entering the abdominal cavity. The abdominal wall defect can be seen adjacent to the cord insertion site: there is loss of continuity of the abdominal skin line where the bowel protrudes through the abdominal wall defect.</div><div class=\"graphic_reference\">Courtesy of Courtney D Stephenson, DO and Andrew P Schuller, RDMS.</div><div id=\"graphicVersion\">Graphic 76768 Version 3.0</div></div></div>"},"76769":{"type":"graphic_table","displayName":"HIPEC parameters","title":"Typical HIPEC parameters used at various centers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical HIPEC parameters used at various centers</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   Duration:\r\n  \r\n   </td>\r\n  \r\n   <td>90 to 120 mins</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   Target temperature:\r\n  \r\n   </td>\r\n  \r\n   <td>40 to 42.5 degrees Celsius</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   Perfusate volume:\r\n  \r\n   </td>\r\n  \r\n   <td>4 to 6 liters</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   Flow rate:\r\n  \r\n   </td>\r\n  \r\n   <td>1 to 1.5 liters/min</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" rowspan=\"3\">\r\n  \r\n   Agents*:\r\n  \r\n   </td>\r\n  \r\n   <td>\t<p>Mitomycin C</p>\n\t<p> \t \t\tDoxorubicin</p>\n\t<p> \t \t\tCisplatin</p>\n</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">HIPEC: hyperthermic intraperitoneal chemotherapy.<br>* Alone or in combination.</div><div id=\"graphicVersion\">Graphic 76769 Version 1.0</div></div></div>"},"76770":{"type":"graphic_figure","displayName":"Manifestations of PCOS","title":"Manifestations of polycystic ovary syndrome in adults, in approximate proportion to their relative prevalence and coincidence","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Manifestations of polycystic ovary syndrome in adults, in approximate proportion to their relative prevalence and coincidence</div><div class=\"cntnt\"><img style=\"width:578px; height:378px;\" src=\"images/PEDS/76770_Manifestations_of_PCOS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutaneous symptoms include hirsutism, treatment-resistant acne, pattern alopecia, or acanthosis nigricans. Anovulatory symptoms include amenorrhea, oligomenorrhea, excessive (dysfunctional) anovulatory uterine bleeding, and infertility. The subclinical prevalence of the PCOS type of ovarian androgenic dysfunction in obese patients who lack the cutaneous or menstrual manifestations of PCOS is unknown.</div><div class=\"graphic_footnotes\">PCOS: polycystic ovary syndrome.</div><div class=\"graphic_reference\">Modified&nbsp;with permission from: Rosenfield RL. Current concepts of polycystic ovary syndrome. Ballieres Clin Obstet Gynaecol 1997; 11:307. Copyright © 1997 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 76770 Version 7.0</div></div></div>"},"76771":{"type":"graphic_table","displayName":"Agents that reduce intraocular pressure","title":"Agents that reduce intraocular pressure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Agents that reduce intraocular pressure</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Examples</td> <td class=\"subtitle1\">Side effects</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Agents that suppress aqueous inflow</td> </tr> <tr> <td class=\"indent1\">Beta&nbsp;adrenergic blockers</td> <td>Betaxolol, carteolol, levobunolol, metipranolol, timolol</td> <td>Ocular irritation and dry eyes. Contraindicated in patients with bradycardia, heart block, heart failure, asthma, or obstructive airway disease.</td> </tr> <tr> <td class=\"indent1\">Alpha-2&nbsp;adrenergic agonists</td> <td>Apraclonidine, brimonidine</td> <td>Red eye and ocular irritation. CNS effects and respiratory arrest in young children (brimonidine). Caution in patients with cerebral or coronary insufficiency, Raynaud phenomenon, postural hypotension, hepatic or renal impairment.</td> </tr> <tr> <td class=\"indent1\">Carbonic anhydrase inhibitors</td> <td>Dorzolamide and brinzolamide (topical), acetazolamide and methazolamide (oral)</td> <td>Oral form can cause transient myopia, nausea, diarrhea, loss of appetite and taste, parasthesiae, lassitude, renal stones, and hematological problems. Topical forms much less likely to cause systemic side effects but can cause local irritation and redness.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Agents that increase aqueous outflow</td> </tr> <tr> <td class=\"indent1\">Prostaglandin analogues, (prostamide)</td> <td>Bimatoprost, latanoprost, tafluprost, travoprost, unoprostone*</td> <td>Brown discoloration of iris, lengthening and darkening of eyelashes, ocular irritation and redness, macular edema or iritis in susceptible individuals</td> </tr> <tr> <td class=\"indent1\">Alpha&nbsp;adrenergic agonists</td> <td>Apraclonidine, brimonidine</td> <td>Red eye and ocular irritation. CNS effects and respiratory arrest in young children (brimonidine). Caution in patients with cerebral or coronary insufficiency, Raynaud phenomenon, postural hypotension, hepatic or renal impairment.</td> </tr> <tr> <td class=\"indent1\">Cholinergic agonists</td> <td>Pilocarpine, carbachol</td> <td>Ciliary spasm leading to headaches especially in younger patients, myopia, dim vision (small pupil). Cataracts and iris-lens adhesions in long term.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system.<br />* Not available in&nbsp;the United States&nbsp;or Canada.</div><div class=\"graphic_reference\">Adapted with permission from: Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004; 363:1711. Copyright © 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 76771 Version 7.0</div></div></div>"},"76772":{"type":"graphic_table","displayName":"Air embolism clinical findings","title":"Clinical findings in air embolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical findings in air embolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptoms</td> <td class=\"subtitle1\">Physical findings</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pulmonary</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Dyspnea (100 percent incidence)</p> <p>\"Gasp reflex\"*</p> \"Sucking sound\"<sup>&#182;</sup></td> <td> <p>Tachypnea</p> <p>Wheeze</p> <p>Rales</p> Respiratory failure</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cardiac </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Substernal chest pain</td> <td> <p>Hypotension</p> <p>Tachycardia</p> <p>Mill wheel murmur<sup>&#916;</sup></p> <p>Signs of right heart failure (eg, elevated JVD)</p> Shock</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neurologic</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Sense of doom</p> Dizziness/lightheadedness</td> <td> <p>Change in mental status</p> Focal neurological deficits</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Skin</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td> <p>Crepitus over superficial vessels (seen rarely in setting of massive air embolus)</p> Livedo reticularis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Ocular</td> </tr> <tr> <td>&nbsp;</td> <td>Bubbles within the retinal arteries</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* A gasp or cough is at times reported when a bolus of air enters the pulmonary circulation.<br />¶ A sucking noise can be heard on occasion when air is sucked into the intravascular space, such as when air embolism occurs as a complication of a central line.<br />Δ The mill wheel murmur is a relatively specific sign classically associated with venous air embolism but only rarely heard. It is a churning sound heard throughout the entire cardiac cycle and is caused by the movement of air bubbles in the right ventricle.</div><div id=\"graphicVersion\">Graphic 76772 Version 2.0</div></div></div>"},"76776":{"type":"graphic_table","displayName":"Uncommon causes of syncope","title":"Major uncommon causes of syncope","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major uncommon causes of syncope</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Cardiovascular disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Arrhythmic causes</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Supraventricular tachycardia</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Long QT interval syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Idiopathic ventricular tachycardia</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Myocardial infarction causing bradycardias and tachycardias</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Right ventricular dysplasia</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Nonarrhythmic causes</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Pulmonary embolus</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Pulmonary hypertension</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Dissecting aortic aneurysm</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Subclavian steal</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Atrial myxoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Cardiac tamponade</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Noncardiovascular disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Reflexes</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Defecation</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Glossopharyngeal</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Postprandial</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Carotid sinus hypersensitivity</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hyperventilation</td>\n\n    </tr>\n\n\t<tr>\n\n      <td>Anaphylaxis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Migraine</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Carcinoid syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Systemic mastocytosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Metabolic</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Hypoglycemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Hypoxia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Multivessel obstructive cerebrovascular disease</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 76776 Version 1.0</div></div></div>"},"76777":{"type":"graphic_figure","displayName":"Pelvic binder","title":"Pelvic binders for open book fractures","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Pelvic binders for open book fractures</div><div class=\"cntnt\"><img style=\"width:541px; height:365px;\" src=\"images/EM/76777_Pelvic_binder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemorrhage from a pelvic fracture may be controlled by binding with a sheet or specialized binder that is centered over the greater trochanter.</div><div id=\"graphicVersion\">Graphic 76777 Version 2.0</div></div></div>"},"76778":{"type":"graphic_figure","displayName":"Clamping cardinal ligaments","title":"Clamping and suture ligation of the cardinal ligaments during vaginal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clamping and suture ligation of the cardinal ligaments during vaginal hysterectomy</div><div class=\"cntnt\"><img style=\"width:414px; height:362px;\" src=\"images/OBGYN/76778_Clamping_cardinal_ligaments.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 76778 Version 2.0</div></div></div>"},"76779":{"type":"graphic_figure","displayName":"Hemat transcription factors","title":"Transcription factors essential for normal hematopoietic development as defined by gene targeting studies in murine embryonic stem cells","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Transcription factors essential for normal hematopoietic development as defined by gene targeting studies in murine embryonic stem cells</div><div class=\"cntnt\"><img style=\"width:503px; height:407px;\" src=\"images/HEME/76779_Hemat_transcription_factors.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The primitive hematopoietic stem cell gives rise to nucleated erythroid cells at the yolk sac stage of development. Subsequently, multilineage hematopoiesis is thought to be derived from the the definitive hematopoietic stem cell. The origins and relationships of the primitive and definitive hematopoietic stem cells remain controversial. Experimental evidence suggests that a common precursor to the primitive and definitive hematopoietic stem cell may exist (blast cell colony-forming cell). The precise hematopoietic pathways remain to be defined.</div><div class=\"graphic_reference\">Reprinted by permission from Nature, Kennedy M, Firpo M, Choi K, et al. A common precursor for primitive erythropoiesis and definitive haematopoiesis. Nature 1997; 386:488. Copyright &#169; 1997 Macmillan Magazines Ltd.</div><div class=\"contractual\"><br/><a href=\"http://www.nature.com/\">http://www.nature.com</a></div><div id=\"graphicVersion\">Graphic 76779 Version 1.0</div></div></div>"},"76783":{"type":"graphic_table","displayName":"Causes of ophthalmoplegia children","title":"Causes of chronic progressive external ophthalmoplegia in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of chronic progressive external ophthalmoplegia in children</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Myasthenia gravis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Myasthenia-like syndromes</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Lambert-Eaton myasthenic syndrome</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Drug-induced (penicillamine, gold)</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Inflammatory and infectious myopathies</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Orbital cellulitis</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Dural sinus thrombosis</td>\n    </tr>\n    <tr>\n\n      <td>Thyroid eye disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Idiopathic orbital myositis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Infiltrative myopathy (eg, amyloidosis)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Abetalipoproteinemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Organophosphate poisoning</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Botulism</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hereditary ataxia syndromes</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Encephalomyopathy</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Leigh syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Mitochondrial neurogoastrointestinal encephalopathy syndrome</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Canavan disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Primary metabolic diseases</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Cytochrome C oxidase deficiency</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Carnitine deficiency</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Vitamin E deficiency</td>\n    </tr>\n    <tr>\n\n      <td>Primary and metastatic muscle tumors</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Episodic ophthalmoplegic syndromes</td>\n\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Familial periodic paralysis</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Muscle trauma</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Ischemia </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Vasculitis </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Ophthalmopolegic migraine</td>\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 76783 Version 2.0</div></div></div>"},"76786":{"type":"graphic_table","displayName":"Cytotoxic T cell targets","title":"Examples of tumor-specific and lineage-specific targets for cytotoxic T cells","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of tumor-specific and lineage-specific targets for cytotoxic T cells</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Tumor-specific</td> </tr> <tr> <td>Idiotype - B cell malignancies</td> </tr> <tr> <td>T cell receptor - T cell malignancies</td> </tr> <tr> <td>EBV epitopes - EBV-associated lymphomas</td> </tr> <tr> <td>Oncogene products - (eg, bcr/abl in CML, Wilms tumor 1 in acute myeloid leukemia)</td> </tr> <tr> <td class=\"subtitle1_single\">Lineage-specific</td> </tr> <tr> <td>MAGE proteins - melanomas</td> </tr> <tr> <td>Proteinase III - acute myeloid leukemia</td> </tr> <tr> <td>Her 2 neu - breast cancer</td> </tr> <tr> <td>Carcinoembryonic antigen - solid tumors</td> </tr> <tr> <td>Minor histocompatibility antigens - hematopoietic malignancies</td> </tr> <tr> <td>CD19 - CD19 positive hematopoietic malignancies</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76786 Version 6.0</div></div></div>"},"76787":{"type":"graphic_figure","displayName":"Plasma K and HCO3 reabsorption","title":"Inverse relation between plasma potassium and bicarbonate reabsorption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inverse relation between plasma potassium and bicarbonate reabsorption</div><div class=\"cntnt\"><img style=\"width:393px; height:243px;\" src=\"images/NEPH/76787_Plasma_K_and_HCO3_reabsorpt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Renal tubular reabsorption of HCO3 (meq/L of glomerular filtrate) as a function of the plasma potassium concentration.</div><div class=\"graphic_reference\">Data from Fuller, GR, MacLeod, MB, Pitts, RF, Am J Physiol,182:111, 1956.</div><div id=\"graphicVersion\">Graphic 76787 Version 1.0</div></div></div>"},"76789":{"type":"graphic_picture","displayName":"Scabies infant foot 1","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:432px; height:297px;\" src=\"images/DERM/76789_Scabies_infant_foot_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules, vesicles, and pustules are present on the sole of the foot of this infant.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76789 Version 6.0</div></div></div>"},"76790":{"type":"graphic_picture","displayName":"Scissors technique to open mouth for laryngoscopy","title":"Scissors technique to open mouth for laryngoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scissors technique to open mouth for laryngoscopy</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/EM/76790_Scissorstechnique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph demonstrates mouth opening using the &quot;scissors&quot; technique, in which the thumb and middle finger flex and cross one another. Use of the finger flexors, which are stronger than extensors, make the maneuver easier to perform.</div><div class=\"graphic_reference\">Reproduced with permission from: Orebaugh SL. Direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 76790 Version 11.0</div></div></div>"},"76792":{"type":"graphic_diagnosticimage","displayName":"Vascular malformation 9fg","title":"Right and left uterine angiograms","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Right and left uterine angiograms</div><div class=\"cntnt\"><img style=\"width:504px; height:196px;\" src=\"images/OBGYN/76792_Vascular_malformation_9fg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right (A) and left (B) uterine angiograms after uterine artery embolization reveal occlusions of both uterine arteries and their intrauterine branches (arrows).</div><div id=\"graphicVersion\">Graphic 76792 Version 2.0</div></div></div>"},"76794":{"type":"graphic_figure","displayName":"Mechanisms linkng periprocedural bleeding and death","title":"Possible mechanisms linking peri-procedural bleeding with increased mortality","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Possible mechanisms linking peri-procedural bleeding with increased mortality</div><div class=\"cntnt\"><img style=\"width:504px; height:598px;\" src=\"images/CARD/76794_Mech_mort_periproc_bleeding.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Copyrighted and used with permission of the Mayo Foundation for Medical Education and Research, all rights reserved.</div><div id=\"graphicVersion\">Graphic 76794 Version 2.0</div></div></div>"},"76796":{"type":"graphic_figure","displayName":"Mainstem bronchial obstr","title":"Functional mainstem bronchial obstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Functional mainstem bronchial obstruction</div><div class=\"cntnt\"><img style=\"width:251px; height:242px;\" src=\"images/PULM/76796_Mainstem_bronchial_obstr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Maximal expiratory and inspiratory flow-volume loops before (inner green loop) and after (outer blue loop) surgery in a patient with mainstem bronchial obstruction. The diameter of the orifice at the site of maximal obstruction both before and after treatment is shown in relation to the corresponding flow-volume loop. Note the relatively parallel rightward shift of the descending limb of the maximal expiratory flow-volume curve after treatment.</div><div id=\"graphicVersion\">Graphic 76796 Version 1.0</div></div></div>"},"76797":{"type":"graphic_table","displayName":"Laboratory monitoring during leprosy treatment","title":"Laboratory monitoring for multiple drug treatment (MDT) for leprosy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory monitoring for multiple drug treatment (MDT) for leprosy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Initial visit</td> <td class=\"subtitle1\">Second visit<br /> (1 to 2 months)</td> <td class=\"subtitle1\">3 months</td> <td class=\"subtitle1\">6 months</td> <td class=\"subtitle1\">12 months</td> <td class=\"subtitle1\">18 months</td> <td class=\"subtitle1\">24 months</td> </tr> <tr> <td>CBC + platelets</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> </tr> <tr> <td>AST</td> <td>X</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> </tr> <tr> <td>ALT</td> <td>X</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> </tr> <tr> <td>Calcium</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>BUN</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Creatinine</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Bilirubin</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>G6PD</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Hepatitis B</td> <td rowspan=\"2\" colspan=\"7\"><br /> Screen if patient requires prednisone for treatment of immunologic reaction.</td> </tr> <tr> <td>Hepatitis C</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CBC: complete blood count; AST: aspartate aminotransferase; ALT: alanine aminotransferase; BUN: blood urea nitrogen; G6PD: glucose 6 phosphate dehydrogenase.</div><div id=\"graphicVersion\">Graphic 76797 Version 4.0</div></div></div>"},"76798":{"type":"graphic_picture","displayName":"Clonorchiasis adult","title":"Clonorchiasis adult","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Clonorchiasis adult</div><div class=\"cntnt\"><img style=\"width:584px; height:234px;\" src=\"images/ID/76798_Clonorchiasis_adult.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Adult of <em>C. sinensis</em>.<br />(B) Adult of <em>C. sinensis</em> stained with carmine. Clearly visible in this image are the oral sucker (OS), pharynx (PH), ceca (CE), acetabulum, or ventral sucker (AC), uterus (UT), vitellaria (VT), and testes (TE).</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Clonorchiasis. Available at: <a href=\"http://www.cdc.gov/dpdx/clonorchiasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/clonorchiasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 76798 Version 5.0</div></div></div>"},"76799":{"type":"graphic_picture","displayName":"Mular lesion bartonellosis","title":"Mular lesion (eruptive-phase bartonellosis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mular lesion (eruptive-phase bartonellosis)</div><div class=\"cntnt\"><img style=\"width:288px; height:286px;\" src=\"images/ID/76799_Mular_lesion_bartonellosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This child from Peru developed an erythematous, round lesion on face.</div><div class=\"graphic_reference\">Reproduced with permission from Maguina C, Garcia PJ, Gotuzzo E, et al. Bartonellosis (Carrion's disease) in the modern era. Clin Infect Dis 2001; 33:772. Copyright © 2001 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 76799 Version 3.0</div></div></div>"},"76800":{"type":"graphic_diagnosticimage","displayName":"CT scan in PKD","title":"CT scan showing polycystic kidney disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan showing polycystic kidney disease</div><div class=\"cntnt\"><img style=\"width:362px; height:252px;\" src=\"images/NEPH/76800_CT_scan_in_PKD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abdominal CT scan in a patient with polycystic kidney disease shows extensive cysts in both kidneys; the cysts have almost completely replaced the renal parenchyma.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 76800 Version 5.0</div></div></div>"},"76802":{"type":"graphic_figure","displayName":"Water shifts hemofiltration","title":"Water movement during isolated ultrafiltration","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Water movement during isolated ultrafiltration</div><div class=\"cntnt\"><img style=\"width:500px; height:207px;\" src=\"images/NEPH/76802_Water_shifts_hemofiltration.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of water movement during isolated ultrafiltration. Plasma at an osmolality of 320 mosmol/kg flows into the dialyzer (filter) (step 1), which is not perfused with dialysate. The favorable hydrostatic pressure gradient results in the <FONT style=\"FONT-WEIGHT: bold\">isosmotic</FONT> removal of fluid in the dialyzer. The fluid returning to the patient is reduced in volume, but not changed in osmolality (step 2). The ensuing rise in plasma oncotic pressure results in fluid movement from the interstitial fluid and the cells into the vascular space (step 3). This last effect will tend to minimize the degree of plasma volume depletion and protect against the development of hypotension.</div><div id=\"graphicVersion\">Graphic 76802 Version 2.0</div></div></div>"},"76803":{"type":"graphic_table","displayName":"Medications and toxins fatal in small doses","title":"Medications and toxins potentially fatal to toddler in one or two doses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications and toxins potentially fatal to toddler in one or two doses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Estimated minimum fatal dose</td> <td class=\"subtitle1\">Major effects</td> </tr> <tr> <td>Benzocaine (eg, Orajel)</td> <td>&#60;20 mg/kg</td> <td>Methemoglobinemia, seizures</td> </tr> <tr> <td>Beta blockers</td> <td>Unclear</td> <td>Seizures, hypoglycemia, bradycardia, hypotension</td> </tr> <tr> <td>Calcium antagonists</td> <td>&#60;40 mg/kg</td> <td>Bradycardia, hypotension</td> </tr> <tr> <td>Camphor</td> <td>Approximately 50 mg/kg</td> <td>Seizures, CNS depression, respiratory depression</td> </tr> <tr> <td>Chloroquine</td> <td>&#60;30 mg/kg</td> <td>Seizures, arrhythmias</td> </tr> <tr> <td>Clonidine</td> <td>Unclear</td> <td>Bradycardia, hypotension, CNS depression</td> </tr> <tr> <td>Diphenoxylate (eg, Lomotil)</td> <td>1.2 mg/kg</td> <td>CNS depression, respiratory depression</td> </tr> <tr> <td>Imidazoline-derived sympathomimetics (eg, Visine, Afrin)</td> <td>Unclear</td> <td>Lethargy, miosis, hypotension, bradycardia, respiratory depression, shock</td> </tr> <tr> <td>Lindane</td> <td>Approximately 6 mg/kg</td> <td>Seizures, CNS depression</td> </tr> <tr> <td>Methadone</td> <td>Approximately 5 mg/kg</td> <td>CNS depression, respiratory depression</td> </tr> <tr> <td>Methyl salicylate</td> <td>Approximately 200 mg/kg</td> <td>Seizures, acidosis, cardiovascular collapse</td> </tr> <tr> <td>Nicotine (liquid)</td> <td>1 to 3 mg/kg</td> <td>Seizures, coma, respiratory arrest, cardiac arrest</td> </tr> <tr> <td>Opioids (eg, methadone, long-acting morphine)</td> <td>Unknown</td> <td>Miosis, CNS depression, respiratory depression</td> </tr> <tr> <td>Phenothiazines</td> <td>Approximately 20 mg/kg</td> <td>Seizures, arrhythmias, CNS depression</td> </tr> <tr> <td>Phenylpropanolamine</td> <td>Unclear</td> <td>Arrhythmia, intracranial bleed</td> </tr> <tr> <td>Quinidine</td> <td>Approximately 50 mg/kg</td> <td>Seizures, arrhythmia, CNS depression</td> </tr> <tr> <td>Quinine</td> <td>Approximately 80 mg/kg</td> <td>Seizures, arrhythmias, retinal injury</td> </tr> <tr> <td>Sulfonylureas</td> <td>&#60;1 mg/kg</td> <td>Hypoglycemia</td> </tr> <tr> <td>Theophylline</td> <td>Approximately 50 mg/kg</td> <td>Seizures, arrhythmias</td> </tr> <tr> <td>Tricyclic antidepressants&nbsp;</td> <td>Approximately 15 mg/kg</td> <td>Seizures, arrhythmias, hypotension&nbsp;</td> </tr> <tr> <td>Toxic alcohols (eg, methanol, ethylene glycol)</td> <td>0.3 mL/kg</td> <td>CNS depression</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system.</div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>Osterhoudt KC. The toxic toddler: Drugs that can kill in small doses. Contemp Pediatr 2000; 17:73. </LI>&#xD;&#xA;<LI>Liebelt EL, Shannon MW. Small doses, big problems:&nbsp;A selected review of highly toxic common medications. Pediatr Emerg Care 1993; 9:292. </LI>&#xD;&#xA;<LI>Koren G. Medications which can kill a toddler with one tablet or teaspoonful. J Toxicol Clin Toxicol 1993; 31:407. </LI>&#xD;&#xA;<LI>Henry K, Harris CR. Deadly ingestions. Pediatr Clin North Am 2006; 53:293. </LI>&#xD;&#xA;<LI>Michael JB, Sztajnkrycer MD. Deadly pediatric poisons: Nine common agents that kill at low doses. Emerg Med Clin North Am 2004; 22:1019. </LI>&#xD;&#xA;<LI>Bassett RA, Osterhoudt K, Brabazon T. Nicotine poisoning in an infant. N Engl J Med 2014; 370:2249.</LI></OL></div><div id=\"graphicVersion\">Graphic 76803 Version 8.0</div></div></div>"},"76804":{"type":"graphic_table","displayName":"Prevalence of UTI in febrile infants and children","title":"Prevalence of urinary tract infection in febrile* infants and children by demographic group","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of urinary tract infection in febrile* infants and children by demographic group</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Demographic group</td> <td class=\"subtitle1\">Prevalence or pretest probability (95% CI)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\">0 to 3 months</td> <td class=\"subtitle2_left\">7.2% (5.8-8.6)</td> </tr> <tr> <td class=\"indent1\">Girls</td> <td>7.5% (5.1-10)</td> </tr> <tr> <td class=\"indent1\">Circumcised boys</td> <td>2.4% (1.4-3.5)</td> </tr> <tr> <td class=\"indent1\">Uncircumcised boys</td> <td>20.1% (16.8-23.4)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\">3 to 6 months</td> <td class=\"subtitle2_left\">6.6% (1.7-11.5)</td> </tr> <tr> <td class=\"indent1\">Girls</td> <td>5.7% (2.3-9.4)</td> </tr> <tr> <td class=\"indent1\">Boys</td> <td>3.3% (1.3-5.3)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\">6 to 12 months</td> <td class=\"subtitle2_left\">5.4% (3.4-7.4)</td> </tr> <tr> <td class=\"indent1\">Girls</td> <td>8.3% (3.9-12.7)</td> </tr> <tr> <td class=\"indent1\">Boys</td> <td>1.7% (0.5-2.9)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\">12 to 24 months</td> <td class=\"subtitle2_left\">4.5%<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Girls</td> <td>2.1% (1.2-3.6)</td> </tr> <tr> <td class=\"indent1\">Circumcised boys &#62;1 year</td> <td>&#60;1%<sup>&#182;</sup></td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\">&#60;19 years with urinary symptoms and/or fever<sup>&#916;</sup></td> <td class=\"subtitle2_left\">7.8% (6.6-8.9)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Temperature ≥38°C.<br />¶&nbsp;95% confidence interval not available.<br />Δ Most of these children were older than 2 years.</div><div class=\"graphic_reference\">Data from: Shaikh N, Morone NE, Bost JE, Farrell MH. Prevalence of Urinary Tract Infection in Childhood: A Meta-Analysis. Pediatr Infect Dis J 2008; 27:302.</div><div id=\"graphicVersion\">Graphic 76804 Version 9.0</div></div></div>"},"76805":{"type":"graphic_table","displayName":"Anaphylaxis severity with multiple stings","title":"Severity of systemic reaction in relation to number of Hymenoptera re-stings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Severity of systemic reaction in relation to number of Hymenoptera re-stings</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"30%\"></colgroup><colgroup span=\"5\" width=\"8%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Re-sting</td> <td class=\"subtitle1\" rowspan=\"2\">Number of patients</td> <td class=\"subtitle1\" colspan=\"5\">Grade of systemic reaction</td> </tr> <tr> <td class=\"subtitle2\">0</td> <td class=\"subtitle2\">I</td> <td class=\"subtitle2\">II</td> <td class=\"subtitle2\">III</td> <td class=\"subtitle2\">IV</td> </tr> <tr> <td>First re-sting</td> <td class=\"centered\">25</td> <td class=\"centered\">11</td> <td class=\"centered\">10</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">1</td> </tr> <tr> <td>Later re-sting</td> <td class=\"centered\">17</td> <td class=\"centered\">3</td> <td class=\"centered\">5</td> <td class=\"centered\">0</td> <td class=\"centered\">6</td> <td class=\"centered\">3</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Grade of systemic reaction in relation to number of re-stings according to HL Mueller<SUP>[1]</SUP> in 25 patients with relapses after discontinuation of&nbsp;venom immunotherapy&nbsp;in relation to number of re-stings<SUP>[2]</SUP>.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Mueller HL. Diagnosis and treatment of insect sensitivity. J Asthma Res 1966; 3:331.</li>&#xD;&#xA;    <li>Lerch E, M&uuml;ller UR. Long-term protection after stopping venom immunotherapy: Results of re-stings in 200 patients. J Allergy Clin Immunol 1998; 101:606.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 76805 Version 6.0</div></div></div>"},"76808":{"type":"graphic_table","displayName":"Anticoagulant herbs","title":"Anticoagulant herbal ingredients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anticoagulant herbal ingredients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Effect</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Anticoagulants</td> </tr> <tr> <td class=\"indent1\">Alfalfa</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Angelica</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Aniseed</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Arnica</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Asafoetida</td> <td>Coumarin constituents, anticoagulant in vivo</td> </tr> <tr> <td class=\"indent1\">Celery</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Chamomile, German</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Chamomile, Roman</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Clove</td> <td>Eugenol powerful inhibitor of platelet activity</td> </tr> <tr> <td class=\"indent1\">Fenugreek</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Feverfew</td> <td>Inhibits platelet aggregation</td> </tr> <tr> <td class=\"indent1\">Fucus</td> <td>Anticoagulant action</td> </tr> <tr> <td class=\"indent1\">Garlic</td> <td>Interaction with warfarin reported</td> </tr> <tr> <td class=\"indent1\">Ginger</td> <td>Inhibition of platelet activity</td> </tr> <tr> <td class=\"indent1\">Ginkgo</td> <td>Inhibition of platelet activity</td> </tr> <tr> <td class=\"indent1\">Ginseng, Panax</td> <td>Reduction of blood coagulation</td> </tr> <tr> <td class=\"indent1\">Horse-chestnut</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Horseradish</td> <td>Peroxidase stimulates synthesis of arachidonic acid metabolites</td> </tr> <tr> <td class=\"indent1\">Liquorice</td> <td>Inhibition of platelet activity</td> </tr> <tr> <td class=\"indent1\">Meadowsweet</td> <td>Salicylate constituents</td> </tr> <tr> <td class=\"indent1\">Poplar</td> <td>Salicylate constituents</td> </tr> <tr> <td class=\"indent1\">Prickly ash, northern</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Prickly ash, southern</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Quassia</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Red clover</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Willow</td> <td>Salicylate constituents</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from Newall, CA, Anderson, LA, Phillipson, JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996, p.282.</div><div id=\"graphicVersion\">Graphic 76808 Version 2.0</div></div></div>"},"76809":{"type":"graphic_picture","displayName":"Rams horn toenails","title":"Markedly thickened, curved, ram's horn type of toenails","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Markedly thickened, curved, ram's horn type of toenails</div><div class=\"cntnt\"><img style=\"width:396px; height:257px;\" src=\"images/PC/76809_Ramshorntoenails.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Atlas of Office Procedures 1999; 2:97. Copyright 1999 WB Saunders.</div><div id=\"graphicVersion\">Graphic 76809 Version 3.0</div></div></div>"},"76811":{"type":"graphic_figure","displayName":"Flow volume loops in airway obstruction","title":"Flow-volume loops in upper airway obstruction","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">Flow-volume loops in upper airway obstruction</div><div class=\"cntnt\"><img style=\"width:784px; height:222px;\" src=\"images/PULM/76811_Flow_volume_loops_airway_ob.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal flow-volume loop: the expiratory portion of the flow-volume curve is characterized by a rapid rise to the peak flow rate, followed by a nearly linear fall in flow. The inspiratory curve is a relatively symmetrical, saddle-shaped curve.<br />(B) Fixed upper airway obstruction (can be intrathoracic or extrathoracic): flow limitation and flattening are noted in both the inspiratory and expiratory limbs of the flow-volume loop.<br />(C) Dynamic (or variable, nonfixed) extrathoracic obstruction: with flow limitation and flattening are noted on the inspiratory limb of the loop.<br />(D) Dynamic (or variable, nonfixed) intrathoracic obstruction: flow limitation and flattening are noted on the expiratory limb of the loop.</div><div class=\"graphic_footnotes\">TLC: total lung capacity; RV: residual volume.</div><div class=\"graphic_reference\">Adapted from: Stoller JK. Cleve Clin J Med 1992; 59:75.</div><div id=\"graphicVersion\">Graphic 76811 Version 5.0</div></div></div>"},"76812":{"type":"graphic_picture","displayName":"Proper mechanics centering load","title":"Proper mechanics: Center the load when carrying an item","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proper mechanics: Center the load when carrying an item</div><div class=\"cntnt\"><img style=\"width:287px; height:381px;\" src=\"images/RHEUM/76812_proper_mech_center_load.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Sharon Alzner, MPT.</div><div id=\"graphicVersion\">Graphic 76812 Version 1.0</div></div></div>"},"76817":{"type":"graphic_table","displayName":"Cystic hygroma outcome","title":"Expected outcomes for first-trimester cystic hygroma and increased nuchal translucency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Expected outcomes for first-trimester cystic hygroma and increased nuchal translucency</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">Cystic hygroma, percent</td>\n\n      <td class=\"subtitle1\">Increased nuchal translucency, percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\">Chromosomal abnormality</td>\n\n      <td>50</td>\n\n      <td>15</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">In absence of aneuploidy</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">No visible malformation</td>\n\n      <td>45</td>\n\n      <td>95</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Major cardiac defect</td>\n\n      <td>25</td>\n\n      <td>3</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Fetal or neonatal death</td>\n\n      <td>25</td>\n\n      <td>5</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Normal pediatric outcome</td>\n\n      <td>20</td>\n\n      <td>90</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=42495&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Cystic_hygroma_outcome.htm</title></head></div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Malone FD, Ball RH, Nyberg DA, et al. First-trimester septated cystic hygroma. Prevalence, natural history, and pediatric outcomes. Obstet Gynecol 2005; 106:288</LI>&#xD;&#xA;<LI>Ducarme G, Graesslin O, Alanio E, et al. Increased nuchal translucency and cystic hygroma in the first trimester: Prenatal diagnosis and neonatal outcome. Gynecol Obstet Fertil 2005; 33:750.</LI></OL></div><div id=\"graphicVersion\">Graphic 76817 Version 3.0</div></div></div>"},"76820":{"type":"graphic_algorithm","displayName":"Calcium and regulation of PTH","title":"PTH homeostasis","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">PTH homeostasis</div><div class=\"cntnt\"><img style=\"width:527px; height:214px;\" src=\"images/NEPH/76820_Calcium_and_regulation_of_P.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of parathyroid hormone (PTH) on calcium and phosphate metabolism. The net effect is an increase in the plasma calcium concentration with no change or a decrease in the plasma phosphate concentration.</div><div id=\"graphicVersion\">Graphic 76820 Version 2.0</div></div></div>"},"76821":{"type":"graphic_figure","displayName":"MHC I antigen processing and presentation pathway","title":"The MHC class I antigen processing and presentation pathway","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">The MHC class I antigen processing and presentation pathway</div><div class=\"cntnt\"><img style=\"width:498px; height:474px;\" src=\"images/ALLRG/76821_MHC_class_I_antigen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proteins from cytoplasmic pathogens and cellular proteins are targeted to the proteasome for proteolysis. Some of the resulting peptide products are selected by the TAP complex for import into the ER, where they can be sampled by newly synthesized MHC class I molecules. Class I heavy chains assemble with beta-2-microglobulin and are retained in association with the TAP complex via the chaperone tapasin to facilitate peptide encounter. Assembled MHC I molecules with bound peptide are then exported through the secretory pathway to the cell surface.</div><div class=\"graphic_footnotes\">MHC: major histocompatibility complex; ER: endoplasmic reticulum; B2M: beta-2-microglobulin; TAP: transporter associated with antigen processing.</div><div id=\"graphicVersion\">Graphic 76821 Version 5.0</div></div></div>"},"76822":{"type":"graphic_table","displayName":"Criteria for drug-induced thrombocytopenia","title":"Criteria for assessing reports of drug-induced thrombocytopenia and levels of evidence for a causal relationship of the drug to thrombocytopenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for assessing reports of drug-induced thrombocytopenia and levels of evidence for a causal relationship of the drug to thrombocytopenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Criteria</td> </tr> <tr> <td class=\"indent1\">1. The candidate drug preceded thrombocytopenia <strong>AND</strong> recovery from thrombocytopenia was complete and sustained after the drug was discontinued.</td> </tr> <tr> <td class=\"indent1\">2. The candidate drug was the only drug used prior to the onset of thrombocytopenia <strong>OR</strong> other drugs were continued or reintroduced after discontinuation of the candidate drug with a sustained normal platelet count.</td> </tr> <tr> <td class=\"indent1\">3. Other etiologies for thrombocytopenia were excluded.</td> </tr> <tr> <td class=\"indent1\">4. Re-exposure to the candidate drug resulted in recurrent thrombocytopenia <strong>OR</strong> drug-dependent, platelet-reactive antibodies were documented.</td> </tr> <tr> <td class=\"subtitle1_single\">Level of evidence</td> </tr> <tr> <td class=\"indent1\">Definite: criteria 1, 2, 3, and 4 met</td> </tr> <tr> <td class=\"indent1\">Probable: criteria 1, 2, and 3 met</td> </tr> <tr> <td class=\"indent1\">Possible: criterion 1 met</td> </tr> <tr> <td class=\"indent1\">Unlikely: criterion 1 not met</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate content on drug-induced thrombocytopenia for further information and a list of drugs implicated in drug-induced immune thrombocytopenia (DITP).</div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998; 129:886.</LI>&#xD;&#xA;<LI>Arnold DM, Nazi I, Warkentin TE, et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev 2013; 27:137.</LI></OL></div><div id=\"graphicVersion\">Graphic 76822 Version 4.0</div></div></div>"},"76824":{"type":"graphic_table","displayName":"Physical findings in the hypertensive child","title":"Physical examination findings associated with possible etiology of hypertension in children and adolescents<SUP>[1-3]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical examination findings associated with possible etiology of hypertension in children and adolescents<SUP>[1-3]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Physical examination finding</td> <td class=\"subtitle1\">Possible etiology</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">General</td> </tr> <tr> <td class=\"indent1\">Obesity</td> <td>Essential hypertension</td> </tr> <tr> <td class=\"indent1\">Truncal obesity</td> <td>Cushing's syndrome, corticosteroid therapy</td> </tr> <tr> <td class=\"indent1\">Growth retardation</td> <td>Chronic&nbsp;kidney disease</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Vital signs</td> </tr> <tr> <td class=\"indent1\">Tachycardia</td> <td>Catecholamine excess (PCC or neuroblastoma)&nbsp;or hyperthyroidism</td> </tr> <tr> <td class=\"indent1\">BP differences in extremities</td> <td>If upper extremity BP &#62; lower extremity BP, coarctation of aorta</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Head and neck</td> </tr> <tr> <td class=\"indent1\">Elfin facies</td> <td>Williams syndrome</td> </tr> <tr> <td class=\"indent1\">Moon facies</td> <td>Cushing syndrome, corticosteroid therapy</td> </tr> <tr> <td class=\"indent1\">Thyroid enlargement or goiter</td> <td>Hyperthyroidism</td> </tr> <tr> <td class=\"indent1\">Webbed neck</td> <td>Turner syndrome</td> </tr> <tr> <td class=\"indent1\">Tonsillar hypertrophy</td> <td>Sleep-disordered breathing, sleep apnea</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Eye</td> </tr> <tr> <td class=\"indent1\">Retinal changes</td> <td>Suggest severe HTN and secondary etiology</td> </tr> <tr> <td class=\"indent1\">Papilledema</td> <td>Increase intracranial pressure</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Skin</td> </tr> <tr> <td class=\"indent1\">Pallor, flushing</td> <td>Catecholamine excess (PCC and neuroblastoma)</td> </tr> <tr> <td class=\"indent1\">Acne, hirsutism, striae</td> <td>Cushing syndrome, corticosteroid therapy</td> </tr> <tr> <td class=\"indent1\">Caf&#233;-au-lait spots and/or neurofibromas</td> <td>Neurofibromatosis</td> </tr> <tr> <td class=\"indent1\">Ash leaf spots and/or adenoma sebaceum</td> <td>Tuberous sclerosis</td> </tr> <tr> <td class=\"indent1\">Rash</td> <td>Lupus nephritis, Henoch-Sch&#246;nlein purpura (IgA vasculitis)</td> </tr> <tr> <td class=\"indent1\">Acanthrosis nigricans</td> <td>Type 2 diabetes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Chest</td> </tr> <tr> <td class=\"indent1\">Widely spaced nipples</td> <td>Turner syndrome</td> </tr> <tr> <td class=\"indent1\">Murmur</td> <td>Coarctation of the aorta</td> </tr> <tr> <td class=\"indent1\">Apical heave</td> <td>Left ventricular hypertrophy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Abdomen</td> </tr> <tr> <td class=\"indent1\">Abdominal bruit</td> <td>Renovascular disease</td> </tr> <tr> <td class=\"indent1\">Mass</td> <td>Hydronephrosis, polycystic kidney disease, renal tumors, neuroblastoma</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Extremities</td> </tr> <tr> <td class=\"indent1\">Traction/casts</td> <td>Orthopedic manipulation</td> </tr> <tr> <td class=\"indent1\">Asymmetry of limbs</td> <td>Beckwith-Wiedemann syndrome</td> </tr> <tr> <td class=\"indent1\">Arthritis</td> <td>Henoch-Sch&#246;nlein purpura (IgA vasculitis), collagen vascular disease (systemic lupus erythematous)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neurologic</td> </tr> <tr> <td class=\"indent1\">Muscle weakness</td> <td>Liddle syndrome, hyperaldosteronism</td> </tr> <tr> <td class=\"indent1\">Diminished pain response</td> <td>Familial dysautonomia</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Genitalia</td> </tr> <tr> <td class=\"indent1\">Ambiguous/virilization</td> <td>Adrenal hyperplasia</td> </tr> <tr> <td class=\"indent1\">Advanced puberty</td> <td>Intracranial tumors</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Flynn JT. Evaluation and management of hypertension in childhood. Prog Pediatr Cardiol 2001; 12:177.</LI>&#xD;&#xA;<LI>The Fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. National Heart, Lung and Blood Institute. National Institutes of Health. May 2004.</LI>&#xD;&#xA;<LI>Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2017; 140:e20171904.</LI></OL></div><div id=\"graphicVersion\">Graphic 76824 Version 5.0</div></div></div>"},"76825":{"type":"graphic_picture","displayName":"DIP joint palpation","title":"Palpation of the distal interphalangeal (DIP) joint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palpation of the distal interphalangeal (DIP) joint</div><div class=\"cntnt\"><img style=\"width:333px; height:305px;\" src=\"images/RHEUM/76825_DIP_joint_palpation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The examiner places two fingers of one hand on the lateral joint lines and two fingers from the opposite hand at the base of the finger. Pressure is applied from the sides while simultaneously feeling for the distensibility of synovial thickening, excessive joint fluid, or both. The synovial lining of the small joints extends 5 to 6 mm above and below the joint line. An excessive amount of fluid causes the characteristic fusiform shape.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 76825 Version 4.0</div></div></div>"},"76826":{"type":"graphic_picture","displayName":"Hypertriglyceride milky plasma","title":"Milky plasma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Milky plasma</div><div class=\"cntnt\"><img style=\"width:246px; height:416px;\" src=\"images/PC/76826_Hypertriglyceride_milky_pla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A milky supranatant is seen in patients with severe hypertriglyceridemia.</div><div class=\"graphic_reference\">Reproduced with permission from: Durrington, P. Dyslipidaemia. Lancet 2003; 362:717. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 76826 Version 1.0</div></div></div>"},"76827":{"type":"graphic_algorithm","displayName":"Assessing fatal asthma risk","title":"Assessing fatal asthma risk","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Assessing fatal asthma risk</div><div class=\"cntnt\"><img style=\"width:453px; height:412px;\" src=\"images/PULM/76827_Assessing_fatal_asthma_risk.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 76827 Version 2.0</div></div></div>"},"76828":{"type":"graphic_diagnosticimage","displayName":"EUS lymph node FNA","title":"Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of a 1 cm posterior mediastinal lymph node","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of a 1 cm posterior mediastinal lymph node</div><div class=\"cntnt\"><img style=\"width:252px; height:371px;\" src=\"images/PULM/76828_EUS_lymph_node_FNA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Fine needle aspiration&nbsp;of a 1 cm lymph node. B) Non-small cell (60X magnification).</div><div id=\"graphicVersion\">Graphic 76828 Version 3.0</div></div></div>"},"76830":{"type":"graphic_figure","displayName":"Distribution of serum creatinine among US males and females","title":"Distribution of serum creatinine among United States males and females","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distribution of serum creatinine among United States males and females</div><div class=\"cntnt\"><img style=\"width:387px; height:260px;\" src=\"images/NEPH/76830_Distribution_serum_creatini.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distribution of the serum creatinine (in mg/dL) among United States males and females for the years 1988 to 1994 (age ≥12 years). Multiply values by 88.4 to convert to units of micromol/L.</div><div class=\"graphic_reference\">Data from Jones CA, McQuillan GM, Kusek JW. Serum creatinine levels in the US population:&nbsp;Third National Health and Nutrition Examination Survey.&nbsp;Am J Kidney Dis 1998; 32:992.</div><div id=\"graphicVersion\">Graphic 76830 Version 3.0</div></div></div>"},"76833":{"type":"graphic_waveform","displayName":"ECG exercise changes on ECG in WPW","title":"Electrocardiogram (ECG) strips showing loss of preexcitation with exercise in person with the Wolff-Parkinson-White (WPW) pattern","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) strips showing loss of preexcitation with exercise in person with the Wolff-Parkinson-White (WPW) pattern</div><div class=\"cntnt\"><img style=\"width:452px; height:353px;\" src=\"images/CARD/76833_Exercise_in_WPW.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Leads aVF, V1, and V5 from the surface ECG of a patient with Wolff-Parkinson-White pattern and a right anterior accessory pathway. Prior to exercise, the resting ECG shows preexcitation with a short PR interval, delta wave, and prolonged QRS interval. With exercise and a heart rate of 130 beats per minute, there is abrupt loss of preexcitation: the PR interval lengthens, the delta wave disappears, and the QRS complex morphology normalizes.</div><div class=\"graphic_reference\">Adapted from: Strasberg B, Ashley WW, Wyndham CR, et al. Am J Cardiol 1980; 45:745.</div><div id=\"graphicVersion\">Graphic 76833 Version 4.0</div></div></div>"},"76837":{"type":"graphic_table","displayName":"Ethnic values waist circ","title":"Ethnic specific values for waist circumference","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ethnic specific values for waist circumference</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Ethnic group</td> <td class=\"subtitle1\">Waist circumference (as measure of central obesity)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Europids*</td> </tr> <tr> <td class=\"sublist1\">Men</td> <td class=\"sublist_other\">&#8805;94 cm</td> </tr> <tr> <td class=\"sublist1\">Women</td> <td class=\"sublist_other\">&#8805;80 cm</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">South Asians</td> </tr> <tr> <td class=\"sublist1\">Men</td> <td class=\"sublist_other\">&#8805;90 cm</td> </tr> <tr> <td class=\"sublist1\">Women</td> <td class=\"sublist_other\">&#8805;80 cm</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Chinese</td> </tr> <tr> <td class=\"sublist1\">Men</td> <td class=\"sublist_other\">&#8805;90 cm</td> </tr> <tr> <td class=\"sublist1\">Women</td> <td class=\"sublist_other\">&#8805;80 cm</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Japanese</td> </tr> <tr> <td class=\"sublist1\">Men</td> <td class=\"sublist_other\">&#8805;90 cm</td> </tr> <tr> <td class=\"sublist1\">Women</td> <td class=\"sublist_other\">&#8805;80 cm</td> </tr> <tr> <td>Ethnic South and Central Americans</td> <td>Use South Asian recommendations until more specific data are available</td> </tr> <tr> <td>Sub-Saharan Africans</td> <td>Use European data until more specific data are available</td> </tr> <tr> <td>Eastern Mediterranean and middle east (Arab) populations</td> <td>Use European data until more specific data are available</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">16</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=58719&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">Data are pragmatic cutoffs, and better data are required to link them to risk. Ethnicity should be basis for classification, not country of residence.</div><div class=\"graphic_footnotes\">* In USA, Adult Treatment Panel III values (102 cm male, 88 cm female) are likely to continue to be used for clinical purposes. In future epidemiological studies of populations of Europid origin (white people of European origin, regardless of where they live in the world), prevalence should be given, with both European and North American cutoffs to allow better comparisons.</div><div class=\"graphic_reference\">Reproduced with permission from: George K, Alberti MM, Zimmet P, et al. The metabolic syndrome - a new worldwide definition. Lancet 2005; 336:1059. Copyright © 2005 Elsevier. Updated data from: the International Diabetes Federation, 2006. Available at: https://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome.</div><div id=\"graphicVersion\">Graphic 76837 Version 6.0</div></div></div>"},"76839":{"type":"graphic_picture","displayName":"Tinea corporis 4","title":"Tinea corporis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tinea corporis</div><div class=\"cntnt\"><img style=\"width:432px; height:285px;\" src=\"images/PC/76839_Tineacorporis4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple lesions collide in this patient with tinea corporis.</div><div class=\"graphic_reference\">Copyright © Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76839 Version 2.0</div></div></div>"},"76840":{"type":"graphic_figure","displayName":"Distribution of aerated lung","title":"Distribution of aerated lung follows cephalocaudal and anteroposterior gradients","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Distribution of aerated lung follows cephalocaudal and anteroposterior gradients</div><div class=\"cntnt\"><img style=\"width:453px; height:370px;\" src=\"images/PULM/76840_Distribution_of_aerated_lun.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distribution (expressed as a percentage) of aerated (open part of bars), poorly aerated (hatched part of bars), and nonaerated (closed part of bars) lung areas along the anteroposterior and the cephalocaudal axis. Each bar represents the lung parenchyma located at a given distance (in centimeters) from the anterior chest wall or from the pulmonary apex. Aerated lung decreases and nonaerated lung increases along the anteroposterior and cephalocaudal axis.</div><div class=\"graphic_reference\">Data from Puybasset, L, Cluzel, P, Chao, N, et al., Am J Respir Crit Care Med 1998; 158:1644.</div><div id=\"graphicVersion\">Graphic 76840 Version 1.0</div></div></div>"},"76841":{"type":"graphic_picture","displayName":"Sterile pustules due to fire ant stings","title":"Sterile pustules due to fire ant stings","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sterile pustules due to fire ant stings</div><div class=\"cntnt\"><img style=\"width:242px; height:372px;\" src=\"images/ALLRG/76841_Sterile_pustules_with_IFA_s.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Individuals stung by fire ants typically experience more than one sting because the ants can sting repeatedly. Most sting sites demonstrate sterile pustules (as shown in this picture) by 24 hours.</div><div class=\"graphic_reference\">Reproduced with permission from: Vinson SB, Sorensen AA. Imported fire ants: Life history and impact. Texas Department of Agriculture 1986. Copyright © 1986 Texas Department of Agriculture.</div><div id=\"graphicVersion\">Graphic 76841 Version 5.0</div></div></div>"},"76843":{"type":"graphic_picture","displayName":"Penile ulcer due to chancroid","title":"Chancroid ulcer on penis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chancroid ulcer on penis</div><div class=\"cntnt\"><img style=\"width:348px; height:266px;\" src=\"images/ID/76843_Penile_ulcer_due_to_chancro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Penile ulcer due to chancroid which is accompanied by marked inguinal lymphadenitis</div><div id=\"graphicVersion\">Graphic 76843 Version 1.0</div></div></div>"},"76845":{"type":"graphic_algorithm","displayName":"Biologic rx to xenotransplant","title":"Schematic representation of the biological responses to organ xenotransplantation","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Schematic representation of the biological responses to organ xenotransplantation</div><div class=\"cntnt\"><img style=\"width:466px; height:160px;\" src=\"images/NEPH/76845_Biologic_rx_to_xenotranspla.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic showing the different possible responses to organ xenotransplantation.</div><div class=\"graphic_reference\">Modified from Platt, JL. Nature 1998; 392:11.</div><div id=\"graphicVersion\">Graphic 76845 Version 3.0</div></div></div>"},"76848":{"type":"graphic_table","displayName":"Verbal skills pt interview","title":"Verbal skills applying to data gathering","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Verbal skills applying to data gathering</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Strategy</td> <td class=\"subtitle1\">Rationale</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td>Joint agenda setting</td> <td>Negotiates priorities together; shares control</td> <td>\"We agree that A is important. I want to be sure we also address B, and you've said you were worried about C. I'm not certain we can cover all our concerns today. Where should we start?\"</td> </tr> <tr> <td>The exhaustive \"what else?\"</td> <td>Seeks patient's entire agenda; minimizes \"oh, by the way\" questions</td> <td>\"What else has concerned you lately?\" \"Are you worried about anything else?\" \"Should we consider anything else before we do your exam?\"</td> </tr> <tr> <td>Storytelling: Open-ended questions (and careful, uninterrupted listening to the story)</td> <td>Invites patient to state the agenda; allows patient to use judgment about problems to emphasize; often is most efficient way to hear story</td> <td>\"How can I be of help to you today?\" \"What problems should we consider today?\" \"Tell me about A.\" \"You say that B is bothering you - tell me about it.\"</td> </tr> <tr> <td>Facilitation</td> <td>Encourages patient to tell story in open-ended fashion; conveys sense that clinician wishes to hear and understand</td> <td>\"Tell me more about that.\" \"Uh-huh, go on.\" Attentive silence, urges patient to continue; echo patient's last few words: \"It hurt when you took a deep breath...\"</td> </tr> <tr> <td>Clarification</td> <td>Seeks specificity and clarity</td> <td>\"Help me understand what you mean by dizziness.\"</td> </tr> <tr> <td>Checking and summarizing</td> <td>Seeks to assure accurate understanding; assures patient that he/she has been heard; invites further clarification</td> <td>\"Let me review what I think I've heard you say.\" \"You were well until...\" \"I'd like to summarize my understanding of the problem and have you be sure I have the story straight.\"</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted by permission from Clark W, Hewson M, Fry M, et al. American Academy on Physician and Patient (AAPP 1998), now the American Academy on Communication in Healthcare.</div><div id=\"graphicVersion\">Graphic 76848 Version 4.0</div></div></div>"},"76849":{"type":"graphic_diagnosticimage","displayName":"Empyema liver biopsy Lateral","title":"Empyema after liver biopsy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Empyema after liver biopsy</div><div class=\"cntnt\"><img style=\"width:324px; height:319px;\" src=\"images/PULM/76849_Empyema_liver_biopsy_Latera.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical characteristics of a pleural mass are shown: a &quot;one-edged&quot; mass, sharply marginated against the lung and with obtuse angles of interface towards the chest wall. Slight &quot;drooping&quot; of the mass caudad is present.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 76849 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lateral chest radiograph</div><div class=\"cntnt\"><img style=\"width:252px; height:368px;\" src=\"images/PULM/57909_Normal_chest_film_Lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Steven Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 57909 Version 1.0</div></div></div>"},"76850":{"type":"graphic_diagnosticimage","displayName":"2D TTE Suprasternal view right pulmonary artery","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the suprasternal notch view showing the right pulmonary artery","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the suprasternal notch view showing the right pulmonary artery</div><div class=\"cntnt\"><img style=\"width:487px; height:180px;\" src=\"images/CARD/76850_Suprasternal_pulmonary_arte.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Imaging the transverse aortic arch (TAo) from the suprasternal notch should be a standard part of every echocardiographic examination; the right pulmonary artery (RPA) can be viewed and when compared to the diameter of the transverse aortic arch, provides valuable information about the differential diagnosis of right ventricular enlargement. In panel A, the patient had a small ventricular septal defect and borderline normal right ventricular size on echocardiography; the RPA is smaller than the TAo, indicating a very small left-to-right shunt. In panel B, the patient had an Ebstein's anomaly of the tricuspid valve, the large right atrium is associated with a smaller than normal RPA, confirming the reduced pulmonary flow resulting from decreased functional volume of the right ventricle, tricuspid regurgitation, and right-to-left shunt across the atrial septum. In panel C, the patient had an atrial septal defect; the RPA is considerably enlarged, confirming that the ASD is likely to be associated with a large left-to-right shunt.</div><div id=\"graphicVersion\">Graphic 76850 Version 4.0</div></div></div>"},"76851":{"type":"graphic_table","displayName":"ACCP Rx mechanical valve","title":"Ninth ed: ACCP evidence-based practice guidelines: Antithrombotic therapy in patients with mechanical heart valves","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ninth ed: ACCP evidence-based practice guidelines: Antithrombotic therapy in patients with mechanical heart valves</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>In patients with mechanical heart valves, vitamin K antagonist (VKA) therapy is recommended over no VKA therapy and over antiplatelet agents for long-term management.</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>In patients with a mechanical aortic heart valve, VKA therapy with a target of 2.5 (range 2.0 to 3.0) is recommended over higher targets and is suggested over lower targets. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>In patients with a mechanical mitral heart valve, VKA therapy with a target of 3.0 (range 2.5 to 3.5) is suggested over lower targets. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>In patients with mechanical heart valves in both the aortic and mitral position, a target INR of 3.0 (range 2.5 to 3.5) is suggested over a target INR of 2.5. </li> </ul> </td> </tr> <tr> <td>In patients with a mechanical mitral or aortic valve at low risk of bleeding, an antiplatelet agent such as low-dose aspirin (50 to 100 mg/day) is suggested in addition to long-term VKA therapy (over not adding such an agent).</td> </tr> <tr> <td>For post-operative bridging immediately after mechanical heart valve replacement, unfractionated heparin (subcutaneous prophylactic dose) or low molecular weight heparin (prophylactic or therapeutic dose) is suggested over intravenous therapeutic unfractionated heparin until the INR is stable on VKA therapy.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The most commonly used vitamin K antagonist (VKA) is warfarin.<br />Note that the above INR ranges relate mostly to bileaflet and newer generation tilting disk valves.<br />For older valves, the 2012 guidelines refer to the 2001 guidelines. The 2001 guidelines recommended a target INR of 3.0 (2.5 to 3.5) for patients with (older) tilting disk valves. A combination of a target INR of 3.0 (range 2.5 to 3.5) plus aspirin 80 to 100 mg/d was recommended for patients with caged ball or caged disk valves.</div><div class=\"graphic_reference\">Data from: Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141:e576S.</div><div id=\"graphicVersion\">Graphic 76851 Version 3.0</div></div></div>"},"76852":{"type":"graphic_table","displayName":"Agonists for platelet activation and their receptors","title":"Physiologic agonists for platelet activation and their respective receptors on the platelet surface","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physiologic agonists for platelet activation and their respective receptors on the platelet surface</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Agonist</td>\n\n      <td class=\"subtitle1\">Source</td>\n\n      <td class=\"subtitle1\">Receptor(s)</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Thrombin</td>\n\n      <td colspan=\"1\" rowspan=\"2\">End product of coagulation cascade</td>\n\n      <td colspan=\"1\">7 transmembrane domain\nreceptor&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      \n\n      <td>GPIb-alpha</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Adenosine dephosphate</td>\n\n      <td>Platelet dense body</td>\n\n      <td>Aggregin</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"3\">Collagen</td>\n\n      <td colspan=\"1\" rowspan=\"3\">Subendothelium component</td>\n\n      <td>GPIa/IIa&nbsp;&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      \n\n      <td>GPIIb/IIIa</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      \n\n      <td>GPIV</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Serotonin</td>\n\n      <td>Platelet dense body</td>\n\n      <td colspan=\"1\">5HT2 receptor</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Thromboxane A2</td>\n\n      <td>Produced by platelets after initial stimulation</td>\n\n      <td colspan=\"1\">PGH2/TxA2 receptor</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Platelet activating factor</td>\n\n      <td>Lipid mediator produced by other cells</td>\n\n      <td colspan=\"1\">PAF receptor</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">GP: glycoprotein; HT: hydroxytryptamine, serotonin; PG: prostaglandin; Tx: thromboxane</div><div id=\"graphicVersion\">Graphic 76852 Version 2.0</div></div></div>"},"76854":{"type":"graphic_figure","displayName":"ICD in NSVT in MADIT","title":"Implantable defibrillator versus conventional drug therapy","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Implantable defibrillator versus conventional drug therapy</div><div class=\"cntnt\"><img style=\"width:473px; height:327px;\" src=\"images/CARD/76854_ICDinNSVTinMADIT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier cumulative survival curves in the MADIT trial showing that selected high-risk patients (prior infarction, left ventricular ejection fraction ≤35 percent, nonsustained ventricular tachycardia, and an inducible sustained ventricular tachyarrhythmia not supressible with procainamide) have a better survival rate with an implantable defibrillator compared&nbsp;with conventional therapy with antiarrhythmic drugs (p = 0.009). The number of patients at each time period is noted at the bottom.</div><div class=\"graphic_reference\">Data from: Moss AJ, Hall WJ, Cannom DS, et al for the Multicenter Automatic Defibrillator Implantation Trial Investigators, N Engl J Med 1996; 335:1933.</div><div id=\"graphicVersion\">Graphic 76854 Version 2.0</div></div></div>"},"76857":{"type":"graphic_table","displayName":"Headache syndromes PI","title":"Characteristics of common headache syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of common headache syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">Migraine headache</td> <td class=\"subtitle1\">Tension headache</td> <td class=\"subtitle1\">Cluster headache</td> </tr> <tr class=\"divider_bottom\"> <td>Location</td> <td>Unilateral (one sided) in 60 to 70 percent; occurs on both sides of the forehead or all over the head in 30 percent of cases</td> <td>Bilateral (involves both sides of the head)</td> <td>Always unilateral, usually begins around the eye or temple</td> </tr> <tr class=\"divider_bottom\"> <td>Characteristics</td> <td>Gradual in onset, builds up over time; pulsating; moderate or severe intensity; aggravated by routine physical activity</td> <td>Pressure or tightness which waxes and wanes</td> <td>Pain begins quickly, reaches a crescendo within minutes; pain is deep, continuous, excruciating, and explosive in quality</td> </tr> <tr class=\"divider_bottom\"> <td>Activity</td> <td>Prefers to rest in a dark, quiet room</td> <td>May remain active or may need to rest</td> <td>Remains active</td> </tr> <tr class=\"divider_bottom\"> <td>Duration</td> <td>4 to 72 hours</td> <td>Variable</td> <td>30 minutes to 3 hours</td> </tr> <tr> <td>Associated symptoms</td> <td>Nausea, vomiting, photophobia (bothered by light), phonophobia (bothered by sound); may have aura (usually visual, but can involve other senses or cause speech or motor problems)</td> <td>None</td> <td>Tearing and redness of the eye on the same side as the headache; stuffy, runny nose; pallor; sweating; eye drooping; rarely neurologic deficits; sensitivity to alcohol</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76857 Version 3.0</div></div></div>"},"76858":{"type":"graphic_picture","displayName":"Squamous papilloma","title":"Squamous papilloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Squamous papilloma</div><div class=\"cntnt\"><img style=\"width:403px; height:254px;\" src=\"images/PC/76858_Squamous_papilloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A projection of skin is evident on the lateral corner of the eyelid (arrow).</div><div class=\"graphic_reference\">With permission from Slomovits, TL (Ed), Basic and clinical science courses section, American Academy of Ophthalmology, San Francisco 1996.</div><div id=\"graphicVersion\">Graphic 76858 Version 1.0</div></div></div>"},"76860":{"type":"graphic_movie","displayName":"ECHO total anomalous pulmonary venous connection","title":"Echocardiogram of cardiac total anomalous pulmonary venous connection to a dilated coronary sinus","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiogram of cardiac total anomalous pulmonary venous connection to a dilated coronary sinus</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/76860_tapvrechconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:508px; height:345px;\" src=\"images/CARD/76860_tapvrech.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Brian Soriano.</div><div id=\"graphicVersion\">Graphic 76860 Version 3.0</div></div></div>"},"76862":{"type":"graphic_diagnosticimage","displayName":"Ectopia cordis","title":"Ectopic cordis","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Ectopic cordis</div><div class=\"cntnt\"><img style=\"width:468px; height:320px;\" src=\"images/OBGYN/76862_Ectopia_cordis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The heart is protruding through a defect in the chest wall.</div><div class=\"graphic_reference\">Courtesy of Courtney D Stephenson, DO.</div><div id=\"graphicVersion\">Graphic 76862 Version 2.0</div></div></div>"},"76863":{"type":"graphic_picture","displayName":"Superficial basal cell carcinoma 2","title":"Superficial basal cell carcinoma: Solitary lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial basal cell carcinoma: Solitary lesion</div><div class=\"cntnt\"><img style=\"width:425px; height:240px;\" src=\"images/ONC/76863_Superficial_basal_cell_CA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This bright red lesion has a slightly elevated, rolled border that can be detected with \"side lighting.\" Although this lesion is typical enough to be diagnosed clinically, a biopsy is necessary to confirm the diagnosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Fitzpatrick TB, Johnson RA, Wolff K, Suurmond D. Color Atlas &amp; Synopsis of Clinical Dermatology. Common &amp; Serious Diseases. (4th Ed). McGraw-Hill, New York 2001. Copyright © 2001 McGraw-Hill.</div><div id=\"graphicVersion\">Graphic 76863 Version 2.0</div></div></div>"},"76864":{"type":"graphic_picture","displayName":"RTT six months","title":"Rett syndrome, six month old","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rett syndrome, six month old</div><div class=\"cntnt\"><img style=\"width:378px; height:252px;\" src=\"images/PEDS/76864_RS_stage_I_develop_arrest_c.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At six months of age, this girl with RTT visually traced people and items in her environment and had purposeful hand use.</div><div class=\"graphic_reference\">Reproduced with permission from: Glaze DG, Schultz RJ. Rett syndrome: meeting the challenge of this gender-specific neurodevelopmental disorder. Medscape Women's Health 1997; 2. Copyright © 1997 Medscape.</div><div id=\"graphicVersion\">Graphic 76864 Version 4.0</div></div></div>"},"76865":{"type":"graphic_table","displayName":"Different forms of CAH","title":"Characteristics of different forms of congenital adrenal hyperplasia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of different forms of congenital adrenal hyperplasia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">21-hydroxylase deficiency</td> <td class=\"subtitle1\">11-beta-hydroxylase deficiency</td> <td class=\"subtitle1\">Aldosterone synthase deficiency</td> <td class=\"subtitle1\">17-alpha-hydroxylase deficiency</td> <td class=\"subtitle1\">3-beta-hydroxysteroid dehydrogenase deficiency</td> <td class=\"subtitle1\">Lipoid hyperplasia</td> </tr> <tr> <td>Defective gene (protein)</td> <td><em>CYP21A2 </em>(P450 21A2)</td> <td><em>CYP11B1 </em>(P450 11B1)</td> <td><em>CYP11B2 </em>(P450 11B2)</td> <td><em>CYP17A1 </em>(P450 17A1)</td> <td><em>HSD3B2 </em>(3-beta-HSD type 2)</td> <td><em>STAR </em>(StAR)</td> </tr> <tr> <td rowspan=\"2\">Ambiguous genitalia</td> <td rowspan=\"2\">+ in females</td> <td rowspan=\"2\">+ in females</td> <td rowspan=\"2\">No</td> <td>+ in males</td> <td>+ in males</td> <td>+ in males</td> </tr> <tr> <td>No puberty in females</td> <td>Mild in females</td> <td>No puberty in females</td> </tr> <tr> <td>Addisonian crisis</td> <td>+</td> <td>Rare</td> <td>Salt wasting only</td> <td>No</td> <td>+</td> <td>++</td> </tr> <tr> <td>Incidence (general population)</td> <td>1:11,000 - 23,000</td> <td>1:100,000</td> <td>Rare</td> <td>Rare</td> <td>Rare</td> <td>Rare</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"7\">Hormones</td> </tr> <tr> <td class=\"sublist1\">Glucocorticoids</td> <td class=\"sublist_other\">&#8595;</td> <td class=\"sublist_other\">&#8595;</td> <td class=\"sublist_other\">Normal</td> <td class=\"sublist_other\">Corticosterone normal</td> <td class=\"sublist_other\">&#8595;</td> <td>&#8595;</td> </tr> <tr> <td class=\"sublist1\">Mineralocorticoids</td> <td class=\"sublist_other\">&#8595;</td> <td class=\"sublist_other\">&#8593;</td> <td class=\"sublist_other\">&#8595;</td> <td class=\"sublist_other\">&#8593;</td> <td class=\"sublist_other\">&#8595;</td> <td>&#8595;</td> </tr> <tr> <td class=\"sublist1\" rowspan=\"2\">Androgens</td> <td class=\"sublist_other\" rowspan=\"2\">&#8593;</td> <td class=\"sublist_other\" rowspan=\"2\">&#8593;</td> <td class=\"sublist_other\" rowspan=\"2\">Normal</td> <td class=\"sublist_other\" rowspan=\"2\">&#8595;</td> <td class=\"sublist_other\">&#8595; in males </td> <td rowspan=\"2\">&#8595;</td> </tr> <tr> <td class=\"sublist_other\">&#8593; in females</td> </tr> <tr> <td class=\"sublist1\">Estrogens</td> <td class=\"sublist_other\">Relatively &#8595; in females</td> <td class=\"sublist_other\">Relatively &#8595; in females</td> <td class=\"sublist_other\">Normal</td> <td class=\"sublist_other\">&#8595;</td> <td class=\"sublist_other\">&#8595;</td> <td>&#8595;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"7\">Physiology</td> </tr> <tr> <td class=\"sublist1\">Blood pressure</td> <td class=\"sublist_other\">&#8595;</td> <td class=\"sublist_other\">&#8593;</td> <td class=\"sublist_other\">&#8595;</td> <td class=\"sublist_other\">&#8593;</td> <td class=\"sublist_other\">&#8595;</td> <td>&#8595;</td> </tr> <tr> <td class=\"sublist1\">Na balance</td> <td class=\"sublist_other\">&#8595;</td> <td class=\"sublist_other\">&#8593;</td> <td class=\"sublist_other\">&#8595;</td> <td class=\"sublist_other\">&#8593;</td> <td class=\"sublist_other\">&#8595;</td> <td>&#8595;</td> </tr> <tr> <td class=\"sublist1\">K balance</td> <td class=\"sublist_other\">&#8593;</td> <td class=\"sublist_other\">&#8595;</td> <td class=\"sublist_other\">&#8593;</td> <td class=\"sublist_other\">&#8595;</td> <td class=\"sublist_other\">&#8593;</td> <td>&#8593;</td> </tr> <tr> <td class=\"sublist1\">Acidosis</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">&#177; Alkalosis</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">&#177; Alkalosis</td> <td class=\"sublist_other\">+</td> <td>+</td> </tr> <tr> <td>Elevated steroid metabolites</td> <td>17OHP</td> <td>DOC, 11-deoxycortisol</td> <td>Corticosterone, &#177;18-hydroxy- corticosterone</td> <td>DOC corticosterone</td> <td>DHEA, 17-delta-5-hydroxypregnenolone</td> <td>None</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Na: sodium; K: potassium; 17OHP: 17-hydroxyprogesterone; DOC: deoxycorticosterone; DHEA: dehydroepiandrosterone.</div><div class=\"graphic_reference\">Reproduced with permission from: White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21:245. Copyright 2000 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 76865 Version 4.0</div></div></div>"},"76866":{"type":"graphic_figure","displayName":"Relative risk disease BMI","title":"Body mass index and the risk of disease","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Body mass index and the risk of disease</div><div class=\"cntnt\"><img style=\"width:584px; height:596px;\" src=\"images/ENDO/76866_Rel_risk_disease_BMI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Increasing body mass index (BMI, kg/m<sup>2</sup>), even within the normal range of BMI (21 to 24.9), is associated with an increased risk of type 2 diabetes, hypertension, coronary heart disease, and cholelithiasis. Panel A shows data for women in the Nurses' Health Study, initially 30 to 55 years of age, who were followed for up to 18 years. Panel B shows data for men in the Health Professionals Follow-up Study, initially 40 to 65 years of age, who were followed for up to 10 years.</div><div class=\"graphic_reference\">Data from: Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341:427.</div><div id=\"graphicVersion\">Graphic 76866 Version 5.0</div></div></div>"},"76867":{"type":"graphic_picture","displayName":"Double cervix in situ","title":"Double cervix","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Double cervix</div><div class=\"cntnt\"><img style=\"width:538px; height:408px;\" src=\"images/OBGYN/76867_Double_cervix_in_situ.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A and B) Two cervices are shown in situ. The rugated vaginal walls can be seen laterally.</div><div class=\"graphic_reference\">Reproduced with permission from the Surgical Planning Laboratory at Harvard Medical School.</div><div id=\"graphicVersion\">Graphic 76867 Version 1.0</div></div></div>"},"76868":{"type":"graphic_figure","displayName":"Pomeroy tubal ligation D","title":"Pomeroy tubal ligation D","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pomeroy tubal ligation D</div><div class=\"cntnt\"><img style=\"width:449px; height:300px;\" src=\"images/OBGYN/76868_Pomeroy_tubal_ligation_D.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 76868 Version 1.0</div></div></div>"},"76871":{"type":"graphic_table","displayName":"Possible risk factors for fatal anaphylaxis","title":"Possible risk factors for fatal anaphylaxis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Possible risk factors for fatal anaphylaxis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Asthma</td> </tr> <tr> <td>Delayed or no epinephrine</td> </tr> <tr> <td>Cardiopulmonary diseases</td> </tr> <tr> <td>Upright posture during anaphylaxis</td> </tr> <tr> <td>Initial misdiagnosis</td> </tr> <tr> <td>Systemic mastocytosis</td> </tr> <tr> <td>Other atopic conditions</td> </tr> <tr> <td>Carelessness with regard to exposures to known triggers, especially food (ignoring advisory labeling) and medications (including iatrogenic medication errors)</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">1</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=591&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div id=\"graphicVersion\">Graphic 76871 Version 4.0</div></div></div>"},"76872":{"type":"graphic_diagnosticimage","displayName":"Angio birdshot retinochoroid","title":"Birdshot retinochroidopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Birdshot retinochroidopathy</div><div class=\"cntnt\"><img style=\"width:373px; height:288px;\" src=\"images/RHEUM/76872_Angio_birdshot_retinochoroi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluorescein angiogram from a patient with birdshot retinochoroidopathy shows cystoid macular edema and perivascular leakage.</div><div class=\"graphic_reference\">Courtesy of Michael Tolentino, MD.</div><div id=\"graphicVersion\">Graphic 76872 Version 2.0</div></div></div>"},"76873":{"type":"graphic_figure","displayName":"Heart PI","title":"Atrial fibrillation","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:522px; height:644px;\" src=\"images/PI/76873_Heart_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows where the heart is located in the chest. In atrial fibrillation, the electrical signals that control the heartbeat are abnormal. As a result, the top two chambers of the heart (see arrows) stop pumping effectively, and blood that should move out of these chambers gets left behind.</div><div id=\"graphicVersion\">Graphic 76873 Version 3.0</div></div></div>"},"76874":{"type":"graphic_table","displayName":"Validated criteria for stenosis in visceral vessels","title":"Validated criteria for stenosis in visceral vessels","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Validated criteria for stenosis in visceral vessels</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Artery</td> <td class=\"subtitle1\">Percent of stenosis</td> <td class=\"subtitle1\">Criteria</td> </tr> <tr> <td>Superior mesenteric artery</td> <td>&#8805;70 percent</td> <td>Peak systolic velocity &#62;275 cm/s</td> </tr> <tr> <td>Celiac artery</td> <td>&#8805;70 percent</td> <td>Peak systolic velocity &#62;200 cm/s</td> </tr> <tr> <td>Renal artery</td> <td>&#8805;60 percent</td> <td>Renal aortic ratio &#62;3.5 (PSV in renal artery/PSV in adjacent aorta)</td> </tr> <tr> <td>Renal artery</td> <td>&#8805;80 percent</td> <td>Renal aortic ratio &#62;3.5 and renal artery end diastolic velocity &#8805;150 cm/s</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br> <ol> <li>Moneta GL, Lee RW, Yeager RA, et al. Mesenteric duplex scanning: a blinded prospective study. J Vasc Surg 1993; 17:79. </li> <li>Gentile AT, Moneta GL, Lee RW, et al. Usefulness of fasting and postprandial duplex ultrasound examinations for predicting high-grade superior mesenteric artery stenosis. Am J Surg 1995; 169:476. </li> <li>Moneta GL. Screening for mesenteric vascular insufficiency and follow-up of mesenteric artery bypass procedures. Semin Vasc Surg 2001; 14:186. </li> </ol> <br> Courtesy of Dr. Erica Mitchell.</div><div id=\"graphicVersion\">Graphic 76874 Version 4.0</div></div></div>"},"76875":{"type":"graphic_table","displayName":"Causes pulmonary eosinophilia","title":"Causes of pulmonary eosinophilia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of pulmonary eosinophilia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Drug- and toxin-induced eosinophilic lung diseases</td> </tr> <tr> <td class=\"sublist1\">Nonsteroidal antiinflammatory drugs (NSAIDs)</td> </tr> <tr> <td class=\"sublist1\">Antimicrobials (nitrofurantoin, minocycline, sulfonamides, ampicillin, daptomycin)</td> </tr> <tr> <td class=\"sublist1\">Phenytoin</td> </tr> <tr> <td class=\"sublist1\">L-tryptophan</td> </tr> <tr> <td class=\"sublist1_start\">Helminthic and fungal infection-related eosinophilic lung diseases</td> </tr> <tr> <td class=\"sublist1\">Transpulmonary passage of larvae (Loffler's syndrome)</td> </tr> <tr> <td class=\"sublist2\">Ascaris lumbricoides</td> </tr> <tr> <td class=\"sublist2\">Hookworm (Ancylostoma duodenale, Necator americanus)</td> </tr> <tr> <td class=\"sublist2\">Strongyloides stercoralis</td> </tr> <tr> <td class=\"sublist1\">Pulmonary parenchymal invasion - mostly helminths, eg, paragonimiasis</td> </tr> <tr> <td class=\"sublist1\">Heavy hematogenous seeding with helminths</td> </tr> <tr> <td class=\"sublist2\">Trichinellosis</td> </tr> <tr> <td class=\"sublist2\">Disseminated strongyloidiasis</td> </tr> <tr> <td class=\"sublist2\">Cutaneous and visceral larva migrans</td> </tr> <tr> <td class=\"sublist2\">Schistosomiasis</td> </tr> <tr> <td class=\"sublist1\">Tropical pulmonary eosinophilia</td> </tr> <tr> <td class=\"sublist2\">Wuchereria bancrofti </td> </tr> <tr> <td class=\"sublist2\">Brugia malayi</td> </tr> <tr> <td class=\"sublist1\">Allergic bronchopulmonary aspergillosis</td> </tr> <tr> <td>Acute eosinophilic pneumonia</td> </tr> <tr> <td>Chronic eosinophilic pneumonia</td> </tr> <tr> <td>Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</td> </tr> <tr> <td class=\"sublist1_start\">Other</td> </tr> <tr> <td class=\"sublist1\">Idiopathic hypereosinophilic syndrome</td> </tr> <tr> <td class=\"sublist1\">Idiopathic lung diseases</td> </tr> <tr> <td class=\"sublist1\">Neoplasms</td> </tr> <tr> <td class=\"sublist1\">Nonhelminthic infections (eg, Coccidioidomycosis, Mycobacterium tuberculosis)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76875 Version 6.0</div></div></div>"},"76876":{"type":"graphic_waveform","displayName":"Atrial flutter CS massage","title":"Atrial flutter at a rate of 250 beats/minute with 2:1 AV conduction in the presence of left bundle branch block","html":"<div class=\"graphic normal\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Atrial flutter at a rate of 250 beats/minute with 2:1 AV conduction in the presence of left bundle branch block</div><div class=\"cntnt\"><img style=\"width:525px; height:117px;\" src=\"images/CARD/76876_AtrialflutterCSmassage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Although every other flutter wave can be seen at the end of the T wave in the first part of the tracing (arrows), a sinus mechanism cannot be excluded. The flutter waves become clearly apparent after carotid sinus massage is applied to slow conduction through the AV node, thereby increasing the degree of AV block.</div><div class=\"graphic_footnotes\">AV: atrioventricular</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 76876 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"76878":{"type":"graphic_movie","displayName":"Right coronary artery in Kawasaki disease","title":"Coronary artery aneurysm","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coronary artery aneurysm</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/76878_rtcorkawconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:320px; height:240px;\" src=\"images/CARD/76878_rtcorkaw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronary arteriogram in left anterior oblique projection in a patient with Kawasaki disease. The left anterior oblique projection of the right coronary artery shows large aneurysms of the proximal and distal right coronary artery.</div><div id=\"graphicVersion\">Graphic 76878 Version 2.0</div></div></div>"},"76880":{"type":"graphic_table","displayName":"Antepartum umbilical vein and artery pH","title":"Antepartum umbilical vein and artery pH","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antepartum umbilical vein and artery pH</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">GA</td> <td class=\"subtitle1\" colspan=\"3\">Umbilical vein pH</td> <td class=\"subtitle1\" colspan=\"3\">Umbilical artery pH</td> </tr> <tr> <td class=\"subtitle2\">5<sup>th</sup> percentile</td> <td class=\"subtitle2\">Mean</td> <td class=\"subtitle2\">95<sup>th</sup> percentile</td> <td class=\"subtitle2\">5<sup>th</sup> percentile</td> <td class=\"subtitle2\">Mean</td> <td class=\"subtitle2\">95<sup>th</sup> percentile</td> </tr> <tr> <td>18</td> <td>7.385</td> <td>7.423</td> <td>7.461</td> <td>7.360</td> <td>7.398</td> <td>7.435</td> </tr> <tr> <td>20</td> <td>7.382</td> <td>7.420</td> <td>7.458</td> <td>7.357</td> <td>7.394</td> <td>7.431</td> </tr> <tr> <td>22</td> <td>7.379</td> <td>7.417</td> <td>7.454</td> <td>7.353</td> <td>7.390</td> <td>7.427</td> </tr> <tr> <td>24</td> <td>7.376</td> <td>7.414</td> <td>7.451</td> <td>7.350</td> <td>7.386 </td> <td>7.423</td> </tr> <tr> <td>26</td> <td>7.373</td> <td>7.410</td> <td>7.448</td> <td>7.346</td> <td>7.383</td> <td>7.419</td> </tr> <tr> <td>28</td> <td>7.370</td> <td>7.407</td> <td>7.445</td> <td>7.342</td> <td>7.379</td> <td>7.416</td> </tr> <tr> <td>30</td> <td>7.366</td> <td>7.404</td> <td>7.442</td> <td>7.338</td> <td>7.375</td> <td>7.412</td> </tr> <tr> <td>32</td> <td>7.363</td> <td>7.401</td> <td>7.439</td> <td>7.334</td> <td>7.371</td> <td>7.409</td> </tr> <tr> <td>34</td> <td>7.360</td> <td>7.398</td> <td>7.436</td> <td>7.330</td> <td>7.368</td> <td>7.406</td> </tr> <tr> <td>36</td> <td>7.357</td> <td>7.395</td> <td>7.433</td> <td>7.325</td> <td>7.364</td> <td>7.403</td> </tr> <tr> <td>38</td> <td>7.353</td> <td>7.392</td> <td>7.430</td> <td>7.321</td> <td>7.360 </td> <td>7.399</td> </tr> <tr> <td>40</td> <td>7.350</td> <td>7.388</td> <td>7.427</td> <td>7.317</td> <td>7.357</td> <td>7.396</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">pH values were determined by cordocentesis in fetuses whose mothers were not in labor.</div><div class=\"graphic_footnotes\">GA: gestational age.</div><div id=\"graphicVersion\">Graphic 76880 Version 3.0</div></div></div>"},"76881":{"type":"graphic_figure","displayName":"FIBSER","title":"Frequency, Intensity, and Burden of Side Effects Ratings (FIBSER)","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Frequency, Intensity, and Burden of Side Effects Ratings (FIBSER)</div><div class=\"cntnt\"><img style=\"width:609px; height:449px;\" src=\"images/PSYCH/76881_FIBSER.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">NOTE: The FIBSER is in the public domain. It may be copied and used without permission.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Reproduced from: Wisniewski SR, Rush AJ, Balasubramani, GK, et al. Self-rated global meaure of the frequency, intensity, and burden of side effects. J Psychiatr Pract 2006; 12:71.</div><div id=\"graphicVersion\">Graphic 76881 Version 2.0</div></div></div>"},"76883":{"type":"graphic_diagnosticimage","displayName":"TEE transverse view aortic rupture","title":"Transesophageal echocardiography transverse view of a traumatic rupture of the aortic isthmus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiography transverse view of a traumatic rupture of the aortic isthmus</div><div class=\"cntnt\"><img style=\"width:419px; height:288px;\" src=\"images/CARD/76883_TEE_aortic_rupture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The subadventitial aortic disruption was associated with the presence of a thick &quot;medial flap&quot; (arrow) and a localized deformity of the aortic wall due to the acute formation of a false aneurysm (arrowheads).</div><div class=\"graphic_reference\">Courtesy of P Vignon, MD.</div><div id=\"graphicVersion\">Graphic 76883 Version 3.0</div></div></div>"},"76886":{"type":"graphic_table","displayName":"FACT fatigue anemia subscales","title":"The fatigue and anemia subscales of the Functional Assessment of Cancer Therapy (FACT) questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The fatigue and anemia subscales of the Functional Assessment of Cancer Therapy (FACT) questionnaire</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Fatigue component for both subscales</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1. I feel weary</td>\n\n    </tr>\n\n    <tr>\n\n      <td>2. I always feel weak</td>\n\n    </tr>\n\n    <tr>\n\n      <td>3. I feel exhausted</td>\n\n    </tr>\n\n    <tr>\n\n      <td>4. I feel tired</td>\n\n    </tr>\n\n    <tr>\n\n      <td>5. I'm too tired to eat</td>\n\n    </tr>\n\n    <tr>\n\n      <td>6. I need to sleep during the day</td>\n\n    </tr>\n\n    <tr>\n\n      <td>7. I need help to carry out daily activities</td>\n\n    </tr>\n\n    <tr>\n\n      <td>8. I feel frustrated because I'm tired and I can't do the things I want to</td>\n\n    </tr>\n\n    <tr>\n\n      <td>9. I have to limit my social activities because I feel tired</td>\n\n    </tr>\n\n    <tr>\n\n      <td>10. I have difficulty in starting to do something</td>\n\n    </tr>\n\n    <tr>\n\n      <td>11. I have difficulty in finishing something I have started</td>\n\n    </tr>\n\n    <tr>\n\n      <td>12. I feel I don't have any energy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>13. I am unable to carry out normal activities</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Nonfatigue component for anemia subscale</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1. I have trouble walking</td>\n\n    </tr>\n\n    <tr>\n\n      <td>2. I am dizzy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>3. I have headaches</td>\n\n    </tr>\n\n    <tr>\n\n      <td>4. I am short of breath</td>\n\n    </tr>\n\n    <tr>\n\n      <td>5. I have chest pain</td>\n\n    </tr>\n\n    <tr>\n\n      <td>6. I lack motivation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>7. I have no interest in sex</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Modified from: Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13:63.</div><div id=\"graphicVersion\">Graphic 76886 Version 2.0</div></div></div>"},"76887":{"type":"graphic_diagnosticimage","displayName":"Esophageal foreign body","title":"Esophageal foreign body","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal foreign body</div><div class=\"cntnt\"><img style=\"width:432px; height:428px;\" src=\"images/PEDS/76887_Esophageal_foreign_body.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The PA chest film demonstrates a coin in the esophagus. Deviation of the trachea as a result is also noted.</div><div class=\"graphic_reference\">Courtesy of Alan E Schlesinger, MD, Department of Radiology, Baylor College of Medicine.</div><div id=\"graphicVersion\">Graphic 76887 Version 2.0</div></div></div>"},"76890":{"type":"graphic_table","displayName":"Assessment of activity RA","title":"Assessment of disease activity in rheumatoid arthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment of disease activity in rheumatoid arthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Symptoms</td> </tr> <tr> <td>Duration of morning stiffness</td> </tr> <tr> <td>Pain score (visual analogue scale)</td> </tr> <tr> <td>Fatigue - severity (visual analogue scale)</td> </tr> <tr> <td>Patient's global score of disease activity (visual analogue scale)</td> </tr> <tr> <td class=\"subtitle1_single\">Physical examination</td> </tr> <tr> <td>Number of swollen joints</td> </tr> <tr> <td>Number of tender joints</td> </tr> <tr> <td>Degree of swelling and/or tenderness</td> </tr> <tr> <td class=\"sublist1_start\">Extraarticular disease:</td> </tr> <tr> <td class=\"sublist1\">Minor: nodules, episclertis, pure sensory neuropathy, pleruropericardial disease </td> </tr> <tr> <td class=\"sublist1\">Major: vasculitis, Felty's syndrome, motor neuropathy, interstitial lung disease</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory</td> </tr> <tr> <td>Elevated erythrocyte sedimentation rate (ESR)</td> </tr> <tr> <td>Increased C-reactive protein (CRP)</td> </tr> <tr> <td>Anemia (in the absence of chronic blood loss or hematuria)</td> </tr> <tr> <td>Leukocytosis</td> </tr> <tr> <td>Thrombocytosis</td> </tr> <tr> <td>Abnormal liver function tests (low albumin, raised alkaline phosphate) in the absence of drug toxicity or liver disease</td> </tr> <tr> <td>Inflammatory joint fluid (high polymorph count, low complement, fibrin)</td> </tr> <tr> <td class=\"subtitle1_single\">Imaging</td> </tr> <tr> <td>Low bone mineral density (juxtaarticular, vertebrae, pelvis) in absence of glucocorticoid therapy or known cause</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76890 Version 3.0</div></div></div>"},"76891":{"type":"graphic_picture","displayName":"Cutaneous mastocytomas on the hand of a child","title":"Cutaneous mastocytomas on the hand of a child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous mastocytomas on the hand of a child</div><div class=\"cntnt\"><img style=\"width:308px; height:331px;\" src=\"images/RHEUM/76891_Mastocytoma_infant_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">From: Soter AN. J Invest Derm 1991; 96:S32.</div><div id=\"graphicVersion\">Graphic 76891 Version 4.0</div></div></div>"},"76892":{"type":"graphic_table","displayName":"Classification of liver test abnormalities","title":"Classification of liver test abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of liver test abnormalities</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td>Hepatitis (hepatocellular)</td>\r\n            <td>ALT &#8805;3 x ULN</td>\r\n            <td>R &#8805;5</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cholestasis</td>\r\n            <td>ALP &#8805;2 x ULN</td>\r\n            <td>R &#8804;2</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Mixed</td>\r\n            <td>\r\n            <p>ALT &#8805;3 x ULN</p>\r\n            <p>ALP &#8805;2 x ULN</p>\r\n            </td>\r\n            <td>\r\n            <p>R &#62;2 to &#60;5</p>\r\n            </td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_footnotes\">ALT: alanine aminotransferase; ALP: alkaline phosphatase; ULN: upper limit normal; R: ALT/ULN divided by ALP/ULN.</div><div id=\"graphicVersion\">Graphic 76892 Version 2.0</div></div></div>"},"76897":{"type":"graphic_table","displayName":"Epidermolysis bullosa","title":"Epidermolysis bullosa","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epidermolysis bullosa</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">EB type</td> <td class=\"subtitle1\">Pathogenesis</td> <td class=\"subtitle1\">Key clinical features</td> </tr> <tr> <td rowspan=\"2\">EB simplex (most common)</td> <td>Autosomal dominant; most due to mutations in genes for keratins 5 and 14 expressed on epithelial cell cytoskeleton</td> <td rowspan=\"2\">Typically presents at birth or early infancy. Bullae with mild trauma, heal without scarring. Most forms with mild or no mucosal involvement. Chronic course but blistering tends to decrease with age, usually normal lifespan.</td> </tr> <tr> <td>Intraepidermal separation</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Junctional EB</td> <td>Autosomal recessive; mutation in genes encoding hemidesmosomal proteins such as laminin 5 resulting in defective cell adhesion</td> <td rowspan=\"2\">More severe variant characterized by widespread bullae and erosions with nonhealing granulation tissue; associated with absent nails, dysplastic teeth, oral lesions, and pyloric stenosis. Death usually occurs in early childhood due to malnutrition or infection. Normal life expectancy in patients with milder variant who develop bullae, primarily on the extremities, that may heal with atrophic scarring.</td> </tr> <tr> <td>Intra-lamina lucida separation</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Dystrophic EB</td> <td>Autosomal recessive and autosomal dominant; type VII collagen mutation leading to defective anchoring fibrils</td> <td rowspan=\"2\">Onset at birth; generalized bullae, heal with extensive scarring, milia. Repeated episodes of severe blistering and scarring lead to contraction flexures at knees and elbows and fusion of digits (\"mitten deformities\") of hands and feet. Oral, GI, and ocular mucous membrane involvement is also frequently seen and can be severe. Risk of developing squamous cell cancer within scars. Patients often die in early adulthood from complications such as infection or severe malnutrition. Milder phenotype seen with autosomal dominant forms.</td> </tr> <tr> <td>Sub-basal lamina separation</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Kindler syndrome</td> <td>Autosomal recessive</td> <td rowspan=\"2\">Blisters induced by mild trauma, progressive poikiloderma, and skin atrophy (particularly of the dorsal hands and feet). Photosensitivity may or may not be present. Additional features may include desquamative gingivitis and strictures of the esophagus, anus, vagina, and urethra. Blistering and photosensitivity may decrease with age.</td> </tr> <tr> <td>Separation at the level of the basal keratinocytes, within the lamina lucida, or sub-basal lamina separation</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76897 Version 7.0</div></div></div>"},"76898":{"type":"graphic_table","displayName":"Classification proximal fifth metatarsal fracture","title":"Classification of proximal fifth metatarsal fractures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of proximal fifth metatarsal fractures</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Tuberosity avulsion (styloid) fracture - Medial end of fracture line lies proximal to intermetatarsal joint of the fourth and fifth metatarsals.</td> </tr> <tr> <td>Acute proximal diaphyseal fracture (\"Jones fracture\") - Medial end of fracture line extends into or toward intermetatarsal joint.</td> </tr> <tr> <td class=\"sublist1_start\">Stress fracture of the diaphysis - Medial end of fracture line typically exits bone distal to intermetatarsal joint, but some fracture lines lie more proximal and extend into the distal portion of the joint.</td> </tr> <tr> <td class=\"sublist1\">Torg type&nbsp;I (early)</td> </tr> <tr> <td class=\"sublist1\">Torg type&nbsp;II (delayed union)</td> </tr> <tr> <td class=\"sublist1\">Torg type&nbsp;III (nonunion)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Quill GE Jr. Fractures of the proximal fifth metatarsal. Orthop Clin North Am 1995; 26:353.</div><div id=\"graphicVersion\">Graphic 76898 Version 7.0</div></div></div>"},"76899":{"type":"graphic_algorithm","displayName":"Management of nonocclusive mesenteric ischemia","title":"Management of nonocclusive mesenteric ischemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management of nonocclusive mesenteric ischemia</div><div class=\"cntnt\"><img style=\"width:382px; height:826px;\" src=\"images/SURG/76899_Mng_nncclsv_msntrc_ischm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography.<br />* Diagnosis typically made based on history and risk factors, and exclusion of embolic or thrombotic mesenteric arterial occlusion, and mesenteric venous thrombosis.<br />&para; Discontinue anticoagulation (if initiated) once other ischemic etiologies have been excluded.<br />&Delta; Depending on the clinical situation, plain abdominal films or CT of the abdomen are appropriate.</div><div id=\"graphicVersion\">Graphic 76899 Version 4.0</div></div></div>"},"76901":{"type":"graphic_picture","displayName":"Lipodermatosclerosis","title":"Lipodermatosclerosis","html":"<div class=\"graphic\"><div style=\"width: 631px\" class=\"figure\"><div class=\"ttl\">Lipodermatosclerosis</div><div class=\"cntnt\"><img style=\"width:611px; height:659px;\" src=\"images/PC/76901_Lpdrmtsclrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patients exhibits features of severe venous insufficiency combined with lymphedema. Chronic venous insufficiency may result in lipodermatosclerosis, a fibrosing panniculitis characterized by advanced hyperpigmentation and induration, in this case involving most of the leg circumferentially.</div><div class=\"graphic_reference\">Courtesy of Patrick C Alguire, MD.</div><div id=\"graphicVersion\">Graphic 76901 Version 3.0</div></div></div>"},"76902":{"type":"graphic_picture","displayName":"PIP joint palpation","title":"Palpation of the proximal interphalangeal (PIP) joint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palpation of the proximal interphalangeal (PIP) joint</div><div class=\"cntnt\"><img style=\"width:348px; height:291px;\" src=\"images/RHEUM/76902_PIP_joint_palpation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The examiner places two fingers of one hand on the lateral joint lines and two fingers from the opposite hand on the top and bottom of the joint. Pressure is applied from the top and bottom while simultaneously feeling for the distensibility of synovial thickening, excessive joint fluid, or both. The maneuver can be enhanced by alternating the pressure from one set of fingers to the other. The synovial lining of the small joints extends 5 to 6 mm above and below the joint line. An excessive amount of fluid causes the characteristic fusiform shape.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 76902 Version 3.0</div></div></div>"},"76903":{"type":"graphic_waveform","displayName":"M-mode echocardiography LV hypertrophy","title":"Symmetric and asymmetric left ventricular hypertrophy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Symmetric and asymmetric left ventricular hypertrophy</div><div class=\"cntnt\"><img style=\"width:440px; height:180px;\" src=\"images/CARD/76903_MmodeLVhypertrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">M-mode echocardiograms contrasting normal left ventricle (LV) (panel A), mild symmetric left ventricular hypertrophy (panel B), and marked asymmetric hypertrophy (panel C). The A wave from atrial contraction, or presystolic ventricular filling, is more exaggerated in mild left ventricular hypertrophy; exaggerated filling during the atrial phase of diastole can be a clue to decreased compliance, which may be more marked for the degree of hypertrophy.</div><div class=\"graphic_footnotes\">IVS: interventricular septum.</div><div id=\"graphicVersion\">Graphic 76903 Version 5.0</div></div></div>"},"76904":{"type":"graphic_picture","displayName":"Pulmonary capillaritis DAH I","title":"Early pulmonary capillaritis in diffuse alveolar hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early pulmonary capillaritis in diffuse alveolar hemorrhage</div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/PULM/76904_Pulmonary_capillaritis_DAH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph showing early pulmonary capillaritis. There is neutrophilic infiltration of the alveolar wall and hemorrhage.</div><div class=\"graphic_reference\">Courtesy of Marvin I Schwarz, MD.</div><div id=\"graphicVersion\">Graphic 76904 Version 2.0</div></div></div>"},"76905":{"type":"graphic_diagnosticimage","displayName":"RA of the elbow","title":"Rheumatoid arthritis of the elbow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rheumatoid arthritis of the elbow</div><div class=\"cntnt\"><img style=\"width:258px; height:287px;\" src=\"images/RHEUM/76905_RA_of_the_elbow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral view of the elbow in a patient with rheumatoid arthritis (RA) reveals soft tissue swelling and osteopenia with destruction of the elbow joint (arrows). There are also secondary proliferative bony changes, which have arisen due to joint space destruction.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 76905 Version 3.0</div></div></div>"},"76906":{"type":"graphic_table","displayName":"Independent predictors of postoperative pulmonary complications","title":"ARISCAT (Canet) risk index: Independent predictors of postoperative pulmonary complications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ARISCAT (Canet) risk index: Independent predictors of postoperative pulmonary complications</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Factor</td> <td class=\"subtitle1\">Adjusted odds ratio (95% CI)</td> <td class=\"subtitle1\">Risk score</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Age, years</td> </tr> <tr> <td class=\"sublist1\">&#8804;50</td> <td class=\"sublist_other\">1</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">51-80</td> <td class=\"sublist_other\">1.4 (0.6-3.3)</td> <td class=\"sublist_other\">3</td> </tr> <tr> <td class=\"sublist1\">&#62;80</td> <td class=\"sublist_other\">5.1 (1.9-13.3)</td> <td class=\"sublist_other\">16</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Preoperative O<sub>2</sub> saturation</td> </tr> <tr> <td class=\"sublist1\">&#8805;96 percent</td> <td class=\"sublist_other\">1</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">91-95 percent</td> <td class=\"sublist_other\">2.2 (1.2-4.2)</td> <td class=\"sublist_other\">8</td> </tr> <tr> <td class=\"sublist1\">&#8804;90 percent</td> <td class=\"sublist_other\">10.7 (4.1-28.1)</td> <td class=\"sublist_other\">24</td> </tr> <tr> <td>Respiratory infection in the last month</td> <td>5.5 (2.6-11.5)</td> <td>17</td> </tr> <tr> <td>Preoperative anemia - hemoglobin &#8804;10 g/dL</td> <td>3 (1.4-6.5)</td> <td>11</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Surgical incision</td> </tr> <tr> <td class=\"sublist1\">Upper abdominal</td> <td class=\"sublist_other\">4.4 (2.3-8.5)</td> <td class=\"sublist_other\">15</td> </tr> <tr> <td class=\"sublist1\">Intrathoracic</td> <td class=\"sublist_other\">11.4 (1.9-26.0)</td> <td class=\"sublist_other\">24</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Duration of surgery</td> </tr> <tr> <td class=\"sublist1\">&#8804;2 hours</td> <td class=\"sublist_other\">1</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">2-3 hours</td> <td class=\"sublist_other\">4.9 (2.4-10.1)</td> <td class=\"sublist_other\">16</td> </tr> <tr> <td class=\"sublist1\">&#62;3 hours</td> <td class=\"sublist_other\">9.7 (2.4-19.9)</td> <td class=\"sublist_other\">23</td> </tr> <tr class=\"divider_bottom\"> <td>Emergency surgery</td> <td>2.2 (1.0-4.5)</td> <td>8</td> </tr> <tr> <td class=\"subtitle1\">Risk class</td> <td class=\"subtitle1\">Number of points in risk score</td> <td class=\"subtitle1\">Pulmonary complication rate<br /> (validation sample)</td> </tr> <tr> <td>Low</td> <td>&#60;26 points</td> <td>1.6 percent</td> </tr> <tr> <td>Intermediate</td> <td>26-44 points</td> <td>13.3 percent</td> </tr> <tr> <td>High</td> <td>&#8805;45 points</td> <td>42.1 percent</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Canet J, Gallart L, Gomar C, et al. Prediction of postoperative pulmonary complications in a population-based surgical cohort. Anesthesiology 2010; 113:1338.</div><div id=\"graphicVersion\">Graphic 76906 Version 12.0</div></div></div>"},"76907":{"type":"graphic_figure","displayName":"Course perinatal chronic HBV","title":"Course of perinatally acquired chronic HBV infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Course of perinatally acquired chronic HBV infection</div><div class=\"cntnt\"><img style=\"width:292px; height:220px;\" src=\"images/GAST/76907_CourseperinatalchronicHB.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the natural history of perinatally acquired chronic hepatitis B virus (HBV) infection. This form of infection consists of three phases:&#xD;&#xA;<ul>&#xD;&#xA;    <li><strong>Immune tolerant</strong> &ndash; This phase lasts for months, years, or decades, and is characterized by high levels of HBV replication, as manifested by the presence of hepatitis B e antigen (HBeAg) and high levels of HBV DNA in serum, but no evidence of active liver disease as manifested by normal serum alanine aminotransferase (ALT) concentrations.</li>&#xD;&#xA;    <li><strong>HBeAg-positive immune active (clearance)</strong> &ndash; During the this phase, serum ALT is elevated, and HBeAg seroconversion may occur.</li>&#xD;&#xA;    <li><strong>Inactive chronic HBV</strong> &ndash; This phase is usually characterized by the absence of HBV DNA and normalization of serum ALT. It is also&nbsp;known as the latent, nonreplicative or carrier phase. Some patients reactivate into the immune active phase or HBeAg-negative HBV.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">HBV DNA: hepatitis B virus DNA; ALT: alanine aminotransferase; HBeAg: hepatitis B e antigen; anti-HBe: antibody to hepatitis B e antigen.</div><div id=\"graphicVersion\">Graphic 76907 Version 2.0</div></div></div>"},"76908":{"type":"graphic_table","displayName":"HPV types disease associations","title":"Disease associations with selected human papillomavirus types","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disease associations with selected human papillomavirus types</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">HPV type frequently associated</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Cutaneous warts</td> </tr> <tr> <td class=\"sublist1\">Common and plantar warts</td> <td class=\"sublist_other\">1, 2, and 4</td> </tr> <tr> <td class=\"sublist1\">Flat wart</td> <td class=\"sublist_other\">3, 10</td> </tr> <tr> <td class=\"sublist1\">Butcher's wart</td> <td class=\"sublist_other\">7, 2</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Bowen's disease</td> </tr> <tr> <td class=\"sublist1\">Genital</td> <td class=\"sublist_other\">16</td> </tr> <tr> <td class=\"sublist1\">Extragenital</td> <td class=\"sublist_other\">2, 3, 4, 16</td> </tr> <tr> <td>Epidermodysplasia verruciformis</td> <td>2, 3, 5, 8, 9, 10, 12, 14, 15, 17</td> </tr> <tr> <td>Condylomata acuminata</td> <td>6, 11</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Squamous intraepithelial lesions*</td> </tr> <tr> <td class=\"sublist1\">Low grade</td> <td class=\"sublist_other\">16, 31, 6, 11</td> </tr> <tr> <td class=\"sublist1\">High grade</td> <td class=\"sublist_other\">16, 31, 52, 18</td> </tr> <tr> <td>Oropharyngeal cancer</td> <td>16</td> </tr> <tr> <td>Anal cancer</td> <td>16</td> </tr> <tr> <td>Respiratory papillomatosis</td> <td>6, 11</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table lists the more commonly reported human papillomavirus types associated with various conditions. However, the most prevalent HPV types associated with particular lesions can vary by geography and demographics of the population studied.<br /></div><div class=\"graphic_footnotes\">* These include squamous intraepithelial lesions and cancers of the cervix, vagina, vulva, anus, and penis. Other high-risk types associated with squamous intraepithelial lesions include 33, 45, and&nbsp;58. </div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hariri S, Unger ER, Powell SE, et al. Human papillomavirus genotypes in high-grade cervical lesions in the United States. J Infec Dis 2012; 206:1878.</LI>&#xD;&#xA;<LI>Insinga RP, Liaw KL, Johnson LG, et al. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008; 17:1611.</LI></OL></div><div id=\"graphicVersion\">Graphic 76908 Version 9.0</div></div></div>"},"76911":{"type":"graphic_table","displayName":"Glossary of Down syndrome screening terms","title":"Glossary of Down syndrome screening terms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Glossary of Down syndrome screening terms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Term</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td>NT measurement</td> <td>The maximum width (in mm) of the translucent space at the back of the fetal neck as determined by ultrasound between 11 and 13 completed weeks of gestation.</td> </tr> <tr> <td>Quadruple test</td> <td>An early second-trimester test based on maternal serum measurements: AFP, uE3, free beta hCG or intact/total hCG, and inhibin A together with maternal age.</td> </tr> <tr> <td>Combined test</td> <td>A late first-trimester test base on sonographic and maternal serum measurements: NT, free beta hCG or intact/total hCG, and PAPP-A together with maternal age.</td> </tr> <tr> <td>Integrated test (full)</td> <td>The integration of measurements performed during the first- and second-trimester into a single screening test result. Typically includes first-trimester NT and PAPP-A with the Quadruple test in the second trimester together with maternal age. Usually the risk is only provided once all tests have been completed in the second trimester.</td> </tr> <tr> <td>Serum integrated test</td> <td>A variation of the Integrated test (full)&nbsp;that does not include the ultrasound component of NT. For this test, the risk is only provided once all tests have been completed in the second trimester.</td> </tr> <tr> <td>Sequential (integrated) test</td> <td>A variation of the Integrated test (full)&nbsp;in which a small proportion (0.5) of the highest-risk women (&#62;1:50) are identified as screen positive in the first trimester. The remaining women are provided a risk after all tests have been completed in the second trimester. In some programs, the first trimester risk is reported to all women, but only those &#62;1:50 are considered screen positive.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NT: nuchal translucency; AFP: alpha-fetoprotein; uE3: unconjugated estriol; hCG: human chorionic gonadotropin; PAPP-A: pregnancy associated plasma protein A.</div><div id=\"graphicVersion\">Graphic 76911 Version 2.0</div></div></div>"},"76912":{"type":"graphic_table","displayName":"TNF ILP unresect extrem sarcoma","title":"Results of TNF-based isolated limb perfusion for unresectable extremity soft tissue sarcoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Results of TNF-based isolated limb perfusion for unresectable extremity soft tissue sarcoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Author;<br /> year</td> <td class=\"subtitle1\" rowspan=\"2\">n</td> <td class=\"subtitle1\" rowspan=\"2\">Treatment</td> <td class=\"subtitle1\" colspan=\"2\">Response rate,<br /> percent</td> <td class=\"subtitle1\" rowspan=\"2\">Limb salvage,<br /> percent</td> <td class=\"subtitle1\" rowspan=\"2\">Overall survival,<br /> percent</td> <td class=\"subtitle1\" rowspan=\"2\">Local recurrence,<br /> percent</td> </tr> <tr> <td class=\"subtitle2\">Complete</td> <td class=\"subtitle2\">Partial</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Multicenter studies</td> </tr> <tr> <td class=\"indent1\">Eggermont A; 1996</td> <td>55</td> <td>TNF+IFN+M</td> <td>18</td> <td>64</td> <td>84</td> <td>64 (two-year)</td> <td>NR</td> </tr> <tr> <td class=\"indent1\">Eggermont A; 1996</td> <td>186</td> <td>TNF&#177;IFN+M</td> <td>18</td> <td>57</td> <td>82</td> <td>NR</td> <td>22</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Eggermont A; 1999</td> <td>246</td> <td>TNF&#177;IFN+M</td> <td>28*</td> <td>47</td> <td>71</td> <td>NR</td> <td>NR</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Single center studies</td> </tr> <tr> <td class=\"indent1\">Gutman M; 1997</td> <td>35</td> <td>TNF&#177;IFN+M</td> <td>37</td> <td>54</td> <td>85</td> <td>NR</td> <td>18</td> </tr> <tr> <td class=\"indent1\">Olieman A; 1998</td> <td>34</td> <td>TNF&#177;IFN+M</td> <td>35</td> <td>59</td> <td>85</td> <td>NR</td> <td>26</td> </tr> <tr> <td class=\"indent1\">LeJeune F; 2000</td> <td>22</td> <td>TNF&#177;IFN+M</td> <td>18</td> <td>64</td> <td>77</td> <td>NR</td> <td>45</td> </tr> <tr> <td class=\"indent1\">Noorda E; 2003</td> <td>49</td> <td>TNF&#177;IFN+M</td> <td>8</td> <td>55</td> <td>58</td> <td>48<sup>&#182;</sup> (five-year)</td> <td>13</td> </tr> <tr> <td class=\"indent1\">Grunhagen D; 2005</td> <td>64<sup>&#916;</sup></td> <td>TNF&#177;IFN+M</td> <td>42</td> <td>45</td> <td>82</td> <td>39 (five-year)</td> <td>45 (two-year)</td> </tr> <tr> <td class=\"indent1\">Lans T; 2005</td> <td>29<sup>&#9674;</sup></td> <td>TNF&#177;IFN+M</td> <td>20</td> <td>50</td> <td>65</td> <td>50 (five-year)</td> <td>31 (two-year)</td> </tr> <tr> <td class=\"indent1\">Bonvalot S; 2005<sup>&#167;</sup></td> <td>100</td> <td>TNF+M</td> <td>49<sup>&#165;</sup></td> <td>17</td> <td>87</td> <td>82 (two-year)</td> <td>24 (two-year)</td> </tr> <tr> <td class=\"indent1\">Grunhagen D; 2006</td> <td>217</td> <td>TNF&#177;IFN+M</td> <td>18</td> <td>51</td> <td>87</td> <td>49 (five-year)</td> <td>26</td> </tr> <tr> <td class=\"indent1\">Hayes A; 2007</td> <td>16</td> <td>TNF+M</td> <td>20</td> <td>33</td> <td>75</td> <td>NR</td> <td>71</td> </tr> <tr> <td class=\"indent1\">Pennacchioli E; 2007</td> <td>88</td> <td>Dox+M&#177;TNF<sup>&#135;</sup></td> <td>28</td> <td>52</td> <td>83</td> <td>47 (five-year)</td> <td>27 (five-year)</td> </tr> <tr> <td class=\"indent1\">Van Ginkel R; 2007</td> <td>73</td> <td>TNF&#177;IFN+M</td> <td>25</td> <td>69</td> <td>61</td> <td>59 (five-year)</td> <td>10 (five-year)</td> </tr> <tr> <td class=\"indent1\">Bonvalot S; 2009<sup>&#167;</sup></td> <td>100</td> <td>TNF+M</td> <td>30<sup>&#165;</sup></td> <td>49</td> <td>87</td> <td>89 (three-year)</td> <td>18 (three-year)</td> </tr> <tr> <td class=\"indent1\">DiFilippo F; 2009</td> <td>75</td> <td>TNF+Dox</td> <td>34</td> <td>48</td> <td>84</td> <td>62 (five-year)</td> <td>21</td> </tr> <tr> <td class=\"indent1\">Deroose J; 2011</td> <td>208</td> <td>TNF+M</td> <td>18</td> <td>53</td> <td>81</td> <td> <p>42 (five-year)</p> 33 (ten-year)</td> <td>30</td> </tr> <tr> <td class=\"indent1\">Deroose J; 2012</td> <td>29<sup>&#134;</sup></td> <td>TNF+M</td> <td>33</td> <td>38</td> <td>87</td> <td>72 (three-year)</td> <td>32</td> </tr> <tr> <td class=\"indent1\">Olofsson R; 2012</td> <td>54**</td> <td>TNF+M</td> <td>21</td> <td>50</td> <td>76</td> <td>44 (five-year)</td> <td>37</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNF: tumor necrosis factor; IFN: interferon; M: melphalan; NR: not reported; Dox: doxorubicin.<br />* Complete response based on a complete necrosis histologically.<br />¶ Disease-specific survival.<br />Δ Multiple tumors in extremity.<br /><FONT class=lozenge>◊</FONT> Previously irradiated field.<br />§ Lower dose TNF.<br />¥ Complete response determined radiographically.<br />‡ 51 treated with TNF, 37 with non-TNF isolated limb perfusion.<br />† All patients with soft tissue sarcoma in the distal parts of the limb.<br />** All candidates for amputation.</div><div id=\"graphicVersion\">Graphic 76912 Version 9.0</div></div></div>"},"76913":{"type":"graphic_picture","displayName":"Annular lichen planus - penis","title":"Annular lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Annular lichen planus</div><div class=\"cntnt\"><img style=\"width:432px; height:306px;\" src=\"images/DERM/76913_Annu_lichen_planus_penis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Violaceous annular plaques and papules are present on the penis and scrotum.</div><div class=\"graphic_reference\">Copyright © Kosman Sadek Zikry, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 76913 Version 5.0</div></div></div>"},"76914":{"type":"graphic_table","displayName":"First-rank symptoms in schizophrenia","title":"First-rank symptoms in schizophrenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">First-rank symptoms in schizophrenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Audible thoughts - hearing one's thoughts spoken aloud</td> </tr> <tr> <td>2. Somatic passivity - the feeling of being touched or strange unexplained sexual sensations</td> </tr> <tr> <td>3. Thought insertion - the feeling an external force is putting thoughts into one's mind</td> </tr> <tr> <td>4. Thought withdrawal - thoughts are withdrawn</td> </tr> <tr> <td>5. Thought broadcasting - the feeling people can read one's mind</td> </tr> <tr> <td>6. Made feelings - the feeling an external force is making you experience something</td> </tr> <tr> <td>7. Made impulses - the feeling an external force is making you want something</td> </tr> <tr> <td>8. Made volition - the feeling an external force is making you act a certain way</td> </tr> <tr> <td>9. Voices arguing/discussing (often referring to the patient as \"he\" or \"she\")</td> </tr> <tr> <td>10. Voices commenting - voices narrate one's actions as if giving a running commentary</td> </tr> <tr> <td>11. Delusional percepts - a physical sensation (such as seeing or feeling something) that is interpreted as a very special event has happened and something important is realized</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76914 Version 1.0</div></div></div>"},"76915":{"type":"graphic_diagnosticimage","displayName":"Nonunion lateral condyle fracture","title":"Nonunion lateral condyle fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nonunion lateral condyle fracture</div><div class=\"cntnt\"><img style=\"width:396px; height:340px;\" src=\"images/EM/76915_NonunionLCfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Avascular necrosis developed in this child because of extensive dissection and difficulty in obtaining a primary open reduction. <br />(A) Injury film. <br />(B) Two years later, there was extensive loss of bone in the metaphysis and a nonunion of the condyle.</div><div class=\"graphic_reference\">Reproduced with permission from: Sawyer JR, Beaty JH. Lateral Condylar and Capitellar Fractures of the Distal Humerus. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 76915 Version 14.0</div></div></div>"},"76917":{"type":"graphic_picture","displayName":"Vein distention SVC syndrome","title":"Superficial venous distention in superior vena cava syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial venous distention in superior vena cava syndrome</div><div class=\"cntnt\"><img style=\"width:368px; height:278px;\" src=\"images/ONC/76917_Vein_distention_SVC_syndrom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 65-year-old male smoker presented with non-productive cough, fatigue, worsening dyspnea on exertion, hoarseness, and a six-month history of progressively enlarging veins over the anterior chest wall. Chest imaging study showed a right-sided superior sulcus (Pancoast) tumor that was compressing the superior vena cava with a serpentine-shaped posterior extension impinging upon the sympathetic chain, phrenic nerve (impairing diaphragmatic motility contributing to the dyspnea) and recurrent laryngeal nerve. Biopsy confirmed a bronchogenic adenocarcinoma.</div><div class=\"graphic_reference\">Courtesy of Vaibhav Parekh, MD, MBA.</div><div id=\"graphicVersion\">Graphic 76917 Version 4.0</div></div></div>"},"76918":{"type":"graphic_figure","displayName":"Weight specific BMR children","title":"Weight-specific basal metabolic rate, activity energy expenditure, and total energy expenditure (MJ/kg per day) of infants and children from birth to 18 years of age","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Weight-specific basal metabolic rate, activity energy expenditure, and total energy expenditure (MJ/kg per day) of infants and children from birth to 18 years of age</div><div class=\"cntnt\"><img style=\"width:484px; height:744px;\" src=\"images/PEDS/76918_Weight_specific_BMR_childre.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BMR: basal metabolic rate; AEE: activity energy expenditure; TEE: total energy expenditure.</div><div class=\"graphic_reference\">Data from: Torun, B, Davies, PS, Livingstone, MB, et al. Energy requirements and dietary energy recommendations for children and adolescents 1 to 18 years old. Eur J Clin Nutr 1996; 50 Suppl 1:S37.</div><div id=\"graphicVersion\">Graphic 76918 Version 2.0</div></div></div>"},"76920":{"type":"graphic_algorithm","displayName":"Evaluation narrow QRS complex tachycardias in stable patients","title":"Algorithm for the evaluation of narrow QRS complex tachycardias in stable patients","html":"<div class=\"graphic\"><div style=\"width: 1010px\" class=\"figure\"><div class=\"ttl\">Algorithm for the evaluation of narrow QRS complex tachycardias in stable patients</div><div class=\"cntnt\"><img style=\"width:990px; height:582px;\" src=\"images/CARD/76920_Eval_narrow_QRS_stable_pts.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AVNRT: atrioventricular nodal reentrant tachycardia; AVRT: atrioventricular reentrant tachycardia (due to an accessory pathway); ECG: electrocardiogram; SANRT: sinoatrial nodal reentrant tachycardia.</div><div id=\"graphicVersion\">Graphic 76920 Version 3.0</div></div></div>"},"76922":{"type":"graphic_figure","displayName":"Prostaglandin and thromboxane synthesis","title":"Prostaglandin and thromboxane synthesis","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Prostaglandin and thromboxane synthesis</div><div class=\"cntnt\"><img style=\"width:522px; height:362px;\" src=\"images/RHEUM/76922_Prostaglandin_syn_AERD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of prostaglandin synthetic pathways and the enzymes that catalyze the specific reactions.</div><div class=\"graphic_footnotes\">PG: prostaglandin (gray-shaded area); COX: cyclooxygenase (can be subdivided into COX-1, COX-2, and COX-3); Tx: thromboxane.</div><div id=\"graphicVersion\">Graphic 76922 Version 3.0</div></div></div>"},"76923":{"type":"graphic_table","displayName":"Granulomatous liver disease causes","title":"Miscellaneous causes of granulomatous liver disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Miscellaneous causes of granulomatous liver disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Primary biliary cholangitis</td> </tr> <tr> <td>Hodgkin disease</td> </tr> <tr> <td>Non-Hodgkin lymphoma</td> </tr> <tr> <td>Renal cell carcinoma</td> </tr> <tr> <td>Berylliosis</td> </tr> <tr> <td>Copper toxicity</td> </tr> <tr> <td>Lipogranulomas (from ingestion of mineral oil)</td> </tr> <tr> <td>Talc or other particulate matter</td> </tr> <tr> <td>Crohn disease</td> </tr> <tr> <td>After jejunoileal bypass</td> </tr> <tr> <td>Inhalation of copper sulfate (vineyard workers)</td> </tr> <tr> <td>Chronic granulomatous disease</td> </tr> <tr> <td>Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td>Ingestion of \"Green juice\"</td> </tr> <tr> <td>Intravesical administration of bacillus Calmette-Guerin</td> </tr> <tr> <td>Idiopathic</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 76923 Version 3.0</div></div></div>"},"76924":{"type":"graphic_picture","displayName":"True hyphae of Candida albicans","title":"True hyphae of <EM>Candida albicans</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">True hyphae of <EM>Candida albicans</EM></div><div class=\"cntnt\"><img style=\"width:374px; height:252px;\" src=\"images/ID/76924_TruehyphaeofCandidaalbi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">True hyphae (as opposed to pseudohyphae) elongate through a process of apical synthesis that does not involve budding. Since buds are not present at the hyphal tips, the hyphae do not exibit periodic constrictions associated with the budding process.</div><div class=\"graphic_reference\">Courtesy of Wiley Schell, MS.</div><div id=\"graphicVersion\">Graphic 76924 Version 2.0</div></div></div>"},"76925":{"type":"graphic_diagnosticimage","displayName":"Magnetic source imaging","title":"Magnetic source imaging (MSI)","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Magnetic source imaging (MSI)</div><div class=\"cntnt\"><img style=\"width:559px; height:535px;\" src=\"images/NEURO/76925_MSI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic source imaging (MSI) showing the right anterior frontal location of the dipoles calculated from the right frontal spike discharges from the case in figure 1 (red). Blue dots indicate the posterior frontal/central location of dipoles calculated from right-sided slow waves in the same patient.</div><div id=\"graphicVersion\">Graphic 76925 Version 4.0</div></div></div>"},"76927":{"type":"graphic_picture","displayName":"Urothelial CIS B","title":"Urothelial carcinoma in situ (CIS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urothelial carcinoma in situ (CIS)</div><div class=\"cntnt\"><img style=\"width:432px; height:452px;\" src=\"images/ONC/76927_Urothelial_CIS_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 76927 Version 1.0</div></div></div>"},"76928":{"type":"graphic_figure","displayName":"Nipple and breast anatomy","title":"Nipple and breast anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nipple and breast anatomy</div><div class=\"cntnt\"><img style=\"width:351px; height:357px;\" src=\"images/PEDS/76928_Anatomy_of_the_breast.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Ruan W, Kleinberg DL. Endocrinology 1999; 140:5075. Copyright &#169; 1999 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 76928 Version 3.0</div></div></div>"},"76929":{"type":"graphic_diagnosticimage","displayName":"Axial view of the sesamoids","title":"Axial view of the sesamoids","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Axial view of the sesamoids</div><div class=\"cntnt\"><img style=\"width:504px; height:408px;\" src=\"images/EM/76929_Axial_view_sesamoids.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A fracture is not apparent on this view because the fracture lies in the same plane as the&nbsp;x-ray film and there is no displacement. This and other views could prove valuable in assessing fractures that are not well seen in anteroposterior (AP), oblique, and lateral views of the foot.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 76929 Version 3.0</div></div></div>"},"76930":{"type":"graphic_figure","displayName":"Women's health initiative risk of heart disease","title":"Women's Health Initiative: Risk of heart disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Women's Health Initiative: Risk of heart disease</div><div class=\"cntnt\"><img style=\"width:385px; height:372px;\" src=\"images/ENDO/76930_HRTCHDWHI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier estimates of cumulative hazard rates of CHD. In the Women's Health Initiative, combined estrogen-progestin therapy was associated with a significant increase in coronary events. CHD included nonfatal myocardial infarction and death due to CHD. The overall hazard ratio for CHD was 1.24 (nominal 95% CI, 1.00-1.54).</div><div class=\"graphic_footnotes\">CHD: coronary heart disease.</div><div class=\"graphic_reference\">Data from: Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523.</div><div id=\"graphicVersion\">Graphic 76930 Version 3.0</div></div></div>"},"76931":{"type":"graphic_figure","displayName":"Thyroid hormone synthesis","title":"Thyroid hormone biosynthesis","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Thyroid hormone biosynthesis</div><div class=\"cntnt\"><img style=\"width:498px; height:296px;\" src=\"images/ENDO/76931_Thyroid_hormone_synthesis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thyroid hormone synthesis includes the following steps: (1) iodide (I<SUP>-</SUP>) trapped by the thyroid follicular cells; (2) diffusion of iodide to the apex of the cells; (3) transport of iodide into the colloid; (4) oxidation of inorganic iodide to iodine and incorporation of iodine into tyrosine residues within thyroglobulin molecules in the colloid; (5) combination of two DIT molecules to form tetraiodothyronine (T4) or of MIT with DIT to form T3; (6) uptake of thyroglobulin from the colloid into the follicular cell by endocytosis, fusion of the thyroglobulin with a lysosome, and proteolysis and release of T4, T3, DIT, and MIT; (7) release of T4 and T3 into the circulation; and (8) deiodination of DIT and MIT to yield tyrosine. T3 is also formed from monodeiodination of T4 in the thyroid and in peripheral tissues.</div><div class=\"graphic_footnotes\">T4: thyroxine; T3: triiodothyronine; DIT: diiodotyrosine; MIT: monoiodotyrosine.</div><div class=\"graphic_reference\">Modified from: Scientific American Medicine, Scientific American, New York, 1995.</div><div id=\"graphicVersion\">Graphic 76931 Version 5.0</div></div></div>"},"76932":{"type":"graphic_figure","displayName":"Burch medial displace bladder","title":"Medial displacement of the bladder for suture placement during Burch procedure (retropubic colposuspension)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Medial displacement of the bladder for suture placement during Burch procedure (retropubic colposuspension)</div><div class=\"cntnt\"><img style=\"width:388px; height:403px;\" src=\"images/OBGYN/76932_Burch_medial_displace_bladd.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Robinson, D, Norton, PA. Diagnosis and Management of Urinary Incontinence. In: Gynecologic Surgery. Mann, WJ, Stovall, TG (Eds), Churchill Livingstone, New York 1996. p.713.</div><div id=\"graphicVersion\">Graphic 76932 Version 2.0</div></div></div>"},"76933":{"type":"graphic_figure","displayName":"McBurney incision 1","title":"McBurney incision 1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">McBurney incision 1</div><div class=\"cntnt\"><img style=\"width:416px; height:305px;\" src=\"images/SURG/76933_McBurney_incision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Incision through McBurney's point. (B) Fibers of external oblique separated. Internal oblique muscle split.</div><div id=\"graphicVersion\">Graphic 76933 Version 6.0</div></div></div>"},"76934":{"type":"graphic_picture","displayName":"Tilted disc","title":"Tilted disc","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tilted disc</div><div class=\"cntnt\"><img style=\"width:281px; height:363px;\" src=\"images/PEDS/76934_Tilted_disc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the oblong, tilted, more elliptical shape.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 76934 Version 1.0</div></div></div>"},"76935":{"type":"graphic_picture","displayName":"Oronasal mask","title":"Oronasal mask","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oronasal mask</div><div class=\"cntnt\"><img style=\"width:249px; height:324px;\" src=\"images/PULM/76935_Oronasal_face_mask.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oronasal mask (Spectrum, Respironics, Inc) adapted for use with noninvasive positive pressure ventilation. To prevent rebreathing in the case of ventilator failure, the mask incorporates an \"anti-asphyxia\" valve and a quick-release strap.</div><div id=\"graphicVersion\">Graphic 76935 Version 5.0</div></div></div>"},"76937":{"type":"graphic_table","displayName":"Empiric oral treatment for MRSA and beta-hemolytic streptococci","title":"Options for empiric oral therapy for treatment of both methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) and beta-hemolytic streptococci","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Options for empiric oral therapy for treatment of both methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) and beta-hemolytic streptococci</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antibiotic agent</td> <td class=\"subtitle1\">Adult dose</td> <td class=\"subtitle1\">Pediatric dose (children &#62;28 days)*</td> </tr> <tr class=\"divider_bottom\"> <td>Clindamycin</td> <td>300 to 450 mg orally three times daily</td> <td>40 mg/kg per day orally divided in three or four doses</td> </tr> <tr> <td>Amoxicillin PLUS</td> <td>500 mg orally three times daily</td> <td>25 to 50 mg/kg per day orally divided in three doses</td> </tr> <tr class=\"divider_bottom\"> <td>Trimethoprim-sulfamethoxazole</td> <td>1 double-strength tablet orally twice daily</td> <td>8 to 12 mg trimethoprim component/kg per day orally divided in two doses</td> </tr> <tr> <td>Amoxicillin PLUS</td> <td>500 mg orally three times daily</td> <td>25 to 50 mg/kg per day orally divided in three doses</td> </tr> <tr class=\"divider_bottom\"> <td>Doxycycline<sup>&#182;</sup></td> <td>100 mg orally twice daily</td> <td> <p>&#8804;45 kg: 4 mg/kg per day orally divided in two doses</p> &#62;45 kg: 100 mg orally twice daily</td> </tr> <tr> <td>Amoxicillin PLUS</td> <td>500 mg orally three times daily</td> <td>25 to 50 mg/kg per day orally divided in three doses</td> </tr> <tr class=\"divider_bottom\"> <td>Minocycline<sup>&#182;</sup></td> <td>200 mg once, then 100 mg orally twice daily</td> <td>4 mg/kg orally once, then 4 mg/kg per day divided in two doses</td> </tr> <tr class=\"divider_bottom\"> <td>Linezolid</td> <td>600 mg orally twice daily</td> <td> <p>&#60;12 years: 30 mg/kg per day orally divided in three doses</p> &#8805;12 years: 600 mg orally twice daily</td> </tr> <tr> <td>Tedizolid</td> <td>200 mg orally once daily</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: Pediatric doses should not exceed the usual adult doses shown.</div><div class=\"graphic_footnotes\">* Dosing for neonates provided separately. (Refer to the UpToDate table on treatment of cellulitis in neonates.)<br />&para; Not recommended for children &lt;8 years of age.</div><div class=\"graphic_reference\">Selected data from: Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children. Clin Infect Dis 2011; 52:e18.</div><div id=\"graphicVersion\">Graphic 76937 Version 10.0</div></div></div>"},"76938":{"type":"graphic_figure","displayName":"Trap door effect","title":"Trap door effect","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trap door effect</div><div class=\"cntnt\"><img style=\"width:428px; height:611px;\" src=\"images/EM/76938_Trap-door-effect-edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Round or elliptical lacerations with partial avulsions (figure A) are prone to bulging in the flap during healing (figure B). This effect can be minimized by approximation of the subcutaneous tissue to the base of the flap and careful apposition of the skin layers. Alternatively, small lacerations may be revised by removal of the flap and pedicle (figure C). Large lacerations warrant primary closure and referral to a plastic surgeon for elective Z-plasty.</div><div id=\"graphicVersion\">Graphic 76938 Version 1.0</div></div></div>"},"76939":{"type":"graphic_movie","displayName":"Membranous VSD with double chambered RV","title":"Membranous VSD with double chambered RV","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Membranous VSD with double chambered RV</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/76939_MembrVSDdoubchambmovie.mp4\" style=\"width:496px;height:400px\"></div><img style=\"width:545px; height:368px;\" src=\"images/CARD/76939_MembrVSDdoubchambposter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the moving clip from the subcostal parasagittal image window, the dynamic nature of the narrowing of the RVOT is highlighted by the superimposed color flow mapping. Systolic left-to-right flow from the VSD is also seen crossing the ventricular septum and entering the right ventricle caudal to the mid-chamber obstruction.</div><div class=\"graphic_footnotes\">PA: pulmonary artery; LVOT: left ventricular outflow tract; LA: left atrium; RV: right ventricle; IVS: intraventricular septum; thin arrow: VSD.</div><div id=\"graphicVersion\">Graphic 76939 Version 2.0</div></div></div>"},"76943":{"type":"graphic_picture","displayName":"Angiofibroma Light","title":"Nasopharyngeal angiofibroma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nasopharyngeal angiofibroma</div><div class=\"cntnt\"><img style=\"width:374px; height:273px;\" src=\"images/ONC/76943_Angiofibroma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph of an angiofibroma. This soft tissue tumor of pubescent males demonstrates a proliferation of thin-walled vessels with irregular or stag-horn shapes. The stroma is densely fibrotic and of variable cellularity.</div><div class=\"graphic_reference\">Courtesy of G Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 76943 Version 4.0</div></div></div>"},"76945":{"type":"graphic_figure","displayName":"Postoperative urinary catheter following hypospadias repair","title":"Postoperative urinary catheter following hypospadias repair","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postoperative urinary catheter following hypospadias repair</div><div class=\"cntnt\"><img style=\"width:385px; height:332px;\" src=\"images/PEDS/76945_Hypospadiascatheter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic diagram of urinary drainage tube or stent used after hypospadias surgery.</div><div class=\"graphic_reference\">Reproduced with permission from: Baskin LS. Hypospadias. In: Handbook of Pediatric Urology, 2nd ed, Baskin LS, Kogan BA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 76945 Version 12.0</div></div></div>"},"76947":{"type":"graphic_algorithm","displayName":"Confirmation of the diagnosis of anaphylaxis","title":"Confirmation of the diagnosis of anaphylaxis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Confirmation of the diagnosis of anaphylaxis</div><div class=\"cntnt\"><img style=\"width:389px; height:527px;\" src=\"images/ALLRG/76947_Anadiagnosisconfirmedt3.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease.<br />* Common entities in the differential diagnosis include acute hives, acute asthma, anxiety/panic attack, syncope/faint, and choking on/aspiration of a foreign body. There are many less common entities, including histamine syndromes, restaurant syndromes, flush syndromes, and other forms of shock.</div><div id=\"graphicVersion\">Graphic 76947 Version 12.0</div></div></div>"},"76948":{"type":"graphic_table","displayName":"Single gene causes of obesity in animals","title":"Single gene causes of obesity in animals","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Single gene causes of obesity in animals</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Animal model</td>\n\n      <td class=\"subtitle1\">Rodent</td>\n\n      <td class=\"subtitle1\">Chromosome Human homologue</td>\n\n      <td class=\"subtitle1\">Gene defect</td>\n\n      <td class=\"subtitle1\">Gene product</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">Dominant inheritance</td>\n\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2_start\">Yellow mouse (A)</td>\n\n      <td class=\"sublist_other_start\" colspan=\"1\" rowspan=\"2\">2</td>\n\n      <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">20q11.2</td>\n\n      <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">Agouti-signalling protein overexpressed in many tissues</td>\n\n      <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">Asp</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Gene= Agouti</td>\n</tr>\n\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">Recessive inheritance</td>\n</tr>\n\n    <tr>\n\n      <td class=\"sublist2_start\">Obese mouse (ob/ob)</td>\n\n      <td colspan=\"1\" rowspan=\"2\">4</td>\n\n      <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">7q31.3</td>\n\n      <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">Stop codon produces truncated leptin</td>\n\n      <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">Leptin</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Gene= Lep</td>\n\n     </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Diabetes mouse (db/db)</td>\n\n      <td>4</td>\n\n      <td>1p32</td>\n\n      <td>Splicing defects or extracellular deletions</td>\n\n      <td>Leptin receptor</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist2_start\">Fatty rat (fa/fa)</td>\n      <td class=\"sublist_other_start\" colspan=\"1\" rowspan=\"2\">5</td>\n      <td colspan=\"1\" rowspan=\"2\">&nbsp;</td>\n      <td colspan=\"1\" rowspan=\"2\">&nbsp;</td>\n      <td colspan=\"1\" rowspan=\"2\">&nbsp;</td>\n    </tr>\n    <tr>\n      <td class=\"sublist2\">Gene= Lepr</td>\n      \n      \n      \n      \n    </tr>\n    <tr>\n\n      <td class=\"sublist2_start\">Tub mouse</td>\n\n      <td class=\"sublist_other_start\" colspan=\"1\" rowspan=\"2\">7</td>\n\n      <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">4q32</td>\n\n      <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">Insert</td>\n\n      <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">Phosphatase (?)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Gene= tub</td>\n </tr>\n\n    <tr>\n\n      <td class=\"sublist2_start\">Fat mouse</td>\n\n      <td class=\"sublist_other_start\" colspan=\"1\" rowspan=\"2\">8</td>\n\n      <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">11p15</td>\n\n      <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">Insert</td>\n\n      <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">Carboxypeptidase E</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Gene= cpe</td>\n</tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 76948 Version 2.0</div></div></div>"},"76949":{"type":"graphic_algorithm","displayName":"Treatment Cushings disease","title":"Treatment of Cushing's disease","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Treatment of Cushing's disease</div><div class=\"cntnt\"><img style=\"width:506px; height:390px;\" src=\"images/ENDO/76949_Treatment_Cushings_disease.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.<br />* The choice of treatment after failed transsphenoidal surgery should be individualized for each patient based upon the presence of dural or cavernous sinus invasion, the presence of a surgical target on MRI, the location of tumor in relationship to optic nerves, the need for prompt resolution of hypercortisolism, contraindication to specific medical therapy, and the patient's values and preferences.</div><div id=\"graphicVersion\">Graphic 76949 Version 3.0</div></div></div>"},"76951":{"type":"graphic_diagnosticimage","displayName":"Obstructive emphysema A","title":"Obstructive emphysema in a child due to foreign body aspiration","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Obstructive emphysema in a child due to foreign body aspiration</div><div class=\"cntnt\"><img style=\"width:468px; height:210px;\" src=\"images/PULM/76951_Obstructive_emphysema_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inspiratory and expiratory chest radiographs from a two-year-old child with a radiolucent foreign body in the left mainstem bronchus. There is marked hyperlucency in the left lung during expiration (right image) compared with inspiration (left image).</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 76951 Version 5.0</div></div></div>"},"76952":{"type":"graphic_picture","displayName":"Morphea - histopathology","title":"Morphea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Morphea</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/76952_Morphea_histopathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thick collagen bundles and a sparse interstitial and perivascular inflammatory infiltrate are present in the dermis. Adnexal structures are absent.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76952 Version 4.0</div></div></div>"},"76953":{"type":"graphic_table","displayName":"Causes of enterocutaneous fistulae","title":"Causes of enterocutaneous fistulae","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of enterocutaneous fistulae</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Cause</td> <td class=\"subtitle1\">Frequency (percent)</td> </tr> <tr> <td>Postoperative</td> <td>85</td> </tr> <tr> <td>Spontaneous</td> <td>15</td> </tr> <tr> <td>Crohn disease</td> <td>39</td> </tr> <tr> <td>Ulcerative colitis</td> <td>13</td> </tr> <tr> <td>Malignancy</td> <td>9</td> </tr> <tr> <td>Radiation</td> <td>6</td> </tr> <tr> <td>Diverticular disease</td> <td>5</td> </tr> <tr> <td>Other*</td> <td>27</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">20.0000000000000</mso:Specialty>\r\n<mso:Publishable_Version msdt:dt=\"string\">0</mso:Publishable_Version>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=91436&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Causes_of_enterocutaneous_fistulae.htm</title></head></div><div class=\"graphic_footnotes\">* &quot;Other&quot; includes rare conditions such as enteric vasculitis or myopathy or no associated condition.</div><div class=\"graphic_reference\">Reproduced with permission from: Fischer JE, Evenson AR. Gastrointestinal-cutaneous fistulae. In: Mastery of Surgery, Fischer JE (Ed), Lippincott Williams &amp; Wilkins 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 76953 Version 7.0</div></div></div>"},"76954":{"type":"graphic_picture","displayName":"Positive patch test reactions","title":"Positive patch test reactions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Positive patch test reactions</div><div class=\"cntnt\"><img style=\"width:251px; height:232px;\" src=\"images/DERM/76954_Pos_patch_test_reactions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) +++ reaction.<br />(B) ++ reaction (note the microvesicles).<br />(C) + reaction.<br />(D) +/- reaction.</div><div class=\"graphic_reference\">(A) Reproduced with permission from: DermNet NZ. For more information, visit <A href=\"http://dermnetnz.org/\" target=_blank>http://dermnetnz.org</A>. Copyright © 2011.</div><div id=\"graphicVersion\">Graphic 76954 Version 2.0</div></div></div>"},"76955":{"type":"graphic_picture","displayName":"Monomorphic epitheliotropic intestinal T cell lymphoma","title":"Histology of monomorphic epitheliotropic intestinal T cell lymphoma (previously enteropathy-associated T cell lymphoma type 2)","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Histology of monomorphic epitheliotropic intestinal T cell lymphoma (previously enteropathy-associated T cell lymphoma type 2)</div><div class=\"cntnt\"><img style=\"width:509px; height:509px;\" src=\"images/HEME/76955_Histology_EATL_type_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The lymphoma consists of monotonous, medium-sized cells with round nuclei having a stippled chromatin pattern (magnification, 250x). (B) The cells express CD56 (magnification, 250x). The mucosa adjacent to the lymphoma, shows villous atrophy (C; magnification, 100x) and intra-epithelial infiltration by lymphoma cells (D; CD56 staining, magnification, 400x).</div><div class=\"graphic_reference\">This research was originally published in Blood. Delabie J, Harald H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. Blood 2011; 118:148. Copyright © 2011 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 76955 Version 2.0</div></div></div>"},"76956":{"type":"graphic_diagnosticimage","displayName":"CT cystogram bladder rupture coronal","title":"CT cystogram of bladder rupture - Coronal view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT cystogram of bladder rupture - Coronal view</div><div class=\"cntnt\"><img style=\"width:432px; height:337px;\" src=\"images/EM/76956_Bladder_rupture_EP_CT_cor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This coronal view of a CT cystogram shows extravasated contrast encircling the bladder.</div><div class=\"graphic_reference\">Courtesy of Michael S Runyon, MD, FAAEM.</div><div id=\"graphicVersion\">Graphic 76956 Version 2.0</div></div></div>"},"76957":{"type":"graphic_diagnosticimage","displayName":"TTTS2","title":"TTTS2","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">TTTS2</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/OBGYN/76957_TTTS2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Polyhydramnios in the recipient's sac with a deepest vertical pocket of 12.66 cm at approximately 22 weeks of gestation.</div><div class=\"graphic_reference\">Courtesy of Kenneth J Moise, Jr, MD &amp; Anthony Johnson, DO.</div><div id=\"graphicVersion\">Graphic 76957 Version 3.0</div></div></div>"},"76959":{"type":"graphic_table","displayName":"Risks neurolytic blockade","title":"Risks associated with neurolytic blockade for pain relief","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risks associated with neurolytic blockade for pain relief</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Anesthesia of the area innervated by the destroyed nerve</td> </tr> <tr> <td>Anesthesia dolorosa (pain superimposed in an area that lacks or has impaired sensation)</td> </tr> <tr> <td>Autonomic dysfunction</td> </tr> <tr> <td>Motor paresis</td> </tr> <tr> <td>Bladder/bowel dysfunction</td> </tr> <tr> <td>Dysesthesias</td> </tr> <tr> <td>Orthostatic hypotension</td> </tr> <tr> <td>Neuritis</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=47873&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n<mso:Media_Notes msdt:dt=\"string\"></mso:Media_Notes>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div id=\"graphicVersion\">Graphic 76959 Version 4.0</div></div></div>"},"76961":{"type":"graphic_picture","displayName":"Intradermal nevus","title":"Intradermal nevus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intradermal nevus</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PEDS/76961_Intradermal_nevus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Soft intradermal nevus that is pink in color. This lesion is symmetric with a regular outline and uniform pigmentation.</div><div class=\"graphic_reference\">Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.</div><div id=\"graphicVersion\">Graphic 76961 Version 1.0</div></div></div>"},"76962":{"type":"graphic_picture","displayName":"Diffuse episcleritis","title":"Diffuse episcleritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse episcleritis</div><div class=\"cntnt\"><img style=\"width:342px; height:214px;\" src=\"images/RHEUM/76962_Diffuse_episcleritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Monocular attack of diffuse episcleritis in a patient with relapsing polychondritis. There is diffuse injection of the episcleral vessels, but the underlying sclera is normal.</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 76962 Version 2.0</div></div></div>"},"76963":{"type":"graphic_figure","displayName":"EMR suction technique cartoon","title":"Cartoon illustrating the cap-assisted suction technique for endoscopic mucosal resection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cartoon illustrating the cap-assisted suction technique for endoscopic mucosal resection</div><div class=\"cntnt\"><img style=\"width:410px; height:249px;\" src=\"images/GAST/76963_EMR_suction_technique_carto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A submucosal saline injection (B) is used to raise the lesion (A), which is aspirated into a hood and permits snare excision of the isolated lesion (C).</div><div class=\"graphic_reference\">Courtesy of Christopher Gostout, MD.</div><div id=\"graphicVersion\">Graphic 76963 Version 3.0</div></div></div>"},"76964":{"type":"graphic_algorithm","displayName":"Natural history diverticulosis","title":"Natural history of diverticulosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Natural history of diverticulosis</div><div class=\"cntnt\"><img style=\"width:404px; height:224px;\" src=\"images/GAST/76964_Natural_history_diverticulo.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 76964 Version 3.0</div></div></div>"},"76965":{"type":"graphic_figure","displayName":"Sling placement","title":"Pubovaginal sling placement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pubovaginal sling placement</div><div class=\"cntnt\"><img style=\"width:291px; height:422px;\" src=\"images/OBGYN/76965_Sling_placement.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Robinson, D, Norton, PA. Diagnosis and Management of Urinary Incontinence. In: Gynecologic Surgery. William, WM, Stovall, TG (Eds), Churchill Livingstone, New York 1996. p.722.</div><div id=\"graphicVersion\">Graphic 76965 Version 1.0</div></div></div>"},"76966":{"type":"graphic_table","displayName":"Thrombophilia test interference","title":"Clinical settings that may interfere with testing for thrombophilia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical settings that may interfere with testing for thrombophilia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Hypercoagulable disorder for testing<br /> </td> <td class=\"subtitle1\" colspan=\"3\">Confounding factors</td> </tr> <tr> <td class=\"subtitle2\">Acute thrombosis</td> <td class=\"subtitle2\">Heparin therapy</td> <td class=\"subtitle2\">Warfarin&nbsp;therapy</td> </tr> <tr> <td>Antithrombin (deficiency) </td> <td>Can be lowered<sup>*</sup></td> <td>Lowered</td> <td>NC; rarely increased</td> </tr> <tr> <td>Antiphospholipid antibodies</td> <td>NC</td> <td>NC</td> <td>NC</td> </tr> <tr> <td>Factor V Leiden</td> <td>NC</td> <td>NC</td> <td>NC</td> </tr> <tr> <td>Factor VIII level</td> <td colspan=\"3\">Acute phase reactant. Do not test while inflammation is still present.</td> </tr> <tr> <td>Lupus anticoagulant</td> <td>NC</td> <td>Cannot measure<sup>&#182;</sup></td> <td>False positives possible</td> </tr> <tr> <td>Protein C (deficiency) </td> <td>Can be lowered<sup>*</sup></td> <td>NC</td> <td>Cannot measure<sup>&#916;</sup></td> </tr> <tr> <td>Protein S (deficiency)</td> <td>Can be lowered<sup>*</sup></td> <td>NC</td> <td>Cannot measure<sup>&#916;</sup></td> </tr> <tr> <td>Prothrombin gene mutation</td> <td>NC</td> <td>NC</td> <td>NC</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Acquired AT deficiency:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Neonatal period, pregnancy, liver disease, DIC, nephrotic syndrome, major surgery, acute thrombosis, treatment with L-asparaginase, heparin, or estrogens</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Acquired protein C deficiency:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Neonatal period, liver disease, DIC, chemotherapy (CMF), inflammation, acute thrombosis, treatment with warfarin or L-asparaginase</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Acquired protein S deficiency:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Neonatal period, pregnancy, liver disease, DIC, acute thrombosis, treatment with warfarin, L-asparaginase, or estrogens</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on the specific hypercoagulable disorders for additional information. If&nbsp;a result is abnormal in a patient receiving an anticoagulant,&nbsp;it may be prudent to repeat the test in the absence of the anticoagulant, if possible.</div><div class=\"graphic_footnotes\">NC: not changed; LMW heparin: low molecular weight heparin; AT: antithrombin; DIC: disseminated intravascular coagulation; CMF: cyclophosphamide, methotrexate, 5-fluorouracil.<br />* Results can be affected by acute thrombosis; it is most cost effective to avoid testing for these deficiencies during the initial presentation. However, if plasma levels are well within the normal range at presentation, deficiency of these proteins is essentially excluded. Common causes for an acquired deficiency of AT, protein C, or protein S are listed.<br />¶&nbsp;Some laboratories can test for a lupus anticoagulant in the presence of heparin, but many cannot.<br />Δ&nbsp;If it is important to measure for these deficiencies while the patient is still anticoagulated, switch the treatment to full-dose heparin or LMW heparin and discontinue coumadin for at least two weeks before measurement. Comparing protein S or C levels with prothrombin antigen in stably anticoagulated patients is not reliable, as accurate measurement of prothrombin antigen levels is a research assay which is not generally available.</div><div id=\"graphicVersion\">Graphic 76966 Version 7.0</div></div></div>"},"76967":{"type":"graphic_diagnosticimage","displayName":"Pulmonary coccidioidomycosis","title":"Pulmonary coccidioidomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary coccidioidomycosis</div><div class=\"cntnt\"><img style=\"width:442px; height:586px;\" src=\"images/ID/76967_Coccidioidomycimaging.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chest radiograph shows consolidation in right lower lung zone (arrow) and right hilar enlargement (arrowhead).<br />(B) Mediastinal window of contrast-enhanced computed tomography (CT) (5 mm collimation) scan obtained at the level of bronchus intermedius shows enlarged right hilar (arrowhead), subcarinal, and paraesophageal lymph nodes (arrows).<br />(C) CT scan obtained at the level of the right middle lobe bronchus shows parenchymal consolidation in the right middle lobe and enlarged subcarinal lymph nodes (arrows).<br />(D) Photomicrograph of the surgical biopsy specimen shows granulomatous inflammation and fibrosis with infiltration of multinucleated giant cells, eosinophils, and lymphocytes (hematoxylin and eosin stain, x100).<br />(E) Photomicrograph shows a yeast form developing a spherule of <EM>Coccidioides immitis</EM> (arrow), which is engulfed by a multinucleated giant cell (arrowheads). The periodic acid-Schiff stain highlights its thick yeast wall (periodic acid-Schiff stain, x400). The patient was a 58-year-old man with a&nbsp;one-month history of dyspnea and fever.</div><div class=\"graphic_reference\">Reproduced with permission from: Fungal and parasitic infections. In: Imaging of pulmonary infections. Muller NL, Franquet T, Kyung SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 76967 Version 15.0</div></div></div>"},"76969":{"type":"graphic_table","displayName":"Palliative care assessment at admission criteria","title":"Criteria for a palliative care assessment at the time of admission","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for a palliative care assessment at the time of admission</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">A potentially life-limiting or life-threatening condition <em>and</em>...</td> </tr> <tr> <td class=\"subtitle2_single\">Primary criteria*</td> </tr> <tr> <td class=\"indent1\">The \"surprise question\": <em>You would not be surprised if the patient died within 12 months or before adulthood</em></td> </tr> <tr> <td class=\"indent1\">Frequent admissions (eg, more than one admission for same condition within several months)</td> </tr> <tr> <td class=\"indent1\">Admission prompted by difficult-to-control physical or psychological symptoms (eg, moderate-to-severe symptom intensity for more than 24 to 48 hours)</td> </tr> <tr> <td class=\"indent1\">Complex care requirements (eg, functional dependency; complex home support for ventilator/antibiotics/feedings)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Decline in function, feeding intolerance, or unintended decline in weight (eg, failure to thrive)</td> </tr> <tr> <td class=\"subtitle2_single\">Secondary criteria<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Admission from long-term care facility or medical foster home<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Older patient, cognitively impaired, with acute hip fracture</td> </tr> <tr> <td class=\"indent1\">Metastatic or locally advanced incurable cancer</td> </tr> <tr> <td class=\"indent1\">Chronic home oxygen use<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Out-of-hospital cardiac arrest</td> </tr> <tr> <td class=\"indent1\">Current or past hospice program enrollee<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Limited social support (eg, family stress, chronic mental illness)<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">No history of completing an advance care planning discussion/document</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Primary criteria are global indicators that represent the minimum that hospitals should use to screen patients at risk for unmet palliative care needs.<br />¶ Secondary criteria are more-specific indicators of a high likelihood of unmet palliative care needs and should be incorporated into a systems-based approach to patient identification if possible.<br />Δ These indicators are included based on a consensus panel opinion.</div><div class=\"graphic_reference\">Reproduced with permission from: Weissman DE, Meier DE. Identifying patients in need of a palliative care assessment in the hospital setting. J Palliat Med 2011; 14:17. Copyright &copy; 2011 Mary Ann Liebert, Inc.</div><div id=\"graphicVersion\">Graphic 76969 Version 5.0</div></div></div>"},"76970":{"type":"graphic_figure","displayName":"Bypass revision for brachiocephalic fistula steal","title":"Bypass revision for brachiocephalic fistula steal","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Bypass revision for brachiocephalic fistula steal</div><div class=\"cntnt\"><img style=\"width:464px; height:653px;\" src=\"images/SURG/76970_Bypass-rev-bc-fistula-steal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical options for bypass revision for brachiocephalic fistula steal are illustrated in the figure.<BR>(A) Distal revascularization-interval ligation (DRIL):&nbsp;The brachial artery just distal to the anastomosis is ligated, and a bypass&nbsp;is created from the more proximal&nbsp;brachial artery to the&nbsp;proximal radial artery. The distal circulation is dependant upon the new bypass.<BR>(B) Revision Using Distal Inflow (RUDI): The origin of the fistula is ligated on the venous side followed by&nbsp;a revsion from a more distal arterial source to the venous limb. In contrast to the DRIL procedure, the RUDI procedure&nbsp;maintains the native arterial circulation.</div><div id=\"graphicVersion\">Graphic 76970 Version 1.0</div></div></div>"},"76971":{"type":"graphic_picture","displayName":"Enophthalmos trauma","title":"Enophthalmos from trauma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Enophthalmos from trauma</div><div class=\"cntnt\"><img style=\"width:396px; height:289px;\" src=\"images/EM/76971_Enophthalmos_trauma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pseudoptosis: enophthalmos secondary to an orbital blow-out fracture (right eye).</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 76971 Version 1.0</div></div></div>"},"76972":{"type":"graphic_table","displayName":"Causes of hyperthyroidism","title":"Causes of hyperthyroidism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hyperthyroidism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Hyperthyroidism with a normal or high radioiodine uptake</td> </tr> <tr> <td class=\"subtitle2_single\">Autoimmune thyroid disease</td> </tr> <tr> <td class=\"indent1\">Graves' disease</td> </tr> <tr> <td class=\"indent1\">Hashitoxicosis</td> </tr> <tr> <td class=\"subtitle2_single\">Autonomous thyroid tissue (uptake may be low if recent iodine load led to iodine-induced hyperthyroidism)</td> </tr> <tr> <td class=\"indent1\">Toxic adenoma</td> </tr> <tr> <td class=\"indent1\">Toxic multinodular goiter</td> </tr> <tr> <td class=\"subtitle2_single\">TSH-mediated hyperthyroidism</td> </tr> <tr> <td class=\"indent1\">TSH-producing pituitary adenoma</td> </tr> <tr> <td class=\"indent1\">Non-neoplastic TSH-mediated hyperthyroidism</td> </tr> <tr> <td class=\"subtitle2_single\">Human chorionic gonadotropin-mediated hyperthyroidism</td> </tr> <tr> <td class=\"indent1\">Hyperemesis gravidarum</td> </tr> <tr> <td class=\"indent1\">Trophoblastic disease</td> </tr> <tr> <td class=\"subtitle1_single\">Hyperthyroidism with a near absent radioiodine uptake</td> </tr> <tr> <td class=\"subtitle2_single\">Thyroiditis</td> </tr> <tr> <td class=\"indent1\">Subacute granulomatous (de Quervain's) thyroiditis</td> </tr> <tr> <td class=\"sublist2_start\">Painless thyroiditis (silent thyroiditis, lymphocytic thyroiditis)</td> </tr> <tr> <td class=\"sublist2\">Postpartum thyroiditis</td> </tr> <tr> <td class=\"indent1\">Amiodarone (also may cause iodine-induced hyperthyroidism)</td> </tr> <tr> <td class=\"indent1\">Radiation thyroiditis</td> </tr> <tr> <td class=\"indent1\">Palpation thyroiditis</td> </tr> <tr> <td class=\"subtitle2_single\">Exogenous thyroid hormone intake</td> </tr> <tr> <td class=\"indent1\">Excessive replacement therapy</td> </tr> <tr> <td class=\"indent1\">Intentional suppressive therapy</td> </tr> <tr> <td class=\"indent1\">Factitious hyperthyroidism</td> </tr> <tr> <td class=\"subtitle2_single\">Ectopic hyperthyroidism</td> </tr> <tr> <td class=\"indent1\">Struma ovarii</td> </tr> <tr> <td class=\"indent1\">Metastatic follicular thyroid cancer</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">4</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=14218&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n<mso:Media_Notes msdt:dt=\"string\"></mso:Media_Notes>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">Major causes of hyperthyroidism according to the presence of a high or low radioiodine uptake. High uptake indicates increased new hormone synthesis by the thyroid, whereas low uptake indicates release of preformed hormone, exogenous ingestion, or extrathyroidal hormone synthesis.</div><div class=\"graphic_footnotes\">TSH: thyroid-stimulating hormone.</div><div id=\"graphicVersion\">Graphic 76972 Version 5.0</div></div></div>"},"76973":{"type":"graphic_diagnosticimage","displayName":"CT perimesencephalic nonaneursymal SAH","title":"Perimesencephalic nonaneurysmal subarachnoid hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Perimesencephalic nonaneurysmal subarachnoid hemorrhage</div><div class=\"cntnt\"><img style=\"width:467px; height:517px;\" src=\"images/NEURO/76973_PMNASAH_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Head CT of three different patients demonstrating subarachnoid hemorrhage in the characteristic pattern of perimesencephalic hemorrhage with blood in the interpeduncular and ambient cisterns.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Images are courtesy of the Neuroradiology teaching file and the Neurosurgery Department at Thomas Jefferson University Hospital.</div><div id=\"graphicVersion\">Graphic 76973 Version 4.0</div></div></div>"},"76974":{"type":"graphic_figure","displayName":"Transtentorial herniation","title":"Transtentorial herniation","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Transtentorial herniation</div><div class=\"cntnt\"><img style=\"width:567px; height:597px;\" src=\"images/NEURO/76974_Transtentorial_herniation.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Plum F, Posner JB. The Diagnosis of Stupor and Coma III. FA Davis, Philadelphia 1995. p. 103.</div><div id=\"graphicVersion\">Graphic 76974 Version 4.0</div></div></div>"},"76975":{"type":"graphic_table","displayName":"Preeclampsia with severe features","title":"In a patient with preeclampsia, the presence of one or more of the following indicates a diagnosis of \"preeclampsia with severe features\"","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">In a patient with preeclampsia, the presence of one or more of the following indicates a diagnosis of \"preeclampsia with severe features\"</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Symptoms of central nervous system dysfunction:</td> </tr> <tr> <td class=\"sublist1\">New-onset cerebral or visual disturbance, such as:<br /> <ul class=\"decimal_heading\"> <li>Photopsia, scotomata, cortical blindness, retinal vasospasm </li> <li>Severe headache (ie, incapacitating, \"the worst headache I've ever had\") or headache that persists and progresses despite analgesic therapy </li> <li>Altered mental status </li> </ul> </td> </tr> <tr> <td class=\"sublist1_start\">Hepatic abnormality:</td> </tr> <tr> <td class=\"sublist1\">Severe persistent right upper quadrant or epigastric pain unresponsive to medication and not accounted for by an alternative diagnosis or serum transaminase concentration &#8805;2 times&nbsp;the upper limit of the normal range, or both</td> </tr> <tr> <td class=\"sublist1_start\">Severe blood pressure elevation:</td> </tr> <tr> <td class=\"sublist1\">Systolic blood pressure &#8805;160 mmHg or diastolic blood pressure &#8805;110 mmHg on two occasions at least four hours apart while the patient is on bedrest (antihypertensive therapy&nbsp;may be&nbsp;initiated upon confirmation of severe hypertension, in which case criteria for severe blood pressure elevation can be satisfied without waiting until four hours have elapsed) </td> </tr> <tr> <td class=\"sublist1_start\">Thrombocytopenia:</td> </tr> <tr> <td class=\"sublist1\">&#60;100,000 platelets/microL</td> </tr> <tr> <td class=\"sublist1_start\">Renal abnormality:</td> </tr> <tr> <td class=\"sublist1\">Progressive renal insufficiency (serum creatinine &#62;1.1 mg/dL [97.2 micromol/L] or a doubling of the serum creatinine concentration in the absence of other renal disease)</td> </tr> <tr> <td>Pulmonary edema</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In contrast to older criteria, the 2013 criteria do not include proteinuria &gt;5 g/24 hours and fetal growth restriction as features of severe disease.</div><div class=\"graphic_reference\">Adapted from: Hypertension in pregnancy: Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122:1122.</div><div id=\"graphicVersion\">Graphic 76975 Version 18.0</div></div></div>"},"76976":{"type":"graphic_waveform","displayName":"12 lead ECG CPVT","title":"12-lead ECG in child with catecholaminergic polymorphic ventricular tachycardia (CPVT)","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">12-lead ECG in child with catecholaminergic polymorphic ventricular tachycardia (CPVT)</div><div class=\"cntnt\"><img style=\"width:526px; height:350px;\" src=\"images/PEDS/76976_12leadECGCPVTedt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is the ECG of a five-year-old with recurrent exertional syncope. The ECG demonstrates bidirectional VT. This child underwent genetic testing and was positive for the RyR2 mutation.</div><div id=\"graphicVersion\">Graphic 76976 Version 10.0</div></div></div>"},"76977":{"type":"graphic_figure","displayName":"Anterior neck muscles A","title":"Anterior neck muscles","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Anterior neck muscles</div><div class=\"cntnt\"><img style=\"width:503px; height:413px;\" src=\"images/PEDS/76977_Anterior_neck_muscles_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anterior neck muscles include the platysma, sternocleidomastoid (SCM), anterior vertebral muscles, and the lateral vertebral muscles. The platysma is a broad, thin muscle that overlies the other muscles and neck structures. The SCM arises from the sternum and the medial third of the clavicle and passes obliquely across the side of the neck to insert into the mastoid process. The anterior vertebral muscles include the longus capitis, longus colli, rectus capitis anterior, and rectus capitis lateralis (only the longus capitus is visible on this view). The lateral vertebral muscles (scalene muscles), attach from the cervical vertebrae to the first or second ribs. The nerves of the brachial plexus pass between the anterior and middle scalene muscles en route to the subclavian area.</div><div id=\"graphicVersion\">Graphic 76977 Version 1.0</div></div></div>"},"76978":{"type":"graphic_diagnosticimage","displayName":"Diabetic neuroarthropathy II","title":"Diabetic neuroarthropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diabetic neuroarthropathy</div><div class=\"cntnt\"><img style=\"width:360px; height:283px;\" src=\"images/RHEUM/76978_Diabetic_neuroarthropathy1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph of the tibia and fibula in the same patient as the previous pictures. The patient had a spontaneous fracture of the right tibia and fibula three years previously, which had healed with bowing (arrow).</div><div class=\"graphic_reference\">Courtesy of LD Hordon, MD and Verna Wright, MD.</div><div id=\"graphicVersion\">Graphic 76978 Version 2.0</div></div></div>"},"76980":{"type":"graphic_picture","displayName":"Mallory Weiss muscularis Endosc","title":"Mallory-Weiss tear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mallory-Weiss tear</div><div class=\"cntnt\"><img style=\"width:216px; height:281px;\" src=\"images/GAST/76980_Mallory_Weiss_muscularis_En.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy shows a mucosal tear extending into the muscularis mucosa at the distal esophagus.</div><div class=\"graphic_reference\">Courtesy of Moises Guelrud, MD.</div><div id=\"graphicVersion\">Graphic 76980 Version 1.0</div></div></div>"},"76981":{"type":"graphic_table","displayName":"Nongastrointestinal sx celiac","title":"Nongastrointestinal nonmalignant symptoms of celiac disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nongastrointestinal nonmalignant symptoms of celiac disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Infertility</td> </tr> <tr> <td>Rheumatic disorders</td> </tr> <tr> <td class=\"sublist1_start\">Vitamin D and calcium deficiency</td> </tr> <tr> <td class=\"sublist1\">Osteomalacia</td> </tr> <tr> <td class=\"sublist1\">Osteoporosis</td> </tr> <tr> <td class=\"sublist1_start\">Neurologic disorders</td> </tr> <tr> <td class=\"sublist1\">Depression - 10.6%</td> </tr> <tr> <td class=\"sublist1\">Epilepsy - 3.5%</td> </tr> <tr> <td class=\"sublist1\">Migraine headaches - 3.2%</td> </tr> <tr> <td class=\"sublist1\">Anxiety - 2.6%</td> </tr> <tr> <td class=\"sublist1\">Suicidal tendency - 2.1%</td> </tr> <tr> <td class=\"sublist1\">Carpal tunnel syndrome - 1.8%</td> </tr> <tr> <td class=\"sublist1\">Myopathy - 1.5%</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Holmes JKT. Non-malignant complications of coeliac disease. Acta Paediatr 1996; 412(Suppl):68.</div><div id=\"graphicVersion\">Graphic 76981 Version 3.0</div></div></div>"},"76982":{"type":"graphic_picture","displayName":"Vulvar sentinel node identification","title":"Left groin sentinel node identification","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left groin sentinel node identification</div><div class=\"cntnt\"><img style=\"width:432px; height:311px;\" src=\"images/OBGYN/76982_Sentinel_node_identificatio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The gamma probe guides identification of the vulvar sentinel node.</div><div class=\"graphic_reference\">Courtesy of C. William Helm, MD.</div><div id=\"graphicVersion\">Graphic 76982 Version 3.0</div></div></div>"},"76984":{"type":"graphic_picture","displayName":"Grade III nipple inversion","title":"Grade III nipple inversion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Grade III nipple inversion</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/SURG/76984_Grade_III_nipple_inversion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In Grade III nipple inversion, there is no projection of the nipple and the papilla is buried below the level of the skin. Despite maximal manipulation, the nipple cannot be pulled out and would be described as invaginated.</div><div id=\"graphicVersion\">Graphic 76984 Version 2.0</div></div></div>"},"76985":{"type":"graphic_picture","displayName":"Seborrheic dermatitis scalp 2","title":"Seborrheic dermatitis of the scalp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seborrheic dermatitis of the scalp</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/76985_Seborrheic_derma_scalp2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse erythema and scaling of the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 76985 Version 5.0</div></div></div>"},"76987":{"type":"graphic_table","displayName":"Ethanol intoxication in children - Rapid overview","title":"Ethanol intoxication in children: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ethanol intoxication in children: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td class=\"indent1\">Ensure that \"alcohol\" ingested is ethanol and not another toxic alcohol (eg, methanol, ethylene glycol): clinical signs of toxic alcohol include a serum osmolal gap out of proportion to the ethanol level soon after ingestion, and delayed onset of severe anion gap metabolic acidosis</td> </tr> <tr> <td class=\"indent1\">Ethanol ingestion in young children carries a significant risk for hypoglycemia</td> </tr> <tr> <td class=\"sublist2_start\">Common findings:</td> </tr> <tr> <td class=\"sublist2\">Vital signs - hypothermia, bradycardia, hypotension, and/or respiratory depression</td> </tr> <tr> <td class=\"sublist2\">Other - lethargy, coma, ataxia, slurred speech, vomiting, and/or sweet breath odor</td> </tr> <tr> <td class=\"sublist2_start\">Other findings:</td> </tr> <tr> <td class=\"sublist2\">Hypoglycemic seizures and death (especially young children)</td> </tr> <tr> <td class=\"sublist2\">Nystagmus</td> </tr> <tr> <td class=\"sublist2\">Mild to moderate hypovolemia</td> </tr> <tr> <td class=\"sublist2\">Signs of trauma or sexual assault (adolescents)</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td class=\"indent1\">Obtain fingerstick blood glucose in all patients with altered mental status and young children</td> </tr> <tr> <td class=\"indent1\">Measure blood ethanol level*</td> </tr> <tr> <td class=\"indent1\">Possible toxic alcohol ingestion: serum electrolytes, BUN, creatinine, serum osmolality, serum calcium, blood gas, serum methanol and ethylene glycol levels</td> </tr> <tr> <td class=\"indent1\">Other studies based on clinical presentation<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"indent1\">Secure airway and support breathing as needed</td> </tr> <tr> <td class=\"indent1\"> <p>Treat hypoglycemia with 0.25 grams/kg IV dextrose bolus (maximum single dose 25 grams). Glucagon is <strong>ineffective</strong> for ethanol-induced hypoglycemia in children.<sup>&#916;</sup></p> <p>The volume and concentration of glucose bolus is infused slowly at 2 to 3 mL per minute and based upon age<sup>&#916;</sup>:</p> <p>2.5 mL/kg of 10 percent dextrose solution (D10W) in infants and children up to 12 years of age (10 percent dextrose is 100 mg/mL)</p> 1 mL/kg of 25 percent dextrose (D25W) or 0.5 mL/kg of 50 percent dextrose (D50W) in adolescents (25 percent dextrose is 250 mg/mL; 50 percent dextrose is 500 mg/mL)</td> </tr> <tr> <td class=\"indent1\">After reversal of hypoglycemia, maintain blood glucose by administering continuous dextrose infusion with &#188; or &#189; normal saline, depending upon maintenance sodium requirements, to maintain blood glucose greater than 60 mg/dL (3.33 mmol/L) or, in conscious patients who are able to drink and swallow safely, provide a regular diet<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Treat hypovolemia with intravenous bolus of normal saline or lactated Ringer's solution 20 mL/kg (maximum 1 L), repeat as needed</td> </tr> <tr> <td class=\"indent1\">Rewarm based on core body temperature</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* All infants and young children with significant ingestion. May provide estimate of symptom duration in moderate to severely intoxicated adolescents.<br />¶ Refer to UpToDate topics on ethanol poisoning in children and adolescents.<br />Δ Refer to UpToDate topics on toxic effects of ethanol in children and UpTodate rapid overview and topics on management of hypoglycemia in children.</div><div id=\"graphicVersion\">Graphic 76987 Version 14.0</div></div></div>"},"76992":{"type":"graphic_table","displayName":"Cytochrome P450 3A4 (CYP3A4) inhibitors and inducers","title":"Cytochrome P450 3A4 (CYP3A4) inhibitors and inducers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cytochrome P450 3A4 (CYP3A4) inhibitors and inducers</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Strong inhibitors</td> </tr> <tr> <td class=\"indent1\">Atazanavir</td> </tr> <tr> <td class=\"indent1\">Boceprevir</td> </tr> <tr> <td class=\"indent1\">Clarithromycin</td> </tr> <tr> <td class=\"indent1\">Cobicistat and cobicistat containing coformulations</td> </tr> <tr> <td class=\"indent1\">Darunavir</td> </tr> <tr> <td class=\"indent1\">Idelalisib</td> </tr> <tr> <td class=\"indent1\">Indinavir</td> </tr> <tr> <td class=\"indent1\">Itraconazole</td> </tr> <tr> <td class=\"indent1\">Ketoconazole</td> </tr> <tr> <td class=\"indent1\">Lopinavir</td> </tr> <tr> <td class=\"indent1\">Mifepristone</td> </tr> <tr> <td class=\"indent1\">Nefazodone</td> </tr> <tr> <td class=\"indent1\">Nelfinavir</td> </tr> <tr> <td class=\"indent1\">Ombitasvir-paritaprevir-ritonavir</td> </tr> <tr> <td class=\"indent1\">Ombitasvir-paritaprevir-ritonavir plus dasabuvir</td> </tr> <tr> <td class=\"indent1\">Posaconazole</td> </tr> <tr> <td class=\"indent1\">Ritonavir and ritonavir containing coformulations</td> </tr> <tr> <td class=\"indent1\">Saquinavir</td> </tr> <tr> <td class=\"indent1\">Telaprevir</td> </tr> <tr> <td class=\"indent1\">Telithromycin</td> </tr> <tr> <td class=\"indent1\">Voriconazole</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Moderate inhibitors</td> </tr> <tr> <td class=\"indent1\">Amiodarone<sup>*</sup></td> </tr> <tr> <td class=\"indent1\">Aprepitant</td> </tr> <tr> <td class=\"indent1\">Cimetidine<sup>*</sup></td> </tr> <tr> <td class=\"indent1\">Conivaptan</td> </tr> <tr> <td class=\"indent1\">Crizotinib</td> </tr> <tr> <td class=\"indent1\">Cyclosporine<sup>*</sup></td> </tr> <tr> <td class=\"indent1\">Diltiazem</td> </tr> <tr> <td class=\"indent1\">Dronedarone</td> </tr> <tr> <td class=\"indent1\">Erythromycin</td> </tr> <tr> <td class=\"indent1\">Fluconazole</td> </tr> <tr> <td class=\"indent1\">Fosamprenavir</td> </tr> <tr> <td class=\"indent1\">Fosaprepitant<sup>*</sup></td> </tr> <tr> <td class=\"indent1\">Grapefruit juice</td> </tr> <tr> <td class=\"indent1\">Imatinib</td> </tr> <tr> <td class=\"indent1\">Isavuconazole (isavuconazonium sulfate) </td> </tr> <tr> <td class=\"indent1\">Letermovir</td> </tr> <tr> <td class=\"indent1\">Netupitant</td> </tr> <tr> <td class=\"indent1\">Nilotinib</td> </tr> <tr> <td class=\"indent1\">Ribociclib</td> </tr> <tr> <td class=\"indent1\">Schisandra</td> </tr> <tr> <td class=\"indent1\">Verapamil</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Strong inducers</td> </tr> <tr> <td class=\"indent1\">Apalutamide</td> </tr> <tr> <td class=\"indent1\">Carbamazepine</td> </tr> <tr> <td class=\"indent1\">Enzalutamide</td> </tr> <tr> <td class=\"indent1\">Fosphenytoin</td> </tr> <tr> <td class=\"indent1\">Lumacaftor</td> </tr> <tr> <td class=\"indent1\">Mitotane</td> </tr> <tr> <td class=\"indent1\">Phenobarbital</td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> </tr> <tr> <td class=\"indent1\">Primidone</td> </tr> <tr> <td class=\"indent1\">Rifampin (rifampicin)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Moderate inducers</td> </tr> <tr> <td class=\"indent1\">Bexarotene</td> </tr> <tr> <td class=\"indent1\">Bosentan</td> </tr> <tr> <td class=\"indent1\">Dabrafenib</td> </tr> <tr> <td class=\"indent1\">Dexamethasone<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Efavirenz</td> </tr> <tr> <td class=\"indent1\">Eslicarbazepine</td> </tr> <tr> <td class=\"indent1\">Etravirine</td> </tr> <tr> <td class=\"indent1\">Modafinil</td> </tr> <tr> <td class=\"indent1\">Nafcillin</td> </tr> <tr> <td class=\"indent1\">Rifabutin<sup>​&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Rifapentine</td> </tr> <tr> <td class=\"indent1\">St. John's wort</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">&nbsp; &#xD;&#xA;<DIV></DIV>&#xD;&#xA;<UL>&#xD;&#xA;<LI>The inhibitors and inducers of CYP3A4 metabolism listed above can alter serum concentrations of other drugs that are dependent upon CYP3A family of&nbsp;liver enzymes for elimination or activation.</LI>&#xD;&#xA;<LI>These classifications are based upon US Food &amp; Drug Administration (US FDA) guidance.<SUP>[1,2]</SUP> Other&nbsp;sources may use a different classification system resulting in some agents being classified differently.&nbsp;</LI>&#xD;&#xA;<LI>Data are for systemic drug forms. Degree of inhibition or induction may be altered by dose, method, and timing of administration.</LI>&#xD;&#xA;<LI>Weak inhibitors and inducers are not listed in this table with exception of&nbsp;a few examples. Clinically significant interactions can occasionally occur due to weak inhibitors and inducers (eg, target drug is highly dependent on CYP3A4 metabolism and has a narrow therapeutic index). Accordingly, specific interactions should be checked using a drug interaction program such as&nbsp;Lexicomp interactions included within UpToDate.</LI>&#xD;&#xA;<LI>Refer to UpToDate topics on specific agents and indications for further details.</LI></UL></div><div class=\"graphic_footnotes\">*&nbsp;Classified as&nbsp;a weak inhibitor of CYP3A4 according to US FDA system.<SUP>[1]</SUP> <br />¶ Classified as a weak inducer of CYP3A4 according to US FDA system.<SUP>[1]</SUP></div><div class=\"graphic_reference\">Data from: Lexicomp Online (Lexi-Interact). Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.<br /><br />References: <br /><br /><OL>&#xD;&#xA;<LI>​US Food &amp; Drug Administration. Clinical drug interaction studies - Study design, data analysis and clinical implications; Guidance for industry (October 24, 2017) available at: <A spellcheck=true href=\"https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf&nbsp; \">https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf&nbsp; </A></LI>&#xD;&#xA;<LI>US Food &amp; Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: <A spellcheck=true href=\"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm\">FDA.gov website.</A></LI></OL></div><div id=\"graphicVersion\">Graphic 76992 Version 50.0</div></div></div>"},"76993":{"type":"graphic_table","displayName":"Differential diagnosis acute knee pain athlete  - Part A","title":"Differential diagnosis of acute knee pain in the young athlete: Part A","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of acute knee pain in the young athlete: Part A</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Condition</td>\n\n      <td class=\"subtitle1\">Mechanism of injury</td>\n\n      <td class=\"subtitle1\">Clinical Features</td>\n\n      <td class=\"subtitle1\">Comments</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"4\" rowspan=\"1\" class=\"subtitle2_left\">Anterior\npain</td>\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"5\" colspan=\"1\" class=\"indent1\">ACL injury</td>\n\n      <td colspan=\"1\" rowspan=\"5\">Twisting or hyperextension</td>\n\n      <td>Sudden pain and giving way</td>\n\n      <td colspan=\"1\" rowspan=\"5\">Often accompanied by MCL and/or meniscal injury</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Unable to ambulate</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Hemarthrosis</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Abnormal anterior drawer, Lachman, or pivot shift test</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Inability to fully squat or duck waddle</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"3\" class=\"indent1\">Rupture of patellar\nor quadriceps tendon</td>\n\n      <td colspan=\"1\" rowspan=\"3\">Fall on partially flexed knee</td>\n\n      <td>Instability with ambulation</td>\n\n      <td colspan=\"1\" rowspan=\"3\">May be associated with patellar fracture</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Significant pain and swelling</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Large effusion</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"4\" class=\"subtitle2_left\">Posterior pain</td>\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"4\" colspan=\"1\" class=\"indent1\">PCL injury</td>\n\n      <td colspan=\"1\" rowspan=\"4\">Direct force to anterior knee with the knee in flexion,\nfall onto flexed knee with foot in plantar flexion; hyperflexion;\nhyperextension (after rupture of ACL)</td>\n\n      <td>Effusion within 24 hours</td>\n\n      <td colspan=\"1\" rowspan=\"4\">Usually combined with other injuries</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Limited range of motion</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Instability</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Tibia in posterior position relative to femur</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"4\" class=\"subtitle2_left\">Medial pain</td>\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"4\" colspan=\"1\" class=\"indent1\">MCL injury</td>\n\n      <td colspan=\"1\" rowspan=\"4\">Valgus force without rotation</td>\n\n      <td>Localized pain, ecchymosis, swelling and stiffness</td>\n\n      <td colspan=\"1\" rowspan=\"4\">Often accompanied by ACL injuries (in which case knee\ndislocation must be considered)</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Pain along course of ligament</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Laxity with valgus stress in 30 degrees of knee flexion</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Laxity with valgus stress in 0 degrees of knee flexion\nindicates concurrent ACL injury</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"8\" class=\"indent1\">Medial meniscal tear</td>\n\n      <td colspan=\"1\" rowspan=\"8\">Twisting injury</td>\n\n      <td>Usually able to ambulate, but weight bearing is limited\nby pain</td>\n\n      <td colspan=\"1\" rowspan=\"8\">&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Knee swelling and stiffness develop over 2 to 3 days</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Mechanical symptoms</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Medial pain with twisting or squatting</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Medial joint line tenderness</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Positive McMurray test</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Positive bounce home test</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Decreased range of motion</td>\n\n      \n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=51388&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>DDx_Acute_knee_pain_athlete.htm</title></head></div><div class=\"graphic_footnotes\">ACL: anterior cruciate ligament; MCL: medical collateral ligament; PCL: Posterior cruciate ligament.</div><div id=\"graphicVersion\">Graphic 76993 Version 3.0</div></div></div>"},"76994":{"type":"graphic_figure","displayName":"Normal nail anatomy","title":"Normal nail anatomy","html":"<div class=\"graphic\"><div style=\"width: 753px\" class=\"figure\"><div class=\"ttl\">Normal nail anatomy</div><div class=\"cntnt\"><img style=\"width:733px; height:601px;\" src=\"images/EM/76994_Nailantmy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The nail has several distinct anatomic areas. The hard nail plate emerges from a matrix of specialized epithelial cells. The matrix begins 7 to 8 mm under the proximal fold, and its distal end is the white crescent called the lunula. The richly vascularized nail bed lies directly beneath the plate to provide adherence and support and is the basis of the characteristic pink color. The proximal and lateral nail folds surround the plate on three sides, and the cuticle, an outgrowth of the proximal fold, provides a seal between the fold and the nail plate.</div><div class=\"graphic_reference\">Reproduced with permission from: Patel L. Management of simple nail bed lacerations and subungual hematomas in the emergency department. Ped Emerg Care 2014; 30:742. DOI: <a href=\"http://journals.lww.com/pec-online/pages/articleviewer.aspx?year=2014&amp;issue=10000&amp;article=00016&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/PEC.0000000000000241</a>. Copyright &copy; 2014 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 76994 Version 4.0</div></div></div>"},"76995":{"type":"graphic_picture","displayName":"PMLE hand and neck","title":"Polymorphous light eruption","html":"<div class=\"graphic\"><div style=\"width: 677px\" class=\"figure\"><div class=\"ttl\">Polymorphous light eruption</div><div class=\"cntnt\"><img style=\"width:657px; height:252px;\" src=\"images/DERM/76995_PMLE_hand_and_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules developed on the dorsal hands (A) and neck (B) of a 40-year-old man following sun exposure. The patient's history and symptoms were consistent with polymorphous light eruption.</div><div class=\"graphic_reference\">Copyright © Shahbaz A Janjua, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 76995 Version 6.0</div></div></div>"},"76996":{"type":"graphic_picture","displayName":"Dieulafoys lesion Endosc","title":"Dieulafoy's lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dieulafoy's lesion</div><div class=\"cntnt\"><img style=\"width:323px; height:317px;\" src=\"images/GAST/76996_Dieulafoys_lesion_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of the stomach showing a bleeding Dieulafoy's lesion.</div><div class=\"graphic_reference\">Courtesy of Rome Jutabha, MD.</div><div id=\"graphicVersion\">Graphic 76996 Version 1.0</div></div></div>"},"76997":{"type":"graphic_figure","displayName":"Pathogenesis of angiodysplasias","title":"Proposed mechanism for the development of angiodysplasia","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Proposed mechanism for the development of angiodysplasia</div><div class=\"cntnt\"><img style=\"width:458px; height:334px;\" src=\"images/GAST/76997_Pathogenesis_of_angiodyspla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This cartoon depicts one possible explanation for the development of gastointestinal angiodysplasias. Mucosal and submucosal venous drainage is intermittently obstructed by muscular contraction or increased intraluminal pressure (panels A, B, and C). After many years of intermittent obstruction, submucosal veins may become dilated and tortuous (panel D) and involve additional veins and venules draining into the system. Eventually, the capillary ring dilates and the precapillary sphincter becomes incompetent resulting in a small arteriovenous communication lesion.</div><div class=\"graphic_reference\">Boley SJ, Sammartano R, Adams R, et al. On the nature and etiology of vascular ectasias of the colon: Degenerative lesions of aging. Gastroenterology 1977; 72:650. Copyright &#169; 1977 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 76997 Version 2.0</div></div></div>"},"76998":{"type":"graphic_table","displayName":"Storage iron pools (adults)","title":"Distribution of body iron in men and women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distribution of body iron in men and women</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">70 kg man</td> <td class=\"subtitle1\">60 kg woman</td> </tr> <tr> <td>Iron stores - transferrin, ferritin, hemosiderin</td> <td>0.7 g</td> <td>0.3 g*</td> </tr> <tr> <td>Hemoglobin</td> <td>2.5 g</td> <td>1.9 g</td> </tr> <tr> <td>Myoglobin</td> <td>0.14 g</td> <td>0.13 g</td> </tr> <tr class=\"divider_bottom\"> <td>Heme enzymes</td> <td>0.01 g</td> <td>0.01 g</td> </tr> <tr> <td><strong>TOTAL</strong></td> <td><strong>3.35 g</strong></td> <td><strong>2.34 g</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate for details.</div><div class=\"graphic_footnotes\">* This value is an average. Approximately 20 percent of menstruating women have no iron stores.</div><div class=\"graphic_reference\">Data from: Schrier SL, Scientific American Medicine, Scientific American, New York, 1995.</div><div id=\"graphicVersion\">Graphic 76998 Version 5.0</div></div></div>"}};